File Three: Selected Chronology of Heimlich Institute's "Malariotherapy" Experiments Via University of Cincinnati's Winkler Library

~Yw!~~--------:--He-nry-J' H-eiml-ich, M-.D.
ProfessorofAdvancedClinicalSciences
J uL y 14, 1986
Mr . Her ber t C. EngL er t
Pr es i dent
F anni e E. Ri ppel F oundat i on
333 Mai n St r eet
Madi s on, NJ 07840
Dear Ber t :
Thi s i s t he s ec ond quar t er L y r epor t on t he Ri ppeL Canc er Gr ant Pr oj ec t .
I n t he i nt er i m s i nc e t he f i r s t quar t er L y r epor t , I hav e s ent y ou L et t er s r e-
gar di ng pos s i bi L i t i es f or s t ar t i ng our pr oj ec t i n Ec uador , Mex i c o, Venez ueL a,
and Chi na, as weL L as my c ont ac t wi t h Dr . J ames Mas on, Di r ec t or of t he Cent er
F or Di s eas e Cont r oL ( CDC) of t he U. S. Depar t ment of HeaL t h and Human Ser v i c es
( HHS)
I hav e mai nt ai ned c ont ac t wi t h Dr . Gi l ber t i n Ec uador t hr ough r epeat ed t eL e-
phone c aL L s . He s ay s t hat ev er y t hi ng i s f av or abL e but i t wi L L t ak e t i me. As
Ambas s ador SoL L i nowi t z wr i t es ( enc l os edr , " Obv i ous L y y ou ar e ar ous i ng i nt er es t
i n y our pr opos aL , and t hi s s houL d be gr at i f y i ng. On t he ot her hand, I k now aL L
t oo we L L how ha r d i t i s t o mov e .some of t hes e peopL e i n t he dev eL opi ng wor L d
t owar d i mpL ement at i on of i deas . You wi L L need aL L t he pat i enc e y ou c an mus t er ,
but I hope y ou wi L L not s L ac k en i n y our ef f or t s . "
Thr ough t he good of f i c es of Dr . Har r y Gi bbons , Di r ec t or of HeaL t h, SaL t L ak e
Ci t y and Count y , a r eL at i ons hi p was es t abL i s hed t hr ough hi s pubL i c heaL t h
c oL L eague i n Mex i c o Ci t y , Dr . L ui s A. Amez c ua. Dr . Amez c ua heL d t wo di s c us -
s i ons wi t h Dr . Ar t ur o BeL t r an Or t ega, Di r ec t or of t he Nat i onaL Canc er I ns t i t ut e
of Mex i c o, who ex pr es s ed i nt er es t i n wor k i ng wi t h us on maL ar i at her apy f or
c anc er .
On J uL y 6, I t r av eL L ed t o Mex i c o Ci t y . A meet i ng was heL d at t he Nat i onaL
Canc er I ns t i t ut e on J uL y 7 at 10: 00 am and I r et ur ned home t hat ni ght , af t er
an ex haus t i ng but f r ui t f uL v i s i t . Dr . Gi bbons and Dr . Amez c ua j oi ned me at
t he I ns t i t ut e. I pr es ent ed our paper on maL ar i at her apy f or c anc er t o Dr .
Be L t r an.
3800VictoryParkway
Cincinnati, Ohio45207-1096
513/531-1053
Mr . Her ber t C. EngL er t
J uL y 15, 1986
P age 2
Dr . BeL t r an, who had t r ai ned at Memor i aL Hos pi t aL i n New Yor k Ci t y and Ros weL L
P ar k i n Roc hes t er , NY, t hen des c r i bed hi s wor k wi t h BCG v ac c i ne f or meL anoma,
demons t r at i ng s ome ex c eL L ent r es uL t s . Hi s i nt er es t i n BCG, an oL d ant i t uber -
c uL os i s v ac c i ne was f or t ui t ous s i nc e i t i s bas ed on bi oL ogi c al i mmuni t y whi c h
i s ak i n i n c onc ept t o maL ar i at her apy . I had r ec ent L y r ead a book on t he us e
of BCG i n c anc er and was abL e t o poi nt out t hat t he f ev er and uL c er at i on f r om
t he BCG may aL s o be pr ov i di ng benef i c i aL r es uL t s .
I t was onL y af t er Dr . BeL t r an bec ame awar e t hat I was t he di s c ov er er of t he
Hei mL i c h Maneuv er t hat hi s ent hus i as m f or our pr oj ec t bec ame appar ent . A t our
of t he I ns t i t ut e and hos pi t aL s howed t hem t o be moder n and weL L equi pped.
They c ar e f or t hous ands of c anc er pat i ent s . We aL L agr eed t hat our t r eat ment
c an do no ha r m.
We L ef t wi t h t he under s t andi ng t hat Dr . BeL t r an wouL d hav e an as s oc i at e r ev i ew
aL L medi c aL L i t er at ur e on ~aL ar i a and i mmuni t y . Af t er ~bout one mont h, we wi L L
ar r ange f or anot her s es s i on i n Mex i c o t o es t abL i s h a pr ot oc oL f or c ar r y i ng out
t he t r eat ment of pat i ent s wi t h maL ar i a. He pr es ent ed me wi t h t he pr ot oc oL f or m
f or r es ear c h us ed i n hi s hos pi t aL ( enc L os ed) and s ai d t her e s houL d be no di f -
f i c uL t y i n s t ar t i ng t he t r eat ment pr ogr am af t er goi ng t hr ough t he f or maL i t i es .
I am pL anni ng t o go t o Venez ueL a i n t he near f ut ur e t o di s c us s es t abL i s hi ng
our pr ogr am t her e. I n addi t i on, I am s c heduL i ng a meet i ng at t he CDC i n At L an-
t a wi t h Dr . Mas on and hi s s t af f .
I n t he meant i me our r es ear c h c ont i nues at Xav i er Uni v er s i t y and has pr ov i ded
new c onf i r mat i on s uppor t i ng t he c onc ept of t r eat i ng c anc er by i nduc t i on of
maL ar i a. We hav e L oc at ed a book i n Ger man by P r of . Dr . Med. Wer ner ZabeL who
t r eat ed ni net een c anc er pat i ent s wi t h maL ar i at her apy i n Bav ar i a i n t he 1950
1
s .
Hi s wor k was under t he di r ec t s uper v i s i on of Br i t i s h per s onneL on L oan f r om
t he MaL ar i a Ref er enc e L abor at or y of Hor t on Hos pi t al at Eps om, near L ondon.
Compar i ng mal ar i at her apy t o aL L ot her anc i l L ar y modaL i t i es f or t he t r eat ment
of met as t at i c c anc er , Dr . Zabel wr i t es " t her e i s pr obabL y no ot her pr oc edur e
t hat i s as s uc c es s f uL . "
We hav e dev i s ed a det ai L ed pr ot oc oL ( enc L os ed) t hat wi L L be av ai L abL e wher ev er
t r eat ment i s c ar r i ed out . I t i s bei ng modi f i ed t o c onf or m wi t h t he f or mat of
the Nat i onaL Canc er I ns t i t ut e of Mex i c o.
Our goaL i s t o c ur e c anc er and we hav e good r eas on t o bel i ev e maL ar i at her apy
wi L L be ef f ec t i v e, but c an onL y be c er t ai n af t er we hav e t he oppor t uni t y t o
t r eat ot her wi s e i nc ur abL e pat i ent s . Wi t h per s i s t enc e and pat i enc e we wi l L
s uc c eed.
A c opy of t he J anuar y 1 - J une 30, 1986 Xav i er Uni v er s i t y f i nanc i al r e~or t of
t he Ri ppeL Canc er Gr ant i s enc L os ed as per t he agr eement wi t h t he uni v er s i t y .
HJ H/ j h
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
C I N C I N N A n . O H 4 5 2 0 8
5 1 3 5 3 1 - 1 0 5 3
Apr il 12, 1988
Mr . Er i c R. Ri ppel
Pr es i dent
Fanni e E. Ri ppel Foundat i on
333 Mai n St r eet
Madi s on, NJ 07940- 2394
Dear Er i c :
Thank you ver y muc h f or t he t hi r d i ns t al l ment of t he gr ant .
Enc l os ed ar e l et t er s gi ven t o me by Har r y Gi bbons about whi c h we
have s poken. Mr . Mc I nt i r e had gi ven a t r ans f us i on t o hi s f at her
s ome year s ago. Hi s f at her , at t he t i me, had f ar advanc ed c anc er
and was al s o c ons i der ed t er mi nal . The f at her r ec over ed
c ompl et el y and l i ved t wel ve year s and di ed of ot her c aus es at a
r i pe ol d age. The f at her di d not devel op mal ar i a but di d have
f ever . Mr . Mc I nt i r e bel i eves t he c ur e was r el at ed t o t he f ac t
t hat he had mal ar i a as per t he r epor t f r om t he San Ber nar di no
St at i on Hos pi t al . He i s wr i t i ng on behal f ; f a r el at i ve, Bar bar a
Met c al f , who has c anc er and i s s eeki ng t r eat ment t hr ough us .
Bes t wi s hes ,
r
I
I
I
FANNIE E. RIPPEL FOUNDATION
333MAIN STREET
MADISON, NEW J ERSEY 07940-2394
Mailing Addr ess:
Post Office Box 758
Madison, New J er sey 07940
Apr i l 18, 1988
Henr y J . Hei ml i ch, M. D. , Pr esi dent
The Hei ml i ch I nst i t ut e Foundat i on, I nc.
Post Of f i ce Box 8858
Ci nci nnat i , Ohi o 45208
Dear Dr . Hei ml i ch:
I n connect i on wi t h t he annual exami nat i on of our account s as
of Apr i l 30, 1988, whi ch i s bei ng made by Er nst &Whi nney, 550 Br oad
St r eet , Newar k, New J er sey 07102. , we wi l l appr eci at e i t i f you wi l l
conf i r m t he cor r ect ness of t he i nf or mat i on set f or t h bel ow per t ai ni ng
t o t he gr ant made t o Teh Hei ml i ch I nst i t ut e Foundat i on, I nc. as
aut hor i zed by our Boar d of Tr ust ees on J une 17, 1987.
Pl ease send your r epl y di r ect l y t o our account ant s i n t he
encl osed st amped, addr essed envel ope.
Ver y t r ul y your s,
FANNI E E. RI PPEL FOUNDATI ON
/ ~?, /'
~q.~~'
j
Er i c R. Ri ppel
Pr esi dent
I nf or mat i on Per t ai ni ng t o Gr ant Made Qy Fanni e ~ Ri ppel Foundat i on
1. Amount of gr ant made t o you dur i ng
t he year ended Apr i l 30, 1988 $200, 000. 00
2. Amount of f unds r ecei ved by you
dur i ng t he year ended Apr i l 30, 1988 125, 000. 00
3. Amount of unpai d gr ant as of Apr i l 30,
1988, subj ect t o t he t er ms and
condi t i ons of t he gr ant r esol ut i on $ 75, 000. 00
4. You have not i f i ed us of your accept ance of t hi s gr ant
pr i or t o Apr i l 30, 1988.
X A V I E R
U N I V E R S I T Y
3 8 0 0 V I C T O R Y
P A R t<!N A Y
C I N C I N N A T I
O H I O
45207
5137451099
B e n e f i t i n g
H u m a n i ~
T h r o u g h
H e a l t h
a n d
P e a c e
May 3, 1989
Mr . Er i c R. Ri ppel , Pr es i dent
Pos t Of f i ce Box 758
Madi s on, NJ 07940
Re: Repor t f or s i x mont hs endi ng December 31, 1988
Dear Er i c:
As you know, a maj or l andmar k i n our r es ear ch pr oj ect ,
" Mal ar i at her apy f or Cancer , " was r eached when we went t o Chi na,
Oct ober , 1988. As a r es ul t of Dr . Hua Hong Shen' s ef f or t s , we
wer e met i n Bei j i ng by Dr . Guang- Wei Xu, Di r ect or of t he Bei j i ng
I ns t i t ut e f or Cancer Res ear ch and hi s s t af f . Dr . Hua di d not do
as wel l i n t r avel ar r angement s and booki ng accommodat i ons ,
l eavi ng us wi t h s ome uncomf or t abl e and t r yi ng t i mes .
I t i s r emar kabl e t o cons i der t hat we ent er ed a huge or i ent al
count r y hal f way ar ound t he wor l d, and, i n l es s t han t wo weeks ,
devel oped a wor ki ng r el at i ons hi p wi t h t hei r l eadi ng cancer
i ns t i t ut e t o t r eat cancer pat i ent s wi t h mal ar i at her apy. I n t hat
per i od of t i me we vi s i t ed t he Bei j i ng I ns t i t ut e f or Cancer
Res ear ch and you par t i ci pat ed i n my pr es ent at i on. The
phys i ci ans , who had r ecei ved pr el i mi nar y i nf or mat i on on our
cancer - mal ar i a t her apy pr ogr am, ent hus i as t i cal l y endor s ed t he
met hod and agr eed t o par t i ci pat e. Bef or e we l ef t Chi na, Dr . Xu
had r ecei ved appr oval f r om t he Mi ni s t er of Heal t h of t he Peopl e' s
Republ i c of Chi na ( PRC) t o pr oceed wi t h t he r es ear ch, i ncl udi ng
pat i ent t r eat ment . He al s o pr es ent ed you wi t h a col l abor at i ve
agr eement t hat i s t o be f i nal i z ed when ar r angement s t o t r ans por t
mal ar i a t o Bei j i ng ar e es t abl i s hed.
Si nce t hat t i me, Dr . Xu has t r avel l ed t o Ha Lnan I s l and, whi ch has
endemi c mal ar i a. He i s al s o s eeki ng ot her s i t es as s our ces f or
t he pr oper par as i t e. Dr . Hua i s i n t ouch wi t h me by phone ever y
week t o r epor t hi s pr ogr es s . Hi s f r i end and cl as s mat e, Dr . Yong,
i n Shanghai , i s a l eadi ng mal ar i ol ogi s t . Dr . Yong has cont act ed
Dr . Xu and i s wor ki ng wi t h hi m t o get t he mal ar i a par as i t es t o
Bei j i ng. Dr . Yong wi l l be s pendi ng t he ent i r e s ummer i n Hunan, a
mal ar i al pr ovi nce. He bel i eves mal ar i a t r ans mi s s i on by mos qui t o
t r ans f er may be mor e expedi t i ous t han by bl ood t r ans f us i on. I f
s o, we wi l l have gai ned new exper i ence t hat can hel p our r es ear ch
el s ewher e.
Bef or e we l eave t he s ubj ect of Chi na, I mus t ment i on Xi ao Dong,
t he gr anddaught er of t he l at e Gener al Fu Ts o Yi , my f r i end dur i ng
my u. S. Navy days i n Chi na dur i ng Wor l d War I I . Xi ao Dong pr oved
t o us t hat s he and her f ami l y' s s t andi ng wi t h t he Chi nes e
gover nment , enabl es us t o expedi t e any pl ans we have i n Chi na.
X A V I E R
U N I V E R S I T Y
3 8 0 0 V I C T O R Y
P A R K W A Y
C I N C I N N A T I
O H I O
45207
513745- 1099
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
I t was ver y gr at i f yi ng t o appear bef or e t he Boar d of t he Ri ppel
Foundat i on wi t h Dr . Ar t ur o Bel t r an, Di r ect or of t he Nat i onal
Cancer I ns t i t ut e of Mexi co. I was pr oud t o be pr i vi l eged t o be
pr es ent when Dr . Bel t r an s poke and am cer t ai n t he Boar d f ul l y
under s t ood t he hi gh medi cal cal i ber and di gni t y of t hi s
out s t andi ng gent l eman.
Dr . Bel t r an has at t empt ed t o i nduce mal ar i a i nt o t wo addi t i onal
cancer pat i ent s . The di s eas e di d not t ake and one, wi t h f ar
advanced mel anoma, l ef t t he hos pi t al . She di ed of t he cancer
af t er t wo weeks , s o i t was j us t as wel l s he i s not par t of our
s er i es . The s econd pat i ent , wi t h ki dney car ci noma s pr ead t o t he
l ungs , al s o di d not devel op mal ar i a f r om t he f i r s t t r ans f us i on
and a s econd i s pl anned.
Ther e i s a di f f i cul t y i n obt ai ni ng and t r ans por t i ng mal ar i al
bl ood. The mal ar i a i s s eas onal and, i n addi t i on, t he peopl e t ake
medi cat i on wi t h t he f i r s t s i gns of f ever . We can t r y t o i mpr ove
t he chances of s ucces s by vi s i t i ng t he mal ar i al ar ea wi t h Dr .
Bel t r an and cons i der i ng compens at i on f or t he phys i ci ans who
acqui r e t he mal ar i al bl ood. As you know, a t r i p f or t hi s pur pos e
i s bei ng pl anned.
Our goal now i s t o expand our pat i ent t r eat ment s er i es , and we
ar e s ur el y on our way. Day- t o- day r es ear ch pr ogr es s s omet i mes
s eems s l ow, but r evi ewi ng t he accompl i s hment s of t he l as t s i x
mont hs , as i n t he pas t , makes us r eal i z e t hat i t i s qui t e
r emar kabl e. The i nt er es t of I nt er s ear ch r es ear cher s i n t he
i mmunol ogy r el at ed t o our f i ndi ngs i s addi t i onal evi dence of t he
accept ance of t he concept .
The mal ar i at her apy r es ear ch has l ed t o anot her of f s hoot . Lyme
di s eas e, caus ed by a t i ck bi t e, i s one of t he mos t r api dl y
s pr eadi ng di s eas es i n t hi s count r y and t he r es t of t he wor l d. I t
caus es s ever e r heumat i s m and ner vous s ys t em di s or der s . Lyme
di s eas e i s caus ed by a s pi r ochet e, s i mi l ar t o t hat of s yphi l i s .
As you know, mal ar i at her apy was f i r s t us ed ext ens i vel y f or t he
t r eat ment of neur os yphi l i s . I wi l l be pr es ent i ng an ar t i cl e
r ecommendi ng t hat mal ar i at her apy be us ed t o t r eat Lyme di s eas e.
Si nce t hi s i s a di r ect out gr owt h of our r es ear ch, t he Ri ppel
Foundat i on wi l l be appr opr i at el y r ef er r ed t o and cr edi t ed.
I l ook f or war d t o cont i nui ng t he t r eat ment of cancer wi t h mal ar i a
wi t h your vi t al cooper at i on. Your wi l l i ngnes s t o s uppor t a new
$200, 000 gr ant i s gr eat l y appr eci at ed.
Cl i ni cal Sci ences
FANNIE E. RIPPEL FOUNDATION
333 MAIN STREET
POST OFFICE BOX 758
MADISON, NEW J ERSEY 07940-0758
201-377-5333
May 15, 1989
Henr y J . Hei ml i ch, M. D.
Pr esi dent
The Hei ml i ch I nst i t ut e Foundat i on, I nc.
Xavi er Uni ver si t y
3800 Vi ct or y Par kway
Dear Hank:
We have your l et t er of 11 May and t hanks. Af t er some
per usal we have det er mi ned t he need t o meet wi t h you at our
of f i ces t o di scuss any pot ent i al f ur t her gr ant s t o t he " mal ar i a-
t her apy" pr ot ocol . We suggest a dat e dur i ng t he f i r st week i n
J ul y f or t hi s and wi l l awai t your r epl y.
To r evi ew, we st ar t ed our l ast gr ant on August 6, 1987,
wi t h a payment of $75, 000 and f ol l owed wi t h per i odi cal payment s of
$25, 000 each unt i l Mar ch 2, 1989, when we compl et ed t he f undi ng
of t hi s gr ant f or $200, 000. Out of t hi s gr ant $30, 000 was sent
t o t he Nat i onal Cancer I nst i t ut e of Mexi co t o cover t he act ual
r esear ch pr ot ocol cost s so onl y 15% of our gr ant went t o f und
t hi s cl i ni cal pr ot ocol . Over t he i nt er veni ng 19 mont hs f r om
August , 1987 t o Mar ch, 1989, The Hei ml i ch I nst i t ut e, I nc.
expended on i t s own over head cost s $8, 950 per mont h on aver age.
We r ecogni ze t hat t he wor di ng of t he gr ant mot i on may
not have been speci f i c enough; however , i t was never our i nt ent
t o i n ef f ect suppor t The Hei ml i ch I nst i t ut e wi t h $17a,000 over 19
mont hs whi l e pr ovi di ng onl y $30, 000 f or t he act ual cl i ni cal
r esear ch i n Mexi co.
As you can see, we have much t o di scuss t oget her bef or e
we can t hi nk of anot her gr ant .
Your s t r ul y,
..~..-
~,,,,- .- - '- - '-
Er i c R. Ri ppel
Pr esi dent
ERR: nl c
X A V I E R
U N I V E R S I T Y
3 8 0 0 V I C T O R Y
P A R K W A Y
C I N C I N N A T I
O H I O
4 5 2 0 7
5 1 3 7 4 5 - 1 0 9 9
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
May 19, 1989
Mr . Er i c Ri ppel , Pr es i dent
333 Mai n St r eet
P. O. Box 758
Madi s on, New J er s ey 07940
Dear Er i c:
Thank you f or your l et t er of May 15. The amount expended, as
det ai l ed i n t he r ecor ds , was $150, 000, whi ch i ncl udes t he $30, 000
t o t he Nat i onal Cancer I ns t i t ut e of Mexi co. Ther e i s $50, 000 on
hand t o pr ovi de f or pat i ent s i n Mexi co as wel l as t o keep t he
pr oj ect goi ng her e. The gr ant was s chedul ed f or 18 mont hs . We
have pas s ed t hat poi nt and s t i l l have 25% of t he f unds .
My des i r e t o know about t he new gr ant i s becaus e Dr . Car r ' s wor k
i s es s ent i al t o t he pr oj ect . He cons t ant l y r es ear ches t he
l i t er at ur e and as s i mi l at es i nf or mat i on and dat a. Hi s knowl edge
wi l l be i ndi s pens abl e when we anal yz e pat i ent dat a. We cannot
expect hi m t o r emai n wi t hout t he s ecur i t y t hat he
des er ves - - knowi ng t hat t he wor k wi l l cont i nue af t er t he pr es ent
gr ant ends . I am now not near l y as i mpor t ant t o t he pr oj ect ,
and, as you know, I r ecei ve no compens at i on f r om t he gr ant or t he
Hei ml i ch I ns t i t ut e.
Not hi ng wi l l make you and me happi er t han i ncr eas i ng t he number
of pat i ent t r eat ment s i n Mexi co. We coul d not pr edi ct t hat f or
t he s econd s er i es , t he pat i ent s woul d not devel op mal ar i a af t er
t r ans f us i on. Our next vi s i t t o Mexi co may enabl e us t o advi s e
t hem on obt ai ni ng and t r ans por t i ng t he mal ar i al bl ood.
You have eval uat ed mor e cancer r es ear ch pr ogr ams t han I have. I
am cer t ai n t hat t her e i s none t hat has pr ogr es s ed t o pat i ent
t r eat ment as r api dl y, wi t h as much s ucces s , and wi t h l es s "
expens e. Nor i s any mor e pr om1s 1ng. I have been i n weekl y
cont act wi t h Dr . Hua and am pl eas ed wi t h t he l et t er he FAXed t o
us f r om Dr . Xu.
I l ook f or war d t o s eei ng you i n J une, as s oon as we can ar r ange
t he t r i p t o Mexi co, and al s o wel come t he oppor t uni t y t o at t end
t he meet i ng at t he Ri ppel Foundat i on i n J ul y.
Si ncer el y,
Henr y J . Hei ml i ch, MD, ScD
Pr es i dent , Hei ml i ch I ns t i t ut e
P. S. : Do you t hi nk our vi s i t i nf l uenced s t udent s s eeki ng
democr acy i n Bei j i ng? Woul dn' t be s ur pr i s ed!

,4.1]>.-1 -t" <p-J?,;.."... Min t.4-
lL 1-
J w- <1.- 1; r-ln
w '/
1- t...ue .;.. J7) 1.0 :.pr .NO' -.J.,..., w .....
R.uL J't- /.J>-Jt r}u..

I . J.&th.Jt 1
-b; ik M.- 'Ad?

i..,;vt t;, %- (;; (,UL-Ifi

MA.J2.- "t; .' . Af Jw.".;k ?tit !
3 . ".
t;.L.r
. M<-1 D-Jt-. we Jw.J k

])bv 'Jr. "-'
HAN Mitt. J 1& Juill- 'r-
. .
fp U1-Li; tI'+t r O

c,Rw.- k, /f q,r .. it ft, -t--Jv j y.1.. .
t;, /fR
1- Htov cJ 1-., 7
r...L ttfA.<l 8 '"" 1$ . "-
. rhk.;r . .
.
fjv.t -If, Dr. ; fur.., .

T
_ .. / 0' 0 " Jf
-I'l::llLADELPiHA; P ..... . 151146- I" .
.
, J

. fr / /#f
w-e-
5' A
U

d k4

Benefiting
HumanITy
Through
Health
and
Peace
_E:::e-=.e= .::.- ,
E_CI
co
-
I
M.D .
3"1 a dwi Av e nu e, 12

. 0 t e, CA 9 1 731
:::>ear Hon g-Shun:
b a nk y ou for your New Year's greeting, and I wish you and
you r family the same. I am sorry to hear of Dr. Cionci's
illness and will write to him.
I have just received from Dr. Cionci, the enclosed letter,
dated September 3, 1990. It is from Guangzhou and speaks
enthusiastically about doing our ma1ariatherapy for cancer
and AIDS there. Why have we delayed in arranging to work
with them? Their reasons for our working there are very
imp r essive.
Please contact Guangzhou as soon as possible, and phone me
regarding your progress.
;r7
Y
'
imli ch, M. D., Sc. D
/ presidd/
Heimlich Institute
Fax 1513-221-0003
HJH/jd
Enclosure
cc: Eric Rippel
9+1
T..le Municipal Health & Anti-epidemic
Station of Guangzhou
Address: No. 23, 3rd Zongshnn Rd. Guangzhou.
People's Republlc of Chine.
Post No. 5 1 0 0 a 0
". ' - SHS (t1il<: :;O Tel: 77. 103 (ext.) 765 % 5 5 (office)
/'. ,
Yb,ff vr. VI p"n (/1 :
r" pal' /dk-
J -. k-;..tJJ 74- 'f
rv.y"U tvu/ AIDS, J evmcf'
t'" 7),-, U r 1;
tm tL- M l ;,.,
SfJd J /....-r.. r J,t.if5
Ju
tv
flwr. -k- 1M! tIu- ttY,
,7 1h-- {-#u-
aWi<t
Lu
,;,., tUt ,en e:i:J ;." tuzd //7-
H1-dY-<- f r -,:"
5r' J ,/99fJ.

The Murucipal Health -& Anti-epidemic
Address: No. 23, Srd Zongshan Rd. Ouan,zhou.
People's Republlc of China.
Post No. 6 1 0 0 8 0 . .
Tel: 7 7 4 1 0 3 (ext.) 7 II 6 2 6 5 (office)
.-. - ' . ,., _ .-. ........... ....... t .... ... .......... ... .... ..-..
:tLt
0- tPU'1 -tii-trr <=1'(/ fnt8Uj
r ;,.. . -t. Tunurr
()A1i1 Tu.-r Hlfff:';w' 1- jd- WI . lin:VMf']
fff .uU ;.. "7 fi-{""p-- fftik-.
n- ?v.ftnJrL,n
:;"td4 c..L....,.,. J "",W':-J It-tt 7
l--
"",;);4. I M 1;; 7 w..tZr
-tb-
hfA'''/ trf
r r / r CAn
{<:<r( muJl ;., CUA41"J<?1f( .
/ : '1 N C<.ft i:""J M1 f'Utds,
The Municipal Health & Anti-epidemic
Address: No. 23, 3rd Zongshan Rd. Ouangzhou.
People's Republic of China.
Post No. 5 1 0 0 8 0
Tel: 77 4 103 (ext.) 785255 (office)
Jr n< C/L-" r t'r al,J (JH< C-dh1 t'
;" w;J;4 r>1<2-, J P f J u.-" ut ,_-tr
/ 0 -tLa'- 1/
!LUMY 6.",( t7Ir...- 1 i71u.. 7u-nw>' JI;.V
tV""'" ""(/ -tu.-t/fu.s
I'f "'VI jd4,P- ;n&w tfut a..--<- ,
, .
;" 17
7

;, v/:.th tl-- ,0t- rr '
,/ .
!
/
I
Iv-4 w..'J/-J
looreign Affa i rs Office
Jiangsu Provincial People's GOirernmcnt
People's Republic of China
( 9 I ) A!f- 2 l- 0 0 057
oh ... ... tv) J. H eih! I ; J,
b,7 p.ci
.. _
YOU ARE KINDLY EXPECTED BY prOtJilt.u... rlfT5fita.i
.. __ __ . _ _ .. __ .. __ . .. ____ ._. _ ... _. _. TO COME TO _____ . ___ .. _. ____ _
___ CHINA ON 15t/z, Iq_t; _' _
FOR ____ 0 THE DURATIO N IN
CHINA WILL DE S Q.V.QIL.
DAYS. PLS APPLY FORTHWITH lo OR
_ ._. ENTRY VISA(S)AT THE CHINESE EMD ASSY (OR CON-
SULATE-GENERAL, COMMERCIAL REPRESENTATIVE'S OFFICE TN
OR VISA OFFICE OF THE MINISTRY OF FOREIGN
AFFAIRS IN lIONG KONG) IN Nee WITH THIS LETTER
( tELEGRAM)
Datil
----
'I'm 85921 'tit. 34027 FAOJS Cr-;
313 North Zhongshan Rd., Nanjing, <;hi.ra Tei. 85921 TLX, 34027 FAOJS CN
As WfL :fia} 8
m
w I As;!-
Oc1ob.er. SO W.t. s-Utf tAR. . JtgMt.
. .,
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
2 3 6 8 V I C T O R Y
P A R K W 6 . Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
45206
51322H X X l 2
FAX: ( 513) 221- 0003
FACSI MI LE TRANSMI SSI ON COVER:
TO:
LOCATI ON:
FROM:
-:
NUMBER OF PAGES TO FOLLOW:
RE:
NAME OF PERSON TRANSMI TTI NG:
(~
F O U N D A T I O N , I N C .
2 3 6 8 V I C T O R Y
P A R '{; ; N A Y
S U I T E 410
C I N C I N N A T I
O H I O
4 5 2 0 6
513- 22H X X J 2
fa x 513- 22H X l O 3
B e n e f i . g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Chen Xi ao- Pi ng, M. D.
c/ o Hua Hong- Shun, M. D.
3708 Bal dwi n Avenue, ' 2
EI Mont e, CA 91731
Ap r iI 30, 1991
Dear Dr . Chen:
Thank you f or your l et t er of Apr i l 11, 1991. I am pl eased t hat
you and your ot her exper t s agr ee wi t h t he val ue of mal ar i at her apy
f or t r eat i ng cancer .
Your suggest i on t hat we t r avel t o Chi na f or f ur t her di scussi on
pr esent s a di f f i cul t y. I t woul d mean r et ur ni ng t o Chi na a second
t i me, a shor t t i me l at er , t o exami ne t he pat i ent s bei ng t r eat ed.
The t r i p, as you know, i s a ver y l ong one and i s ver y expensi ve.
I t wi l l dr ai n f unds t hat can be used f or t he pr oj ect .
Dr . Hong- Shun Hua has pr ovi ded you wi t h t he pr ot ocol . As you
know, pat i ent s can have squamous cel l , adenocar ci noma, or
mel anoma. Vi si bl e t umor s such as nasophar yngeal cancer or
mel anoma, pal pabl e t umor s, or t ho~e seen on X- r ay ( such as i n t he
l ungs) enabl e us t o measur e t he r esul t s. The cancer shoul d be
i ncur abl e wi t h st andar d t r eat ment s such as sur ger y, r adi ot her apy,
or chemot her apy; t her ef or e, t her e i s no r i sk t o t he pat i ent s and
t her e i s t he possi bi l i t y of benef i t wi t h mal ar i at her apy. The
car e of a mal ar i a pat i ent i s wel l known t o you.
Dr . Hua can di scuss r esear ch f undi ng wi t h you,
benef i ci al ar r angement can be r eached. By mai l ,
we can exchange suf f i ci ent i nf or mat i on f or
t r eat ment .
and I am sur e a
phone, and FAX,
you t o st ar t
As you know, t her e i s i nt er est i n ot her l ocat i ons t o cooper at e i n
t hi s pr oj ect . We ar e obl i gat ed t o par t i ci pat e f i r st wi t h t hose
sci ent i st s who can st ar t t r eat ment on f our t o f i ve pat i ent s a f ew
weeks bef or e we t r avel t o Chi na, f or r easons st at ed above.
I hope pat i ent t r eat ment can begi n i mmedi at el y. Pl ease l et me
know i f you can do t hi s. When, t oget her , we ar e r eady t o pr esent
r esear ch r esul t s at a medi cal meet i ng i n t he uni t ed St at es, i t
wi l l be our pl easur e t o i nvi t e you and your col l eagues t o
par t i ci pat e her e i n t he pr esent at i on.
M. D. , Sc. D.
Hei ml i ch I nst i t ut e
cc: Er i c Ri ppel , Pr esi dent , The Ri ppel Foundat i on
Dr . J ohn Ci onci
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 5 2 0 0
513- 221- 0012 Apr i l 30, 1991
f ax 513- 221- <XXl 3
Hua Hong- Shun, M. D.
3708 Bal dwi n Avenue, 12
El Mont e, CA 91731
Dear Hong- Shun:
Pl ease send t he encl osed l et t er t o Guangzhou i f you appr ove of
i t . Cal l me ~o di scuss f undi ng bef or e you speak t o Guangzhou.
We must convi nce t hem t hat i t i s necessar y t o st ar t t r eat ment on
t he f i r st pat i ent s bef or e we t r avel t o Chi na.
Pl ease cal l when you have a chance.
M. D. , SC. D.
HJ H/ j d
Encl osur es
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Dear Dr . Hua:
Mar ch 27, 1991
Encl osed i s a semi - of f i ci al l et t er wr i t t en by t he vi ce
Di r ect or of t he Muni ci pal Heal t h &Ant i - epi demi c St at i on
of Guangzhou and t he di r ect or of Guangzhou Tumor Hospi t al .
Thi s i s t he r esul t af t er we had sever al meet i ngs.
Pl ease keep i n cont act . I n addi t i on t o l et t er and phone,
you may send FAX 862482 c/ o Dr . Wang Bao- chang.
Al so pl ease gi ve us your FAX number .
Si ncer el y,
Chen Xi ao- pi ng, M. D.
Li u Shu- kuo, M. D.
Vi ce Di r ect or
The Muni ci pal Heal t h &
Ant i - epi demi c St at i on of Guangzhou
23, 3r d Zongshan Rd.
Guangzhou 510080
Peopl e' s Republ i c of Chi na
Yu Chang- t ao, M. D.
Di r ect or
Guangzhou Tumor Hospi t al
Pr esi dent
The Hei ml i ch I Nst i t ut e
c/ o Hua Hong- shun, M. D.
3708 Bal dwi n Ave. #2
EI Mont e, CA 91731
Dear Dr . Hei ml i ch: Mar ch 26, 1991
The l et t er s and a packet of paper s on ' Mal ar i a- t her apy of
Cancer ' sent by Dr . Hua Hong- shun t o Dr . Chen Xi ao- pi nghave
been r ecei ved and st udi ed by us. We have i nvi t ed exper t s of
r el at ed f i el ds t o di scuss wi t h t hi s mat t er i n det ai l . As t o
t he pr obl ems ment i oned i n t hese l et t er s, we woul d l i ke t o
r epl y as f ol l ows:
1 We do i nt end t o par t i ci pat e i n t hi s ' Mal ar i a- t her apy of
Cancer " j oi nt pr oj ect .
2 The Muni ci pal Heal t h &Ant i - epi demi c St at i on of Guangzhou i s
r esponsi bl e f or t he pr event i on and t r eat ment of mal ar i a i n
t hi s di st r i ct . Accor di ng t o epi demi c i nvest i gat i on of
mal ar i a i n r ecent year s, t her e ar e sUf f i ci ent number of
mal ar i a vi vax pat i ent s avai l abl e t o ser ve f or bl ood
donat i on. Al so, we have exper i ence i n t r eat i ng mal ar i a
pat i ent s.
3 The epi demi c season of mal ar i a her e cover s most par t of t he
year , and wi l l basi cl y f asci l i t at e t he car r yi ng out of
t hi s r esear ch pr oj ect .
4 We woul d l i ke t o have f ur t her i nf or mat i on as t o:
what ki nd of t umor and pat i ent s of what st age shal l be
sel ect ed, how t o set t r eat ment gr oup and cont r ol gr oup,
number of pat i ent s needed, t he r esear ch f und et c.
We mi ght say, on one aspect , t hat we can r eadi l y sel ect donor
pat i ent s f or ar t i f i ci al l y i nduci ng mal ar i a. But we ar e not
qui t e cl ear about t he pr ot ocol and r equi r ement f or t umor t r eat ment .
So we wi sh t hat you and ot her r el at ed exper t s of your par t y
coul d vi si t Chi na t o di scuss t he f easi bi l i t y of our j oi nt r esear ch
and t he det ai l ed pr ot ocol . To our bel i ef , t he of f i ci al
or gani zat i ons, t he Guangzhou Muni ci pal Gover nment and Guangzhou
Mi ni st r y of Heal t h wi l l appr ove our pr oj ect , once we, t he
par t i ci pat i ng or gani zat i on and exper t sconvi nce t he pr oj ect
and appl y f or l ocal gover nment ' s appr oval .
Because by aski ng l ocal gover nment t o send you of f i ci al i nvi t at i on,
we shoul d go t hr ough many pr ocedur es and t hat i s t t me consumi ng,
so we woul d suggest t hat you woul d vi si t Chi na as t our i st s
f or gi vi ng l ect ur e and academi c exchange.
We woul d suppl y your expendi t ur e and make ar r angement f or your
st ay i n Guangzhou f or t wo days, not i ncl udi ng t he f l i ght
t i cket s.
Pl ease keep i n cont act wi t h Dr . Chen Xi ao- pi ng. We ar e l ooki ng
f or your vi si t and f or a pl easant and successf ul cooper at i on.
Si ncer el y,
Vi ce Di r ect or
Di r ect or
2 3 6 8 V I C T O R Y
P A R '{; ; N A Y
S U I T E 410
C I N C I N N A T I
O H I O
4 5 2 0 6
513- 22H X X J 2
fa x 513- 22H X l O 3
B e n e f i . g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
EI Mont e, CA 91731
Ap r iI 30, 1991
Dear Dr . Chen:
t r eat ment .
and I am sur e a
phone, and FAX,
you t o st ar t
M. D. , Sc. D.
Dr . J ohn Ci onci
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
2 3 6 8 V I C T O R Y
P A R K W 6 . Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
45206
51322H X X l 2
FAX: ( 513) 221- 0003
FACSI MI LE TRANSMI SSI ON COVER:
TO:
LOCATI ON:
FROM:
-:
RE:
NAME OF PERSON TRANSMI TTI NG:
(~
2 3 6 8 V I C T O R Y
P A R '{; ; N A Y
S U I T E 410
C I N C I N N A T I
O H I O
4 5 2 0 6
513- 22H X X J 2
fa x 513- 22H X l O 3
B e n e f i . g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
EI Mont e, CA 91731
Ap r iI 30, 1991
Dear Dr . Chen:
t r eat ment .
and I am sur e a
phone, and FAX,
you t o st ar t
M. D. , Sc. D.
Dr . J ohn Ci onci
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 5 2 0 0
513- 221- 0012 Apr i l 30, 1991
f ax 513- 221- <XXl 3
El Mont e, CA 91731
Dear Hong- Shun:
M. D. , SC. D.
HJ H/ j d
Encl osur es
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Dear Dr . Hua:
Mar ch 27, 1991
Encl osed i s a semi - of f i ci al l et t er wr i t t en by t he vi ce
Di r ect or of t he Muni ci pal Heal t h &Ant i - epi demi c St at i on
of Guangzhou and t he di r ect or of Guangzhou Tumor Hospi t al .
Thi s i s t he r esul t af t er we had sever al meet i ngs.
Pl ease keep i n cont act . I n addi t i on t o l et t er and phone,
you may send FAX 862482 c/ o Dr . Wang Bao- chang.
Al so pl ease gi ve us your FAX number .
Si ncer el y,
Chen Xi ao- pi ng, M. D.
Vi ce Di r ect or
The Muni ci pal Heal t h &
Ant i - epi demi c St at i on of Guangzhou
23, 3r d Zongshan Rd.
Guangzhou 510080
Peopl e' s Republ i c of Chi na
Di r ect or
Guangzhou Tumor Hospi t al
Pr esi dent
The Hei ml i ch I Nst i t ut e
c/ o Hua Hong- shun, M. D.
3708 Bal dwi n Ave. #2
EI Mont e, CA 91731
Dear Dr . Hei ml i ch: Mar ch 26, 1991
The l et t er s and a packet of paper s on ' Mal ar i a- t her apy of
Cancer ' sent by Dr . Hua Hong- shun t o Dr . Chen Xi ao- pi nghave
been r ecei ved and st udi ed by us. We have i nvi t ed exper t s of
r el at ed f i el ds t o di scuss wi t h t hi s mat t er i n det ai l . As t o
t he pr obl ems ment i oned i n t hese l et t er s, we woul d l i ke t o
r epl y as f ol l ows:
1 We do i nt end t o par t i ci pat e i n t hi s ' Mal ar i a- t her apy of
Cancer " j oi nt pr oj ect .
2 The Muni ci pal Heal t h &Ant i - epi demi c St at i on of Guangzhou i s
r esponsi bl e f or t he pr event i on and t r eat ment of mal ar i a i n
t hi s di st r i ct . Accor di ng t o epi demi c i nvest i gat i on of
mal ar i a i n r ecent year s, t her e ar e sUf f i ci ent number of
mal ar i a vi vax pat i ent s avai l abl e t o ser ve f or bl ood
donat i on. Al so, we have exper i ence i n t r eat i ng mal ar i a
pat i ent s.
3 The epi demi c season of mal ar i a her e cover s most par t of t he
year , and wi l l basi cl y f asci l i t at e t he car r yi ng out of
t hi s r esear ch pr oj ect .
4 We woul d l i ke t o have f ur t her i nf or mat i on as t o:
what ki nd of t umor and pat i ent s of what st age shal l be
sel ect ed, how t o set t r eat ment gr oup and cont r ol gr oup,
number of pat i ent s needed, t he r esear ch f und et c.
We mi ght say, on one aspect , t hat we can r eadi l y sel ect donor
pat i ent s f or ar t i f i ci al l y i nduci ng mal ar i a. But we ar e not
qui t e cl ear about t he pr ot ocol and r equi r ement f or t umor t r eat ment .
So we wi sh t hat you and ot her r el at ed exper t s of your par t y
coul d vi si t Chi na t o di scuss t he f easi bi l i t y of our j oi nt r esear ch
and t he det ai l ed pr ot ocol . To our bel i ef , t he of f i ci al
or gani zat i ons, t he Guangzhou Muni ci pal Gover nment and Guangzhou
Mi ni st r y of Heal t h wi l l appr ove our pr oj ect , once we, t he
par t i ci pat i ng or gani zat i on and exper t sconvi nce t he pr oj ect
and appl y f or l ocal gover nment ' s appr oval .
Because by aski ng l ocal gover nment t o send you of f i ci al i nvi t at i on,
we shoul d go t hr ough many pr ocedur es and t hat i s t t me consumi ng,
so we woul d suggest t hat you woul d vi si t Chi na as t our i st s
f or gi vi ng l ect ur e and academi c exchange.
We woul d suppl y your expendi t ur e and make ar r angement f or your
st ay i n Guangzhou f or t wo days, not i ncl udi ng t he f l i ght
t i cket s.
Pl ease keep i n cont act wi t h Dr . Chen Xi ao- pi ng. We ar e l ooki ng
f or your vi si t and f or a pl easant and successf ul cooper at i on.
Si ncer el y,
Vi ce Di r ect or
Di r ect or
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 5 2 0 0
513- 221- 0012 Apr i l 30, 1991
f ax 513- 221- <XXl 3
El Mont e, CA 91731
Dear Hong- Shun:
M. D. , SC. D.
HJ H/ j d
Encl osur es
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
AGREEMENT FOR J OI NT PROJ ECT

" MALARI ATHERAPY OF CANCER"
BETWEEN
J I ANGSU PROVI NCE PEOPLE' S HOSPI TAL
AND 81 st.HOSPI TAL
AND
FANNI E E. RI PPEL FOUNDATI ON
AND THE HEI MLI CH I NSTI TUTE
Summar y
Bot h si des hol d t hat i t i s benef i ci al t o pat i ent s t o expl or e
mal ar i at her apy f or cancer s and t o assess t he cl i ni cal ef f ect i n
t r eat i ng cancer as compar ed t o ot her convent i onal met hods.
The pr i mar y obj ect i ve of t hi s pr oj ect i s t o per f or m a cl i ni cal
t r i al by means of bl ood t r ansf er met hod so as t o demonst r at e t hat
t he t her apy coul d be appl i ed t o cancer wi t h no har m, or onl y wi t h
a l i mi t ed amount of si de ef f ect s, and t o assess t he ef f ect i veness
of t hi s t r eat ment .
Col l abor at i ve Covenant enact ed by J i angsu Pr ovi nce Peopl e' s
Hospi t al i n t hi s act i on by Dr . Zhao Zhi - Quan, t he 81 st . Hospi t al ,
and t he Fanni e E. Ri ppel Foundat i on r epr esent ed i n t hi s act i on by
t he pr esi dent , Mr . Er i c R. Ri ppel , and t he Hei ml i ch I nst i t ut e by
Dr . Henr y J . Hei ml i ch, who her eaf t er f or t he pur pose of t hi s
i nst r ument ar e desi gnat ed as " J i angsu" f or t he f i r st par t y and as
" The Hei ml i ch I nst i t ut e" f or t he second par t y i n accor dance wi t h
t he f ol l owi ng:
PROMISES
On " J i angsu" par t :
To desi gnat e Dr . Wang Mi ng- Xi u and Dr . Ma Yong- Quan as pr i nci pal
sci ent i st s i n char ge of t he pr oj ect .
To cont r i but e t he ser vi ces of t he human r esour ces wi t h whi ch t he
hospi t al s now oper at e, f or t he dur at i on and compl et i on of t he
pr esent covenant .
To compl y wi t h al l t he medi cal , t echni cal and et hi cal
r equi r ement s t hat det er mi ne t he st andar ds appl i cabl e t o t hi s
pr ot ocol . I deal l y, mal ar i at her apy shoul d be car r i ed out f or a
mi ni mum of 30 days, pr ef er abl y 45, i f t ol er at ed by t he pat i ent .
Subsequent addi t i onal cour ses may be i ndi cat ed.
To send wr i t t en r epor t s, i ncl udi ng t emper at ur e char t s, t o t he
Hei ml i ch I nst i t ut e at st ar t of t r eat ment , end of t r eat ment , t hr ee
mont hs af t er compl et i on of t r eat ment , and t hr ee mont hs t her eaf t er .
Si nce changes i n t umor si ze and qual i t y ar e essent i al t o t he st udy,
whenever possi bl e, vi si bl e l esi ons wi l l be document ed by
phot ogr aphs, pal pabl e t umor s and x- r ay f i ndi ngs by sket ches on t he
di agr ams pr ovi ded i n t he pr ot ocol , and measur ement s wi l l be ci t ed.
The si x mont h f ol l ow- up af t er t r eat ment wi l l i nsur e t hat pat i ent
sel ect i on has been based on pat i ent s i n f avor abl e condi t i on f or
t r eat ment . Shor t er f ol l ow- up wi l l be of l esser val ue. I t i s
under st ood t hat an occasi onal pat i ent may sur vi ve onl y f i ve mont hs
but wi l l st i l l war r ant i ncl usi on i n t he ser i es.
To submi t r epor t s t o t he Hei ml i ch I nst i t ut e on al l pat i ent s t o be
i ncl uded i n t he ser i es, who have al r eady r ecei ved mal ar i at her apy
1
2
pr i or t o si gni ng.
On " The Hei ml i ch I nst i t ut e" par t :
To desi gnat e Dr . Henr y J . Hei ml i ch as pr i nci pal i nvest i gat or
r esponsi bl e f or t he i nvest i gat i on.
To desi gnat e Dr . Hong- Shun Hua as coor di nat or .
To cont r i but e t he necessar y medi cal , t echni cal and r el at ed
i nf or mat i on f or t he i mpl ement at i on of t he t her apy pr ocedur es.
To suppor t a f und of USD 2, 000. 00 f or each mal ar i at her apy- t r eat ed
pat i ent af t er t r eat ment and f ol l ow- up cour se of si x mont hs and
submi ssi on of pat i ent r ecor ds and r epor t s.
I n vi ew of i ni t i al expenses, USD 4, 000. 00 wi l l be pai d wi t hi n one
mont h of t he si gni ng of t hi s Agr eement . Thi s amount wi l l be
appl i ed i n advance agai nst t he f i r st t wo pat i ent s pr ovi ded wi t h a
f ul l cour se of mal ar i at her apy, who wi l l subsequent l y be f ol l owed
f or t he agr eed upon si x mont hs f ol l ow- up. When t he t wo si x- mont h
r epor t s have been del i ver ed, an addi t i onal USD 4, 000. 00 wi l l be
sent as an advance on t he next t wo pat i ent s, who have compl et ed a
f ul l cour se of mal ar i at her apy. Ther eaf t er , payment wi l l be made
f or each subsequent pat i ent af t er t he submi ssi on of t he si x mont h
f ol l ow- up r epor t .
On t he par t of bot h par t i es:
Up t o December 31, 1992, t en ( 10) cancer pat i ent s wi l l be t r eat ed
under cl ose i nvest i gat i on wi t h compr ehensi ve r ecor ds.
An assessment mi ght be pr ocessed t o war r ant f ur t her r esear ch
pr ocedur es.
About t he r esul t s:
The par t i es agr ee t hat t he pr ogr ess and r esul t s obt ai ned f r om
t hi s i nvest i gat i on cannot be ut i l i zed uni l at er al l y by any of t he
par t i es.
These pr omi ses of col l abor at i on i mpl ement a medi cal r esear ch
pr ot ocol ent i t l ed " Mal ar i at her apy of cancer " i n Nanj i ng, J i angsu,
Peopl e' s Republ i c of Chi na on t he t wel f t h day of t he mont h of
November i n t he year 1991.
Zhao Zhi - Quan
Vi ce Pr esi dent ,
J i angsu Pr ovi nce
Peopl e' s Hospi t al
Er i c R. Ri ppel ,
Pr esi dent
The Fanni e E. Ri ppel
Foundat i on
Ma Yonq- Quan
81 st Hospi t al
Honor ar y wi t nesses:
Mr . Li u Hong- Qi ,
Di r ect or Gener al ,
Heal t h Depar t ment , J i angsu,
P. R. C.
3
Henr y J . Hei ml i ch
Pr esi dent
The Hei ml i ch I nst i t ut e
Dr . J ohn L. ci onci
Dat e of Si gni ng
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
S UMMARY
Bo t h s i d e s h o l d t h a t i t i s b e n e f i c i a l t o p a t i e n t s t o e x p l o r e
ma l a r i a t h e r a p y f o r c a n c e r s a n d t o a s s e s s t h e c l i n i c a l e f f e c t i n
t r e a t i n g c a n c e r a s c o mp a r e d t o o t h e r c o n v e n t i o n a l me t h o d s .
T h e p r i ma r y o b j e c t i v e o f t h i s p r o j e c t i s t o p e r f o r . a c l i n i c a l t r i a l b y
me a n s o f b l o o d t r a n s f e r me t h o d s o a s t o d e mo n s t r a t e t h a t t h e t h e r a p y
c o u l d b e a p p l i e d t o c a n c e r wi t h n o h a r m, o r o n l y wi t h a l i mi t e d a mo u n t
o f s i d e e f f e c t s , a n d t o a s s e s s t h e e f f e c t i v e n e s s o f t h i s t r e a t me n t .
Co l l a b o r a t i v e c o v e n a n t e n a c t e d b y t h e Mu n i c i p a l I n s t i t u t e f o r
P r e v e n t i v e Me d i c i n e o f Gu a n g z h o u i n t h i s a c t i o n b y P r e s i d e n t Xi a o Bi n -
Qu a n a n d Dr . Ch e n Xi a o - P i n g , Gu a n g z h o u Y i s h o u Ho s p i t a l b y Vi c e
P r e s i d e n t L i Na i - Du a n d T h e He i ml i c h I n s t i t u t e b y P r e s i d e n t He n r y J .
He i ml i c h , wh o h e r e a f t e r f o r t h e p u r p o s e o f t h i s i n s t r u me n t a r e
d e s i g n a t e d a s u Gu a n g z h o u
u
f o r t h e f i r s t p a r t y a n d a s u T h e He i ml i c h
I n s t i t u t e " f o r t h e s e c o n d p a r t y i n a c c o r d a n c e wi t h t h e f o l l o wi n g :
P ROMI S E S
ON " GUANGZHOO" P ART :
T o d e s i g n a t e Dr . Ch e n Xi a o - P i n g a s p r i n c i p a l i n v e s t i g a t o r i n c h a r g e o f
t h e p r o j e c t .
T o d e s i g n a t e Dr . L i u S h u - Gu o , Dr . L i Na i - Du , Dr . L u Y u e - He n a n d Dr .
Xi a o Bi n - Qu a n a s c o - i n v e s t i g a t o r s .
T o c o n t r i b u t e t h e s e r v i c e s o f t h e h u ma n r e s o u r c e s a n d e q u i me n t s wi t h
wh i c h t h e i n s t i t u t e a n d t h e h o s t i p a l n o w o p e r a t e , f o r t h e d u r a t i o n a n d
c o mp l e t i o n o f t h e p r e s e n t c o v e n a n t .
T o c o mp l y wi t h a l l t h e me d i c a l . t e c h n i c a l a n d e t h i c a l r e q u i r e me n t t h a t
d e t e r mi n e t h e s t a n d a r d s a p p l i c a b l e t o t h i s p r o t o c o l . I d e a l l y .
ma l a r i a t h e r a p y s h o u l d b e c a r r i e d o u t f o r a mi n i mu m o f t e n ( l O) p a r o x y s ms
o f h y p e r t h e r mi a , ! , S u b s e p u e n t a d d i t i o n a l c o u r s e s may b e i n d i c a t e d .
T o s e n d wr i t t e n r e p o r t s , i n c l u d i n g t e mp e r a t u r e c h a r t s , t o t h e He i ml i c h
I n s t i t u t e a t s t a r t o f t r e a t me n t , e n d o f t r e a t me n t , t h r e e . o n t h s a f t e r
c o mp l e t i o n o f t r e a t me n t , a n d t h r e e mo n t h s t h e r e a f t e r . S i n c e c h a n g e i n
t u mo r s i z e a n d q u a l i t y a r e e s s e n t i a l t o t h e s t u d y , wh e n e v e r p o s s i b l e ,
v i s i b l e l e s i o n s wi l l b e d o c u me n t e d b y p h o t o g r a p h s , p a l p a b l e t u mo r s a n d
X- r a y f i n d i n g s b y s k e t c h e s o n t h e d i a g r a ms p r o v i d e d i n t h e p r o t o c o l ,
a n d me a s u r e me n t s wi l l b e c i t e d . T h e s i x mo n t h f o l l o w- u p a f t e r
t r e a t me n t wi l l i n s u r e t h a t p a t i e n t s e l e c t i o n h a s b e e n b a s e d o n p a t i e n t s
i n f a v o r a b l e c o n d i t i o n f o r t r e a t me n t . S h o r t e r f o l l o w- u p wi l l b e o f
l e s s e r value, I t i s u n d e r s t o o d t h a t a n o c c a s i o n a l p a t i e n t ! ' i may s u r v i v e
o n l y " f o u r o ' t ~ f i v e mo n t h s b u t wi l l s t i l l wa r r a n t i n c I u s i o n i n t h e
s e r i e s .
T o s u b mi t r e p o r t s t o t h e He i ml i c h I n s t i t u t e o n a l l p a t i e n t s t o b e
i n c l u d e d i n t h e s e r i e s , wh o h a v e a l r e a d y r e c e i v e d ma l a r i a t h e r a p y p r i o r
t o s i g n i n g .
ON " T HE HE I ML I CH I NS T I T UT E " P ART :
T o d e s i g n a t e Dr . He n r y J . He i ml i c h a s p r i n c i p a l i n v e s t i g a t o r
r e s p o n s i b l e f o r t h e i n v e s t i g a t i o n .
T o d e s i g n a t e Dr . Hu a Ho n g - S h u n a s c o o r d i n a t o r .
T o c o n t r i b u t e t h e n e c e s s a r y me d i c a l , t e c h n i c a l a n d r e l a t e d i n f o r ma t i o n
f o r t h e i mp l e me n t a t i o n o f t h e t h e r a p y p r o c e d u r e s .
At t h e f i r s t 1 0 c a s e s , t o s u p p o r t a f u n d o f u s n 3 0 0 0 f o r e a c h
ma l a r i a t h e r a p y - t r e a t e d p a t i e n t a f t e r t r e a t me n t a n d f o l l o w- u p c o u r s e o f
s i x mo n t h s a n d s u b mi s s i o n o f p a t i e n t r e c o r d s a n d r e p o r t s . Af t e r
t h a t , t o s u p p o r t US D 1 5 0 0 f o r e a c h c a s e .
I n . v i e w o f i n i t i a l e x p e n s e s , DS D 6 0 0 0 wi l l b e p a i d wi t h i n o n e mo n t h o f
t h e s i g n i n g o f t h i s a g r e e me n t . T h i s a mo u n t wi l l b e a p p l i e d i n a d v a n c e
a g a i n s t t h e f i r s t t wo p a t i e n t s p r o v i d e d wi t h a f u l l c o u r s e o f
ma l a r i a t h e r a p y , wh o wi l l s u b s e q u e n t l y b e f o l l o we d f o r t h e a g r e e d u p o n
s i x mo n t h s f o l l o w- u p . T h e r e a f t e r , P a y me n t wi l l b e ma d e f o r e a c h
s u b s e q u e n t p a t i e n t a f t e r t h e s u b mi s s i o n o f t h e s i x mo n t h f o l l o w- u p
r e p o r t s . I f n e c e s s a r y , o n e p a t i e n t r e c e i v e t h e s e c o n d c o u r s ~ o f
ma l a r i a t h e r a p y a c c o r d i n g t o a b o v e r e q u i r e me n t , t h e p a y me n t c a n b e v'
c o n s i d e r e d a s f o r t wo c a s e s .
ON T HE P ART OF BOT H P ART I E S :
u p t o Ka r c h 3 0 , 1 9 9 3 , t e n ( I O) c a n c e r p a t i e n t s wi l l b e t r e a t e d u n d e r
c l o s e i n v e s t i g a t i o n wi t h c o mp r e h e n s i v e r e c o r d s .
An a s s e s s me n t mi g h t b e p r o c e s s e d t o wa r r a n t f u r t h e r r e s e a r c h p r o c e d u r e s .
ABOUT T HE RE S UL T :
T h e p a r t i e s a g r e e t h a t t h e p r o g r e s s a n d r e s u l t s o b t a i n e d f r o m t h i s
i n v e s t i g a t i o n c a n n o t b e u t i l i z e d u n i l a t e r a l l y b y a n y o f t h e p a r t i e s o r
c a n n o t b e u t i l i z e d u n i l a t e r a l l y b y any o f t h e p a r t i e s wi t h o u t t h e
a g r e e me n t o f b o t h p a r t i e s .
T h i s a g r e e me n t o f c o l l a b o r a t i o n wr i t t e n i n Ch i n e s e a n d E n g l i s h
l a n g u a g e s e a c h o f wh i c h h a s t wo c o p i e s i mp l e me n t s a me d i c a l r e s e a r c h
p r o t o c o l e n t i t l e d " ma l a r i a t h e r a p y o f c a n c e r " i n Gu a n g z h o u , P e o p l e ' s
Re p u b l i c o f Ch i n a o n t h e f i f t e e n t h d a y o f t h e mo n t h o f J u n e i n t h e 1 9 9 2 .
2
LIST OF PERSONNEL IN CHARGE OF "MALARIATHERAPY OF CANCER"
PROJECT IN CHINA
LU WENMIN
DIRECTOR, OFFICE OF INTERNATIONAL COMMUNICATION
HEALTH DEPARTMENT, JWANGSU PROVINCE
42 ZHONG YANG ROAD
NANJING 210008 PHONE
P R CHINA FAX
ZHAO ZHIQUAN ,M.D.
VICE PRESIDENT
THE PEOPLE's HOSPITAL OF JIANGSU PROVINCE
300 GUANGZROU ROAD
NANJING 210024 PHONE 86-25-537024
MA YONG QUAN ,M.D.
HEAD OF MEDICAL ONCOLOGY
Y ~ l S T HOSPITAL
Y YANG GONG JING
NANJING
CHEN XIAOPING, M.D.
VISITING DOCTOR
PHONE 86-25-648090 EXT344
THE MUNICIPAL HEALTH &ANTI-EPIDEMIC STATION OF GUANGZHOU
23 THIRD ZHONG SHAN ROAD
GUANGZHOU 510080 PHONE 86-20-765255
XIAO BIN QUAN ,M.D.
DIRECTOR
THE MUNICIIAL HEALTH & ANTI-EPIDEMIC STATION OF GUANGZHOU
23 THIRD ZHONGSHAN ROAD . ,
GUANGZHOU .510080
PHONE 86-20-765255
r
2368 VICTORY
PAR'(:;NAY
SUITE410
CINCINNATI
OHIO
45200
513-221-r0J2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
March 24, 1993
Professor Qi Qi Chen
Vice Mayor of Guangzhou
Canton Medical College
Guangzhou, 510182, China
Dear Qi Qi Chen:
Thank you so very much for being my host at the elegant
banquet. I enjoyed being able to meet with you.
I am afraid that I am getting old. It had been my intention
to thank you in person for your lovely letter and picture that
I received at Christmas time. After you left, I realized I
had not done so. Please accept now my appreciation for your
thoughtfulness.
When you come to the united states again,
like you to be our guest in cincinnati.
possible, I would travel to meet you and
dinner guest.
enry J. M.D., Sc.D.
Presiden
Heimlich Institute
I would very much
If that is not
ask you to be my
The Municipal Institute For Preventive Medicine of Guangzhou
.p fliI r-ffi .p lli
510080
No, 23, The 3rd Zhongshan Road. Guangzhou
The People's Republic of China
rt! rili : 7771103 ( .(,?,t;1 )
Henry J. Heimlich, H.D., Sc.D.
Heimlich Institute Foundation, Inc.
2368 Victory Parkway
Cincinnati , Ohio 45206
Dear Dr. Heimlich:
Tel: 7774103 (ext)
April 8, 1993
we have considered thoroughly the use of malariatherapy for treating HI\-
infected patients. Malariatherapy has proven to be a safe and effective method
for treating cancer . There is every reason to be cominced that it can be
effective and safe for treating AIDS. we are ready to provide malariatherapy to
HIV positive patients at this time.
My background experience with AIDS includes: I have worked in the field of
infectious diseases for thirteen years and special ill the field of AIDS for
years. I have extensive and deep knowledge on AIDS in the respests of eteology,
epidemiOlogy and clinics., Four years ago, I first proposed the hypothesis of HIV
orlgenating from human spirm genes in an international conference. In my
laboratory, I can do many things on AIDS including HI\ culture.
The scientific evidence we possess of the possibility of increasing production
of immune substances is sound. The sho\o;ing the survival of children
who have AIDS and rnalarib, hile 35% of those with AIDS alone died is \er)
convincing.
It is obviously not possible to predict what our findings will be from our
research studies. To not attempt malariathelapy, however, leaves AIDS patients
with no possibility of effective treatment.
Sincerely yours,

The rluuicipal Health and Anti-epidemic St"ation of Guangzhou,
No.23 , 3rd Zhong shan Road, Guangzhou 510080, P.R. China
J. /VI/), Sci).

2-3Cg Su.l:6-. !fl()
J oL t!-.J"2-tJ6
71)y tkvr tid.
J reW-vd 0 ttrrMUL'x Jl ( Ldftr) k;f
b!f Pr. }ltu- tftY(j5kun tJ17 Apr. 6/ -;6b; ) -:tii
lAX E r restorH- . Sf)) >ent
i;tr fr rJ&U ?! J WtncU L& 7T
l6 r '4 twA ryj
./dt.ir ahui (f nu-rrd.e,.. tt:. CffrrdJ

u{ <nQct/ ?7
UfIZb
c!f =&;-- -;t-ned -tiu 71.-X7J
rf
/;;;td 1nK'- U (ftrv Sture- ok r
-t;1u:- &'f ;" !Jew 'frf
<P IN i:Hi 'ft 111-"-: llIr23-<;-
510080
rl! 7774103 ( ,(Mil )
Henry J. Heimlich, MD. ScD.
President, Heimlich Institute
2368 Victory Parkway, Suite 410
Cincinnati, Ohio 45206
My dear friend, Dr. HeimlIch:
No. 23, The 3rd Zhongshan Road. Guangzhou
Tel: 7774103 (ext)
19, 1993
We are applying for the approval of the government for the use of malariatherapy
for HIV positive patients. But the situation of using this therapy for this
purpose is very different from that for treating cancer patients. The first thing
is that HIV carriers are verJ in Guangdong Plo\ince, we have onh a fe' cases
on hand. The secnod thing is that none of the cases to recei\e the therapy
because they have no any symptoms (just HI\' POSItive) and theJ want to keep the
secret because of the AIDS discrImination in COlna. If want to persuade them to
receive the therapy, we have to paJ all medIcal fee and accomodations for them
(all the patients live in the other city, not in Guangzhou). The thIrd thing is
that none of the hospitals willing to cooperate with us except we are able to give
them an enough quantity of muneJ for all kinds of relative use. The reasons
that the AIDS-phobia IS verJ severe in China even among the medical of
hospitals and not onlJ this is the first time of malariathelapj for AIDS, but also
the first time of am therapJ for AIDS in Guangdong Province.
Besides of the above reasons, the another important thIng is that we must first
get the power to culture HIV, just as you said, the observation of HIV culture
result is essentIal for this research. This thing is under the control of our
Cen ral Government (like the Federal Govel1lBlel t of [SA). But borne office's of the
local go\ernment saId that if GSA give filillncial support to train a doctor of ours
in the special field of AIDS in USA for a bholL telm buch ab 3 months, it is a
good reason for us to get the power for dnd uther relati\e items
(herewith the budget of malar iatherapy for the fir t two Hn' positive patients).
lours sincerel> cbr
Dr. Chen liaopins
The Municipal Health and Anti-epidemi Stalon of Guangzhou.
io. 23, 3rd Zhongshan Road, Guangzhou 510080
P. R. China
cc: Dr. Hua Hong Shun
i
The Municipal Institute For Preventive Medicine of Guanozhou
c
* 00 rffl * lll= Blf23-l}
510080
i-l! 5 :
No. 23, The 3rd Zhongshan Road . Guangzhou
The People' s Republic of China
Tel : 7774103 (ext)
Budget for the First Two Cases (USD)
Ite ms
1 Case 2 Cases
Hospitalization
1500 3000
Routine treatment and Nursing 1500 3000
Special Medicine
(Albumin. Blood Tr-ansfusion. etal) 1000 2000
Medical Workers Reward
for the contact with HIV 1500 3000
Articles for One Time Use 1000 2000
Special Tests
(Western Blot.HIV Culture. CD4. etal) 1000 2000
Research Activities 1000 2000
Ward Equipment 1500 3000
Total 10000 20000
If possible. additional 5000 USD for one doctor training in
USA for 3 months.
;
j -c.-<- ;. .Y._ / P9.3
f,12/'i 3 c,'
at /,JAi /II. . /I -I; "/Lu-e.A v- L . .d C1 !>-er,"1 -Dr.
IJ-< :a if"" .-
I/-< -/, 'IY'-f! .4 t-...='-o / J...4-.---d F /l-)q is' Ij-i.. ..
"" L ,; l : (,t {l I j( 1::'.-_-J /1 ! . '-t.-< v-<-J t:t. I'I.--V?-t-<..; o{l r:-t.y, c::..-( , .q .
/H t-f/I v <: j t <r.'.? 5/ tr ifZ> -c'lA---.d tL-crt ("-if p-t. . .,.,. . .)I/ 7i -J.-<<-.J.

-1-< <'H.4 . Jay . ;;'lY<.1 . S. . ztCl- _
3
tH
) ': ' \ t-c.'1- ,cv" . .cA.. JI-v.. J"\..<r( t<.fl-c/")--c! I elY -jrt. ....... tLd-' " '
')" . { {. .-I.e- <N " I;.L.", .t-
.Vi t"l. h> 'l . t'or-i- (J . ,.A./'" - . (J
.4".1' " .. vi'" b>'-ty -likd- .;J d,,, ""--l,"'--.....J-p "t1f'r.u'.E;.- . ,
a" n,- lit" (-1./ /'" ZU": I; . .4"'7 "'-'t.L "j":L..- di(f<A<-J rfJM"> :"':,.{Y). f,,27id;
Il'J "-"< '(1-1' ';<>- 1..(.0-<' F-:..c. ",-,,"d M /l"" . . 41 .,(--e. - .
jr,.rrrc
J
( , ?c.--."-;-.-:(. ... f ' i<.. di:',(!I>j
t't 'H".c;>{ r"-'-<- . a4-6 ... .... a;u ?v-r:;-..J-t."';-.,{ a./; -(..",./
" / {_ ifltl-.- 41: 4'"0 (-{(ti("; )/".?tiZZL:'l; . dJ-Jl<! {l/ 'f)1
'I - 1 ;/ ( ()
(7 db 6 . '/u-tf./C-Ad , // 1:"'-;;""7' PAi"-' It..
/(rfdIJ (.1 , ,{ ti. c:/, ( Iff vii:; IflZZ; .. : [ 1
1
.(..e.L( ,{ ..-l>"" .' (.:.r . .l."') <-'i.7""1.... .i
h
r-
,/ .-/ . .. ."1 ' .. 'v_:7;"
(.';> (l -<1 -t. . )1&..<. 'c-<-"f ;tt,nH..,,; ()I. '-t."' ..;{-('.(J /. (..1 ()j./I,t4-()-v---f" c..I- .-
' r" d .<L);,k- (t , /"1A.t, .;;.,..u ..A..c .... .(::;C:tt- ,a...(-A-4<---'L-I- /.-. i r ..J r . "o!..
,,' - .- ...........-z. .1 _. -ur , . - '
. a
. ",(/j', -,vv . 14! p-'1-Cl--v---'d<4 -f)/].-c--a-y --i!.-.U-U1.-7
(I . cr l VJ 0 .<.::, , Ut- 1ic.( . .(.-"-(..77'u."" -:'} e.e.-..J,d 0(
ron ,,( /'.' .0-6" '/ k '-' 1/(0,.,." 6-.4-, .a:.::r --?-tA:-;:-
'1(:; .. c{-<--- 0 ..... 7 HI V (-r) F'i.. ....l; ,?iCi.-c.-r ..
;{.i> l :'i\ '''' ( ct.;-c..t;-v- to-d .... ,t.{, ::>- ,a n, _ ,:. ':> ",- ..
I " V r';l p" /
,e)./ /I1.I."""-II,,,-f-.;( tf /JI[)S ;;""-'-o{ t<!.-e., J ... ,....&.t;...:t. Jt.JI"l.-<-..to(f!-) -o; .. ,, ... t.-<.
;tiL--. ... "c/l ..t-.,t," t,;v{ iJ. c...t.; to C.l-?--r--h--t-- ti{-C.' ltV, 7AAf- tb- 17
,..tl-l )10 t .rt )ll.'(,fAj-0
.. ) :a,'1 .. :tIv.d . .JJ.-tl -l7tJu. "..d-t..L .. "') ... ... ;-.!t,)." .. /:.J;/
.
(1 ' 1 ,d ?\--H //APr 0

L Ll1.- ])y, k
Daar Dr Hua :
August. 24,1993
1 have receivect tbe wired amount USD 10,000
from the HeiMlich Institute, I sent a letter informing Dr. He i mlich
that we shall finish the first 10 cases within this ;year
As to AIDS project, we do agree to have the sponsored fung provided in
separate installments. We would like to know that the sponsored
amount will be USD 10,000 for each case, because our budget is
proposed according to exact expenditures. Once the fund project
is we could start the treatment.
As I have mentioned in a previous letter, the hE.!altl1 department hag
already giver us oral approval, that once we have solved the fund
problem, we CQuid start treatment and it would be not necessary
to wait for the written approval. Because we have malaria-
therapy experience about two years, we could start the treatment.
the H1V infected patients, we observe and record mainly
the immunological and some clinical data J
as T lymph cells ( CD3, CD4, CDS), 19G, 19M, IgA, H1V antibody
and antigen titration ( because it is demonstrated that HIV in
HiV infected patient could not be irradicated by malariatherapy
we HIV culture when it is
We hope that we could finish treatment of 10 cancer patients and 2
HIV infected pat1ents within this year.
with our jOint effort I we hope that we could get succe5S.
S 1 l"lcercly,
Chen M.D.
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
P A R ~ A Y
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
September 2, 1993
Dr. Chen Xiao-Ping
The Municipal Health and Anti-Epidemic
No. 23, The 3rd Zhongshan Road
Guangzhou, 510080
China
Dear Dr. Chen:
I understand verbal approval has been given the HIV (AIDS)
research project by the Health Department. We hope to study
10 patients in this study. Please send us their written
approval as soon as you receive it.
The final protocol, candidate selection criteria, report and
consent forms are enclosed. You should have received earlier
drafts from Dr. Hua that you can replace with these.
Dr. Heimlich sends his best to you, Dr . Chen, his son.
Sincerely,
INFORMED CONSENT
TITLE OF RESEARCH STUDY:
INDUCED MALARIA as THERAPY for HIV INFECTION
Sponsor: This research study is being funded by The Heimlich
Institute Foundation, Inc. Dr. Chen Xiao Ping and Dr.
Henry Heimlich are the Co-Principal Investigators.
Neither the Heimlich Institute Foundation, Inc. nor Dr.
Henry Heimlich practice medicine. Their interest in this
project is solely in evaluation of scientific results.
Medical care is provided solely by physicians of the
country in which treatment takes place.
INTRODUCTION
The increasing incidence and the devastating mortality and
morbidity of human immunodeficiency virus (HIV) infection have been
matched by intense scientific efforts aimed at finding a means to
help those infected with HIV and prevent its spread.
PURPOSE OF STUDY
The purpose of this study is to assess the effectiveness and safety
of Induced Malaria Therapy (IMT). It is hoped that IMT will cause
a sUbstantial reduction in the body's HIV viral load and allow
improved immune function. Improvement in immune function may
demonstrate itself by beneficial change in CD4 cell numbers, and
other monitored markers of immune system function.
DURATION OF STUDY
The duration of the study will be unlimited. You will be required
to stay in the hospital during the malarial phase of treatment, and
to make appropriate visits to the physician for appropriate follow-
up.
STUDY PROCEDURE
You will undergo a medical history and physical examination at
study entry. Women of childbearing potential will be tested for
pregnancy.
Natural infusion of malaria parasites will be administered on day
one. Blood tests will be performed prior to starting treatment:
base line, weekly during febrile response to malaria and one, three
and six months after antimalarial treatment has begun.
You may withdraw from the study at any time without jeopardizing
your future medical care or possible involvement in subsequent
clinical studies.
Your participation may be terminated by the researchers under these
circumstances:
1. Deteriorating health or other conditions that might make
continued participation detrimental to your health.
2. Failure to follow treatment protocol.
3. Decision by the investigators to stop the study on
medical grounds.
4. Decision to change your anti-retroviral regimen.
RISKS AND DISCOMFORTS
You understand and acknowledge that Induced Malaria Therapy in the
treatment of HIV will only be used in a very limited number of
human beings for evaluation of treatment of symptoms from HIV /AIDS.
There may be discomfort from the infusion of Induced Malaria
Therapy and the blood draws. Such discomfort may include pain from
the needlestick and/or bruising. You further understand that there
is a risk of adverse side effects or complications as a result of
you receiving treatment. such adverse side effects or
complications may include, but are not necessarily limited to the
following: fever, chills, fatigue, nausea, vomiting, headache,
flushing, shortness of breath, tightness of the chest, back pain,
muscle aches, sweating, fall in blood pressure, rash, joint pain,
muscle weakness, and acute allergic reaction (which could on rare
occasions be fatal). There is also a possibility that treatment
with Induced Malaria Therapy may accelerate your HIV disease
condition. The potential risks of malaria include, but are not
limited to ruptured spleen and death.
POTENTIAL BENEFITS
By signing this document, you understand that
investigators do not guarantee, represent, or
treatment with Induced Malaria Therapy may stop
progress or recurrence of symptoms of AIDS or ARC.
the research
warrant that
or retard the
The investigators cannot promise that your participation in this
research study will guarantee any direct or immediate benefit to
you. However, the Induced Malaria Therapy you receive may benefit
you by elevating the total CD4 cell population and/or reduce your
HIV viral load. It is hoped that the knowledge gained from this
study will be of benefit to others in the future.
OTHER INFORMATION
In case of any medical problems, side effects or other reactions
the patient should contact his or her primary care physician for
treatment at the following number:
( )-- ----
If it is believed the problem is related to the study, contact the
study coordinator at:
You realize that the administration of this agent is being done as
a pilot study for medical research and there is no commitment by
the Principal investigator to provide access to this modality in
the future.
POLICY REGARDING PREGNANCY and CONTRACEPTIVE
You understand that if you are a woman of childbearing age, you
will be admitted to the study only if you are not pregnant and if
you agree to use a barrier contraceptive or an effective means of
birth control for the duration of the study. If you should become
pregnant while on this study, you must inform the investigator
immediately so that you can be . withdrawn from the study. You
understand that all participants should use barrier contraceptive
methods for the duration of the study.
CONFIDENTIALITY
You understand that all information will be held confidential and
will not be released without your written permission. Furthermore,
you understand that your records and results will not be identified
in any publications as pertaining to you specifically. You will be
identified only by a code number for the purposes of the study,
known only to study personnel. You understand that you will also
be giving consent for the Principle Investigator to review your
medical records as may be necessary for the purpose of this study.
CONSENT
You understand that you have the right to request the Principle
Investigator and/or your physician to answer any and all questions
you might have concerning this therapy at any time prior to or
during the course of the study. You understand that you have the
absolute right to terminate your participation in this study at any
point during its course.
You hereby agree to hold harmless the Heimlich Institute
Foundation, Inc., Dr. Henry Heimlich, Dr. Chen Xiao Ping and all
other health care providers involved in any way in this study.
You understand that the use of Induced Malaria Therapy is on an
experimental basis, and that this research treatment has been
approved by the Health Department of Guangzhou. You voluntarily
accept all risks associated with the use of the method, known or
unknown. You understand that this agreement is binding on you,
your estate, your heirs and assigns, and extends to all liability
of any nature whatsoever, including any claim for negligence or
failure to warn. You hereby bind yourself, your estate, your heirs
and assigns, and any other person or entity claiming to act on your
behalf or on the behalf of your estate, your heirs or assigns, not
to make claim against any person or entity whatsoever, for anything
of value, arising out of the use of this method.
Your signature indicates that you have read and understand this
consent form. You have decided to participate in this research
study. You have received a copy of this informed consent. You
understand the nature of the study, the procedures, the benefits,
and the risks.
I have had the opportunity to ask questions and have all responses
explained to you by the Principal Investigator in a language I
understand.
I freely agree to enroll in this study having read, in detail, this
Informed Consent Form.
Patient or Legal Guardian (Signature) Date
Address
witness (Signature) Date
I certify that I have explained fully to the above patient the
nature and purpose, the potential benefit and possible risk of the
indicated study.
Physician (Signature) Date
If signed by other than the patient, please explain below:
'.
PATIENT INFORMED CONSENT FORM
MALARIOTHERAPY FOR HIV STUDY
INTRODUCTION
Before agreeing to participate in this study, it is important
that the following explanation of the proposed procedures be
read and understood. It describes the purpose, procedures,
benefits, risks, discomforts and precautions of the study. It
also describes alternative procedures available and the right
to withdraw from the study at any time. It is important for
the participant to understand that no guarantee or assurance
can be made as to the results. It is also understood that
refusal to participate in the study will not influence
standard treatment for the participant.
1-- -
PATIENT INFORMED CONSENT FORM
MALARIOTHERAPY FOR HIV
This is to certify that I, (patient),
hereby agree to participate voluntarily in the clinical
evaluation of malariotherapy for the treatment of HIV. This
clinical evaluation will be conducted under the supervision of
Chen Xiao Ping, M.D. Dr. Chen Xiao Ping has explained and
fully defined the methods and purposes of the study to me and
has offered to answer any questions I may have during my
participation in the study.
I understand that my medical records in connection with this
clinical study will be maintained as CONFIDENTIAL. However my
records will be made available to and reviewed by authorized
persons associated with the malariotherapy research group, if
requested. Information that may be gained from this study
will be used only for research and educational purposes.
Information may be published with permission of the principal
investigator in medical journals, but my identity will not be
revealed.
I CERTIFY THAT I FULLY UNDERSTAND THE
ABOVE CONSENT.
Patient or Legal Guardian (Signature) Date
Address
Witness (Signature) Date
I certify that I have explained fully to the above patient the
nature and purpose, the potential benefit and possible risk of
the indicated study.
Physician (Signature) Date
If signed by other than the patient, please explain below:
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PAR'r-WAY
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HlOO3
Benefiting
Humanity
Through
Health
and
Peace
September 2, 1993
Dr. Chen Xiao-Ping
station of Guangzhou
No. 23, The 3rd Zhongshan Road
Guangzhou, 510080
China
Dear Dr. Chen:
I received a letter you sent to Dr. Hua on August 24, 1993
regarding the cancer and AIDS projects which he translated for
us. Your letter confirms receipt of the $10,000 for the five
cancer patients. .
Please let us know the status on the two patients under
treatment now. We look forward to your selection of the next
three patients. You can fax your replies directly to us now
that we have had someone change the fax so we can receive at
night. If you provide us with your fax number, we can fax
these letters to you as well.
In the future, please send separate letters when speaking
about the fund information versus project details/status on
either cancer or HIV (AIDS) projects. We'd like to be able to
use your letters on the project status in newsletters or notes
to our supporters, but we can't when they include anything to
do with funds. Thank you for your help in this matter.
Susan S udrette
Executive Director
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY

SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-22 HXXl3
Benefiting
Humanity
Through
Health
and
Peace
September 2, 1993
Dr. Chen Xiao-Ping
No. 23, The 3rd Zhong shan Road
Guangzhou, 510080
China
Dear Dr. Chen:
This letter will confirm our agreement on the fund arrangement
for the HIV (AIDS) research project. The Heimlich Institute
Foundation will provide you $10,000 for each case studied
under the HIV (AIDS) research project protocol. The funds
will be wired to your account per the arrangements as follows:
$2,500
$2,500
$5,000
Downpayment for each case when photos and patient
history are received here, and the first malaria
shot has been given.
When patients have had no less than 30 days of
fever and an update and fever charts are sent to
us.
At completion of malariatherapy when photos and
reports have been submitted to us including follow-
up reports per protocol at I, 3, and 6 months.
In an effort to expedite this project, a $5,000 wire has been
sent to you today for the downpayment on the two HIV patients
cases. Please send the case histories and photos you have on
your first two HIV patients as well as the start date as soon
as possible. Dr. Heimlich will come to China during the
fevers. If you could give us notice when you plan to begin,
we can make his travel arrangements.
It is imperative that this project start immediately or the
supporters of the project will withdraw their funding. If you
have any questions, please do not hesitate to call me.
Sincerely,

Executive Director
- _ , _ _ . _ .:...-, ,, ' , _ . ' _ '''' _ ' _ ' __' ,...., I I I I U ,....,
5-L/; f I b .. ( 9 93
-rt.:> M.s I
/rIU-A .. M.:P.
irE- I flt.p * .. .
'7- , Z
V,.. C-M,... .../A"..I--
/tk.. :d:iJe '-e +-
.. 7LutWd/
IY.1 1'Uc. ....
7t...., t!. #"14-0'-1

wU-t ..
4/- S ... p-I),'J.

k I L. 5"/.......,1...-..
(J--J

l.. 4-
<91ii-- 'bJ-..., t-... - A. .&-tSb #' I J"t>t). -

( '1t-+f .;; --r.
.. ;J

J aW : 1'f?3
(0 : flr. 'e-t,
Q
Htllt .. H ':/J. r
I( f . HIV-r
J 9p.., .
-ftw IJ."""r
S
.
Ji Dr. y,.,..., /h.:"- . l' DJ ZL.t').'.c.4..-fM .
Jh. 1!4 MjA.d1 ..
. __ LC
.. ..
.....;
II

.1 4. Q- At:: t(
sr.l)C ...

krr;s
J ""
J);. 7t4-
d)-t /.k1)s. II-L

:
Ilee tt-L
",,(/-1-

.,_,;.(. -.r ......... it ( a-I ;t;;;
,
- '"'
,
, .... c:tn,..( .IV '" tt4.r. D /'. to-d-{J
% '"" 1-111/+
b
o i d::. tv A-I:- :s
I
.. (G

.
4/.{ "w.lA!' 41>1 ?1 I
"HJ.'X lS) A.l..J44-

:If
,
('II'. X\60 Pins. ChIef of
the fot, Pr'<lventiv!? of
R(Jr>ubllc: of China on Nl>velnber 10. '993.
SIGNATORIES OF BOTH PARTIESl
Bin Quan
Pt'o:;id('ll'lt,
The idpa.l lost! for' Preventive Medicine of
Henry J.
Prasldent.
Tho !\e1mllch llU1tltuto.
\)f1to of SignIng
To MS
FtrIM I Hv I ,1:> ,
Roe... I
16 t1f. ,
H' Yt.M
TIi ... l>r HtV1' Wltl-S %
f-'\AL4R-lQ Wr'l/ k tt.$ '0'tI'M I4-,S. a&./-

.. LA "
OC T-16-93 S AT 0 7 : 00 P M HUA
8 18 442 8676
.. .. 7Z!. .. .. . _" .. .
I IfDNfir$htlN Hull. b I
R -e.. C4'1Wt ,
.... ". . .. .. , .. ...... _ . .. . . .. . . a . . . .. . " .. - ... . . . ' .. ' . .... . _.. " . , , --.' -,
. ,L t>-'v4PI..""" l ... Z4. """ Y-t -1!;l"aH MoP 'n._
J!:i. __ . . <>I A.t: .. ?JiIy
ph. TAt:; lu,d- II..tJfX--" ...... 1-..,f ,;. UN"''-;'" ",;TIt
...,. rite/" ' .... rnA- . --:.,M /;.It
..; .. -. . . ' . --.-. .. .
No. .. b
. . lJ-e f4ri> ---'1
.. r4ts. ..
Mr. Lt.( tl'-IIIMoW, zu.,.J 'i WIll
. .i ' ""},.. ... .. . . _ .. ... " .. . . .. .. .... ... ... .. . . .,
...t;., S 1/tt.!'ttfl. .z AU-,I.-' A.f"", a '-.... ; <Z
(fJl;!A:4/ /,'/(J.1b II:.-.Ittt 0/-- B... .. ,
7J, .. .. z.r"77/Z!s"z... % ....... .
, . , " . ... . .. . . ... M " ""
10"
ffll'h 0'
R&- .'
.vllrE"--.
X lt-l G T lt-lG E L E . I C.
""DR. H'iIM(.JCh f 101$
tI(.)A -SHVN 1M. Z,
C#IIJ/J 'II *'r"I-f6'1(4p Y
ItJ/2? 1".3
372 268
(He 1$1- HIVof was wlM "'AI.,.,-"
bltHJq "fI....'s . ifl..I eHEW JusJ-
inform&el WI.. 7Ae e.cJ:t1 -IeJ
h AlIt!! 1-3 d.l ' ; # e.. 7 .
filE 6,..,7' f 71e-,...rnJ-u.f'Et ;F
-f 7k w,'n J,.4?
.fe, 6y a./se> Wtbu"'r.-l 7iL
f
i
"J""S4,..et)/rtIt,.r M..A #: ANI.
r&. firrJ.. #/v.;- #,
1(- n.A-I'e not 7t<.- 4fh!.l!Jt1t111tl-
"'r.ff F!rX -fr, j'''-u /?.J Pts (e.J-
])r. t:!I-liHJ wtJuld -ID $ iL"I.
<!t1'
41
c1 $IfJ? tltt
G M#IA.
p e:::
,... ,om ; HH 1 HU\,j
Case report: 1.
No. of hospit:3689.
Name: ___ \lInle.
Address:
DDte Qf nd.isscon! Octohor22. 1993.
Chief Found HIV positive for 3
uf t.he illness and its epioollliology! This patient wont AbroRd
for tourism In _ 1992, Lo Hong Kon5 for one week nnd then to Tid land
for two no the hi&tory of homos(lIKuol or
and no the of injection such os of blood products in Hong
Kong and Tai land. Ina? 1993. he went to Phi 1 ippines. about 3 IIOnths
later he found a job in a clothes manufacturer's in that countr'y. In
the time of be got l1 high fever about 39t fOT'
several days. so he went to see a local doctor and
injection and one time of blood taking for examination, then the fever
disappeared. He said l..htlt. the needles and syringes were not for one-
time-use. In the period of staying in Philippines hn found that an
oversea Chinese man often used his without his agreement. lie
said the man had the of sexual with many people
(heterosexuals) and suffered from STD. He sometimes hert himself with
the shaver for shaving. which had been used perhaps by that man. About
1993 (before he came back to China). he fought with a man from
Hong Kong and was beaten to hert with bleeding and so was that man. He
said that man had skin disease with penis pyorrhea (the man often
his penIs to other people). He denied the history of any sexual
intercoutse. Besides of the severe} day's fever roentioned above. he h!:1d
no any other' SYlIlPtol8S In th i s two When he clime back to Ch ins in
July 1993. he was found HIV posit.ive in Ouangzhou Customs.
In 1989. he had appendicitis and received appendectomy in the First
Hospital of Sun Yet-Sen Nedical University. He have the history of
allergic rhinitis and denied homosexual. behavior and addiction in his
1 ife. lie also denied the history of tuberculosis and malar'ia .
-1-
. .....
-"
.
"...
r
'\ " ,J. ,
.,r.
,.J
, \.1 I
('
Examinat.ion at wall1ht: 56 1{g, vital signs
normaL development nurllla}. No JDunuice and edema in general skin. No
petechhlO, ul(:er, whit.ish excrul.lon end II\flSg in the orfll cavity. Thera
"ete 1-2 lYlIIPh nudes in two lnguans, each of which as t.he SiZA of
8 pea. DlQvtiule, 1\0 tender-nes::>. No Anlarge8lent of other-
nodes. No special rlndings in lunF,;s and hcart. l.ivQr and splp.p.n
were haps Ipab 1 c. Thera Is 8 I:Ibout 5 CIII long itl tho right low
abdomlml1 wall. no abnunllZ11 findinss in exo-genitllis Hnd in four 1 imbs.
Lub.: lIb 14d. RBe 4.80 mll./mlll lJBC 5000/mm N 66%. band-
cell 2%. lobulated-cell 65%. F. 1%. L 33%, Ab90lutc lymphocyte count
1650/11 1. Pc 1.4 x 10 /mm. RF negative. 1. CD4:706111 1.
CD8:446111 I. IgG;10.4g/L. IgM:O.95g/L, }gA:l.52g/L. IFH :
IFNP : IFNrl sorr normal. HBsA& negative. HIV-1 antibody
pos it i ve (before adm i S5 ion): El.. ISA (+). Wes tar'n Blot ( + ) . H IV -1 l'int I body
titer (ELISA):
Chest X-ray: There was a shadow about the size as a thumb in tho top of
the loft lung. "considered as inflammation. lung 18 )'S to be I>V ) d d It
, ,."C U e .
Diagnosis: HIV-l infection. asymtomatic carrier,
Malariotherapy: malarial blood of 10 c.c. was injected in the Illorning
of October 27, 1993, the sizG of Plasmodia vivax
No inoculum fever. Anti-inflammation (top of the left lung) with
cefoperazone IV drip and cefalexin P.O., one week later X-ray
re-examination
-2-
.'
,"
---=-
9
1
fi4 rfli tp LlJ ::B*23 \}
EU&i.1iIl>'L 510080
"0. 23. The 3rd Zhongshan Road . GuangZholl
The People 's Republic of China
it:.
Henry J. Heimlich. MD. ScD.
President.
The Heimlich Institute
2368 Victory Parkway Suite 410
Cincinnati. Ohio 45206
Tel: 7774103 (ext)
My dear friend and dear dad. Dr. Heimlich:
October 28. 1993
I am glad to tell you that malariotherapy for HIV infection has begun.
The HIV positive patient received malarial blood on October 27. 1993.
The incubation is about 1-3 weeks. So you can arrange your travel to
Guangzhou according to that situation. I hope to see you again in
Guangzhou. We will talk on detail with each other in the time of your
visiting. Wellcome your wife. my mum. being with you to come to
Gungzhou!
Your Son.
f

Dr. Chen Xiao Ping
Chief of Microbiology Department.
The Municipal Health and Anti-epidemic Station of Guangzhou.
No. 23. 3rd Zhongshan Rd . Guangzhou 510080. P.R. China.
2368 VI CTORY
PAR'f::oNAY
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
I
and
Peace
DATE: November 5, 1993
TO: Hong-Shun Hua, M.D.
FROM: Henry J. Heimlich, M.D.
RE: HIV Patient - Malariatherapy
I received a report on the HIV -positive patient from Dr. Chen. He says
that the patient was HIV -positive in Guangzhou Customs. He does not
say whether the tests for HIV were repeated when the patient entered
the hospital. Call Dr. Chen and be sure that this is done. If the patient
has proven malaria with the plasmodium in the blood, then visit
Guangzhou to see the patient and be certain that the tests and fevers are
being followed.
I will consider visiting Guangzhou if the patient is proven to have
malaria, or I will wait until the second patient is treated. Just one page
of the Agreement you sent on November 3 arrived, please send the other
pages unless you will be back in California soon. I will be going to
California on November 18, and we can visit together then.
X ING TING ELE. INC. 372 2687
70 I]),r< J.I '
t/
I HUll "
, M. D
/1- - 'f 3. .
t(E : PATlf7I1T #
1.. t!a..tI -f6141 "Dr.
P:":!. :?Af' lsf II/V+ p4lt-r !/"f lsi- f<!Vd- t:CI/4U<
yuludAf[ mA/4r,'a 61-.1
IItfNC..../, 6...1- WM "-4-1- f--d ... ;
yd.
7::< w".Jd To htAIu tf- r'"'"
:tii 1/1,;1- k wa..l"'td,

])1< . A.(. w,..d tI 4#1< Iut. zIi:i
*f 7#6- INH1'+r,J-.... t>f
M.uUcJ.t!. #If wv..dq "11'1,1 tl
.t:lu",,14.4f
J Aft,{ r'/"tl f :f1fY
d"1
s
. .Jf r
oPst
a.-y pl-, iT'>' "/- hJLU{ 1rJe.
..f.n fltsH- K....,.,v .
My P4-x NC. OI'-8'6--:J.!- 3722'87
P.01
THE I NSTITUTE OF PARASITIC DISfASES
CHINESE ACADEMY OF PREVENTIVE MEDICINE
Dear Hong-shun December 6,1993
As we have discussed during your recent visit in Shanghai, if we could
establish a plasmOdium banK in China, we are able to treat cancer/AIDS
patients at any time. The malariatherapy project could be carried out
with a much faster speed. Once malariatherapy is proved to be effective
to these disea5es, even limitted to certain stage or certain type of
these diseases, that wOUld be a remarkable contribution to medicine.
Since your project seems to be promising, the pressing problem ie how
to proceed the project in a bigger scale and with a faster speed.
I reported this matter to Dr. Fong zheng, the Director of our institute,
asking if we could establish such a plasmodium bank in our
whenever the Heimlich Institute needs our co-operation. Dr. Fong told
me yesterday. that he fully support my suggestion,and authorized me to
inform Dr. Heimlich and you.
For better application of malariatherapy, 'mosquito transfer' possesses
many such as , to innoculate patient with a specified
plasmodium of specified quantity, capable to let patient get fever at
predicted time and with a predicted number of episodes, or to let the
malaria episodes relapse when there is such a therapeutic demand.
But at the same time, to establish a plasmodium bank is a complicated
team work,and needs plenty of time. By the way, time is of
If you want me to co-operate with you, we better start early.
If you are considering and planning ,please let me know as soon aB possible,
so that I could make plan Of 1994 and make arrangement accordingly.
I could make a research program exclusively for my lab.
After we both convince to establish such a bank, we shall discu8s the
project in more detail.
TO inform me ,please FAX 86-21-4332670.
Sincerely,
Yang
Dear Dr Heimlich
December 9,1993
During my recent two months' travel in China, I have visited
5 hospitals in Nanjing,Xuzhou and Guangzhou, where
patients were treated with AS I was
by physicians ,who treated these patlents, that among 10
patients, 5 demonstrated rather results, 1
with slight favorable result, and wIth nO effect. None of
the patients showed adversive effect from malariatherapy-
The patients of rather satisfactory results were;
cancer: 1,Karposi sarcomai l,fibrosarcoma and 1,adenocarclnoma
of lung respectively. The patient of slight favorable result
suffered from small cell carcinoma of lung. The patients of
no effect were of CA of esophagus, nasopharyngeal CA, Ca of
head of pancreas and small cell carcinoma of
The result of 'rnalariatherapy of cancer' clinical research
might pe sUmmarized as follows:
1 The process of malaria blood innoculation from malaria donor
to cancer receptor were handled safely in 5 hospitals.
2 Malaria episodes induced by innoculation did not produce
adverse effect, that is, cancer patient could
malariatherapy.
3 It is very impressing that rnalariatherapy could benefit
certain Kind of malignant tumor patient. more than half
or the patients of this group got favorable results.
4 Cancer patientsl their family mempers, and hospital staffs
are all convinced that malar1atherapy could well be accepted
and warrant further application.
since the procedure proved to be promising to cancer patients,
we would continue this therapy in cancer patient and also we
shall initiate the therapy in HIV+ patient_ Now we have started
the first HIV+ patient in Guangzhou.
There. are certain reasons that we could not proceed with a
taster speed :
1 To select appropriate patient is not easy. The patient has
to fulfill the indication/would willingly accept the treat-
ment and shOUld be at the right time when malaria blood is
available. I visited the first HIV+ client and his family_
and I could realize that the amount of work needed.
2 We did not have much malaria donor blood source. Even though
provided with a well organized anti-epidemic station network
there is not many malaria pabient now-a -days. Sometimes,
a whole day is needed to get a malaria donor blood by sending
a technician to a far remote rural area.
3 Due to technical or some other reason,our fund could not
reach the hospitals in time. And because of increase in
expense and inflation, they felt the fund was not enough or
barely enough.
,
4 Through all these two years, we ,both only have a
rather loose connection and our communication is not
convenient. For example, more than 12 months is needed to
sign an agreement after a draft was drawn; and physicians
of Xuzhou Hospital let me examine the two patients and x-ray
reports and video taped the proce55 all in one day, but they
could not provide the tapeand X-ray films until
n01'l.
During the recent visit of Jiangsu delegation in LA, I discussed
with Mr. Lu , director of International Communication
and Dr. Ctang Hua-chan, Vice Director of Health Department.
They grateful for my arrangement for their visit here on
behalf of the Heimlich Institute. They said that they will
give tull 5upport and promote the malariatherapy project in
Jiangsu. Through my connection, they were invited by Dr. Cionci
to stay in Phiiadelphia for three days. They visited six
hospitals and health facilities,and started the contact between
heaith departments of and state of Pennsylvania.
I would like to suggest the following to our project
imalariatherapy of cancer and AIDS'
1 To contact SOme other medical tacilities where they have more
malaria, cancer and Aids patients and they would like to join
in the project. For this purpose, I have sent letters to
Dr. Gu to contact Health Department of Yunnan Province.
2 To consider the possibility to establish a 'plasmodium bank'
to carry out 'mosquito transfer'. I discussed several times
with Dr. Yang Bei-ling while I was in Shanghai.
Enclosed herewith 1s a FAX received 2 days ago,informing us
that he and his institute would liKe to join in our project.
I hope that you will take this into consideration and let
him ronowyour decision.
3 To accelerate enforce our connection and communication with
china. There are so much both administrative and technical work
to do. Just by FAX and telephone is barely enough. prObably
we have better stay there for a certain period several times a year
or even set a standing office over there. Then we miqht
entighten our connection with better
or even supervision. According to agreement, we were not
even to rinish one year's work in two years, we
need to have improvement.
Very soon will come the h&liday season, if we have any plan ,
please start early. As you know, ror orient people, new year
lunar new year and spring festival will take months for
to celebrate and enjoy.
Merry Christmas and Happy New Yeari
Fraternally
_____
* j]j 1:1'1'1 T
510080
I{l. . 7774103 ( ,{MfL )
Henry J. Heimlich, MD. SeD.
President.
2368 Victory Parkway. Suite 410b
My dear friend. Dr. Heimlich:
No. 23, The 3rd Zhongshan Road . Guangzhou
Tel: 7774103 (ext)
Dec. 18. 1993
I want to tell you two pieces of good news . The f irst one is that the
second HIV positive patient received malarial blood on Dec. 14, 1993.
the incubation is about 6-21 days; and next group of cancer patients
will receive malariotherapy very soon. You can make your arrangement
of coming to Guangzhou according to that situation. The second one is
that the Municipal Health Bureau of Guangzhou approved our application
of inviting you as our honorary president. the Municipal Institute for
Preventive Medicine of Guangzhou.
I hope to see you again very much. Merry Christmas to you!
Your good friend.
t

Dr. Chen Xiao Ping .
Chief.
. No.23.
Municipal Health and Anti-epidemic Station of Guangzhou.
3rd Zhongshan Rd. Guangzhou 510080. P. R.China .
I

--.
2368 VICTORY
P A R ~ A Y
SUITE 410
CINCINNATI
OHIO
45206
513-221-00J2
fax513-22HOO3
Benefiting
Humanity
Through
Health
and
Pp.ar.p.
January 25, 1994
Dr. Chen Xiao Ping
Chief, Department of Microbiology
The Municipal Health and
Anti-epidemic station of Guangzhou
No. 23 3 rd Zhongshan Rd.
Guangzhou 510080
Dear Dr. Chen:
I am working with Dr. Heimlich, analyzing the results of the
malariotherapy project. I am now going through your reports
on the cancer cases and entering them into a database. I know
that your time is valuable, however , there are several points
that I hope can be clarified with your assistance.
Case 1 Do you have any more information
on her progress since May, 1992? The success of her
treatment was very exciting.
Case 2 Your last statement indicated that you
were having difficulties reaching him through his
father. Have you been able to obtain further infor-
mation regarding his post-treatment status?
Case 3 We have not received a copy o f
the follow-up report on this patient. Can you provide
this information? Also, do you have measurements to
show the extent of the adenocarcinoma before and after
treatment? (Your report mentions X-ray results, but
we d i d not receive copies of the X-rays.)
Case 4
We are missing the pretreatment
Hb value. Do you have any tumor measurements, as well
as follow-up reports on this patient?
Case 5 Is any follow-up information
available on this patient?
Case 6 Dr. Heimlich would like to know
if photos are available before malariotherapy. Anoth-
er point that you might be able to help us with is
whether or not the tumor mass showed evidence of cel-
lular necrosis at the time of removal. Again, is any
follow-up evaluation available?
The results which you have obtained so are interesting. While
there is still much to be understood about the specifics of
how malaria interacts with the immune system to kill cancer,
the information you have sent us shows the promise of this
technique. We hope the follow-up reports will show if immune
system stimulation lasts beyond the febrile period.
We look forward to hearing about the results with the HIV
patients. Meanwhile, please send a copy of the pre-treatment
physicals, blood tests and cell counts for the HIV patients.
Enclosed are forms for the HIV patients. We anxiously await
your reports on them.
Dr. Heimlich has told me of your friendship and I look forward
to working with you. Thank you for your cooperation. Your
efforts to collaborate on these projects is greatly
appreciated.
Sincerely,
Eric G. Spletzer, PhD
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45200
513-221-00)2
fax 513-221-00)3
Benefiting
Humanity
Through
Health
and
Peace
January 27, 1994
Dr. Chen Xiao Ping
Anti-Epidemic station of Guangzhou
No. 23 3rd Zhongshan Road
Guangzhou 510080 China
Dear Friend:
Thank you very much for your holiday greetings. Please accept
my best wishes for the New Year and convey that to your
colleagues. The desire to make me Honorary President of The
Institute of Preventive Medicine of Guangzhou is very
thoughtful, and I appreciate the honor. We are pleased that
a second HIV+ patient is being treated and hope you will send,
at your earliest convenience, his history, physical, and
laboratory findings.
There are a few changes to discuss concerning the agreement
you sent. It should be entitled "Malariatherapy of HIV
Infection" as the patients should be treated before they
develop AIDS symptoms. The treatment would be more
satisfactory if there were 15 paroxysms of hyperthermia,
lasting 30 days.
Regarding the funding, we agreed to pay $10,000 for each of
the first two patients because of the difficulties you
described in getting the program started. It is not possible
to pay that large amount for each of the additional eight
patients, and it should not be necessary since the first two
patients have provided sufficient experience for the
investigators and the hospital. A fee of $3,000 each, which
is $1,000 more than the cost of treating a cancer patient, is
within reason. It is very likely we can get additional funds
for treating more patients depending on the outcome of the
first ten. I am sure these costs are suitable, so please let
me know that you agree.
Travel to China is difficult for me, but I believe I could do
so sometime in February or March at a time when the treatment
of HIV patients is in progress.
with
Henry J.
President:
Heimlich Institute
all my friends,
2368 VICTORY

SUI TE 410
CINCINNATI
OHIO
45200
513-221-CXX)2
fax 513-22HXlO3
Benefiting
Humanity
Through
Health
and
eace
January 27, 1994
Edward W. Probert
President
Fannie E. Rippel Foundation
The Concourse at Beaver Brook
P. O. Box 569
Annandale, NJ 08801-0569
Dear Ted:
I hope that you are well and that the new year will be a happy
one.
I have not contacted the Foundation because I was aware of the
difficulties that you were undergoing and did not feel it
proper to impose. I understand things are now functioning
normally.
Our malariatherapy project for the treatment of cancer has
been progressing with very encouraging results. Enclosed is
a picture of a patient treated with malariatherapy for Kaposi
Sarcoma, and one of a patient with breast cancer that I sent
last year, but which you may not have seen. Charts of some of
the cancer patients treated in China are included.
Essentially one-half the cancer patients have a positive
result. Patients with Lyme disease who were totally disabled,
have completely or partially recovered in almost all cases.
Most importantly, a fine university with a medical college and
hospital just outside of Monterey, Mexico has agreed to accept
our patients and carry out malariatherapy. It is an affiliate
of Lorna Linda Unviersity in California. Recently I travelled
with a doctor from the University to Villahermosa where the
Minister of Health of Mexico arranged for us to obtain a
steady source of malaria for treatment.
Our funds have run out, and I wish to apply for a new grant.
If this is possible, please let me know whether I should meet
with the Board. In any case, it would be good to see all of
you again. Otherwise, I would welcome speaking with you over
the telephone.
ishes,
/
H imlich, M.D.
P:tesiden
Heimlich Institute
-_._--_._--_ .. _-- -- -- _ .. _-----_. ---- -_._._- .. - .
-.-- _._- ------------------- ---------------------
- - _._--- ------ . . - - -- _.
- '- ----- ---------
- . --- ------ -
-_._ .. ----- --
--------- -- -----------
--'--' -_.-- - - - .---_.... _-- -_ ..
- --- --... -- -- .- - -
. ----_. - -_._----- - -- -- _.-
- - _._--------- -
- .. -- -- -- ------
-- . __ ._._- -------
C k:t::' __ _ _ _ A
r
ar
h.':<i'1.z,''-
?wL
jj-',--21. 3 - __ Ticer
E- ------ :- .--
.. -.---. ---- --.- -
- _.-_._-------
------------ -- --- - ----
--.- -_._. ----- -- - ---'-" ----- - ._- -- -- -----. ,- .. _----------
- -- ---- .---- ----------- ----- --
--- ---- ----- --- -- -_. _ .. ----------
-----_ .. _---_.- -.-.
-_ .. -._-------- '--'--- -
--_. __ ._------------- -_.----- ---'-'-'- ----
.------_._- -
--.. - _. __ .- ---- _.------------------
-- - -.----- ------------
---------_ ._----- - - -
-' --- - ----- ----------------------------
--- ---- ------ ---
--- ----- -----------_.-----
---- --- ----
-----
- ------------------
_. __ .. _----
FOUNDATION, INC.
2368 VICTORY
PAR'f:'NAY
SUI TE 410
CINCINNATI
OHIO
45200
513-221-CXXJ2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
March 7, 1994
Dr. Chen Xiao Ping
Anti-epidemic station of Guangzhou
No. 23 3 ~ Zhongshan Rd.
Guangzhou 510080
Dear Dr. Chen:
Thank you for forwarding the case reports so quickly. The HIV
case reports look encouraging, but we are not certain what
some of the abbreviations mean. What is ALC? I have asked
several people, and no one is quite sure what it means. I
assume 00 means "optical density", but does this really tell
us anything about the HIV titer? The actual HIV titer will
show if HIV is in remission. If the HIV titers for these
patients is available, we would like to see how these have
changed.
Our feeling is that the increase in CD4 is a positive sign.
If we can show that the HIV titer has decreased, then we have
some very good results. What do you think about the HIV
cases? Do you feel the HIV patients show clinical improve-
ment?
Again, thank you for your assistance and I look forward to
hearing from you.
Sincerely,
L ~ , J ~ ~
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VI CTORY
PARI<:WAY
SUI TE 410
CINCINNATI
OHIO
45200
513-221-00)2
fax 513-221-00)3
Benefiting
Humanity
Through
Health
and
Peace
March 8, 1994
Dr. Chen Xiao Ping
chief, Microbiology Department
No . 23, 3rd Zhong shan Road
Guangzhou, 810080, China
My dear friend, Dr. Chen:
Thank you for your excellent reports on the HIV+ patients.
There should be no problem to arrange for your coming to the
United states as soon as ten or more HIV+ patients are treated.
You are now the most authoritative physician in the world on the
effect of malariatherapy on AIDS. When ten or more patients
have been treated, that fact will be firmly established. We can
then, together, along with your colleagues and Dr. Spletzer,
submit a scientific paper to a medical journal in China and in
the United states to describe our findings. You will have made
a contribution which you can teach at an American institution
while studying other aspects of AIDS.
I met with Dr. Hua last week. We agree that it is urgent, for
those patients who can benefit from this research , to treat at
least ten additional patients in order to complete the study.
It is our plan, if you agree, to increase the number to fifteen.
For this reason, we suggest the following . Dr. Hua and I,
accompanied by my sister, will arrive in Guangzhou on or about
April 6. We hope you can start immediately with the treatment
of five HIV+ patients. By the time we arrive , therefore, the
five patients will be under treatment , and we can observe them.
I had mentioned that we think that the cost of treatment should
be less than $10,000 per patient at this time. You can proceed
with the treatment of five patients with the knowledge that we
will reach an amount that is fair to your organization and the
Heimlich Institute when we meet.
Please send to me and to my sister, Cecil i a Rosenthal, a letter
of invitation by fax as soon as possible so that we can apply
for our visas . My sister is not involved in the project and
comes as a visitor. Dr. Hua will call you to discuss firm
arrangements for our visit.
to all my friends, your dear
M. D.
Institute
' I
} rtf Ii .1?1i. ?!t fJJf 1 , JiJi
lllarC: /{ ll/
;?I.H!-:;J- J . fVI.P.

eVr-
(f,u In- rw $1'

.>cd tMt/ J(J1<-r 1:f-- 1'A-;( -:L
lie u<$
h r frU- r __ .
C
fr 3 riu;f6;
;, / .OtL can

pta.!? kI fJ)r . JfjI1ff//,/ ALe
J -.p. Ii I?Ji iJf JiJi .
P-/r'/
L c 1/ an
./ ./ '--- 0
;'7 &ot;( t"J-M'
L{);tf --flu- rJI/z/ ttlzr w;w, 0 (!ur-e-

/ 7

:J),. {' f;ir-----
df <fIt.

1- 6--r j-;PCM / dnA--
.,
>l J trJ,,,chvJt.4 7)./ in'! 1"-C><1 .. 71{,(4') a<d ~ ..
--- - -- - __ _ _ L.
/Ja,f?>fp ~ ttt.rf" M " ' d ~ 7 ~ , '-. _- .----- -----
Date
Apr. 10
Apr. 11
Time
9-11.30AN
2.30-5.30PM
Arrangements of Meeting Dr. Heimlich,
Dr. Hua Hong-Shun and Mrs. Rosenthal
Items
Report Project Progress
Visit Patients
Place
the Institute
Yisou Hosp.
Ra il way Hosp.
8. 30-11 . 30AN Discuss Next Step the Institute
3-4PM Vice-mayoress. et al the Institute
Meet Guests. Ceremony
of the Honoray President
Apr. 11-12. 5PM-3PM: Sightseeing. Evening: Depart to Kunming
.J
Participants
Ye Guo-Xong. Xong Lang-Min.
Malar. Group
Xong Lang Min. Malar. Group
Fan Meng-Hau. Ye Guo-Xong
Xong Lang-Min. Malar . Group
Vice-mayoress Yau. Fan Meng-Hau
Ye Guo-Xong. Xong Lang-Min.
Liu Shu-Gua. Major Members
of the Institute
<.J
"
<P 00 iri'l <P ili '::: J/!23.f;J-
510080
f!! 7774103
No . 23, The 3rd Zhongshan Road . Guangzhou
Tel: 7774103 (ext)
Introduction of Dr. Heimlich
Professor of advanced clinical sciences and president of the Heimlich
Institute in Cincinnati. Ohio. the United states. a great internationalist.
Dr. Henry Jay Heimlich was born in 1920. obtained MD degree in 1943. But
his internship at Boston City Hospital was interruped in 1944 by World War
IT service in the United States Navy. Volunteering for especially hazardous
duty. Heimlich served as a surgeon in the Army of General Fu Zhuo-Yi in the
Gobi Desert and Inner Mongolia, to help the Chinese People repel the
Japanese invasion. He greatly admired the late Dr. Bathume and the late Dr.
Ma Hai-De. Many years later, he was honored in China by the ministry of
health, in 1984. Dr. Chui Ye-Li. the Minister of the Health Ministry of
China accompanied by Dr. Ma Hai-De. especially invited Dr. Heimlich and his
wife to visit China and met them in the Great People's Congress Hall. in
recognition of his contributions to the Chinese People during World War II.
After the completion of Anti-Japanese War in 1945. Dr Heimlich returned to
the United States to continue his medical career. Having worked in the
medical field for 50 years. as a well-known thoracic surgeon. he published
'-
many many scientific papers and have many technological inventions, among
them the most famous is the Heimlich maneuver for saving the victims of
choking and drowning. Because of the Heimlich maneuver. he has been
credited with having saved more lives than anyone else in the world. His
name has become a household word in the United states. even though
thousands of persons who refer to the "Heimlich maneuver" may not know who
Heimlich is or how to perform the simple antichoking procedure that bears
his name. Among the honors that he has received are the Albert Lasker
Public Service Award (the top award in clinical science) and the Golden
<P IE r-m <P 1lJ :::: !ilf23-\}
510080
It!. li'fi:
No . 23, The 3rd Zhongshan Road. Guangzhou
The People 's Republic of China
Tel : 7774103 (ext)
Plate Award of American Academy of Achievement. and he has been enshrined
in the Engineering and Science Hall of Fame. He is an honorary professor of
surgery at the University of Athens. Greece and at the University of
Argentina. and in these two years he is the honorary president of the
People's Hospital of Jiangmen City. and now he is our honorary president.
the Municipal Institute for Preventive Medicine of Guangzhou.
Dr. Heimlich had a great contribution to the Chinese People in the
Anti-Japanese War. now he have another great contribution to the Chinese
People and the People of the World through the cooperation with us on
malariotherapy for cancer and for HIV infection.
Dr. Heimlich is a real friend of the Chinese People's. we sincerely give
him the best wishes. may him longevity and health forever!
Speech in the Ceremony of Inviting Dr. Henry Jay Heimlich
as the Honorary President of the Municipal Institute for
Preventive Medicine of Guangzhou. by Vice-president of the
Institute. Dr. Liu Shu-Guo. April 11. 1994.
MON 11: 39 PM HUA
818 4 42 P '3 1_ .
------
' JUN 06 94
_, ..._ ,2 _" sraaa
i&iALaa
_122,-=+=, \
:w=:=
!
,
.
Date: 04-13-1994
Attendant8:
I
i
i
I
i
I
MEMO!
Public Health
Yang Qi M.D.
Bur@au of YUnpan, F.R.China
Vice Chief of sanitation and Anti-epidemic Division
Pl'Ogramme Offici,al in charge Of unan Provincial
OFFICE FOR and Prevention
You Weichang M.D.
Li Xue-zhong M.D.
I
Chief of the Pharmceutic and Drug Administration
Deputy of Eprdermic Disease Prevention
Office j
Pirecbof of Yunnan Province Malaria Reseach
Henry J. Heimlich M.D. pr J fes8or, President
Hua Hong-shun M.D. prdfe55Dr
Meeting held at; Kunming, Yunnan iprovince, P.R.China
I
At first, Dr. Hua made a brief about the contributions
Dr. Heimlich has made in clinical research and in tIle promotion of
friendship and co-operation the American and Chinese people.
The purpose or thi s vi 5 i t of Dr. IHeiml i ch to China is to introduce
the theoretioal basis of malaria Itherapy in the treatment of malignant
tumor and HIV + patients and the clinical trial undertaken in
Jiangsu and Guangzhou since By communicating and exchange of ideas
on those problem5 of malaria concern, the both parties would
lika to find the possibilities t q initiate malaria therapy on malignant
tumo,t: and HIV+ patients in yunnax1'
I
As recommended by the American for sixty more years,
malariatherapy has been used in treating neurosyphylis.
Through malaria infection, the ability of the patients is
Tumor incidence was f9und to be low in high malaria incidence
area. The mortality rate of suffering AIDS and malaria was
significantly lowered than those :children only suffering AIDS.
Among the 10 malignant tumor patiients treated since 1991, Six patients
showed improvement in various deJ ree,flve of the ' six patients showed
marked improvement. Two cases HIV+ patients,one patient showed
the same high level of CD4 count treatment,as another case
his CD4 count increased from low jleVel to a significantly high level.
As cons idered by the American proifessors, to Observe the effect of
malaria therapy on AIDS patients , ; .AIDS patients could be innoCulated
with malaria blood,or by the course of AIDS patients who
also malaria. That be easier to observe by the latter
method. But tha t would be di ft' iciul t I to hold the malaria trea tmen t
during the course when the AIDS episodes.
To the opinion of American doctors,the latter trial could only be
taken patient voluntarily part with full understanding and
C'O-Operatlon. I
The experts of the Chinese party
malaria therapy: the basic therrY,
of clinical effectiveness and med cal
They considered that ,as a scient fie
much inspired and raised questions
the scientific design, the assessmen t
ethics aspect etc.
researc'h , malaria therapy is of
MON
Pt1
HUA
..
818 442 8676
. .._; .. . ' ---. --1
I
ME110 (CONTutUED)
significance. but the .itaatioD in Yunnan for the time being i.
not entirely mature, they woJld make further consideration.
They expressed their hope to ~ e e p on the contact, and to procure
fUrther material and information.
SIGNATURE:
China Party
(sigl1ed)
Yang 01 M.D.
U.S.A. Party
P.02
ItL:
Jun 07 94
11:42 NO.UU2
p . t-- .
j l-<:--<YV 'AJ 7) t c/D /- . Dr'. Ya_-
I
'--f
</ a /l.rt.:;, 5 .
. .... 4 H41. Lf)
.. ;:,>.fh, d.A....e.L--<--J --/Y.(J;4.U / -a--K-tJ'/
---. J .J.:,/ " [;> /.- /7 .<-vt..l....(
7' f/-{,"1"-Pf 411-Vz,-f:--l'.4/1", A.--IA-l.A.<
A.I i!"t-t-. .
]) Y- II--<>', ... -f, (:.-.tl a'i--P-f1A-<- c,< 'f-d.r:d ,.ct,.., .-e:v' ) a- a."lp/U'"qd--.

7 C. ),y-""" .. D' C:",l.;'-LlI l-Lf '1/,-1.:((-<:" i!..dp
P7j.a/I.:!:;;- .. /."';" (Ir (7\'1
. ,
;I;b ---?.-t/)--f1-4-----t'-<--...:t., eI c;( - .('-A- ,<..-L' ..
,/- 1 --- /
/1t-'1 .(,.<. ... . ,:"<-L-< (.--1. -t t7

6/
7
(ry-,
2368 VICTORY
P A R ~ A Y
SUI TE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
To: - ShlNVl H vJA.. , fV1" b " l-Ar: (R",t)tr(I'l .. - !67t
/ Ct> -
1994-4-13
:
tflOO

m.tme:

m. ,

M 1Ilf nJiJf
KENRY J . HEMLICH

**J@i

:ttl!. d:i " J .... , tflOO

&H I V

1 9 9 1 4

2i9UH I V
mJJffi!7,k-Sf, 1 0

T
lttfro

AGREEMENT FOR JOINT PROJECT
"MALARIOTHERAPY OF HIV INFECTION"
BETWEEN
THE MUNICIPAL INSTITUTE FOR PREVENTIVE
MEDICINE OF GUANGZHOU
AND
THE HEIMLICH INSTITUTE
s U I<fi.(AR Y
Both sides hold that it is benefic ial to human race to explore
ma lariotherapy for HIV infect ion.
The primary objective of this project is to perform a clinical trial
by means of blood transfer met hod so as to demonstrat e that the therapy
could be applied to HIV infection with no harm. or only with a limited
amount of side effects. and to assess the effectiveness of this
treatment.
Collaborative covenant enact ed by the Municipal Institute for Preventive
Medicine of Guangzhou in t his action by President Xiao Bin Quan and the
Heimlich Institute by President Henry J. Heimlich. who hereafter for the
purpose of this instrument are designated as "Guangzhou" for the first
party and as "the Heimlich Institute" for the second party in accordance
with the following:
PROMISES
ON"GUANGZHOU" PART:
To designate Dr. Chen Xiao Ping as principal investigator in charge of
the project. He is to follow the patients and visit them at least once
each week during their hospitalization and examine each patient before
each follow-up report.
To designate Dr . Xiao Bin Quan. Dr. Lu Vue Hen and Dr. Liu Shu Guo as
co-investigators
To comply with all the medical. technical and ethical requirements that
determine the standards applicable to the protocol. In the respect of
concrete measure to do well the management of fifteen patients and
guarantee the security of the medical workers on medical activities.
prevent cross-infection in hospital and obtain signed informed consent
from the patients and respect their confidentiality. The course of
malariotherapy is primarily decided to be at least fifteen paroxysms of
hyperthermia. But if there are any special conditions occurring. the
course can be changed.
-1-
To send complete and accurate written reports (including the histories.
physical and lab. exams. according to the protocal ) and photos to the
Heimlich Institute at start of treatment. end of treatment and three
months. six months. one year. one year and a half and two years after
completion of treatment.
There is anothor cooperation instrument between the Municipal Institute
for Preventive Medicine of Guangzhou and Guangzhou Yishou Hospital as
the internal agreement of "Guangzhou" Part. because of the consideration
that there may be more hospitals joining us with the project development.
ON "THE HEIMLICH INSTITUTE" PART:
To designate Dr. Henry J. Heimlich as principal investigator responsible
for the investigation.
To designate Dr. Hua Hong Shun as coordinator.
To contribute the necessary medical. technical and related information
for the implementation of the therapy procedure.
Funding: at the first two cases. to support a fund of ten thousand USD
for each malariotherapy-treated patient with two years follow-up with
periodic reports as noted below for the subsequent patients. After that.
to support a fund of five thousand USD for each patient for the
treatment and follow-up course of two years and submission of patient
records and reports. The way of paying is one thousand at the start of
malarial fever. one thousand three months after the end of treatment.
one thousand six months after the completion of treatment. Then one
thousand one and a half years after completion of treatment and one
thousand two years after the completion of treatment. Total follow
UP is for two years after end of treatment. The patient will be examined
fully physically and with lab. tests and reports sent to the Heimlich
Institute at intervals of no less than six months after the first six
months posttreatment follow up.
Each payment to be made after the Heimlich Institute receives a complete
and accurate report of physical and laboratory findings for the previous
period. also a recent photo of the patient. if possible. For patients
-2-
~
followed for six month, total payment will be three thousand dollars.
~
ABOUT THE RESULT:
The parties agree that the progress and results obtained from this
investigation cannot be utilized unilaterally by any of the parties or
cannot be utilized unilaterally by any of the parties without the
agreement of both parties.
This agreement of collaboration written in the English language which
has two copies was enacted in Guangzhou, the People's Republic of China
on April 23, 1994.
SIGNATORIES OF BOTH PARTIES:
Xiao Bin Quan
President,
The Municipal Institute for Preventive Medicine of Guangzhou.
Henry J. Heimlich
President,
The Heimlich Institute.
Date of Signing
-3-
9' [,;j 1m rf'IIJ-=-IIIt23%
510080
iiI, : 7771103 ( )
The People ' s Republic of China
Tel: 7774103 (ext)
Budget .for Each HIV Patient for Matariotherapy
ItellS USD
Hospitalization 1000
Routine Treatment and Nursing 750
Special Medicine (Albumin. Blood Transfusion. et al) 500
Medical Workors Reward 1000
Articles for Single-Use 500
Special Tests (Western Blot. HIV Titer. CD4. et al) 750
Research Activities (including Receptions of US Experts) 500
Total 5000

510080
Q! 7774103 ( )
Li Hai-Du
No, 23, The 3rd Zhongshan Road. Guangzhou
The People's Republic of Chi na
Tel.: 7774103 (ext)
Co-investigator. 1964: graduated from Guangdong Medical College. specialized
in internal medicine. Vice-president of Yishou Hospital of Guangzhou.
visiting doctor.
Kuang Fu-Yian
Participant. 1964: graduated from Guangzhou Medical College. specialized in
internal medicine. visiting doctor.
Yau Zi-Li
Participant. 1952: graduated from the First Medical Technician School of
Guangzhou. specialized in epidemiology. parasitic diseases. expert of
malaria. associate chief doctor.
Lian \Ie i -Quan
Participant. 1973: graduated from Guangzhou Medical College. specialized in
internal medicine. President of Yishou Hospital of Guangzhou. visiting
doctor.
MAY-23-94 MON 11:17 PM HUA 818 442 8676
P.01
CHINA TRAVEL
I
4/1 -4/2 LA to Shanghai i
4/3 Call Beijing, Dr. Fong Dr. Fong is making arrangement
for our visit to
Call Dr. Yang Bei-ling. Hd will introduce to discuss with
Dr. Zhen about & mosquito bank ror
malariatherapy. Dr. is the director of their
institute. i
4/4 Monday I
Call Kumm1ng, the government of Yunan Province.
They have received from Chinese Consulate General
of LA concerning our project. The Health Department of
Yunan Province will decision.
Call Beijing & Hainan, they would like to co-operate with us
and welcome our vis i t.
1
4/5 Visit Dr. Feng zhen of of parasitic Diseases & Dr.Yang,
they would co-operate with us by furnishing a 'plasmodium
bank' but they need f9nd.
Ca 11 Kumnling, the Rea 1 th Dep' t of YunCln Provi nce. They are
considering.
4/6 Shanghai to Guangzhou
Discuss with Chen Xlao-
P
19g and make ready our in
Guangzhou. .
I
Train tickets from to Guangzhou are difficult to
due to rest i . '
Chen called rriend in HK to get tickets for Dr. Heimlich.
Call LA to inform Dr. c/o my home.
4/7 Call Kumming, Mr.Xie . of D6f't of International Communication of
Health Dep't told me Dr. YangCi will be in charge Of
AIDS project and he going to make decision.
4/8 Call Kumming, a group of experts will discuss with us and
they are interested Joint project with us. They
asked for our
I
Make arrangement for tickets from fiK to Guangzhou.
Our tentatIve China traveV schedule is set except that part of
boat trip. . .
4/9 Dr. Heimlich and sister at Guangzhou.
4/10 AM contact Travel Agency Dr. chen for flight tiCKets &
boat trip.
PM ViSit Yisur Hospital interview fiIV+ pts.
4/11 AM Contact Travel Agency Dr. Chen for flight tickets &
trip. !
PM Ceremony for Dr. as Honorary President of Guangzhou
Institute of Medicine.
4/12 AM- 3PM Contact Travel ageeCy and got atl schedule decided.
Eve Call Kuming & Hainan, our schedule for these places.
4/13 AM Guangzhou to Kumming.
PM Discussion with Dr. Yang ,Dr. Yiu & Dr. Li.
4/14 Al1 Visit Stone Forest. ;
Eve
4/15 AM
PH
Sightseeing & dinner downtown Kumming.
Visit National Village
A report on on malariatherapy in Kumming is
ctrafted.
Kumming to Chungking
4/16 to 4/18 noon Boat Trip
4/18 PM Ylchang Visit Gu-zhou, Dam & China Stur-gent Museum.
4/18 Eve - 4/19 AM Y1chang to
4/19 Wuhan to Haikou, Hainan
Eve Dinner & discussion Drs. 1n Hainan.
4/20 Haikou to Sanya I
Eve Dinner & Drs. 1n Sanya.
4/21 to Haikou .
PM Visit Haikou Hospital:
Eve Dinner & discussion Drs. of Haikou.
4/22 Haikou to Guangzhou I
AM Discussion on agreement : with Guangzhou
PM Got flight ticket from puangzhou to Shanghai
Got boat ticket from to Hongkong
I
I
4/23 Noon Dr.Heimlich to HK
PM Hua Guangzhop to Shanghai
4/25 visit Dr. Yang & Dr. Feng
4/27 ShanghaI to Nanjing
Contact Dr. Chang et al **
4/28 Contact Dr. Ma et al **
4/29 Contact Dr. Xu **
Pm Nanjing to Shanghai
5/2 Shanghai to LA
** Detail on attached page
.. -....... -.. ...... -------- .-" .. ---.-.. -,....... .. ,.. .
'PE 1>{ Ra"'/: ..;. ,9 Dr. ?
I
7-'<- M,,," 7M(j-
4lAJ7 .d .. 'F d;.;;- . .'
C'!b c: U4 . 4M'L ,u A 01-
"(J.l<->?><-<-d .. -> f<r>-

])/0 V"""#..;:.,,,;..u duUe.J.:: a.M ..;., --=Wit 0 7"-Qt <.v dA
"" j<n- wtM ?< =J t;, u-u ..
"it7 . .. ,," d<' c;;:
_ -[11 ..
b
ugl4p-f'i (I.....ut. > -or 13" > Se..P;,f,'(-,;c i
'hU- , L,..,
c. Dr InA Yn'-'l- f4uYV/ <I f:..,:.., If, V>A'/><r
;dtM -Nd! ....
;a; t<"-),...t. : p" htA .4>(.u -zk..
? )-- RA-<,t of -4 pl-r . 71.., t/>o k..Vxr 02.[>h
't6 tA.<J . U . /YLC\ w u1 l/t 1-1,,<::,( I-,.,L e '{:.-i-. un I -/
.t:u vY1 J$ ..
i
"" /-IN p-/$ . . 1>r.rt'1 WP->< -V ...... '" .... ./J/,4-<j
1-1 (V p-f i P--&tJ,-..dP-'&<f<f { .
'i 1- J" IV J Z>r w ..... -y,e..,., > !Jho .. <d;.... '3 P,..M',Cvt; 7-
7.J-0-M-"""'-&-qr -I 7).-' ..In Fe!; 1-1/11 W ,,,--
1.t4wv cl<J.,....,
w/.M t..c /-ltV u,4A--.,( z
J)r, /0.4'( <J>'f-bt
/-( I v r-t- - [)I' 4 '1 Zd; \
X"M 1 L (luG Jtcn-J- eJ.f DJ2>r. hi&l
. .l /1A.;[;..'&k . fJ4--C5 .. J
1>r Ma fI.c4 .. d.<. W<M- c _: .. 4. .t. F .a 4vJ'
! \ '
J......A;;.'tu.I..: oj P-t-r#'-"..ci0i' 1 ... &0 Dr,/Iu'"../k.h .
$-h s, / all
/ti--/l.e 2/ /
2/r. rl-c G.
/k :hftZ?Z; =>
.?-3/;J?
tilt?
Cfs-.z4
J'J>/L r J'nw Ulif tfUl-ci .J'dnaz <ff?
)/Ir/ J (?CR- LJ a.-r r .
I/IV-ittil', k;t- reR. I-,)I/I/!us r
.uceH7' '4-
k- V.J?( t.ftZ"7t", 7i.
?Yj-. )f w..PY U7<!- .s:-ne .2. 0/ {?CP7? t/ s P
x$1 -t& 7;ir -Zf Cf
1 c-tW-.J-e- J tL&im;r..e- w.e.- U<47 tu-e.-7k-
J rtf fi I?Jj ?!t if JiJi
/ r t'eVr rj.4 > btkf -1 :d- nff
/ :vi.)o [;LI5/J-
WM-lir11 'J?U t-
{see " JoLlrtZd 1- JlZ-f,dfiuJ (rrt;,
112 (2) -' J-t;-2 - J-Cf-j-) .
uJa- ,;w-.- 1H" 'J1.UlrT )-1/1/' .
(d:; 7Lb17e "r --ph
17ufJ-. ?&v.te--t::f( V/" YdmW tnVr
1Jt'Jo- tU/a TCrd.J !fi7U anq zj
Pr. ;;; -evmU " .
2)r. cd"
cq. ))11. + .
If.e.vt#b wnt! f
cur rl .. ",J!t:J. C,{;'a
,

.
,

,

i

~
_

,

i
,

'"""d.
/'lA-c-!/V\1 (? p ___ ..,{ 1-0'21 W L-<.4-
,d"N 4';', ';3 7'rvvv> -'41 "'- J,' h ' " U
Q
oJ . .,( ,tL;;.
1)/, , .A. . ./ ' J /_ IA! ' /o=- 1 _. J .c ,:-!. .........,....y
f .......-r -&:(/\...:Po.// U"l..-<.-) 4-'(LD,. ,vo ?n-</1-- c7(..I'll"L-"'t. .......... , c;;>. - / 1
.J .Ak'''" Nf<---v; FAX C -V r 6"-,-", 4A>-h.-..."
t-z e..t'-h.he'/-- f.,-(JU/<-f ,to ft4-- 4, A-
fur et..,..,1L.t itt- + u..rL
1
r-v. t';'
,,;, tA.f:..r r'A/YLd (j; 'I dL,,--<'d--4, N<- ", .. -..Jr;f
l.a-ti-< a . J.JT-V"O 7.)1- - ...
w ,d,,- It: (,'1.jJ"'Y'. e.r-- !' ,9 I1J-!.- M ..
o -:7
,{b..d - ,-f:.(L-d ,LO -t-<. for vf-O , v:, ',/.-/').1 4 J,...?' > ,
/ /U"l'l C-I'Vt-c.-;( 4<"- ! p_ 4-e-V( b . L __ '/ ?f
i--<rP.--7.-; ''">Y1--o'i/l- C t' .
Ir,L/\ j' 4 7J r )1-1..M b-ZlZ <h-1 It; tv--/ .
(){>kt.. o-f l' L.J 1 X- Il'''-]1 " .K-- :< of /if w-.cf
,( t;:. /"7v./-$ '! d.-:..- N I--?< t- 113 K",)'("" w <-L( t!--< .-R-...:z;;v - .d,.-.
rt.c ""uJ.,.'MAJ 'J d:... j>Co ..;., 7i4""" ,,,Up f4 .
a _ &ktC 1/ 1''''''' 1<4..-.' /U-A d <4 1<-<--< b-<d.i..- d",! ,"Dr kh-t .f

th o 0
1t.<'-1-j . ''ad 4 ,.- . 7fv.( f-V"l,p-py'J1.'1 /twr.
tv to/i,,- d .
) h.-<--y l,jT('V1..L d...eJv Ll> -t-tA-:J- ''''I-'I..-(JJ}. &4t."."I, -hv?< . f {%
p _ v
tt;;.'L4"-<' .(V-{ .. . .oJ- "'''fo- '
tJ--')-L-d 1,/-f/Vl1 t---L--1 Kf t:n-7 I
. () ..[4-;t- 14 {}. (3-(., JI.--zAL' /U
t1,1 <-,-.,I ,f...-<. ......j l/V4!...- d. . l.
p.:)' X-I( C4f 1-ife(w.h tVa; 6-e S81-t.f- ( ,
. -l/7'1.-"Y?
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-221-00:)3
Benefiting
Humanity
Through
Health
and
Peace
June 22, 1994
Dr. Chen Xiao Ping
chief, Department of Microbiology
No. 23 3
r
Zhongshan Rd.
Guangzhou 510080
Dear Dr. Chen:
We received your reply of June 2 and thank you.
points require further discussion.
Several
With regards to the question of ELISA or PCR for HIV titers,
the article that you referenced was very good, but does not
answer the question which I posed. If you injected pure HIV
antibody into a heal thy person, the ELISA analysis would
indicate that the person were HIV infected, although there is
no virus. Similarly, if one of our HIV infected patients has
all of the virus eliminated after malariotherapy, they will
still test positive for HIV antibody despite having no virus.
Unless we know that the antibody level will decrease rapidly
in response to HIV titer decreases, ELISA analysis won't tell
how much virus has been eliminated from the patient's body.
Dr. Heimlich recalled that you mentioned it was possible for
PCR analyses to be done in Beijing. Can you let us know: (1)
How much it would cost to have PCR analyses run there, and (2)
Is it practical to have samples sent there? Please note that
we would not want PCR analyses done on all cases. These would
only serve as a check on the ELISA measurements.
You mentioned that you were ready for the next set of HIV
patients. Have you begun the treatment or can you give us any
more details so that we can arrange for Dr. Hua to come to
Guangzhou at the appropriate time?
Do you have any more case data prepared for us? We have the
initial data you sent us for the HIV cases, but none of the
treament data or follow-up reports as of yet.
Could you provide a summary of patient funding which you have
received from us, so that we may make the appropriate
payments.
We have provided a return Federal Express envelope for your
reply. I look forward to hearing from you soon.
Best wishes and regards,

Jul y 11, 1994
h i r G. Sp l e t ze r , PhD
Heimli ch Ins titute
2368 Vi c tory Parkway, Sui t f' 410
De ar Or. Spletzer:
re ce i ved your l etter uf May 20,19 94. Thall k vou.
agr ee that PCR rna;' be the best way t o measu re HIV titer; but it i s not
ava i l able in Gu angzhou by now. It i s noi convenient t o send samp l es to
Beij ing for doing ?CR 'if I we can not tel l Beij ing we r ece ived HIV patients
from Yunnan Province ( they mus t ask us wh er e the pa t ient s are from), be cause
we do that on the way of Or . Heirn! ieh knows about that si tuat ion.
Othe rwise, we should est abl i sh PCR in our labarato ry. But if no PCR, it i s
al so OK to use ELISA for HIV antibod y t o [ppr es en t HIV ti t er because we have
known by now that HI V antibody i s iden ti cal to HI V in hwnan body, If only we
follow up them for over a half year.
Please t el l Dr.Heimlich and Dr. Hua that we have re ceived seven HIV patient s
in this group. The y wi ll receive malari otherapy after giving up their drug
addiction, maybe 10 days tater .
Bes t wishe s and regards to YOII , to Dr.He im li ch and Dr.Hua.
I )

c:- .
Dr. Chen Xiao Ping
Chief, Department of Microbiology,
The Muni cipal Health and Anti-epidemic Station of Guangzhou.
No.23, 3rd Zhongshan Rd. Guangzhou 5100 80, P.R. China.
The Municipal Institute For Preventive Medicine of
of' fiil r ffl of' lli '=:' !l/f23%
510080
r.l!, n5 ,7774103( .M!1 >
July 28. 1994
Henry J. Heimlich. MD,ScD
2368 Victory Parkway. Suite 410
Dear Dr. Heimlich:
Tel, 7774103 (ext)
Seven HIV patients received malarial blood yesterday; the incubation is
about ten days. you can make your tour arrangement according to that
situation.
We have used UP all funds from you, because all the seven HIV patients
in this group came from Yuili County. Yunnan Province; We three doctors
visited them three times in their home town before they agreed to come
to Guangzhou to receive malariotherapy. All patients with whom our
three doctors (including the doctor who was responsible for giving up
their drug addiction) accompanied came to Guangzhou by air (Yuili to
Mangshi by bus. Mangshi to Kunming by air and Kunming to Guangzhou by
air too). Before they received malarial blood. we had spent a lot of
money on giving UP their drug addiction. So we hope you can mail the
money to us in advance before you come to Guangzhou so as to carry out
the treatment smoothly. The money you should pay this time is:
- .
.p I!I im .p III
510080
t.l!
No. 23, The 3rd Zhong shan Road. Guangzhou
Tel: 7774103 (ext)
-----------------------------------------------------------------------
2000 USD: for the sixth cancer patient
5000 USD: for the first two HIV patients whom we have followed up for
a half year
7000 USD: for the seven HIV patients on their start of treatment
Toa 1: 14000 USD
By the way. if you consider the report of seventh cancer patient has
some significance. I'll give you the report: but we insist in that yoU
should pay for this because we have spent both money and time on his
treatment and follow-up even though he just survived one month after the
completion of malariotherapy. It is not we selected patient unproperly.
instead the patient varied very complicatedly and no effect on this
patient. since his general condition was good before the treatment.
Wellcome you visit Guangzhou again!
Best wishes to you. to Hua. Dr. Spletzer and my aunty. Cecilia.
Yours sincerely.
? I
Dr. Chen Xi,o Ping
Chief. Department of Microbiology
Municipal Health and Anti-epidemic Station of Guangzhou
No. 23. 3rd Zhongshan Rd . Guangzhou 510080. P. R. China
2368 VICTORY
PAR'f:Y.IAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXJ2
fax 513-22HXXJ3
Benefiting
Humanity
Through
Health
and
Peace
August 9 , 1994
Dr. Chen Xiao Ping
No . 23 3
rd
Zhongshan Rd.
Guangzhou 510080
Dear Dr. Chen:
We received your letter of July 28 and thank you. We were
delighted to know that you have started to treat the new HIV
patients.
According to Dr. Spletzer, the current status of data for the
different patients is:
HIV:
Patient 1: We have not received febrile data, post-
treatment and followup reports.
Pat i ent 2: We have not received febrile data, post-
treatment and followup reports.
Patients 3-9: We have not received histories,
pretreatment physicals and lab results.
CANCER:
Pat i ent 3
Patient 4
Was any followup examination
given prior to the patient's death?
We have recieved no followup
reports on this patient.
Patient 5 : Was any followup examination
given prior to the patient's death?
Patient 6 : No followup examination has been
returned.
Patient 7 What was the cause of death?
Was an autopsy done? Do we have data to show
what impact malariatherapy had on his
condition? Do we have biopsy information to
show that the cancer cells were undergoing
necrosis? If you can give us a complete report
that shows what happened with the cancer then
we will consider paying you for his treatment.
I would again stress that in the post-treatment and followup
examination that patients' physical appearance and condition
be reported in as detailed a manner as the pretreatment
physical. The patients' feelings about their condition is
also important.
As you can see from our agreement (attached), I have
highlighted the sections on what data is to be provided to the
Heimlich Institute as well as when it should be sent. The
payment schedule is also highlighted. You are to receive
$1,000 usn for each patient at the start of malarial fevers,
and upon our receipt of the histories, preexaminations and lab
results.
The list provided above by Dr. Spletzer shows where we stand
on each patient. When all necessary reports are received by
us, the funds will be wired to you, as per the contract. In
the meantime, because of your expenses, we have wired $3,000
usn as an advance.
We hope that things go well with the new HIV patients. I look
forward to hearing from you soon.
Best wishes and regards, ~ I ~ k
,
7dt1t I /{ C#id 0 r " UA
}' A!llllA
Henry J. Heimlich, Mn,kbn
The Municipal Institute For Preventive Medicine.of Guangzhou
,t
J
[l\j J"til l' IlJ ::: Be23%
i1(i if.{lIilfillJ, 51 0080
If:!, ;f,1i , 77741 03 ( )
No. 23. The 3rd Zhongshan Road. GuangzllOu
Tel, ?i7 t [ 03 ( ext)
II/' l'Ift(-
Jlb/1/?/ J . J1D
;h.5i2!?c.&i
2-J6f
/J_I I c;...j1t' )/r

>1/11 )flz! r;dtp,L; . b< tftrlf (ever;
6'LW yr
b2
tn.n-T'; 4/ n
r
Pr
-/ fi"d/ r
-t:b::r tr.MZ/1Zffi;i1. u/ W ;0,ze r ud!f
t me -&-8r / tiza.re-=!c:t(: J,9U-T
It r r Cd-tnMv'r-:
---cr-;;rVL / !lab?' d'=zI
{!)r Cfctl .
fh,2J. 3r'/2b;#k" 120" CtiLUj#z.k" s-tvP,P" , f'. I!, cL;,.,.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HXXl3
Benefiti
Humanity
Through
Health
and
Peace
August 17, 1994
Dr. Chen Xiao Ping
No. 23 3 ~ Zhongshan Rd.
Guangzhou 510080
My dear friend, Dr. Chen:
We received your letter of August 11. We are glad to know
that the new HIV patients have begun the fever stage of
treatment. We have not yet received the pretreatment
histories, physicals, lab results and photos (if possible), as
per the agreement. We hope to receive these soon. I have
instructed Susan Soudrette to wire the 7,000 USD to you when
we receive this information, as per the agreement.
We are trying to see if Dr. Hua can come to Guangzhou while
these patients have the fevers. I would like to come to
Guangzhou soon and visit you, however my schedule is uncertain
and I cannot give you any definite information at this moment.
Again, we hope that things go well with the new HIV patients.
I look forward to hearing from you soon.
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45200
51:}-221.{XX)2
fax 51:}-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
August 18, 1994
Hua Hong Shun, MD
3708 Baldwin Ave . #2
El Monte, CA 91731
Dear Hong Shun,
This is to confirm Dr. Spletzer's conversation with you
concerning your trip to Guangzhou, China.
Your trip to Guangzhou is to monitor the course of
ma1ariatherapy being given by Dr. Chen Xiao Ping to seven HIV
patients. We anticipate that you will be in Guangzhou for one
or two weeks, while the patients are s t ill in the fever stage.
We would ask you to observe the end of the patients' fevers
and visit the patients in the hospital every day to check that
they are receiving appropriate treatment and care. will you
also please observe where blood work a nd laboratory tests are
being done, and how they are being done. Please keep us
informed by FAX every few days during the course of your stay.
Your trip will not require you to go anywhere other than
Guangzhou, and we ask that you not leave Guangzhou until you
have completed these things. After you have finished in
Guangzhou, should you wish to take any side trips, you may do
so, at your expense. Do not schedule any trips for the time
you are in Guangzhou.
Currently, we are unable to make any commitment to
financially support malariatherapy research anywhere else
other than Guangzhou. You may wish to telephone Hainan Island
or Kunming, to maintain contacts with them and see if they are
still interested in malariatherapy, but we cannot start
research there at this time.
We will compensate you for your airfare to and from China
and expenses incurred while working on malariatherapy in
Guangzhou. In addition, you will be paid $1000 USD for your
time and effort. We would hope Dr. Chen's group will take
care of your lodging in Guangzhou.
If any difficulties arise, please let us know so that we
may be of assistance. We hope you have a good trip and keep
us informed.
I hope all is well with your family.
regards.
Sincerely,
\ { "
\ i r't' i I, '\
I jl !
\ I
\ i
1 '
I
I
'-
I I ',1_ C (
\ J Himl i ch ,
MD, ScD
I : ( ) :/
/
\. {. -
:;' .1
, ,- J \..,
I i / i '-"
_ L. ,_ ..
I
: "
L I -' :
,f - '- _ /1.-
/. ' ..
I I' 1.,1.
I "L l,. \( ) t... '
I,' _ .. /
I f.. :..
I ) " --
/U I ,
r / '
. /i ./1, I, f," 1/
,,( '
Give them my
(
/
....- I ( ...
2368 VICTORY
PARKWW
SUITE 410
CINCINNATI
OHIO
FAX: (513) 221-0003
FACSIMILE TRANSMISSION COVER:
D ATE: 8/1 J / 9t
TO:
LOCATION:
513 221.r0J2
Benefiting
Humanity
Through
Health
and
Peace
R E :
NAME OF PERSON TRANSMITTING:
If you do not receive all of the pages indicated above,
please call the above-named person at (513) 221-0002.
C/}"' . (

-- kU. "'Ir ;", . ()A. ""-- %
;- t,. Jr" :JW-l-l,.-.

Augus t 23, 1994
Henry l.Heimlich,MD,SCD
Cininnati,Ohio 46206
My dear friend, Dr. Heimlich:
I received your letters of August 9 and 17, thank you. I am
lorry to know that you have not yet received the reportl
(including the follow-up reports) of the first two HIV
patients and the cancer patient. you mentioned. Ie must
han miued the reports in mailing courses, because I sent
them per iodicd h according to our agneement. Last week I
lent the reports of the 7 new HIV patients who hafe all got
"
malarial paroxysms to you by FED. EXPRESS, hafr you received
them? Now I sent again the completed reports of the first
two BIV patients to you also by FED. EXPRESS. I look foward
to hearing from you fery soon so that I confirm you haTe
received them. Some time later, I will lend you the
completed caneer case reports. From now on, I will mail
them to you by FED. EXPRESS on your account number in
order to be life, do )'OU Igree? According to our Igreement,
when )'OU rece i red the case repor ts, )'ou shou 1 d wire 7000
usn for the 7 new HIV patientsjand Inother 7000 USD for
the fir.t two HIV patients, beclule we hale I.nt their
a hlU year's follow-up reports to you (20000X '01-6000=7000>-
So when you recei,e this letter attached the ease reports,
you should wire 14000 USD tottlUY to us, 10 II to
smoothl), complete the mallriotherap), on the 7 HIV pltientl.
By the WI)" the lib. sheet of CD3, 4, 8 of the els, i on
March 1,1994 wis milsed, but we cln cheek it in the lab.
records when Dr. Chai who i. re.ponsible for the telts come
back Iffer her summer 'Icltion; IDd the last time ELISA
titer will be done ,.r), soon, which dellYs som. tim. due to
reagentl llckness. I hl,e I small suggestion that if )'OU
. ,
certainly ,is it GUlnglhou again, you hid better do that
nry loon before the comp1eHoll of mallriotherlpy on the 1
BIV paUents.
A'tJtL5f IrtJtr
J/tU1'd' J. II p. SeD

2.3t5'<f? /,JirV:;y / /f-t)
if-f205
d/<w-(lOU -tile 7 -new mt/ Ti
briJ
anoi
--t,. f,j-f _ H 11/ t;a.k.- rerrtr tIz4 .J - -iF
JIJU reU4-tf:; 0/; Ft=:DEX,? \J c.-frm
,
tJ/$W c.pk ubiarl1 Mid
w..;ti Lic-t:.g #kef
1 p-rr ( dt;uhui ), ;;1 =ad k tid 'IUI't.J
Jle;J!t;fz, and CMe!
M HIV (&J
/ f/w ./ L,ISIJ allti
P A Me all "lUre- ) JIiU Ctl-rI >=-dz-,
I fN rtf M iJf 1 J9f.
/),dr). Ju
M CM1 be- M tl-. ccn:f;-N/ ;"
8tM' fro)ed? a.i;d )

I1Ie -it; -ViM, rna's t/
6r
'J SMm fij -
.!"!1 )Ir ',;k H7);W fr -tA j?ddnn I MZ4
5l2e !f1Jtl- 0" .
7ksi ""wi
@. I
tiki.', t! 2)1:1=:'7 t: . ,.
MttM-e:t.l jI-tiA IUtd .
1- Po
Ca-.se. s- .>
Case 6)
Case 7)
W5 i .>
Case 1 .>
tJ}) .. 2 .. 3 I C 7/2 :?Cf).
: R F (+) / tJ]):./ I tf-7 (7/
22
f! 1-);
b Inontiu 1-b-r.
Cl),J -- 7R2 -' CH1" LD,p,\ ]'11
( J /1 /q'f) / m17lltiz ) .
We-$tA-ll 8u;{ +; OJ): ;,17 (7P2/1lfj .
W/estM--n +- J ()]) : 2 I 0/ ( /!Z2/tt t).
WesiZrn +; OJ) (7/
22
/rf).
OJ): 1,1'1- (7/
22
/ tf lf).
u!est-rl1 '8!..ot T) OJ) 2 J) I (7/22/1ifj
OJ) : 2 \ 1]-( 7/22./rtt-)
BltJt-) l;LISA -.J Pli-
eD 0 (7/
22
/rf) .
BIf AI oW 'lY 71te J Mb cases !ottew-uf P f 6' t7ZdniiJ
Iws bl2n CJ7tnt&.. tLa{ and fC flf ir JO .
@ Tk 7 Ci:UCL.f' /u'stcT/f)
e X tJA11. tvn d Uub . htl-t/e bee 17 f--e 11 f i:tJ
;r.
JtlUr dear 7Jr Cill/ X,:W J/z/j'ltt .
A'tJtL5f IrtJtr
J/tU1'd' J. II p. SeD

2.3t5'<f? /,JirV:;y / /f-t)
if-f205
d/<w-(lOU -tile 7 -new mt/ Ti
briJ
anoi
--t,. f,j-f _ H 11/ t;a.k.- rerrtr tIz4 .J - -iF
JIJU reU4-tf:; 0/; Ft=:DEX,? \J c.-frm
,
tJ/$W c.pk ubiarl1 Mid
w..;ti Lic-t:.g #kef
1 p-rr ( dt;uhui ), ;;1 =ad k tid 'IUI't.J
Jle;J!t;fz, and CMe!
M HIV (&J
/ f/w ./ L,ISIJ allti
P A Me all "lUre- ) JIiU Ctl-rI >=-dz-,
I fN rtf M iJf 1 J9f.
/),dr). Ju
M CM1 be- M tl-. ccn:f;-N/ ;"
8tM' fro)ed? a.i;d )

I1Ie -it; -ViM, rna's t/
6r
'J SMm fij -
.!"!1 )Ir ',;k H7);W fr -tA j?ddnn I MZ4
5l2e !f1Jtl- 0" .
7ksi ""wi
@. I
tiki.', t! 2)1:1=:'7 t: . ,.
MttM-e:t.l jI-tiA IUtd .
1- Po
2368 VICTORY
PARKWAY
SUI TE 410
CINCINNATI
OHIO
45206
513-221-CXXl2
fax 51 3-221-CXXl3
Benefiting
Humanity
Through
Health
and
Peace
August 29, 1994
Dr. Chen Xiao Ping
Municipal Health &
Guangzhou 510080 P.R. China
Dear Dr. Chen:
Thank you for your letter of August 23, 1994, with the case
reports on the first two HIV patients and your letter of
August 26 with the ELISA titers . We agree that you should
continue sending the patient information via Federal Express
using our account number.
We have wired $7,000 USD for these first two HIV patients'
six-month reports. Once Dr. Cha i returns, please send us the
remainder of the lab results for patient 2 . Additional funds
will be wired when we receive copies of the signed informed
consent forms for the HIV+ patients.
Please let Dr. Hua and us know when the fevers will be ending
f or the HIV+ patients. We hope Dr . Hua will be coming to
Guangzhou within the week.
Sincerely,
t ~ ~ . ~ ~
Er ic Spletzer, Ph.D.
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PAR'{.:NAY
SUITE410
CINCINNATI
OHIO
45200
513-221-0002
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
DATE:
TO:
FROM:
August 29 , 1994
Dr. Hong- Shun Hua
Dr. Eric Spletzer
Susan Soudrette
RE: China Tr i p
We met with Dr. He i mlich today about the status of the China
trip. Dr. Heimlich insists you must see at least the last
week of fevers for these HIV+ patients. In order to do this,
you must talk to Dr . Chen.
1. Specifically, you must call Dr. Chen today to find out
exactly when the fevers will end. The fevers started
approximately August 10 and may be ending early next
week. You will need to adjust your travel according to
Dr. Chen -- it may be that you will need to leave in the
next day or two. Dr. Heimlich suggests that you can
leave Los Angeles on one of the daily flights direct to
Hong Kong then proceed to Guangzhou as he has done.
2. Please tell Dr. Chen that $7,000 USD has been wired.
:3
Also, tell him that we need to have the signed informed
consents from the HIV+ patients in order to wire
additional funds.
Which of the patients was stopped
jaundice? Was it the HIV- patient?
of jaundice?
early because of
What was the cause
4. Call Dr. Spletzer after your call to Dr. Chen to discuss
the status of the trip. His home number is (513) 761-
0722.
Thank you for your help.
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
August 30, 1994
Dr. Chen Xiao Ping
Municipal Health &
Guangzhou 510080 P.R. China
Dear Dr. Chen:
I am sorry I cannot go to China at this time. As you know,
I was very sick after my last trip and will have to be fully
recovered before I can return.
Dr. Hua has just told me that he will be in Guangzhou on
september 1. The patients should still have their fevers
and be in the hospital at that time. We look forward to his
report.
Thank you for the very fine records you are sending to Dr.
spletzer and Susan Soudrette.
In one letter you mentioned that I know about an
"underground". I think that is a misinterpretation of an
American word. I could not participate in an underground;
neither could the Municipal Health and Anti-Epidemic Station
of Guangzhou. I do remember you speaking of a network of
physicians who are helping with the project and that is
admirable. In any case, I wish I could speak Mandarin as
beautifully as you speak English.
Dr. Hua informed us that one patient became jaundiced and,
according to the protocol, treatment was discontinued. That
is a correct action.
The ELISA shows that one patient did not have HIV infection.
We cannot run controls, but his record may help our later
determinations. I am sure that when you sent him home he
was grateful, since other physicians had misinformed him
that he had HIV.
Your letter indicates that some
questionable character and made
hospital. That is unfortunate.
course, treat whoever needs our
of the patients were of
difficulties for you and the
As physicians we must, of
help.
As you know, we need the consent forms signed in
order to complete our initial records for the 7 patients, as
we did for the first 2 patients.
Thank you again for your thorough and dedicated work. My
regards to our friends in Guangzhou.
Hen y
President
Heimlich Institute
HJH/jlm
10 //cr'VR.. " J. /.IeI'M ficA MD.
Ft..'ut\1 /-/ON6 -.'i(.-IuN f.(V'4 I lvf-. D .
ICE l..""Uf tVl1 7<?fP A1/i'Lli,Q/4 fly ('IF ?--ts .
P4,/i- :
;" .\e-i- oc-of f
r
t-'1 I .....; i;1 t'J1? 0.8/3 r /f'<t ff AM </ /{ R R {I/ D o.-{- C;flll-I/117 114-( 11,.1 /::VC#,l f '.l '7
{J ,/o/ /11'1- ?11t;v LG-F-T 01\) oro '?'!'If a.-I" A),1(1t1,/ If 471!t:';1 a.f-
rt.: ''t,,,; t?.Lt-'i
, ;;(? LJ-( Yf(-illf,y (a/Myl;fX./-r;>c( Ii" cf../:l-Ir;e f)..f ,--,-/ .. " -'
i J VI l-e1 J (.It-{ /L7tt-<.,- &;-f k-'4,.--r;f ,
-/v M 1/..:,,-, 'i 10if 'I'T b .. ..f I "",_J-(<-' r.tJ. n&.. pd'S" \
I
A
u. 'r: . 7 If rJ
""'''1C--f/1Cr 111-4"b.. Ofe. r." ' ,flUt 4. t, fy 1f{1.J4 I ,A
erR. (.It\lt= -Z 0 It . J)1f11u_j pe<Jp(<;, ex."-e clr'lAj (f./cn:1IN eO) culd1'rJ" .... .;;:f . .f mo>-Hy
t.rI.A.A.-H''I,lc '1 <-Ie...rCJ .. ?h..l.-tr u4 t>r Or. a, ? 5 +-0
6(,1.4 '-1 tal Fir.::-I- rt.'l'1 :(:()- sfop dr;1 I II,.
6Ic-
rr
r::! of IOG<-; z: (v.W c.>f.
(1U..J-" ;:;, .,., .!t ':;;''';"7 / .
CdA<: tI Nal1fe
,
7'Aeir- C'(t, ( .ale. bf7'e-/Cy :
Aj-e.. .
St.;>: I \I 1 Mau:f/.1 rt .. G--<J<64' N"d D'f/7
l
{ . .tf
3 3jJj vx .
,
7
1
:!d
:o'7
i
/
t9{$
L.W
/.. . L .
G. '4
Y,L
.}
JtI I ..
. ,'( X' ilr IS .?lA-
7
I
i I i!J
,(
1.7
I. (
8/1
&/ J J!> <L X
I 8 /;.;1 ;<.
I r- . I ,
I
:)( 8/ 0/;0 HIII' PAl-Hi (+-) F.e,lrf!..r
2,:7
X
X
$/ ;,'
/
I
'-J -I
'-'
"
;(
3(!
X
S/..7
I
(
: ( I '>11' it;
r If! tI i rtf- -I-.r.../ .1-0 ht:J..<--f' iaLl<j <" rts; ,dtJefm'J { NP..f) e 5' (,I! e.,lt ov>7 _.
(I,"pl- tk.- L(1-6 .ff ..... "-'/ f .Ut CI f..-:s;r-I.''' 11.(
/11 e<.l-i"..tf Z l'lf f (Ph ",-';116e "",-...}- 11 I <
. " Co. (l'_ -C1...("
I ' .-' 1.....;. (J.ifihJ1.J'. O(f- 81."'1-:7.-0
A('1
fL
"t."'1 (Jo{ it')" 1'11<: Iv f
A
fr:r
f
f1.. ,'rm./ Ihl! IJ Y
fA Y. 0 /1 8'6 - 7-0 .- ] -6 - t 7' 6'0 Rolf! :#
i __ ,I j .' __
I
I
..
y..R.M Pt UsP.1' - i'" 1- ......( w..:f,.J/ -j;;I..
f1ALA.RIATHERAPY 1\ ()
A '',.n g., was held on 9/7/9
4
f iTl the In sti tut e {.)f Pr event t ve
() f Guangzhou t Chin
Per50nD1
L
"I., ...
. ',.. -
Dr.
Dr'1
Liu Shou-gou, vice
edicine
Xi
Lu t t Vic e dl:r'ect
Director of ii Ser H05p
of Institute of Preventlve
Dr. 1...1 T set'-5
1
.Ul
Dr. Kuang , Visiting docto t Yi Ser Hospital
fir. YI.\S , D,trector of Cl nic81 La 0, In sti tute of Preven ti v
e
Dr. H1)8. Hcngshun. He.imlich n .. t:i tute
D1' HU8!
Ei'or this tlm9 , I am assig; ed by Dr. Heimlich to monItor Uit?-
joint projectof malariath rapy of HIV+ patients in Guangzhou.
II the HIV+ pati ents here hAve filii the treatment s'C:::),ge
of m3.lrt rla e'lQ'(' , h::we th 11' blood drs'fm for leb test, and
ready to go back to the r hometown. I shall report what
1: t13ve observed to Dr. Hei li(:b and the Insti and I
bel i eve thnt we a re deepl ir.lpressee by the work you have
perforrne:i. It is high tim now fClr us to what we
done. Comments and sugge 'ions \'lelcome to pl:'C'1mote and
further o \.U' clinical T'B5e8 eh.
Cornments and suggest.ions are swnmarized followl3
The purpose of the projec ts to initiate mAlaria therapy to
HIV+ patients and to asset s t
l
1e effect. Patients have
t r)le:'Bted thQ malarJa fev r stage. What and how shall we do
next?
Ttlese ti ents are examin d <?nd found to be H1V+ by F:LISA
and "Je$tlrn Blot. They we e IV drug Rddicted ar'ld
expo SGd to heterosexual, iigh ri sk p3rtnet's. 'rhey
HIV+sinoe 1991 but they re stlll free from cl:1.ntcal symptoms.
'l'he enlarged lymph gland. Itlere not specific, Oecause they
.1ere 1 ikely to have tnte tions clue to non-sterile, '11.11 ttple
IV ,injeotions on extreml ies by themselves. Their CD4 counts
.',
',..,ere nonm).l, nove 500.
The p$tleots cerne from reT ote OOJ'oP,X" line ci ties near Burma.
t"lost of them af'e n;:ttiOnl''l.l mir'lorlties. Havlng Deen d_t'ug
they (l0 not mAint(c1in good, mor:':l.l in tegr1.ty. It is hard to
pt'cdict that they could l< . free from drug. DU:r'i'rlg their
st.ElY in Yj, Shou Ho 3Pi t thoy could not comply well ,..,i th
the h05pit8:L 5teff ( did net 11 sten to other phySicl.ans E)nd
nurses except Dr. Chen, q with other patients, borrow
money from hospital, a s fo):" Detter rflood, etc). Security
were to m0.i t.he in orner. These ktnd.
of tients not app opriete candidate for our project.
AS required by the proje t, the laD facilities are of importance.
The cells 1tlere mamUB 1y counted. We need Qquipment
that CQuld do the counto CDb cells automa tica11y.
To perform peR antigen t trotion, a lab of P3 level is needed
to set up for fUrth!r tl, c
It \'/111 take Lf days, 2 ays tly train and 2 deys by cor, .for
thesE' patients to rea.ch Quangzhou. a temporary lab is needed
to set up in their 0''''1) fot' fol lOh'Up.
To better undertake tbe mi a standing or-geni Zft t,i(m
is required. The(} Dr. C . en Xiaoping could devote full time
fO!' triG proj ect fl A'ltj. a will be staffee for the
pr1 uerwork.
Dr. Liu sized thF.i. .. AIDS a very problem
in this country. To un ert:l.ke this LJroject. they shouldered
aocial and polit cal responsioilitias. Because it is
not a ll-owed. to do any :regearch except in they had to
keep 'the research con! dgnttal. The Institute of Prevootive
t1 ed1.ci.n 0 of G1,.\angzhou i 1.1. keep suoportj.ng :for the furthel'"'ing
for tne prOl!ct. They ish their effor-t wtll be fully
reali"cd nnd full supp rt be provlded.bV .
that CQuld do the coun tof CDb cel ls auto a tics .y.
To perform peR antigen. t t t'r'<Jt1on, a lab of P3 ll?vel is. needed
to set up for fUrth!l"' tl:, a
It Hill take Lf days, 2 ays r)y train and 2 d8YS by car, .for
thp.se plti eots to rea.ch GUBngzhou, a tempol'cll:'Y 1e b is n
to set up in their horrie OWli fot' fal tovrup.
To better undertake the a standing organtzat.ton
is required. Then Dr. C . en Xiaoping could devote full time
foc 't,('IO pr'oj ect a nd a will be staffea for the
pt1 uerwork.
Dr. Liu sized thF.!., AIDS is a very problem
in this country, To un this project. they shouldered
500ial find polit cal reaponsioilltiQs. Because it is
not a llowed. to do any :research exoept in they had to
keep the research con! The Institute of
r1 edtci.n a of G1,.\angzhou i 1.1 keep sunportlng for the furthet'ing
for tne pro i eat. They 1 $h their effot't wt II be fully
reali(:cd nnd full supp rt be .l41-S'--h'hJ-e. .
. _-----
<P 00 r-m <P lU -=: Blf23%
510080
The Peopl e' s Republi c of China
r11 ali; 777.1103 ( .!;!, T-:' ) Tel; 7774103 (ext )
-
September 19, 1994
Henry J.Heimlieh, MD
It was a pity you could not come to Guangzhou due to
your healthy condition this time. I hope you are healthy
forever from now on, and may you be of longevi ty!
I mailed the informed consent forms signed by the 7
patients about two weeks ago, please wire the funds for
their feTer starts of malariotherapy according to our
agreement. Their treatment was completed and we sent
them home several days ago. I will mail their detail
reports to you. Dr. Hua will also give you some
imformation when he go back to USA.
Yours sincerely, /

Dr. Chen Xi Ping
Chief, Dept. of Microbiology,
Municipal Health and Anti--Epidemic Station of Guangzhou,
Guangzhou 610080, P. R. China.
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXJ2
fax 513-221-00J3
Benefiting
Humanity
Through
Health
and
Peace
September 22, 1994
Dr. Chen Xiao Ping
Anti-Epidemic Station of Guangzhou
No. 23 3 rd Zhongshan Rd.
Guangzhou 510080
People's Republic of Ch ina
Dear Dr. Chen:
In response to your letter of september 19, we have received
the informed consents, pretreatment histories, physicals, lab
results and photos, as per the agreement. We were sorry to
here of the difficulties that you had with these patients.
Susan Soudrette has wired the 7, 000 USD to you for completion
of the first stage.
Upon our receipt of the full reports and post treatment lab
results, physicals, photos, etc., we will send you the next
payment. We look forward to hearing from you soon.
...
: I .{.A.--r dc.eo f'
.-
'-'i
7h A){J t't7 fr.-() "';;' I (N'] .
7lc t!7 I\JO . q 7 (qct-y
,;;../..,......1";'
i ) ,"
iF )1;' Sf- ...., s:..p.(Ilt1'1
.cL. H(I!f
7tv- <" __ <<J7<.<> +
(x."1, f Itt f I' e. .
b
<!. .
,
J 4 , ... t&. 11A-!><LJ IYt ...., {; I - I' \;'0 A
r tL <vi;?.....e.. p..T-""'" -4-\'
tA.A q .
k-'"V\A ..
/ ..
.p m r-ffi.p ,L, ::: lllf23"-
iB; i!t!.fl li!1 : 510080
Ii! a;s : 7771103 ( ,(,HJL )
Oc tober 11, 1994
Henry J. Heimlich, MD, ScD
2368 Vitory Parkway, Suite 410
No . 23, The 3rd Zhongshan Road . Guangzhou
Tel: 7774103 (ext)
I received the letter of september 22 from Dr.Spletzer and
two paymen t s (2 x 6986USD) fr om you; thanks a lot. Now I send
you the full reports and post treatment lab results,
physicals and photos. Please wire us the next payment when
you receive them if posible. Dr . Hua may have told you the
detail about the patients' treatment; the payment
arrangement does be unsuitable for patients from Yunnan
Province. According to the situation of this time, it was
not enough to pay for the patients' treatment of
hospitalization and transportations; we still owe money to
Yi shou Hosp i tal after payed it the 14000 USD. So we wi 11
have difficulty to follow up them three months later due
to fund lackness if completely follow our agreement.
We discussed the plan of our project development when Dr.
<poorffl <PW'=:B!f23Ji}
510080
rt! om: 7774103(,tH./], )
No , 23, The 3rd Zhongshan Road . Guangzhou
Tel: 7774103 (ext)
Hua visited Guangzhou, he may have told you about that. By
now we can say that malariotherapy is safe for HIV patients
and from case 2 we can see a hope.
By the way, Dr.Xiao Bin-Qian, the president of our station
want to send me to USA to study AIDS in the ear ly of 1995,
I myself hope so when the follow up of three months later
is completed. Could you arrange that for me as a part of
the cooperation project? We look forward to hearing from
you soon.
u/un f 21< 1
8tH
C >-tnJ
Dr. Chen Xiao Ping
Chief, Dept. of Microbiology
Municipal Health and Anti-Epidemic Station of Guangzhou.
Guangzhou 510080, P. R. China.
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PAR'f,)NAY
SUITE410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-221-00J3
Benefiting
Humanity
Through
Health
and
Peace
october 11, 1994
Dr. Chen Xiao Ping
Anti-Elidemic station of Guangzhou
No. 23 3
f
Zhongshan Rd.
Guangzhou 510080
Dear Dr. Chen:
We hope that the funds Susan Soudrette wired reached you
without difficulty. Dr. Hua returned safely and has sent us
the videotapes and audio translations to review.
We look forward to receiving the full reports and post
treatment lab results, physicals, photos, etc., from you soon.
-
Dr. Heimlich October 11,1994
Enclosed is the Memo of our meeting with Dr.Li and
Dr. You, during our visit in Kumin9, Yunan province. I called
and discussed with Dr. Yang several by phone' 'while ' I was
in Guangzhou about the clinical investigation of AIDS patients.
He wrote me this time informing me that he would like to

follow up AIDS patients with malaria to compare those AIDS
patients without malaria. He agreed tp an addendum as a
suppiimentto the original memo.
Please find the English and the Chinese version of the memo
and sign at the pl a ces designated by pencil writing,if you
do convince with the merna. Then we shall FAX of send. by mail
to Dr. Yang to ask him to complete his
Enclosed also is the list of expenditure of my recent China trip.
"
Thank you.
I
Yours fraternally,
4- 13-1994
_-_::-e::. -e t s:
? b lic Health
Yang Qi M.D.
You Weichang
Li Xue-zhong
'"
MEMO
Bureau of Yunnan, P.R.China
Vice Chief of Sanitation and Anti-epidemic Division
Programme Off,icial in charge ofYunan Provimcial
OFFICE FOR AIDspontrol and Prevention )
M.D. Chief of the Pharmceutic and Drug Administration
Deputy Director of Eptdermic Disease Prevention
Office .
Director of Yunnan Province Malaria Reseach Committee
Henry J. Heimlich M.D. Professor, President
Hua Hong-shun
Meeting held at: Kunming, Yunnan P.R.China
At first, Dr. Hua made a brief introduction about the contributions
Dr. Heimlich has made in clInical research and in the promotion of
friendship and co-operation between the American and Chinese .people.
The purpose of this visit 6f Dr. Heimlich to China is to introduce
the theoretical basis of malaria therapy ift the treatment of mal i gnant
tumor and HIV + patients and about the clinical trial undertaken in
Jiangpu and Guangzhou since 1991. By communicating and exchange of ideas
on those problems of -", malaria therapyin concern, the . . both .parties wpuld,
like to find the possoibilities to initiate malaria therapion ma l i-grr:ant
tumor and HIV+ patients in Yunnan. .
As by the American professors, for sixty more , years, .
malariatherapy has been used effectively in treating
Through malaria infection, the immunity ability of the patients is '
increaseq., Tumor incidence was found to be low in high malaria incidence
area. The"1nortality rate of children suffering AIDS and malaria was
significantly lowered than those children only suffering AIDS.
Among the 10 malignant tumor patients treated since 1991, Six patients
showed improvement in various degree,five of thet six patients showed
marked improvement. Two, cases of HIV+ patients,one patient showed
the same high' level of CD4 count after treatment,as another case
hisCD4 count increased from low level to a significantly level.
As considered by the Ameri c an professors, to .observe the effect of
mal,aria ,therapy on AIDS patients, AIDS patients , could be, innoculated
wtth;' lnalaria blood, or by observing the . c'ourse of .AIDS patiehts who
aiso contacted ' malaria. That lnightbe easier to observe by the latter
that would be difficult, to hold the malaria treatment
during the course when the AIDS malaria episodes.
To the opinion of American doctors,the latter trial could only be
taken when patient voluntarily take part with full understanding
co-operation.
The experts of the Chinese party felt much inspired and raised
on malaria therapy: the basic theory, the scientific design, the ' assessment
of clinical effectiveness and medical ethics aspect etc.
\ They considered that ,as a scientif i c researc'h , malaria therapy is of :.:. ;' .i ni [' i
\'
MEMO (CONTINUED)
but the situation in Yunnan for the time being is
enti rely mature, they would make further consideration.
e ' expressed their hope to keep on the contact, and to procure
= rther material and information. .
J
SIGNATURE:
China Party U.S.A. Party
(signed) .
. Yang Qi M.D. , Henry J Heimlich M.D
,
?r:or t o departure of Dr. Heimlich and Dr. Hua, Dr. Yang made
5 ggestion, i.e. to initiate an to follow up
AIDS patients in Yunnan, by making comparison to those with
ma l aria, spontaneously infected and later been treated, and
those AIDS patients not complicated with malaria. By investi-
g ating this adult HIV+ PATIENTS and to find there is similar
result as reported among children in Africa.
Dr. Heimlich appreciated the suggestion as a rational - approach.
The Heimlich Institute will support this suggestion and would help
the experts in Yunnan to prepare the report of clinical research,
to have the paper published in major medical journal or presented
in appropriate academic meeting.
.'
2368 VI CTORY
PARKWAY
SUI TE 410
CINCINNATI
OHIO
45206
513-221-oo:l2
fax 513-221-oo:l3
November 10, 1994
Dr. Chen Xiao Ping
No. 23 3
r
Zhongshan Rd.
Guangzhou 510080
Dear Dr. Chen:
In reviewing and updating the computerized HIV case records,
we have been unable to find the fol lowing information in the
materials you have sent us:
1. Pretreatment HIV antibody mea surements for the last
group of patients that you t r eated (A side question:
Were these patients Western blot positive?) .
2. HIV antibody measurements for the six-month followup
examinations on the first two HIV patients.
3. The CD3, CD4 and CD8 data for the one-month followup
examination of patient 2 (Wang Wen-Guang).
Any help you can provide in obtaining this information will be
greatly appreciated.
After looking at the results for the first two HIV patients,
we think malariotherapy was beneficial. In the the next group
of patients (3-8), the trends observed in blood changes
between pre- and posttreatment seem to be too diverse to draw
any conclusions. Hopefully, the one-month followup
examinations will clarify things. What are your thoughts on
the results we have gotten so far?
Upon our receipt of the missing data, we will send you the
next payment . We look forward to hearing from you soon.
Benefiting Er ic G. Spletzer, PhD
Humanity
Through
Health
and
Peace
r
nfE
HEIMLICH
INSTITUTE
FD
Benefiting

Through
Health
, and
\ Peace
January 4, 1995
Dr. Chen Xiao Ping
No. 23 Zhongshan Rd.
Guangzhou 510080
Dear Dr. Chen:
I am writing to ask your help in obtaining some information
about the test procedures used in the MT-HIV proj ect. Are the
CD3, CD4 and CD8 counts that are being measured soluble
receptor protein or are they cell-bound receptor protein?
Also, what method is used for doing these analyses (i.e., is
cell bound protein being measured by rosette formation, or is
this being done by a fluorescence technique)? Please send
details about the analysis procedure.
We also are looking forward to seeing the next set of patient
reports this month. Thank you for your attention in these
matters.
Regards and best wishes for the new year,
C2C6
513-22 -roJ2
'ax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
January 30, 1995
Dr. Chen Xiao Ping
No. 23 3rd Zhongshan Road
Guangzhou, 510080
Dear Dr. Chen:
I hope all is well with you.
I sent the enclosed paper to you on January 4, 1995, and
urgently await a fax from you agreeing that the report be
submitted for pUblication in a medical journal. Please let me
know your answer as soon as possible.
Your comments on the paper will be appreciated. We thought
that Dr. Xiao Bin Quan should be mentioned in the
acknowledgements for his role in helping this proj ect go
forward. What do you think of this?
Dr. Hua informed me that you have just returned to Guangzhou
after doing follow-up examinations on the patients. We look
forward to seeing the next set of patient reports when they
are ready. It is not necessary to wait for the reports before
sending your permission to publish the paper since the paper
concerns only the first two patients.
With best wishes to all my good friends. u ~
Sincerel , ~ , ~ - I /"
~ . . . . . . . . I S \If'
Henry J. Heimlich, M.D. ~ ~
President
Heimlich Institute ~ ~ t
Heimlich Institute
Suite Cincinnati, OR 45206
Dear Dr. Sp letzer:
Feb. 16, 1995
Thank you for your letter of Jaa4, asking about the test
method for and CDS. Now I tell you that the test
call APAAP method, a measurement detecting cell- bound
protein neither by rosette for.mation nor fluorescence
technique, see Fig.!. The method is very believable since
the kits are made by the Chinese Military
Scientific Academy and have been widely used in China for
over 10 year s.
If you have any other questions about the metho4 it will
be my pleasure to tell you the answers.
Best wishes and Happy New Year to you
Sincerely
/l
(// 11
/
Dr. Chen Xiao Ping
Municipal Health and Anti-Epidemic Station of Guangzhou
No. 23, 3rd Zhongshan Roa4 Guangzhou 510080
P. R. of Ch ina
cell
APAAP staining
Fig. 1
-f Ce II Receptor (CDS, CIU, CDS)
-{ The First MeAb
(An t i Anti -ClU, Anti -CDS)
-< The Second Ant ibody
APAAP Cmlp leI (Bas ic Phosphatase)
( Substance (Red coloration)
Henry J. He imlich, H), ScD
Heimlich Institute
Su ite 410, C inc inna t i, (11.5206
Feb. 16, 1995
I received your letter of Jan. 30 and the second copy of
our paper enclosed I agree to publish our paper as that
I mentioned in my last letter. It is important that yon
added the sentence'COS cells playa part in controlling
HIV replication' in the second coppy.
I am sending the reports and photos of follow up of the
first two patients for one year and the second group of 6
patients for 3 months. Please send the payment for us to
pay Yishon Hospital of Guangzhou for the patients'
treatment of hospitalization and pay for the follow up. It
was a hard job for us to follow them up village by
village in Yunnan Province. We could not weigh them since
there was no any scale in their villages. Ie also have no
OD values of ELISA for HIVantibody this tbne( but all
Were ELISA positive) , because we used up Pasteur ELISA
Kits fran France, changing to use the Kits frun U. S. ( cut
off value is different fran that of Pastenr Kit) .
Fortunately we can do it again when Pasteur Kits arrive,
staying their sero-samples in freezer.
We will establish a effective therapy for HIV patients
when we complete the follow up of the 8 patients for two
year s, I th ink!
Best wishes and Happy New Year to you .
Sincerely f
(07
Dr. Chen XiaoPing
Health and Anti-Epidemic Station of Guangzhou
No. 23, 3rd Zhongshan Guangzhou 610080
P. R of China
Aprd 4 / Iqq.s-
C . Sfl1Jvr / p(J)
:m stt/u;&
.23U fcuw
d
/ 01e?
/ OH
91h IlIlnll;! itlllill
COlIgrc<>\ ( r I iii 11111110"
Please read i."15-
on pa es I II be =t'
completin
e
:his 'orr..
1)0 .... 01 n>LD
Cl)4 AND CDS CELL RESPONSE IN HIV PATIENTS INFECTED WITH PLASMODIUM
VN AX. Henry J. Heimlich and )Ciao Ping Chen, Bin Quan )Ciao, Shu Guo Liu, Vue Hen LIl, Ji Li
Yao. Heimlich Institute, Cincinnati, OK USA and Municipal Health & Anti-Epidemic stltion of
GuangzhOIl, Guangzholl, Guangdong. China
H1V.positive patients are susceptible to secondary infections that prove fatal because of
weaken,d inununity. In controst to other opportuntistic diseases. malaria does not Rccelerate the
T2!e of progression of HIV -I disease, nor does HlV infection worsen malaria effects or interfere
with response of malaria to treatment. Malaria and HJV coinfetion has been shown clinically, and
m 2:"limaI experiments, to improve Ole course of both diseases. This finding may be related to the
fsa 1hZ malaria infection stimulates Ole body to produce inunUlle substances. CD4 cells are
' -rteled 2.3 HlV progresses; initial results of our study, however, show that CD4 and CDS counts
E:"e ==-"11 in HlV positive patients who have had a planned febrile period of mslaria
tty of the interaction of malaria with HJV infection, two HJV+ patients alBa infected
. '- - ' (p. \.ivax) were allowed to undergo a series of fever paroxysms over a 23 week
>tru1 medical monitoring. The patients have been followed for six months post-
3oL': pa:mus ha ' e had a sustzined increase in CD4 and CDS levels (See Table I). Study
on HlV-positive patients. including further manges in CD4 and CD8
I mo. 3 mo.
follow-up follow-up
9361562 1260/977
4691391 6261288
rt'"S I lines: do not type on or clilSide these lines
6 mo.
follow-up
116211129
953/459
Poster ! Worksho p Preference
(see over for workshops)
Signature of
-;.-,r J.AO
1st Choice: tAl 7 .2
11 1 _ )
'_ =!L':". _-",'..=v--L1-:.... _________ _
Complete Mailing Address of Presenting
(please print or type)
uthor
-s will be considered assurance of the merit
PO=UiJOll and that all authors listed have had a signifi
;oIr - ;.'>e =ch being reported.
Important
' ail the Completed Abstract Form, Four Photo-
copies and the Acknowledgement letter to:
Secretariat
9th International Congress of Immunology
9650 Roc \'lIle Pike, Room 3200
Bethesda, MD., USA 208143998
19
Ca-5e: I )

CCL-J-6- 3
/
2. ,2-6
: / Iff
, 21/.J
<---"""- --::>
., ... 7);;1 ':Yl l-c! new
( l L 5-<. )" -'
(C<-5 C /
{ a . 5 ~ l /
{a-s: i I
2. I 2-0
2,2-2-
; 2.
2
7
2,JO
t
( ,
Address: No. 23, 3rd Zongshan Rd. Guangzhou.
li!!. :l.!I:: .p OO i 1H.pili=: l!lt23%
People's Republic of China.
5100 8 0
f\!i1S: H
Post No. 5 1 0 0 8 0
Tel: '/ -; 4 16 :1 (ext.) of G 535 5 (off ice)
J).eflY])r I 7
w
y
, ;6', I}jt
ar.e- .r am 1/7 jtio/P/ flwvf-
5J)r Ch.lM1 w:K atf-tm4 jt/,
0/ Immtv/l " Scm
,hpt/f It- tVf// witt k "1M
;, fl1<- f>+- g1Vr Cfflnm@?J 01
1 r-/-I1i/
ho I ; r aUc; atD.i fo !aif
1 "-
if i It p'';iIwr I CAn 40
f})r cJz <iN7 -{;j 71q yo j t1'n J +v V X ( fy'tl
t , V
h . @' 'PI} ,{" J t'.JP1J{{ ,,1J f??} vm
1;1-. i
,
..
} #1 rtf J! Wi ftIi
2 :
;'.(fiii'3 : 510080
El!. L Ii3 1"6-&!) 5 5
Address: No. 23, 3r d Zongshan Rd. Guangzhou.
People's Republi c of China.
Post No. 5 1 0 0 8 0
Tel: "7"1""1110 g (ext.) (office)
MALARIOTHERAPY FOR HIV
Addendum to Protocol
Study Size: The initial study will consist of 100 patients; up to 30
f these will be treated in the first year. criteria for possible
sel ection are: documented HIV-positive, CD4 counts between 200-550
cells/mm
3
(not as the result of drug therapy), non-drug users,
asymptomatic, no secondary infections. (Non-drug users are
preferred, because it is easier to modify behavior that led to the
initial infection.) In addition to these criteria, candidates must
agree to take all appropriate measures to avoid reinfection during
the follow-up period. Female candidates must be non-pregnant
during treatment and follow-up.
Patient Confidentiality: Confidentiality of patient identities are
subject to two restrictions: 1) Normal standards of patient
confidentiality; 2) National regulations regarding identification
of HIV patients to national health organizations. The Heimlich
Institute holds the relationship between all candidates considered
for malariotherapy and the Institute to be that of patient to
doctor. National regulations regarding identification of HIV
patients are beyond the scope of the Heimlich Institute to
regulate.
Patient Follow-up: Patients in foreign countries will be followed by
doctors in charge of conducting the studies in those countries, as
is being done in China. Costs and physician fees for follow-up
studies are included in the allotted patient costs.
One criterion for participation of u.s. patients is that their
physicians be willing to participate in the follow-up studies.
This will be complemented by telephone and correspondence contact
with the patients and physicians at appropriate intervals. While
it is anticipated the patients will participate in follow-up
physicals and laboratory testing to keep track of their progress,
a possible incentive to ensure that the appropriate follow-ups will
be to offer payment for laboratory tests for those not covered by
insurance.
The Institute recognizes that despite all efforts, some
patients will be lost during the follow-up period as a result of
withdrawal from the study and other factors. The Institute will
attempt to make changes as necessary to minimize such losses,
provided that such changes do not compromise the scientific
integrity of the study.
Data Collection, Transmission and Analysis: Treatment data is to be collected
at treatment sites by the physicians administering malariotherapy.
Follow-up data will be collected for foreign patients by the
treating physicians. U. s. patients will have follow-up data
provided by their physicians as per the study agreement.
As in our China study, data transmission will be accomplished
by FAX, overnight mail, standard correspondence, telephone and
visits, as appropriate.
I nitial data analysis will focus on primary changes such as
ecreases in HIV-PCR values, changes in CD4 and CD8 count, changes
HIV-antibody titers and clinical heal th. Secondary analysis
~ . , I examine correlations between HIV t i ters and/or CD4 and CD8
ce I counts with the cytokine profiles that are able to be obtained
these patients. Additional studies that might be performed
include examination of changes in HIV-induced synctinium formation
d HIV reproduction rate.
Project Status: Initial subjects have exhibited increased CD4 levels
' e ll beyond the treatment. During this time, patients have had
di sappearance of persistent lymph node swelling and patients
remained clinically well. A portion of these results were
presented at the IX International Congress of Immunology, July 24,
1995.
Future Plans: Assuming that this study meets all anticipated goals,
then bringing malariotherapy to the u.S . can be considered.
Unfortunately, we cannot predict at what point the NIH, the CDC,
the scientific community and the AIDS activist community will be
f ully satisfied. Thus, while the Institute will give due
consideration to the concerns of these groups, final decisions will
have to be made on the basis of scientific and ethical
considerations. It is unlikely that malariotherapy will be
wi thheld in this country should the results warrant the use of this
t reatment.
Factors that would encourage bringing malariotherapy to the
u. S. include: reduction or elimination of HIV, reduced HIV
reproduction rate, altered cellular propert i es of infected cells,
a nd/ or sustained elevation of CD4-cel l levels combined with
pe r sistent clinical wellness. Furthermore, in addition to
laboratory measurements, clinical status of the patients must also
be carefully monitored to ensure that problems are not created by
the use of malariotherapy. Likewise, expansion of malariotherapy
to patients with T-cell counts lower than 200 cells/mm
3
,
symptomatic HIV infection or secondary infections will require
careful scrutiny to ensure that malariotherapy can restore such
s everely depressed immune systems and that it does not adversely
interact with these conditions. Applicati on of malariotherapy to
these situations will be treated as new research problems.
The Institute insists on demonstrating the effects of
ma l ariotherapy in a measurable scientific manner. At no time must
i t be claimed that HIV is cured by malariotherapy without very
solid supporting evidence.
Table of Contents
1. CD4 and CDS cell response to induced Plasmodium vivax
infection in HIV patients.
2. Decreased mortality from malaria in children with
symptomatic HIV infection.
3. A CDC study concluding that co-infection of malaria and
HIV does not endanger the patient.
4. People in isolated malaria-endemic regions have HTLV
antibody reactions, yet no AIDS or AIDS-like disease is
found in those areas.
5. Presentation made at the International Congress of
Immunology, San Francisco, July 24, 1995, reporting the
results of malariotherapy in the first HIV + patients
treated.
6. Series of papers showing the role of malariotherapy 111
Lyme disease, cancer i: and neurosyphilis.
7. New York Times and Cincinnati Enquirer articles
indicating the of drugtberapy and vaccines
for HIV. ' ., i
fJo.#875
ABSTRACT
-
e
PRESENTED BY INVITATION AT THE
I NTERNATIONAL CONGRESS OF IMMUNOLOGY
JULY 24 , 1995 , SAN FRANCISCO, CALIF
HIV + patients are susceptible to secondary infections that prove fatal
because of weakened immunity. In contrast to such opportunistic
diseases, malaria does not accelerate the rate of progression of HIV-l
disease, nor does HIV infection worsen malaria effects or interfere
with response of malaria to treatment. Malaria and HIV co-infection
has been shown clinically, and in animal experiments, to improve the
course of both diseases. This finding may be related to the fact that
malaria infection stimulates the body to produce immune sub-
stances. CD4 cells are depleted as HIV progresses, initial results of
our study, however, show that CD4 and CD8 counts are increased in
HIV + patients who have had a planned febrile period of malaria.
In our study of the interaction of malaria with HIV infection, two
HIV + patients inoculated with malaria (P. vivax) were allowed to
undergo a series of fever paroxysms over a 2-3 week period with
strict medical monitoring. The patients have been followed for one
year post-treatment. Both patients have had a sustained increase in
CD4 and CD8levels without further treatment. Study of the effects
of malaria on HIV + patients including further changes in CD4 and
CDS levels and their relationship to the clinical course, continues.
No.HB75
lAND cor RESPONSE IN HIV PATIENTS WITH PLASI
-..-----...
_ .. - ... - __ --o..- ____
,....--._-------------
... -- ..
... ------ ............ -
..... -.......... .......... ......... _ .... _..-......-... _ -.... ___ c.-_c-_
____ r-_--..... . ..-.-...._,.-.....-..... ..
.. ---.. ......----------_ . .--.. -
...........--.....-.. -_---. ... ---_..-.... __ ..--.
_....--.........--..-.. c--a-------
............ _____ .-. ____ .. ., .. -' 1 .......
--..-......... .. _----
Henry J. Heimlich, MD*; Xiao Ping Chen, MD+; Bin Quan Xiao, PhD+; Shu Gou Liu, MD+; Yue Hen Lu, MD+; Eric G. SpIt
*Heiml ich Institute, Cincinnati, Ohio, U.S.A. ; +Municipal Health & Anti -Epidemic Station of Guangzhou, Guangzhou, (
BACKGROUND
,=-=-=-=---
Malariotherapy, successfully used for 60 years to
treat neurosyprulis, strengthens tlH' immune system by
stimulating production of TNF- a, IFN-a., IFN-,, IL-6,
IL-2R & sCD8.
In contrast, drug therapy can weahn HIV virus and
increase CD4 cells temporarily. However, the virus then
mutates, multiplies, and depletes Cl)4 cells, resulting in
fu ll -blown AlDS.
TREATMENT
Two HIV+ males, 23 and 40, were inoculated with screened malarial blood
(P. vivax). After 14 and 11 febrile episodes, resoo' , tively, malaria was
cured with chloroquine. Patients continue to be Inonitored one year post
treatment.
RESULTS
CD4, CDS levels of two HIV +
adults rose significantly after
one cQurse of malariotherapy.
persist one year later
", ...... .., . _ . t,:-"",.
" treatment.
are clini(cally well and
feelg()nger.
ADDITIONAL EVIDEtIGE OF MALARIOTHERAPY'S EFFECTIVENESS & SAFETY WITH AIDS
EFFECTIVENESS
Study of 112 children with AIDS, 41 of whom also had malaria:
None of the AIDS patients with malari<l died; 35% of AIDS
patients without malaria died.
Independent research by US Naval Medical Research Unit 2
and University of Nebraska found people in certain malaria l
regions posssess HIV antibcxlies. AI DS does not exist in these
malari;)l regions.
-----
SAFETY
CDC study: HIV did not worsen or interfere with
treatment of malaria, nor did mal aria accelerate HIV
progression.
Malaria is not an opportunistic disease endangering
AlDS patients,
Eli Chemin, Harvard School of Pllbli c Health:
"Records of treatment -related deaths or extrf'lne debil itat ion
following malariotherapy (for neuTOS yphilisJ are few
relative to the thousands of patients I renit'd "
No known report exists of ind un' d malil ri il not
being cured.
I,*,-
1,400 ]
1,200
1.000
800
CD4
GOO
400
200
i
1<*1_1
1,400
1,200 -\
1,000
800
CDS
GOO
CD4 Counts
lzaG
/ ____ 1181
I I --r-
ll1mlll 311mthl G IImUIii
Time

CDS &aunts
IIli
4 iii

200 r r
811mlhl
I J 1 IImlll 311mthl
i
1
Time
CONTINUING RES - __ --=--:c..:;.;:..:;
En larging Se ri es
Foll owing (or l. ong' 1 1"' ll od
Addi ng (l111l' 1
SIM l ln).; 1 nci<'r"nli " n I SI " II I II () t ii"
M .IiMl ol lw r"J' Y With () tl l "1 I ),.
and (n Iht' /0118, 11'1"' ,
(h"l nl(, lIt y l)"pl )("I II I I ; M" t,II I.11 ,"I,
NO CD 1ELL RESPONSE IN HIV PATIENTS( WITH PLASMODIUM mUlA.
I kimlich,. MD*; Xiao Ping Chen, MIY; Bin Quan Xiao, PhD+; Shu Gou Liu, MD+; Yue Hen Lu, MD+; Eric G. Spletzer, PhD*; Ji Li Yao, MO+.
II Insti tute, Cincinnati, Ohio, U.S.A.; +Municipal Health & Anti-Epidemic Station of Guangzhou, Guangzhou, China.
[NO
- -
"I (,0 yea rs to
Ilt l n1une system by
II IN a, IFN-y, IL-6,
II I IIV virus and
IWt'vC'r, the virus then
:, 1 )' \ ce lls, resulting in
Iii .; li 'I' ned malarial blood
, Ily;ly, ma laria was
II;II11; lorcd one year post
RESULTS
CD4, CD8 levels of two HIV +
adults rose significantly after
one cQurse of malariotherapy.
persist one year later
.' . , . . ... .. ;-;..: r :.,.
. . ' wftIlljtiFfurther treatment .
. --. -; - r;-:.;.:::
. -',
. Patrents :are chnH::ally well and

.: .,: f:
,) OF MALARIOTHERAPY'S EFFECTIVENESS S. SAFETY WITH AIDS
III 111\ <l isa had malaria:
I ;\ I" d; 35% of AlDS
<I I; .il l<esearch Unit 2
I II, II I certain mal<lrial
,lill ', not exist in these
------
SAFETY
CDC study: HJV did not worsen or interfere with
treatment of ma laria, nor did mal a ri a accelerate HIV
progression.
Malari a is not an opportunisti c di sease endangering
A1DS patients.
Eli Chernin, HaTV<l rd School of P' lblic Il ea lth:
"Records of treatment-related deaths or exl rnll e debil itat ion
f ollowing malariotherapy (jor neuros yphilis) art' ft'w
relative to the thousands of patienls I rt'l1/t'r!. "
No known repo rt exis ts of ind uct' J mZl !il riZl not
being cured .

CD4 Counts
1,400
lZ90 lltil
1,200 11;1
1.000
800
CD4
GOO
400
200 r ,
1.011111 3 _mills 6.1I11hs 1 year
Time
I Pati ent I

CDS Counts
1,400
1,200
en
1118
___ 11,eo
1,000
800
Co8
600
400
200 '"
I J 1.1I11h 3 .mllls
i!
6.1I11hs
Time
CONTINUING RESEARCH
En lu g in g Series
Fo ll owi ng I'a t,cnt s fo r Lo nger Pe ri od
Add i ng Vlra l l.oad s, Other Tes ts
StMl ,ng i ndepend e nt Stud ies In O the r l.or" les
L!s,ng M,l IMH)l hc' rapy Wi th O ther Diseases
and ;11 /I"' 1o,,:.! I .. ! m.
( hemlc.lll y Du p lica ting Mal ar ia Fu nc t ,on
1 y8lll'
The Charles A. Dana Foundation
745FifthAvenue, Suite700, NewYork, NewYork 10151 (212) 223-4040
( q 1 ,., r , . )
\/~(}-5 . . . . - ; V . . " i : ; >
October 4, 1995
Dr. Henry J. Heimlich
President
HeimlichInstituteFoundation
Suite410
Cincinnati, Ohio45206
Dear Dr. Heimlich:
DavidMahoney mentionedtomethat hehadavery interesting conversationwithyouat
theLasker Awardsdinner last Thursday. Hesuggesteditwouldbevaluableif I weretolearn
moreabout thevarious researchprojects youhaveunderway. Withthat inmind, I wouldlike
toinviteyoutojoin mefor lunchor ameeting inour officesthenext timeyoufindyourself in
NewYork City. Ifyouhavenotravel plansthat includeNewYork inthenear future, perhaps
wecouldtalk by telephone. I will ask my executiveassistant, BarbaraPeterson, tocontact your
officetolearnof your schedule.
I look forwardtomeeting youinthenear future.
Withregards. .
s~~
StephenA. Foster
President
SAF:bp
HJ H/ ms
Encl osur es
/
Ic , " : : /"'-f
,
/ r
/
~I - \
d (
(7//1
B e n e f i t i n g
L
-
H u m a n i t y
!!..<//
/~.-
t
T h r o u g h
' 1 -7 __ ,
1 -c: { I
H e a l t h ""... t-- \,
'-:, t{
a n d
v
P e a c e
T H E
H E I M L I C H
I N S T I T U T E
F O U N D A T IO N , IN C .
2 3 6 8 V I C T O R Y
P A R ' f.: o N A Y
S U I T E 41 0
C I N C I N N A T I
O H I O
452 06
51 3 -2 2 H X X l2
fa x 51 3 -2 2 H X X l3
I / 0 / ' -I ,,,,
r- ----.-----' \
, (I /J I (\..._ ,
Oct ober 10, 1995
Mr . and Mr s. Davi d Mahoney
I nst i t ut e f or Br ai n I ni t i at i ves
800 Fi f t h Avenue
New Yor k, NY 10021
Dear Davi d and Hi l degar de:
I t was a gr eat pl easur e t o be wi t h you l ast week. We seem
t o have so much i n common. J ane and I bot h l ook f or war d t o
get t i ng t o know you bet t er .
The encl osed l et t er j ust ar r i ved. Thank you ver y much f or
maki ng t he suggest i on t o Mr . Fost er . I l ook f or war d t o
hear i ng f r om Ms. Pet er son t o est abl i sh a t i me t o meet wi t h
t hem. At pr esent , Fr i day, November 3r d, l ooks f avor abl e.
I wi l l cal l when a dat e i s ar r anged and hope t hat I can get
t oget her wi t h you at t hat t i me.
J ane and I ar e bot h i nt er est ed i n t he I nst i t ut e f or Br ai n
I ni t i at i ves and woul d l i ke ver y much t o know mor e about i t .
I am encl osi ng a l et t er I sent t o Mar y Fi sher j ust a f ew
weeks ago. Hi l degar de br ought up her name at t he Lasker
l uncheon - - our mi nds must be on t he same wave l engt h. I
have al so at t ached some i nf or mat i on on mal ar i at her apy f or
your i nt er ~
/'
r~,
/
nr J . M. D. , Sc. D.
Pr esi dent
r
, /) I
AJ L/I.-(l-. ~\_t( II. ,
' ' ' ' .
/~' "
" , _, ' - i.... _. >'I . . ~,' /' (
(
\.,
tfj; (P ! /C
;
"
/J/,r7 / f -
/1' . I
, I <;
'\ "
,
~' ;' ;
~: /1 ,~ ~'
745 Fifth Avenue, Suite 700, NewYork, NewYork 10151 (212) 223-4040
The CharlesA. DanaFoundation
DAvID MAIIONEY, CHAIRMAN
(.1.... Q .-/ )..-
~,j
\ "
\ )
oct ober 13, 1995
Dr . Henr y J . Hei ml i ch
Pr esi dent
Hei ml i ch I nst i t ut e Foundat i on
2368 Vi ct or y Par kway
sui t e 410
What a del i ght i t was t o be wi t h you at t he Lasker di nner .
I know my wi f e enj oyed t he oppor t uni t y al so t o vi si t wi t h
your br i de, as t hey had much t o di scuss on al t er nat i ve
medi ci ne.
I do hope our pat hs cr oss. I have asked our Pr esi dent ,
St ephen Fost er , t o be i n cont act wi t h you r egar di ng some of
t he mat t er s we di scussed.
J ust f or your i nf or mat i on, I am encl osi ng some mat er i al on
what t he Dana Foundat i on i s doi ng.
Pl ease gi ve me a cal l i f at anyt i me I can be hel pf ul t o you.
Si ncer el y,
OM/ pm
Encl osur e
800 FIFTHAVENUE
NEWYORK CITY, NY 10021
Henry J . Heimlich, M.D., Sc.D.
President
Heimlich Institute
October 27, 1995
' ). . " , / Z ~ . ~ [I
, .._/I~'/1 r-I _'
: ____r f ~; 1) 1: - ; ... ' / i
rr t/ ; Jv ~ --~ /
.~{ /..---
, /d(
11/ , ) . "
/
Dear J ane and Hank,
David and I enjoyed so much meeting you both at the Lasker
dinner and having the chance to share many interesting thoughts and
stories. We also thank you for sending the information on
malariatherapy, which interested me because of the treatment as well
of Lyme disease, as one of our grandchildren recently was diagnosed
with it at age two and a half. It is also remarkable in what it seems
to be capable of doing with the HIV virus.
In any event, wewill definitely have to plan to meet again and
are delighted that you are able to be with us at the Dana Awards
dinner on November 8th.
David joins me in sending you our very best. Looking forward
to seeing you,
Sincerely,
+ll;~t-f~
F O U N O A T I O N , I N C .
2 3 6 8 V I C T O R Y
P A R 'f0 N A Y
S U I T E 410
C I N C I N N A T I
O H I O
452 0 0
513 - 2 2 1- 0 0 0 2
fa x 513 - 2 2 1- 0 0 0 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
November 13, 1995
Mr . Davi d Mahoney
I nst i t ut e f or Br ai n I ni t i at i ves
800 Fi f t h Avenue
New Yor k, NY 10021
Dear Hi l l i e and Davi d:
So much has happened si nce our f at ef ul meet i ng at t he Lasker
di nner .
Thur sday af t er noon, I at t ended t he l ect ur es gi ven by Rober t
Hor vi t z and Car l a Shat z at t he Rockef el l er Uni ver si t y, and was
i nt r oduced t o t he f asci nat i ng new concept s of pr ogr ammed cel l
deat h i n t he br ai n and ner vous syst em devel opment . Davi d' s
pr esent at i on at t he Awar ds di nner , as wel l as t he sci ent i st s
I met , gave me a bet t er i dea of your br i l l i ant accompl i shment s
t hr ough t he Dana Awar ds.
Di nner was del i ght f ul , and we so enj oyed bei ng wi t h you
af t er war ds. I hope you di dn' t obj ect t o my est abl i shi ng t he
" Hi l l i e Maneuver " . Your br i ngi ng us t oget her gave me a chance
t o speak at l engt h wi t h J ames Wat son about hi s r ecent wor k.
The next day I went t o Washi ngt on f or a meet i ng of t he Medi cal
Consul t ant s t o t he Ar med For ces wher e I spoke wi t h Sur geon
Gener al Vi ce Admi r al Har ol d M. Koeni g. I was pl eased t o
r ecei ve t he encl osed l et t er upon my r et ur n f r om t he Dana
Awar ds di nner .
The Naval Resear ch and Devel opment Command has sever al
sci ent i f i c bases t hr oughout t he wor l d wher e t hey st udy ant i -
mal ar i al vacci nes. We ar e di scussi ng wor ki ng wi t h t hei r
sci ent i st s t o anal yze t he mal ar i a par asi t e i n or der t o
det er mi ne what subst ances i n t he par asi t e i nduce t he
st i mul at i on of i mmune subst ances i n t he body.
I had a most pl easant and i nf or mat i ve l unch wi t h St ephen
Fost er on Thur sday, November 2. I am sur e he has t ol d you
about i t . Hi s under st andi ng of mal ar i at her apy was most
i mpr essi ve.
M. D.
-
DE PA RT M E N T OF T HE N A V Y
NAVAL MEDICAL RE5!ARCH AND D!VELOPM!NT COMMAND
NATlONAl NAVAL MEDICAL CENTER
BETHESDA. MARYLAND ZOI89-S044
IN REPLYREfER TO
9N ovember, 1995
F rom: Dr. Scott B. Halstead
Scientific Director, Infectious Diseases
T o: Dr. Henry Heimlich
F A X: 513-221-0003
Subject: M A LA RIA T HE RA PY
1. I enjoyed our conversation of the T uesday, N ovember 7, 1995
2. I have spoken to a number of N avy scientists, including some of the world's experts in
treatment of HIV . I feel confident that they would appreciate having an opportunity to
learn more about your experience with malaria therapy of HIV infections. Y ou
understand, I'm sure, that the N avy has no extramural program to support research on the
treatment ofHIV . A ny lessons learned or research leads from your work would have to
be integrated into a rather small intramural program of A IDS treatment. N eedless to say
the discovery of an effective method of treating or curing mvinfections would be of
great military importance.
3. Do you have data describing your study design and results to date which I could read
and digest to help me assess the possibility of organizing a follow-on meeting?
4. I will be away from my desk from N ovember 15through December 1,1995. A ny
materials which you might be able to provide I will review on my return. We can discuss
follow up plans at that time.
!.
I.E
515 Park Avenue
New York, New York.
10152
(212) 754-2890
FAJ\(212) 754-2892
'Dustees
David Mahoney,
Chainnan
A J. Signorile,
Theasurer
Robert A Good, M.D.
Carlos MOseley
Robert E. WISe, M.D.
-.
November 14,1995
Dr. Henry J: Heimlich
President
Heimlich Institute Foundation
Suite 410
Dear Dr. Heimlich:
I enjoyed our brief conversation the other night at the Dana Awards Dinner.
As promised I am enclosing the Eleanor Naylor Dana Charitable Trust
guidelines for requesting medical grant support.
All the best for your continuing success.
r.
\
\
;
-----------------:~
'5 l5 Park Avenue
New York, New York
10152
( 2 1 2 ) 7 5 4 - 2 8 9 0
F A J C ( 2 1 2 ) 7 5 4 - 2 8 9 2
November 29, 1995
Trustees
David Mahoney,
Chairman
AJ . Signorile,
Treasurer
Robert A. Good, M.D.
Carlos Moseley
Roben E. WISe, M.D.
Dr. Henry J . Heimlich
President
Suite 410
Dear Dr. Heimlich:
This is just a Pour Memoire for The Eleanor Naylor Dana Charitable Trust
Christmas Luncheon Tuesday, December 12th at 12.15 P.M to be held at the
"21" Club, in the J ack Room, 21 West 52nd Street.
David Mahoney and The Trustees of the Trust look forward to seeing you and
Mrs. Heimlich.
J
H E I M L I C H
I N S T I T U T E
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 410
C I N C I N N A T I
O H I O
452 06
513 - 2 2 1- C X X l2
f ax 513 - 2 2 1- (003
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
December 15, 1995
Mr . and M1; S~d !1a~
Char l es A( , _~
745 Fi f t h Avenue
sui t e 700
New Yor k, NY 10151
Dear Davi d and Hi l l i e:
J ane and I t r ul y enj oyed t he l uncheon on Tuesday. Ever yone
was so pl easant and i nt er est i ng. Bi l l Saf i r e' s t al k was
f asci nat i ng and has st i mul at ed us t o wat ch hi s pr edi ct i ons
devel op.
We cher i sh our f r i endshi p wi t h you, and l ook f or war d t o
seei ng you i n t he near f ut ur e.
When I saw t he Har var d Mahoney Neur osci ence I nst i t ut e Let t er
" On t he Br ai n" , Davi d, I envi saged how much we coul d
accompl i sh i f our I nst i t ut e had a si mi l ar r el at i onshi p wi t h
you. Your posi t i ve r esponse t o t he possi bi l i t y of our
wor ki ng t oget her st i r s me wi t h expect at i ons of t he cr eat i ve
goal s we can achi eve. I l ook f or war d t o your f ur t her
t hought s.
Best wi shes t o ~bot h
//
rI D ; : , egar ds,
-:
f or t he hol i days.
wi t h
M. D. , Sc. D.
HJ H/ ms
2368 V I C T O R Y
P A R ~A Y
S U I T E 410
C I N C I N N A T I
O H I O
45206
513- 22H X X l2
fa x 513- 22H X X l3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
/
December 28, 1995
I
Mr . Davi d Mahoney
1296 S. Ocean Bl vd.
Pal m Beach, FL 33480
Dear Davi d,
I t was wonder f ul hear i ng f r om you and Hi l l i e. J ane and I
ar e del i ght ed t hat we wi l l be seei ng you i n Mar ch. I was
most gr at i f i ed t o l ear n t hat your daught er saved your
gr andson' s l i f e. Pl ease l et me have t he boy' s name and
addr ess and I wi l l si gn a Hei ml i ch Maneuver post er t o hi m t o
bear wi t ness t o t he i nci dent when he i s ol der .
So much i s happeni ng al l at once i n r egar d t o
mal ar i at her apy, Davi d, t hat I woul d l i ke t o keep you post ed
on r ecent event s.
CHI NA
Pat i ent t r eat ment cont i nues. The doct or s have agr eed
t o appr oach t he Mi ni st r y of Heal t h on t he possi bi l i t y
of t r eat i ng hundr eds or t housands of AI DS pat i ent s i n
sout hwest er n Chi na.
DOMI NI CAN REPUBLI C
The encl osed l et t er i ndi cat es t hat t hey ar e r eady t o
get st ar t ed i mmedi at el y.
COSTA RI CA AND GUATEMALA
Bot h count r i es ar e now r eady t o go. I i nt end t o
vi si t Cost a Ri ca and Guat emal a t he week f ol l owi ng
J anuar y 27t h. At t hat t i me I hope t o negot i at e
agr eement s so we can pr oceed wi t h t r eat ment s. I wi l l
t hen go t o t he Domi ni can Republ i c when t he pat i ent s
t her e ar e under goi ng mal ar i at her apy.
When we l ast met , t he quest i on was r ai sed as t o whet her t he
t r eat ment of HI V woul d r equi r e an except i on. I have r ead
t he Dana Foundat i on Pol i ci es and Pr ocedur es t hat you gave me
and was pl eased t o f i nd t hat t her apy f or HI V dement i a i s
i ncl uded i n t he Foundat i on' s goal s. That i s pr eci sel y what
we ar e i nvol ved i n.
Mr . Davi d Mahoney
December 27, 1995
Page Two
The Chi cago Hope epi sode on mal ar i at her apy was ver y posi t i ve
and made many peopl e awar e of what we ar e doi ng. I wi l l
br i ng a copy of t he t ape when J ane and I vi si t .
t f or your heal t h and happi ness i n t he new year ,
Hei ml i ch
HJ H/ ms
Encl osur es
Consulado de la Republica Dominicana
Ohio, Kentucky y Indiana
1840 Anderson Ferry Road Suite 109
Cincinnati, OR 45238-3936, USA
December 16, 1995
HenryJ. Heimlich, MD., Sc.D.
2368 Victory Parkway Suite 410
Cincinnati, OH 15202
Dear Dr. Heimlich:
We are delighted to confirm that you have accepted our invitation to commence your Malariotherapy
treatment for HW. We confirm that the original phase will commence by January 30, 1996. Twenty four
patients will be chosen. The government of the Dominican Republic warmly welcomes you.
The hospital, laboratory and medical personnel are gearing up for the start up phase. We estimate that
by March 15, this first phase will conclude with the treatment to cure the malaria. The second phase will
commence by April 1, 1996, and conclude by May 15,1996.
As you well know, medical treatment is expensive. The Dominican Republic will provide you with the
best we have to offer. However, we are not a rich country. Your offer tofond the treatment and research
is essential for the IfUccessful completion of your Malariotherapy treatment for HW. We await your
arrival in the Dominican Republic around the middle of February.
We are excited to assist you In this humanitarian effort. We thanJcyou for the opportunity to work with
you. Feliz N.aviJatl, Prospero Ano Nuevo y Felicidadlt!
.... ". to. ~
Amigo's P~a Siempre,-_
, .. , "
- , .
Telephone: 513-451-0077 Facsimile: 513-451-0066
e-mail: CONSULRDOHKYIN@MSN.COM
--. - -- --.--------- ~.4_4 _
GUATEMALA
~~P-27-95 WED 18; 50 BOB CARPENTER
OJ 1"'50;::~2+777784
F'. I)I
FAX TO WAYNE &: BE"I'rt: ;}JJ-928-0150
F ROM BOB: 011-502-2-771784
WE TA L K ED TO DOCTORA V IL l..A TORO THIS MORNlNG WEDNES DAY THE 27th A ND THE'i
HA D THIr.IR 16 Of ~TORS FROM 16 nIFl'ERF.m' ME:DJ CA L C()J IMmlTIES IN A MEE-TINO
YES TER DAY AS PlA NNED. DOC TOR A V IWTORO G AVE EA CH DOCTQR IN A 'ITENDlmCE A
COP'! OF: MA k!BIJ .'l'aERA FY SliQWS PROMISE A S.. .A IDS .. TBF..A .TMENo:r &: eM &; cDS CEJ ..L R E-
!f9t!S~. IN H!V p~rlENTS INFroTEp 'WITH J >IA SMODIY M V lV A X.
THE DOCTORS .AR E TO S TU DY THESE PA PERS A ND THERE WII.L BE A NOTHER MEETING
WITH THri)f NEXT WEEK
.A T 005 TIME T1tt P R OS & : C ONS WIL L BE DISCUSSED A ND DOCTORA V 1L L A .TORO WIll
MA K E HER DFDrSION A S TO WHEN Tl{g PROGRA M 'W!L L BE INITIA TED.
rr A PPEA RS THA T THE'{ A RE BEING V ERY PRFCISE IN UNDERSTA NDING THE PROGRA M.
A Fl'ER DOC 'l'OR A V It..L A TORO MA K ES HER DEX)ISION I PL A N TO HA V E A MEFl'n~o WITH
HF.R 'l'O DISCUSS THE DErA IL S OF THE PROGRA M.
WA Y NE CA N Y OU SEND ME MORE CO Ql0 &: MEL A .'rONIN ? I A M oor OF CO Q10.
GOD BLES S Y OU BOTH.
IN CHRIST.
'J.l,J ':t II(_
Nov. 15. 1~95
FAX to Henr y Hei ml i ch
FAX 513- 221- 0003
Fr om Wayne Mar t i n
FAX 334- 928- 0150
Hank:
J have a f AX f r om Boh Car pent er .
He r epor t s as f ol J ows:
DJ', J ose Monj es and Bob met l ast ni ght wi t h Dr. Al eman and
seven ot her doct or s f r om Hospi t al Especi al i dad,
He says t hat t hey gave a posi t i ve yes f or your pr ogr am. l i e
says t hat t hi s hospi t al has an i nt ensi ve car e uni t , 35 beds
a bl ood t est i ng l abor at or y and a doct or on dut y at al l
t i mes.
We have al l gr own ol der f or a long t i me whi l e t hi s has been
happeni ng, 1 hope t hat you have an i nt er est .
Af t er you have r ead this FAX I hope t o t al k t o you on t he
phone,
Wayne
San J os~, May 9 1995
Dr . Henr y J . Hei ml i ch, Pr esi dent
The Hei ml i ch I nst i t ut e Foundat i on
Fax ( 513) 221- 000J
Dear doct or Hei ml i ch:
Many t hanks f or your l et t er of Apr i l 25. I am ver y gl ad t hat Ar nol d
i s our mut ual f r i end and t hat he suggest ed t hat you get i n t ouch
wi t h me.
Iam i ndeed associ at ed wi t h a ver y ser i ous AI DS or gani zat i on cal l ed
Fundaci 6n Vi da, whi ch i s i nvol ved i n t he ar eas of r esear ch,
pr event i on, councel i ng and ot her ar eas r el at ed wi t h AI DS. Vi da i s
l ed by a ver y r Gspect ed Boar d, chai r ed by Dr . J avi er Moya, a l ong
t i me chanpi on of t he f i ght agai nst AI DS.
Dr . Moya i s pr esent l y away f r om t he count r y, but he wi l l be back at
t he end of t he mont h. I n t he meant i me, Iam del i ver i ng your l et t er
and i nf or mat i on t o hi s of f i ce, and we wi l l get i n t ouch wi t h you as
soon as he r et ur ns.
I am l ooki ng f or war d t o a ver y pr oduct i ve reLat . Lcnst i Lp bet ween
Fundaci 6n Vi da and The Hei ml i ch I nst i t ut e Foundat i on. Needl ess t o
say, I am l ooki ng f or war d t o m~et i ng you dur i ng your next t r i p t o
cost a Ri ca. Pl ease convey my t hanks and r egar ds t o Ar nol d and hi s
f ami l y.
si ncer y,
4~)!/~~~
. ~l ; ; : o Ugal dQ~Envi r onment al Advi sor
UNDP- Cost a Ri ca
cc:
Hans D. Kur z, Resi dent Repr esent at i ve
J avi er Moya, Fundaci 6n Vi da
San J OSe, August 30, 1995
Dr . Henr y J . Hei ml i ch I nst i t ut e
Fax 631- 2210003
A f ew weeks ago I was wonder i ng about t he communi cat i on bet ween you
and Dr . Moya. I was about t o cal l hi m when your r ecent l et t er
ar r i ved. Iapol ogi ze f or what happened, but Ihaven' t been abl e t o
f i nd hi m t hi s week. ~par ent l y he moved t o anot her ol i ni o.
Thi s t i me, wi t h al l t he i nt er est i ng i nf or mat i on you sent on
mal ar i at her apy agai nst AI DS, I pr omi se t o get i nvol ved mysel f and
t o do a bet t er j ob. I have sent copi es of your i nf or mat i on t o t he
Nat i onal AI DS Commi ssi on, Fundaci 6n Vi da, t he Uni ver si t y of cost a
Ri ca and t o ot her i nt er est ed par t i es. I wi l l cont i nue t o do t hi s
and make cal l s and per sonal vi si t s unt i l I get some act i on.
By t he way, i f you ar e pl anni ng t o vi si t Cost a Ri ca and i f you l et
me know wi t h a f ew weeks not i ce, I coul d ar r ange a meet i ng wi t h
sever al peopl e ( physi ci ans, ai ds suppor t gr oups, gover nment , et c. ) .
As you can i magi ne, we have many quest i ons about mal ar i at her apy and
pr obabl y some i ndi vi dual s woul d l i ke t o t ake t he t r eat ment i t
possi bl e. What ar e t he pr ecaut i ons t hat shoul d be t aken? Ar e t her e
l egal aspect s i nvol ved? I S t hi s t r eat ment danger ous f or somebody
who isal r eady ver y compl i cat ed and si ck?
As you can i magi ne, your i nf or mat i on has l i f t ed my spi r i t and
r evi ved my hopes. I ' m sur e i t wi l l do t he same f or many peopl e.
Iapol ogi ze agai n and Iwi l l be i n t ouch wi t h you soon.
Si ncer el y,
hcuv/__/~~
--Al~ ugal de/ ~
cc:
Hans D. Kur z, Resi dent Repr esent at i ve
Dr a. Gi sel a Her r er a, comi si 6n Naci onal de aI DA ( f ax 227- 7705)
Dr . J avi er Moya, Fundaci 6n Vi da ( f ax 233- 3316)
Dr . Pedr o Le6n, Uni ver si t y of cost a Ri ca ( f ax 289- 6746)
~,......" ,',T'" .......,.. ,-..rrT lOr- .,::::.,.....,u 1.11I ;>.1-l
E S CUE LA AUTONOMA DE CIE NCIAS ME DICAS DE CE NTRO AME RICA
U Dr. ANDRE S VE S ALIO GUZMAN CALLE J A "
AFILIADA A LA UNIVE AS IDAD AUTONOMA DE CE NTRO AME RICA
November 26, 1995.
HENRY J . HEI MLI CH, M. D.
Pr esi dent Hei ml i ch I n5t i t ut e
Fax ( 513) 221- 0003 ~
Dear Dr Hei ml i ch
As Al var o Ugal de t ol d you. I di sagr eed wi t h t he t er ms st at ed
i n t he l ast f ax f r om t he Ad Hoc Commi t t ee on Mal ar ' i ot her apy
f or HI V- AI DS. I t i s cl ear f or me and f or t hou6ands of si ck
peopl e, t hat t her e i s no cur e f or t he di sease al t hough
t r emendous ef f or t s f r om t he bi omedi cal f i el d have been
t aken. We need t o be i nnovat i ve 1 open mi nded and been abl e
t o chal l enge t he par adi gms t hat we f ol l ow t oday.
Your i dees on mal ar i ot her apy f ol l ow t hose l i nes and
cer t ai nl y t her e i s some epi demi ol ogi cal suppor t t o encour age
t hem. I don' t t hi nk i s necessar y t o ser ot ype mal ar i al or HI V
3t r ai ns i n or der t o appr oach mal ar i ot her apy al t hough i f your
I nst i t ut e deci de t o hel p i n t hi s r egar d your par t i ci pat i on
wi l l be hi ghl y appr eci at ed.
To my under st andi ng. st udi es mor e i n t he l i ne t o i ni t i at e
mal ar i ot her apy ar e :
i. Those i ncr easi ng t he knowl edge on t he i mmune r esponse
i nduced by mal ar i a i n r el at i on t o CD4, CDB and ot her i mmune
cel l t ag6.
2. Def i ni ng i f t he r esponse can be obt ai ned not wi t h act i ve
st r ai ns of mal ar i a, but wi t h t r eat ed / macer et ed speci mens.
3. Tr eat HI V cel l cul t ur es wi t h ser um f r om act i ve and
conval escent mal ar i a.
I bel i eve t her e ar e mor e r esear ch avenues t hat can be t aken
i n or der t o avoi d t he act ual " t r eat ment " of HI V wi t h
mal ar i a. Anyhow, above . st udi es mav eer ve e.e t he aoLi d
sci ent i f i c evi dence t o appr oach human r esear ch.
I f I can be of any assi st ance i n t hese t asks I ' l l be happy
t o par t i ci pat e. Si ncer el y
DR J AVI ER E. MOYA ~
Fax (506) 2~
cc Al var o Ugal de . Fax 296 1545 ~
,APAI!.TADO 638-1007 CE NTRO COLON
$.,,"" JOSE . COS1''' RIC.",
t'E LFONOS : 3A2194_
312860
FAX 31-43-68
,
2368 V I C T O R Y
P A R K W A Y
S U I T E 410
C I N C I N N A T I
O H I O
4S 200
51J ..22H xm
tax 51J ..22H X X X l
B e n e f i t i n g
H u m a n i ~
T h r o u g h
H e a l t h
a n d
p p .~r p .
December 5, 1995
Dr . J avi er E. Moya
Escuel a Aut onoma De Ci enci as Medi cas
De Cent r o Amer i ca
Apar t ado 638- 1007 Cent r o Col on
San J ose, Cost a Ri ca
Dear Dr . Moya:
Thank you f or your t hought f ul and knowl edgeabl e l et t er of
November 26, 1995. I am sendi ng t o you a sci ent i f i c paper
we have submi t t ed f or publ i cat i on, and a ser i es of publ i shed
sci ent i f i c st udi es t hat document t he basi s f or
mal ar i ot her apy and i t s saf et y i n HI V+ pat i ent s.
Unf or t unat el y, most of t he U. S. Gover nment ' s AI DS r esear ch
f unds have gone f or dr ugs over t he past t en year s. The
ef f ect of dr ugs, such as AZT, on t he vi r us i s t r ansi ent - -
t he AI DS vi r us r api dl y mut at es and devel ops r esi st ance t o
dr ugs. Such vi r al mut at i ons do not al t er t he ef f ect i veness
of a st r engt hened i mmune syst em r esul t i ng f r om
mal ar i ot her apy - - our body' s i mmune syst em i s const ant l y
over comi ng a var i et y of i nvadi ng vi r uses.
Your suggest i ons ar e wel l t hought out , however , we ar e not
f unded f or such pur poses.
Per haps I di d not make cl ear t he st at us of our
mal ar i ot her apy pr ogr am. A maj or medi cal soci et y, af t er
r evi ewi ng our successf ul t r eat ment r esul t s t o dat e, gr ant ed
I nst i t ut i onal Revi ew Boar d ( I RB) appr oval f or t he t r eat ment
of addi t i onal HI V+ pat i ent s wi t h mal ar i ot her apy. We have
l i mi t ed f undi ng maki ng i t possi bl e t o of f er t r eat ment of
U. s. ci t i zens, as wel l as HI V+ pat i ent s i n sever al
count r i es, and ar e sel ect i ng t hese count r i es at t hi s t i me.
Tr eat ment wi l l be car r i ed out at t he hi ghest sci ent i f i c
l evel and par t i ci pat i ng sci ent i st s wi l l , of cour se, be
i ncl uded as aut hor s i n sci ent i f i c r epor t s submi t t ed t o
medi cal j our nal s.
I woul d l i ke t o have you j oi n i n t hi s pr oj ect as I have t he
gr eat est admi r at i on f or Cost a Ri ca and i t s peopl e. I wi l l
be vi si t i ng one or mor e count r i es i n Cent r al Amer i ca dur i ng
t he Week of J anuar y 27t h. Shoul d you wi sh t o meet wi t h me,
and have an i nt er est i n t r eat i ng HI V+ pat i ent s wi t h
mal ar i ot her apy, pl ease l et me know and I wi l l pl an t o set a
dat e t o vi si t you and your col l eagues dur i ng t hat per i od.
Dr . J avi er E. Moya
December 5, 1995
Page Two
I l ook f or war d t o meet i ng you. I n t he meant i me, I woul d
appr eci at e your t hought s af t er you r evi ew t he mat er i al I am
sendi n you.
Henr y J . M. D. , Sc. D.
Pr esi dent
Encl osur es
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 410
C I N C I N N A T I
O H I O
452 00
513 - 2 2 H X X l2
fa x 513 - 2 2 1- r0J 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
/
/.. .(-\____
I ( Y ( q ~
~7J~~~J
~ _ 5) ~
_ ~ /S' ~ ( /~ __ ~ F ~ /~
~ ~ "~ ." S~ tf"t/~ r
~~~ ..d' l<~ _
!f/~*fidtfrI7~dP 7'
~ v ~ ~ ~ : L" :/ h,H;UP~h
r-:>: . >4j/L.~ '~tkL
~ ~ 3Wd~ ~ ~ ,
~ ~ jJw~ cv~ d~ ~ .
S~ d-tfUpw/:t /fi~~1 ~~
~p& s. 4Y{; ~ ~ Wr)~
JIfM__.~/~~P1~, $U.~
~ o / P j!};ja 0Mt~~/up~ I s
!jcw~ " 3 ~~
_ . : : . - -:
.:>
. . _ . .
_ '_11 .~ '~'.....:wH' NrwtI NltWG ............. NI[WH NlCwfJ Ny"''' NII:WII N!:WH. NP.:WA ~." '1
f"(~W8. f"{E;WB ~tJ ~ r..flInu ,....... N_V'o[JI r'4n.,....... - ,
I
i
MalariaTherapy ShowsPromise asAIDSTreatment
Dr. Hcnry J. Heimlich, of the." .. tn conrrast to tho drug approach,
Heimlich Institute, Cincinnati, Ohio, 1I\&.lariatherapy strongthoTl8 thebody's
presented an ....IDS treatment study at Immune eyHLuUl,which webelleve wlll
the Ninth International Oongrelle of ellu\}lo it to control tho virus In all Its
Immunology in Sun Frtu\ci6C(, on July mutll.tione. ~lICan;h f'rvmUC Borlwloy,
~4, 1995, Cu'prt:8cnter was Xiao l'1n: Walter' Reed Reseurch Ccntor, tl~c
Chen, MD, ofthe Municipal Health and University of Heidelberg and many
Anti-Epidemic Station of Quangzhol1, other Institutions "hows that malaria
China, where the reaearcb was stimulates t.he body's production of
conducted. The study dcacr ibea immune substances, including
promising reaults from the use of interleuklns and interferons. Theae
malaria t.herapy to' trent AW:) virus substances have been found beneficial
(lilY)infected patienta byboosting their infighting avariety of serious diseases
Immune systems. and their reduced supply In AIDS
Two patients with JflV infections patiente diminishes Immunity, which
were inoculated wi th8. curable formof inturn leads todeath.
malaria which was cured with Dr. Henry J. Hefmlich'e use of
medication three weeks later. The malaria therapy totreat AlDS isbneod,
patients CD4 (helper Tvcells) and their Inpart. onItsso-year history of auccess
CD8 (killer Tcells) both increased to withnmrroayphilts, syphilis of thebruin.
hlgh level and haue remained euuated Dr. von Jauregg won the Nobel Prize
for a full year with no other treatment. for discovering malaria therapy. Infact,
Inthemoreadvanced patient, CD4cella the approach was used for nearly 30
rose from269 to 953; the other's from years aner penicillin was discovered
889 to 1258. Both patients remain because antibiotics could not penetrate
clinically well, .. theblood-brain barrier, Malaria. therapy
Drug therapy call weaken HIV virus we olllydiscontlnued in 197~because
and increase CD4cells, but theefl'act 18 it had dono!tt!work: neurosyphilis hR-d
short-lived. The vlrue then mutstee, been eradicated and nowly acquired
multiplies, and- depletes CD4 cells, lIyph!lfscouldbecured i nitsearly stages
resulting infull blown AIDS... :. .. bypenicillin,
For 60yearS, theU.S. Public Health From 1931 to 1965. the US Public
SOMCO provided malariablood totreat Health Service, theCenters for Disease
tens or thousllnde of neurosyphllts Control, Johns Hopkine Hoepltal and
(syphilill of the brain) patlenu with' NIH laboratorioe providod malaria blood
excellent results. In 1975. malnr'ia to hospitals for injection into tens of
thoTapy was discontlnuod .bocAuu thousande of peoplewithneurollyphUls.
neurosyphilis had been. eradicated.
Otherexamples oruatngonedilouo to
cureor prevent another include Cowpox
.toprevent 8mallpox and Sabin livepoUo
vacclae, '" .,/." '. .'"';:. ":"<.1 > .:;".'
. . ~. . ', ~. ' " \'
Baokground ..
The AIDS virus. wa~e. .an
unremitting battle with th~bodY'1J
immune system. Immune cella'of the
CD4 typedocreaee iil number durln:g ;
the course of HI\)' Infeetion, ind1cJlting ~
that thevi rus has anhninediate impact .
on CD4 cell doplotion. Whon the CD4
oount falla low enough, symptAlmatio
AIDS occurll and opportunistio;
infection,)" Cause death. Drugs can .
weaken thevirus and i ncreBBe CD4cells "
temporarily, hut nft.cr two (Ieks the ;
virus mutates and multiplies i'n
patientH. (Nal.ure, January. 1 9{H~;
Scientific Anu~clIn. April. 1995.)
SRle. EvenwithAI l')S Patient. ..
;.' Ell Chemin ofHarvard Univorsity'1J
School of Public Health atatGs in the
lTorlmal of Para,itololfY. October, 1984:
"Rooord. oftnmtment-related deaths or
extreme deblllty arefewrelative tothe
thouaands of patienta treated ... It Is
not hard to fmRgi ne thealmost certain
fate of the thoulJands of paretics
{neuroeyphf1lspatients] whowould have
eickonod .and died horribly but for
malaria therapy."
. There exl.st4 no known report in
whichinduood malaria WWl not cured.
Confirmation ofmalaria thempy'llsafety
for treAti ng HIVinfeded pationte c()mOI l
from!lConters for DIseI\B6Control study
InAfriC'8 pubHBhec:llntheNew EnSland
Journol of Medicine, July 11,1991. 'Tho
CDC study concludod: -No s!gnlfico.nt
dltTeronoo! werefound IntheIncidence.
lIeverlty, or response to therapy of
mulu rlu bclw(JCII 1.1.0 ol dldr on with
prog roeuivu HIV1 Infoctlon and lh"
lJoroncgllt.ivo controla., .. No evidonco
Wi lli i'ound toI I UgftVllt thut. mulo r ln !tn9
uny rolo In "coolorlltlns (.h& r8lIJ of
progrooelon of rrrv-l (!ieelllllJ ... tb'tlrtl 18
no adverse clinical or epidemiological
aaaocl etlon btlt.wu,," Ll.ese two
Important public health problems."
Other published studies also conclude
that malaria is not one of the
opportunistic dtsoaaea that endanger
AIDS patients.
Additlonnl Evidence of Malaria .
The'rapy'8 EtTectivenes8 tor AIDS
A study of 112 children with AIDS,
reported fromthesame hospital where
the above CDC study was performed,
was present.ed at the 1990 AIDS
conference inFlorence, Italy. Follow-up
data reported that all 41 children
Infected with malaria and AIDS were
still alive, while 35% of the 71children
infected with AIDS, but not malaria,
had diod. ~
Independent research by USNaval
Medical Research, Unit No.2 and the
Unlveraity of Nebraaka found that
peopleincertain malaria reglons of the
world possess HI Y. antibodies, but AIDS
dOG!not eXist inthese locations.
Continuing Research
'rne initial patients will continue to
be examined and rested at regular
intervals. Additional patients will be
treated-with malaria therapy and tested
through suchmeasures WI viral loading.
Duplicate studios will beconducted in
otherloeatJons ... ~"'. 1,:":.'.) 1\:':.IIIu{ ,
Future research will locus on. th~
process bywhich the malarie parasite
sUmulnt.os the immune system 80 that
thomalaria's function canbeduplicated
through chomtcal means.
Coauthors Include Bin Qunn Xino,
Ph.D.; Shu G1luLiu, MD; YueHen Lu,
MD; Eric O. Spletzer, Ph.D.; and Ji Li
Yao, MD.
Correspondencel .
Henry J . Heimlich, M.D.
Heimlich Institute .,
2368 Victory PArkway, Suit.e410
Cincinnati, Ohio 45206 USA
513 221-0002
Fax 513-2210003
I '
TOWNSI'!NO L.fTTl!R for DOOTOR9 .. PAnENTU - DECEMBI!R 10U
\
__ J. __ _
__ _ . _____
236* UCi;;7/ pMr k-wat t---
, 0 0
='>uliz 410
._------- ------
I
~ a k l /
- ~ - - - - - - - - - - -
---- ---
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
H E I M L I C H
I N S T I T U T E
2368 V I C T O R Y
P A R ~A Y
S U I T E 410
C I N C I N N A T I
O H I O
45200
513-22H X m
f a x 513-22H X X l 3
Mar ch 4, 1996
Mr . St ephen Fost er
Pr esi dent
Char l es A. Dana Foundat i on
745 Fi f t h Avenue, sui t e 700
New Yor k, NY 10151
Dear St ephen:
I enj oyed speaki ng wi t h you l ast week about mal ar i at her apy.
I n r egar d t o comment s t hat non- speci f i c AI DS t r eat ment has not
been successf ul , we know of no publ i shed st udy t hat suppor t s
t hat st at ement .
Her e ar e some f act s about mal ar i at her apy f or t hose eval uat i ng
t he t r eat ment . ( Number s r ef er t o t he Tabl e of Cont ent s i n t he
l oosel eaf bi nder " Mal ar i at her apy f or Tr eat i ng HI V I nf ect ed
Pat i ent s" . )
1. I n t he di scussi on, Pages 7 and 8 of t hi s paper , t her e ar e
ei ght een r ef er ences t o st udi es showi ng t hat mal ar i a i nduces
~r oduct i on of i mmune subst ances i ncl udi ng a var i et y of
1nt er l euki ns and i nt er f er ons.
2. Thi s i s an abst r act of a paper pr esent ed at t he 1990
I nt er nat i onal AI DS Conf er ence, Fl or ence, I t al y. Of t he 112
chi l dr en wi t h AI DS who wer e st udi ed, 41 had associ at ed
mal ar i a. None of t he 41 chi l dr en wi t h bot h mal ar i a and AI DS
di ed, and al l r ecover ed f r om t hei r mal ar i a. Of t he r emai ni ng
71 chi l dr en wi t h AI DS who di d not have mal ar i a, 25 ( 35%) di ed.
3. The CDC st udy by Gr eenber g t hat I sent you concl udes t hat
co- i nf ect i on of mal ar i a and HI V does not endanger t he pat i ent .
Thr ee addi t i onal st udi es conf i r mi ng t hat mal ar 1a i s not an
oppor t uni st i c di sease t hat woul d har m HI V i nf ect ed pat i ent s
ar e i ncl uded i n sect i on 3.
The pat i ent s i n Chi na demonst r at e posi t i ve f i ndi ngs i n
t r eat i ng HI V wi t h mal ar i at her ap and t hey have r emai ned
cl i ni cal l y wel l f ol l owi ng mal ar 1at her apy. I t i s a smal l
ser i es, but pr el i mi nar y r esul t s make i t i mper at i ve t hat we
t r eat addi t i onal pat i ent s.
I wel come t he oppor t uni t y t o r espond t o any quest i ons t hat
ar i se.
t
j, h .>: .r:"
B e s: ; t r > E l S J .>
H~j~i~l ch, M. D. , Sc. D.
Pr es1denn /
Hei ml i chEf nst i t ut e
HJ H/ ms
2 3 6 8 V I C T O R Y
P A R 'fJ N A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 52 0 0
51 3 - 2 2 1 - <X X l2
fax 51 3 - 2 2 H X X l3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
r
L) I f . -t..,i"_
Mar ch 5, 1996
Mi chael Saag, M. D.
Uni ver si t y of Al abama/ Bi r mi ngham
700 S. 19t h St r eet
Room 2B- 113
Bi r mi ngham, AL 35233
Dear Dr . Saag:
I l ook f or war d t o our meet i ng i n Pal m Beach l at er i n t he
mont h.
Mr s. Mahoney suggest ed t hat you may have an i nt er est i n
knowi ng about our use of mal ar i at her apy f or t r eat i ng HI V
i nf ect ed pat i ent s. Some backgr ound mat er i al i s encl osed.
You ar e undoubt edl y pl eased t hat t he Uni ver si t y of Al abama
was r anked number one as an ACTG si t e.
t o hear i ng about your wor k.
M. D. , Sc. D.
I nst i t ut e
HJ H/ ms
Encl osur e ~~~~~--------
745 Fifth AVt'IIIJ t>, Suit!' 700, Nt'w York, Nt'w York 10),')1 (212) 22:J -4040
The Charles A. Dana Foundation
March 15, 1996
Henry Heimlich, M.D., SC.D.
President
Heimlich Institute
Dearlli~
Thank you for your faxes andfollow-up information of March 1and4onthemalariatherapy
project. I appreciate the speedwith which you sent the information.
After reviewing thenew information anddiscussing this project with J imO'Sullivan, our health
program officer, I wouldliketo suggest to you thebest way, inour opinion, to proceed successfully with
forming ablue ribboncommittee andpreparing aproposal for Foundation consideration.
It seems likely to us that any scientific committee worth its salt wouldwant to seeaformal protocol
for theproposed trial. J imdidaquick review of protocols for clinical studies fromFoundation supported
projects andidentifiedthe following pieces as key: background andagent rationale; study overview;
inclusion/exclusion criteria; treatment regimen; study procedures; adverse events reporting plans; analysis
criteria; andethical, confidentiality, andregulatory concerns. Many of these elements exist inthematerial you
have provided; afew aremissing. Putting these pieces together inaformal protocol wouldalso provide you
with theopportunity to address some of the CDC's concerns, such as the issue of other blood-borne
pathogens inthemalariadose.
J imandI believe that this experiment will generate great mediainterest, andthat thevarious
communities affectedby AIDS will have many questions about the study whenit is announced. Itis our hope
that theprotocol development process will allow you andtheFoundation to anticipate (anddefuse) these
potential concerns.
The Foundation looks forwardto developing this study with you. If you agree that afull protocol
wouldbehelpful, J imandI wouldliketo discuss apotential time linewith you for developing this process.
Please let us know your thoughts.
Sincerely,
~
Stephen A. Foster
President
SAF/ajh
cc: DavidMahoney
J imO'Sullivan
M A R , - 1 8 ' 9 6 ( ~l O N ) 1 5 : 0 3 M A H O \ E Y P A L ~I B E A C H
T E L : 4 0 ~ 8 3 2 6 5 5 9 p, 0 0 1
MAHONEY
1296 South Ocean Boulevard
PalmBeach, Florida 33480
TEL: (407)832-6485 FAX: (407)832-6559
TO: Dr. andMrs. Henry Heimlich DATE: March 18 1996
FROM: Rillie Mahoney #OF PAGES INC.COVER: _l_
Dear J ane and H ank,
Thanks for your letter of March 5
th
with the article from Science Magazine and
your fax today giving us your flight information with theNew Y ork Times article of
March 14thattached.
We are looking forward to seeing you on Friday and our houseman, Raul, will
meet you at the baggage claimarea with asign saying "Heimlich". He will then bring you
to our house where we'll have lunch waiting!! As I mentioned earlier, that night we go to
the Max Fisher's where you'll meet Mary Fisher. Unfortunately, Dr. Saag had to regret at
the last minute. The following night we'll have adinner here at home and the dress for
both nights is much the same- tie andjacket for men - glamorous pajamas or cocktail
dress for the ladies!! The weather has turned beautiful so bring bathing suits, tennis
clothes, walking shoes, warm-ups - whatever you'd liketo do inthe sun!!
All best,
2 3 6 8 V I C T O R Y
P A A y ; y . jA Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
45200
513- 22H X X l 2
l ax 513- 221- r0J 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Mar ch 18, 1996
Pr esi dent
745 Fi f t h Avenue
New Yor k, NY 10151
Dear St ephen:
The at t ached Mar ch 14, 1996 New Yor k Ti mes ar t i cl e " Panel
Of f er s Shar p cr i t i ci sm of AI DS Resear ch Pr ogr ams" answer s al l
t he quest i ons we di scussed concer ni ng t he NI H and
mal ar i at her apy f or AI DS. They ar e f i nal l y r ecogni zi ng t he
i mpor t ance of human st udi es and t he need t o r est or e t he
damaged i mmune syst em.
I am advi sed t hat t he Hei ml i ch I nst i t ut e pr esent at i on " T- Cel l s
I ncr ease i n HI V+ Pat i ent s Af t er Mal ar i ot her apy; Remai n Hi gh
One Year Lat er " , at t he I nt er nat i onal Congr ess of I mmunol ogy
l ast J ul y ( see l oosel eaf bi nder Sect i on 5) was a f act or i n t he
panel ' s deci si on.
t i scuss your t hought s.
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 52 0 0
513-221-00)2
fa x 513-221-00J 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Mar ch 19, 1996
Pr esi dent
745 Fi f t h Avenue, sui t e 700
New Yor k, NY 10151
Dear St ephen:
The encl osed pr ot ocol , i nf or med consent and sci ent i f i c paper
cont ai n al l t he i nf or mat i on you r equest ed. I t i s t he pr ogr am
we have al r eady been usi ng and t he basi s f or r ecei vi ng t he
I nst i t ut i onal Revi ew Boar d ( I RB) appr oval f r om t he Gr eat Lakes
Associ at i on of Cl i ni cal Medi ci ne.
The New Yor k Ti mes ar t i cl e of Mar ch 14, 1996, " Panel Of f er s
Shar p cr i t i ci sm of AI DS Resear ch Pr ogr ams" t hat I f axed t o you
on Mar ch 18 i ndi cat es t hat t he medi a as wel l as t he NI H ar e
r eady t o accept r est or at i on of t he i mmune syst em as a pr i mar y
means of t r eat i ng AI DS. Dr . Leanna St andi sh of Bast yr
Uni ver si t y i n Seat t l e has r ecei ved a maj or gr ant f r om t he NI H
t o st udy al t er nat i ve t r eat ment s f or AI DS. We wer e i nf or med
t oday t hat she woul d l i ke t o wor k al ong wi t h us on t hi s
pr oj ect .
I f any f ur t her i nf or mat i on i s needed, pl ease cal l me.
CC: Davi d Mahoney
J i m O' Sul l i van
,;;~;_,
. . . .. ~,
- ~-
M A R 2 0 1 9 9 6
I
Clinical lrnmunnloav Center of PLA
r ' : : ~ . .~ 1: ~ -! or, ft_ ti,1-,\ : !O rJ 003
:,._Ff~r.();',ifi\']p~_,. J . :_:n'''(J ! . ;. J I 200003. P. R. Ch,r. ,
f,: 0:! ; ?,,,:. ,Gi r,' J ~8. f-:n:86}i- 'l,7!:'~2~
Dear Dr. Fahey:
I am grateful to hear your attention and support to clinical
immunology in China. I believe Dr. Renqian Zhong will give you
an excellent answer to your hope.
The materials sent from you about international meetings
program have been received, which can help me to know the
procedure of academic activities in recent two years. Thank you
very much.
"Clinical inununology--A distinct area of18I manology" is a
wonderful article which isof great interest tome. The problems you
put forward in this article are also bewildering us. I n China clinical
immunology is not a medical specialty, such as internal medicine,
etc. So it can not be put c ' a proper position infund application
and degree granting. Thus, we will translate this authoritative
article into Chinese and publish it in China. I wonder if it is
convenient to you. _
Dr. Zhong will complete the training in the-U. S-. l look forward
tokeeping further contact with you.
Sincerely yOUI"SJ
~::K~~
Professor, Director
Clinical I mmunology Center
Changzheng Hospital
Shanghai 200003
SOM SPEAKING POINTS FOR YOU WITH DR. HEIMLICH
This will be viewed as very controversial research. Before they agree to serve on any
blue-ribbon panel, the scientists gathered to oversee this research will need to be assured
that all aspects of the proposed clinical trial of malaria therapy have been considered

With that in mind there are several items that remain unaddressed in Dr. Heimlich's ~
materials Examples are. $ \
-"From his materials there is no evidence that any of the work already done in \~
China has been reviewed by experts in the field. This makes it difficult to know --"
what weight to place on the results he has reported.
-- There is no description of the overall plan of research. For example: How many
subjects will be studied? How will the data be analyzed? How will he manage the
information flow of data from the Dominican Republic and Guatemala back to the
U.S. How will he keep track of patients all over the U.S.
-- There is no discussion of ethical or confidentiality concerns. For example, how
will access to the study be controlled? Will citizens of the Dominican Republic and
Guatemala be able to maintain the confidentiality of their HTV status and still have
access to this treatment?
Iam sure experts would have other concerns also Dr. Heimlich needs to understand that
this research will have to withstand enormous scrutiny from the scientific community, the
AIDS activist community, and the NTH and the CDC Any of these groups could
effectively block his efforts in the U.S. if they somehow felt their concerns were ignored.
The blue ribbon panel will recognize this and, therefore, Iam sure have the same concerns
and want the same issues addressed.
A problem with all non-traditional AIDS therapies has been their uncontrolled use when
there is no strong evidence of their benefit Thousands of AIDS patients have traveled all
over the globe to tryout therapies that have absolutely no scientific backing They have
spent thousands of dollars and, in some cases, shortened their lives for no benefit The
research protocol for this study needs to be "air-tight" so that it does not become yet
another therapy that becomes popular without the appropriate scientific testing before it
becomes well-known.
We need to get some behind the scenes help for Dr. Heimlich to put together this proposal
in a way that will be acceptable to such scrutiny. I don't think I am the right person to do
it But if he is willing to accept such help 1think I could find someone for him to work
with.
0 'd
6 E 8 8 8 ~1 ~ ' ON X ~j
A 3 NOH~W a I tWa
A ) ._../
(//.
Mar ch 25, 1996
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 52 0 0
513- 22H X l O 2
fa x 513- 22H X l O 3
Edwar d Rover , Esq.
Whi t e &Case
1155 Avenue of t he Amer i cas
New Yor k, NY 10036
Dear Mr . Rover :
Per your conver sat i on wi t h Dr . Hei ml i ch, encl osed pl ease f i nd:
1. I nt er nal Revenue Ser vi ce 501( c) ( 3) det er mi nat i on l et t er ,
2. By- Laws and Ar t i cl es of I ncor por at i on
3. Li st of Di r ect or s
4. For m 990 - - endi ng May 31, 1995
5. Audi t - - endi ng May 31, 1995
I f I can pr ovi de any f ur t her i nf or mat i on, pl ease do not
hesi t at e t o cal l .
Si ncer el y,
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
r.
!);'L y_ ..~.
HENRY J. HEIML ICH, M. D.
17 Elmhurst Place
Mar ch 26, 1996
Dear Hi l l i e and Davi d,
I wi l l never f or get t he wonder s and del i ght s of l ast
weekend. To be i n such a beaut i f ul home wi t h car i ng peopl e
l i ke you made me f eel happy and r el axed.
Meet i ng so many dynami c peopl e who wer e f r i endl y and
r eachi ng out t o hel p ot her s was most gr at i f yi ng.
As I sai d on t he phone, Davi d, your abi l i t y t o assess a
si t uat i on and accompl i sh a goal i s t r ul y i nspi r i ng t o me.
I t was so i nt er est i ng t o l ear n of your many achi evement s.
Hi l l i e, knowi ng what you had gone t hr ough i n t he pr evi ous
days, we wer e t ouched t hat you made us f eel so comf or t abl e
and want ed.
I am encl osi ng a l et t er t hat was on my desk on Monday.
Al t hough I r ecei ve many l et t er s r el at ed t o t he Maneuver ,
t hi s one was so unusual t hat I want t o shar e i t wi t h you.
Our hear t f el t t hanks f or a wonder f ul vi si t .
Fondl y,
From The Desk Of
James E. Spamm Jr.
March 4, 1996
Mr. Henry Heimlich
Xavier University
Clinical Science Department
Cincinnati,OH 45207
Dear Mr. Heimlich:
I amabig fan of your maneuver. I have used it several times to dislodge food fromthe wind pipes of my
family members.
WeSpamms were born with extra small esophaguses and no uvulas which has spelled disaster inthe past
Your maneuver has helped to save each of my current family members at least once each.
Dad saidthesmall wind pipegene was passed down fromhis sideof thefamily and before you invented the
maneuver they useto haveto mashall their food into apaste to insurethat they wouldn't choke. A s l'msure
you can imagine this was no kindofa life. Now thanks to you andyour maneuver we can eat whatever we
want (even beef ribs, our familyfavorite) and if the food gets stuck wejust reach around thechoking victim
and pop it out. It's become so common place inour household, its liketurning on the television.
Even though we've never met youweconsider you afamily friend. We'd sure liketo know more about you.
We looked you up inthe World Book Encyclopedia, but it listed the maneuver and not the man who in-
vented it. To methat's likelistingthe Mona Lisa, but not Leonardo Da Vinci.
My mother, Pam, iscelebrating her 65th birthday on March 29th, could you please send her anautographed
picture, pamphlet, or postcard. I think she'd get areal kick out of it.
Thank you for saving my family,
U ~e :'E :~}
P.O. Box 10232
Fullerton, CA 92635
H E I M L I C H
I N S T I T U T E
2 3 6 8 V I C T O R Y
P A R 'f, ;N A Y
S U I T E 410
C I N C I N N A T I
O H I O
452 00
513 -2 2 1-(0)2
fa x 513 -2 2 1-(0)3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Mar ch 26, 1996
Mr . Davi d Mahoney
1296 s. Ocean Bl vd.
Pal m Beach, FL 33480
Dear Davi d,
si nce we' l l be i n t ouch t hr ough Apr i l , I t hought i t woul d be
hel pf ul f or you t o know my schedul e.
The f i r st week i n Apr i l I pl an t o be i n Cuba. I became an
honor ar y member of Rot ar y sever al year s ago. Rot ar y has an
i nt er nat i onal pr ogr am t o i nocul at e al l t he chi l dr en i n t he
wor l d agai nst pol i o. I have been asked t o par t i ci pat e i n
Cuba t hat week. I wi l l cal l my of f i ce per i odi cal l y.
Apr i l 10 t o 15, J ane and I wi l l be at Al t a Lodge, Al t a,
Ut ah, Tel ephone: ( 801) 742- 3500, Fax: Ext . 301.
Apr i l 21st t o 25t h, I pl an t o be i n t he Domi ni can Republ i c.
Apr i l 25, I r et ur n t o Ft . Lauder dal e. I have meet i ngs on
t he 26t h, gi ve my pr esent at i on on t he af t er noon of t he 27t h,
and t hen wi l l head f or Pal m Beach.
I l ook f or war d t o bei ng wi t h you Apr i l 27 and 28, depar t i ng
f or Ci nci nnat i Apr i l 29 at ar ound 11: 00 A. M. J ane wi l l not
accompany me at t hi s t i me, but appr eci at es your i nvi t at i on.
_/'
Best l W~s. hes~/ / /
I .>.
i! -> .~--.-~
, , ~/
! , )/, ~. - , -
, . . r , .
~~r ( ~f : / .Hei ml i ch, M. D.
1155 AVENUE OF THE AMERICAS
NEW YORK
212-819-8516
May 7,1996
Henry I. Heimlich, M.D.
The Heimlich Institute Foundation, Inc.
Dear Dr. Heimlich:
I am pleased to inform you that the trustees of the Eleanor Naylor Dana Charitable
Trust approved a grant of $50,000 for unrestricted support of the Institute. This action was
taken at the suggestion of David Mahoney and was unanimously approved.
Enclosed is check #5322 in the amount of $50,000 as payment of the grant. At your
convenience, kindly return a receipt for this directly to:
A. I. Signorile
Trustee/Treasurer
E. N. Dana Charitable Trust
745 Fifth Avenue, Ste. 700
New York, NY 10 151
It is a pleasure to assist you with your work, and all the trustees join me in wishing
you continued success.
i:}J(
Edward F. Ro er
EFR:mem
Enclosure
cc: David Mahoney
-
ELEANOR NAYLOR DANA
CHARITABLE TRUST
375 PARK AVENUE
NEW YORK, NY 10152
PAYTOTHE h . l' h' d' I
ORDEROF T e Helm lC Instltute Foun atlon, nc.
CHEMICAL BANK
277 MADISON AVENUE
NEW YORK, NY 10016
1- 12/210
5322
4/28/96
**50,000.00
$_------
Thousand and 00/100********************************************** ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ______________________________ ~ _________ OCUARS
The Heimlich
Institute Foundation
Suite 410
MEMO Grant
r!1
Socurtly ........
. -- lloCoII ... bodI.
I
The Eleanor Naylor Dana Charitable Trust
was established in 1982 under the provisions
if the !ali! Mrs. Charles A. Dana's Will. In
keeping with her lifelong interest in medicine
and the performing arts the Tru'lt will foster
and finance progress and the pursuit if
excellence mainly in these fields. A panel if
experts has been engaged fry the Trw;t to
evaluate applications and recommend
priorities for the allocation if funds.
~ L E
375 Park Avenue
New York, New York
10152
(212) 754-2890
Please address
correspondence to
The Trustees
E
leanor Naylor Dana,
philanthropist, social leader
and longtime resident of
Wilton, Connecticut, died in
New York on May 30, 1982. Through-
out her life, and largely through the
Charles A. Dana Foundation, she
devoted her energies and personal
resources to supporting programs
in the arts and sciences having
far-reaching humanitarian and
cultural impact.
In 1950, she and her
husband, the noted industrialist
Charles A. Dana, established the
Foundation that bears his name and
which, under their joint direction,
donated over $105,000,000 to medi-
cal research, education and the arts.
With an incisive mind that
cut straight to the core of any issue
and a sense of humor that was appro-
priately disarming or engaging,
Mrs. Dana provided thrust, direction
and purpose to many programs. She
helped to establish policies and
priorities for providing financial
support to institutions of higher
education. Many advances in preven-
tive medicine, and improvements in
the quality of education in this
country can be attributed to her
efforts and the financial support the
Foundation provided.
While her perspective was
broad, she never lost touch with the
traditional values of rural America
she acquired in Carthage, Texas,
where her family settled after moving
from Tennessee, and in which she
maintained a continuing lifelong
interest.
rants will generally be
made to support clin-
ical investigation by established
scientists in qualified institu-
tions in the United States, to
pursue innovative proj ects
designed to improve medical
practice or prevent disease .
Grants are generally limited
to no more than three years and
not to exceed $100,000 per year,
with no overhead costs. The
Trust \vill not normally support large
scale field studies of a therapeutic
or epidemiological
nature. Support for
instrumentation \, ... iIl
be limit ed to that rc-
quired for a specific
project. Grants \,viII
not be made for
Robert L Wise, M.D.
'. \
" "-
\
Robert A. Good, :\1.0.
instrumentation
alone.
Grants \vill not be made
solely to support conference or
individual travel nor wiII they be
transferrable bctween
institutions without the
expressed approval of the Trust.
Initial inquiri es must be
submitted as a Lett er of Int ent
not to exceed OIle thousand
words. Selected applicants will
be invited to submit detailed
proposals which must include
evidence of approval by the
applic3nt\ Insti t lit ional Review
Board .
D
n the field of the
Performing Arts,
the Trust will make a limited
number of grants to qualified
institutions within the United
States. Generally, grants in
response to specific proposals will
not exceed $100,000 per year and
will consider, among other points:
(1) The anticipated benefit to the
public as a result of the grant, and
the long-range potential;
(2) the stature of the organiza-
tion, the history of its public
selV'ice and its contribution
to the Art involved;
(3) demonstrable need for the
grant;
(4) the financial viability of the
program .
In general, grants will not be
made to fund deficits; for
exhibits, publications or
conclaves; nor will grants be made
to individuals. Initial inquiries
should be submitted as a
Letter of Intent not to
exceed one thousand
words. Selected appli-
cants will be invited to
submit detailed
proposals .
Trustees
David Mahoney.
Chairman
A.j. Signorile.
Treasurer
Robert A. Good. M.D.
Carlos Moseley
Robert E. Wise. M.D.
??
Tel/ FAX 570/659-0229
e
June 7, 1996
Dear Doctor Wang:
It was such a pleasure having you with us. We so admire and enjoy your zest for
living, your wonderful knowledge, your friendliness.
I am so thrilled with your beautiful lace tablecloth, and will enjoy using it on
special occasions. You were so generous and thoughtful to give this special gift
to us.
Thought of you reading the enclosed article, particularly the remark that one's
belief plays a role in the outcome of a treatment.
Feel sure you're having a lovely time with your son and daughter-in-law.
enclosures
Wang Yi-Tang, M.D.
%Hai Wang
4454 Fern Common
Fremont, CA 94538
Warm wishes,
Jane Heimlich
June 17 1996
Henry J. Heimlich, M.D.
President
Heimlich Institute
Suite 410
Cincinnati
Ohio 45206
The United States
Dear friend Dr. Heimlich:
I sent the enclosed paper in Chinese to you about two weeks ago, now I
send its English version to you and await a reply from you agreeing the
paper be submitted for publication in a Chinese medical journal and a
U.S. journal. ( Prepare to submit to the Chinese Journal of Infectious
diseases and the New England Journal of Medicine)
Your comments on the paper will be appreciated and your correction of
English will be very welcomed.
By the way, it will be the time of next follow up for the second batch
of HIV patients in Yunnan Province, therefore we hope you arrange the
payment of four thousand U. S . dollars to us for the two years follow
up of the first two HIV patients according to our agreement so as to
smoothly complete our project.
Best wishes and regards.
Sincerely,
Dr. Xiao Ping Chen
Director, Department of Microbiology
The Municipal Health and Anti-Epidemic Station of Guangzhou
No. 23, 3rd Zhongshan Road
Guangzhou 510080
CHARACTERISTICS OF ARTIFICIALLY INDUCED HEMATOGENOUS
PLASMODIUM VIVAX MALARIA ON ADVANCED TUMOR PATIENTS
Xiao Ping Chen
1
Henry J. Heimlich
2
Shu Guo Liu
1
Bin Quan Xiao
l
Nai Du Li
3
Hong Shun Hua
2
Ji Li Ra0
1
Fu Yuan Kuang-
3
1. The Municipal Health and Anti-Epidemic Station
of Guangzhou, Guangzhou 510080, China
2. The Heimlich Institute, Cincinnati, U.S.A.
3. Guangzhou Yishou Hospital, Guangzhou, China
Abstract This paper reports the clinic characteristics of artificially
induced hematogenous Plasmodium vivax( Pv.) malaria on advanced tumor
patients, which were found during the time the authors studied
malariotherapy for cancer. The characteristics were that, first, there was
a big variation of incubation in these patients. This implies that the
variation of incubation of malaria would increase with the digree of
individual difference, since tumor patients can be considered as a
different host population compared with the health one and different
kinds of tumor patients can also be considered as different host
populations. This suggests that incubation of malaria will be decided
not only by the species, atrains and dose of Plasmodia, but also by the
reactive nature of hosts. Second, most patients manjfestated typical
every other day's ( tertian) paroxysm of high fever in the early days
and then presented irregular every day' a ( quotidian) paroxysm. This is
contIw!.1A .. suggests that
of paroxysmal of Pv. malaria should be supplemented or the
regular pattern .of Pv. malaria needs to be further studied.
Key words
Fever pattern
Pv. malaria . Hematogenous infection
Advanced tumor Malariotherapy
Incubation
Malaria as a therapy namely malariotherapy was successfully used to
treat progressive paralysis and neurosyphilis in clinic, for which its
inventer, Dr. Jauregg JWV won the Nobel Prize of Medicine of 1927."1-
Later some doctors tried it to treat tumors.
2
3
In recent years, we
reexplored the clinic values of malariotherapy for advanced malignant
tumors (see our another report); during which we had an opertunity to
observe the whole courses of artificially induced hematogenous Pv. malaria
( the course from Plasmodium inoculation to clinical paroxysms then to
natural disappearing of onsets) and found some new phenomena which
were difficultly observed under the natural circumstances. This paper
reports the content in the respects so as to provide a reference for
colleagues.
Cases and methods of Plasmodium inoculation
1. Cases Total 7 patients with advanced tumor volunteerly came
to our research cooperation group for malariotherapy during 1991-1993.
Now their conditions are simply described as follow: Case 1, female, 38
year-old (Y), lactoadenocarcinoma with multiple osteometastases. Case 2,
male, 38y, undifferentiated small cell carcinoma of up right lung with
metastasis of mediastinum. Case 3, male, 41y, lung adenocarcinoma with
m u l t i p l ~ 08teometastases. Case 4, male, 40y, nasopharyngocarcinoma,
poorly differentiated squamous epithelial carcinoma with metastases of
lungs, liver and bonea. Case 5, female, 57y, no pathological confirmation
,in this case, CT showed masses in liver and the head of pancreas,diagnosed
clinically carcinoma of head of pancreas with metastasis of liver. Case 6,
male, 31y, Carposi sarcoma of left thigh with metastases of lymph nodes
and wide infiltration of left thigh. Case 7, male, 4Oy, relapse after
resection of rectoInyxoadenocarcinoma with metastasis of pelvic cavity
and multiple osteOmetastases.
2. Methods of Plasmodium inoculation Patients were devided to four
batches for-inoculation: Cases 1-2 were the first batch; cases 3-5 were
the second batch; case 6 was the third batch; case 7 was the fourth
batch. The same inoculations of each batch were at the same time,and the
Plasmodia came from the same ' patient of malaria ( the same host, all
hosts were the patients of Pv. malaria in the areas of Guangzhou and
Shenzhen ). Per time injected suitable quantity of malarial whole blood
(all doses of Plasmodia were near to 1.0 X 10
7
parasites, see table I ).
All blood 80urses were 'strictly confh"med no any- other infections
especially no syphilis, viral hepatitis, and infection of human immuno-
deficiency viruses ( HIV ) but only Plasmodium vivax.
Results and discussion
1. lncubation In this study all 7 cases got a typical first paroxysm
of malaria ( chilly tremble, fever and perspiration 80 called" three step
melody" ) and all patients were found Plasmodia in blood smears only
after presentation of typical onset, therefore the concept of incubation
used in this paper refers to clinical incubation namely the period
from inoculation of Plasmodium to first clinical paroxysm, see table 1.
Table 1 Incubations(days) of artificial hematogenouB Pv. malaria
Bat. No. 1 2 3 4
Case No. 1 2 3 4 5 6 7
Dose ofQ) 1.2X 10
7
1.2x 10
7
1.0 X 10
7
0.8 X 10
7
0.8 x 10
7
1.4 X 10
7
0.9 X 10
7
Plasmo. @1.5 x 10
7
, 1.5 X 10
7
2.9x l07 2.9 x 10
7
lncub- CD
22 18 6 28 10 20 10
ation @ 8 6 18 0
Note: Dose of Plasmodium ,..1) indicates the dose of the first inoculation; @indicates the
dose of the second inoculation. Incubation (Dindcates the days from the first inoculation to
the first paI'9xysm; @ indicates the days from the second inoculation to the first paroxyEID .
... 0 ... of case 5 indicates the first typical paroxysm was just on the day of the second
inoculation, shows this paroxysm was definately caused by the Plasmodia of the first
inoculation.
We can see from table 1, inoculation dose of Plasmodium of every
case was very closed to each other ( equal or nearby 1.0 X 10
7
), but
the variation of their incubations was relatively bigger, especially in
the Second batch of patients; their difference was most probably between
6 and 28 days compared with that of Pv. malaria , by blood
transfusion, that was if transfused 1-5 million by vein,
the incubations would be commanly 8-12 days (Guangdong Provincial
Institute for Prevention and Treatment of Parasitic Diseases: Tel(tbook
of Parasitic Diseases, published in May, 1982, P91 ). This phenomenon
implys doubt of the Theory of Polymorphism of Sporozoites
4
for
explaining incubation and relapse meChanism of malaria (although the
Plasmodium used in this research was not sporozoite but the form of
erythrocytic stage, that the host factors could not be ignored it implied
was consistent with each other ). The obvious lackness of the Theory of
Polymorphism of Sporozoites is its ignoration of exist of host factors.
Under the influence of this idea, most authors studied the mechanism of
incubaion and relapse by inoculating different strains and different
doses of Plasmodia to the same host population, few payed attention to
the differences among individuals and among populations of hosts in
their experimental designs; that is to say, few used the same dose and
same strain of Plasmodium to infect different bost populations (in our
research, the patients with different kinds of tumors can be considered
as coming from different host populations). One ( Chen) of the authors
proposed the Inhibitor TheOry that not only concerns the Plasmodium
but also the host itself to argue with. the Theory of Polymorphism of
Sporowites, and emphatically demonstrated the decisive role of host
factors on the incubation and relapse regularity of malaria.o
2. Clinical onsets and temperature curves The clinical onsets and
temperature curVes ( see Fig. 1 ) of artificially induced hematogenous
Pv. malaria of 7 patients with basic diseases, different kinds of advanced
tumors had a few characteristics as follow: 1, all patients had a typical
first clinical paroxysm. 2, every paroxysm manifestated typical chilly
tremble, high fever or fever and perspiration so called" three step
melody:" 3, most patients ( case 1, 2, 4 and 5) manifestat.ed typical
every other day's ( tertian) paroxysm of high fever in the early days
and then presented the irregular every day's (quotidian) paroxysm. 4, the
second batch patients were inoculated the Plasmodia of coming from the
same host and almost the same dose, but some manifestated regular tertian
paroxysms ( case 4 and 5 ) and some appeared irregular quotidian one
( case 3). This demonstrates the reactivity of host play an important
role iIi the decision of clinical course of malaria. 5, among 7 cases, we
observed ,,2 cases' natural disappearing of clinical onsets, with
recrudescences after 5 and 10 days resPectively ( contIDUiJig parasiun:ma
confirmed by examinations of blood smears); among them one was
inoculated two times of Plasmodia, but another just inoculated one time.
We also noticed that in our research of malariotherapy for mv
infection, 6 lllV positive patients were just one time inoculated with
Plasmodia of the same dose and coming from the same patient host of
Pv. malaria, some first manifestated typical tertian paroxysms of high
fever and then the irregular quatidian paroxysms, but some manifestated
other clinical characteristics ( see another report). The results also
showed that the clinical regularity of malaria was not only decided by the
quality and quantity of infected Plasmodium, but also by the reactivity
of host, its exact ' mechanism is to be further demonstrated.
r--
U
0
-.......'
(1)
H
;J

H
X
p..
8
0

42
41
40
39
30
l;
42
41

39
38
37
42
41
40
39
38
37
42
41
40
39
38
37
42
41

39
3S
37

41
.. .. . .
" :' ,( " , ;' 39
, ,42
_ _ 4i
... . . .
,/L, ", \w
: . . " 38
37
, \
Cae
4
-:-.=..
..
' :'i Case 7 1
"
- - )
.' --- - - - - .
Fig. 1 Temperature curves of artificial hematogenous Pv. malaria- on
.. tumor patients ("tv{ indcates the time of use of chloroquine)
@
, '.
c'
.,
, ', : ' ;',: It,.
,- , ,.; .. '.,:. ."
" .... . -;
j
. \- .
"
3. Other clinical manifestations Among 7 cases, one (case 3 )
complicated asthma at the times of 8-10th paroxysms, but through the
treatment of antisplasmodic and termination of malaria, asthma disappeared
soon. One (case 6) presented thrombocytopenia, recovered after
transfusion of platelets. One ( case 4 ) presented. irregular low fever
with slight pain of knee joints during recuperation at home after
termination of malaria and discharge, not found Plasmodium in repeated
thick and thin blood smears, fever abated when used dichlofenac sodium.
Hepatosplinomegaly induced by malaria in all 7 patients was not obvious,
most were just palpable under the rib; all recovered to original state
after a short time of termina tion of malaria. Anemia was not
obvious during the period of fever; one ( case 7) complicated
quickly progressing anemia after natural abatement of fever, but
recovered very soon after termination of malaria and blood transfusion.
4. Therapeutical response to chloroquine All 7 cases of
artificially induced hematogenous Pv. malaria were very sensitive to
the treatment of chloroquine; all clinical symptoms and parasitemia
quickly disappeared after one course of 10 tablets ( per tablet contains
0.15 gram ground substance of chloroquine) therapy, no any cases with
recrudescence and relapse after antimalarial administration.
Conclusion
During the time of researching malariotherapy for cancer, we found
that artificially induced hematogenous Pv. malaria on different kinds
of advanced tumor patients had some special or new clinical regularity:
1, variation of incubation was big. 2, most patients first . presented
; tertian . paroxysms . of . high . then . quatidian
ParOiysms; this is )contraiy to the traditional knowledge. a, . although
patients were infeCted the same strain and the same dose of Plasmodium,
it seems that there were different fever pattern of Pv. malaria iIi
different kinds of advanced. tumor patients. This phenomenon indicates
in one respect that not only advanced tumor patients can be considered
as a host population different from health one, but also different
kinds of tumor patients can be also considered as different host
populations; it shows in another respect that past description on
clinics of Pv. malaria should be Bupplimented. So we consider that the
research of malariotherapy for cancer not only has important significance
on treatment of cancer, but also has a big theoretical value on research
of malaria itself, as well as provides a model of research of relation
between malaria and tumor.
6
REFERENCES
1. Yang JY, Zhu XM: Dictionary of Nobel Prize Winners. 1st eeL,
Changsha: Hunan Publish House of Science and technology, 1994. P296.
(in Chinese)
2. Giugni F: Considerazioni sui risultati della malarioterpia in alcuni
casi di tumore malarigno, n Policlinico (Sez Frat), 1965, 72: 197.
3. Greentree LB: Malariotherapy and cancer, Medical H y p o t h ~ 1981,
7:43.
4. Lysenko AJA, Beljaev AE, Rybalka VM: Population studies of
Plasmodium vivax 1. The theory of polymorphism of sporowites and
epidemiological phenomena of tertian malaria, Bulletin of the World
Health Organization, 1977, 55(5):541.
5. Chen XP, Guan WE: Inhibitor theory: A new exploration of relapse
mechanism of malaria, Transaction of Chinese Public Health, 1994,
13: 74. ( in Chinese )
6. Chen XP, Xiao BQ: Relation between malaria and tumor, Chinese
Journal of Preventive Medicine. 1996, 30(4): 61. ( in Chinese )
June 20
J
1996
President
Heimlich Institute
Suite 410
Cincinnati
Ohio 45206
The United States
Dear friend Dr. Heimlich:
Thank you very much for your letter of June 11 and
success and your participation of the XI Interational
AIDS in Vancouver and the FICIA in Bethesda!
congratulate our
Conference on
It is too late for me to apply the attendance of Vancouver conference.
As you know that it is a complicated procedure for application of
going abroad in China especially the application of funding.
Three days ago I sent you our paper on cancer in English and I am
awaiting your agreement for publication in Chinese journal and US
journal, welcome your comment and correction of English.
Please give our best to our colleagues in the Heimlich Institute.
Sincerely yours,
Dr. Xiao Ping Chen
Director, Department of Microbiology
Guangzhou 510080
I
2368 VICTORY
PARKWAY June 25, 1996
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-221-0083
Benefiting
Humanity
Through
Health
and
Peace
Ms. Valerie Harper
Eleanor Naylor Dana Charitable Trust
375 Park Avenue
suite 3807
New York, NY 10152
Dear Valerie:
Here are some materials for starters. The binder gives
extensive background on malariatherapy for HIV.
Malariatherapy for cancer is described in the accompanying
research paper.
When you have had a chance to go through all of this, please
give me a call. I look forward to working with you.
I,d' .
,'1 , '1- ~ , ~ -( ~ ."
.'
;
J"'< -:-.-
. , ,_/ .f.' ",i/_
/,,1
"
II' I
..
07/25
/
1996 15:48 21275Cl28'32
July 26, 1996
To: Dr. Heimlich
From: Valerie Harper
DAHATRUST
Memorandum
Subject: Confirmation of Dr. Heimlich's Malaria Immunotherapy ProJect- Grant .Road Map
T h ~ Eleanor Naylor Dana Charitable Trust (ENDCT) has agreed to the following:
1. Chlna.. To fund the next ten cases (which will not include needle users). For this
purpose, the ENDeT has agreed to give a grant of $100,000.
PAGE 02
2. The ENDeT's $60,000 grant awarded to Dr. Heimlich In April 1996 Should be utilized
for Costa Rica, Guatemala, Columbia & India Etc.
3. It should be understood that further grant mOlleys which would eX(;t:t:..J lht:
$150,000 already agreed upon ;by the ENDCT will have to come from other funding
sources for the Malaria Immunotherapy project.
4. Valerie Harper, from the ENDeT, will serve as liaison -"project Manager" for
Dr. Heimlich and the Malaria Immunotherapy project and ENDCT.
5. Or. Heimlich and V.lone Harper have a meeting Scheduled at the Trust office on
the morning of August 29, 1996
ce. David Mahoney
Ed Rover
- I
UNIVERSITY OF CALIFORNIA, LOS ANGELES
"Center for Interdisciplinary Research
inImmunology and Disease
UCLA
BERKELEY DAVIS IRVINE LOS ANGELES . RIVERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA SANTA CRUZ
August 8, 1996
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
UCLA SCHOOL OF MEDICINE
CENTER FOR THE HEALTH SCIENCES
10833 LE CONTE AVENUE
LOS ANGELES. CALIFORNIA 900241747
(310) 825-6568
(310) 206-1318 (FAX)
Henry 1. Heimlich, M.D., Sc.D.
Suite 410
Cincinnati,OH 45206
Dear Henry:
It was apleasure to seeyou again in Vancouver and have achance to talk further about
malariotherapy that you have been exploring. The work is striking and certainly points towards
the possibilities for resetting the disturbed immune balances of'HfV infection by major immune
stimulation.
I wondered if we could help you. Two contexts come to mind. One is our interest incytokines
and their products, especially the soluble markers of activation. We have the capacity to measure
most of the cytokines incirculation as well as the capacity of peripheral blood mononuclear cells
to produce cytokines under various forms of stimulation. These might be interesting to assess in
selected patients treated with malariotherapy.
The second context is inthe formof aFogarty International Center (Nlli) AIDS International
Training and Research Program (AITRP), which we have at UCLA and which is becoming
increasingly involved with studies with intervention and quality control efforts. Inthis context,
we could, perhaps, develop ameans of helping your Chinese colleagues incarrying out their
studies. Assistance with reagents and quality control samples for CD4 measurements as well as
for other parameters of'HfV infection. I would be glad to explore these further with you.
Sincerely,
J O M L 2 :
Director of CIRID at UCLA
lLF/jm
cc: Evelyn Najera, MPH
Hong Bass, M.D., Ph.D.
b:IHcimlich
UNITED STATES
LOS ANGELES
MIAMI
NEW YORK
WASHINGTON,O.C.
EUROPE
BRUSSELS
BUDAPEST
HELSINKI
ISTANBUL
LONDON
MOSCOW
PARIS
PRAGUE
STOCKHOLM
WARSAW
AFRICA
..JOHANNESBURG
August 14, 1996
Henry J. Heimiich, M.D;
WHITE & CASE
1155 AVENUE OF THE AMERICAS
NEW YORK, NEW YORK 10036-2787
TELEPHONE: (I - 212) 819-8200
FACSIMILE: (1-212)354-8113
212-819-8516
The Heimlich Institute Foundation, Inc.
Dear Dr. Heimlich:
ASIA
ALMATY
ANKARA
BANGKOK
BOMBAY
HANOI
HONG KONG
JAKARTA
SINGAPORE
TASHKENT
TOKYO
MIDDLE EAST
JEOOAH
RIYADH
LATI N AM ERICA
MEXICO CITY
I am pleased to inform you that the trustees of the Eleanor Naylor Dana Charitable
Trust approved a grant of $100,000 for unrestricted support of the Institute. This action was
taken at the suggestion of David Mahoney and was unanimously approved.
Enclosed is check #5442 in the amount of $1000,000 as payment of the grant. At
your convenience, kindly return a receipt for this directly to:
A. J. Signorile
Trustee/Treasurer
E. N. Dana Charitable Trust
745 Fifth Avenue, Ste. 700
New York, NY 10151
It is a pleasure to assist you with your work, and aU the trustees join me iIi wishing
you continued success.
EFR:mem
Enclosure
cc: David Mahoney
Edward F. Rover
,
PO BOX 8858
CINCINNATI , OH 45208
513-221-0002
Fax 51 3-221-0003
Benefiting
Humanity
Through
Health
and
Peace
September 3, 1996
Mr. A. J. Signorile,
Trustee/Treasurer
Eleanor Naylor Dana Charitable Trust
745 Fifth Avenue, suite 700
New York, New York 10151
Dear Mr. Signorile:
Your generous contribution to the Heimlich Institute
Foundation in the amount of $100,000.00 is most gratifying.
Be assured that your contribution will be used to further our
research as expeditiously as possible. Your donation will
help us continue our quest to save lives through research,
education, and creative thinking in solving the problems
facing each of us.
It is through such caring support that our endeavors can
progress in finding treatments for otherwise incurable
diseases. Thank you again.
THE September 4, 1996
HEIMLICH
INSTITUTE
FOUNDATION,INC.
PO BOXB858 Dr. Chen Xiao Ping
CI NCI UAII , OH 45208 Chief, Department of Microbiology
513-221-0002 The Municipal Health and
faI513-221-0003 Anti -Epidemic Station of Guangzhou
Benefiti
Humani ty
Through
Health
and
Peace
No. 23 3rd Zhongshan Rd.
Guangzhou 510080
Dear Xiao Ping:
This is a follow-up to my letter of July 19, 1996. I am
enclosing a copy of that letter in case you didn't receive it
for some reason. I have sent to your account number
475010101140192114, at the Bank of China, Guangzhou branch,
$2,000 for the two year follow-ups for the first two patients.
Should you have reason to believe that another $2,000 is
warranted, please let us know what it is for.
A leading United states university which has a center for
immunology has asked to participate in our malariotherapy
project. They have a National Institutes of Health center and
laboratories to which bloods can be sent for viral loads if
necessary. They also said they can help you in China. I
believe there will also be an opportunity for you to corne to
the united States and study here as the program progresses.
Do you agree that we should try to complete such arrangements?
We look forward to receiving the results of the tests on the
last six patients as soon as possible. Please advise me as to
when we might start on the ten new patients, as I would like
to visit while they are under treatment.
I look forward to hearing your thoughts.
family and our colleagues are well.
regard ,
/tJ-
eimlich, M.D., Sc.D.
Enclosures
I hope you, your
HEIMLICH
INSTITUTE
FOUNDATION, INC. September 17, 1996
p.o. BOX BB5B
513-221-0002
faI513-221 -0003
Benefiting
Humanity
Through
Health
and
Peace
Mr. A. J. signorile,
Trustee/Treasurer
375 Park Avenue
Dear Mr. Signorile:
/.
of
We received your generous grant to the Heimlich Institute
Foundation in the amount of $100,000.00. Be assured that your
grant will be used to further our research as expeditiously as
possible. Your donation will help us continue our quest to
save lives through research, education, and creative thinking
in solving the problems facing each of us.
It is through such caring support that our endeavors can
progress in finding treatments for otherwise incurable I
diseases. Thank you again.
/:
{_'-<-->1
{
. ".,.;> . I , .. .J- 1L.t.-<-. ,. ... ...
.. ( 1)"('1...,.t. I<C .. -
r .- .- "
) +o-f cI c t'L-iI'.-kl .6-t{-'l_-' IJ ntA_ .... .. "-.:.,L Lc .. f- ?U c-&.<. c.-t...{ /0 (:tf 5' .
/f. .. -'1-,-,f{ ,1,...( . .(..cI
v
. r ,f..e... d>,,;o",-<:Lt;
t'.[.--;1 ,-.,.:'-1 'S' 11. /.....<.r-C..{SIvL-- C L-4 " t3.elZi'1_1"t. AJ--UL1.tZd 0 ,
{P-'1\ .. C..{. pot;. a,'l--<._ .. .t2.e4 . 1 J <+1;<:/ 6 "-<-'*-.N} ?.L; ,,. ....... .
P . O . B O X 8 8 5 8
C I I C I I l A T I , 0" 45208
51 3 22H J 002
fiI 51 3 - 221 - 1 ) 003
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Sept ember 25, 1996
J ohn L. Fahey, M. D.
Di r ect or of CI RI D at UCLA
Depar t ment of Mi cr obi ol ogy & I mmunol ogy
UCLA School of Medi ci ne
Cent er f or t he Heal t h Sci ences
10833 LeCont e Avenue
Los Angel es, CA 90024- 1747
Dear Dr . Fahey:
At t he r equest of Dr . Hei ml i ch, encl osed pl ease f i nd a copy of
t he Pr ot ocol f or AI DS.
I f I can be of any f ur t her ser vi ce t o you, pl ease do not
hesi t at e t o cont act me.
Encl osur e
Mal ar i ot her apy f or HI V
Pr ot ocol f or Sel ect i on and Tr eat ment
I . Candi dat e Sel ect i on
A. Mal e candi dat es onl y
B. Document at i on of HI V i nf ect i on ( and cl assi f i cat i on
i nt o HI V- 1 or HI V- 2)
C. Must be WR1 or WR2 st age of HI V i nf ect i on
D. CD4+ T- cel l bet ween 300- 500 cells/BL
I I . I nf or med Consent
A. Knowl edge of di agnosi s and pr ognosi s
B. Ment al Compet ence
1. Under st andi ng of exper i ment al nat ur e and
unpr edi ct abi l i t y of pr oposed t her apy
2. Under st andi ng of r i sks at t r i but abl e bot h t o
mal ar i a and HI V
a) Mor bi di t y
b) Mor t al i t y
c) Recur r ence
C. Aut hor i zat i on f or r epor t i ng and pUbl i cat i on of
cl i ni cal i nf or mat i on ( si gned and wi t nessed)
D. Abi l i t y and wi l l i ngness t o spend pr ol onged per i od
of t i me at and i n cont act wi t h t he t r eat ment si t e
I I I . Admi ssi on st udi es
A. Hi st or y and physi cal exami nat i on
B. CBC, hemogl obi n el ect r ophor esi s, par asi t emi a
scr een
C. BUN, ser um al bu~n, t ot al pr ot ei n
4
i mmunogl obul i n
el ect r ophor esi s , i nt er f er on assay , bi l i r ubi n D/T,
af kal i ne phosphat ase, ot her enzymes as i ndi cat ed
( i f f easi bl e)
D. Ur i nal ysi s
E. Chest X- r ay ( pneumoni a)
F. El ect r ocar di ogr am
G. HI V t i t er f r om PCR
H. Whol e body phot o ( swi m t r unks)
I V. Abnor mal i t i es r equi r i ng possi bl e excl usi on f r om st udy
A. Er yt hr ocyt e mor phol ogy ( st andar d hemat ol ogy mi cr o-
scopi c exami nat i on of Wr i ght / Gi emsa st ai ned per -
i pher al bl ood cel l s
B. Hemogl obi n el ect r ophor esi s
C. Red cel l G6PD ( gl ucose- 6- phosphat e dehydr ogenase)
D. Renal f unct i on
E. Sei zur es
F. Act i ve chr oni c pul monar y condi t i ons
1. Br onchi al ast hma or br onchospasm
2. Tuber cul osi s
3. Hypoxemi a compl i cat i ng any ot her condi t i on
G. Cachexi a and hypopr ot ei nemi a
1
H. Car di ac ar r yt hmi a ( st r ess t est , i f war r ant ed by
el ect r ocar di ogr am)
I . J aundi ce, l i ver f unct i on i mpai r ment , or por t al
hyper t ensi on
J . Spl enomegal y
K. Obesi t y ( mor e t han 30% above i deal body wei ght )
L. Aor t i c aneur ysm
V. Tr eat ment
A. I nduct i on of t her apeut i c mal ar i a
1. Sel ect i on of mal ar i ous donor s
a) Appr opr i at e pl asmodi al st r ai n i n adequat e
concent r at i on
( 1) Pl asmodi um vi vax
b) Absence of ot her bl ood- bor ne i nf ect i ous
di sease
( 1) Repeat ed t hi ck and t hi n bl ood smear
exami nat i on f or par asi t es ot her t han
desi r ed pl asmodi um
( 2) Negat i ve ant i body scr eens f or
syphi l i s, hepat i t i s, HI V, and any
ot her i nf ect i ons suggest ed by hi st or y
and physi cal exami nat i on
2. wi t hdr awal ( ant i coagul at i on as i ndi cat ed) of
mal ar i ous bl ood f or di r ect i nocul at i on, f or
pr epar at i on of washed cel l s, or f or pl asmodi um,
cul t ur e
3. Pat i ent i nocul at i on ( i nt r avenous) wi t h
pl asmodi um sour ce
B. Al i ment at i on as i ndi cat ed wi t h mai nt enance of 300
gr am dai l y car bohydr at e i nt ake
C. Moni t or i ng of r esponse
1. Pr odr ome
a) I nocul at i on f ever spi ke
b) Or al t emper at ur e char t ed q. 4 h. dur i ng
waki ng hour s
c) No ant i pyr et i cs t o be t aken
2. Mal ar i a syndr ome
a) Bed r est when f ever at t ai ns 38C
b) Temper at ur es t o be char t ed ( consi st ent
met hod of measur ement )
( 1) Q. 30 mi n. dur i ng f ebr i l e par oxysm
( 2) Q. 2 h. whi l e awake
( 3) Temper at ur es and f ever dur at i on t o be
r ecor ded on r epor t f or m, as wel l char t
c) Bl ood pr essur e r ecor ded b. Ld. ( mor e of t en
i f hi gh or l ow)
d) Body wei ght r ecor ded weekl y
e) Sodi um i nt ake ( p. o. or I . V. ) of 5 gr ams
dai l y ( f or di aphor esi s l oss)
f ) CBC, ur i nal ysi s, BUN ever y 4 days
g) Acet ami nophen 650 mg q. 4 h. p. r . n.
2
. .
unt ol er at ed f ever above 41C or r epeat ed
t epi d sponge bat hs and aspi r i n 975 mg p . o .
or p. r . q. 4 h. p. r . n.
3. Modi f i cat i on or i nt er r upt i on of t r oubl esome
at t acks
a) Quot i di an f ever i f debi l i t at i ng
b) Mor e t han 4 hour s and/ or 42 C of f ever per
par oxysm
c) I mpendi ng vascul ar col l apse
( 1) Tachycar di a of 130 or mor e when
af ebr i l e
( 2) Syst ol i c BP bel ow 80 despi t e
i nt r avenous f l ui d and el ect r ol yt e
suppor t ( combi ned wi t h di gi t al i s
and/ or vasopr essor s as i ndi cat ed)
d) I nt r act abl e vomi t i ng
e) BUN over 60 mg/ dl
f ) Sever e pr ogr essi ve j aundi ce
g) Repeat ed hypot her mi a
h) Uncont r ol l ed del i r i um
i ) Hemat ocr i t bel ow 20% or hemogl obi n bel ow
7 gr ams/ dl
j ) Shock ( possi bl e spl enet i c r upt ur e)
4. Rei nocul at i on i f r equi r ed by i nocul at i on/
hyper t her mi a f ai l ur e ( def i ned as ei t her no
par asi t emi a wi t hi n 6 days of i nocul at i on, or
l ess t han 10 par oxysms dur i ng mal ar i al syn-
dr ome)
a) I n t he absence of chemot her apeut i c
modi f i cat i on
b) Fol l owi ng i at r ogeni c modi f i cat i on or '
i nt er r upt i on of t r oubl esome at t acks
5. Ter mi nat i on of mal ar i a af t er 30 days or 10
par oxysms, whi ch ever comes l ast
D. Dr ug t r eat ment of mal ar i a
E. Conval escent car e
1. Bed r est unt i l af ebr i l e f or 7 t o 14 days
2. Resumpt i on of act i vi t y *
3. I mmupogl obul i n el ect r ophor esi s, i nt er f er on
assay , and st udi es i ndi cqt ed f or compar i son
wi t h pr et r eat ment ser um ( i f f easi bl e)
4. Ser um chemi st r i es as i ndi cat ed by
abnor mal i t i es f ound on admi ssi on or dur i ng
t r eat ment
5. Fi nal CBC and ur i nal ysi s
6. HI V t i t er f r om PCR
7. Whol e body phot o ( swi m t r unks)
F. Di schar ge and dr ug t her apy f or mal ar i a
VI . Fol l ow- up ( 1, 3, 6 mont hs) ; no sexual cont act pr ef er -
r ed, ot her wi se pr ot ect ed sexual cont act ( condom) onl y
A. Hi st or y and physi cal exami nat i on
3
B. CBC, hemogl obi n el ect r ophor esi s, par asi t emi a
scr een
C. BUN, ser um al bu~n, t ot al pr ot ei n~ i mmunogl obul i n
el ect r ophor esi s , i nt er f er on assay , bi l i r ubi n D/ T,
al kal i ne phosphat ase, ot her enzymes as i ndi cat ed
( i f f easi bl e)
D. Ur i nal ysi s
E. Chest X- r ay ( pneumoni a)
F. HI V t i t er f r om PCR
G. Whol e body phot o ( swi m t r unks)
VI I . Anal ysi s of r esul t s
A. Ef f ect of t her apy on HI V
1. El i mi nat i on of HI V
2. Changes i n HI V t i t er
B. Cor r el at i on of HI V changes wi t h dur at i on/ i nt ensi t y
of mal ar i ot her apy
C. Cor r el at i on of HI V changes wi t h i mmune syst em
changes
D. Cor r el at i on of i mmune syst em changes wi t h dur -
at i on/ i nt ensi t y of mal ar i ot her apy
4
HI V CANDI DATE SELECTI ON CRI TERI A
Candi dat e must be:
HI V posi t i ve ( HI V- I or HI V- I I cl assi f i ed)
Mal e
WRI or WR2 cl ass
CD4+ T- cel l count s bet ween 300- 500
PRE- TREATMENT REQUI REMENTS
I n addi t i on t o f ul l medi cal hi st or y, f ul l body phot ogr aphs
( swi msui t ) wi l l be t aken pr i or t o t r eat ment , af t er t r eat ment
and at f i nal f ol l ow- up exami nat i on. Al l dr ug t her api es shoul d
be t er mi nat ed 2 weeks pr i or t o st ar t of mal ar i ot her apy, f or
dr ug washout t o occur .
DURI NG TREATMENT
Dur i ng t he cour se of MT, al l pr ecaut i ons f or deal i ng wi t h HI V
cont ami nat ed mat er i al wi l l be obser ved by al l , i ncl udi ng
nur ses, et c. Devel opment of any compl i cat i ons r el at ed t o
AI DS- r el at ed compl ex shoul d be t r eat ed i n t he nor mal manner .
CRI TERI A FOR EARLY TERMI NATI ON
OF MALARI OTHERAPY
St andar d mal ar i a r el at ed event s i ndi cat i ng need f or t er mi n-
at i on of t her apy.
POST TREATMENT
Sexual abst i nence dur i ng f ol l ow- up t o pr event r ei nf ect i on
( pr ot ect ed sex i s accept abl e, but not pr ef er r ed) .
Tr eat ment Recor d
For Research Only
Name of Pat i ent : Name of Physi ci an:
wei ght :
Dat e of Exami nat i on:
Age: Sex: M F
Physi cal Appear ance ( i ncl ude phot o) :
Pat i ent ' s Gener al Feel i ngs:
Dat e of Onset ( hi st or y) :
Dat e of Di agnosi s:
Dat e of Tr eat ment s, et c. :
Gener al Pr ognosi s:
Descr i pt i on of physi cal i mpai r ment due t o HI V i nf ect i on:
Bl ood Anal ysi s:
I I
Hb WBC Pc LT RF
I
CD4+ CD8 CD3
I I
I I
I gG I gA I gM I gD I FNa
I
I FN, 8 I FNy
I I
HI V t i t er f r om PCR:
Mal ar i at her apy I ni t i at i on
Mal ar i a Type:
I nj ect i on 1- Vol ume:
Dat e:
concent r at i on:
Obser vat i ons:
I nj ect i on 2- Vol ume:
Dat e:
concent r at i on:
Obser vat i ons:
Mal ar i al Phase
st ar t of f ebr i l e per i od ( dat e) :
Recor d hi gh and l ow body t emper at ur es and dur at i on of f ever
( f ever shoul d be consi der ed as any t emper at ur e gr eat er t han
38. 3 C or 100 F) .
Day 1 2 3 4 5 6 7
Hi gh Temp.
Low Temp.
Fever
Dur at i on
Medl cat l on adml nl st er ed:
Reason f or medi cat i on:
Day 8 9 10 11 12 13 14
Hi gh Temp.
Low Temp.
Fever
Dur at i on
Day 15 16 17 18 19 20 21
Hi gh Temp.
Low Temp.
Fever
Dur at i on
Day 22 23 24 25 26 27 28
Hi gh Temp.
Low Temp.
Fever
Dur at i on
*
Day 29 30 31 32 33 34 35
Hi gh Temp.
Low Temp.
Fever
Dur at i on
Day 36 37 38 39 40 41 42
Hi gh Temp.
Low Temp.
Fever
Dur at i on
*Cour se of mal ar i a t r eat ment i s t o be hal t ed af t er t he 30
th
day
or 10 par oxysms of f ever , whi ch ever occur s l ast .
Ter mi nat i on of Mal ar i a
Dat e:
Met hod of mal ar i a t er mi nat i on:
Reason f or t er mi nat i on:
. .
Post Tr eat ment Eval uat i on
Name of Pat i ent :
Name of Physi ci an:
Wei ght :
Age:
Sex: M F
Gener al Condi t i on of Pat i ent :
Physi cal Appear ance ( i ncl ude phot o) :
Pat i ent ' s Gener al Feel i ngs About Cur r ent Physi cal Condi t i on:
Cur r ent st at e of Physi cal I mpai r ment Due t o HI V:
Bl ood Anal ysi s:
[ I
Hb WBC Pc LT RF I gG I gA I gM
I [
[ I
I gG I gA I gM I gD I FNa I FN, 8 I FNy
I [
, '"
Fol l ow- up Eval uat i on
( To be gi ven 1, 3,
and 6 mont hs af t er
Post Tr eat ment Eval uat i on)
For Research Only
Name of Pat i ent : Name of Physi ci an:
Wei ght :
Age:
Sex: M F
Gener al Condi t i on of Pat i ent :
Physi cal Appear ance:
Pat i ent ' s Gener al Feel i ngs About Cur r ent Physi cal Condi t i on:
Cur r ent st at e of Physi cal I mpai r ment Due t o HI V:
Bl ood Anal ysi s:
I I
Hb WBC Pc LT RF I gG I gA I gM
I I
I I
I gG I gA I gM I gD I FNa I FN, B I FNy
I I
=
I met wi t h Dr . Fahey and col l eagues at UCLA. On hi s r et ur n
P O B O X B B 5 8 f r omt he AI DS conf er ence i n Vancouver , he had pr esent ed our
C I N C I H H A T I , O H 4 5 2 0 8 mal ar i ot her apy pr ogr am t o t hem. T gave t hemmor e det ai l s and
5 1 3 - 2 2 1 - D 0 0 2 r esponded t o t hei r quest i ons and suggest i ons. They al l ar e
f a I 5 1 3 2 2 1 - 0 0 0 3 i nt er est ed and appr ove. Af t er t he conf er ence Dr . Fahey and I
met f or 3 hour s.
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Repor t on Dr . Hei ml i ch' s t r i p t o Los Angel es Sept ember 24 - 27
t o meet wi t h Pr of essor J ohn L. Fahey, M. D. , Di r ect or of t he
Cent er f or I nt er di sci pl i nar y Resear ch i n I mmunol ogy and
Di sease ( CI RI D) at UCLA, Depar t ment of Mi cr obi ol ogy &
I mmunol ogy, UCLA School of Medi ci ne.
Our meet i ngs wer e on 9/ 24 and 9/ 25.
descr i bed hi s pr ogr am i n f our par t s:
Dr . Fahey ( Dr . F)
I . Resear ch i n AI DS
I n 1981, t he f i r st t hr ee young men t o be r ecogni zed as havi ng
a di sease l at er named AI DS, was r epor t ed i n t he New Engl and
J our nal of Medi ci ne f r omUCLA by Dr . Got t l i eb, wi t h whom Dr .
F wor ked. Si nce t hat t i me Dr . F has been i nvol ved i n
i nvest i gat i ng i mmunol ogi cal l y, i mmune def i ci ency and
oppor t uni st i c di seases.
Dr . F' s st udi es i ncl ude f ol l owi ng t he cour se of a gr oup of
homosexual men f r om 1984 t o t he pr esent . Of 1, 600 men, 800
wer e ser o- posi t i ve i n 1984, and 800 wer e ser o- negat i ve. The
even di vi si on of number s was coi nci dent al , not pl anned. He
has f ol l owed t he cel l s and pl asma of t hese i ndi vi dual s ever y
si x mont hs si nce 1984, i n addi t i on t o cyt oki ne st udi es and t he
pat hogenesi s of t he speed of pr ogr essi on of t he di sease and
dysr egul at i on of t he i mmune syst em. NOW, t wel ve year s l at er ,
hal f of t hose wi t h AI DS have di ed. Of t he negat i ve
i ndi vi dual s 135 ar e now HI V posi t i ve.
I I . Ther apy Ef f or t s
Dr . F i s i n char ge of l abor at or y st udi es and does not wor k
cl i ni cal l y wi t h pat i ent s. Hi s pr ogr am i s associ at ed wi t h
ACTG, and i ncl udes adul t and pedi at r i c cases. ( ACTG i s t he
NI H suppor t ed pr ogr am - AI DS Cohor t s Tr i al Gr oup) . He i s
r esponsi bl e f or st andar di zi ng met hodol ogi es, i n hi s and ot her
l abor at or i es. St udi es i ncl ude f unct i onal t est i ng and f l ow
cyt omet r y.
I I I . I nt er nat i onal
Thi s pr ogr am
I nt er nat i onal
concer ni ng:
i s under
Cent er of
and
t he
suppor t ed
NI H. I t
by t he
pr ovi des
Fogar t y
gr ant s
- 1 -
1. AI DS epi demi ol ogy
2. Resear ch suppor t and t r ai ni ng of sci ent i st s as
par t of t he AI TRP ( AI DS I nt er nat i onal Tr ai ni ng
Pr ogr ams) . The l ocat i on of hi s wor k i s:
a. The Asi an Paci f i c Ri m, pr i mar i l y Chi na and
I ndi a; secondar i l y Thai l and and vi et nam.
b. Lat i n Amer i ca, Mexi co, and Br azi l .
Dr . F' s r esear ch f or Chi na i s headed by Dr . Hong Bass ( an
Amer i can ci t i zen) i n Hong Kong and Bei j i ng. Dr . F had br ought
her t o my pr esent at i on at t he AI DS conf er ence i n Vancouver i n
or der f or us t o meet r el at i ve t o wor ki ng t oget her . I n t he
past she has t aught at Peki ng Uni on Medi cal Col l ege, Bei j i ng
Medi cal Uni ver si t y, and t he I nst i t ut e f or Tr adi t i onal Chi nese
Medi ci ne, al l i n Bei j i ng, and at t he Second Medi cal Mi l i t ar y
uni ver si t y i n shanghai . Dr . Bass has ar r anged f or Dr . F t o
car r y out hi s wor k i n al l t hese i nst i t ut i ons.
Each year t r ai nees f r om t he above i nst i t ut i ons and t he Chi nese
Mi ni st r y of Heal t h come t o UCLA t o st udy i n Dr . F' s l abor at or y
f or t hr ee mont hs. The Cent er al so pr ovi des t o t he
i nst i t ut i ons, at no char ge, r eagent s t o car r y out l abor at or y
st udi es.
3. An i nt er nat i onal ef f or t under t he UCLA Fogar t y
Cent er t o est abl i sh cont r ol s f or measur i ng CD4 l evel s
t hr oughout Asi a.
Hi s wor k i ncl udes est abl i shi ng nor mal l evel s f or CD4, CDS, and
CD3 f or al l t he count r i es st udi ed, si nce t hese l evel s di f f er
f or each count r y. Dr . F ment i oned t hat Cust oms i n Chi na i s
ver y di f f i cul t . He sends r eagent s t o Chi na f r om Aust r al i a.
He al so st udi es var i ous met hods f or CD4 t est i ng, i ncl udi ng
i mmunof l uor escence, ELI SA ( TRAX 4) , and Beads t hat bi nd t o
CD4. He has f ound t hat mi cr oscopi c, ELI SA, and f l ow met hods
al l have val i di t y. Mi cr oscopi c met hods, whi ch we have been
usi ng i n Chi na, ar e best f or smal l ser i es.
UCLA and t he Hei ml i ch I nst i t ut e
1. Dr . F wi l l wor k wi t h The Hei ml i ch I nst i t ut e t o
est abl i sh t he t est i ng desi gn t hat wi l l best enabl e eval uat i on
of t he pat i ent s we ar e t r eat i ng.
2. Labor at or y t est s t hat ar e done i n Chi na wi l l be
checked by conf i r mat or y t est i ng of t he same bl ood sampl es at
UCLA.
- 2-
3. Our Chi nese col l eague, Dr . Chen xi ou Pi ng i s
i nvi t ed, at t he expense of UCLA, t o spend t hr ee mont hs i n 1997
st udyi ng i n Dr . F' s l abor at or i es. Dr . F. wi l l have Hong Bass
cont act Dr . Chen and pr ovi de hi s l abor at or i es i n Guangzhou
wi t h t r ai ni ng and assi st ance. He wi l l al so pr ovi de r eagent s
f or l abor at or y st udi es t o Chen wi t hout cost .
Dr . F ment i oned hi s i nt er est i n t r ai ni ng t he Chi nese mi l i t ar y
t o f ol l ow u. S. mi l i t ar y met hods i n t r eat i ng and ar r angi ng
di schar ges f or HI V i nf ect ed per sonnel . I t hen i nf or med hi m
t hat Vi ce Admi r al Koeni g, Sur geon Gener al of t he U. S. Navy,
was goi ng t o Bei j i ng f or t he I nt er nat i onal Congr ess on
Mi l i t ar y Medi ci ne oct ober 11 - 17 and had cal l ed me l ast week
hopi ng t o meet my associ at es. Dr . F advi sed t hat he woul d
ver y much l i ke t o have Admi r al Koeni g meet t wo Chi nese
doct or s, a Gener al and a Col onel f r om t he Second Mi l i t ar y
uni ver si t y i n Shanghai , who wi l l ver y l i kel y be at t he
Congr ess.
The next day I cal l ed Har ol d Koeni g, who f axed t he Congr ess
pr ogr am t o Dr . F, and ar r angement s wi l l now be made bet ween
t hem. I n addi t i on, Dr . F i s schedul ed t o go t o Bei j i ng t o
t each f r om Oct ober 18 t o 23, and bot h ar e st ayi ng at t he same
hot el . Dr . F wi l l be i n t ouch wi t h our Dr . Chen i n Guangzhou
and Chen wi l l l i kel y go t o Bei j i ng t o meet Dr . F.
On Thur sday mor ni ng, Sept ember 25, Dr . Hong Shun Hua and I had
a pl anned meet i ng i n my hot el . Dr . Hua came t o me as a Fel l ow
many year s ago and has been our cont act wi t h Dr . Chen i n
Guangzhou. Dr . Hua t r avel ed t o Guangzhou when our pat i ent s
wer e r ecei vi ng mal ar i ot her apy i n or der t o f ol l ow t hei r
pr ogr ess. He vi deot aped i nt er vi ews wi t h our pat i ent s.
Dr . Hua t el ephoned Dr . Chen i n Guangzhou f r om t he hot el and we
spent a ver y i nf or mat i ve hour speaki ng wi t h hi m. ( Dr . Chen
speaks excel l ent engl i sh. ) Dr . Chen was al r eady pr epar i ng t o
i ncl ude i n our pat i ent st udi es cur r ent l y devel oped l abor at or y
t est s, i ncl udi ng vi r al l oadi ng, l ymph f act or measur ement ,
i nt er f er ons, vi r us gene anal ysi s, et c. He was t hr i l l ed wi t h
t he possi bi l i t y of wor ki ng wi t h Dr . F and spendi ng t hr ee
mont hs i n hi s l abor at or i es.
Dr . Chen wi l l be at t endi ng an AI DS conf er ence i n November i n
Hong Kong. I l at er t ol d t hi s t o Dr . F who wi l l ar r ange f or
hi m t o meet Dr . Hong Bass t her e. Chen advi ses t hat t her e ar e
700 HI V posi t i ve pat i ent s i n Hong Kong. He sai d t hat on J ul y
1, 1997, Hong Kong wi l l be r et ur ned t o mai nl and Chi na,
t her ef or e, t he Guangzhou Heal t h St at i on, wher e our
mal ar i ot her apy pr ogr am i s cent er ed, wi l l cooper at e wi t h t he
Publ i c Heal t h Depar t ment of Hong Kong. Dr . Chen' s st at i on has
- 3- ...-------:~------------- - --
/'1,
r ecei ved 2, 000, 000 Chi nese dol l ar s f r omt he Chi nese Mi ni st r y
of Heal t h ( r at i o t o USD i s about 8. 5 t o 1) t o expand t hei r
f aci l i t i es and r emodel Chen' s l abor at or y. He says he can
st ar t t he new mal ar i ot her apy pat i ent t r eat ment s when t he
r emodel i ng i s f i ni shed, i . e. af t er November . ( The above was
conf i r med i n a Fax f r omChen of 9/ 27. )
On t he second day, ( 9/ 25) , Dr . Hua and I met wi t h Dr . F and
advi sed hi mof our di scussi ons wi t h Dr . Chen. Dr . Hua i s now
consi der i ng spendi ng t he next t wo mont hs i n Dr . F' s
l abor at or y.
Thi s has been a wonder f ul year . I n summar y, our dat a has been
r evi ewed and accept ed by panel s of exper t s of t hr ee l eadi ng
i nt er nat i onal conf er ences on i mmunol ogy and AI DS ( San
Fr anci sco, J ul y 1995; The NI H, J une 1996; Vancouver , J ul y
1996) ; by uni ver si t y pr of essor s who ar e AI DS aut hor i t i es; by
t he u. S. Ar my Resear ch and Mat er i el Command; by edi t or s of a
medi cal j our nal , and was r epor t ed f avor abl y i n t he pr ess.
Thi s r ecogni t i on st ems f r omour car ef ul l y pr epar ed pr ot ocol ,
accur at e dat a, and pr omi si ng r esul t s.
The f ut ur e i s even br i ght er . The st udi es ar e enhanced by t he
r el at i onshi p wi t h UCLA. The af f i l i at i on wi t h Dr . Fahey
est abl i shes a cont i nui t y t o our mal ar i ot her apy pr ogr am t hat
assur es t he ongoi ng and f ut ur e pr ogr ess of our r esear ch.
Submi t t ed:
Hei ml i ch, M. D. , ScD.
Center for Interdisciplinary Research
UCLA
BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DIEGO SAN FRANCISCO SANTABARBARA' SANTACRUZ
October 2, 1996
10833LE CONTE AVENUE
LOSANGELES, CALIFORNIA 90024-1747
(310) 825-6568
(310) 206-1318 (FAX)
Hemy Heimlich, M.D.
TheHeimlich Institute
Foundation, Inc.
2368 Victory Parkway, Ste. 410
Cincinnati, OH. 45206
Dear Henry:
I want to express my appreciation to you for your taking thetimeto visit with us at
CIRID at UCLA last week. Our group was stimulated by your presentation on
malaria therapy. Indeed, several asked meif it would bepossible to have amore
complete description (CD4 counts, clinical features, etc.) of all of thepeople treated
inChina? These may be inamanuscript that is inpreparation or submitted but we
would appreciate whatever information you can share with us.
I very much enjoyed talking to Dr. Hua. He has called and I amsending' him
information about acourse onmv that is starting next week which, I think, will
meet his needs better than spending timewith our group. Our working conferences
involve laboratory personnel and arenot designed for individuals without that kind
of background and experience. We will try and help himwith anupdate on
mV/AIDs.
I must thank you for thereprints of thepapers concerning Lyme Disease and the
accompanying nervous systemmanifestations. I have taken tins up with a
neurologist and have arranged for aserologic test for theborrelia spirochete
infection.
Heruy Heimlich, M.D.
October 2, 1996
Page 2
Ihave also written to Dr. Chen Xiao Ping in Guangzhou to inquire about the
possibilities of talking with him during my upcoming visit to China. Also, Ihave
contacted my colleagues in the Chinese Army to see ifthey are attending the
International Conference on Military Medicine in Beijing.
Many thanks for telling me about so many things that are going on. Iamsure they
will all turn out to be fruitful. Iwill be certain to provide you with a follow-up.
Sincerely,
J ohn L. Fahey, M.D.
Director, CIRlD* at UCLA
Chair, Clinical Immunology Committee, International
Union of Immunological Societies (lUIS)
J LFIkhl
b:\Heimlich
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 410
C I N C I N N A T I
O H I O
452 00
513 - 2 2 1- 00J 2
fa x 513 - 2 2 1- 00J 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Oct ober 14, 1996
Depar t ment of Mi cr obi ol ogy & I mmunol ogy
Dear J ohn:
Thank you f or your l et t er of Oct ober 2, 1996. I hope t hat
your ar r angement s t o meet Dr . Chen Xi ao Pi ng wor k out . You
wi l l f i nd hi m t o be a f i ne young man, wel l i nf or med, ver y much
i nt er est ed i n your wor k, and ami abl e. Your i nvi t at i on t o Dr .
Hua t o at t end your conf er ence i s appr eci at ed by hi m and by me.
I under st and you had a l engt hy and i nf or mat i ve conver sat i on
wi t h Davi d Mahoney. He i s a f i ne gent l eman and ver y
i nt er est ed i n our pr oj ect .
Dr . Er i c Spl et zer , my associ at e, wi l l get t oget her det ai l s on
our cases and you shoul d have t hem when you r et ur n f r om your
t r i p.
Have a pl easant and pr oduct i ve j our ney. I f I can do anyt hi ng
t o hel p, pl ease l et me know.
Best ~i
!I
j
i ch, M. D. , Sc. D.
HJ H: j ws
October 22, 1996
Cincinnati
Ohio 45206
U. s. A.
Dear Dr. Heimlich: .
ltd J
I -did not receivelt.. Dr. Fahey's letter of October 2 until yesterday. I
contacted with him last night and this morning by telephone. It is a
pity that it is too late for me to meet him in Beijing because he
will return home tomorrow and I could contact him just yesterday. But
we talk a lot by telephone. He told me that they win have a HIV
training program in Los Angeles from March to April, 1997, just about
one month. But I want to stay there for three months to study some
things more. Could you please contact him to let me study there from
January to April and then return to G118
n
gzhou for continuing our clinic
trial ? If so, I need your or his invitation letter to deal with my
paBBport and visa, the sooner the better. Since in China, as you know,
people usually have to spent at least 3 months on dealing with paBBport.
So I hope you or Dr. Fahey give me invitation letter as soon as
poBBible after you receive this letter.
Now I want to let you know my schedule as follow:
November, 1996: Attend Hong Kong AIDS Conference and visit
Hong Kong Health Department.
December, 1996: Visit the second batch of HIV patients for their 2
January- April,
1997:
April, 1997:
years follow up to Yunnan Province.
Bring HIV samples to Dr. Fahey' center for testing
and attend HIV training progrom in Los Angeles
Return to Guangzbou to treat the 8rd batch of HIV
patients ( 10 cases ).
During the whole course of next batch patients who will receive
malariotherapy, I plan to test their cytokines ( ll-2, 6, IFN-r, TNF ),
CD4 by cytometer, HIV load by PCR, HIV sequence and apoptosis. But
before doing this, I need study some. things in USA as mentioned above.
So I hope you to help me to complete my training for our project to be
more perfect.
F
I have mentioned in my last letter, you should pay 2000USn each patients
each time for the two years follow up of the first two patients (
according our agreement, in the first two patients, you should pay
10000 usn for each ). The part of Guangzhou agrees to continue
following up the first two patients, we count the payment to be 1000
usn for each patients each time.
Enclosed are the 1.5 year follow up reports of the 6 patients in Yunnan.
Case 6 died on July 5, 1996; the cause of his dead is unknown, but I
guess there are two possibilities, see the report. We consider ' that you
should pay for the follow up this time because we visited his family to
get the information about his dead and you did not pay any for his 1
year follow up. We do need enough money to successfully complete our
project. We have applied funding from Guangzhou Government to buy
flow cytometer and other instruments for our project. We hope your part
can pay some if possible. Dr. Fahey suspects our method ( APAAP) for
CD4 testing, I have the sense from my talk with him in telephone. We
must make our results be widely acceptable in the world, we must use
the best instruments to do our tests. So our following research will
be much more expensive. We should have this idea.
I agree that Dr. Spletzer is as our coauthor in our paper "
Characteristics of artificially induced ... ". There are some changes in
component in this paper, so I hope you or Eric revise it in English
wording and grammar and then send back to me as soon as possible.
We are waiting for your payment to complete our each part of the
research.
We look forward to hearing from you soon.
Best wishes and regards to you and my mum, Jane, I miss her very much.
d u 1 ~ ~
Dr. Chen Xiao Ping
Station of Guangzbou
No. 23, 8rd Zhongahan Road
Guangzhou 510080
2
Malariotherapy for HIV
Follow-up Evalultion
(To be g hen 1, 3,
and 6 month after
Post Treatment Ev!luation)
For Researeh Only
Name of Patient
Name of Phys ie ian: C
bn
X P
Date of Eumlnallo.: srI." I'f'l t
Age: Sel: M ~
Ganelal Condition of Patient:
( ] ~
Physical Appearance:
/Vormd- .
Patient' s Oeneral FaelingG About Current Physical Condition:
Current States of Phyftieal Impairment Due to HIV:
/'1011.4
Blood Analys is:
Hb WBe Pc LT RF CD4 CD8
CD3
IIT/ fot liftJ-
IgG IgA
I
IgM IgD IFN a. IFN a IFN y
It,oo
/,0/0
/\fo
i
IIIV titer from peR: ELI5A t.l O P ~ I, 92-
Name of Patient
Follow-up Evaluation
(To be given 1, 3,
and 6 month after
Post Treatment Evaluation)
For Research Only
Name of Phys icTan: )0 r
Weight: guf::-y ale of Examinallon: sri 7) lu6
Sel: M Age:
General Condition of Patient:

Physical

Patient' s: General '.elings About Current Physical Condition:
Current States of Physical Impairment Due t o HIV:
;\!Of/U!.-
Blood Ana lysis:
I
lIb
I
iBC Pe 1T RF CD4 CDS
/21 / JltrO
/If
- 2-vlj
. /}tP6
IgG IgA IgM IgD IFN a. I FN a
//i{fO
(Jlt)
/lOO
HIV titer from peR: ELISA -t; /.)6
. CD3

IFN'y
'0
".!
Name of Patient
(To be ghen 1, 3,
and 6 month after
Posi Treatment
For Research Only
Name of Physicioan: X?
. Weight: 60 I J-Ij Date Gf Examination: 58ft.J / //Irl ,
Age:
Sex: If \
G#Jct{

Patient' s-General Feelings About Current Physical Condition:
Current States of Physical Due to
t/OflJ2..-
Blood Analys i s:
- .
Db 0 WBC Pe LT RF CD4 CDS
IJ.2
1 Jrrz? I 1ft -
2-.1-22- 1/'fO
{gG IgA IgM IgD IFN Cl IFN a
20.
0
()
/.J-L

HIV titer from peR: t::::LI5/f-r; /.60
. CD3
. s
." 2.T+)
.
tFN. 'Y .
Co
Name of Pa t ten
Weight:
Age:
(To be given -l;-S;- IS
& month afier
Post Treaiment Evaluation)
For Research Only
Name of Physician:' eke-11 )( p
Date of I'll) /
I - . , / 7 b
Sel: 111 , .
,}Ie- et:.d tm tf9t. One. ,')n(mth 6ejc-re-/u.. Iu.lu4
Phys ical Appearance: !/)f fU/..er>
( stAo!) ttA1q / tlt4WYe?(
Patient' s-General About Current Physical Condition:
t1c.:t6eh-t? ct)d 1 dr"j u-:e tJr
bit-t =uLd J4 cJ-.f- h;a
Current of Phye ;.01 Impairment Ifue to HIV: P'i-; t:Jr
h.e. c&;d 1 hIPS J ntJbtJofI krw7.0s.
Blood Analysis:

Hb iBC Pc LT RF CD4 CD8
.' CD3
'"
, ;c "
IgG IgA IgM IgD IFNa IFN a IFN y
-
HIV titer from peR:
I
1
I
Name of Pa t ien
lIb WBe
Itf.2- /f4tn?
IgG IgA
10,/0
/ \ ] {}
Mmlariotherapy for HIV
Evaluation
(To be ginn -1,-8,-
eel 6 afhr - -
Post Evaluation)
For Res.arch Only
- '.1,-,
of Phys ieian: X p
Date of Elaminat ion: 7) fl/q {;
Sel: ld
Pc LT RF CD:! CDS CD3
lof
-
/tl?/
Iq/
Is-J7--
IgM IgD IFNa IFN a IFNy
I
I, l!l
HIV titer from peR: EL/3fj-t-;
MalariGtherapy for HIV
(To be given 1. 8.
IDa 6 month after
Post Treatment Evaluation}
For Research Only
Name of C/z.w)(p
Weight: nate of Rumination: Seft?, /,/'16
Sel: M \ .
Age:
/fOl'md
Patient' s General About Current Physical
Current States of PhYBieai Impairment Due to HIV:
None.
Hlood Analys is:
Hb WBC Pe LT RF CD. CDS CD3
'3.2,
11
0
-r
J-)O
s-t/f /lr::
IgG IgA IgM IgD IFN a. IFN IFNy
171 q{)
(, q,o I( q.o
HIV titer from peR: GLI5"It-t-; {)j):.1.7f
.;,
November 4, 1996
Dr. Chen Xiao Ping
Guangzhou 510080
Dear Chen:
Thank you for your letter of October 22, 1996. It was very
thorough and informative. I am sorry you missed seeing Dr.
Fahey, but I am pleased that you spoke with him on the
telephone. Dr. Fahey is visiting other countries and will not
be home for another two weeks, at which time I will contact
him. It is my understanding that he only gives the training
program in March.
On November 7th I have been invited to visit David Ho's new
laboratories. If that looks promising I can ask him to have
you spend a month with him in New York. Perhaps we can
arrange a third month with either Dr. Fahey or Dr. Ho or at
another laboratory. Let me know your thoughts.
Should you not be able to come to the united states prior to
March, I would like to suggest that you treat two or three
patients in the new group before you leave China. That will
be favorable in the eyes of those who are funding our work.
However, I do not think you should treat any new patients
until your new laboratory has been proven to get accurate
determinations of all the new tests that you have mentioned
and Dr. Fahey has given us a revised protocol.
Your reports of the six patients in Yunnan are very good.
They are not really 1. 5 year follow-up reports since they
actually completed treatment two years prior to September 7,
1996. Follow-up blood studies should not be done on any of
the seven older patients until we discuss this, probably after
you return to China from the united states.
$4,000 has been wire transferred to your account
#475010101140192114, Bank of China Guangzhou Branch. This
completes the total payments for the first two patients . When
you are in the united states we can discuss the amount that is
proper for future laboratory studies.
If we are able to progress as suggested, I have been promised
funds to extend our progress, but we must keep them at a
reasonable level. Since the tests will be done in your own
new laboratory, which will be used for treating many other
patients, and Dr. Fahey will provide reagents, it should keep

costs down at a lower level. As always, we will be fair in
meeting our obligations and your needs. I am sure that you
will do the same.
My best wishes to my Chinese friends and family,
~.
~-- -. . . .
*Center for Interdisciplinary Research
UCLA UNIVERSITY OF CALIFORNIA, LOS ANGELES
BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SANDIEGO SAN FRANCISCO SANTA BARBARA SANTA CRUZ
LOS ANGELES, CALIFORNIA 900951747
( 310) 825- 6568
FAX: ( 310) 206- 1318
November 6, 1996
Henry J . Heimlich, M. D. , Sc. D.
President
TheHeimlich Institute Foundation, Inc.
2368 Victory Parkway, Suite410
Dear Henry,
Ijust returned frommy trip that included stops inIndia and Europe before returning
to UCLA. My stay inBeijing was busy and informative. Fortunately Iwas able to
talk with Dr. Chen Xiao Ping on thephone at some length. He was very helpful and
certainly speaks English well. I've invited himto take theFogerty mV/AIDS
course at UCLA next spring. The general theme is anupdate and design of
mV/AIDS research. We'll be sending himmore information inthe coming days,
and Icertainly hope hecan make arrangements in Guangzou to be away for that
time. Ioffered himthe opportunity to bring samples fromhis studies inChina so
th. . ,t more detailed studies can be conducted while h'" 1C' her". at UCLA
U~U" . . . .&..a. _...... '"'''~.&.'"' t. tJ ' "'. \.i. '''' . a. ,-,_ tJ.&..1. .... " " - .L.
He identified amethod for measuring CD4 T-cell levels that I was not familiar with.
Apparently flow cytometry was not used inthemalarial therapy studies. I look
forward to having more information about the CD4 method that was used. We will
try to help himwith satisfactory flow cytometry or alternative methods for accurate
CD4 T cell measurements. That is part of our course here at UCLA. He assured
me that flow cytometry was available at his institute and that hewould have access
to that for future malarial therapy studies.
1
He did mention that hewould be going to Hong Kong early inNovember for the2-
day AIDS meeting there. I have informed my associate inHong Kong, Dr. Hong
Zhao Bass(whom you also met inVancouver), about our conversations with Chen
Xiao Ping, and hope that thetwo of themcan talk further. Shecan tell himmore
about the set up at UCLA and help prepare himto take advantage of that
opportunity .
I did enjoy my conversation with David Mahoney, who calledjust before I left for
China. I was able to tell himabout our plans to interact with your colleagues in
Guangzou and the plans to bring Dr. Chen Xiao Ping here to UCLA for six weeks
next spring.
I hope your work is continuing to gowell.
Sincerely,
J ohn L. Fahey,
Director, CIRID* at UCLA
2
2 3 6 8 V I C T O R Y
P A R 'f. W A Y
S U I T E 410
C I N C I N N A T I
O H I O
452 00
513- 22H X X l 2
fa x 513- 221- ((X )3
November 8, 1996
Depar t ment of Mi cr obi ol ogy &I mmunol ogy
Dear J ohn,
I hope you had a successf ul and i nt er est i ng t r i p i n Asi a. Dr .
Chen t ol d me you had phone cont act , but coul d not meet , and
t hat he wi l l be spendi ng Mar ch 1997 wi t h you. I am del i ght ed.
Encl osed ar e r ecent pi ct ur es and some of t he per t i nent dat a on
pat i ent s t hat have been f ol l owed f or t wo year s.
We al so have i nf or mat i on on t he CD8 count s and ot her t est s, as
wel l as f ul l pat i ent r epor t s, and wi l l send t hem t o you when
I r et ur n t o Ci nci nnat i .
Shoul d you have any quest i ons, pl ease f eel f r ee t o cal l . I
wi l l be out of t own f or t he next t en days, but wi l l be
avai l abl e t hr ough my of f i ce and wi l l cal l you on my r et ur n.
/
B e n e f i t i n g J'
H u m a n i t y / . Hei ml i ch, M. D. , Sc. D.
T h r o u g h /' Pr esi dent "I_~AJ! -
H e a l th P S . , r: ~ 4 =r:: - - Cl 1 dIf~ v-M
~~~ce fNMW ~ .
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-221.r0J3
Benefiting
Humanity
Through
Health
and
Peace
Fax
To: Dr. John L. Fahey
Of: Center for Interdisciplinary Research in Immunology & Disease
Fax: (310) 206-1318
Pages: 1, including this cover sheet.
Date: December 16, 1996
Once again, thanks for your invitation to Chen Xiao Ping.
He asked me to speak to you about his need for a Letter of Invitation as soon as possible.
In China, it takes considerable time when dealing with passports and visas. I suggest you
send such a letter by Federal Express to Chen at:
Dr. Chen Xiao Ping, Chief/Department of Microbiology
No. 23, 3'd Zhongshan Road
Guangzhou 510080
You may also wish to attempt a fax, but even if you think it goes through, don't rely on it.
His fax number is: 011-86-20-83814993.
My best wishes for a happy holiday d a new year of working together. .
From the desk of ...
Henry J. Heimlich. M.D.
2368 VICTORY
P A R ~ A Y
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
December 16, 1996
Professor Chen Qi Qi
Canton Medical College
Guangzhou 510182
China
Dear Chen Qi Qi:
Thank you so much for your thoughtful seasons greeting. It was nice to hear from you.
I thought you would be interested in the Heimlich Maneuver now being used to stop
asthma attacks. It saves a great deal of money and patients lives. I can send you a video
tape of how to do the Heimlich Maneuver for choking, drowning and asthma if you have
a compatible VCR for our VHS tape. The Heimlich Institute will be pleased to cooperate
with you in disseminating the information for China.
1 look forward to seeing you again in Guangzhou or should you come to the United
States.
HJM:jws
Enclosures
2 3 6 8 V I C T O R Y
P A R ~A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 52 0 0
513- 22H X X l 2
fa x 513- 22H X X l 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
December 17, 1996
Dr. Chen X iao Ping
Chief, Department of Microbiol ogy
The Municipal H eal th and Anti- Epidemic
No. 23, 3,dZhongshan Road
Guangzhou 510080
The Peopl e's Republ ic of China
Dear Chen:
Thank you for your l etter of November 28, 1996. Did you receive my fax of November
28
th
as wel l as the l etter? I suggest you respond to us by fax. Our fax number is:
00- 1- 513- 221- 0003.
We are now connected to the computer Internet. I f you can al so do so through your
computer, it is thebest way of communication between us. Our E- Mail address is :
"heiml ich @igl ou.com".
I ampl eased Dr. Fahey has extended your visit to three months. I twil l be good if you
pl an time tovisit me at my home inCincinnati. We may al so pl an atrip to New York
City so you can meet our sponsor.
Inmy l etter of November 8
th
, I recommended you treat two or three patients in the new
group before you come to the United States. You coul d then al so bring their bl ood
specimens to Dr. Fahey. That is stil l recommended, particul arl y since future treatments
wil l bedel ayed until J ul y rather than April , as you earl ier advised. Shoul d that not be
possibl e, it woul d then be good for you to sel ect the next ten patients now and take
specimens of bl ood from each patient every week; then bring those specimens and resul ts
of your tests to Dr. Fahey. But the best way wil l stil l be to treat two or three patients
before you come to the United States.
I tis agreat honor to have our work recognized by Dr. Fahey and for him to extend his
invitation to you. H e is one of the most widel y known AIDS authorities and I know you
wil l benefit greatl y fromyour visit. I have cal l ed Dr. Fahey to remind himof your need
for an invitation l etter and he is sending it to you.
""'"
, )
. ,
Dr. Chen Xiao Ping: 12/17/96
Page 2
You and our other Chinese colleagues will bepleased to know our report on our first two
patients has been accepted for publication in an international medical journal and should
beprinted by the time you arrive here. Eric is still working on "Characteristics of
Artificially Induced Hematogenous Plasmodium Vivax Malaria on Advanced Tumor
Patients". He is also preparing anew paper with the two year results of our eight
patients.
How was theAIDS meeting in Hong Kong? Did you meet Dr. Fahey's associate? Is
your new laboratory functioning?
Please let me know your thoughts by return fax or Federal Express, if possible.
Your "Mum", J ane, also looks forward to your visit.
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PAR'f.WAY
SUITE 410
CINCINNATI
OHIO
45200
513-22HlOO2
fax 513-22H)003
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
............... - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: V ALERIE HARPER
Of: THE ELEANOR NAYLOR DANA CHARITABLE TRUST
Date: January 3, 1997
Should you wish to contact me over the weekend, you may call me at home (513/871-
7711).
2368 VICTORY
P A R ~ A Y
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-22HXX)3
Benefiting
Humanity
Through
Health
and
Peace
January 3, 1997
Ms. Valerie Harper
375 Park Avenue
New York, NY 10152
Dear Valerie:
I have enclosed a tentative three year budget for our project, Malariotherapy for AIDS.
Also attached is a copy of the original budget I submitted to Mr. Stephen Foster on
February 20, 1996.
The original three year budget came to $2,031,245.00. These costs were diminished for
the following reasons:
1) Central America is eliminated.
2) The $290,795.00 for equipment, which was designated for China, is
now eliminated since the Ministry of Health of China is providing the
funds to update and equip their laboratories
3) The number of patients to be treated in years one and two has been
diminished.
The figures are estimates and are based upon ideal circumstances. I appreciate that the
funds may not be immediately available through the Eleanor Naylor Dana Charitable
Trust. Should this be the case, there are ways to modify our needs and our rate of
progress. For example, we may not meet the contemplated number of patients, thirty for
the first year, because treatment will commence upon Dr. Chen's return to China from
UCLA. That will diminish the cost by $10,000.00 per patient not treated. Furthermore,
our arrangement with Chen is that the cost per patient is spread over a two-year period.
The payment per patient, therefore, does not have to be available at the outset as long as
we know the installments will be met over the following two years. In fact, since they
will start treating the patients in July, approximately 20% of the total costs for patients
will be spent during the remainder of the 1997 calendar year (i.e., up to $60,000.00 if
they treat thirty patients). Depending on the results we can, anytime, hold off on treating
additional patients or, by obtaining additional funds, speed up the process.
Valerie Harper
Page 2
As you know, the report on our first two cases is in print in a medical journal. Dr.
Spletzer is already working with me on a scientific publication of the first eight cases. As
these are presented and published, and our results with new cases are satisfactory,
financing and rapidly increasing the number of patients treated will not be a problem.
Not stated in the budget are expenses for developing programs in other countries. We are
in conversation with the U.S. Army Medical Research Institute and they are establishing
contacts for us in Bangkok. This activity can be considered as we progress.
I understand that without outside help immediate funding may have to be limited.
Further, I understand funding will depend on the discussions you and David will have
about availability. I will greatly appreciate your advice and recommendations.
encl.
-,
2368 VICTORY
PARi<:NAY
SUITE410
CINCINNATI
OHIO
45200
513-221-C002
fax 513-22WXl3
Benefiting
Humanity
Throug
Health
and
Peace
February 20, 1996
Mr. Stephen Foster
President
Charles A. Dana Foundation
745 Fifth Avenue, suite 700
New York, NY 10151
Dear Stephen:
r
VALERIE, FOILCWS ARE 3 PAGES
OF 1996 BUDGET SENT TO MR.
FOSTER 2/ 20/ 96 .
IAST THREE PAGES OF THIS FAX
IS THE 1997 BUDGET.
Per our conversation today, enclosed you will find our
protocol for the Malariatherapy for HIV+ patients, and a
proposed budget. In addition to contributions we receive from
individuals, the following are some of the foundations that
have supported our research:
William P. Anderson Foundation
John C. Griswold Foundation
Donna Mills Charitable Foundation
Fannie E. Rippel Foundation
Thrasher Research Fund
Combined Federal Campaign
Paul Winchell
Joseph & Helen Regenstein Foundation
Shipley Family Foundation, Inc.
We have always been fortunate that additional support comes
whenever we have started a project. This has been due to the
success and credibility of our various projects. The results
generate confidence. Our desire and plan is to treat 100
patients. There is no doubt that if the results continue to
be in accordance with those patients in China, this will be a
much sought after method.
Two physicians with whom you may wish to discuss our
malariatherapy project are:
Neal Barnard, M.D. (202) 686-2210
President, Physicians Committee for Responsible Medicine
John Parks Trowbridge, M.D. (713) 443-2584
Past President, Great Lakes Assn. of Clinical Medicine
If provide please do not hesitate
__
M.D.
Institute
DETAILED BUDGET FOR INITIAL BUDGET PERIOD
JANUARY 1,1996 - DECEMBER31, 1996
PERSONNEL ROLE ON % EFFORT SALARY FRINGE
NAME PROJECT ON PROJ. REQUEST BENEFITS
Henry J. Principal
Heimlich, M.D. Investigator 75% -0- -0-
Eric Spletzer, Ph.D. Research 100% $60,000 $12,000
Coordinator
Heimlich
Institute
To Be Named Research 100% $50,000 -0-
Coordinator
& 7-10 Staff
China
To Be Named Research 100% $50,000 -0-
Coordinator
& 7-10 Staff
Central America
TOTAL PERSONNEL COSTS:
EQUIPMENT: (Startup costs ONLY for first year of grant)
Medical
Office
PCR Vironometer
Flow Cytometer
Centrifuge
Flourescence Microscope
Analytical Balance
Magnetic Stirrers
Antigens and Reagents included in patient costs
2 Fax Machines
3 Computers w/software & modem
(includes hardware, statistical and
medical software, database management,
printers, modems, wiring, setup and
programming for compatibility between US,
China and Central America)
Copy machine
$ 85,800
$156,000
$ 14,000
$ 10,000
$ 2,395
$ 1,000
$ -0-
$ 600
$20,000
$ 1,000
TOTAL EQUIPMENT COSTS:
TOTAL
-0-
$ 72,000
$ 50,000
$ 50,000
$172,000
$290,795
DETAILED BUDGET FOR INITIAL BUDGET PERIOD
JANUARY 1, 1996 - DECEMBER 31, 1996
Page Two
SUPPLIES:
Medical (included in patient costs for all three years)
Office
$ 5,000
TOTAL SUPPLIES COSTS:
TRAVEL
Henry Heimlich, M.D. -- trips to China & Central America
Eric Spletzer, Ph.D.
Research Coordinator - China
Research Coordinator - Central America
$10,000
$ 5,000
$10,000
$10,000
TOTAL TRAVEL COSTS:
PATIENT CARE COSTS:
$10,000 per patient x 100 patients
(includes treatment, hospitalization, laboratory tests,
follow-up physicals and laboratory tests for 2 years)
.
We will be treating the 100 patients in the timeframe below:
40 patients in year 1
OTHER EXPENSES:
Central Office Space
Central Office Telephones & Faxes
Postage & Federal Express for all 3 locations
Central Office Bank Charges for wire transfers
$400,000
$200,000
$ 11,000
$ 3,000
$ 1,500
$ 500
TOTAL OTHER EXPENSES:
TOTAL COSTS FOR INITIAL BUDGET PERIOD:
------------ --------- - ---- - --
$ 5,000
$ 35,000
$400,000
$ 16,000
$918,795
BUDGET FOR ENTIRE PROPOSED PERIOD OF SUPPORT
January 1, 1996 - December 31, 1998
BUDGET CATEGORY TOTALS 1ST YEAR 2ND YEAR 3RD YEAR
PERSONNEL
EQUIPMENT
SUPPLIES
TRAVEL
PATIENT CARE COSTS
OrnER EXPENSES
TOTAL COSTS FOR
ENTIRE PROPOSED
PERIOD OF SUPPORT:
JUSTIFICA nONS:
$172,000
$290,795
$ 5,000
$ 35,000
$400,000
$ 16,000
$918,795
$189,200 $ 197,BOO
$ -0- $ -0-
$ 5,500 $ 6,000
$ 38,500 $ 40,250
$400,000 $200,000
$ 17,600 $ 18,400
$650,800 $462,450
PERSONNEL
NAME
Henry J.
Heimlich, M.D.
Eric Spletzer, Ph.D.
Dr. Hung Shun Hua
(of Los Angeles)
Secretarial &
Administrative
DETAILED BUDGET FOR BUDGET PERIOD
JANUARY 1, 1997 - DECEMBER 31, 1997
ROLE ON % EFFORT SALARY FRINGE
PROJECT ON PROJECT REQUEST BENEFITS
Principal
Investigator 75% -0- -0-
Research 50% $30,000 $6,000
Coordinator
Heimlich
Institute
Research 50% $25,000 -0-
Coordinator
China
50% $26,000 $2,000
TOTAL
-0-
$ 36,000
$ 25,000
$ 28,000
TOTAL PERSONNEL COSTS: $ 89,000
SUPPLIES:
Medical (included in patient costs for all three years)
Office $ 5,000
TOTAL SUPPLIES COSTS: $ 5,000
TRAVEL: Trips to China & Medical Conferences
Henry J. Heimlich, M.D. $ 10,000
Eric Spletzer, Ph.D. $ 5,000
Research Coordinator - China $ 10,000
TOTAL TRAVEL COSTS: $ 25,000
PATIENT CARE COSTS:
$10,000 per patient
Detailed Budget for Budget Period
Page 2
(includes treatment, hospitalization, laboratory tests,
follow-up physicals and laboratory tests for 2 years)
We plan on treating patients in the timeframe below:
OTHER EXPENSES:
Central Office Space and Equipment Usage
Central Office Telephones, Faxes, Computers,
Postage & Federal Express
Central Office Bank Charges for Wire Transfers
$ 300,000
$ 200,000
$ 200,000
$ 13,000
$ 7,000
$ 500
TOTAL OTHER EXPENSES: $ 20,500
TOTAL COSTS FOR INITIAL BUDGET PERIOD (Year One): $ 439,500 **
BUDGET FOR ENTIRE PROPOSED PERIOD OF SUPPORT
BUDGET CATEGORY TOTALS
PERSONNEL
SUPPLIES
TRAVEL
PATIENT CARE COSTS
OTHER EXPENSES
TOTAL COSTS FOR
ENTIRE PROPOSED
PERIOD OF SUPPORT:
Page 3
1
ST
YEAR 2
10m
YEAR
$ 89,000 $ 98,800
$ 5,000 $ 5,500
$ 25,000 $ 28,500
$ 300,000 * $ 200,000
$ 20,500 $ 20,500
$ 439,500 ** $ 353,300
*
Actually $60,000 in this calendar year, remainder spread over two years.
** Actually $199,500 in the calendar year
3
RD
YEAR
$ lO8,000
$ 6,000
$ 30,250
$ 200,000
$ 20,500
$ 364,750
MEMORANDUM
TO: DR. HENRY HEIMLICH DATE:
FROM: VALERIE HARPER SUBJECT:
Thank you for being my guru on all matters.
JANUARY 3, 1997
MALARIA IMMUNOTHERAPY
PROJECT
As I mentioned to you on the telephone, I think the article is fair in that AZT and
Protease Inhibitors have for some people prolonged their life and quality, which
heretofore, has been impossible. Also, it is well documented.
On the positive side, it makes our project easier with the CD-4 levels we received from
China to interest, for example, a Mr. Modell.
Thanks for doing the "Essential" and "Optimal" cash-flow projection for the Trust. I
believe it will be very timely.
Best regards, as always, to you and Jane.
attachment
January 8, 1 H9 7
John L. Fahey, M.D.
Direct.or
Evelyn G. N a j f ~ r a , MPH
Manager
Fogarty Prngr8rJl
CIRID at UCLA
10833 La Contn Avenue
Los Angeles, CA 90024-1747
The UnitAd States
Doar Dr . Fahey Li!)(J Ms. Najera:
Did you receive my fax attached U ... e operation routine of APAAP
method and the address of Professor Yu Chun Shan on
December 30, 1996? I am urgent to have an invitation letter
with your signature and the mention of financial support for me
to deal with my passport otherwise I would be too late to attend
the Fogarty Program because somethings progress slowly in
China. Would you please fax it and then Federal Express its
original to me. It wilf be a big help to me.
I am Federal Expressing the original letter and the attached
application meterials that you request, please checklist:
1. My letter: tow pages.
2. Dr. Xiao Bin Quan's recommendation letter: two pages.
3. Dr. Chen GlJan Jin's recommendation letter: two pages.
4. Assurance letter by my President, Dr. Xiao: one page.
S. The resume "CHEN XIAO PING": five pages.
6. My certificate of degree: one page.
7. My curriculum vitae of graduate student: one page.
8. Application forms: pages 1-5.
-1-
From : , Ci kUcJ=p>ek 5Ud,="( i Zh"m
PHOI1E llo. 0085 20 3828281
I look toward to from you.
Sincerely,
C kr1 rt<'etV
Dr. Chon Xiao Pinq <::_-'
Director, Dopurtnwnt of Microbiology
Anti , Epidomic Stc'3tion of Gunngzhou
No. 23, 3rd Zhonqshan Road
Guangzhou 510080
The people's Republic of China
-2-
Jan, 10 1'397 10: 34AI'1 F'(32
MEMORANDUM
To: Valerie Harper \;\ /
\ ,,} '<
t(
}\ . ~ \
Henry J. Heimlich, M.D., Sc.D.j ' , \ 1\
.\, \
~ ~ t \
From:
. I
'J
Attached is an accounting of the expenditures for the malariotherapy/AIDS program for
the period May-December, 1996. Please note, this is from the Heimlich Institute ledgers
which have not yet been audited by our accountants, Arthur Andersen & Co. Their audit
is based on a June I-May 31 fiscal year.
The total expenditures are $69,394.23. As you know, from the recently submitted
budget, anticipated expenses for the 1997 calendar year are $199,500.00. Consequently,
a grant of $150,000.00 will carry the program through this year and into 1998. However,
there are several variables. Thirty patients are scheduled for treatment starting in July.
We plan to treat ten patients at a time, with one to three months between patient groups,
but the number could be somewhat more or less.
The report on the first two patients followed for two years is in print in a medical journal
and will be coming out any day. We are also in the process of preparing another report
on the eight patients treated thus far and followed for two years or more. They received
three weeks of malariotherapy. Seven had an increase in CD4 T cells at the end of the
treatment and have sustained the increase without any other treatment! No other
procedure for HIV patients has come close to accomplishing this.
Based on the results, we are justified in treating 100 patients as soon as is feasible. It is
also our goal to initiate inquiries into treating patients within the United States. As we
have discussed, these efforts will require substantial funding. I know David appreciates
this from his mentioning possible external forms of financing at the Board meeting
luncheon and to me.
The Eleanor Naylor Dana Charitable Trust Grant
ElINDS RECEIVED
May 8, 1996 $ 50,000
August 16, 1996 $100,000
Total $150,000
DISBlJRSEMENTS
Use of
Month
Eacil.i4'
fhoru: fus1age Supplies Salaries IraYci Equip.. Thtal
May 433.34 150.00 240.50 41.70 4418.24 1315.75 -0- 6599.53
June 450.00 120.99 206.34 189.60 8240.43 668.60 -0- 9875.96
July 450.00 157.72 908.50 91.55 6373.66 1528.95 -0- 8431.43
August 450.00 130.32 139.00 98.72 4496.07 500.14 -0- 5914.25
September 450.00 144.64 149.00 30.70 7129.76 337.50 -0- 8241.60
October 450.00 150.00 110.50 132.02 1614.94 1261.63 7942.50 11211.59
November 450.00 203.84 178.50 84.28 5018.84 1202.06 -0- 7137.53
December 450.00 75.0 50.00 30.52 5949.06 1104.35 323.64 7982.34
Totals 3583.34 1132.51 1982.34 699.09 43241 7918.98 8266.14 65394.23
Interval Payment to China - 11/19/96 400000
Total Disbursements
69394.23
2368 VICTORY
P A R ~ A Y
SUITE 410
CINCINNATI
OHIO
45200
513-221-00J2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
FACSIMILE TRANSMISSION COVER: DATE:
TO:
LOCATION:
FROM:
PERSON .
SENDING:
RE:
If you do not receive all of the pages indicated above,
please call the above-named person at (513) 221-0002.
Memo
To: Memo to File
From: Henry ~ .. Heimlich, M.D.
Date: February 7, 1997
Last night I spoke to Colonel Brewer in Bangkok. Dr. Brewer said that they had
forwarded some material through Washington to me, but I have not received it. He
received several replies from the Thai professors with an expression of interest and will
have Dr. Ed Brown send them directly to me. Dr. Brown is now in Cambodia. He will
be my contact because he originally worked in the field of malaria and now is working in
the AIDS project.
Brigadier General Zajtchuk arranged the contact with Dr. Brewer.
2368 VICTORY
PAR'lYiAY
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
February 10, 1997
Dr. James McIntyre
The Reproductive Health Research Unit
P.O. Box 1477
Johannesburg 2000
South Africa
Dear Dr. Mc Intyre:
I am writing to you at the suggestion of Dr. Drew E. Altman, as per the enclosed letters.
I am aware of the high level of medical practice in South Africa, and I believe that it
would be an excellent place to carry out malariotherapy for HIV infected persons. We
have a grant which funds this research, and are prepared to go ahead with it. I am free at
our mutual convenience to travel to South Africa if interest is shown.
Please advise me of your thoughts through the address, phone or fax numbers shown on
this letter, qr to our e-mail <!.ddress:heimlich@iglou.com.
I ! 1 --
Sinceret, ! . ~
. I I
, I ~ '
sident
Enclosures
c.c. Michael R. Sinclair, Ph.D.
January 8, 1997
Mr. Henry Heimlich, M.D., Sc.D.
Suite 410
Dear Dr. Heimlich:
1450 G STIU!ET NW, SUITE 250
WASHINGTON, DC 20005
2023475270
Eu 202 3475274
Dr. Altman shared your letter of November 21, 1996 with me. I suggest you contact
Dr. James Mcintyre: The Reproductive Health Research Unit
P.O. Box 1477
Johannesburg 2000
South Africa
Tel: 11-407-6780
Fax: 11-403-3214
Dr. Mcintyre is very well placed to facilitate your further contact with South Africans' in
the AIDS field.
Sincerely,
{ b ~
Vice President
FOUNDATION HEADQUARTERS: 2400 SAND HILL ROAD MENLO PARX, CALIFORNIA 94025 " 41585-4 9400
. .)
UNITED STATES
LOS ANGELES
M I AMI
NEW YORK
WASHINGTON , D . C .
EUROPE
BRUSSELS
BUDAPEST
HELSINKI
ISTANBUL
LONDON
MOSCOW
PARIS
PRAGUE
STOCKHOLM
WARSAW
AFRICA
JOHANNESBURG
February 14, 1997
Dr. Henry Heimlich
President
WHITE & CASE
1155 AVENUE OF T HE AMERICAS
NEW YORK, NEW YORK 10036-2787
TELEPHONE: (1-212) 819-8200
FACSIMILE: (1-212)354-8113
DIRECT DiAl: 212-819-8516
Suite 410
Dear Dr. Heimlich:
ASIA
ALMATY
ANKARA
BANGKOK
BOMBAY
... ANOI
HONG KONG
JAKARTA
SINGAPORE
TASHKENT
TOKYO
MIDDLE EAST
JEDDAH
RIYADH
LATIN AMERICA
MEXICO CITY
I am pleased to enclose a check in the amount of $100,000 representing a grant from
the Eleanor Naylor Dana Charitable Trust in support of the work of the Foundation. Please
acknowledge receipt on the enclosed extra copy of this letter.
EFR:bhr
Enclosures
cc: Ms. Patricia Mangini
Ms. Valerie Harper
Sincerely,
Edward F. Rover
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-22HXXl3
February 19, 1997
Edward F. Rover, Esq.
White & Case
1155 Avenue of the Americas
New York, New York 10036-2787
Dear Mr. Rover:
We received the generous grant from the Eleanor Naylor Dana Charitable Trust to the
Heimlich Institute in the amount of $100,000. Be assured that your grant will be used to
further our research as expeditiously as possible. Your donation will help us continue our
quest to save lives through research, education, and creative thinking in solving the
problems facing each of us.
It is through such caring support that our endeavors can progress in finding treatments for
otherwise incurable diseases. Thank you again.
As requested, I am enclosing a signed acknowledgment of this grant.

Jo.an Steinberg (
Duector
Benefiting
Humanity
Through
Health
and
Peace
Enclosure
cc: Ms. Patricia Mangini .
Ms. Valerie Harper
T H E
H E I M L I C H
I N S T I r U T E
R l U l l I I A 1 D i . I f C .
2 3 6 8 V I C T O R Y
P A A r : : N A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 52 0 0
513-221.f f i )2
f ax 513-22H X X l 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
February 20, 1997
Di rector of CIRID at UCLA
Department of Mi crobi ol ogy &Immunol ogy
Center f or the H eal th Sci ences
10833 LeConte Avenue
Los Angel es, CA 90024-1747
Dear J ohn:
I have heard f rom Dr. Chen X i ao Pi ng that he wi l l be arri vi ng at UCLA on March 23. I
ampl eased that he has thi s opportuni ty to work wi th you. I twi l l greatl y enhance the,
program when he returns to Chi na. Perhaps I wi l l come out and vi si t when he i s there.
Dr. H ua has recentl y spoken wi th Chen and I bel i eve i t i s hi s i ntent to bri ng bl ood
sampl es of treated pati ents f or anal ysi s.
Many peopl e i nterested i n our research woul d l i ke to know about our af f i l i ati on wi th you,
and I amnot sure how you woul d wi sh to express i t. Perhaps you coul d advi se me on
that matter, or woul d care to gi ve me a cal l so that we can di scuss how i t can best be
descri bed.
H ope al l i s wel l .
Best wi shes,
oH ei m!,MoDo
-:
"Center for Interdisciplinary Research
in Immunology and Disease
UCLA
BERICELEY DAVIS IRVINE WS ANGELES RNERSIDE SAN DIEGO SAN FRANCISCO
SANTA BARBARA SANTA CRUZ
March 6, 1997
LOSANGELES, CALIFORNIA 90024-1747
(310) 825-65~& _ .
(310) 206-1318(FAX)
President
Dear Henry:
I was pleased to have your recent letter. Indeed, we are looking forward to meeting
Dr. Chen Xiao Ping and having himhere this spring. We had told himthat we
would bepleased to help himanalyze. any specimens that hebrings fromChina in
connection with HlV studies conducted there..
Itoccurred to us that you might liketo have himvisit you in Cincinnati. We can be
flexible here about the arrangements. Itmight be more interesting ifhe came after
the course here, and you could review the findings and discuss future plans, with the
added benefit of the experience hehas had here. Of course, you arewelcome to
visit anytime.
Iwould like to help you in any way that Ican. Certainly our association has been
stimulating and mutually rewarding. Iwould beglad to discuss whatever
description would be appropriate to meet your needs. I could call after March 17,
as Ihave apending grant deadline and ameeting 'out of town before that date.
J ohllL. F' ~y,:M~D... .: :'_:.. " .
Director CIRID* at UCLA '
,.-' ,:.'. " .,' !.' -, .:, .. ',' ... ,". ..... '. .' ., ",
Chair, Clinical InllIlunoldgy Committee, International
Union of Immunological Societies (lUIS) .,.. v
'.' "": :.::
J LF/dm
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45200
513-221.(X))2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
.......... - - - - - - - - - - - - - - - - - -
To: Valerie Harper
Of: The Eleanor Naylor Dana Charitable Trust
Fax: (212) 754-2892
Date: March 14, 1997
We keep making progress!
<)
,
OHIO DEPARTMENT OF HEALTH
MAR 1 0 1991
246 N. HIGH STREET
Post Office Box 118
Columbus. Ohio 43266-0118
Telephone: (614) 466-3543
Henry 1. Heimlich, M.D.,
President
Dear Dr. Heimlich:
GEORGE V. VOINOVICH
Governor
PETER SOMANI. M.D .. Ph.D.
Director of Health
It was indeed an honor and pleasure to have you visit me and other staff at the Ohio Department
of Health_ I was most delighted to hear first hand about the new application of the Heimlich
procedure to treat asthma. I believe that both ODH and Medicaid should be interested in
supporting your project. I have talked briefly to Mr. William Ryan, Medicaid Director for Ohio
about this project, and shall be sending to him you fiscal proposal as soon as I receive it from you.
I believe that we can find support for your project to carry out a sound clinical study to determine
the effectiveness of the Heimlich procedure in management of asthma.
I am also intrigued by your preliminary data on the effect of malaria in the treatment of AIDS, and
as I indicated to you, I shall be contacting Dr. Hutton of University of Cincinnati College of
Medicine to include this topic during our meeting on Monday, March 17.
I shall also contact you regarding the possibility of working together on this project in India and
Asia.
Many thanks for taking time from your very busy schedule to visit with us. With best regards,
Sincerely yours,
~ ~ ~ ,
Peter Somani, M.D., Ph.D.
Director of Health
HEA 6413 (Rev. 5/93)
An Equal Opportunity Employer/Provider
i'
-
*Center for Interdisciplinary Research
UCLA UNIVERSITY OF CALIFORNIA, LOS ANGELES
BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DIEGO SAN FRANCISCO SAi\'TA BARIlAIIA SANTA CRUZ
March 27, 1996
DEPARTMENT OF \lICHOBIOLOGY AND IMMUNOLOGY
UCL.A SCHOOL OF ~EDICINE
CE:"iTEH FOH THE HEALTH SCIENCES
10833LE CONTE AVE!'<UE
LOS A\:CELES CALIFOHNIA 90024-1747
(310) 825-6568
(310) 206-1318 (FAX)
-1p~ ~~I!c
\(f_v;._~'~ . I~ '7.
\}_~Z~~ ~<X:.A ..~~~~ 0~~
Dr. Xiantao Kong:-1J D~o'l / I f ' > - _ . .
Clinical Immunology Center
Changzheng Hospital ) ?LA
Shanghai 200003,
CHINA
Dear Professor Kong:
Thank you for your recent letter. We arepleased that the article on, "Clinical
Immunology .,A Distinct Area of Immunology," is of interest to you. You certainly
have my permission to translate thearticle into Chinese and to publish it inChina. I
hope it will be helpful.
IntheUnited States, Clinical Immunology isundergoing substantial development
and facing new challenges inthe area of Clinical Care Immunology. Itis generally
regarded as asubspecialty of both Internal Medicine and Pediatrics. Thus, it does
not compete with these two large areas of Clinical Medicine but contributes
significantly to each.
There are suggestions that Clinical Irrununology could be accommodated well in
conjunction with both Allergy and, especially, theautoimmune aspects of
Rheumatology. I amenclosing an articleby Robert Rich, M.D., that was published
intheDecember issue of theJournal of Immunology that addresses this issue ina
creative manner,
,,.".......'.
~
c
,
.
{)",.I,.""/,, ../,......,'" (;,." ,.,.." .. 1 . " . , ..
2 3 6 8 V I C T O R Y
P A R o r::N A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 52 0 0
513- 22H X X l 2
fa x 513- 22H X X l 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
April 29, 1997
Director of Center for Interdiscipl inary
Research InImmunol ogy and Disease
UCLA School of Medicine
Center for the H eal th Sciences
Dear J ohn:
I have spoken with Dr. Chen X iao Ping and he is greatl y appreciative of your program.
As per your l etter of March 6, 1997, I woul d l ike to suggest the fol l owing description of
our association based on your l etter of August 8, 1996:
The University of Cal ifornia, Los Angel es (UCLA), and The H eiml ich
Institute of Cincinnati, have establ ished an affil iation for the treatment of
H IV patients using mal ariotherapy.
The H eiml ich Institute is carrying out acl inical study, treating H IV patients
with mal ariotherapy, in Guangzhou, China at The Municipal H eal th and
Anti- Epidemic Station of Guangzhou.
UCLA has thecapacity to measure most of the cytokines incircul ation as
wel l as the capacity of peripheral bl ood mononucl ear cel l s to produce
cytokines under various forms of stimul ation. These wil l be used to
assess sel ected patients treated with mal ariotherapy.
Secondl y, aFogarty International Center (NIH ) AIDS International
Training and Research Program (AITRP), at UCLA, is increasingl y
invol ved with studies with intervention and qual ity control efforts. AITRP
is hel ping the Chinese col l eagues of The H eiml ich Institute to carry out
their studies. UCLA is al so providing assistance with reagents and
qual ity control sampl es for CD4 measurements as wel l as other parameters
of H IV infection.
InMarch, Dr. Chen Xiao Ping, Chief, Department of Microbiology, The
Municipal Health and Anti-Epidemic Station of Guangzhou, commenced
studies at UCLA where he is attending lectures and participating in
laboratory work. J uly 1, 1997, the Guangzhou Health Station will take
over theduties of the Public Health Service of Hong Kong. J ohn L.
Fahey, M.D., is Director of the Center for Interdisciplinary Research in
Immunology and Disease (CIRID), UCLA. Henry J . Heimlich, M.D., ScD:,
is President of The Heimlich Institute.
I amsure, J ohn, you can put this inbetter lay terms and I will appreciate your thoughts.
A PHASE I-II STUDY OF MALARIOTHERAPY FOR HIV/AIDS
XlAO PING CHEN, MD
Trainee of Fogarty AIDS Interational Training and Research Program
At Department of Microbiology and Immunology, School of Medicine
University of California, Los Angeles, U. S. A.
RESEARCH PLAN
May, 1997
Chief, Associate Professor, Department of Microbiology
( Public Health Center of Guangzhou )
No. 23, 3rd Zhongshan Road, Guangzhou 510080, the People's Republic of China
Phone number: (020) 8382829l. Fax number: (020) 83815255
A PHASE I-II STUDY OF MALARIOTHERAPY FOR mY/AIDS
XIAO PING CHEN, MD
SPECIFIC AIMS
To determine whether malariotherapy (MT, an old therapy used for thetreatment of
neurosyphilis) changes the clinical and laboratory parameters of mv /AIDS
patients.
1. To determine the safety of malariotherapy for HfV/AIDS by observations of side
effects and complications.
2. To determine the effects on CD4 counts, HfV loads and cytokines and soluble
activation markers during themalarial phase ( MT )
3. To determine whether after termination of treatment by MT,
a. CD4 counts will increase.
b. HfV viral loads will decrease.
c. Cytokines and activation markers (Ams) will significantly decrease to around
normal level.
MT Termination ofMT
1
Fig. 1. AMs' dynamics ofMT
(Hypothesized by Chen)
._._._._._._._._._._._._._._._._._._._.High level of AMs inmvpatients
L.....- Normal AMs level
4. To determine whether or not changes inCD4 counts, viral loads and cytokines
and activation markers after MT are different inpatients stratified by CD4
numbers (>500,500-201, 200-51/mm3 ).
5. The extent and duration of changes of theparameters will be determined.
-1-
BACKGROUND AND SIGNIFICANCE
1. Malariotherapy for neurosyphilis
Malariotherapy was discovered by Dr. Wagner-J auregg in 1917. He won the
Nobel Prize of Medince in 1927 due to his great success of the therapy for
neurosyphilitics. This therapy had been used until 1975and combined with
penicillin since which was invented.
2. Malariotherapy for cancer
a. Epidemiology: Malarial prevalence adversly correlates with theprevalence of
tumors.
b. Clinical trials: During 1950s, 19advanced cancer patients were treated with
malariotherapy inGermany, it was claimed to be effective. During 1991-1993,
we treated 7advanced cancer patients with this therapy, finding that it was
effective in treating breast cancer and Kaposi sarcoma.
c. Complications ofMT inour cancer patients were not severe: Among 7cases,
one complicated anemia, Hb from 124gIL at pretreatment decreased to 74gIL at
termination of malaria; another complicated thrombocytopenia during malarial
phase, but both recovered to baseline quickly by transfusions of whole blood
and platelet respectively, didnot need to terminate malaria before completion of
MT' One case complicated bronchial asthma during malarial phase, needed to
terminate malaria before completion of the therapy, but recovered quickly after
termination ofMT. No complication occurred inother 4cases.
3. Antiretroviral therapies for HIV/AIDS:
a. Nucleoside reverse transcriptase inhibtors: Zidovudine (ZDV, AZT),
Didanosine (DDI), Zalcitabine (DDC), Stavudine (d4T), Lamivudine (3TC).
b. Nonnucleoside reverse transcriptase inhibitors: Nevirapine (NVP), Delavirdine.
c. Protease inhibitors: Saquinavir, Ritonavir, Indinavir (illV).
d. Antiretroviral combination therapies: Potential for greater suppression of viral
replication than with monotherapy
e. Effectiveness: Clinical improvement, viral load decrement for ahalf to two
years; no change of CD4 count ( mv can temporarily increase CD4 count ).
f. Gaps of antiretroviral therapies: HIV mutation, drug resistance and transient
effectiveness.
-2-
4. Immune-based therapies:
a. Interferon-a (IFN-a): Inhibition of Hl V assembly and release.
b. Recombinant soluble CD4 (rsCD4): Blockage ofIllV binding to CD4 cell.
c. Recombinant human interleukin-2 (rhIL-2): Increasing CD4 cell.
d Combination therapy of immune-based plus antiretroviral therapy: Potentiation
of CD4 cell increment with suppression of Hl V replication.
5. Evidences of theproposal of malariotherapy for IllV IAIDS
a. Report 1: 71 AIDS patients died at therate 35%, but 41 AIDS patients
coinfected malaria, nobody died inthe same observed period.
b. Report 2: HfV-likevirus infection decreases the mortality of experimental
animals with malaria.
c. Report 3, 4, 5: InVenezuela, Indonesia and Philippines, malarial endemic
regions, HIV-likeantibodies existed, but no AIDS patients inthese regions and
AIDS did exist innearby non-malarial areas.
d. A lot of reports: Malaria does not accelelate HfVinfection progress and neither
HfV infection deteriolate malarial patients.
e. Safety of malariotherapy has been confirmed by:
Hundreds of thousands neurosyphilitics treated with thetherapy.
b. 8HIVpatients treated by us with this therapy, no any complication occurred.
PRELIMINARY STUDIES
Our preliminary results of malariotherapy for 8HIV patients have been recently
published inMechanisms of Ageing andDevelopment: 1997, 93: 79-85.
1. CD4 dynamics:
Table 1, HIV 2atient CD4 counts {cells/mnr' }*
CD4 at: Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8
Pre-treatment 889 269 1610 731 1868 1056 924 705
Post -treatment 853 527 979 1183 1248 1000 600 826
6 months 1162 953 750 1631 1813 875 1260 572
12months 1258 656 510 465 630 665 842
18months 1072 864 1151 2062 2422 1081 570
24 months 941 650
30 months 1697 1199
* CD4 measurement were made by Chinese APAAP ( enzyme link ) method.
-3-
2. Dynamics of serum neopterin (NPT, nmollL), beta-2 microglobulin(B2M, mg/L)
and Hl V P24 antigen (pg/ml, case 1, 3, 4, 5 and 6 were undetectable in all
times; case 8was 13pg/ml at pretreatment and 27pg/ml at 3 months follow up)
are shown inpage 5-7.
3. Plasmodium vivax ( Pv) malaria manifestations were not more serious than
those ( HIV negative) Pvmalaria that we observed in our previous clinical
practice; no any complication occurred.
DESIGN AND METHODS
1. Design: Anopen label single center phase I-II study of malariotherapy for mv
infected patients.
2. Sample size: 10 subjects with entry CD4 counts >50 cells/mnr'.
3. Population: mv infected adults with entry CD4 count >50 cells/mar' ( stratified
by CD4 numbers, >500,500-201,200-51 cells/mnr' ) who are anyantiretroviral
and immune-based therapies naive at entry, but not excluding traditional
Chinese medicine therapy.
4. Pvmalarial blood sourses: Thin and thick blood smears confirmed Plasmodium
vivax, strictly excluding Plasmodium falciparum exist and blood specimen
tests for excluding HIV, hepatitis B virus, syphilitic spirochete and other blood-
borne pathogens exist.
5. Regimen: Inoculation of Plasmodium vivax by intraveneous injection of 10 CC
malarial blood. Observations and recordings of incubation ( malaria) and
clinical manifestation; termination of malaria with chloroquine after 10 malarial
high fever episodes and in case any severe complications.
6. Schedule of events: See APPENDIX I.
- 4 -
-
0
0
"
l
C
o
>
.
.
.
.
0
1
m
-
0
0
0
1
m
i
O
1
1
1
i
O
1
1
1
\
"
l
-
,
,
-
-
"
l
\
3
:
:
-
,
~
-
.
-
-
-
3
:
:
\
~
\
Q
.
i
.
>
:
>
-
,
0
-
0
\
"
.
-
0
.
.
I
>
0
1
-
/
1
3
C
o
>
0
C
o
>
1
1
1
3
"
'
-
1
1
1
3
0
"
l
"
l
3
:
:
m
3
:
:
m
0
0
m
I
I
I
(
j
'
)
I
I
I
3
t
o
t
.
-
+
t
.
-
+
(
!
)
C
D
(
!
)
C
D
Z
<
0
c
o
Z
<
0
-
-
1
0
.
"
"
D
3
"
"
D
3
-
o
f
-
o
f
N 3
O
J
a
;
3
3 "
l
.
.
.
.
3
z
Z
"
l
"
"
D
C
o
>
"
"
D
.
.
.
.
-
o
f
0
-
o
f
3
0
"
l
C
o
>
.
.
.
.
0
1
m
3
0
I
;
)
C
o
>
.
.
.
.
0
1
m
0
0
0
0
0
0
0
0
0
0
0
0
I
V
l
I
-
0
0
.
.
.
.
0
1
m
-
0
0
i
O
1
1
1
i
O
"
l
3
:
:
Q
.
:
>
0 "
C
V
.
~
0
\
"
C
3
~
1
1
1
0
1
1
1
0
N
N
C
o
>
3
:
:
m
3
:
:
0
3
m
0 I
I
I
(
j
'
)
I
I
I
o
:
t
.
-
+
t
.
-
+
(
!
)
C
D
(
!
)
m
C
D
3
z
~
z
I
\
)
"
"
D
"
"
D
-
o
f
-
o
f
C
o
>
N
3
3 O
J
3 N .
.
.
.
3
z
Z
N
"
"
D
C
o
>
"
"
D
.
.
.
.
-
o
f
0
-
o
f
3
0
-
I
;
)
C
o
>
.
.
.
.
0
1
m
3
0
-
N
C
o
>
,
.
0
1
m
0
0
0
0
0
0
0
0
0
0
0
0
,
,
0
J
>
0
1
O
!
,
,
0
0
1
O
!
.
.
I
I
I
.
.
I
I
I
'
"
'
"
?
;
:
?
;
:
I
1
/
"
"
'
"
~
\
\ \ \
'
"
'
"
t
\
I
I
I
3
0
I
I
I
3
1
/
0
'
"
h
J
!
l
:
m
!
l
:
m
C
l
0
.
.
~
Q
:
l
(
j
'
)
Q
:
l
(
j
'
)
t
.
.
-
+
t
.
.
-
+
(
T
)
C
D
(
T
)
.
!
I
C
D
z
'
"
-
J
z
'
"
(
)
l
"
l
1
3
"
l
1
3
I
f
-
I
-
I
~
0
;
0
;
3
3
z
Z
h
J
"
l
1
'
"
"
l
1
J
>
-
I
J
>
-
I
3
0
a
'
"
'
"
.
.
0
1
O
!
3
0
-
h
J
'
"
J
>
0
1
'
"
0
0
a
0
0
a
0
0
0
a
0
I
0
\
I
'
1
:
!
0
'
"
,
,
0
l
'
l
'
"
.
.
I
I
I
.
.
I
I
I
l
'
l
h
J
!
l
:
?
;
:
" .
.
'
"
3
'
"
0
I
I
I
3
I
I
I
0
l
'
l
l
'
l
?
;
:
m
!
l
:
m
0
0
Q
:
l
(
j
'
)
I
I
I
(
j
'
)
t
.
.
-
+
t
.
.
.
.
(
T
)
C
D
(
T
)
C
D
Z
<
0
c
o
Z
(
j
)
"
l
1
3
"
l
1
-
I
-
I
<
0
3
S 3
z
z
'
"
"
l
1
0
;
"
l
1
J
>
-
I
-
I
3
0
-
l
'
l
'
"
J
>
0
1
O
!
3
0
-
l
'
l
'
"
J
>
0
1
'
"
0
0
0
0
0
0
0
0
0
0
0
0
.
.
~
o
'
"
0
0
;
"
l
a
a
a
"
l
Z
.
.
a
a
'
"
a
0
"
'1
7
.
-
'
"
"
l
~
.
.
<
,
.
.
'
0
0
.
:
J
'"
"
1
:
J
"
r
~
(
l
>
I
C
I
C .
.
I
:
J
'
0 '"
"
1
,
(
l
>
I
.
-
'"
"
1
(
(
l
>
C
>
P
l
3
e
-
e
-
B (
l
>
\
:
;
:
l
\
\
~
0
_
0
"
'1
7
I
I
I
"
l
0
.
.
.
"
l
<
D
3
~
:
;
:
l
.
.
O
Q
'
I
(
j
)
I
0
.
.
.
I
C
D
c
0
;
\
I
'
\
)
:
:
1
.
I
:
;
:
l
3
I
(
J
Q
/
.
.
.
.
.
'"
"
1
/
/
(
l
>
P
l
.
.
.
.
.
"
l
B
.
.
(
l
>
3
:
;
:
l
.
.
.
.
.
.
0 .
.
.
.
.
,
~
'
"
I
a
-
.
l
~
~
I
"
0 (
J
)
.
.
.
.
.
'
0 0 (
J
)
a
"
l
.
.
.
.
.
.
'
"
"
l
.
.
.
.
.
a
a
'"
"
1
a
a
'
"
(
l
>
a
P
l
"
'1
J
e
-
e
-
"
l
B
.
.
(
l
>
.
.
:
;
:
l
:
J
-
.
.
.
.
.
Q
-
-
~
.
.
P
l
:
J
.
.
.
.
.
e
-
e
-
:
:
:
:
:
r
'
(
l
>
.
.
.
.
.
(
l
>
.
'
"
3
:
;
:
l
P
l
0
0
e
-
e
-
O
"
'1
7
I
I
I
"
l
r
+
P
>
:
;
:
l
.
.
(
!
)
0
o
:
.
.
.
.
.
,
t
o
C
D
~
3
-
.
.
.
.
.
J
'
-
"
0
;
3
~
~
~
6
~
-
~
~
P
:
>
....
P
-
3
I
>
-
0
N
o
0
.
.
'#
r
-
1
-
_
.
_
-
t
:
P
~
3
I
.
.
.
.
.
.
0
\
_
-
<
o
_
_
P
:
>
;
:
J
<
g
_
3
~
t
:
j
P
:
>
_
-
r
'"
"
1
:
:
s
I
'
"
0
.
.
.
.
.
.
.
~
0
o
;
2
t
:
-
-
-
p
;
-
'
1
:
:
!
:
:
:
:
1
"
-
-
0
~
:
:
s
3
~
.
P
:
>
0
.
.
:
:
s
~
~
0
o
.
-
'
"
0
P
:
>
.
.
.
.
.
.
.
-
~
-
:
I
.
~
?
~
t
o
g
~
t
i
l
S
~
I
_
.
N
=
I
0
0
I
+
+
+
~
'
"
0
;
:
J
'"
"
1
Q
~
~ :
:
s
.
.
.
.
.
.
~
0
.
.
'
1
:
1
~
<
?
;
0
'
1
:
:
!
0
.
.
t
r
J
~
,
8
w
.
.
.
.
.
.
.
>
<
(
t
'
.
.
.
.
.
.
.
.
.
.
.
.
.
<
~
(
/
)
~
(
)
'"
"
1
@
(
t
'
~
d
<
:
:
r
~
~ '"
"
1
t
r
J
(
t
'
.
.
.
.
.
.
.
0
<
S
?
'
"
r
1
~
:
:
r
t
r
J
0
.
.
0
~
~
g
:
z
0
0
>
-
3
'"
"
1
(
/
)
0
.
.
r
!
<
.
.
.
.
.
.
.
0
.
.
.
.
.
.
.
3 w 3 0
\
3 .
.
.
.
.
.
.
N 3 .
.
.
.
.
.
0
0
3 N _
J
::,..
3
z o .
.
.
.
.
.
~
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
t
i
l
o '"
"
1
~ ~ ;
:
J
in Immunology and Disease (CIRlD)
UCLA
BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DIEGO SAN FRANCISCO SANTABARBARA SANTACRUZ
May 7, 1997
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOCY
- UCLA SCHOOL OF MEDICINE
CENTER FOR TIlE HEALTII SCIENCES
LOSANGELES. CALIFORNIA 90024-1747
(310) 825...1)S68
(310) 206-13 18(FAX)
President
Dear Henry:
Thank you for your letter of April 29th. I had some suggestions for revisions of the
description of our association included inyour letter of April 29 but will have to get some
clearances here at UCLA. I will get back to you soon on that.
Dr. Chen Xiao Ping has been an active participant in the Fogarty program. He seems
eager to learn everything inhis time here, and we are trying to provide himwith plentiful
opportunities to gain both practical, and conceptual knowledge and e~eriel!~.' :.'_, "
~__ . . . ; 4'...-_ - -,' _, . -. ~#1 --'~-.\ ~~~_~i~ ~ -~ .; ~.~.~* ; :~._:::~~_~.~-:_ .'
.__ .~.:.' .~:. .:-- .-" ... .:~,.~j ."':f .'~"_.' . . . . . ~~-:;;;. ~: '.
Dr. Chen brought samples from8patients studied previously inGuangzhou. -_Because of
the limited quantities of these samples, we have been very careful to concentrate initial
testing inafew subjects and progress to increased numbers of tests as well as increased
numbers of samples tested. In2 individuals examined, so far, they have been found to
have elevated neopterin and J hM levels consistent with active progression of HIV
infection. We have planned to do further testing of the 3individuals with additional
cytokine measurements and to measure viral load by the acid-soluble quantitative p24
antigen method. The quantities of sample available are not sufficient to do HIV viral load
measurements by the RT-PCR or bDNA quantitative methods.
One area that has not developed well relates to quantitative assessment of CD4 T cells.
We have some reservations about the validity of the CD4 T cell measurements made on
the HIV+patients treated with malarial therapy in China. We asked Dr. Chen to obtain
one of the APAAP kits used in China to quantify CD4 T cells. We hoped that he could
compare the method directly with CD4 measurements made by flow cytometry here.
However. one of the key reagents did not work, perhaps because the shipment required 10
days, and the ice used for packing had melted. Thus, comparisons could not be made.
However, we have had the opportunity to learn the principles of the APAAP method.
We inquired further about the availability of aflow cytometer in Guangzhou, and Dr.
Chen told us that there is one at his institution that is used to evaluate transplant patients
and some rheumatology patients. For reasons that are obscure to us, Dr. Chen has not
arranged to have blood samples fromthe 3malaria-treated HIV+patients in Guangzhou
(or other HIV+patients inhis clinic) evaluated for CD4 T cell levels by flow cytometry.
That would also present an opportunity to compare the APAAP method with flow
cytometry.
One aspect of the studies in Guangzhou has presented amajor difficulty to interpretation
of the findings. That is the absence of pre-treatment, baseline measurements. When we
compared date of the plasma sample and "CD4 level" data with the schedule of malarial
administration, it was apparent that the first samples were obtained after malaria
injection. Dr. Chen confirmed that this was the case for all eight patients. It may be that
we do not have the correct facts, but we did want to bring this possibility to your
attention.
One of the projects required of each Fogarty trainee is the preparation of aresearch plan
for return to home country. This forms the basis for any continuing assistance that the
UCLA Fogarty program may provide. In Dr. Chen's case, I have asked him(a) to
become familiar with the rationale employed in the current ACTG 328 protocol for
evaluation of IL-2 therapy (in addition to intensive antiretroviral therapy) and (b) to
develop aplan for evaluating malarial-therapy on return to Guangzhou. I expect him. to
present tills plan to you for further development after he completes the program here on
May 23rd. We will also send you acopy of the ACTG 328 protocol.
alley, t-.1.D.
Direct r, CIRID at UCLA
J LF/dm
2
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PAR'f:oNAY
SUITE 410 May 8, 1997
CINCINNATI
OHIO
45200
513-22HXXJ2
fax513-221-00:J3 Mr. Berkley Bedell
Benefiting
Humanity
Through
Health
and
Peace
1807 Snook Drive
Naples, FL 33962
Dear Berkley:
Enclosed is a reprint of our recent article and sample requests we are getting for it
throughout the world.
UCLA asked to be affiliated with us on this project and we have now done so. The
Chinese physician in charge of our work iSJre now spending two months updating our
laboratory studies. I .
Hope all is well with you. if /{t, LA
encl.
'I
i! II!!
3102061318 UCLA-CIRIU
IltJlJ(tt.r.:r O A v r ~ HIVlNE u"fi ANCELES R!VE1lSIOE SAN 01(;0 Si\N nN'/ClSCQ
May 19, 1997
President
Cincirmati, OR 45206
Dear Heruy:
l'IH ( 1 ':;1 ":::1'/ 1'(: 4t::
UCLA
DEPARTMENT OF M1Cl\OBIOLOGY AND IMMUNOLOCY
UCLA SCl(OOL OF M1!:DIGINE
GENTER FOR THE HEALTH SCIENCF-S
LOS ANGELES. CALIFOR?-.'lA 00024-1741
(310) 825-6568
(310) 206-1318 (FAX)
This follows my letter of May 7, 1997, and contains a correction. I wrote that Chen
Xiao Ping had told us there were no baseline samples, e.g., pre-therapy blood
samples from the ma1aria treated group in Gual1gzhou. That is what he told 3 of us
about 2 weeks ago. We asked repeatedly.
Last week we decided to look at the data - the dates that therapies were started and
the dates that the first samples were obtained. Last Friday, we reviewed this and it
appears that blood samples were drawn on the day malaria was given to 7 of the 8
persons. Patient #2 may also have had a baseline sample if the ftrst sample label
date is incorrect. Dr. Chen's ex-planation was that he understood baseline to mean
samples obtained some time before the start of treatment. A problem in
cOlmnunication.
My regrets regarding the incorrect infoTInation sent to you.
Jolm Lahey, M.D.
Director, CIRID at UCLA
Chair, Clinical Immunology Committee, Intematiollal
Union of InmHmological Societies (lUIS)
JLF/dm
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
2 3 6 8 V I C T O R Y
P AR ~AY
S U I T E 4 1 0
C I N C I N N AT I
O H I O
4 5 2 0 0
5 1 3 - 2 2 1 - 0 0 J 2
fa x 5 1 3 - 2 2 1 - o o :l3
May 19, 1997
Center for the Health Sciences
Los Angeles, California 90024-1747
Dear J ohn:
Your letter of May 7was most informative. I tis apparent that your expertise is needed to
obtain meaningful test results.
I greatly appreciate the preparation of aresearch plan and look forward to receiving the
protocol. The significance of your continued participation in this study is certainly
recognized.
With best wishes,
lich, M.D., Sc.D.
,.
} i .: . i : J - DAHATFLIST
Memorar.ci!! rn DRAFT
June f., 199'
Subject: Heanlich : HiVf MIT
From V.H
Dr Fahey Chcmrnan of thL UCL.A. of ,rnrnuilo!oqv President
and ChaIr of Immunology Associ ati(}f)
2 l)r. . ahey re4' did Dr Che 1'S and tJ}fJod for cred!o:lny
PAGE 02
OJ:.. J::.ah$)' ia Quotfld MIT be:$t Hty n;Sl) lt-$ I,
have jf6eo"( li ra! and counts )
.. Dt', Fahoy to take the Heimlich M!T results to th""
iF (> months the next 10 patients ,should be tho '1Gxt e:lI; ceilerH hrst
marker f or testi ng of the- Dre HGimHch'u H1V -MIT f ollow2d by two years,
Fahey has asked Dr. to test me w:"xt leri patient";/ fnr;=I' rncr: th
befor administering Ni! T ino(;u/&kH1S. This wi!! bC!]in v,,'he': L,
Chen returns to Chin(. in J I.Vl1:l .
For Discussion :
Future Raquirem9nt9 : The Timing ijf Additi onAl F"um't ing Va was
Sources to be considered.

100 patient s test '.\'01 '! d u2 Di Mt' ,in'l.--:h <:: un to
t h& sa,ne of !e(':_Qnltior: the medical cL
P
, -.r1 i_Tl! ':'/
Vaccine and Protease inhibltorB Th,s ',vou d requiro $1 and (j hal Million
the ENDeT grant is included in this
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VI CTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
5132210002
fax 513-2210003
Benefiting
Humanity
Through
Health
and
Peace
M E
To:
From:
M o R A N D u
David MahoneyNalerie Harper: The Eleanor Naylor Dana Charitable
Trust
Henry J. Heimlich, M.D., Sc.D. and Eric G. Spletzer, Ph.D.
M
SUbject: Report from Xiao Ping Chen, M.D. , following studies at UCLA March 23
to May 31 , 1997 with John L Fahey, Director of the Center for
Interdisciplinary Research in Immunology and Disease (CIRID) at UCLA.
Chair, Clinical Immunology Committee International Union of
Immunological Societies
Date: June 6, 1997
Dr. Chen gave four lectures at UCLA to Dr. Fahey, his colleagues and doctors from
other countries. He first presented the results of his laboratory findings done in China
on the blood of our eight HIV patients. They showed that after malariotherapy, the CD4
cells in all patients increased and remained elevated, at normal levels for two years with
no further treatment of any kind. This finding illustrates that the patients' immune
systems have been strengthened and have overcome the attack by the HIV (AIDS virus) .
Dr. Fahey responded that the results of Dr. Chen's sbJdies in his laboratory in China
might be inaccurate.
Dr. Fahey tested Dr. Chen's ability by haVing him perform studies in the UCLA
laboratories and had a member of the UCLA staff do the same studies on the same
material. The two sbJdies came out identicaJ. (See attached graph "Comparision of
assay variation between Tech.")
Dr. Chen was then asked to carry out studies in the UCLA laboratories on the blood
specimens he had brought with him, of the eight HIV patients treated with
malariotherapy in China. His work was done under the direct supervision of Dr. Fahey
and included tests of greater depth than those done in China. These tests confirmed
those done in China, leading Dr. Fahey to say to Dr. Chen that he must be very excited
with this kind of results. He congratulated Dr. Chen and asked him to congratulate Dr.
Heimlich.
Dr. Fahey asked for a copy of the findings and told Dr. Chen that he would help us to
show our data to the National Institutes of Health (NIH). He had Dr. Chen draw up a
new protocol to be used for treatment of the next group of patients and Dr. Fahey
reviewed and agreed with it (enclosed). The protocol provides greater in-depth
laboratory studies that will suffice to prove the value of malariotherapy for HIV.
Dr. Chen has already selected the next ten patients and will proceed with their
malariotherapy on his return to China, June 14". Ten patients with results similar to the
previous eight will provide strong confirmation of the value of malariotherapy for AIDS.
The new protocol calls for performing baseline laboratory tests starting one month prior
to malariotherapy. Dr. Chen promises to commence malariotherapy in August or
September. Six months thereafter, based on the results of the present series, there
should be good evidence of the trend of the new patients.
The goal has been to treat one hundred patients. This number, in fact incremental
approaches to it, will guarantee that the results are acceptable to all medical authorities if
the results are in keeping with the progress thus far. The next ten patients are
considered the first group of the one hundred patients. Dr. Chen states he is prepared
to treat one hundred patients at any time. The estimate of costs Dr. Heimlich presented
originally for treating one hundred patients was one and-a-half million dollars. This
included the ENDCT grants to date. It has not changed. Perhaps the NIH or other
sources of funding will eventually help in this endeavor if need be.
Dr. John Cionci, of Philadelphia, specializes in treating AIDS patients. Drs. Chen and
Heimlich originally met in China through his good auspices. We called him on June 8
th
and informed him of the above information. He was not surprised and stated that all
drugs in all diseases have led to resistance in bacteria and virus infections and he expects
the same to happen with Protease inhibitors. Malariotherapy is not affected by this
limitation. Vaccines are in early stages of research and have the disadvantage of not being
able to overcome every variety of AIDS virus that is developing.
Dr. Fahey and his wife accepted an invitation to dinner, on Dr. Chen's last night in L.A.,
at a Chinese restaurant. The dinner was given by Dr. Hua Hong Shun, the Heimlich
Institute's Fellow in Los Angeles. Also present were Dr. Hua' s wife and daughter, and
Dr. Chen. Drs. Fahey and Chen have obviously developed a good relationship.
We believe that the biotherapy - Malariotherapy - is the most likely and most practical
method for treating HIV infection and, as has been reported by the media, does not pose
the problem of excessive cost for treating the entire world population of such patients.
Dr. Heimlich will be calling Dr. Fahey to get a report directly from him.
J une 10, 1997: Phone conversation between Dr. Heimlich and Dr. Fahey
Dr. Fahey:
There is additional information based on tests done with p24 and activation marker data.
Itis astep forward, Itwill warrant areport and he will participate in ajoint paper with
me. He is going to Amsterdam and Germany this week and, if he cannot get areport to
us before heleaves, he certainly will get afull report to me by J uly I.",
He has offered Chen the reagents he needs (more than he needs) for neopterin, cykotines
and all others. He could not provide funds, but could offer reagents and kits as
compensation for the use of the flow cytometer by Chen's friends at theUniversity. Itis
important CD4's be done by flow cytomertry.
Chen kept referring to the tests coming back to normal after an initial elevation. Fahey's
impression was that, for the most part, cytokines and activation markers came down to or
below the baseline but not to normal. In two cases that were normal before treatment,
they came down to normal. He said the effect is similar to IL2 administration. Dr.
Fahey said he is very interested in the use of malariotherapy and will work with us. He
helped Chen write it into aprotocol though it took quite awhile to do so,
Itis very important to stratify CD4's. Inthe future we can do also it with viral load and
activation markers. This can be done by simply saving plasma since these substances are
stored in theplasma. Itis important that no patient was made worse with malariotherapy
He is going to stay in touch with Dr. Hua to avoid language difficulties, although he said
Chen spoke very well.
Fahey got the idea they arehesitant using flow cytometer apparatus for AIDS patients,
but Fahey said there is no problem with the spread of disease.
NOTE: Ask Fahey about NIH and our results.
2368 V I C T O R Y
P A R K W A Y
S U I T E 410
C I N C I N N A T I
O HI O
45200
513-22H X X l 2
f ax513-22H X l O3 Dr. Najid Aziz
Department of Microbiol ogy and
Immunol ogy
Box 951747
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
J une 13, 1997
Dear Dr. Najid:
Dr. Chen X iao Ping reminded me that I had promised you this book. I amsorry to be l ate
with it.
Dr. Chen said hegreatl y appreciated your support and his stay at UCLA.
W.ithr,est w~, I /
1</IY ~~
H enry ~&, i i Q ' . , Sc.D.
President
The H eiml ich Institute
Encl osure
3102061318 UCLH- '_I f-e I U
-UNIVERSITY OF CALIFORNIA, LOS ANGELES
0 .".\'15 . IIIV,,,,,, LOS A:<C[l.ES RIVERSIDE . SAN OIECO . SAN FRANCISCO
June 17, 1997
TO:
CC:
FROM:
Henry Heimlich, M.D.
Dr. Hua
Oto Martinez-Maza, Ph.D.
Evelyn Najera, M.P.H.
lornl L. Fahey, M.D. J Lr:
J UI. 1" J r 1. ..:.'; _"
UCLA
DEPARTMENT OF MICR0810LOGY AND IMMllNOJ..OGY
CENTER FOR 11-IE HEAI,nt SCIENCES
10833 lE CONTE AVeNUE
LOS .... CALIFORNIA 90095-1147
(310) 825-6568
(310) 206-1318 (FAX)
RE: Name of the institutional chief or division chief under whom Chen Xiao
Ping works in Guangzhou
I do not have this info011ation and think it would be helpful to have some contact
with this perSOll. It would be very helpful if you could provide me with the name
and title of such a person or
TIlls is especially important if we are going to provide continuing assistance in the
fonn of reagents or supplies to Dr. Chen Xiao Ping. In this context, we are
surprised that he did not request any supplies or materials to take with him nor
indicate that he would be writing for some on his retum. I know he was specifically
asked by two of roy colleagues and by me ifhe wanted reagents. \Ve tried to be
clear to the Fogarty group about this matter. Other UCLA Fogarty program trainees
that were here for the same course did take of this (")I)t){n1uu\tY. We de..)
have some limits, and we would suggest a $5,000 limit for initial reagents and
supplies. The procedure is for us to purchase needed items here and ship them to
the UCLA Fogarty trainee. We have successfully done this in a number of other
laboratories in China.
Yom" assistance in these two matters would be appreciated.
JLF/dm -
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-22HlOO3
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
- ----- - ---- ---- ----- ----
To: John L. Fahey, M.D./CIRID/Dept. Microbiology & Immunology
Of:
Fax:
From:
Pages:
Date:
(310) 206-1318
Henry 1. Heimlich,
1, including this cover sheet.
June 18, 1997
Dr. Chen Xiao Ping's chief is: Xiao Bin Quan, Director
Address: The Municipal Health and Anti-Epidemic Station of Guangzhou (Public Health
Center), No. 23 3
rd
Zhongshan Road, Guangzho, Guandong, People's Republic of China
510080
After you and I spoke, I asked Dr. Chen why he did not request reagents. Apparently he
was unclear about what reagents were available and he intended to contact you. I advised
him to do so. I do know he is in need of the reagents, particularly for the flow cytometer,
and will greatly appreciate them.
I hope you have a pleasant trip to Europe and I look forward to speaking with you upon
your return.

.: ::J:
Henry J. Heimlich. MD
IE
~ 5 Pclrk Avenue
New York, New York
10152
(212) 754-2890
FAJ212) 754-2892
1hlstees
David Mahoney,
Chainnan
AJ. Signorile,
Treasurer
Robert A Good, M.D.
Carlos Moseley
Robert E. WISe, M.D.
June 25, 1997
Dr. H e ~ Heimlich
President:"
Suite 410
Dear Henry:
It was nice speaking to you today. All of us are very
enthused about the results you are getting. Keep up the
good work, and if I can be of help, please call me.
warmest best wishes,
4 J ~
David Mahoney
DM/lek
2368 VICTORY
P A R ~ A Y
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
~ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: John L. Fahey, M.D . ./CIRID/Dept. Microbiology & Immunology
Of: UCLA School of Medicine
Fax: (310) 206-1318
From: Henry J. Heimlich, M.D.
Date: July 22, 1997
I hope you had a pleasant and productive trip to Europe.
Dr. Chen spent a few days with me before going to New York and returning to China. I
have recently tried to contact him through Dr. Hua who informs me there has been some
difficulty in communications due to activities related to Hong Kong.
When you have the opportunity, I would greatly appreciate the report of Dr. Chen's stay
at UCLA which we discussed when you and I last spoke, and your thoughts as to the next
steps in our malariotherapy project.
With best wishes,
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-221-0002
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
- ---------------
To: Valerie Harper
Fax: (212) 754-2892
Date: July 22, 1997
I don't recall whether I sent these to you.
Henry J . Heimlich, MD
3102061318 UCLH- '_I f-e I U
-UNIVERSITY OF CALIFORNIA, LOS ANGELES
0 .".\'15 . IIIV,,,,,, LOS A:<C[l.ES RIVERSIDE . SAN OIECO . SAN FRANCISCO
June 17, 1997
TO:
CC:
FROM:
Dr. Hua
Oto Martinez-Maza, Ph.D.
lornl L. Fahey, M.D. J Lr:
J UI. 1" J r 1. ..:.'; _"
UCLA
DEPARTMENT OF MICR0810LOGY AND IMMllNOJ..OGY
CENTER FOR 11-IE HEAI,nt SCIENCES
10833 lE CONTE AVeNUE
LOS .... CALIFORNIA 90095-1147
(310) 825-6568
(310) 206-1318 (FAX)
RE: Name of the institutional chief or division chief under whom Chen Xiao
Ping works in Guangzhou
I do not have this info011ation and think it would be helpful to have some contact
with this perSOll. It would be very helpful if you could provide me with the name
and title of such a person or
TIlls is especially important if we are going to provide continuing assistance in the
fonn of reagents or supplies to Dr. Chen Xiao Ping. In this context, we are
surprised that he did not request any supplies or materials to take with him nor
indicate that he would be writing for some on his retum. I know he was specifically
asked by two of roy colleagues and by me ifhe wanted reagents. \Ve tried to be
clear to the Fogarty group about this matter. Other UCLA Fogarty program trainees
that were here for the same course did take of this (")I)t){n1uu\tY. We de..)
have some limits, and we would suggest a $5,000 limit for initial reagents and
supplies. The procedure is for us to purchase needed items here and ship them to
the UCLA Fogarty trainee. We have successfully done this in a number of other
laboratories in China.
Yom" assistance in these two matters would be appreciated.
JLF/dm -
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXXl2
fax 513-22HlOO3
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
- ----- - ---- ---- ----- ----
To: John L. Fahey, M.D./CIRID/Dept. Microbiology & Immunology
Of:
Fax:
From:
Pages:
Date:
(310) 206-1318
Henry 1. Heimlich,
June 18, 1997
Dr. Chen Xiao Ping's chief is: Xiao Bin Quan, Director
Address: The Municipal Health and Anti-Epidemic Station of Guangzhou (Public Health
Center), No. 23 3
rd
Zhongshan Road, Guangzho, Guandong, People's Republic of China
510080
After you and I spoke, I asked Dr. Chen why he did not request reagents. Apparently he
was unclear about what reagents were available and he intended to contact you. I advised
him to do so. I do know he is in need of the reagents, particularly for the flow cytometer,
and will greatly appreciate them.
I hope you have a pleasant trip to Europe and I look forward to speaking with you upon
your return.

.: ::J:
2368 VICTORY
PARKWAY
SUITE410
CINCINNATI
OHIO
45206
513-221-0002
fax 513-2210003
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
............... - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: Valerie Harper
Fax: (212) 754-2892
Date: July 23,1997
The following was sent to Dr. Fahey yesterday.
Vicki Roberts
Associate Director
2368 VICTORY
P A R ~ A Y
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
~ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: John L. Fahey, M.D . ./CIRID/Dept. Microbiology & Immunology
Fax: (310) 206-1318
Date: July 22, 1997
I hope you had a pleasant and productive trip to Europe.
Dr. Chen spent a few days with me before going to New York and returning to China. I
have recently tried to contact him through Dr. Hua who informs me there has been some
difficulty in communications due to activities related to Hong Kong.
When you have the opportunity, I would greatly appreciate the report of Dr. Chen's stay
at UCLA which we discussed when you and I last spoke, and your thoughts as to the next
steps in our malariotherapy project.
With best wishes,
THE
HEIMLICH
INSTITUTE
FOUNDATION, INC.
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
facsimile
TRANSMITTAL
.............. - - - - - - - - - - - - - - - - - - - - - - - - - - -
45200 To: John L. Fahey, M.D.
513-22HXXl2
fax 513-22HXXl3
Benefiting
Humanity
Through
Health
and
Peace
Of:
Fax:
Pages:
Date:
Dear John,
Center for Interdisciplinary Research in Immunology and Disease
(CIRID)IUCLA School of Medicine
(310) 206-1318
July 30, 1997
I just received a message from Dr. Chen and I am sending it to you as it pertains to your
question as to why Chen did not take reagents with him. I trust this is self explanatory,
but would appreciate receiving your thoughts.
With best wishes,
From the desk of...
J uly 23, 1997
Henry 1 . . Heimlich, M. D.
2368 Victory Partway
Suite410
The United States of America
Dear friend, Dr. Heimlich:
Ireached home Guangzhou on J une 15. Thank you for your hospitality when
Iwas home inCincinnati.
Ireceived afax letter fromDr. Hua, attached the letter Dr. Fahey wrote toyou
on J une 1 7. Dr. Fahey did mention that he would supply apart of reagents
to us and his colleagues, Dr. Najib Aziz ( the fellow who asked you to send
him a book of Heimlich's Home Guide to Emergency ) and Dr. Pari
Nishanian respectively mentioned that they would provide us with a part of
reagents for cytokine testing, CD4 rosette forming testing ( or ELISA testing)
and P24 testing and I told them that we did not need P24 reagent and the
CD4 reagent other than that for flow cytometry. I also told Dr. Aziz our need
for cytokine reagents and he promised to ship them to us during our
preparation of next 10 patients due to expiration of reagents. As Dr. Fahey
said in his letter for you that they did have some limits and they suggested a
$ 5,000 for initial reagents. Sothesituation is basically the same as our talks
in Cincinanti, Even Dr. Fahey provides us with the reagents for flow
cytometry, the cost for test procedures and equipment upkeep and
mantenance is still very much because flowcytometer isvery expensive and
the cytometer we will use in Guangzhou has not yet been used for HIV
samples.
I
~
in Immunology and Disease (CIRID)
UCLA
BERKELEY DAVIS IRVINE . LOS ANGELES RIVERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA SANTA CRUZ
August 6, 1997
LOS ANGELES, CAUFORNIA 900951747
(310)825~6.~68.~
(310) 206- 1318 (FAX)
President
Dear Henry:
Enclosed aretables of the data obtained onthe samples provided by Chen Xiao
Ping. We have problems with interpretation because of uncertainty as to when the
samples were obtained in relation to therapy inmost of the patients. Hopefully,
you have more exact data. Chen Xiao Ping gave us shifting information at
different times during his stay here.
Patients 4003 and 4004 areprobably the clearest. Presumably, the first samples
were obtained before malariotherapy, the second samples during malariotherapy
and the subsequent samples were after malariotherapy. 4003 had abaseline
neopterin of 6.97 (within the normal range). P2Mwas normal and sTNF-RII was
at the upper end of normal. A marked rise is seen about 3weeks later during
therapy. About 11days later, there is substantial subsidence. Subsequently,
values are inthe normal range (but gradually falling) in 1994 and progressive
increases in 1995 and 1996 until abnormal levels arerecorded 9/11/96.
Patient ID 4004 follows asimilar course with the exception that his baseline was
elevated in 1993. His post therapy values were generally below baseline and were
mostly inthe normal range in 1995 but were increased again inthe 1996 sample.
The other patients present the problems of not knowing if the first values were
pre-treatment or were obtained during or soon after malariotherapy. The absence
of certainty about these first values (Do they represent just disease or disease plus
malariotherapy or disease plus some other infection?) presents difficulties for
interpretation of the subsequent values,
In the accompanying graphs, please understand that the "0" time point only
indicates the first sample that wehad for patients 4001, 4002, 4005, 4006, 4007
and 4008. Weare uncertain about their relationship to malariotherapy.
Please feel free to use this data inreports and publications. Wewould appreciate
an acknowledgment and credit to the support provided by NIH grants TW 00003
and AI 36086.
The difficulties outlined above contributed to our concern that Chen Xiao Ping
have acarefully 'Writtenout experimental plan (in English and in Chinese) in
advance of future malariotherapy studies. Both versions of the plan should be
available to you (I would beglad to review these).
As you know, I believe that malariotherapy may act by similar mechanisms to
those operating inthe 5-day continuous intravenous IL-2 treatments developed by
Lane, Kovacs and their colleagues. Both malaria and IL-2 stimulate marked
increases in all or almost all cytokines. IL-2 induces CD4 increases without
reductions in viral load. That is why we have been concerned to help Chen Xiao
Ping have accurate CD4 measurements. He still has to develop aworking
relationship with the persons who have aflow cytometer at his institution.
Sincerely
J ohn L. ahey, M.Do
Director" CIRID at UCLA
J LP/dm
2
MEMORANDUM
August, 11, 1997
Department of Microbiology and Immunology
Center for the Heal thSciences
174718
To: J ohn LFahey M.D.
From: Najib Aziz M.D. N.1\
./}
Re: CMTS ID#and CSM Normal Plasam Levels;
ID#
ID# Int.
4001 GHYM
4002 LW
4003 wnw
4004 WWG
4005 XBP
4006 XLL
4007 YL
4008 YXW
NORMAL plasma Level
Analytics MeanSD 10% 25% 50% 75% 90%
B2-M 1.27O.34 0.94 1.05 1.18 1.42 1.61
Neopterin 5.743.16 3.56 4.10 5.10 6.29 8.45
11-2 fila
sTNF-RII 1.87O.80 . 1.13 1.40 1.64 2.19 2.74
0
0
'
"
'
"
:
2
:
2
'
<
t
c
:
C
O
c
:
0
0
0
0
0
0
0
C
\I
E
0
C
\I
E
'
<
t
.
'
<
t
:
.
.
-
0
Q
)
-
0
Q
)
,
E
.
.
0
0
o
o
.
1
.
d
N
.
1
.
d
N
0
0
'
"
'
"
:
2
:
2
C
'
)
c
:
r
-
.
.
.
c
:
0
0
0
0
0
0
0
C
\I
E
0
C
\I
E
'
<
t
.
'
<
t
c
:
=
-
0
Q
)
-
0
<
D
,
E :
;
:
:
;
)
0
0
0
0
0
8
0
9
O
t
>
O
~
0
0
9
0
9
O
t
>
O
c
:
0
.
1
.
d
N
.
1
.
d
N
0
0
'
"
'
"
:
2
:
2
C
\
J
c
:
<
0
c
:
0
0
0
0
0
0
0
C
\I
E
0
C
\I
E
j
'
<
t
.
'
<
t
c
:
=
1
:
J
<
D
1
:
J
<
D
0
0
0
0
~
0
9
0
9
o
t
>
o
~
0
0
8
0
9
O
V
O
C
:
0
.
1
.
d
N
.
1
.
d
N
0
0
'
"
'
"
~
:
2
:
2
,
.
.
.
.
c
:
i
o
c
:
0
0
0
0
0
0
0
C
\I
E
0
C
\I
E
'
<
t
c
:
'
<
t
e
.
=
1
:
J
<
D
:
2
Q
)
E
:
;
:
:
;
a
0
o
o
0
9
0
9
o
t
>
0
(
:
o
'
>
0
9
0
9
o
t
>
.
1
.
d
N
.
1
.
d
N
0
0
C
O
)
C
O
)
:
2
:
2
"
<
t
C
C
O
C
0
0
0
0
0
0
0
N
E
0
N
E
"
<
t
c
"
<
t
c
<
:
:
:
-
-
=
-
"
'
0
Q
)
:
:
!
:
!
C
D
E
E
"
"
"
"
0
0
o
o
o
o
0
0
C
O
)
C
')
:
2
:
2
C
'
)
C
r
-
,
c
0
0
0
0
0
0
0
N
E
0
N
E
"
<
t
2
-
"
<
t
2
-
"
'
0
C
D
:
:
!
:
!
Q
)
0
0
o
a
o
o
V
'
l
Z
8
0
0
C
O
)
C
O
)
:
2
:
2
C
\
J
C
C
D
C
0
0
0
0
0
0
j
0
N
E
0
C
\
I
E
"
<
t
.
"
<
t
2
-
"
'
0
C
D
"
'
0
C
D
E
:
;
:
:
;
0
0
0
0
E
:
0
0
V
'I
<
:
S
V
'
l
Z
8
0
0
C
O
)
C
O
)
1
:
2
:
2
.
-
C
i
n
C
0
0
0
0
0
0
0
N
E
0
C
\
I
E
"
<
t
2
-
"
<
t
2
-
"
'
0
Q
)
:
:
!
:
!
Q
)
0
0
c
{
~
!
0
0
E
:
0
E
:
Z
0
V
'I
<
:
S
'
z
.
V
'
l
Z
8
'
<
c
/
)
0
<
: C
'
d
N
l
.
S
O
~
o
0
<
: <
:
l
:
:
I
N
l
.
S
o
o
s
-
o
0
<
: c
l
:
:
l
N
l
.
S
O
~
.
.
-
o o '
<
t
"
0
o
s
0
(
; <
:
l
:
:
I
N
l
.
S
O
~
'
i
3
:
c
:
e
n
~
~
g
.
'
<
t
"
,
:
!
2
3
,
.
c
r
-
o
C
I)
"
0
E
:
;
:
:
;
o o
'
i
3
:
c
:
L
O
o
0
0
(
\
j
E
0
.
'
<
t
o
o (
'
)
o
o
o
s
0
<
: <
:
l
:
:
I
N
l
.
S
o (
'
)
C
I)
E
:
;
:
:
;
o
O
0
<
: <
:
l
:
:
I
N
l
.
S
O
~
o
o (
'
)
'
i
3
:
c
:
o
0
(
\
j
E C
I)
E
:
;
:
:
;
o
0
1
: <
:
l
:
:
I
N
l
.
S
o
o (
'
)
'
i
3
:
c
:
o
0
(
\
j
E C
I)
E
:
;
:
:
;
o
o
s
-
:
:
:
2
'
0
0
<
: <
:
l
:
:
I
N
l
.
S
O
~
" '
r
CMTS
PID DATE NPT(runol/l) B2M(mgll) STNRll(nglml) IL2(pglml) P24(pglml)
WHW 10/27/93 6.97 1.77 2.61 0 0
WHW 11115/93 46.92 2.78 22.68 0 0
WHW 11126/93 12.2 2.26 4.82 0
WHW 114/94 8.14 1.51 2.85 0
WHW 311/94 8.43 0.58 2.54 0
WHW 4/5/94 7.35 1.94 0
WHW 8/1/94 5.39 1.37 2.19 0
WHW 1110/95 6.67 1.92 3.44 0
WHW 6/6/95 8.13 2.12 2.99 0
WHW 2/6/96 9.05 2.36 2.91 0
WHW 9111196 11.78 4.32 2.82 0
WWG 12/16/93 15.33 3.55 5.3 0 32
WWG 1/11194 82.56 4.76 32.05 2 121
WWG 1125/94 26.54 3.4 16.9 -
WWG 3/1194 11.75 3.56 6.5 -
WWG 4/5/94 16.18 3.16 7.2 -
WWG 8/11/94 10.02 2.07 4.8 107
WWG 1110/95 7.39 2.13 5.2 159
WWG 6/6/95 10.52 2.54 5.5 165
WWG 2/6/96 7.34 2.19 5.55 95
WWG 9/11/96 14.76
-
5.95 250
YXW 7/27/94 41.35 3.31 6.11 2 0
YXW 9/1/94 52.24 5.04 7.2 18 0
YXW 1/2/95 30.66 4.4 11.29 0
YXW 5/27/95 52.01 4.33 5.91 0
YXW 1/27/96 33.6 4.05 5.34 0
YXW 9/7/96 31.37 3.74 5.46 0
XBP 7/27/94 24.32 2.11 4.2 4 0
XBP 9/1194 19.39 2.66 2.49 11 0
XBP 112/95 9.33 2.04 2.54 0
XBP 9/7/96 11.84 2.29 4.92 0
LW 7/27/94 27.95 1.96 5.29 7 0
LW 9/1/94 19.9 2.04 7.3 10 0
LW 1/2/95 21.85 2.5 7.35 0
LW 5/27/95 22.96 1.78 4.91 0
LW 1127/96 10.94 2.05 4.86 0
06/24/97 NA CIRID at UCLA
CMTS
LW 917196 14.11 2.08 4.74 0
XLL 7/27/94 31.61 2.23 9.43 0
XLL 1/2195 14.07 3.31 5.08 0
XLL 5127/95 17 2.79 6.37 0
XLL 1127/96 10.96 2.66 4.91 0
GHYM 7/27/94 27.39 1.81 7.24 8 19
GHYM 911194 23.4 2.84 4.85 22 24
GHYM 112/95 13.8 2.32 4.58 17
GHYM 5/27/95 10.31 1.97 3.29 21
GHYM 1127/96 10.51 2.13 10.34 29
GHYM 917196 28.9 3.34 11.34 73
YL 7/27/94 49.89 3.71 4.76 13
YL 911194 32.79 3.43 6.13 0
YL 112/95 28.21 3.36 6.65 27
YL 5/27/95 25.99 3.59 7.36 0
YL 1127/96 22.83 3.62 7.09 0
YL 9/6/96 31.61 3.3 5.27 -
06/24/97 NA CIRID at UCLA
... ms.edu.cn%20&number=26 mailbox:/C%7C/progr am% ... ms.edu.cn%20&number=26
. 0: 2
Subject: Re: Letters and E-mail
Date: Wed, 20 Aug 1997 15:40:33 +0900
From: "Chen Xiao Ping" <chenxp@gzsums.edu.cn>
To: "Heimlich" <heimlich@iglou.com>
CC: "Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich:
I have received your two express letters and email and I have told Dr.
Xiao Bin Quan your descriptions about funding issue. He requested me to
review our agreements and our case reports and then to report to him. Now
he let me tell you his points based on our agreements: "It is understood
that an occasional patient may survive only four or five months but will
still warrant inclusion in this series" ( ON GUANGZHOU PART ) . We have S
cancer cases who survived at least 4 months ( easel: 22 months; case2: he
refused to be followed up; case3: 4 months; case4: 8 months; caseS: 4
months; case6: over 36 months; case7: 3months ). It is unpredictable how
long to survive a patient who suffers from an "incurable" disease to
receive an unconfirmed therapy ( clinical trial, not routine treatment ).
It is possible that a trial therapy may promote the progress of an
"incurable" disease. So you should pay us at least for S cancer patients
according to our agreements. Dr. Xiao said that you did not overpay for
cancer patients but owe us 1,000 USD. He says that we do not ask for the
1,000 USD any more, but we have to receive the 6,000 USD that you owes us
for HIV/AIDS project. Please remember that we have totally treated eight
HIV patients, instead of seven patients that you mentioned in your letter.
( In fact, we treated 9 HIV patients; do you remember that case 9
complicated jaundice, we terminated malaria before finishing therapy and
then we did Western Blot again with negative result? But I brought his
blood sample to UCLA for further testing. It showed postive and we did it
again recently in Guangzhou, the result was positive, but we have cancelled
this patient). We do not want to delay our nex clinical trial , if only you
complete your payment on the project. Dr. Xiao also mentioned that any
financial support from UCLA can not be deducted from your payment. The
reasons are that, 1) 7,000 USD for one patient is the least, not the enough
according to our new protocol. 2) We can not accept UCLA as a joining part
if its payment is deducted from yours; for example, Dr. Fahey has to be as
a member of Heimlich Institute if he wants to join us. As a joining part,
Guangzhou payed a lot, took a lot of responsibility and faced high risk.
So, any additional payment should be used to improve our resea rch
conditions. Above are Dr. Xiao's point s. Dr. Xiao also let me tell you that
a university in Italy is willing to pay a great deal of money to cooperate
with Guangzhou, but we refuse it, because we have set up a gre at friendship
between us for a long time. As you know, my dear friend, Dr. Xiao is a very
important person in our project. I am unable to change any point of his
this time. What time we can do next clinical trial, it is completely
decided by you, my friend.
I hope all things are going well with you. Best regards.
Dr. Chen xiao ping, from Guangzhou, China
> From: Dr. Henry J. Heimlich <heimlich @iglou.com>
> To: chenxp@gzsums.edu.cn
> Subject: E-mail and other communicat i ons
> Date: Tuesday, August 19, 1997 5:42 AM
>
> Dear Dr. Chen,
>
> We received your e-mail at both heimlich@iglou.com and
> egspletzer@hotmail.com. We hope that you have no problems getting this
> e-mail.
>
> An important American organizat ion will be holding seve ral AIDS
> conferences in China in March, 1998 . Dr. Heimlich has been asked to lead
> a delegation for a possible meeting in Guangzhou. This would be a great
> opportunity for you to show your wor k to a group of American AIDS
> doctors.
>
> We sent two letters to you regarding MT-cancer and MT-HIV projects
08/21/97 08 : 43:26
mailbox : /C%7C/program% ... ms.edu.cn%20&number=26 mailbox:/C%7C/program% ... ms.edu.cn%20&number=26
> which you had apparently not received when you sent your e-mail. Copies
> of these are attached to this e-mail note. We hope that this addresses
> the matter so that we can go ahead with the next batch of patients.
>
> Please advise as to what dates you will start the work-up and
> treatment of the next 10 patients. The foundation providing the funds
> wishes to know this as soon as possible.
>
>
>
>
>
- 2
Sincerely,
08/21/97 08:43:26
~1~2~bl ~1~ ULLH- Cl kI U
BERI:ELEY O.ll\')$ UIVINE ' LOS ANCtLES ' RIVERSIDfr M,'J 1?!J :;vQ ' MN fll"'!'ir.r.~r.o
August 20, 1997
President
2:108Victory Parkway. Slllip,410
Cl.l1(,~J .lla.t~,U11 4~206
Dear Henry:
HUI.) c: 1. '=' ( 1eJ : t:J "l
UCLA
HNTt 1.. 11116(" I UlWT'rllI1'7
DCl'ARTMENT OP MlCR0810LOGY AND IMMVNOLOGY
UCLA. SCHOOL OF MEDIClNE
CEN'TER FOR THE HEAUf{ SCIENCES
10833LECONtEAVENUE
lOS ANGeLCS, CAUFORNlA 900?31747
(310) 825-6568
(310) 2061318 (FAX)
Twas ploased to have Y01l1' 110tP: nhout the planned visit to China that Y OU will be
chairing next March. I amsure the Citizen Ambassador Program has a mailing list
!~~lhUItt tD n j tm lb ~ l1fb !~tn m m !Q~ruP.rvt~ ~~J lq e J \!Q ~6 Q rt!lq iIll\J Q ~~U~r My
oVlI1visits are built around research sites where wehave ongoing or potential
collaborative work, so Ihave not been able to take advantage of this kind of
opportunity.' I amsure they will benefit enormously fromyour past experience
and interests.
1 hnpn )fnll hmrn nn intnnorrting gnOtlp of pnnticipnnto.
Sincerely,
J ohn L. ." ey, M.D.
Director, CIRln at UCLA
J LF/dm
f acsi mi l e
TRANSMITTAL
-------------------------------------
P O B O X B B 5 8 To: J ohn L. Fahey, MoD.
C I N C I N N A T I , O H 4 5 2 0 8
5 1 3 - 2 2 1 - 0 0 0 2
fill 5 1 3 - 2 2 1 - 0 0 0 3
Fax: 3102061318
Phone: 3108256568
Date: August 26, 1997
Dear J ohn,
Dr. Spletzer found the accompanying article. I tconfirms our results and suggests an
approach for our studies.
B en ef i t i n g
H u man i t y
Th r o u g h
H eal t h
an d
P eace
From the desk ot..
J oan Steinberg
C incinnati, O H 4 5 2 0 6
.,-
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45200
513-22HXXl2
lax 513-221-rol3
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
............... ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ -
To: Valerie Harper
Fax: (212)754-2892
Date: August 27, 1997
'.
' , ~
HEIMLICH
INSTITUTE
FOUNDATION, INC.
PO BOX BB5B
513-221-0002
Fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
Where are we now?
Our results have been presented at the International Immunology Conference in San
Francisco, the International Immunology Conference at the NIH in Bethesda, and the
International AIDS Conference in Vancouver. Each presentation represents approval by
the leading AIDS experts. We also received very positive press.
Those presentations led to the interest of Professor John Fahey of UCLA. He invited and
paid for Dr. Chen, our Chinese counterpart, to study at UCLA for two months. Chen has
prepared a very complete protocol for the next series of patients and is ready to treat
them. We are arranging to send funds to him. Dr. Fahey is providing an initial $5,000 of
laboratory reagents to China from his NIH grant, and is confirming our Chinese blood
tests at UCLA. Dr. Fahey, in a recent detailed report on our work, asked that we
acknowledge the support received from his NIH grants in scientific papers we write. He
is taking an active part in our project.
Dr. Eric Spletzer, Heimlich Institute's researcher, found an in depth study of the
relationship between malaria and HIV published in the Pasteur Institute of France journal.
It reviews the medical literature, and reports on their own detailed animal studies,
concluding that the effects of malaria and HIV infections on each other are protective
rather than harmful. The scientists recommend long term studies comprising a large
number of human subjects be done - which is what 'we are about to do.
We have published our early results in a scientific paper and received requests for reprints
from all over the world. -Our work is widely recognized. Furthermore, as reported in a
front page story in the New York Times, August 8, 1997, failures with drug treatment of
AIDS are increasing as we predicted
When we started our research, it was challenged by several doctors. Yet David believed
in the work, because he understood it, and provided funds. There is no known evidence
of opposition at this time.
Where do we go from here?
We have spoken of treating a hundred HIV patients and budgeted $1.5 million for this
when the next 10 patients have been treated and also have good results. Our work is
successful; we cannot afford to delay. We should not wait for further results, that wastes
valuable time and lives. Nor need we wait until we can gather the entire $1.5 M. Instead,
we start raising funds right now, and for each $10,000 raised treat an additional HIV
patient.
I have been invited to go to South Africa with a delegation of American AIDS specialists,
which is further evidence of the acceptance of our research. It is my hope that we will be
asked to carry out malariotherapy treatment of AIDS patients there. That would be ideal.
INSTITUTE
FOUNDATION, INC.
P.o. BOX B858
. CINCINNATI, 0" 45208
513-221-0002
Fax 513-221-0003
. Benefiting
Humanity
Through
Health
and
Peace
September 8, 1997
John L. Fahey, M.D.
University of California, Los Angeles
10833 Le Conte Avenue
Dear John:
I have just returned from my week of relaxation. Thank you very much for your fine
report of August 6, 1997.
I appreciate your efforts and contribution to this work. We will certainly acknowledge
and credit the support provided by your NIH grants in any report that is issued. Would
you please send me the appropriate wording for the acknowledgment. I hope that "you
will participate as an author of such a report and look forward to our drawing it up.
I will send the protocol that Chen Xiao Ping had worked out with your colleagues. I am
asking him to send a copy in Chinese to you.
I agree with your statement that malaria and IL-2 treatments may act by similar
mechanisms.
You raised the question whether the first values were pre-treatment. It was my
impression, from your letter of May 10, 1997, that had been a problem in communication
that was now settled. Please advise.
I would greatly appreciate your thoughts on what our next steps should be in working on
this project together.
John L. Fahey, M.D.
September 8, 1997
Page 2
I note in an Associated Press article of September 5,1997 that others are working on a
virus to target HIV-infected cells as rei>Orted in Cell. Another effort to give a disease to
cure another disease. We will get hold of the article when Dr. Spletzer returns from a
conference he is attending.
HEIMLICH
I ~ ~
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
4S2OO
513-22HXX)2
fax 513-221-<Xm
Benefiting
Humanity
Through
Health
and
Peace
To:
From:
Location:
Pages:
Date:
From the desk of...
INSTITUTE
FOUNDATION, INC.
P.o. BOX B858
. CINCINNATI, 0" 45208
513-221-0002
Fax 513-221-0003
. Benefiting
Humanity
Through
Health
and
Peace
September 8, 1997
John L. Fahey, M.D.
University of California, Los Angeles
Dear John:
I have just returned from my week of relaxation. Thank you very much for your fine
report of August 6, 1997.
I appreciate your efforts and contribution to this work. We will certainly acknowledge
and credit the support provided by your NIH grants in any report that is issued. Would
you please send me the appropriate wording for the acknowledgment. I hope that "you
will participate as an author of such a report and look forward to our drawing it up.
I will send the protocol that Chen Xiao Ping had worked out with your colleagues. I am
asking him to send a copy in Chinese to you.
I agree with your statement that malaria and IL-2 treatments may act by similar
mechanisms.
You raised the question whether the first values were pre-treatment. It was my
impression, from your letter of May 10, 1997, that had been a problem in communication
that was now settled. Please advise.
I would greatly appreciate your thoughts on what our next steps should be in working on
this project together.
John L. Fahey, M.D.
September 8, 1997
Page 2
I note in an Associated Press article of September 5,1997 that others are working on a
virus to target HIV-infected cells as rei>Orted in Cell. Another effort to give a disease to
cure another disease. We will get hold of the article when Dr. Spletzer returns from a
conference he is attending.
mai l box: / C%7C/ pr ogr am% . ms. edu. cn%20&nur nber =38 mai l box: / C%7C/ pr ogr am% . ms. edu. cn%20&nur nber =38
Subject: Re: Aug 26 E-mail
Date: Mon, 22 Sep 199715:56:43 +0800
From: "Chen Xiao Ping'v-cchenxptgigzsums.edu.cn>
To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com>
CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
We ar e pl eased t hat you agr eed t o send us t he 6, 000 USD accor di ng t o our
agr eement . As you know, t hi s payment i s ver y i mpor t ant f or us, because we
need i t t o bal l ance our account vs our agr eement and t o st ar t our next
cl i ni cal t r i al . Pl ease wi r e t r ansf er t hi s payment t o our account
( 475010101140192114 ) . Pl ease not i ce t hat t he 2, 000 USD you wi r ed t o our
account ( 4776213- 01140007599 ) on t he dat e 9/ 8/ 95 was i ncl uded i n t he
Tabl e 2, Fundi ngs of Mal ar i ot her apy f or HI V/ AI DS i n my E- mai l of 8/ 6/ 97 and
i n my r ecent l et t er by FedExpr ess.
Yes, i t is gr at i f yi ng t hat we can bot h di scuss t he quest i ons and
r el at i onshi ps openl y because of our gr eat t r ust and mut ual r espect . We do
cher i sh our gr eat f r i endshi p t hat has been est abl i shed by us si nce 1990.
Yes, we have over 10 pat i ent s i n Guangzhou. 1. They ar e def i ni t el y HI V
posi t i ve. 2. But t hey ar e al l dr ug user s. 3 . . We have not yet t est ed t hei r
CD4 cel l s. 4. t hey ar e i nt er est ed i n our mal ar i ot her apy. So I woul d l i ke t o
di scuss t he i ssue on pat i ent sel ect i on wi t h you. I n my i mpr essi on, t hese
HI V pat i ent s i n Guangzhou ar e much bet t er t han t hose pr evi ousl y f r om Yunnan
Pr ovi nce i n t he case of pat i ent sel ect i on because t hey have good heal t h now
and have much mor e hi gher educat i on l evel as wel l as have good vei ns f or
t hei r b, l ood bei ng t aken. They agr eed t o avoi d shar i ng needl es wi t h ot her s
and pr omi sed t o cooper at e wi t h us. I t wi l l be much mor e easi er f or us t o
f ol l ow t hem up. So I t r end t o sel ect t he pat i ent s i n Guangzhou even t hough
I have' cont act ed ot her HI V pat i ent s who' ar e not dr ug user s but t hey wi l l
cor ne f r om ot her pr ovi nces i ncl udi ng Si chuan Pr ovi nce and Henan pr ovi nce. As
you know, i n Chi na, most HI V pat i ent s ar e dr ug user s. I f we want t o t r eat
100 pat i ent s i n Chi na i n t he comi ng year s, we have t o sel ect t hem. But , t o
t el l t he t r ues, I am abl e t o get 10 pat i ent s who ar e not dr ug user s f r om
ot her pr ovi nces t hi s t i me. Ther ef or e I hope t o see what is your opi ni on.
Anot her t hi ng I want t o t al k t o you is t hat on t he basi s of our new
pr ot ocol made i n UCLA, our pat i ent sel ect i on is not l i mi t ed t o t hose CD4
count s bet ween250- 500 but t he HI V i nf ect ed adul t s wi t h ent r y CD4 count over
50 cel l s/ mm3 ( st r at i f i ed by CD4 number s, over 500, 500- 201, 200- 51 ) who
ar e any ant i r et r ovi r al and i mmune- based t her api es nai ve at ent r y, but not
excl udi ng t r adi t i onal Chi nese medi ci ne t her apy ( Pl ease see t he DESI GN AND
METHODS of our new pr ot ocol ) . ~Dr . J ohn L. Fahey agr eed t o t hi s pr ot ocol
and you agr eed t oo i n my i mpr essi on when I was i n UCLA and at home i n
Ci nci nnat i .
Dr . Xi ao want s t o know whet her you have pr omi sed t hat 1, you wi l l pay 7, 000
USD f or each HI V. pat i ent i n t he comi ng ' cl i ni cal t r i al ; 2, you wi l l not
deduct t he f i nanci al suppor t s by UCLA f r om your payment s because 7, 000
USD/ each i s j ust t he l east budget . He sai d t hat he woul d wel come UCLA t o
j oi n us i f i t pay some and t ake some r esponsi bi l i t y i n t he pr oj ect . He
pr omi sed once mor e t o pay f or a - 80 cent i gr ade f r eezer and pay some f or
i mpr ovi ng our AI DS l abor at or y speci al f or t he r esear ch of mal ar i ot her apy.
He added t hat i f you pr omi se bot h ment i oned above, he woul d pay and l et t he
cl i ni cal t r i al st ar t i mmedi at el y.
I f you and Dr . Xi ao bot h agr ee and pr omi se, I am abl e t o st ar t t he cl i ni cal
t r i al i mmedi at el y.
I l ook f or war d t o hear i ng f r om you.
Si ncer el y,
Dr . Chen xi ao Pi ng
Chi ef , Associ at e Resear ch Pr of essor
1of 2 09/ 22/ 97 08: 53: 41
2368 V I C T O R Y
P A A r:wt{{
S U I T E 410
C I N C I N N A T I
O HI O
45200
513-22HX 02
fa x 513-221-00:J 3
B e n e fi t i n g
Hu m a n i t y
T h r o u g h
He a l t h
a n d
P e a c e
M
u N D A M
M o R E
To: Valerie Harper
Henry J . Heimlich, M D
Interim Report on M alariotherapy and A IDS: P lease transmit to David
M ahoney
Date: September 25, 1997
Resume of our conversation:
R e : J ohn LFahey, M .D., Director Center for Interdisciplinary Research inImmunology
and Disease (CIRID), Chair, Clinical Immunology Committee, International; Union of
Immunological Societies (lUIS)
I. Dr. Fahey isproviding Dr. Chen X iao P ingwith $5,000 worth of reagents to carry out
CD4 levels with aflow cytometer, the latest method.
2. Dr. Fahey sent us laboratory data obtained from the blood of our patients in
Guangzhou and states we should feel free to use this data inreports and publications.
The results confirm Dr. Chen's analysis. Dr. Fahey says he would appreciate an
acknowledgment inour publications of the work done on our patients at UCLA and asks
that we givecredit inour reports to histwo NIH grants that supported this work.
3. Dr. Fahey states that he believes malariotherapy may act by similar mechanisms to
those operating inthe 5-day continuous intravenous IL-2 treatments tested by the NIH.
He sa y s both malaria and IL-2 stimulate marked increases inall or almost all cytokines
(immune substances produced by the body). I told himI agree. M alariotherapy is
superior since IL-2, an expensive, genetically engineered interleukin that causes severe
reactions, and must be repeated every month or two.
4. Dr. Fahey isgoing to send me his recommendations for the next steps inour
continuing work together to expedite the malariotherapy program.
A two-year follow-up of our eight patients has been prepared for submission to a
medical journal. It reports on the seven of our eight patients who continue to be ingood
health and mentions the one who died at twenty-one months, unrelated to
malariotherapy.
Valerie Harper
Page2
September 25, 1997
Our work has become more urgent since The New York Times revealed there are
limitations inthe response to protease inhibitors indicating the drugs are failing, at arate
approaching 50%. As you know, I have always said the drugs will fail due to resistance of
the HIV virus; whereas boosting the immune system with malariotherapy continues to
succeed.
We now have a protocol developed by Dr. Chen inconjunction with Dr. Fahey suitable
for the treatment of 100patients. The sooner we attain that figure, the quicker our
work will be accepted and the benefits extended to the world's population. You will
recall the opposition to malariotherapy that occurred when David Mahoney first
presented the concept to several doctors. I know of no opposition now.
. : J
.' ~.
2368 VICTORY
PARKWAY
SUITE410
CINCINNATI
OHIO
45206
513-221-0002
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
M E
To:
From:
Subject:
Date:
M o R A N D u
Valerie Harper
V
I
-' j
v '
Henry J. Heimlich, MD
Interim Report on Malariotherapy and AIDS: Please transmit to David
Mahoney
September 25, 1997
Resume of our conversation:
M
Re: John L. Fahey, M.D., Director Center for Interdisciplinary Research in Immunology
and Disease (CIRID), Chair, Clinical Immunology Committee, International; Union of
Immunological Societies (lUIS)
I. Dr. Fahey is providing Dr. Chen Xiao Ping with $5,000 worth of reagents to carry out
CD4 levels with a flow cytometer, the latest method.
2. Dr. Fahey sent us laboratory data obtained from the blood of our patients in
Guangzhou and states we should feel free to use this data in reports and publications.
The results confirm Dr. Chen's analysis. Dr. Fahey says he would appreciate an
acknowledgment in our publications of the work done on our patients at UCLA and asks
that we give credit in our reports to his two NIH grants that supported this work.
3. Dr. Fahey states that he believes malariotherapy may act by similar mechanisms to
those operating in the 5-day continuous intravenous IL-2 treatments tested by the NIH.
He says both malaria and IL-2 stimulate marked increases in all or almost all cytokines
(immune substances produced by the body). I told him I agree. Malariotherapy is
superior since IL-2, an expensive, genetically engineered interleukin that causes severe
reactions, and must be repeated every month or two.
4. Dr. Fahey is going to send me his recommendations for the next steps in our
continuing work together to expedite the malariotherapy program.
A two-year follow-up of our eight patients has been prepared for submission to a
medical journal. It reports on the seven of our eight patients who continue to be in good
health and mentions the one who died at twenty-one months, unrelated to
malariotherapy.
"'-- r ---- - -------- - - ---r -- - -.--._ --.. _ - .. --.--.
I
Valerie Harper
Page 2
September 25. 1997
Our work has become more urgent since The New York Times revealed there are
limitations in the response to protease inhibitors indicating the drugs are failing, at a rate
approaching 50%. As you know, I have always said the drugs will fail due to resistance of
the HIV virus; whereas boosting the immune system with malariotherapy continues to
succeed.
We now have a protocol developed by Dr. Chen in conjunction with Dr. Fahey suitable
for the treatment of 100 patients. The sooner we attain that figure, the quicker our
work will be accepted and the benefits extended to the world's population. You will
recall the opposition to malariotherapy that occurred when David Mahoney first
presented the concept to several doctors. I know of no opposition now.
2 3 6 8 V I C T O R Y
P A R ~A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 5 2 0 6
5 1 3 - 2 2 1 - {X X )2
la x 5 1 3 - 2 2 H X X X 3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
Sept ember 26, 1997
Geor ge D. Lundber g, M. D.
Edi t or
J AMA
515 N. St at e St .
Chi cago, I L 60610
Dear Dr . Lundber g:
Encl osed i s a manuscr i pt ent i t l ed " Mal ar i ot her apy f or HI V
pat i ent s: Two year s of f ol l ow- up exper i ence. "
We cer t i f y t hat we have par t i ci pat ed suf f i ci ent l y i n t he
concept i on and desi gn of t hi s wor k and t he anal ysi s of t he dat a,
as wel l as t he wr i t i ng of t he manuscr i pt , t o t ake publ i c
r esponsi bi l i t y f or i t . We bel i eve t he manuscr i pt r epr esent s
val i d wor k. We have r evi ewed t he f i nal ver si on of t he submi t t ed
manuscr i pt and appr ove i t f or pUbl i cat i on. Nei t her t hi s
manuscr i pt nor one wi t h subst ant i al l y si mi l ar cont ent under my
aut hor shi p has been publ i shed or i s bei ng consi der ed f or
publ i cat i on el sewher e. Fur t her mor e, we at t est t hat we shal l
pr oduce t he dat a upon whi ch t hi s manuscr i pt i s based f or
exami nat i on by t he edi t or s or t hei r assi gnees i f r equest ed.
I cer t i f y t hat af f i l i at i ons wi t h or i nvol vement i n any
or gani zat i on or ent i t y wi t h a di r ect f i nanci al i nt er est i n t he
subj ect mat t er or mat er i al s di scussed i n t he manuscr i pt ( e. g. ,
empl oyment , consul t anci es, st ock owner shi p, honor ar i a, exper t
t est i mony) do not exi st .
I n consi der at i on of t he act i on of t he Amer i can Medi cal
Associ at i on ( AMA) i n r evi ewi ng and edi t i ng t hi s submi ssi on, t he
under si gned aut hor s her eby t r ansf er , assi gn, or ot her wi se convey
al l copyr i ght owner shi p t o t he AMA i n t he event t hat such wor k
i s publ i shed by t hem.
We l ook f or war d t o your deci si on r egar di ng pUbl i cat i on i n J our nal
of t he Amer i can Medi cal Associ at i on. I f changes ar e r equi r ed,
pl ease not i f y Henr y J . Hei ml i ch, at 2368 Vi ct or y Par kway, Sui t e 410,
--- __ -
3102061318 UCLA-CIRID
BERKELE DAVIS IRVINE LOS . RIVBIISIOIl SANOIl!:GO SAN I'IIANCISCO
Center for InterdiSciplinary Research
September 26, 1997
Henry J. Heimlich, M.D., Sc.D.
President
Dear Henry:
022 P02 SEP 29 '97 15:23
UCLA
SANTA . SANTA caul,
Or-PARTMF-NT OF MICROBIOLOGY AND IMMUNOLOGY
UCLA SCHOOL OF MEDIClNE
CENT6R FOR nJl:: HEALTH SCIENCES
10833 i.E CONTE AVENUE
COS ANGELES. CALIFORNIA 9(j)95-1747
(310) 825-6568
(310) 206-1318 (FAX)
I have your recent letter of September 8. I have been working on a schedule that will allow me to
visit China near the end of October and, specifically, to be in CantoniGuangzhou on October 24.
I am writing to Chen Xiao Ping about this bec.ause the principal reason for going to Canton will
be to discuss how he is progressing with plans for the malarial therapy trial and to become
acquainted firsthand with the setup at his institution and to meet some of the other people that are
involved in AIDS and immunology research there. Of course, I will want to discuss the plans for
the new protocol. If you could make a copy available to me in the next week or two, that would
be very much appreciated.
The citation to credit the work that we have contributed would be "assisted in part by NIH grants
TW-00003 and AI-35040." There is no need to include me among the authors but an
acknowledgment would be quite sufficient. I do still have some reservations about the
relati011ship of his first samples to the adntinistrati<)1l of malaria. These impinge on my
confidenc.e about interpretation of the data. TIlere were a nwnber of switches on specific.
infonnation from Chen Xiao Ping while he was here that caused this unease. Perhaps, I can
settle my qualms after the visit to Guangzhou.
I have several appointments in Beijing (prior to going to Guaugzhou) at the Peking Union
Medical College, the Beijin.g Medical School, and the Academy of Preventive Medicine. Is there
anything that I could do on your behalf at any of these sites? I would be glad to try to help.
Director.
Chair, Clinical Immunology Committee, lUIS
JLF/dm
mailbox:/C%7C/Program% ... ms.edu.cn%20&number=41 mailbox:/C%7C/Program% ... ms.edu.cn%20&number=41
1 of 1
SUbject: Re: E-mail
Date: Tue, 30 Sep 1997 16:43:59 +0800
To: "Dr. Henry 1. Heimlich" <Heimlich@iglou.com>
Dear Dr. Heimlich and Dr. Spletzer:
Thank you for your E-mail of 9/24/97. I agree with you that we should
select HIV patients who are not drug users this time even though there are
more difficulties to do so. Yes, it is true that there are more than 700
HIV patients in Hong Kong, but the Health Department of Hong Kong was
unwilling to introduce the patients to us ( I visited the Department two
times on this issue ) and I have not yet been able to contact the patients
directly. I am continuing my effort on keeping touch with Hong Kong. On the
other hand, we can find other patients in other cities in Guangdong
Province and in other provinces. It will take one to two months to
re-organize them to come to Guangzhou to receive our therapy. We delayed
some time in our discussion of funding issue; but we are pleased that we
reach our agreement finally.
There are some points that I want to discuss with you. In my opion, first,
malariotherapy ( MT ) is not IL-2 therapy; because IL-2 can not induce
production of CSFs including multi-CSF( IL-3 ), GM-CSF, M-CSF and G-CSF
which promote stem cells regeneration, but MT can do so theoretically, see
Appendix. Second, malariotherapy is not natural malaria. Many doctors
consider that malaria suppress immune system. It is not all true. A lot of
data show that in the early stage of malaria, it definately boosts immune
system; the decrease of peripheral white blood cell ( WBC ) in some
patients with malaria is due to redistribution of WBC, especially
concentrating in the spleen and liver, not real decrease of WBC. But it is
true that the late stage of malaria suppresses immune system. As we know,
our malariotherapy is just to use the early stage of malaria ( no more than
15 fever episodes ). Third, there are no any forms of relapsing Plasmodia
in our MT, this point was discussed by us before we started our MT for
cancer. Forth, high fever can inhibit RNA synthesis and HIV belongs to RNA
virus.
So we should widen our patient selection so that we are more earlier to
confirm that MT is much better than IL-2 therapy. But if we do not want to
take any risk, I agree with you this time.
Appendix. MT: P.Ag---> Macrophage--->IL-l, CSFs--->stem cells
---> Macrophage
--->IL-l, HLA-DR, IL-6
--->resting T cell
--->activated T cell--->IL-2, IL-4,IL-6,IFNs
--->T, B cell-->-->-->
IL-2 therapy: IL-2--->T, B cell-->-->-->
Note: P.Ag: Plasmodium antigen.
Sincerely,
Chen Xiao Ping, M.D.
09/30/97 08:52:25
HEIMLICH
INSTITUTE
2368 VICTORY
PARKWAY
SUITE410
CINCINNATI
OHIO
45206
513-221-()()()2
fax 513-221-()()()3
Benefiting
Humanity
Through
Health
and
Peace
Fax
To: Valerie Harper
Of: The Eleanor Naylor Dan
From:
Fax: (212) 754-2892
Date: September 30,1997
The following article, front page in The Cincinnati Enquirer, is also in today's New York
Times, (Science Times section).
Also being sent is a fax received today from John Fahey and his letter of May 19, 1997.
Last is an e-mail received today from Chen.
Give me a ring this morning when you have read these, as I will be at your favorite spot -
the dentist - this afternoon.
THE CINCINNATI ENQUIRER
A GANNI II N Ws/'AI'Ek . 501.100 RuJ' ERS DAI LY !:' (I' II(MII " k 30,1997 FlNAJ. EnmoN/EAsT 50 er.N"!';
Study: AIDS cocktails failing half of patiel
BY DANIEL Q. HANEY
The Associated Press
TORONTO - Widely
heralded new AIDS treat-
ments that seemed to stop
the virus' advance and revive
patients from near death are
now beginning to fail in about
half of all those treated, doc-
tors said Monday.
The disappointing reports
suggest the tough virus is
coming back after being
knocked briefly into submis-
New drug
The FDA has OK'd an anti-HIV
combination pill that will cut
down on "drug cocktails." A4
sion, just as many experts
feared it would.
Dr. Steven Deeks pre-
sented data from the Univer-
sity of California at San Fran-
cisco' s large public AIDS
clinic at San Francisco Gen-
eral Hospital.
Prescriptions of so-<:alIed
three-drug cocktails - two
older AIDS drugs plus one of
the new class of medicines
called protease inhibitors -
have clearly revolutionized
AIDS care.
In many places. more than
90 percent of AIDS patients
are taking these combina-
tions. and typi call y people
start on them even before
they get sick,
Patients whose disease-
fighting T cells were ravaged
by HIV have regained normal
uves and even gone back to
work. However, many wor-
ried the virus would eventual-
ly grow resistant to the prote-
ase inhibitors and resume its
insidious destruction,
New data. presented Mon-
day at an infectious disease
conference sponsored by the
American Society of Microbi-
ology, suggests this is indeed
happening regularly.
"There is a whole mixture
of explanations," said Dr.
David Ho of the Aaron Dia-
mond AIDS Research Center
in New York City.
Dr. Ho said that for people
who had relatively low virus
levels when they started tak-
ing the drugs and had not
used other AIDS medicines.
failure almost always means
they did not take their pills
on schedule.
"Compliance is ;
critical," Dr, 0"
"When we say
we mean rigid adh
over 20 pills a day,
Also at high ri sk
who were on oll
drugs before start!
ase inhibitors or wI'
counts were very I,
Dr. Deeks sai,
ments by ph ar O!
companies show
couraging resullS,
mailbox:/C%7C/Program% ... ms.edu . cn%20&number=41 mailbox:/C%7c/program% ... ms.edu.cn%20&number=41
1 of 1
SUbject: Re: E-mail
Date: Tue, 30 Sep 1997 16:43:59 +0800
Thank you for your E-mail of 9/24/97. I agree with you that we should
select HIV patients who are not drug users this time even though there are
more difficulties to do so . Yes, it is true that there are more than 700
HIV patients in Hong Kong, but the Health Department of Hong Kong was
unwilling to introduce the patients to us ( I visited the Department two
times on this issue ) and I have not yet been able to contact the patients
directly. I am continuing my effort on keeping touch with Hong Kong. On the
other hand, we can find other patients in other cities in Guangdong
Province and in other provinces. It will take one to two months to
re-organize them to come t o Guangzhou to receive our therapy. We delayed
some time in our discussion of funding issue; but we are pleased that we
reach our agreement finally .
There are some points that I want to discuss with you. In my opion, first,
malariotherapy ( MT ) is not IL-2 therapy; because IL-2 can not induce
production of CSFs including multi-CSF( IL-3 ), GM-CSF, M-CSF and G-CSF
which promote stem cells regeneration, but MT can do so theoretically, see
Appendix. Second, malariotherapy is not natural malaria. Many doctors
consider that malaria suppress immune system. It is not all true. A lot of
data show that in the early stage of malaria, it definately boosts immune
system; the decrease of peripheral white blood cell ( WBC ) in some
patients with malaria is due to redistribution of WBC, especially
concentrating in the spleen and liver, not real decrease of WBC. But it is
true that the late stage of malaria suppresses immune system. As we know,
our malariotherapy is just to use the early stage of malaria ( no more than
15 fever episodes ). Third, there are no any forms of relapsing Plasmodia
in our MT, this point was discussed by us before we started our MT for
cancer. Forth, high fever can inhibit RNA synthesis and HIV belongs to RNA
virus.
So we should widen our patient selection so that we are more earlier to
confirm that MT is much better than IL-2 therapy. But if we do not want to
take any risk, I agree with you this time.
Appendix. MT: P.Ag---> Macrophage--->IL-l, CSFs--->stem cells
---> Macrophage
--->IL-l, HLA-DR, IL-6
--->resting T cell
- - - >activated T cell--->IL-2, IL-4,IL-6,IFNS
--->T, B cell-->-->-->
IL-2 therapy: IL-2--->T, B cell-->-->-->
Note: P.Ag: Plasmodium antigen.
Sincerely,
09/30/97 08:52 : 25
3102061318 UCLA-CIRID
BERKELE DAVIS IRVINE LOS . RIVBIISIOIl SANOIl!:GO SAN I'IIANCISCO
Center for InterdiSciplinary Research
September 26, 1997
Henry J. Heimlich, M.D., Sc.D.
President
Dear Henry:
022 P02 SEP 29 '97 15:23
UCLA
SANTA . SANTA caul,
Or-PARTMF-NT OF MICROBIOLOGY AND IMMUNOLOGY
UCLA SCHOOL OF MEDIClNE
CENT6R FOR nJl:: HEALTH SCIENCES
10833 i.E CONTE AVENUE
COS ANGELES. CALIFORNIA 9(j)95-1747
(310) 825-6568
(310) 206-1318 (FAX)
I have your recent letter of September 8. I have been working on a schedule that will allow me to
visit China near the end of October and, specifically, to be in CantoniGuangzhou on October 24.
I am writing to Chen Xiao Ping about this bec.ause the principal reason for going to Canton will
be to discuss how he is progressing with plans for the malarial therapy trial and to become
acquainted firsthand with the setup at his institution and to meet some of the other people that are
involved in AIDS and immunology research there. Of course, I will want to discuss the plans for
the new protocol. If you could make a copy available to me in the next week or two, that would
be very much appreciated.
The citation to credit the work that we have contributed would be "assisted in part by NIH grants
TW-00003 and AI-35040." There is no need to include me among the authors but an
acknowledgment would be quite sufficient. I do still have some reservations about the
relati011ship of his first samples to the adntinistrati<)1l of malaria. These impinge on my
confidenc.e about interpretation of the data. TIlere were a nwnber of switches on specific.
infonnation from Chen Xiao Ping while he was here that caused this unease. Perhaps, I can
settle my qualms after the visit to Guangzhou.
I have several appointments in Beijing (prior to going to Guaugzhou) at the Peking Union
Medical College, the Beijin.g Medical School, and the Academy of Preventive Medicine. Is there
anything that I could do on your behalf at any of these sites? I would be glad to try to help.
Director.
Chair, Clinical Immunology Committee, lUIS
JLF/dm
3102061318 UCLA-CIRIU
IltJlJ(tt.r.:r O A v r ~ HIVlNE u"fi ANCELES R!VE1lSIOE SAN 01(;0 Si\N nN'/ClSCQ
May 19, 1997
President
Cincirmati, OR 45206
Dear Heruy:
l'IH ( 1 ':;1 ":::1'/ 1'(: 4t::
UCLA
DEPARTMENT OF M1Cl\OBIOLOGY AND IMMUNOLOCY
UCLA SCl(OOL OF M1!:DIGINE
GENTER FOR THE HEALTH SCIENCF-S
LOS ANGELES. CALIFOR?-.'lA 00024-1741
(310) 825-6568
(310) 206-1318 (FAX)
This follows my letter of May 7, 1997, and contains a correction. I wrote that Chen
Xiao Ping had told us there were no baseline samples, e.g., pre-therapy blood
samples from the ma1aria treated group in Gual1gzhou. That is what he told 3 of us
about 2 weeks ago. We asked repeatedly.
Last week we decided to look at the data - the dates that therapies were started and
the dates that the first samples were obtained. Last Friday, we reviewed this and it
appears that blood samples were drawn on the day malaria was given to 7 of the 8
persons. Patient #2 may also have had a baseline sample if the ftrst sample label
date is incorrect. Dr. Chen's ex-planation was that he understood baseline to mean
samples obtained some time before the start of treatment. A problem in
cOlmnunication.
My regrets regarding the incorrect infoTInation sent to you.
Jolm Lahey, M.D.
Chair, Clinical Immunology Committee, Intematiollal
Union of InmHmological Societies (lUIS)
JLF/dm
American Medical Association
Physicians dedicated to the health of America
Journal o f
The AmeriC8ll
M~dical Association
October 1, 1997
515 North State Street
Chicago, Illinois 60610
312 464-5000
312464-5824 Fax
httpJ /www.ama-assn.org
Hemilich Institute
Cincinnati, OH45206
USA
RE: MS#J PC710l9, MALARIOTHERAPY FOR HIV PATIENTS: TWOYEARS OF
FOLLOW-UP EXPERIENCE
Dear Dr. Heimlich:
Thank youfor giving us this opportunity to consider your manuscript. Please refer to the
manuscript number and first author in all subsequent communication. Your manuscript has
been assigned to Carin M. Olson, MD, who can be reached at 312-464-2442.
We agree to consider this manuscript with the understanding that its content, figures, and
tables have not been published or submitted elsewhere in print or electronic format, and will
not be submitted elsewhere during the period of review by THEJ OURNAL.
Your manuscript will be reviewed by Carin M. Olson, MD, and possibly by two or more peer
reviewers. Every effort will be made to expedite the review process and to notify youof our
decision as soon as possible.
It is the policy of THEJ OURNALnot to return manuscripts that have been rejected (unless the
author has specifically requested the manuscript's return). Only the original artwork, if
submitted, will be returned. The original manuscript and any copies will be destroyed and
recycled.
. cerezyyoureD~
E~~~berg, MD~- : f rf D / f
Scientific Publications
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22HXlO2
fax 513-22HI003
Benefiting
Humanity
Through
Health
and
Peace
Fax
To:
Of:
Fax:
From:
Subj:
Pages:
Date:
1.
2.
3.
Valerie Harper
(212) 754-2892 ( /
Henry J. Heimlich, M.D. ~
Summary of E-mail of 9/30/97 from Dr. Chen Xiao Ping
1, including this cover sheet
October 7, 1997
Dr. Chen agrees that we should not treat drug users.
He is continuing his effort to try to work with Hong Kong to obtain
patients.
In addition, he has patients in other cities in his and other provinces. It
will take one to two months to organize them to come to Guangzhou to
receive treatment.
The remainder of his message is scientific.
Regards,
: : ~
. -)
1B/27/97 18:35:11
RightFAX NT-) 513 221 BBB3
FROST & JACOBS LLP
CINCINNATI, OHIO
COMMUNI CATIONS CENTER
FAX COVER SHEET
Facsimile Transmission
Date and time of transmission: MOll 10/27/97 10:34AM
Number of pages: 05 (Including this cover page.)
TO
Name:
Company:
Location:
Fax Number :
Voice Number:
FROM
Name:
Fax Number:
Voice Number:
COMMENTS
Dr. Heimlich,
Dr. Heimlich
Heimlich Institute
92210003
DOUGLASD. THOMSON
(513) 651-6935
Attached is a draft of the letter to the IRS requesting that the
Institute be reclassified as an MRO. Please take a moment to review
and let me know if you have any questions or comments. As Joan
and I discussed, the information from the Institute's 990 will be
inserted. Doug Thomson
Page BB1
THE INFORMATION CONTAINED IN THIS FA., '{ IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT
IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED. CONFIDENTIAL. ATTORNEYS' WORK PRODUCT
.-\ ND!OR EXEMPT FROM DISCLOSURE UNDER APPLI CABLE LA.W. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED
RECIPIENT (OR THE H IPLOYEE OR .'\GENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPI ENTl. YOU ARE HEREBY
NOTIFIED THAT ANY DISSE!v!I NATION. DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS PROHIBITED. IF YOU
HAVE RECEIVED THIS COMMUNICATIOl\ IN ERROR. PLEASE NOTIFY US BY COLLECT TELEPHONE.
CINCINNATI FAX NUMBER
(513) 651-6981
OTHER OFFICES (FAX NUMBERS)
COLUMBUS (614) 464-1737
MIDDLETOWN (51 3) 422-3010
LEXINGTON (606) 253-2990
NAPLES (941) 261-2083
SHOULD YOU HA VE ANY PROBLEMS RECEIVI NG THIS TRANSMISSION,
PLEASE CALL (:' 13) 6:' I -677:'
1B/27/97 18:35:45
DOUGLAS D. THOMSON
(513) 651.6935
RightFAX HT->
513 221 BBB3
Page ElEI2
d thomson@frojac.com
October 27,1997
Internal Revenue Service
EPIEO Division
P.O. Box 3159
Re: The Heimlich Institute (23-7303161). Request for change in non-private Institute
status to a medical research organization.
Dear Sir or Madam
This letter is to request a change in the status of the Heimlich Institute (the "Institute")
from an organization described in Section 509(a)( 1) and Section 170(b)(1)(A)(iv) to an medical
research organization described in Section 509(a)(1) and Section 170(b)(1)(A)(iii).
A copy of the Institute's determination letter is attached recognizing the Institute as a
Section 501(c)(3) organization classified as a non-private Institute described in Section
509(a)( 1).
In order to assist your determination of the Institute' s classification as a r-v1RO under
Section 170(b)(l)(AXiii) a completed Schedule C, Section 2 from Form 1023 is attached to this
correspondence. Also attached is a Form 2848 naming the undersigned as power of attorney for
the Institute.
Should you have any additional questions, please cont act the undersigned .
DDT/gvs
Enclosure
457723.01
Very trul y yours,
Douglas D. Thomson
18/27/97 1B:36:13 RightFAX HT-> 513 221 B883 Page BB3
DRAFT 10/27/97
The Institute's Affiliation with the UCLA Medical Center
The Institute has for many years been engaged in the continuous active conduct of
medical research. The Institute's most notable activities relate to research and the promulgation
of information concerning the I'Heimlich Maneuver" developed by Dr. Henry J. Heimlich the
Institute's President. Attached as Exhibit is material describing the Institute's research about
the Heimlich Maneuver.
While the Institute continues to engage in research concerning the Heimlich Maneuver,
the Institute's primary research focus is currently the treatment of HIV (AIDS) patients using
malariotherapy.
The Institute's malariotherapy research is being conducted by the Institute in conjunction
with two hospitals. Patients are treated and results initially analyzed at the Municipal Institute
for Preventative Medicine (the I'Municipal Institute") of Guangzhaou, China. An agreement (the
"Agreement") describing the relationship between the Municipal Institute and the Institute is
attached as Exhibit
The Agreement requires that the Municipal Institute provide medical treatment and
testing (using the clinical protocalls developed by the Institute and modified with the assistance
of the UCLA Medical Center) to the patients involved in the malariotherapy clinical trials. The
Municipal Institute forwards the test results from the clinical trials to the Fundation and the
UCLA Medical Center for review and analysis . The Institute finances the cost of the clinical
trials, has established and continues to revise clinical protocols and analyzes the data from the
clinical trials .
Results of the Guangzhaou clinical trials are also analyzed by the Center for
Interdisciplinary Research in Immunology and Disease at the UCLA Medical Center. The chief
researcher for the Institute is Dr. Heimlich. The chief researcher for the Municipal Institute is
Dr. Xaio Ping Chen and the principal contact at the UCLA Medical Center is Dr. John L Fahey.
The Institute has arranged for Dr. Chen to spend significant time working with Dr. Fahey's staff
at the UCLA Medical Center. The close cooperation between the UCLA Medical Center
(through Dr. John Fahey), the Institute (through Dr. Heimlich and Dr. Chen) is evidenced by the
material attached as Exhibit
The first sentence ofTreas. Reg. Section 1.170A-9( c)(2Xvii) states that an MRO need not
be formally affiliated with a hospital. Likewise, the last sentence ofTreas. Reg. Section 1.170A-
9(cX2Xvii) provides that not all of an MRO's research efforts need to occur on the hospital's
premises, only that there be "cooperative of appropriate [MRO and hospital] personnel and the
use of facilities of the particular hospital. whenever it would aid such research." It is clear that
there is an affiliation between the Institute and the UCLA Medical Center contemplated by
Treas . Reg. Section 1.170A-9(c)(2)(vii)
18/27/97 18:37:87 RightFAX HT-> 513 221 8883 Page 884
The Institute Devotes a Substantial Amount of its Assets to Medical Research
In order to qualify as a MRO, the Institute must devote a substantial amount of its assets
to medical research. Treas . Reg. Section 1. 170A-9(c)(2Xiii) defines medical research as " ... the
conduct of investigations, experiments and studies to discover, develop, or verifY knowledge
relating to the causes, diagnosis, treatment, prevention, or control of physical or mental diseases
and impairments of man."
A. The Institute's Medical Research
As discussed above, while the Institute continues to engage in research concerning the
Heimlich !\.1aneuver, the Institute' s primary research focus is currently the treatment of HIV
(AIDS) patients using malariotherapy.
HIV-infection weakens patients ' immune systems by outstripping the ability of the
body' s immune cells to respond to the virus. This effect of HI V infection leads to the equivalent
of rapid ageing of the immune system, resulting in decreased ability of the body' s immune
system to respond to secondary infections that can prove futal. Restoration and preservation of
the immune system are crucial elements in the successful clinical management of HIV infection.
The aim of malariotherapy is to restore immunological function by providing a general stimulus
to the immune system. Strengthening the immune system allows for the {X}tential elimination of
the virus . A 1996 article from A1echanisms of Aging and Development (a medical and scientific
journal) discussing the Institute's malariotherapy treatment ofHIV is attached as Exhibit _ .
Based on the foregoing it is clear that the Institute conducts medical research 'within the
meaning ofTreas . Reg. Section 1.170A-9(c)(2)(iii).
B. Use of the Institute's Assets for Medical Research
Not only must the Institute conduct medical research, but it must also devote a substantial
part of its assets to the conduct of such medical research. According to Treas. Reg. Section
1.170A-9(c)(2)(v)(b), the Institute will be considered to devote a substantial part of its assets to
the conduct of medical research if it expends funds equaling 3.5% or more of its endowment for
the conduct of medical research. The determination of whether the Institute has spent the
required 3.5% is based on the Institute' s expenditures for the prior year (i.e., for 1997, a review
of expenditures for 1996) or for the prior four years (i .e., for 1997, a review of 1993-1996) .
1B/27/97 1B:37:56 RightFAX HT-> 513 221 BBB3 Page BBS
The analysis below, drawn from the Institute's Form 990 for 1996, 1995, 1994 and 1993
clearly show that the Institute devotes a substantial part of its assets to medical research. The
calculation of the Institute' s endowment is a combination of the cash and investment totals from
Part IV of the Form 990. The detennination of the amounts the Institute spent for medical
research is determined by totaling lines (a) and (b) of Part III of the Form 990.
1996
[To be provided]
1995
Endowment = $502,3 83
3.5% of endowment is $17,583
Amount spent on medical research is $106,178
1994
Endowment = $593,623
1993
Endowment = $570,337
457723.01
2368 VICTORY
PARKWAY
SUITE410
CINCINNATI
OHIO
45206
513-221-0002
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
To:
From:
Subject:
Date:
Re:
MEMORANDUM
Valerie Harper
Interim Report on Malariotherapy and AIDS: Please transmit to David
Mahoney
November 4, 1997
John L. Fahey, M.D., Director Center for Interdisciplinary Research in
Immunology and Disease (CIRID), Chair, Clinical Immunology Committee,
International; Union of Immunological Societies (lUIS)
Resume of Dr. Heimlich' s conversation with Professor John L. Fahey, M.D. , November
4, 1997, shortly after Dr. Fahey' s return from China:
1. Dr. Fahey believes malariotherapy may act by similar mechanisms to those operating
in the 5-day continuous intravenous IL-2 treatments tested by the NIH. He says both
malaria and IL-2 stimulate marked increases in all or almost all cytokines (immune
substances produced by the body). I told him I agree. Malariotherapy is superior since
IL-2, an expensive, genetically engineered interleukin that causes severe reactions, and
must be repeated every month or two.
2. Dr. Fahey was positively impressed concerning the laboratories, and other facilities,
in China and said they can carry out all tests as well as those done at UCLA.
3. The medical personnel working with Dr. Chen were impressive and the Municipal
Health Group impressed Dr. Fahey with their interest in malariotherapy. They supported
Dr. Chen' s work.
4. Dr. Fahey is in agreement with using intravenous drug users and reported most of the
clinical trials in the U.S. include such individuals. He suggested, if possible, two HIV
positive non-drug users would be worthwhile including.
November 6, 1997
Dr. IIel'l:}:" cit
DAVID
745 FIFTH AVESUE
SUITE 700
NEW YORK, NEW YORK 10151
212/838-3710
17 Elmhurst Place
Dear Hank:
I write this for two reasons. First, to congratulate
you on the wonderful news from Dr. Fahey. It seems you
are really on track, and should be indeed proud.
My second reason is to inquire why a man of your
demonstrated brilliance can possibly consider touring
Africa in any form at this time. We need all of your
efforts behind this major breakthrough, and your family
and friends don't look forward to you doing bongo dances
when they're not necessary. Keep in touch. Know how
much we miss you.
Warmest best wishes,

David Mahoney
DM/lek
BERKELEY DAVIS IRVI NE LOS ANCELES . RIVERSIDE SAN DI ECO . SAN FRANCISCO
November 13, 1997
Department of Microbiology
No. 23, 3
rd
Zhongshan Road
Guangzhou 510080, P.R. China
Dear Dr. Chen:
UCLA
CENTI:R FOR TIlE HEALTII SCIENCES
10833 LE CO/'ITE AVENUE
LOS ANGELES. CAUFORNIA 90095 1747
(310) 825-6568
(310) 206-1318 (FAX)
I must thank you for a very pleasant and enlightening visit to Guangzhou and to
The Municipal Health and Anti-Epidemic Station. Both are very impressive. You
and Dr. Shi Wen lun were very kind to meet me at the train station and to take me
to the hotel and then see that I had lunch, and later in the evening to take me on a
driving tour of Guangzhou. The Pearl River, especially at night, is quite
impressive, and all of the lights and activity of the streets are quite amazing in that
it goes on and on with other activities such as the huge trade fair. Clearly,
Guangzhou is a major and dynamic center in China.
The afternoon meetings with Dr. Xiao Bin Quan and his associates Dr. Wang
Ming and Professor Xiu Qiong of the AIDS laboratory and Dr. Raoji Li, the
parasitologist, were quite impressive colleagues of yours. Also, I particularly
enjoyed talking with Dr. Xu Hui Fang, the epidemiologist, who clearly has an
important role in AIDS research in The Municipal Health Group. They were kind
to answer my many questions. It is clear that Dr. Xiao Bin Quan is a dynamic
leader. AJso, the Municipal Health and Anti-Epidemic Station is an interesting
place to work with many resources that should be of great assistance to you.
I was impressed with their interest in your proposal for Malarial Therapy. It .
seemed to me that there was substantial support for your work. The opportunity to
talk with so many of your colleagues was very valuable. They represent many
resources. Unfortunately, with all of the activities, there were one or two
questions that I had not had a chance to discuss with you. One has to do with
where the HIV+ patients in your Malarial Therapy study would be seen during the
febrile periods with malarial infection. Will they also be at a single hospital
during the time that they have malaria or will they be at home? Is there a
physician at one of the hospitals who is involved in this study, or are you entirely
responsible for the health of the patients during the time of the experimental
induction of malaria until its cure? A clear delineation of responsibilities and
roles of individuals participating in studies is important for the success of clinical
trials such as the one that you have proposed. I do understand that you have the
capacity to get the blood samples and see people in follow-up through the facilities
of the Anti-Epidemic Station.
I can see that you have established a good relationship with Dr. Yu Chun Shan,
Chief of the Central Laboratory at the Sun Yat-Sen University of Medical
Sciences and Hospital. It is not clear to me, however, that his technician has
agreed to accept HIV positive samples. He seemed extremely reluctant during the
time we visited there. I have seen this sort of problem before from technical
people. I am sending, separately, information about handling the samples in
relation to the machine. I hope that there are no further difficulties in having CD4
tests done there. Indeed, it would be very important to have blood samples from
some of your patients tested by flow cytometry and be sure that testing runs
smoothly before you start your critical induction of malaria. I believe Dr.
Heimlich will want reassurance on this point. It is possible that Emily Huang,
who is a very knowledgeable person in the Central Laboratory group, might be of
help. Certainly, she is more comfortable with spoken and written English than
Professor Yu.
Indeed, we will all be interested to know what the CD4 levels are in your patients
before therapy as well as in control subjects. You remember, I am sure that all
clinical trials in the USA obtain CD4 T cell measurements on two (2) blood
samples before starting the treatment.
I am writing to Dr. Heimlich about the use of intravenous drug abusers in the
study. I have talked to one of the leaders of the AIDS Clinical Trial Group in the
United States who assures me that most of the clinical trials in the United States
currently involve some HIV+ individuals with drug abuse. The requirement, of
course, is that they be able to stay on the protocol. I think this is less of a problem
in your case when the treatment period is a defined period of time. Could you
include at least 2 HIV+ non-IV drug abusers in the whole study, with the bulk of
2
the patients being drug abusers. It is important that you have a protocol for serial
evaluation before, during and after the Malarial Therapy and that the evaluation
includes assessments for other diseases such as TB, hepatitis or other infections.
Be sure to save plenty of plasma on each date, as you will need it for viral load
testing as well as other studies.
Again, I want to thank you for your courtesy and for a very stimulating visit in
Guangzhou.
'Dt f L ~ ~
John L. Fa ey, M.D. < . . ~
Union of Immunological Societies (lurS)
JLF/dm
P.S. Enclosed are copies of several pictures I took during my visit.
cc: Henry Heimlich, M.D.
Hong Bass, M.D., Ph.D.
3
John L. Fahey , M. D.
UNIVERSITY OF CALIFORNIA. LOS ANGELES
MICROBIOLOGY &. IMMUNOLOGY
LOS ANGELES. CALIFORNIA 90095. 1747
MG-13
.
J- '.,
Henry J. Heimlich, M.D. , Sc.D. "
President
I. "
----

"'rl ., "" ,
:
..
..
..
..
..
1111.111 .111111111111111111111111111111111111111111111111111 11
,
MEMORANDUM
November 20,1997
To:
cc:
From:
1.
2.
3.
4.
5.
David Mahoney
Ed Rover
Valerie Harper
I . ,.,.'.: "
The enclosed material Is a documented progress report on Dr. Heimlich's MIT. The
November 4th telephone conversation between Dr. Heimlich and Dr. Fahey and the letter
from Dr. Fahey to Dr. Chen which reviews his trip to China as well as his continued
support and involvement with MIT. In addition, I am including the latest NIH news
release re: HIV which says that HIV persists and "can replicate despite prolonged
combination therapy".
The next ten patients to be treated with MIT are available and the specific protocol
requested by Dr. Fahey is being organized. ;;,;4vovtV flcc It.};
Dr. Fahey believes that MIT has a sound, scientific rationalef"nd is since IL-2 is
an expensive. genetically engineered interieukin that causes "Severe reactions and must
be repeated every month or two in addition to being more costly.
It is clear that the Protease Inhibitor drugs have been successful in giving HIV patients
remlsAion without cum.
In conclusion. Dr. Heimlich would appreciate the opportunity for the three of us to discuss
either in person or on a conference call in December, some of the ideas he feels strongly
about re: the future strategy for MIT.
mailbox:/C%7C/Program% .. ms.edu.cn%20&number=12 mailbox:/C%7C/Program% . ms.edu.cn%20&number=12
1 of 1
SUbject: Send reagents
Date: Fri, 21 Nov 199708:03:39 +0800
To: "Najib Aziz" <naziz@ucla.edu>
CC: "Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
"Dr. Henry 1. Heimlich" <Heimlich@iglou.com>,
"Henry 1. Heimlich" <heimlich@juno.com>,
"Debbie" <dmathies@microimmun.medsch.UCLA.edu>
Dear Dr. Aziz:
Dr. Fahey'S visit to Guangzhou last month was very helpful to our project
of malariotherapy for HIV infection. Now we will start the next batch of
clinical trials very soon. So I hope that you send us the following
reagents as soon as you can by Federal Express or other express.
1. Kits for flow cytometry including CD4, CD8, CD25, HLA-DR and CD4 PCD
(apoptosis) testings.
2. Kits for activation markers including NPT, B-2-M, TNF-a, IFN-r,
sTNF-aRII, sIL-2R and plus sing IL-2 ( if possible, plussing IFN-a, IL-6 and
IL-10 ) testings.
By the way, I have now another hypothesis that malaria stimulates a shift
from Th2 to Th1 pattern of immune response in HIV patient. I believe that
it will be confirmed by our coming trials.
Best regards.
Dr. Chen Xiao Ping
Research Associate Professor
11/21/97 09:18:54
2368 VICTORY
PARKWAY
SUITE410
CINCINNATI
OHIO
45206
513-22HlOO2
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
............... - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: Valerie Harper
Fax: (212) 754-2892
Date: November 21,1997
Dr. Aziz is Dr. Fahey's assistant.
From the desk of...
mailbox:/C%7C/Program% .. ms.edu.cn%20&number=12 mailbox:/C%7C/Program% . ms.edu.cn%20&number=12
1 of 1
SUbject: Send reagents
Date: Fri, 21 Nov 199708:03:39 +0800
To: "Najib Aziz" <naziz@ucla.edu>
"Dr. Henry 1. Heimlich" <Heimlich@iglou.com>,
"Henry 1. Heimlich" <heimlich@juno.com>,
"Debbie" <dmathies@microimmun.medsch.UCLA.edu>
Dear Dr. Aziz:
Dr. Fahey'S visit to Guangzhou last month was very helpful to our project
of malariotherapy for HIV infection. Now we will start the next batch of
clinical trials very soon. So I hope that you send us the following
reagents as soon as you can by Federal Express or other express.
1. Kits for flow cytometry including CD4, CD8, CD25, HLA-DR and CD4 PCD
(apoptosis) testings.
2. Kits for activation markers including NPT, B-2-M, TNF-a, IFN-r,
sTNF-aRII, sIL-2R and plus sing IL-2 ( if possible, plussing IFN-a, IL-6 and
IL-10 ) testings.
By the way, I have now another hypothesis that malaria stimulates a shift
from Th2 to Th1 pattern of immune response in HIV patient. I believe that
it will be confirmed by our coming trials.
Best regards.
Dr. Chen Xiao Ping
Research Associate Professor
11/21/97 09:18:54
Juno e-mail printed Fri, 12 Dec 199709:49:44, page 1
Return-path: <chenxp@gzsums.edu.cn>
To: "Evelyn" <enajera@microimmun.medsch.UCLA.edu>
Cc: "Mathieson, Deborah" <dmathies@microimmun.medsch.UCLA.edu>,
"Henry J. Heimlich" <heimlich@juno.com>,
"Dr. Eric G. Spletzer" <egspletzer@hotmail.com>,
"Dr. Henry J. Heimlich" <Heimlich@iglou.com>,"NajibAziz" <naziz@ucla.edu>
Date: Fri, 12 Dec 199711:04:42 +0800
Subject: Reagent package
Message-ID: <199712120300.LAA01200@ gzsums.edu.cn >
X-Status: Read
X-Mailer: Microsoft Internet Mail 4.70.1155
Dear Evelyn:
We have just received the reagent package for testing sTNF-RIl and NPT
and
the enclosed letter model that you wrote to New Delhi Customs
authorities.
We have to pay customs tax this time. I suggest that you do not send
other
reagents untill we have delt with the customs tax-free procedure. It is
complicated in China and different from India. But I will let you know
this
as soon as possible. Thank you.
Merry Christmas and happy New Year!
Dr. Chen Xiao Ping
HEIMLICH
INSTITUTE
2368 VICTORY
PARKWAY
SUITE 410
CINCINNATI
OHIO
45206
513-22Hl002
fax 513-221-Q003
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
.............. - - - - - - - - - - - - - - - - - - - - - - - - - -
To: Valerie Harper
Fax: (212)754-2892
Just received this e-mail from Chen. It's a copy of a letter to Evelyn, John Fahey's
secretary. This will make it possible for Chen to get started with the patients.
Juno e-mail printed Fri, 12 Dec 199709:49:44, page 1
Return-path: <chenxp@gzsums.edu.cn>
To: "Evelyn" <enajera@microimmun.medsch.UCLA.edu>
Cc: "Mathieson, Deborah" <dmathies@microimmun.medsch.UCLA.edu>,
"Henry J. Heimlich" <heimlich@juno.com>,
"Dr. Henry J. Heimlich" <Heimlich@iglou.com>,"NajibAziz" <naziz@ucla.edu>
Date: Fri, 12 Dec 199711:04:42 +0800
Subject: Reagent package
Message-ID: <199712120300.LAA01200@ gzsums.edu.cn >
X-Status: Read
X-Mailer: Microsoft Internet Mail 4.70.1155
Dear Evelyn:
We have just received the reagent package for testing sTNF-RIl and NPT
and
the enclosed letter model that you wrote to New Delhi Customs
authorities.
We have to pay customs tax this time. I suggest that you do not send
other
reagents untill we have delt with the customs tax-free procedure. It is
complicated in China and different from India. But I will let you know
this
as soon as possible. Thank you.
Merry Christmas and happy New Year!
Dr. Chen Xiao Ping
mailbox:/C%7C/Program% .. ms.edu.cn%20&number=18 mailbox : /C%7C/Program% ... ms.edu.cn%20&number=18
Subject: Re: Patient selection
Date: Thu, 18 Dec 1997 08:27:41 +0800
To: <heimlich@iglou.com>
"Henry J. Heimlich" <heimlich@juno.com>
We have 20 HIV patients at hand, among them 3 are sexually transmitted and
others are drug users. The most important thing right now is that we are
waiting for the reagents from UCLA ( and we are dealing with the customs
issue ) to screen CD4 levels of the patients due to other criteria of
patient selection. According to the principal of scientific research, we
need the same batch ( or the same resource ) of reagents to test patients
before and after treatment. All things are progressing here in Guangzhou.
The number of tested and officially reported HIV positive patients in China
is about 2800 by now. All other numbers are estimated and I believe that
nobodies know the exact number. But we can say that HIV/AIDS has been a
real problem in China; in some regions such as Yunnan Province the problem
has been really severe.
Yes, we have received the funds from the Heimlich Instiute.
Merry Christmas!
Dr. Chen Xiao Ping
> From: Dr. Henry J. Heimlich <heimlich@iglou . com>
> To: chenxp@gzsums . edu . cn
> Subject: Patient selection
> Date: Thursday, December 18, 1997 6:57 AM
>
> Dear Dr. Chen,
>
> We received copies of the e-mail concerning the import of test
> reagents, and are glad to see that things are proceeding. However,
> we are still interested in knowing how patient selection is going,
> especially for the sexually transmitted cases.
>
> A recent lecture by R. Peter Piot , Executive Director of the UNAIDS
> program, stated the following:
>
> "In China - on the other hand, dramatic developments with consistent
> increase in HIV infections may be expectedin the coming future.
> The national AIDS committee in China just released estimates projecting
> the number of people living with HIV/AIDS rising from 400,000 at the
> end of 1997 to about 1.2 million by the year 2000. Whereas most of the
> HIV infections in the past occurred in inj ecting drug users, the
> dramatic increases in sexually transmitted diseases in China suggest
> that the main mode of transmission of HIV may rapidly change in the
> coming years. STDs are becoming particularly widespread in China's
> coastal regions with their booming economies, growing disparities in
> wealth, and vast population movements. A study in Yunnan Province,
> for example, has already shown how easily the epidemic can break out
> of the drug user group to their sex partners and ultimately their
> children. Here around 7% of the spouses of infected drug users are
> already infected with HIV. As elsewhere in Asia and the Pacific,
> where the tiger economies are bringing in new wealth, the potential
> also exists for an acceleration of the epidemic . "
>
. > Do you feel this is accurate?
>
1 of 2 12/19/97 08:48:12
rnailbox:/C%7C/Proqram% rns.edu.cn%20&number=18 rnailbox:/C%7C/Proqram% rns.edu.cn%20&number=18
2 of 2
> We hope that everthing else is going well for you and your colleagues.
>
~
> Happy holidays!
>
>
> Eric G. Spletzer. Ph.D.
>
> P.S. Did the funds we wired make to your account?
12/19/97 08:48:12
Dr. Chen has sent the enclosed progress report stating he has twenty patients ready for
treatment and is awaiting reagents from UCLA. His recent exchange with UCLA
indicates reagents have arrived.
As you wrote in your last letter, we have both been anxiously awaiting treatment of the
ten patients. The delay has been worthwhile because it is due to success of our project
beyond my greatest expectations. In addition to publishing our first paper, we have
gained acceptance of malariotherapy and affiliation with one of the leading experts on
AIDS immunology, Dr. John Fahey of UCLA.
This recognition led to the NIH-sponsored, two-month trip of Dr. Chen to UCLA for
training in the latest laboratory studies for AIDS and to development of a protocol for
testing patients that is so thorough it must be accepted by all experts in the field. The
NIH, through Dr. Fahey, is now providing reagents to Dr. Chen. Dr. Fahey made a
special trip to China and, as you know, wrote a glowing report on the facilities and the
caliber of scientists working with Dr. Chen.
During this period, it was officially documented that the highly touted drug treatment of
AIDS is not a cure and is failing to hold back the virus in fifty percent of cases. We have
the only existing treatment with the potential for cure.
When we first spoke, I advised it would take one-and-a-half million dollars to prove the
effectiveness of malariotherapy and I have no reason to change that figure. The sooner
we can obtain the balance of that amount, the quicker we can treat one hundred patients
and prove we have the ability to cure HIV infection. The Chinese will act much more
rapidly when they know we are prepared to do this since it takes just as many
professionals and, just as much laboratory and clinical equipment, to treat ten patients as
to treat one hundred, particularly since the reagents are available.
I hope you will consider raising these funds through those who hold you in such high
regard for your knowledge and accomplishments in the world of medical science.
With warm regards and friendship,
,
i ~ )

VALERIE HARPER
139 E. 94tb Street
212-289_0747
<.
? B
OM f . OU(
QW OW' D().r D8C4t " u.\
.
C\D
Juno e-mail printed Tue, 13 Jan 199820:16:46, page 1
From: "Najera, Evelyn" <ENAJERA@microimmun.medsch.ucla.edu>
Return-path: <ENAJERA@microimmun.medsch.ucla.edu>
To: Chen Xiao Ping <chenxp@gzsums.edu.cn>
Cc: "Mathieson, Deborah" <DMATHIES@microimmun.medsch.ucla.edu>,"HenryJ. Heimlich" <heimlich@juno.com>
Date: Mon, 12 Jan 98 12:04:00 PST
Subject: Reagents and customs
Message-ID: <34BA77 A9@deans.medsch.ucla.edu>
X-Status: Read
X-Mailer: Microsoft Mail V3.0
Dear Dr. Chen:
I hope you are having a pleasant beginning in 1998. Thank you for the
photos and for your wishes. I will also forward the photos to Matt which
I
am sure he will be pleased to receive.
Thank you for sending such thorough explanation on your customs
situation.
You may also want to speak with 2 of our trainees in China conducting
work
there. They have been able to obtain clearance through customs with the
same documentation I provided to you and DHL. They may be able to
provide
some advise on the procedure from their end:
1) Dr. Hong Wang-School of Basic Medical Sciences
Tel. 86-106-209-1155
Fax 86-106-209-1436
2) Dr. Xudong Lin-Chinese Academy of Preventive Medicine
Tel. 86-106-353-8621-71
Fax. 86-106-302-2960
In the meantime, I will discuss this issue with Dr. Fahey and we will be
in
touch with you.
Best Regards,
Evelyn
From: Chen Xiao Ping
To: Mathieson, Deborah
Cc: Najib Aziz; Dr. Eric G. Spletzer; Dr. Henry J. Heimlich; Evelyn;
Henry
J. Heimlich
Subject: Reagents and customs
Date: Wednesday, January 07,1998 9:18AM
Dear Dr. Fahey:
It is complicated to deal with customs duty-free in China. We have not
known the procedure until just now. We need in advance your donation
letter
( by express, not by fax) in which all reagents and their values should
be
.)
2 3 6 8 V I C T O R Y
P A R K W A Y
S U I T E 4 1 0
C I N C I N N A T I
O H I O
4 52 0 0
513-221-(0)2
l ax 513-221{(X )3
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
J anuary 23, 1998
Chair, Cl inical Immunol ogy Committee, International Union of Immunol ogical Societies
University of Cal ifornia
Department of Microbiol ogy and Immuno!ogy\UCLA School of Medicine
Center for Heal th Sciences
Dear J ohn:
It was good speaking with you the other day.
Encl osed is the paper we have written and Peter Piot's speech. I anticipate your
comments.
We seem to beprogressing nicel y in China and I aml ooking forward to my visit there.
What woul d you think of extending thetreatment to other Asian countries such as India,
Thail and or the Phil ippines? Woul d any of the doctors with whom you work in those
areas be interested?
To bring you up-to-date on my heal th, encl osed is one articl e that appeared after El ection
Day. The picture makes me l ook as ifI amin a straight jacket! Some write-ups and TV
reports sounded l ike an obituary, but as Mark Twain said more than 100 years ago, in
1897, "The rumors of my death aregreatl y exaggerated." My cardiac exams came out
100% normal , but I missed my trip to South Africa. Having had a week of skiing two
weeks ago, and my reg~ennis games, I can't compl ain.
/7
Wi best wis!l e(/
~Jl J . Heiml ich, M.D., ScD.
.IPresident
encl .
2368 VICTORY
PARKWAY
SUITE 410
CINCI NNATI
OHIO
45206
513-22HXlO2
fax 513-221-0003
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
.............. - - - - - - - - - - - - - - - - - - - - - - - - - -
To:
Of:
Fax:
Pages:
Date:
Valerie Harper
(212) 754-2892
April 21, 1998
Vicki Roberts
Associate Director
Dr Alan 8 Stone
Dr Henry J Heimlich MD DSc
Medical Research Consultant
38 Hollycroft Avenue LONDON NW370N
mail alan.stone@headoffice.mrc.ac.uk
Telephone & Fax: 01714318532
The Heimlich Institute Foundation Incorporated
Suite 410
USA
Dear Dr Heimlich
People to People Ambassadors Program: AIDS expert delegation to China
I was very sorry indeed to hear that you were unwell , but your being unable to lead the
above delegation gave me the opportunity to do so! I have just returned from China
and thought you might like to have a copy of my brief report (enclosed).
I thought you might be especially interested in our experience of the malariotherapy
work which you yourself initiated. Our view of this is covered in Section 13 of the
report. It is of course difficult to carry out a proper clinical trial in China, not least
because the necessary patient numbers are not available. What struck me most about
this approach is that (a) there is a solid rationale for it and (b) ifit works in HIV
infection it may be the only available treatment for most of the developing world,
where drug ' cocktails' are too expensive to contemplate.
I mentioned to our colleagues in Guangzhou that I would approach the UN AIDS
Programme and WHO about the possibility of collaboration (and funding) for a well-
designed malariotherapy trial. I have no idea at this point as to how they might react to
this suggestion. Naturally, nothing is guaranteed, but I will certainly try my best.
With best wishes
Yours sincerely
Alan Stone
",
LE
375 Park Avenue
New York, New York
10152
(212) 754-2890
FAJ212) 754-2892
TrusteeS
David Mahoney,
Chainnan
A. J. SignOlile,
Treasurer
Roben A. Good, M.D.
Carlos Moseley
Roben E. WISe, M.D.
June I, 1998
The Goetze Center
415 Straight Street
Dear Hank:
Valerie has advised me that your Institute has now
become affiliated with The Deaconess Hospital in
cincinnati. It is a fine organization and you should be
very pleased.
Keep up the good work. I am glad you are back safely
from Iran. Give our best to Jane.
Warmest best wishes,
~ ~
DM/pm
cc: Ms. Valerie Harper
I St-RA:lqltr 01
off

Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
...............
To: Valerie Harper
Fax: (212) 754-2892
Pages: 2, induding this cover sheet.
Date: June 23, 1998
The following is FYI.
Vicki Roberts
Associate Director
BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DI EGO SAN FRANCISCO
June 15, 1998
Deaconess Hospital
311 Straight Street
Dear Henry,
UCLA
LOS ANGELES. CALIFORNIA 90024-1747
(310) 825-6568
(310) 206-1318 (FAX)
I was interested to catch up on your many activities. The move to Deaconess Hospital sounds
like an advantageous change for you. The trip to Iran must have been interesting. I was glad to
hear that things were opening up there again but not surprised to hear that you were again leading
the way.
I was pleased to discuss the progress that Chen Xiao Ping is making in Guangzhou. We do look
forward to seeing the data that he has supplied to you and Eric Spletzer.
The issue of the viral load measurements is one which we will be glad to help with. We can do
the tests at UCLA but we need 2ml of plasma. I do not know if Chen Xiao Ping has made other
arrangements for viral load measurements in China. If he has, we would like to know that the lab
is experienced and satisfactory. We certainly would want to check some of the samples at
UCLA. However, we can do them all but they could be sent to us perhaps 4-6 months into the
study so that the samples could be tested in a batch style. We will be in contact with Chen Xiao
Ping about arrangements to send the samples. Of course, we would want a small number of
samples to be sent first to be sure the process of shipment works all right and I think it will take
several months to work this out. We have supplied reagents to him in the past. However, we
would appreciate assistance with the cost of the viral load test. They cost about $175 each
because of the cost of the reagents and the equipment. We will be glad to share this with you
50:50. It would certainly be of great help to us.
In considering other possible sites for malarial therapy, I would like to wait until this study is
further along and we have good data on the findings in the current study. I will be glad to discuss
this with you a bit further on.
With best regards, I remain sincerely yours,
QL
John L. Fahey, M.D. -!
Union oflmmunological Societies (lUIS)
JLFlkw
cc: Naj ib Aziz
BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DI EGO SAN FRANCISCO
June 15, 1998
Deaconess Hospital
311 Straight Street
Dear Henry,
UCLA
LOS ANGELES. CALIFORNIA 90024-1747
(310) 825-6568
(310) 206-1318 (FAX)
I was interested to catch up on your many activities. The move to Deaconess Hospital sounds
like an advantageous change for you. The trip to Iran must have been interesting. I was glad to
hear that things were opening up there again but not surprised to hear that you were again leading
the way.
I was pleased to discuss the progress that Chen Xiao Ping is making in Guangzhou. We do look
forward to seeing the data that he has supplied to you and Eric Spletzer.
The issue of the viral load measurements is one which we will be glad to help with. We can do
the tests at UCLA but we need 2ml of plasma. I do not know if Chen Xiao Ping has made other
arrangements for viral load measurements in China. If he has, we would like to know that the lab
is experienced and satisfactory. We certainly would want to check some of the samples at
UCLA. However, we can do them all but they could be sent to us perhaps 4-6 months into the
study so that the samples could be tested in a batch style. We will be in contact with Chen Xiao
Ping about arrangements to send the samples. Of course, we would want a small number of
samples to be sent first to be sure the process of shipment works all right and I think it will take
several months to work this out. We have supplied reagents to him in the past. However, we
would appreciate assistance with the cost of the viral load test. They cost about $175 each
because of the cost of the reagents and the equipment. We will be glad to share this with you
50:50. It would certainly be of great help to us.
In considering other possible sites for malarial therapy, I would like to wait until this study is
further along and we have good data on the findings in the current study. I will be glad to discuss
this with you a bit further on.
With best regards, I remain sincerely yours,
QL
John L. Fahey, M.D. -!
Union oflmmunological Societies (lUIS)
JLFlkw
cc: Naj ib Aziz
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@igloucom
Benefiting
Humanity
Through
Health
and
Peace
June 22, 1998
Mr. David Mahoney
375 Park Avenue, Suite 3807
New Y o r ~ New York 10152
Dear David:
Thank you very much for your good wishes. Being affiliated with Deaconess greatly
expands our research potential. Most importantly it establishes The Heimlich Institute as a
permanent institution. We have been provided with a fine facility and moved in
June I
S
[ .
An e-mail from Dr. Chen today says "A piece of good news is that the results of post-
treatment CD4 tests by flow cytometry are very good with no clinical complication in our
10 new cases." Laboratory studies are being done in China and in Dr. Fahey's
laboratories at UCLA
Iran was a most interesting and gratifying experience. Everyone knew the Heimlich
Maneuver, and the people were warm and friendly to me. I spoke at nine institutions -
The Iranian Life Saving Federation, Universities, Hospitals, and Medical Colleges.
Congratulations on the national attention your fine book is getting. Seeing the picture of
you presenting a copy to Hillary Clinton was most impressive.
Janejoins me in sending our love to you and Hillie, and hope to see you soon.
Sincerely,
c.c. Valerie Harper
Affiliated with The Deaconess Associations, Inc.
DEACONESS AssOCIATIONS
311 Straight Street Cincinnati, Ohio 45219
FOR IMMEDIATE RELEASE
(513) 559-2100
CONTACT: Barbara Lohr or
- Bryan E. Wright
(513) 559-2760
National Health System Steps up to
Promote Work of Renowned Lifesaver
(JUNE 30, 1998) -- A joint endeavor unveiled today will ensure the long-term continuation of the
work of one of the century's most influencial physicians. The Heimlich Institute, directed by
founder and namesake Henry Heimlich, M.D., recently became a member of Deaconess
Associations, Inc., a national health system based in Cincinnati.
Through the partnership, Deaconess will assume responsibility for advancing and promoting the
mission and vision of the Heimlich Institute in perpetuity. Why? According to Deaconess president
and chief executive officer E. Anthony Woods, inviting the Institute on board gave the health system
a rare opportunity to positively impact people throughout the world.
"Deaconess and the Heimlich Institute share a common commitment to values such as
compassion, creativity and service," Woods said. "We felt that Dr. Heimlich's innovative spirit and
caring tradition should be preserved and advanced for the benefit of future generations."
Dr. Heimlich is best known for developing the Heimlich Maneuver, a technique used since the
1970s to save choking victims worldwide. He also invented the Heimlich Chest Drain Valve, which
was first used during the Vietnam War to save the lives of soldiers and civilians on both sides. The
device continues each year to save thousands of people with chest wounds who would otherwise die
from fluid and air buildup resulting in a collapsed lung.
Originally founded in New York in the 1960s, the Heimlich Institute moved to Cincinnati 30
years ago. Now located on the campus of Deaconess Hospital in Cincinnati, the Institute continues to
conduct scientific, cultural and social research into issues of importance to the medical and scientific
community, as well as addressing social concerns in the United States and abroad.
(MORE)
HEIMLICH / DEACONESS
JUNE 30, 1998
2-2-2-2
"I welcome the opportunity to work with Deaconess Associations," said Dr. Heimlich. "This
affiliation ensures that the Heimlich Institute will always be led by creative scientists who will
continue to seek logical, frequently simple, methods of saving lives."
Through the Heimlich Institute, Dr. Heimlich is now researching new treatments for AIDS and
cancer, and he is teaching the use of the Heimlich Maneuver to save drowning victims and asthma
sufferers.
Dr. Heimlich is also working to promote peaceful solutions to international problems through the
Heimlich Institute's "A Caring World" program. In May, he traveled to Iran to speak with Iran Life
Saving Federation members and healthcare professionals, as well as college students and faculty, to
gather their insight on the relationship between Iran and the United States. His visit was subsequently
detailed in the Iran News.
Deaconess Associations, Inc. is a multi-faceted, not-for-profit healthcare system which provides
a diversity of health services nationwide. In addition to the Heimlich Institute, key divisions include
Deaconess Hospital of Cincinnati, Deaconess Long Term Care, Inc., Deaconess HomeCare, Inc.,
MCH Services and the Deaconess Health Associations Fund.
-- 30 --
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
July 8,1998
Ms. Valerie Harper
375 Park Avenue
New York, NY 10152
Dear Valerie,
In keeping with our telephone discussion last week, I have, as you requested, summarized
for the files our progress re Malaria Therapy (MT uses Malaria Vivax which is curable, as
opposed to the virulent Falciparum Malaria.).
Background
The following is a brief recap of the past two years:
The initial funding began in June of 1996 by the Eleanor Naylor Dana Charitable
Trust. The $250,000 granted to date covers the second group of ten patients
presently undergoing treatment.
Presentation of the MT abstract at the Worldwide AIDS Conference 1996 in
Vancouver.
At the Worldwide AIDS Conference, Dr. John Fahey of UClA, approached Dr.
Heimlich to request a collaboration between himself, UCLA and Dr. Heimlich.
In 1997, Dr. Chen, who spearheads the Heimlich MT clinical trials in China, at
the invitation of Dr. Fahey of UCLA, spent two months at UCLA to establish a
uniform blood-testing protocol for MT treatment in China.
MT boosts the immune system increasing the CD4 T-cells of the HIV patients we
treated. With no other treatment given, this increase of CD4 T -cells persisted
for two-to-three years after the three-week course of MT was completed.
Present Status
Dr. Chen, who has been in charge of the Heimlich MT clinical trials in China, has
been appointed Director of the Center for AIDS Control and Research in
Guangzhou.
Affiliated with The Deaconess Associations, Inc. ~
--
As of June 1998, nineteen patients have been treated with MT in China.
Eight of the first nine HIV -positive patients treated with MT are, clinically
free of HIV after three years (one died of unrelated causes).
As of July 1998, the results of the CD4 test flow cytometry of the ten patients
treated with MT in June of 1998, are very good with no evidence of clinical
complications. '
If the ten patients currently being treated with MT are clinically free of HIV after
six months, Dr. Fahey has agreed to treat U.S. patients with MT who have not
responded to the present drug therapy now available in the U.S.
This would perhaps be an appropriate time to approach your friend, Dr. Henri
Meier of Hoffman La Roche in Switzerland, with the idea of trying to chemically
replicate the curative properties of malaria parasites (Vivax) which
strengthens the immune system.
You will recall my saying that drugs have never cured a virus, even a cold.
Recognizing the failure of drugs, the NIH scientists and others who have spent billions
researching drugs, immediately came up with developing a vaccine, another billion dollar
expenditure. Scientists estimate that developing a vaccine will take ten years or more.
In any case, a vaccine will not cure the thirty-four million already infected with HIV. In
reporting on the 1998 Worldwide AIDS Conference in Geneva, The New York Times
headline stated, "AIDS MEETING ENDS WITH LITTLE HOPE OF
BREAKTHROUGH - Drugs and Vaccines Have Had Setbacks, and Politics Has
Hindered Other Efforts".
MT has the strongest rationale for the successful treatment of HIV infected patients and it
can be offered to the world at little cost. As mentioned above, we have started treatment
on ten new patients. Early results are favorable and the treatment has proven safe.
When I first spoke with David, I said it would take $1.5 million to complete studies that
prove the value of MT. That figure has not changed. We owe it to the millions who are
dying of HIV infection to obtain those funds now and treat enough patients to prove the
validity of MT. With additional funds, we can make arrangements to treat HIV patients
in the U.S., particularly those who have undergone drug treatment that failed. Dr. Fahey
agrees with this.
In the early 1950's, U.S. medical authorities tried to prevent Jonas Salk from testing his
,
polio vaccine. Clinical trials were undertaken because Basil O'Connor, founder of the
Polio Foundation, fought the medical establishment on Salk's behalf. MT requires the
same kind of courage.
As you know, The Deaconess Associations, Inc., a national health corporation which
consists of twenty-seven institutions in eleven states, invited The Heimlich Institute to
become a part oflhe prestigious Deaconess Hospital in Cincinnati. We moved into
our new quarters last month. This affiliation established the Institute in perpetuity
and our work will continue after I am gone.
In the event David obtains the use of the VA hospital he has in mind for treating patients,
the Deaconess Associations, Inc., will be invaluable in organizing staff and
administration of the hospital.
I hope you will discuss with David the importance of raising the funds needed at this
time. Such funds will enable us to enlarge our clinical trials and save the world from this
epidemic.
Henry 1. Heimlich, M.D., SeD.
President
DEACONESS FOUNDATION
3 11 Straight Street Cincinnati, Ohio 45219
July 14, 1998
Ms. Valerie Harper
375 Park Avenue
New York, NY 10152
Dear Ms. Harper,
(5 13 ) 559-2323
Fax (513) 475-5057
I thought that you might be interested in receiving a copy of our recently published
1977 Annual Report in addition to several articles regarding Dr. Heimlich. They will provide
you with an introduction to our corporation prior to your visit.
We are very excited about Dr. Heimlich and The Institute joining us and look forward to meeting
you next week.
Have a safe and pleasant trip.
Sincerely,
Charles P. McDowell
President
Serving Th e Deaconess AssociaLions, Inc.
l i E I M U C H
I N S T I T U T E
X A V I E R
U N I V E R S I T Y
3 8 0 0 V I C T O R Y
P A R K W A Y
C I N C I N N A T I
O H I O
4 5 2 0 7
5 1 3 7 4 5 1 0 9 9
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
J ul y 20, 1988
Madi s on, NJ 07940
Re: Repor t f or t he year endi ng J une 30, 1988.
Dear Er i c:
The $25, 000 f our t h i ns t al l ment of t he gr ant f or t he cl i ni cal t r i al i n
Mexi co, " Mal ar i at her apy f or Cancer , " has been r ecei ved and i s gr eat l y
appr eci at ed by ~he Hei ml i ch I ns t i t ut e Foundat i on. Encl os ed ar e t he
det ai l ed r epor t s of expendi t ur es and copi es of cancel l ed checks f or $30, 000
t o t he I ns t i t ut o Naci onal de Cancer ol ogi a ( I . N. C. ) . Al l expens es ot her
t han payment s t o t he I . N. C. ar e made Under t he aus pi ces of Xavi er
Uni ver s i t y and ar e s ol el y t i ed t o t he Mexi can r es ear ch. Not e t hat
per s onnel s al ar i es have di mi ni s hed i n r ecent mont hs as l es s t i me has been
r equi r ed of empl oyees .
Expens es ar e wi t hi n t he f r amewor k of or i gi nal expect at i ons and wi l l l as t
f or t he 18 mont hs budget ed. Subs t ant i al gr ant f unds have had t o be
ut i l i z ed, however , due t o del ays beyond our cont r ol or t hat of t he Mexi can
phys i ci ans ; dur i ng t hat per i od, s al ar i es and ongoi ng expens es cont i nued, as
di d r es ear ch. The medi cal l i t er at ur e i s r egul ar l y s canned by Dr . Car r and
anal yz ed, and a r es ear ch paper i s bei ng compl et ed t hat you wi l l s oon
r ecei ve.
The del ays encount er ed coul d not be ant i ci pat ed and ar e cons i s t ent wi t h
medi cal exi genci es r el at ed t o s t ar t up of or i gi nal r es ear ch wher e cl i ni cal
exper i ence mus t be gai ned as t r eat ment pr ogr es s es . Fi r s t , t he Mexi can Ci t y
phys i ci ans had t o es t abl i s h a s our ce of Pl as modi um vi vax mal ar i a i n ot her
pr ovi nces , ar r ange f or obt ai ni ng mal ar i al bl ood donor s , and cr eat e a s ys t em
f or pr es er vat i on and t r ans f er of t he mal ar i al bl ood. Cancer pat i ent s wer e
t hen s el ect ed i n keepi ng wi t h t he pr ot ocol . Over a per i od of t i me t he
f i r s t t hr ee t er mi nal cancer pat i ent s vol unt eer ed f or mal ar i at her apy.
Pat i ent #1, a f emal e wi t h ext ens i ve r ect al cancer , met as t at i c, r ecei ved t he
f i r s t mal ar i al bl ood t r ans f us i on i n December . Mal ar i a f ever di d not occur
and af t er a mont h a s econd mal ar i al t r ans f us i on was gi ven. A t ot al of f our
at t empt s t o i nduce mal ar i a wer e uns ucces s f ul and af t er t hr ee t o f our mont hs
t he pat i ent l ef t t he hos pi t al and, as a r es ul t of t he advanced s t age of her
cancer , di ed at home t wo weeks l at er . Di f f i cul t y i n i nduci ng mal ar i a may
be r el at ed t o an i nadequat e concent r at i on of par as i t es i n t he donor bl ood,
damage t o cel l s dur i ng t r ans f er , or t he pat i ent ' s r es i s t ance bas ed on
pr evi ous bout s of mal ar i a. Anot her pos s i bi l i t y i n l i ne wi t h our concept i s
t hat t he mas s i ve t umor s conveyed an i mmunol ogi cal r es pons e agai ns t t he
mal ar i a i n t he s ame manner t hat t he mal ar i a wor ks agai ns t cancer .
Pat i ent #2, mal e, had mel anoma wi t h met as t as es t o t he gr oi n and l ungs .
Pat i ent #3, mal e, has col on cancer wi t h r ecur r ent cancer i n t he pel vi s ,
pl us l ung met as t as es . Bot h pat i ent s over a per i od of s ever al weeks
r
Page 2
r ecei ved t hr ee mal ar i al bl ood t r ans f us i ons wi t hout i nduct i on of cl i ni cal
mal ar i a. The f our t h t r ans f us i on i nduced mal ar i a i n bot h pat i ent s . Our
Mexi can col l eagues at t r i but e t he s ucces s f ul i nnocul at i on t o i nt r avenous
i nj ect i on of ver y f r es h mal ar i al bl ood and t he i ncr eas e i n mal ar i al
par as i t es i n t he bl ood obt ai ned dur i ng t he r ai ny s eas on.
Pat i ent #3 compl et ed mal ar i at her apy and has r et ur ned home. Ches t xr ays
s howed pos s i bl e s hr i nkage of cancer nodul es . He wi l l be r epor t i ng t o t he
Nat i onal Cancer I ns t i t ut e, Mexi co Ci t y f or f ol l ow- up.
Pat i ent #2 expi r ed as he was compl et i ng a mont h of mal ar i at her apy. Deat h
was due t o exi s t i ng wi des pr ead met as t as es . Aut ops y pr ovi ded val uabl e
i nf or mat i on. Met as t at i c t umor s i n t he l ungs s howed ext ens i ve necr os i s
( deat h of t umor cel l s ) . Thi s necr os i s i nvol ved ext ens i ve ar eas i n t he
per i pher y of cancer nodul es . Tumor cel l s r emai ned onl y i n t he cent er of
t he nodul es . Dr ; Abel ar do Menes es Gar ci a, pat hol ogi s t at t he I . N. C. ,
pr oj ect ed t he s l i des of t umor nodul es , and s t at ed t hat i n t hei r i ns t i t ut e,
whi ch has ext ens i ve exper i ence wi t h mel anoma, per i pher al necr os i s has never
been s een.
The s l i des wer e s hown t o Dr . Lawr ence VonKos t er , Pr of es s or of Pat hol ogy,
Uni ver s i t y of Ci nci nnat i , s peci al i s t i n mel anoma, wi t hout f i r s t t el l i ng hi m
of t he mal ar i at her apy. He was s hown s l i des of t umor bi ops i es bef or e
t r eat ment and t hen s ubs equent t o mal ar i at her apy. Dr . VonKos t er had
pr evi ous l y s een nei t her per i pher al necr os i s of mel anoma nodul es nor s uch
ext ens i ve necr os i s .
Dr . Car r has been r es ear chi ng t ext s and medi cal l i t er at ur e concer ni ng
mel anoma and f ound t hat per i pher al necr os i s i s r ar e and occur s i n r el at i on
t o i mmune r eact i ons .
The f i ndi ngs i n Pat i ent #2 s t r engt hen t he concept t hat mal ar i a t her apy
des t r oys cancer cel l s , and t hat i t may act t hr ough i mmune r eact i ons as wel l
as hyper t her mi a. The s ucces s f ul r es ul t s have encour aged Dr . Bel t r an,
Di r ect or , I ns t i t ut o Naci onal de Cancer ol ogi a, t o of f er t o s el ect pat i ent s
wi t h l es s advanced cancer and wi t h cancer s known t o r eact f avor abl y t o
s t i mul at i on of i mmuni t y.
Al t hough t her e wer e unavoi dabl e del ays , we have gai ned t hi s val uabl e
i nf or mat i on t hat mi ght not have been f or t hcomi ng had 20 pat i ent s been
t r eat ed car el es s l y. Our Mexi can count er par t s have exhi bi t ed cour age,
br i l l i ance, and per s i s t ence i n t he f ace of s eemi ngl y adver s e ci r cums t ances .
We can al l be pr oud of our r el at i ons hi p wi t h t hem.
I n pr evi ous communi cat i ons you have r ecei ved l et t er s f r om t he Bei j i ng
Cancer I ns t i t ut e, Bei j i ng, Chi na and a t el ex f r om I ndi a i ndi cat i ng i nt er es t
i n par t i ci pat i ng i n t hes e cl i ni cal t r i al s . Thes e communi cat i ons i l l us t r at e
t he i ncr eas i ng accept abi l i t y of t he pr i nci pl es of our pr oj ect . I ndi a
advi s es t hat many of t hei r cancer pat i ent s r equi r i ng bl ood t r ans f us i on
r ecei ve mal ar i al bl ood, t her ef or e, pr epar at or y t i me can be avoi ded and
r et r os pect i ve i nf or mat i on gat her ed and anal yz ed. Chi na of f er s a degr ee of
exper i ment al cont r ol not avai l abl e el s ewher e. On Monday, J ul y 18, 1988, I
r ecei ved a phone cal l f r om Dr . Xu, di r ect or of t he Bei j i ng Cancer
I ns t i t ut e, who i s i n Was hi ngt on, D. C. as gues t of our Nat i onal Cancer
,
Page 3
I ns t i t ut e of t he N. I . H. Dr . Xu wi s hes us t o vi s i t Bei j i ng i n Oct ober t o
di s cus s es t abl i s hi ng mal ar i a t her apy f or cancer t her e. He wi l l have ' an
of f i ci al i nvi t at i on s ent f r om t he gover nment of Chi na on hi s r et ur n next
week.
The Ri ppel Foundat i on has s uppor t ed t hi s wor k pat i ent l y. We have al l had
s ome t r epi dat i on as i t s eemed t o f al t er - - awai t i ng CDC cooper at i on, I . N. C.
appr oval , and i ni t i al cl i ni cal r es ul t s - - t hen each s t ep r es ul t ed i n
accept ance and pr ogr es s . How l ong does i t t ake t o f i nd a cur e f or cancer ?
We ar e al r eady ahead of met hods f or whi ch bi l l i ons of dol l ar s and decades
wer e s pent wi t h no decr eas e i n t he cancer r at e f or 50 year s . I bel i eve i n
t hi s pr oj ect and, as al ways , wi l l cont i nue t o par t i ci pat e wi t hout
compens at i on. I hope and t r us t t hat , i n t he next f ew year s , we wi l l s ee
t he s ucces s f ul r es ul t s t owar d whi ch we appear t o be headed, and t hat t he
Ri ppel Foundat i on wi l l cont i nue t o gr aci ous l y s uppor t t hi s wor k.
enr y Hei ml i ch, M. D. , Sc. D.
r es i dent , The Hei ml i ch I ns t i t ut e
Pr of es s or of Advanced Cl i ni cal Sci ences
Xavi er Uni ver s i t y
HJ H/ nc
Enc.
Time
9:00 - 9:30 a.m.
9:30 - 10:00 a.m.
10:00 - 10:30 a.m.
10:30 - 11:30 a.m.
12:00 - 2:00 p.m.
2:00 - 3:00 p.m.
3:00 - 4:00 p.m.
VALERIE HARPER
THE ELEANOR NAYLOR DANA CHARITABLE TRUST
Visit Schedule - Wednesday, July 22,1998
Host
Charles McDowell
President, Deaconess Foundation
Tim Crowley
Chief Operating Officer
Barbara Lohr
Director, Corporate Mktg. &
Communications
Dr. Heimlich and Eric Spletzer
Jim Pahls
Chairman, Board of Trustees
Heimlich' s Residence
Open House
Activity
Review Foundation, Deaconess History,
Organization Structure, Connection with
Heimlich Institute
Deaconess Hospital Operations and
Services
Tour - Hospice and Hospital Operations
Research Project
Lunch, Board of Trustees Review,
Deaconess Associations, Inc. Mission
and Future Plans
. )
Bardes, June
Barrows, Winnie
Bernstein, Shirley
Briggs, M/M Peter
Budig, Otto M., Jr.
Capuder, Corrine & Daughter
Carr, Ray & Kathy
Collier, Peggy
Collier, Phyllis
Crowe, James
6J ~ . : f l t IN J v /) I i1-t
I
Dehner, Joseph
Economou, Bob & Carole (?)
Gall, John & Nydia
Gandersman, Nancy
Gardner, Ted & Naomi
Gertrude
Goodwin, John
Harper, Valerie
Harrington, Sr. Jean Patrice
Hatki, Anna Mae
OPEN HOUSE
JULY 22,1998
HI Board of Trustees
HI Board
President, HI Board of Trustees
(Deaconess)
Phil Heimlich's Assistant
Dana Foundation
Deaconess
Heimlich, Jane
Heimlich, Phil
Helfrich, Reverend Herman J.
Horwitz, M/M Harry (?)
Jones, Dorsey & Kathy Collins
Jones, Judge Nathaniel
Kenworthy, Marlene
McDowell, Charlie
Malloy, Terri
Messer, Mari
Moll, William
Moore, Jacqueline & Alex
M l/ Je S ( ' 1 ) ~ - ; t t
N eergaard, M/M Richard
Nerish, Dorothy
Pahls, Jim & Kathy
Richardson, Melody
Sauer, Shirley
Sternberger, M/M Claudio
Stolley, M/M Alex
Vogel, Rick
VP HI Bd of Trustees,Cincinnati Council Member
Deaconess
President, BankOne
(Deaconess)
"
President/General Mgr. Channel 12
HI Supporters
HI Contributor
Deaconess
President, Deaconess Auxiliary
HI Board
X A V I E R
U N I V E R S I T Y
3 8 0 0 V I C T O R Y
P A R K W A Y
C I N C I N N A T I
O H I O
4 5 2 0 7
5 1 3 7 4 5 1 0 9 9
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
J ul y 22, 1988
Madi s on, NJ 07940
Dear Er i c,
Thanks f or f axi ng me t he l et t er f r om Pet t i t . I t onl y t akes t hr ee days f or
a f ax t o r each me s i nce i t goes t o a f r i end who mai l s i t t o me!
Dr . Pet t i t ' s des cr i pt i on i s qui t e t ypi cal of t hos e who ar e i nvi t ed t o
l ect ur e i n Chi na, but , of cour s e, he i s not awar e of my r el at i ons hi p wi t h
t hat count r y. As he i ndi cat es , we don' t expect t o l ear n much f r om t he
t r i p, but t hat i s not our pur pos e, nor , wi t h my exper i ence i n Chi na, do we
need " cul t ur al i nf us i ons . " Wear e goi ng t o Chi na. t o s et up t he
mal ar i a t her apy pr ogr am. When I was l as t i n Chi na, I s aw a i as er t her apy
t r eat ment f or s ki n cancer bei ng car r i ed out i n Henan Pr ovi nce i n
col l abor at i on wi t h t he Uni ver s i t y of Roches t er and i t was pr ogr es s i ng wel l
- - t her e ar e s o many pat i ent s avai l abl e.
Ther e ar e i nvi t at i ons and t her e ar e i nvi t at i ons . I t i s one t hi ng t o know
s omet hi ng about Chi na and anot her t o know Chi nes e f r i ends . The Chi nes e
have never f or got t en my wor k wi t h t hem i n Wor l d War I I and, i n 1984,
honor ed me wi t h a di nner at t he Gr eat Hal l of t he Peopl e t wo days af t er
Pr es i dent Reagan had hi s di nner t her e. The Chi nes e never f or get - - t hey
r each out wi t h gr eat er war mt h and cooper at i on t han even t hat we have
r ecei ved i n Mexi co.
As you know, Dr . Hua ( r ef er r ed t o by Dr . Pet t i t by hi s f i r s t name, Hong
Shun - - Chi nes e f ami l y names ar e s t at ed f i r s t ) , a hi ghl y r es pect ed Chi nes e
s ur geon, came t o Ci nci nnat i t wo year s ago as a f el l ow t o obs er ve my wor k.
He was r es pons i bl e f or s pr eadi ng t he Hei ml i ch Maneuver i n Chi na and my name
i s known t hr oughout t he count r y as a r es ul t . Hi s f r i ends head var i ous
medi cal s chool s as wel l as t he Mi ni s t r y of Heal t h. As I wr ot e i n my r ecent
r epor t , Dr . Hs u, Di r ect or of t he Bei j i ng Cancer I ns t i t ut e, r ecent l y s t opped
t o vi s i t Dr . Hua ( who now l i ves wi t h hi s f ami l y i n Los Angel es - - hi s wi f e
i s an obs t et r i ci an) . Dr . Hs u t ook t i me t o phone me f r om Was hi ngt on when
vi s i t i ng t he Nat i onal Cancer I ns t i t ut e.
Dr . Hua t r ans l at ed our mal ar i at her apy pr ot ocol i nt o Chi nes e ( encl os ed) and
i t was r evi ewed by medi cal col l eges i n Shanghai and Cant on, t he Bei j i ng
Cancer I ns t i t ut e, and t he Mi ni s t r y of Heal t h. The hos pi t al s we wi l l vi s i t
i n Cant on, Shanghai , and Bei j i ng have det er mi ned t hat mal ar i at her apy f or
cancer i s a vi abl e s t udy and ar e i nvi t i ng us t o es t abl i s h a pr ogr am
compar abl e t o Mexi co. Dr . Hua' s as s oci at es have al r eady l ocat ed a s our ce
of mal ar i a i n Cant on Pr ovi nce.
I am pr epar ed t o per s onal l y pay my own expens es and t hos e of Dr . Hua, i f
nec es s ar y, bec aus e I am c er t ai n Dr . Hua' s pr epar at i ons have paved t he way
t o ac c ompl i s h our mal ar i a t her apy pr oj ec t . You ar e an es s ent i al par t i c i pant
i n t he pr oj ec t and mus t s ur el y j oi n us . I t i s al s o an oppor t uni t y you wi l l
appr ec i at e t hat oc c ur s onc e i n a l i f et i me. '
Pl eas e c al l and l et me know your t hought s .
\'vl~
Hei ml i c h, M. D.
HJ H/ nc
Enc .
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@i glou.com
8enefitin
Humanity
Through
Health
and
Peace
facsimi l e
TRAN SM ITT A L
To: Mr. & Mrs. David Mahoney
Fax: 011-4121-613-4424
Date: July 23, 1998
Dear David & Hillie,
Jane and I offer our best wishes and love on your anniversary. May you have many,
many more. We are so sorry we were unable to attend.
Yesterday, The Heimlich Institute had a reception to mark our affiliation with Deaconess
Hospital. Moving here has been very gratifying. It was particularly pleasant to have
Valerie Harper attend the functions. Prior to the afternoon reception, she met with
Trustees and officials of the Institute and the hospital, and gained a great deal of
knowledge about the enthusiasm and status concerning our malariotherapy project. I am
certain she will have a thorough report in your hands shortly.
There is no question we are on the right track and will progress toward the final proof.
The affiliation with Deaconess is a great plus in that direction.
Sincerely,
From the desk of...
DEACONESS fOUNDATION
311 Straight Street Cincinnati , Ohi o 45219
Ms. Valerie Harper
Administrator
375 Park Avenue
New York, NY 10152
Dear Valerie:
July 23, 1998
(513) 559-2323
Fax (513) 475-5057
I enjoyed the opportunity to meet you and look forward to working together for the benefit of Dr.
Heimlich's research. If you need any additional information regarding Deaconess, please don' t
hesitate to call me.
In the meantime, I will work with Dr. Heimlich to prepare a project business plan including budget
and timetable of events for your and David Mahoney's review. If you have a sample copy of a
preferred format, please send it to me. Also, any information regarding either ofthe Dana Trusts for
our files would be helpful.
Again, it was a pleasure to see you and I hope you have a wonderful vacation in France. It sounds
like a delightful time.
Best regards,
Charles P. McDowell
President
Serving The DeocoI7ess A ss()cioLions. I nc.

\ 311 Straight Street*Cincinnati, Ohio 45219*Phonc (513) 559-2323*FAX (513)475-5057
TO: Hank
FROM: Charlie
DATE: July 27, 1998
This fax transmission is 4 pages, including the cover sheet. If you have any difficulty
with the reception of this transmission or have any questions, please call me (513) 559-2323 for
assistance.
COMMENTS:
Hank:
Please review and comment.
I will be at home (860-2717) if you need to discuss tonight. Loretta can make any changes on her
word processor.
The U. S. patient cost is based on $1,500 per day for 30 days ($45,000) plus four viral load tests at
$500 each ($2,000). That leaves a $3,000 per patient same as China for unanticipated
costs.
./
Thanks
MALARIOTHERAPY PROJECT BUDGET
Year One
A. STAFF ROLE ON SALARY FRINGE
PROJECT REOUIRED BENEFITS TOTAL
Henry 1. Principal
Heimlich, M.D. Investigator - 0 - -0- - 0 -
Eric Spletzer, Research Associate $21,000 $3,600 $24,600
Ph.D. Heimlich Institute
Secretarial and Administrative $18,000 $3,200 $21,200
Administrative and clerical duties
TOTAL STAFF COST: $ 45,800
B. SUPPLIES:
Office $5,000
TOTAL SUPPLIES COST: $5,000
C. TRAVEL: Trips to China & Medical Conferences
$10,000
Eric Spletzer, Ph.D. $ 5,000
TOTAL TRAVEL COST: $15,000
Year One (Continued)
Malariotherapy Project Budget
D. OTHER EXPENSES:
Institute Office Space & Equipment Usage
Page 2
Institute Office Telephone, Faxes,
Computers, Postage & Federal Express
Institute Office Bank Charges for Wire
Transfers
TOTAL OTHER EXPENSE:
COSTS
$ 8,500
$ 4,000
$ 500
$13,000
TOTAL NON-PATIENT CARE ONE YEAR COST:
-
TOTAL
$ 78,800
Page 3
CONSOLIDATED MALARIOTHERAPY THREE YEAR BUDGET
BUDGET CATEGORY 1st YEAR
PERSONNEL $45,800
SUPPLIES $ 5,000
TRAVEL $15,000
OTHER EXPENSES $13,000
TOTAL ANNUAL EXPENSE $78,800
TOTAL NON-PATIENT CARE EXPENSE:
PATIENT CARE COST
100 Chinese patients including treatments,
hospitalization, laboratory tests, follow-up
physicals and laboratory tests for 2 years;
compliation, analysis, and pUblication of
data.
or
10 U.S. patients in addition to 50 Chinese patients
including treatments, hospitalization, laboratory
tests, follow-up physicals and laboratory tests
for 2 years; compilation, anaylsis and
publication of data.
TOTAL EXPENSE & PATIENT CARE COST:
2nd YEAR 3rd YEAR
$ 50,400 $ 55,000
$ 5,500 $ 6,000
$18,000 $ 21 ,000
$15,000 $ 18,000
$88,900 $100,000
TOTAL
$267,700
$1,000,000
$1,267,700
10/ 14/ 1995 19:39
2127542892
The Eleanor Naylor
Dana Charitable
Trust
FAX
To:
Dr. Heimlich
PERSONAL
CONFIDENTIAL
Phone:
Fax phone:
CC;
REMARKS: o Urgent
DAtlATRUST
PAGE 01
Date: .July 27, 1.998
Number of pages including C0ver sheet: 3
---
From:
Valerie Harper
Phone:
212-754-2890
Fax phone:
212-754-2892
!81 For your review 0 Reply ASAP 8J Please comment
1 0 / 1 4 / 1995 19 : 39
375 Pari Avenue
New Yorlr.. N ~ Yon
10152
(212) 75+2890
FAX (212) 7542892
Thlstccs
David Mahot\ty.
Chairman
AJ Signorile.
Trt:"a.Surcr
Robot A. Good. M.D.
CarlWMoscley
Robert E. W ~ . M.P
. -1- . . , 1.
, .
2127542892
July 24. 1998
Dr. Henry Heimlich
The Goetze Center
415 Straight Street
Cincinnati Ohio 45219
Dear Hank:
DANA TRUST
Thank you and Jane for making me feel so at home in every way. It made all the
difference to my visit.
PAGE 02
It was impressive even though well deserved to witness the enthusiasm of
everyone I met at the Deaconess for The Heimlich's Institute's achievements. and
their commitment to assure the continuity and future of your vision.
I hope that my candid approach In the various meetings we had was constructive.
An honest and practical entente is critical for all the parties concerned to provide
MT with an optimal environment for success. I do not think it unreasonable as we
are only talking about a few months that we give Dr. Chen's latest ten patients
Inoculated with MT the consideration necessary. This yardstick is important. The
Trust committed funds for this.
Thank you for working on the budget projection so swiftly with Charles McDowell .
which should include the continuation of our work in China and the initial trails in
the U.S.
It was exdting to hear that the Deaconess would consider using the unoccupied
space of the Vitas Hospice facility for the treatment of HIV /MT patients. Just think
if we could eventually add UCLA's failed Protease inhibitors drug patients and the
V& A Hospitals in the future.
As you remarked It has only been two years and we have come a long way to
achieving a sol id foundation for such an enormous undertaking as MT. You truly
have the support of David Mahoney . The Deaconess executives. Trustees. John
Fahey. I can appreciate your impatience, the last stretch always appears to be
the longest and the most demanding. Visionaries like yourself must find patience
and due diligence trying
10/ 14/ 1995 19 : 39
2127542892
DAI-IATRUST
PAGE
. Our diner meeting with John Gall was in my opinion most important. For you to
have such a staunch ally as head of your board of Trustees, who has such a
penetrating business mind to interface with The Deaconess as we proceed, as
well as your best interest at heart is an enormous asset
I am sure you know how involved and committed I am to your latest "Brain Child".
I do appreciate that every day that passes must seem like an eternity when you
have such a creative and compaSSionate mind set as yours,
This is a rather long thank you letter for the privilege of knowing and working with
you.
st regards as always,
LE
375 Park Avenue
New York, New York
10152
(212) 754-2890
FAX (212) 754-2892
Trustees
David Mahoney,
Chairman
A J. Signorile,
Treasurer
Robert A Good, M.D.
Carlos Moseley
Roben E. WISe, M.D.
July 27, 1998
Mr. Charles P. McDowell
President
Deaconess Foundation
311 Straight Street
Dear Charles:
Thank you for taking time out of your busy schedule to expose me
to the Deaconess's myriad activities to promote and provide
community-centered services to improve the health of people
across the nation.
It was impressive even though well deserved to witness the
enthusiasm of everyone I met for Dr. Heimlich's achievements and
their commitment to assure the continuity and future of his vision.
Thank you for giving your immediate attention to creating a much
needed project business plan, timetable of events and budget
projection, which as we discussed should include the continuation
of Malaria Therapy in China and initial trails in the United States.
It was exciting to hear that the Deaconess would consider using
the unoccupied space of the Vitas Hospice facility for treatment of
HIV/MT patients. Dr. Fahey of UCLA, as you know had
suggested to Dr. Heimlich that he would consider administering
MT to HIV patients who had failed to respond to the protease
inhibitors. David Mahoney would be willing to explore using The
V&A hospitals should the ten patients now being treated respond
as successfully as the first ten patients treated.
I requested that Eric Spletzer send me a synopsis of Pertinent
findings to Malaria Therapy from the XII Worlds Aids Conference, I
I think you would find it very interesting.
I enjoyed so much our first evening together with you and Mrs.
McDowell and the Heimlich's. What a festive introduction to what I
hope will be a productive and successful cooperation for all

t regards,
DEA CONESS A s s OCIA TIONS
311 Straight Street Cincinnati, Ohio 45219
(
-1")--9 noo :) ,"} :)J -_ u,
August 5, 1998
Ms. Valerie Harper
375 Park Avenue
New York, NY 10152
Dear Valerie:
Thank you for your letter of J uly 27. I amhappy to hear that you were impressed with the
enthusiasm and commitment that we all have for Dr. Heimlich's work. Ican assure you that
what you witnessed is genuine!
Mr. McDowell and Dr. Heimlich continue to make progress on enhancing the plan, timetable and
budget you have already received. Iamalso looking forward to reviewing the synopsis of
findings on Malaria Therapy that you referenced.
Valerie, Kathy and Ivery much enjoyed the opportunity to lunch with you, and Ilook forward to
our future cooperation leading to extremely successful results. Thank you for your continued
interest!
5L:~
J ames L. Pahls
Chairman of the Board
cc: Mr. C. McDowell
Dr. H. Heimlich
tvlr. E. A. Woods
311 S TR AIG K T
S TR E E T
C INC INNATI
O H IO
45219
513-559-2391
F AX 513-559-2403
heimlich@ iglou.com Dear Amy,
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
August 10, 1998
Ms. Amy Irving
2034 La Mesa Drive
Santa Monica, CA 90402
Considerable time has passed since you put your faith and support behind our
malariotherapy program for treating HIV patients. That is the nature of original research;
it is done deliberately and thoroughly.
You will be interested to know our HIV research has progressed very well. We have
begun malariotherapy treatments on anew group of HIV patients in China, and once
again, the results arevery promising.
In 1996, after we presented the results of the first group of patients at the National
Institutes of Health (NIH) and the International AIDS Conference in Vancouver, our
findings were so good that the University of California in Los Angeles (UCLA) asked if
they could join our program. They have done so. As aresult, UCLA brought our head
doctor from China to spend two months in their laboratories. We are now carrying out
thevery latest studies on the new Chinese patients both in China and at UCLA.
Our work incurred interest, as you know from the enclosed news article I previously sent
you. Itwas overshadowed, however, by the hype about new drugs as acure for AIDS.
That seemed unlikely to me because no virus has been eradicated by drugs, including the
common cold.
This year, at theAIDS conference inGeneva, the primary reports were, unfortunately, on
drugs not being acure, their failure and complications inHIV patients, and the fact that
drugs create resistant forms of the virus. Now they aretalking about avaccine ten-to-
twenty years away. The probability of asuccess is questionable, however. Should a
vaccine work against anAmerican HIV virus, it will not necessarily do so on one from
Thailand or Africa. The latter will then spread rapidly through travel. In any case, a
vaccine is of no use to the forty million HIV patients.
I hope to hear fromyou and see you should I get out to California.
Consequently, my concept of building up the immune system with malariotherapy is
gaining increased respect. When thepresent group of patients has been followed for six
months, we intend to treat HIV patients in the United States whose treatment with drugs
has failed. They have no other hope.
Another big piece of news is that The Heimlich Institute was invited into Deaconess
Hospital in Cincinnati, thereby fulfilling my hopes of making the institute apermanent
institution. Please note our new address and telephone number should you wish to
contact me.
Best regards,
311 Strclight Street Cincinnati, Ohio 45219
Ms. Valerie Harper
375 Park Avenue
New York, NY 10152
Dear Valerie:
(513) 559-2323
Fax (513) 475-50S7
September 16, 1998
Enclosed is the grant request for funding the continuation of Dr. Heimlich's important research work
using malariotherapy to cure HIV infection. As we both know, initial results are promising and we
need to push forward as rapidly as possible. If this therapy works, it could result in preventing the
deaths of the 40 million people currently infected and eradicating the disease worldwide.
I trust the enclosed document, in addition to your conversations with Dr. Heimlich, adequately
explain the process and need for funding. If you have any questions, please call me at (513) 559-
2323.
Thank you in advance for your consideration.
Enc. _.
Sincerely,
Charles P. McDowell
President
--- --------- - ------ ------- -------------------- -------- -
Servi ng, Th e J)('{lC()17CSS Associations. In c.
Project Title:
Malariotherapy to Cure HIV Infection
Principal Investigators: Henry J.Heimlich, MD, ScD, The Heimlich Institute
John L. Fahey, MD, UCLA
Chen Xiao Ping, MD, Guangzhou, China
Eric G. Spletzer, PhD, The Heimlich Institute
Proposal Submitted: September 11, 1998
Malariotherapy to Cure HIV Infection Project
Table of Contents
I. Introduction
II. Current Knowledge Base
III. Malariotherapy
IV. Research Goals and Objectives
V. Program Protocols and Methods
VI. Timetable
VII. Budget
VIII. Project Leadership
IX. Publication of Results
2
I. Introduction
The increasing incidence of human immunodeficiency virus (HIV) has been matched by intense
efforts to help those infected and to prevent its spread. In a recent article, The World Bank
predicted that the HIV epidemic is about to explode into a worldwide epidemic that has, to date,
infected 40 million people and killed 11 million.
In developing countries, nearly one-half of the cases are among women. In Africa, the HIV-
AIDS cycle, has shortened life expectancy by 22 years in Zimbabwe, and by 11 years in the
Ivory Coast. Large epidemics are likely to occur unless immediate action is taken to find a cure.
II. Current Knowledge Base
Medical researchers continue to work to find a cure for HIV before it develops into AIDS. The
majority of effort and research money has been spent on developing drugs or a vaccine to
eradicate the disease. The World AIDS Conference, held in Geneva June 29 - July 2, 1998, was
in sharp contrast to the conference held in Vancouver two years prior. In Vancouver, there was a
strong belief that recently developed drug inhibitors (protease) were the answer to cure HIV. In
Geneva, however, research results proved the contrary.
A. Drug Therapy
Study results of "cocktail" therapy (treatment using all classes ofHIV drugs) report this method
has created a number of patient problems. More than 50 percent of the patients were not able to
remain on the drugs because of complications. A number of dangerous side effects which
include disfigurement from fat deposits, increased risk of heart disease, and kidney stones exists.
In fact, the virus became resistant to the drugs themselves and, when the drugs were discontinued
or failed, the critical CD4 cell count rapidly dropped.
Considering the high rate of patient withdrawal from drug therapy, Jhe dangerous side effects,
and the ability of the virus to rebound after drug therapy is stopped, the drugs currently available
are not a cure for HIV. While drugs provide additional time for many HIV victims, a major
prohibiting factor is cost. Most countries cannot afford the drugs. This concern, expressed at the
Geneva conference, has no immediate answer and more importantly, no virus to date, has ever
been cured by drugs.
3
B. Vaccines
Another issue discussed in Geneva was the prevention of HIV infection through the development
of vaccines. The main problem with vaccines is the large variety ofHIV subtypes and their wide
geographic distribution. For example, the type ofHIV prevalent in Thailand is not the same type
generally found in the United States. With increasing international travel, the probability of
exposure to the various HIV subtypes and their spread worldwide becomes more likely.
Consequently, either a universal vaccine needs to be developed or the world population will have
to be inoculated for every subtype. Neither choice is practical.
There are five primary types of vaccines. Two have significant risk of causing HIV infection.
Two other varieties generate only a partial immune response which may not provide adequate
protection. The final method uses DNA fragments; full immune response does result, but studies
indicate protection only extends to non-virulent HIV types.
Vaccines are designed to prevent, not cure, infection. This option offers little consolation to the
40 million currently infected with HIV.
C. Immune System Restoration
Despite the negative outlook for HIV treatment using drug therapy and/or vaccines, many of the
results reported in Geneva reinforced the value of reactivating the immune system. Studies using
drugs reveal that immunological restoration of the immune system can occur ifHIV is not too far
advanced. This is particularly true if the viral count of the individual is less than 500 (HIV is not
too advanced and the immune system still functions) and the CD4 cell count is greater than 200
(normal is 1000 in a healthy individual).
Restoration of the immune system after high active antiretroviral therapy (HAAR T) drugs was
limited. Patients receiving HAART produce T-cells that respond to diseases to which the
patients were previously exposed. Their T -cells do not, however, respond to new infections.
4
III. Malariotherapy
HIV infection weakens patients' immune systems by stripping the body's ability to respond to
the virus. This effect of HIV infection leads to rapid aging of the immune system, and results in
the body's decreased ability to respond to secondary infections that can prove fatal. Restoration
and preservation of the immune system are key to successful clinical management of HI V
infection.
The purpose of Malariotherapy is to restore the individua1's immunological function by
stimulating the immune system. Strengthening the immune system then allows for the potential
elimination of the HIV virus. Malariotherapy, a well-established treatment, was introduced in
the early 1900's. Drugs that cured generalized syphilis were ineffective against neurosyphilis,
which attacks the brain. A blood-brain barrier prevented medications from effectively reaching
brain tissue. As a result, the disease persisted in the brain causing progressive neurological
damage.
In 1927, Wagner-Jauregg was awarded the Nobel Prize for discovering malariotherapy cured
neurosyphilis. Between 1931 and 1965, the United States Public Health Service administered
malariotherapy to tens of thousands of neurosyphilis patients. By 1975, the treatment was
discontinued because neurosyphilis was, essentially, eradicated. Penicillin cured early syphilis;
therefore, new cases of neurosyphilis did not develop.
Malariotherapy proved to be safe during the 50+ years it was successfully used to treat
neurosyphilis. There is no known report of induced malaria not being cured or of malaria
infecting other persons. Examples of using one disease to prevent another include: cowpox to
prevent smallpox, developed by Edward Jenner, and the Sabin live polio vaccine. The findings
presented in Geneva prove the continuing need for an effective treatment for HIV, a need that
can be met by malariotherapy.
A. How It Works
IL-2 and CD4 cells are key elements in coordinating the body's response to HIV infection.
Malariotherapy results in the production of both. HAART seeks to eliminate HIV by controlling
viral replication. Malariotherapy cures HIV infection by stimulating the immune system which
then kills the virus. HAART does not restore immune functions, has not been able to eliminate
the HIV from the body, and is so toxic that many cannot tolerate the regimen required to
suppress the virus. In contrast, malariotherapy has been well-tolerated by patients and is a one-
time treatment producing lasting results. Malariotherapy provides a general stimulus to the
immune system, which produces T -cells that respond to both previous and new diseases alike.
The advantages of malariotherapy are decisive. Past studies have shown HIV is only able to
destroy the immune system following a protracted struggle with CD4 cells. Increasing the CD4
cell production, and lowering the viral count, allows the body to effectively respond.
5
B. How It Is Done
Malariotherapy consists of inoculating patients with a curable form of malaria. After three weeks,
the malaria is cured. A detailed case history, physical examination, and blood testing is
performed prior to the malarial inoculation. Patients are hospitalized and monitored continually
during the malaria infection. CD4 cell counts are measured prior to and following the therapy.
An increase in CD4 cells, and a reduction in viral loading, indicates restoration of the patient's
immune system. A sustained increase of CD4 cells to normal levels for two years following
malariotherapy,with no further treatment of any kind, indicates the HIV virus has been controlled
and/or eradicated.
IV. Research Goals and Objectives
The goal of this study is to determine whether malariotherapy can j ump start the immune system
to cure and prevent HIV. If this therapy works, it could result in preventing the deaths of the
40,000,000+ people currently infected.
V. Program Protocols and Methods
A. Selection Criteria
Candidates for malariotherapy must have asymptomatic mv infection with a CD4 count
between 200 and 550 cells (healthy individuals have a count of 1000). They must not be on any
other therapy. Female candidates must not be pregnant and must use barrier contraceptives for
the duration of the study.
The origin of the HIV infection is unimportant. Subjects who have had drug therapies that failed,
can be considered candidates if they meet the selection criteria mentioned above. All subjects
are volunteers.
B. Test Sites
Test sites can be located anywhere providing they meet four criteria: (1) availability of malaria
blood, (2) suitable testing arrangements, (3) satisfactory quality of patient care and
(4) acceptable testing and hospitalization costs.
The malarial blood used is Plasmodium vivax to ensure minimal possibility of complications. It
is screened for the absence of other blood-borne pathogens, such as hepatitis, to prevent infection
with a new disease during treatment. The study is currently being conducted in h i n a and there
are plans to expand to the United States.
6
C. Consent
Volunteers are required to sign a consent agreement indicating they understand they have the
right to request the Principle Investigator, and/or their physician, to answer any questions
concerning the therapy. The subject can terminate participation at any time.
The signed consent indicates the volunteer understands the induced malariotherapy is on an
experimental basis and he/she accepts all risks. It also holds harmless The Heimlich Institute, the
Principal Investigators, and all health care providers involved in the study.
D. Study Procedure
Upon commencement of the study, volunteers submit to a medical history and undergo a
physical examination. Women of childbearing age are tested for pregnancy. Malaria parasites
are administered on the fIrst day. Blood tests are performed prior to the start of treatment,
weekly when hospitalized. Participation in the study will be terminated by the investigators if: 1)
it is determined that continuing will be detrimental to the subject's health, 2) protocol treatment
is not followed or 3) a decision is made to change the patient's antiretroviral regime.
E. Study Duration
The duration of the study is unlimited. Participants are required to remain in the hospital during
the malarial phase of treatment, typically three to four weeks. Subjects are then required to make
follow-up visits to the participating physician one, three, six, twelve, eighteen, twenty-four, thirty
and thirty-six months following treatment to have blood drawn for CD4 and viral load counts.
7
VI. Project Timetable
The sequence of events for each patient is listed below. It is our intent to commence with groups
often patients at a time every four weeks. Iften groups are tested in China (100 patients) and
funding allows us to begin in October, 1998, the tenth group will commence in July, 1999 and be
completed September, 2002. If five groups are tested in China (50 patients) and ten patients in
the United States, the [mal group will start in March, 1999 and be completed May, 2002. In both
instances, however, reports will be published every six months following onset of treatment,
since early favorable results are significant in obtaining general acceptance and spread of the
treatment method.
Weeks
Weeks 1-2
Week 3
Week 10
Week 18
Week 32
Week 58
Week 84
Week 110
Week 136
Week 162
Action
Medical history, pre-treatment physical examination, blood
draw to determine baseline immunological counts (CD4,
CD8, CD25, interleukins, interferons)
Inoculation with malaria virus and hospitalization. Blood
draws for CD counts and viral loads. Complete malaria
treatment and release from hospital.
One month follow-up medical examination in addition to
blood draw to determine immunological and viral load count.
Three month follow-up medical examination, in addition to
blood draw to document immunological and viral load count.
Six month follow-up medical examination, in addition to
12 month follow-up medical examination, in addition to
blood draw to document immunological and viral load
count.
blood draw to document immunological and viralloaa count.
8
VII. MALARIOTHERAPY THREE YEAR BUDGET
BUDGET CATEGORY 1st YEAR 2nd YEAR 3rd YEAR GRAND
TOTAL
PERSONNEL $45,800 $50,400 $55,000
SUPPLIES $ 5,000 $ 5,500 $ 6,000
TRAVEL $15,000 $18,000 $21,000
OTHER EXPENSES $13,000 $15,000 $18,000
PATIENT CARE
100 Chinese patients including $940,000 $40,000 $20,000
treatments, hospitalization,
laboratory tests, follow-up
physicals and laboratory tests
for 2 years; compilation, analysis,
and publication of data.
or
10 U.S. patients in addition to 50
Chinese patients including treat-
ments, hospitalization, laboratory
tests, follow-up physicals and
laboratory tests for 2 years;
compilation, analysis and
publication of data.
TOTAL COST: $1,018,800 $128,900 $120,000 $1,267,700
9
VIII. Project Leadership
The principle investigators for this project presently include Henry J. Heimlich, M.D., ScD., The
Heimlich Institute, John L. Fahey, M.D. ,UCLA, Chen Xiao Ping, M.D., The Public Health
Service, People's Republic of China and Eric G. Spletzer, Ph.D., The Heimlich Institute.
Following is a synopsis oftheir credentials and their respective roles in the project:
A. Lead Investigator
Henry J. Heimlich, M.D., ScD. , President The Heimlich Institute, Cincinnati, Ohio;
Cornell Medical College, M.D. 1943; Wilmington College, ScD. 1981; Adelphi
University, ScD. 1982; Rider College, ScD., 1983; Vice President, American
Broncho-Esophagological Association, 1985; Senior Member, Central Surgical
Association; The Society of Thoracic Surgeons, Founder Member; American College of
Chest Physicians, Fellow; American College of Gastroenterology, Fellow; American
College of Surgery, Fellow; Recipient of Lasker Award
Dr. Heimlich is responsible for the procedure concept formulation and contributes medical,
technical and related information for the implementation of the therapy procedures.
His World War II association with Chinese allows the research project for
malariotherapy to be conducted in China
In 1992, he established his relationship with Dr. Chen Xiao Ping
Dr. Heimlich commenced his affiliation with Dr. John L. Fahey during the 1996
XI World AIDS Conference in Vancouver and National Institutes of Health (NIH)
Conference where Dr. Heimlich presented the preliminary results of
malariotherapy for HIV infection.
Project duties:
Program overseer
Facilitates methods to expedite progress on malariotherapy with Drs. Chen, Fahey
and Spletzer
Presents results at internationaVdomestic conferences
B. Treating Physician/China Liaison
Chen Xiao Ping, M.D. , Director, Associate Chief Doctor, Research Associate Professor at
the Center for AIDS Control and Research, The Municipal Health and Anti-Epidemic
Station of Guangzhou; Sun Yat-Sen University of Medical Sciences Department of
Infectious Diseases, M.S. 1988; M.D. 1998; University of California at Los Angeles,
Fogarty AIDS International Training and Research Program, Postdoctoral Training, 1997
Dr. Chen provides extensive knowledge on AIDS with respect to etiology, epidemiology and
clinics. -
10
Project duties:
Locates and identifies candidates for malariotherapy via medical reports or
requests information from physicians
Coordinates malariotherapy monitoring and treatment during candidate's inpatient
and outpatient stays
Secures malarial blood donors
Conveys data to The Heimlich Institute
Forwards blood samples to UCLA for in-depth immunological testing
C. Immunologist
John L. Fahey, M.D., Director, Center for Interdisciplinary Research in Immunology
and Disease (CIRID) at UCLA, Chief, Immunology Branch; Harvard University
Medical School M.D., 1951; Wayne University College of Medicine, M.S., 1949;
National Cancer Institute (NCI), National Institutes of Health (NIH), 1964-1971; Member
National Advisory Council, NIAID, NIH 1983-1987; Chair, Immunology Committee,
Multicenter AIDS Cohort Study (MACS) 1987-1992; Member, Task Force for
California-wide University AIDS Research Program
Dr. Fahey's primary role is to supervise immunological studies.
Project duties:
Tests Dr. Chen's samples for viral loads and immunological markers of HI V
progression on the immune system
Furnishes technical support for immunological conclusions
Supplies reagents for some of the tests conducted in China
D. Study Coordinator
Eric G. Spletzer, The Heimlich Institute, Cincinnati, Ohio; University of Cincinnati,
Ph.D. 1986; Member, American Chemical Society; Member, American Association for
Advancement of Science; attended XI World AIDS Conference in Vancouver and XII
World AIDS Conference in Geneva to monitor research results
Dr. Spletzer confirms all data available from Dr. Chen and communicates with him on a regular
basis.
Project duties:
Analyzes information for beneficial immunological changes and effect of
malariotherapy on virus
Provides general technical support (writes scientific papers, analyzes available
scientific data for information relevant to malariotherapy)
11
IX. Publication of Results
Malariotherapy research results for HN patients have previously been published by The
Heimlich Institute. They were presented at the IX International Congress ofImmunology
held in San Francisco, 1995, and the XI World AIDS Conference held in Vancouver, 1996.
Papers on the topic have been published in The New England Journal of Medicine and
Mechanisms of Ageing and Development.
A. Periodicals
Significant findings from on-going research will continue to be shared. Publication of
results will appear in national and international journals. Articles will be prepared and submitted
for pUblication to the following:
* Journal of the American Medical Association
* New England Journal of Medicine
* AIDS
* Journal of Immunology
B. Conferences
Results will be presented at major international conferences. Conferences providing the
appropriate platform include:
* The World AIDS Conference
* The International Congress of Immunology
* International Conference on Immunology and Aging
Participation in other conferences will occur as developments warrant. Data will be disseminated
via news and/or press releases.
12
08/ 18/ 1998 17: 28 310- 2E15- 1318 C:IPID AT UCLA PAGE 132
MEMORANDUM
Depanment of Microbiology &Immunology
DATE: August 18, 1998
TO: Dr. Henry Heimlich - VIA FAX
Dr. Eric Spletzer - VIA FAX
J ohn L. Fahey. M.D. ~ (:f-
FROM:
Do you have a more detailed protocol for the current malaria studies of Chen Xiao
Ping? Enclosed are 2pages of a larger documents he gave us in May 1997.
I hope to go Guangzhou in late October 1998 and need an update on the study
plan.
Many thanks.
enclosure
Subject: Re: Viral Load Testing
Date: Fri, 25 Sep 1998 16:02:33 -0700
From: chenxp <chenxp@gzsums.edu.cn>
Organization: chenxp
To: III Heimlich <heimlich@iglou.com>
Thank you for your email. Shipment ofHlV samples is complicated. We
will discuss the detailed about viral load testing when Dr. Fahey visits
Guangzhou next month. Here attaches Dr. Fahey's email.
Best regards and wishes.
Chen Xiao Ping, MD
Attached:
SUbject: Letter
Date: Fri, 18 Sep 98 12:01:00 PDT
From: "J ohn L. Fahey, MD." <jIfahey@microimmun.medsch.ucla.edu>
To: "Chen Xiao Ping, MD." <Chenxp@gzsums.edu.cn>
September 18, 1998
Dear Dr. Chen,
I am writing to arrange avisit with you in Guangzhou on Wednesday,
October 28, 1998. I am anxious to know how all of your work is going.
Itwill be interesting to learn about your recent studies of HIV
infection and of the progress of the malarial therapy study.
Some of the reagents that we sent were to measure CD25 and HLA-DR
expression on lymphocytes. Also, kits for TNFa, TNF-RII, neopterin and
b2M determinations were provided. I am sending under separate cover
data
obtained at UCLA on the levels of these factors in a reference HlV
negative population as well as in HlV positive individuals. We know
that there are substantially fewer HIV+ persons in Guangzhou. However,
it would be interesting to review your preliminary data with both HIV-
and HIV+ populations in Guangzhou. We do not expect that the data would
be the same in both locations, but a look at the initial data might be
advantageous at this time, particularly ifmore reagents will be needed.
Separately, of course, there is the interest in the clinical and
laboratory status of the participants in your study of malarial therapy.
It would be interesting to know how many febrile episodes each of the
recipients had and any other clinical manifestations of the malarial
infection or of HIV induced AIDS. Also, the CD4 T-cclI levels and other
laboratory parameters that you have been able to measure should be quite
interesting. I do hope that you will be willing to share that with me.
We can discuss the shipment of samples for viral load determination. It
would be reasonable to wait until I have visited Guangzhou before
sending
any samples here. I would be glad to talk more with you about that and
any other matters that you wish during my visit to Guangzhou on October
28th.
My travel plans call for arriving on the same morning train as last
March, but I should return to Hong Kong by the evening train on the
28th. That should provide 5or 6 hours to review data, meet your
colleagues and discuss future plans. I regret missing the opportunity
tohave one of the fabulous dinners that Guangzhou is famous for but I
look forward to that on another visit
Sincerely,
J ohn L. Fahey, MD.
J LFIkw
cc: Hong Bass, MD., Ph.D.
Najib Aziz, MD.
Barbara Hered
B e n e f i t i n g
H u m a n i t y
T h r o u g h
H e a l t h
a n d
P e a c e
f a c si m i l e
T RANSMIT T AL
The following is for your information.
311 S T R A IG HT
To: Valerie Harper
S T R E E T
C IN C IN N A T I
O HIO
45219
513-559-2391
Fax: (212) 754-2892
F A X 513-559-2403
heimlich@iglou.com
Date: September 28, 1998
F rom the desk of ...
Vicki R oberts
A ssociate Director
Heimlich Institute
F ax: +1 (513) 559-2403
Subject: Re: Viral Load Testing
Date: Fri, 25 Sep 1998 16:02:33 -0700
To: III Heimlich <heimlich@iglou.com>
Thank you for your email. Shipment ofHlV samples is complicated. We
will discuss the detailed about viral load testing when Dr. Fahey visits
Guangzhou next month. Here attaches Dr. Fahey's email.
Best regards and wishes.
Chen Xiao Ping, MD
Attached:
SUbject: Letter
Date: Fri, 18 Sep 98 12:01:00 PDT
From: "J ohn L. Fahey, MD." <jIfahey@microimmun.medsch.ucla.edu>
To: "Chen Xiao Ping, MD." <Chenxp@gzsums.edu.cn>
September 18, 1998
Dear Dr. Chen,
I am writing to arrange avisit with you in Guangzhou on Wednesday,
October 28, 1998. I am anxious to know how all of your work is going.
Itwill be interesting to learn about your recent studies of HIV
infection and of the progress of the malarial therapy study.
Some of the reagents that we sent were to measure CD25 and HLA-DR
expression on lymphocytes. Also, kits for TNFa, TNF-RII, neopterin and
b2M determinations were provided. I am sending under separate cover
data
obtained at UCLA on the levels of these factors in a reference HlV
negative population as well as in HlV positive individuals. We know
that there are substantially fewer HIV+ persons in Guangzhou. However,
it would be interesting to review your preliminary data with both HIV-
and HIV+ populations in Guangzhou. We do not expect that the data would
be the same in both locations, but a look at the initial data might be
advantageous at this time, particularly ifmore reagents will be needed.
Separately, of course, there is the interest in the clinical and
laboratory status of the participants in your study of malarial therapy.
It would be interesting to know how many febrile episodes each of the
recipients had and any other clinical manifestations of the malarial
infection or of HIV induced AIDS. Also, the CD4 T-cclI levels and other
laboratory parameters that you have been able to measure should be quite
interesting. I do hope that you will be willing to share that with me.
We can discuss the shipment of samples for viral load determination. It
would be reasonable to wait until I have visited Guangzhou before
sending
any samples here. I would be glad to talk more with you about that and
any other matters that you wish during my visit to Guangzhou on October
28th.
My travel plans call for arriving on the same morning train as last
March, but I should return to Hong Kong by the evening train on the
28th. That should provide 5or 6 hours to review data, meet your
colleagues and discuss future plans. I regret missing the opportunity
tohave one of the fabulous dinners that Guangzhou is famous for but I
look forward to that on another visit
Sincerely,
J ohn L. Fahey, MD.
J LFIkw
cc: Hong Bass, MD., Ph.D.
Najib Aziz, MD.
Barbara Hered
OCT- 2-98 FRI 11 :29
DAVID M A.HON:.EY
F1FT.1I A VEN U E
S U l'l' lo. 7(l0
N[:\\' YOHK, NEW YOf(K H)l51
October 2, 1998
Dr. Henry Heimlich

415 Straight street
cincinnati, Ohio 45219
Dear Hank:
18/dUt:.H.3710
It wa s a delight talking to you last night and knowing
that your optimism is still so solid. I am sorry for the
confusions in our relationships that were brought about
and I wish I would have been of them. But, at any
rate , that is behind us.
wil l get a chance to visit in New York on Tuesday,
October 27ch at 10:00 am.
Meanwhile, my best Wishes to you and Jane,
Dlvl !pm
cc : Valerie Harper
I
I
/
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAA 513-559-2403
October 28, 1998
Mr. David Mahoney
745 Fifth Avenue, Suite 700
New York, NY 10151
heimlich@iglou.com Dear David:
Benefiting
Humanity
Through
Health
and
Peace
Thank you for taking the time to meet with me Tuesday. Your interest in our project
touched me deeply. You can imagine what a comfort it is for me to have your personal
support and your friendship. As you pointed out, my forte is not business.
This morning I met with Tony Woods (E. Anthony Woods, President and CEO of
Deaconess Associations, Inc. , 513/559-2111). I made him aware of your
recommendations concerning the relationship between Deaconess Associations, Inc. and
The Heimlich Institute. Tony will be pleased to discuss this with you. Should he call your
office to schedule a phone conversation?
Thank you again for giving top priority to my research and my future. It may not be a
fair exchange, but I would be happy to teach an intelligent guy like you how to make a
new esophagus.
Jane and I had such a good time at the Dana Awards dinner. Many thanks. Our love to
Hillie.
Henry J. Heimlich, M.D., ScD.
President
cc: Valerie Harper I
Affiliated with The Deaconess Associations, Inc. ' ' ~
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
Fax
To: Valerie Harper
Fax: (212) 754-2892
Date: November 23, 1998
'.
Joan Steinberg
Director
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
November 23, 1998
Mr. David Mahoney
745 Fifth Avenue
Suite 700
Dear David:
I had a very pleasant and rewarding meeting with Dr. John Fahey in Los Angeles on
Friday, November 20
th
. We discussed at length his meeting, in Guangzhou, with Dr. Chen
Xiao Ping, Director of our malariotherapy for HIV/AIDS program.
The enclosed e-mail and letter from Dr. Fahey to Dr. Chen describes in detail the
gratifying results in the patients being treated and the capability of the Chinese scientists
who are working with us. He also makes some excellent suggestions concerning
advanced studies that should now be carried out.
Please let me know if you have any questions in regard to the information he has provided.
cc: Valerie Harper
E. Anthony Woods
Affiliated with The Deaconess Associations, Inc. - ;)
j

J o n L Fahey. M.D.
Fro
To:
Cc:
Date:
November 10, 1998
VIAEMAl L
Department of Mi crobiology
The Municipal Health and Anti-Epidemic Station of G gzhou
No. 23, 3rd Zhongshan Rd.
Guangzhou 510080, P.R China
Dear Dr. Chen,
I want to follow-up on some of the many topics that we discussed on my visit on October 28th to the Municipal
Health and Station in Guangzhou.
First of all, congratulations on your appointment as head of the HIV/AlDS Program in the Municipal Health and
Anti-epidemic Station of Guangzhou. You certainly have developed substantial resources for evaluating .HIV/AIDS
and have developed innovative approaches to therapy. This certainly must be one of the most dynamiC centers
for HIV/AlDS research and education in all of China. I do hope you are able to continue doing your excellent work
with malarial therapy.
It was kind of you to suggest using my name among the authors on the paper assembling data from the 2nd study.
However, it is more appropriate if you simply acknowledge assistance of Dr. Najib Azjz and myself in some
aspects of the study in an acknowledgment paragraph or at the end of your manuscript or abstracl You must
understand that we want very much to see this study succeed but we think that we should not be among
manuscript authors at this time.
I am quite willing to provide assistance in manuscript review and preparation of manuscripts that may be aimed at
international or US journals. We are anxious that the findings be clearly presented in a balanced manner so that
they can be readily judged by the many people interested in the treatment of HIV/AIDS.
I know that you will need some more reagents. We would bE! glad to send you some more reagents for your flow
cytometry. It was not clear to me when I was there what the specific needs were. 1 gather you may need more
CD8 reagents but you should send an email to Barbara Hered and Najib Aziz about this. We do not want to order
large amounts in advance because, if they are used slowly, they may become outdated. Instead, we prefer to
send you more reagents in the future as they become necessary.
Testing of reference populations of people of approximately the same age as your patients was one of the topics
we discussed on October 28th. You have made a good start. At least 20 people should be tested for normative
values of all the measurements that are being made in the HIV popUlation. Also, to check on consistency of
testing you will want to get serial samples from individuals at daily or, better weekly, or monthly intervals on
representative persons in a control population.
Also, when you obtain blood from reference populations you will want to save both plasma and PBMC from those
controls in the same manner that you are saving PBMCs from the HIV+ population. This will provide you with
Page 1
'.
.-
ffiZ'..eria!S collected under the same circumstances for the assays to be done subsequently on the stored PBMCs.
I you deserwe great congratulations for your plan of obtaining 50ml of blood on each of the testlng dates.
This so ld provide for current and future testing of both cells and plasma. I think this is setting important
preceden or other clinical studies in Asia. "
We ook forward to seeing the data that you promised to send. We were intrigued with the fever charts and very
impressed. They are striking and clearly Illustrate what you mean by febrile episodes and indicate,the extent of
bologic response to the malarial parasites. The information on specific dates on when the chlocoguin' is ,giVen and
when subsequent blood samples are taken also help us to have a clear picture of the progress of the study. If the
data that you already haVe on the wec count. differential and the other data in a sIngle table In the tabular format
that we discussed and outlined on October 28th. it WI'I certainly facilitate making judgments about tests where the
results appeared to changed substantially during the malarial period as well as subsequently. We hope to be of
assistance in this data analyses. The data for the CD4 and COB measurements obtained at the 1 month and 3
month time pOints after the end of malarial infection will also be interesting to see.
! greatly appreciated all the data you shared with us on this visit. I want to assure you that we regard this as
confidential information. My colleagues and I will help with the analysis but not share it with others. You should
report your result directly to Dr. Heimlich and not through me.
I want to congratulate you on organizing the data of the patients in the order from highest to lowest CD4 levels.
That certainly faalitates discerning the types of changes that may occur in the different groups stratified by CD4
levels.
I believe that you have reagents for neopterin, soluble TN Fa-receptor 2 and b2M measurements. We would be
glad to provide reagents for additional tests after you have conducted tests for those parameters in November and
December. We would prefer to defer sending additional reagents because we do not want the reagents to get out
of date before you are able to use them. Thus. it would be better 'to send the reagents later on when your current
test are completed. '
The shipment of frozen plasma samples from Guangzhou to Los Angeles is certainly a high priority. We are
checking into obtaining a shipping container for this. As soon as it is obtained. we will send it off to you.
Your assistance in answering all of our questions is much appreciated. They were designed to help us understand
the study since we are some distance from all the action. We appreciate the dedication that you and your
colleagues have to making this a successful study.
Sincerely.
John L. Fahey. M.D.
Director. CIRIO at UCLA
Chair, Clinical Immunology Committee. International
JLF/kw
cc: Barbara Hered
Najib Aziz. M.D.
Hong Bass, M.D .. Ph.D.
Page 2
11/20/1998 12:11
310-206-1318 CIRID AT UCLA
PAGE 02
. ~
IEJU:EUY DA'\"(S IJtVtl'l lOS AlIICELES IrvERSIDE SAl'! D1ECO SAN nv.HCSCO
in Immunology and Disease (ClRID)
November 6, 1998
Chen Xiao Ping. M.D.
Fax: (020)83815255
Dear Dr. Chen,
UCLA
DEPARTMENT OF M'CROIlIOLOGY AND IMMUNOLOGY
1JClA SOIOOL OF MEDICINE
ceN'I'CJt tfoR l1{ fffiAUli SCIENCES
10833 I.E CX>NlE AVENUE
LOS ANGIiL6S. CA1JFOR.N1A 109501747
(310) 825-6568
(310) 206-1318 (fAX)
jlfahcy@miaoimmmuncdsch.ucJa.cdu
I want to thank you very much for your kindness in providing such excellent assistance to Dr. Hong Z. Bass and
myself during our visit on October 28
th
to you at the Municipal Health and Anti-Epidemic Station in
Guangzhou. The two banquets were just marvelous. Once again, I appreciate the opportunity to enjoy the
excellent Cantonese cuisine at Rubin Restaurant The hotel accommodations were fine. We were able to get to
the station in good time on the 29
111
and have a comfortable return trip to Hong Kong.
I was very impressed with all the progress you have made in your studies of malarial therapy in HIV infection.
r think most people do not really appreciate how much work it is to carry out a clinical trial of this type.
Extensive work is required to identify subjects. organize the study to begin at a certain date and have all the
resources available including extensive clinical, laboratory and administrative support Then to maintain
continued follow-up contact, obtaining blood samples, seeing that appropriate analyses are done and that the
data. is collected is an enormous task. You have only a small staff to assist you in this. So, a great range of
responsibilities fall directly on you. In addition, there are the challenges of seeing that all the laboratory tests
are well developed ana that suitable controls are being obtained and reference populations tested, e.g. those
without HIV infection. This requires a variety of laboratory skills and technologies which you have organized
in Guangzhou. They seem to be working effectively and I was impressed. with the extensive data already
obtained in the study.
Again, congratulations on developing such an interesting study and seeing that it is well underway. This study
is sure to address a number of very important questions relating to HIV infection and to the novel approach of
using malarial therapy. Clearly, the therapy is having an impact on the immune system and future tests on
samples to be collected in coming months will establish the dimensions of changes on the immune parameters
of HIV infection. My congratulations to those in the Municipal Health and Anti-epidemic Station of
Guangzhou who have supported you in such a way as to make this important study possible.
Also, my thanks for your hospitality. r look forward to my next visit to Guangzhou.
Sincerely,
Oof.-
JOZF:ey, M.D.
Union ofImmunological Societies (lUIS)
JLF/kw
I
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
Fax
To: Valerie Harper
Fax: (212) 754-2892
Valerie, the following is for your information.
From the desk of...
Joan Steinberg
Director
.. -

.,.' _____ -:--____ .....-.. ... o.
.. "::.
- -.... -. ... ". ...
...
. - .. "
Page ";-o-t 1 r Sunday, November 29, 199'8- 12:48:17 AM -'
Guatemala 29 de noviembre 1998
TO: Hemy Heilmich M.D. FAX: 513 5592403
FROM: Jose Fco. Monjes Angeles M.D. Phone: 011 5024770583/011 5024760263
Dear Hemy Heilmich: The International Medicinal Research and Development (::Qmpany
is going to open in Guatemala City, Guatemala C.A a hospital (includes AIDS and HIV patients),
a research laboratory, a capacitation center, clinics, boarding patients and their families and also
foundations.
We are a group of 65 profesionals in the medioine field and also we have been working
with-Wayne Martin. We are trying to get as many help as we can from organizations here in
Guatemala or other countries to profesionilise our services. I don' t know if you can help us.
I have talk to a M.D. that specializes in malaria and works for a research laboratory of the
university ofUSAC here in Guatemala, his name is Alej andro Samayoa M.D. , he suggests to
have a farm of mosquitos infected with Plasmodium Vivax, so each patient only has to put his arm
m<;ide and get infected. I don' t know what do you think of this idea. He would be encharge of
cheking the fann and to be sure that they have onl y Plasmodium Vivax.
I have a business parter Jim Dunn that was introduced to me through U.S.A embassy
in Guatemala by Raul Villagran.
We are in the process of buying an offi ce, an in-out patients Hospital and a land to build a
general hospital here in the capital of Guatemala. Our proyect its to continue to the rest of the
country.
I don' t now if Henry Heilmich wants to send patients to Guatemala to be infected. I
would like your opinion in that respect and how we can work togheter in your study that you are
making.
Thanks. T hope to hear from you soon.

11:3BP
" .
P . Ol

/ , " Muuu 1001/1000
/, .. .1 - > Ol 02tl.QOO Po ul o 5P
FQl( 5S 1I 229.1103

l
(Oil)
November 11th, 98.
Dr. Heimlich
l cJf
USA :.{I A ................ li t
,.
Dear Dr. Heimlich,
!
Your naoo has been reffered fO me by Hober t Coheri of the Anti Dairy CoaU.tioo.
I Robert on a Health in New .. Yok and he carrrented about your str-dtegy
of usjng Malaria inn<X::ulatlons to creat e hyperti1ermia thereby dri ving the host
towards a Th-1 type ei'fe<; tive irrm..lne reoction .
Being a I-CY carrler (chroniC carr:ier ) I would be most 1nter-est in learning more
about this therapy.
I have also a f'rJend who lives :i n Kentucky nared Jim Nevel s who l.s also interested
in IJyperthermi.a and would be w:i.lling to talk you you. I took the libert y of giving your
fax rU,Inber to him abel you cem t herefore watt for his contact.
Meanwhile
t
I would be most pl eased t.o rece ive aITj ktnd or sugges tton or ccmrent that
could help me t;o jrrprove my current corldi tion.
Wai tine for your reply t I remain
Sircerely YOUI'S
\
<, .c
.Jose ia
. I
( Rua abara, 4: 7 - Apt. 122
".
Or239-011 SaO Paulo - S.P.
BRAZIL
Fax 011 55 11 229.1463
.............. -! 1 __ . f
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
Fax
To: Valerie Harper
Fax: (212) 754-2892
Date: November 23, 1998
'.
Joan Steinberg
Director
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
November 23, 1998
Mr. David Mahoney
745 Fifth Avenue
Suite 700
Dear David:
I had a very pleasant and rewarding meeting with Dr. John Fahey in Los Angeles on
Friday, November 20
th
. We discussed at length his meeting, in Guangzhou, with Dr. Chen
Xiao Ping, Director of our malariotherapy for HIV/AIDS program.
The enclosed e-mail and letter from Dr. Fahey to Dr. Chen describes in detail the
gratifying results in the patients being treated and the capability of the Chinese scientists
who are working with us. He also makes some excellent suggestions concerning
advanced studies that should now be carried out.
Please let me know if you have any questions in regard to the information he has provided.
cc: Valerie Harper
E. Anthony Woods
Affiliated with The Deaconess Associations, Inc. - ;)
j

J o n L Fahey. M.D.
Fro
To:
Cc:
Date:
November 10, 1998
VIAEMAl L
Department of Mi crobiology
The Municipal Health and Anti-Epidemic Station of G gzhou
Guangzhou 510080, P.R China
Dear Dr. Chen,
I want to follow-up on some of the many topics that we discussed on my visit on October 28th to the Municipal
Health and Station in Guangzhou.
First of all, congratulations on your appointment as head of the HIV/AlDS Program in the Municipal Health and
Anti-epidemic Station of Guangzhou. You certainly have developed substantial resources for evaluating .HIV/AIDS
and have developed innovative approaches to therapy. This certainly must be one of the most dynamiC centers
for HIV/AlDS research and education in all of China. I do hope you are able to continue doing your excellent work
It was kind of you to suggest using my name among the authors on the paper assembling data from the 2nd study.
However, it is more appropriate if you simply acknowledge assistance of Dr. Najib Azjz and myself in some
aspects of the study in an acknowledgment paragraph or at the end of your manuscript or abstracl You must
understand that we want very much to see this study succeed but we think that we should not be among
manuscript authors at this time.
I am quite willing to provide assistance in manuscript review and preparation of manuscripts that may be aimed at
international or US journals. We are anxious that the findings be clearly presented in a balanced manner so that
they can be readily judged by the many people interested in the treatment of HIV/AIDS.
I know that you will need some more reagents. We would bE! glad to send you some more reagents for your flow
cytometry. It was not clear to me when I was there what the specific needs were. 1 gather you may need more
CD8 reagents but you should send an email to Barbara Hered and Najib Aziz about this. We do not want to order
large amounts in advance because, if they are used slowly, they may become outdated. Instead, we prefer to
send you more reagents in the future as they become necessary.
Testing of reference populations of people of approximately the same age as your patients was one of the topics
we discussed on October 28th. You have made a good start. At least 20 people should be tested for normative
values of all the measurements that are being made in the HIV popUlation. Also, to check on consistency of
testing you will want to get serial samples from individuals at daily or, better weekly, or monthly intervals on
representative persons in a control population.
Also, when you obtain blood from reference populations you will want to save both plasma and PBMC from those
controls in the same manner that you are saving PBMCs from the HIV+ population. This will provide you with
Page 1
'.
.-
ffiZ'..eria!S collected under the same circumstances for the assays to be done subsequently on the stored PBMCs.
I you deserwe great congratulations for your plan of obtaining 50ml of blood on each of the testlng dates.
This so ld provide for current and future testing of both cells and plasma. I think this is setting important
preceden or other clinical studies in Asia. "
We ook forward to seeing the data that you promised to send. We were intrigued with the fever charts and very
impressed. They are striking and clearly Illustrate what you mean by febrile episodes and indicate,the extent of
bologic response to the malarial parasites. The information on specific dates on when the chlocoguin' is ,giVen and
when subsequent blood samples are taken also help us to have a clear picture of the progress of the study. If the
data that you already haVe on the wec count. differential and the other data in a sIngle table In the tabular format
that we discussed and outlined on October 28th. it WI'I certainly facilitate making judgments about tests where the
results appeared to changed substantially during the malarial period as well as subsequently. We hope to be of
assistance in this data analyses. The data for the CD4 and COB measurements obtained at the 1 month and 3
month time pOints after the end of malarial infection will also be interesting to see.
! greatly appreciated all the data you shared with us on this visit. I want to assure you that we regard this as
confidential information. My colleagues and I will help with the analysis but not share it with others. You should
report your result directly to Dr. Heimlich and not through me.
I want to congratulate you on organizing the data of the patients in the order from highest to lowest CD4 levels.
That certainly faalitates discerning the types of changes that may occur in the different groups stratified by CD4
levels.
I believe that you have reagents for neopterin, soluble TN Fa-receptor 2 and b2M measurements. We would be
glad to provide reagents for additional tests after you have conducted tests for those parameters in November and
December. We would prefer to defer sending additional reagents because we do not want the reagents to get out
of date before you are able to use them. Thus. it would be better 'to send the reagents later on when your current
test are completed. '
The shipment of frozen plasma samples from Guangzhou to Los Angeles is certainly a high priority. We are
checking into obtaining a shipping container for this. As soon as it is obtained. we will send it off to you.
Your assistance in answering all of our questions is much appreciated. They were designed to help us understand
the study since we are some distance from all the action. We appreciate the dedication that you and your
colleagues have to making this a successful study.
Sincerely.
John L. Fahey. M.D.
Director. CIRIO at UCLA
Chair, Clinical Immunology Committee. International
JLF/kw
cc: Barbara Hered
Najib Aziz. M.D.
Hong Bass, M.D .. Ph.D.
Page 2
11/20/1998 12:11
310-206-1318 CIRID AT UCLA
PAGE 02
. ~
IEJU:EUY DA'\"(S IJtVtl'l lOS AlIICELES IrvERSIDE SAl'! D1ECO SAN nv.HCSCO
in Immunology and Disease (ClRID)
November 6, 1998
Chen Xiao Ping. M.D.
Fax: (020)83815255
Dear Dr. Chen,
UCLA
DEPARTMENT OF M'CROIlIOLOGY AND IMMUNOLOGY
1JClA SOIOOL OF MEDICINE
ceN'I'CJt tfoR l1{ fffiAUli SCIENCES
10833 I.E CX>NlE AVENUE
LOS ANGIiL6S. CA1JFOR.N1A 109501747
(310) 825-6568
(310) 206-1318 (fAX)
jlfahcy@miaoimmmuncdsch.ucJa.cdu
I want to thank you very much for your kindness in providing such excellent assistance to Dr. Hong Z. Bass and
myself during our visit on October 28
th
to you at the Municipal Health and Anti-Epidemic Station in
Guangzhou. The two banquets were just marvelous. Once again, I appreciate the opportunity to enjoy the
excellent Cantonese cuisine at Rubin Restaurant The hotel accommodations were fine. We were able to get to
the station in good time on the 29
111
and have a comfortable return trip to Hong Kong.
I was very impressed with all the progress you have made in your studies of malarial therapy in HIV infection.
r think most people do not really appreciate how much work it is to carry out a clinical trial of this type.
Extensive work is required to identify subjects. organize the study to begin at a certain date and have all the
resources available including extensive clinical, laboratory and administrative support Then to maintain
continued follow-up contact, obtaining blood samples, seeing that appropriate analyses are done and that the
data. is collected is an enormous task. You have only a small staff to assist you in this. So, a great range of
responsibilities fall directly on you. In addition, there are the challenges of seeing that all the laboratory tests
are well developed ana that suitable controls are being obtained and reference populations tested, e.g. those
without HIV infection. This requires a variety of laboratory skills and technologies which you have organized
in Guangzhou. They seem to be working effectively and I was impressed. with the extensive data already
obtained in the study.
Again, congratulations on developing such an interesting study and seeing that it is well underway. This study
is sure to address a number of very important questions relating to HIV infection and to the novel approach of
using malarial therapy. Clearly, the therapy is having an impact on the immune system and future tests on
samples to be collected in coming months will establish the dimensions of changes on the immune parameters
of HIV infection. My congratulations to those in the Municipal Health and Anti-epidemic Station of
Guangzhou who have supported you in such a way as to make this important study possible.
Also, my thanks for your hospitality. r look forward to my next visit to Guangzhou.
Sincerely,
Oof.-
JOZF:ey, M.D.
Union ofImmunological Societies (lUIS)
JLF/kw
I
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
Fax
To: Valerie Harper
From: Joan Steinberg
Fax: (212) 754-2892
The following three pages are a listing of the Diamond Mines in South Africa. This
information was retrieved on the Internet. As you can see from the Table of Contents, I
was able to get a listing of the members of Mines of South Africa. I will be mailing you
the complete list comprising 19 pages today.
I am also faxing you a copy of a letter we received today from David Mahoney.
In case I don't speak with you before Santa Claus day, I hope you have a Happy Holiday.
From the desk of .. .
Joan Steinberg
Director
members list
lof19
February 1998
Chamh;:r
of [VI iut's of
South Africa
'''VebDirectory:
News and Announcements
13 Commodity Prices and
Economic Indicators
li3Media News of the Day
Ii! Media Releases
11 Speeches
13 Publications (inel downloads)
13 Industry Agreements
13 Events
Data Library
Ill! Data Library Index
13 Monthly Gold Data
13 Analysis of Quarterly Gold
Mine Working Results
m Progressive Analysis of Gold
Mine Working Results
fa SA Mining Industry
Statistical Tables (to download
link)
E! General Mining Facts and
Figures
http://www.bullton.org.zalbulZ8lchaorg/memt>er l.nlmH Ulamona
THE CHAMBER ORGANISATION:
Members of the Chamber
of Mines of South Africa
Contents:
E3
Gold Mining Members
13
Coal Mining Members
m Diamond Mining Members
13 Platinum Mining Members
m Antimony Mining Member
f3 Asbestos Mining Members
Ii! Copper Mining Member
I!
Lead Mining Member
E3
Base Minerals Members
13
Iron Ore Members
m Financial Corporation Members
tia A vgold Limited
Hartebeestfontein Division
Private Bag 800 Stilfontein 2550
TELEPHO'\F
(018)
487-3690
(018)
484-4048
12n198 2:22 PM
members list
110fl9
http://www.bullion.org.zalbulzalchaorgimemberl .htm#Diamond
13 De Beers Consolidated
Mines Limited
POBox616
Kimberley
8300
FinschMine
POBox 7Lime Acres8410

Koffiefontein Mine
POBox 80
Koffiefontein 9986
Namaqualand Mines
Private Bag XO 1
Kleinzee
8282
Premier Mine
POBox44
Cullinan 1000
Venetia Mine
POBox 668
Messina
0900
m Ocean Diamond
Mining Holdings Limited
POBox 15012
Vlaeberg, Cape Town 8018
fAX E";},
0531 0531
807111 807210
(Admin. or
Office) 807230
lion
0531 21040
887111 (Mine
(Mine Office) office)
0533 0533
859911 850791
0532 053
051111 2051002
Ql
0258
8072080
0258
Gen.Mgr
8071911
8073480
(Other
Faxes)
01213 01213
92911 31706
Qm:
01553
49911 01553
(Admin 2019
Office)
01554
01554 0207
0000
Nt
(Mine Office) 01553
49445
01553 (Gen
49911
Mgr)
(Gen. Mgr)
\:'-'\1,
021 021
4399635 4399939
12n198 2:22 PM
December 2, 1998
Dr. Henry Heimlich
DAVID M A H O ~ E Y
7 45 FIFTH AYE}lt;E
SUITE 700
NEW YORK. NEW YORK 10151
2 12/838-3710
The Goetze Center
311 Straight street
Dear Hank:
I am in receipt of your letter and material. It seems
encouraging and I look forward to further results with
optimism.
If I do not see you before the holidays, I would like to
wish you and Jane a great holiday season.
wishes,
David Mahoney
DM/pm
. . ..,',. :t';. . .
,
'From: John L. Fahey, M.D.
.1
To:
'
.. :-:,,:.../.-
..... .
Thursday, january 21,1999 2:39PM
.. ;: " center for Interdisciplina'ry Research
: in Immunology and Disease (CIRID)'
January 21, 1999
VIA EMAIL
Dear Dr. Chen: -
".,"
.. -.; ...'
;
f
"
I want to acknowledge receipt of the manuscript draft and the patients' temperature charts. I have rapidly scanned
the manuscript and I find that you have assembled lots of information. However, I will have some suggestions to
make about the focus of individual manuscripts. Unfortunately I am going to be away for the coming week and so
it will be several weeks before I can get back to you. Continue your good work. I believe several fine manuscripts
can be published.
My travel plans for February are not set but I hope to be able to stop in Guangzhou late next month. This would
give us an oppqrtunity to review data and discuss publications further. I will write when my plans are settled.
Sincerely,
John L. Fahey, M.D.
cc: Aziz, M.D.
Vlenry Heimlich, M.D.
Page 1
',. - - ,I:. i
(-f,
J rH m' J! Jf}j ftIi !
!
The Municipat Health and Anti-Epidemic Station of Guangzhou i
r#l51OO80,
January 25, 1999
John L. Fahey, MD
No. 23, 3rd Zhongsban Road, Guangzhou 510080
Chair, Clinical Immunology Committee,
International Union of Immunological Societies
Dear Dr. Fahey:
This follows my last letter by Federal Express. Enclosed here is the manuscript for
submitting to Science. Please you review and correct it and then mail back to me as
soon as you can. There was a mistake in my first manuscript, that is, it should ' be
"levels of lymphocyte proliferative responses to ..... were correlated positively with
the levels of CD25 expression on PBMCs and negatively with the levels of HLA-DR
expression on CD4 cells" cited from the paper written by Dr. Bass and you. Thank
you again.
With best regards and wishes.
0;:;17 14;---
Chen Xiao Ping, MD
Director, Center for AIDS Control & Research .
The Municipal Health & Anti-Epidemic Station of Guangzhou
No. 23, 3rd Zhongshan Road, Guangzhou 510080
Tel: (020) 83802426
Fax: (020) 83815255
E-mail: chenxp@gzsums.edu.cn
!
INSTITUTE
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
............... - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: David Mahoney
cc: Valerie Harper / !
Fax: (561) 832-1721
Date: February 4, 1999
Dear David:
We have received a detailed report from Dr. Chen on the present group of patients in
China. Once again, the current results are favorable. I am pleased to say that in this
group there are 12 patients rather than the 10 we had originally spoken of. This brings
the total malariotherapy patients to 20.
The CD4 cells (immune cells) in all patients either held their own or increased. The 12th
patient, a 35-year-old female, had full-blown, far advanced AIDS. Her CD4 count was
only 15 (normal is above 500). She had ulceration of the external genitalia, pneumocystis
carinii pneumonia (PCP) with difficulty breathing requiring oxygen inhalation. After
malaria treatment, her AIDS symptoms, including the pneumonia, disappeared
(confirmed by chest x-ray) and the ulceration of the external genitalia healed. The CD4
count increased from the original 15 to 41. Significantly, no patient had any
complication from the malariotherapy, indicating the safety of the method.
Dr. Spletzer and I reviewed the work carefully and I discussed it on several occasions
with Dr. Fahey. The attached letter from Dr. Fahey to Dr. Chen indicates his favorable
opinion of the work. We are working together to finalize several scientific papers on the
results to be published in medical journals.
On Monday night's (February 1) CBS national TV news, Drs. Saag and Fauci showed
that drug treatments are failing and the death rate from AIDS in the U.S. has been
climbing rapidly. This lends additional urgency for the development of malariotherapy.
I hope all is well with you. Please send our love to Hillie.
Affiliated with The Deaconess Associations, Inc.;.,:
President
Heimlich Institute
Fax: +1 (513) 559-2403
. . ..,',. :t';. . .
,
'From: John L. Fahey, M.D.
.1
To:
'
.. :-:,,:.../.-
..... .
Thursday, january 21,1999 2:39PM
.. ;: " center for Interdisciplina'ry Research
: in Immunology and Disease (CIRID)'
January 21, 1999
VIA EMAIL
Dear Dr. Chen: -
".,"
.. -.; ...'
;
f
"
I want to acknowledge receipt of the manuscript draft and the patients' temperature charts. I have rapidly scanned
the manuscript and I find that you have assembled lots of information. However, I will have some suggestions to
make about the focus of individual manuscripts. Unfortunately I am going to be away for the coming week and so
it will be several weeks before I can get back to you. Continue your good work. I believe several fine manuscripts
can be published.
My travel plans for February are not set but I hope to be able to stop in Guangzhou late next month. This would
give us an oppqrtunity to review data and discuss publications further. I will write when my plans are settled.
Sincerely,
John L. Fahey, M.D.
cc: Aziz, M.D.
Vlenry Heimlich, M.D.
Page 1
Follow-up reports and paper manuscripts mailbox:/C% 7C/Program %20Files/Mail... 7.79857121@gzsums.edu.cn&number=57
Subject: Follow-up reports and paper manuscripts
Date: Tue, 09 Feb 1999 17:35:35 +0800
From: Chen Xiao Ping <chenxp@gzsums.edu:cn>
CC: "Henry J. Heimlich" <heimlich@juno.com>,
"Dr. Eric G. Spletzer" <egspletzer@hotmail.com>
Dear Dr. Heimlich:
Thank you for your letter of January 7, 1999. I am sending the follow-up
(1, 3 and 6 months) reports and our paper manuscripts to you via Federal
Express today. I look forward to receiving your email or written
response after you read them. By the way, Dr. Fahey will visit me again
on Chinese New Year holiday in Guangzhou. We will talk many topics
during his visit and I will let you know the detail after that.
Give my best regards to you, your family and your colleagues. Happy
Spring Festival (Chinese New Year)!
Xiao Ping from Guangzhou
2/9/998:14 AM
m:w papers
Subject: new papers
Date: Fri, 12 Feb 1999 16:37:40 -0500
From: "Dr. Henry J. Heimlich" <heimlich@iglou.com>
Organization: Heimlich Institute
To: chenxp@gzsums.edu.cn
CC: jlfahey@rnicroimmun.medsch.ucla.edu
February 12, 1999
VIA E-MAIL
Director, Center for AIDS Control & Research
Guangzhou 510080
Dear Dr. Chen,
We received your e-mail of February 9, as well as a copies of your
papers from Dr. Fahey.
When you visited my home, you asked me whether you could put your name
as first author on a paper to be published in China. I agreed providing
the paper contains the words, "One of us (Dr. Heimlich) conceived that
malariotherapy could be a safe, inexpensive and potentiall y effective
tratment for controlling or eliminatin g HIV infection. Dr. Heimlich's
conclusion was based on the following: 1 } He was aware that
malariotherapy had been used for treati ng neuro syphi l is. 2} Whi l e
researching malariotherapy for c ancer and Lyme disease (NEJM
1990;322:1234), he discovered and revi ewed references whi ch
demonstrated malaria induces production o f i mmune s ubs tances and ha s a
positive and safe effect on AIDS patients." Thi s stat ement , whi ch is
not present in the preliminary papers you sent to Dr. Fahe y , shoul d b e
included in the "Introduction" or the " Di scussion " section of e very
paper we submit. You have done s o much work on these papers, it is
appropriate your name appear first, a s l ong as the paper incl udes the
above statement.
We are fortunate to have Dr. Fahey rev iew a nd e d i t our paper s. As you
know, in addition you and I agreed we mus t each r e view and app r ove the
final version of any papers on our wo r k befo re submi tting them fo r
publication. This is particularly i mport a n t s ince I understand from Dr .
Fahey that one paper will be submitted to Sc ienc e. I am a member o f t he
American Association for the Advancement o f Science, wh i ch publishes
Science. They may very likely contac t me when the paper is submitted.
We look forward to seeing the followup results. Have you sent the
samples to Dr. Fahey for viral load measurement and testing?
We are in the process of securing funding to treat 100 HI V+ patients
with malariotherapy. Are you interested and able to participate in this
large of a study?
I hope you are able to meet with Dr. Fahey. This will be beneficial for
all of us.
Best wishes and may you have a very happy New Year,
2/ 19/9911:47 AM
mailbox:/C% 7ClProgram%20FilesINetscape/N a ... Sent?id=36C49 F24. 7074@iglou.com&numbcr=3 1
President
cc: Dr. John L. Fahey
Please let us know as soon as possible when you receive this e-mail.
Not having received an answer to our previous e-mails to you, we would
like to be certain you are receiving them.
2/19/9911:47 AM
~ Re: your e . of Feb. 12 and discussion of paper publicatmailbox:/C%7C!Program%20Files!Mail...7.209D9877@gzsums.edu.cn&number=59
bj oct: Re: your email of Feb. 12 and discussion of paper publication
Date: Sat, 13 Feb 1999 15:16:07 +0800
From: Chen Xiao Ping <chenxp@gzsums.edu.cn>
CC: "Henry J. Heimlich" <heimlich@juno.com>,
"John L. Fahey" <jlfahey@microimmun.medsch.ucla.edu>
February 13, 1999
President, The Heimlich Institute
311 Straight Street
Dear Dr. Heimlich:
I have received your email of Feb. 12, 1999 (and your former email, but
I replied you on Dec. 6, 1998). I agree with you one hundred per cent
that you are the first person who proposed malariotherapy for HIV/AIDS.
But this has been documented in many places. When I wrote the first
abstract of malariotherapy for HIV infection in our first studies for
submitting to the 9th International Congress on Immunology in 1995 in
San Francisco, I put your name first. Then you did this again in two
International Conference on AIDS in Vancouver and in Geneva. And also,
you wrote our first paper manuscript and publised it as the first author
in the journal of Mechanisms of Ageing and Development. Then I wrote the
second paper manuscript "Phase-I studies of malariotherapy for HIV
infection" in which I mentioned again in the part of Discussion that you
first proposed this idea for submitting to a Chinese medical journal
(English edition). All these have been documented or will be documented
in the history of science. I think that there is no need to mention this
in every paper or every publication because there is continuation in
documentation of science.
In my eyes, your proposal of malariotherapy for HIV/AIDS is definately
right, but (at least part of) the reasons you proposed to try the
therapy for the disease was not appropriate, that is, "malaria causes
the patient's immune system to increase production of a variety of
immune substances" (please note, I did not review the final manuscript
for submitting to the journal of Mechanisms of Ageing and Development)
which was just the reasons that many board members criticized us in a
couple of review board discussions in 1993 in Guangzhou, China (you did
not participated in these discussions). It was that I proposed the
hypothesis that these harmful immune substances would do increase during
malarial phase, but after termination of malaria they would sharply
decrease to around baselines even to lower than baselines due to a feed
back mechanism of immune system in the review board discussions.
Finally, the board agreed us to try the therapy for no more than 10
cases of HIV infection in our phase-l studies. I mentioned this to Dr.
Fahey before I tested the activation markers (NPT, B2M and sTNF-RII)
during my visit to UCLA and mentioned it again in our second paper
manuscript. I remember that I mentioned this in another way when I first
time visited your horne during our talks with John ("malariotherapy
boosts the immune system" is a better way to discribe the mechanism even
though many researchers say that "malaria suppresses immune system") in
1995. But there is no need to mention this in our following paper
manuscpripts. This is a non-regulatory principal of the field of
scientific research worldwide.
It is very clear, if you persist in doing so, such as, my colleagues
will insist in writing that "Dr. Heimlich proposed the idea, Dr. Chen
did the research design, Dr. Chen and his colleagues did the patients'
selections, patients' treatment, follow up and laboratory testing" in
our all papers about our second studies, but as you know, it is no need
doing so.
2/15/998:03 AM
: and discussion of paper publica1mailbox:/C%7C/Program%20Files/MaiL.7.209D9877@gzsums.edu.cn&number=59
- reasonable that we both publish our results in turn as the first
based on our project agreement. I hope you can understand this
my e xplanation above. I believe that some misunderstandings
benree n us is due to lack of direct (face to face) contact. I can
this situation. I hope that this argument does no affect our
exce llent cooperation and friendship has been established since 1991.
Best regards and happy Chinese New Year to you, your family and your
col leagues.
Chen Xiao ping, MD
Director, Center for AIDS Control & Research
The Municipal Health and Anti-Epidemic Station
No. 23, 3rd Zhongshan Road, Guangzhou 510080
of Guangzhou
2/15/99 8:03 AM
i,/(XiaO Ping/Manuscripls
mailbox:/C%7C/Program%20Filcs/Mail, . .3@mcdhub.mcdclr.uc1a.cdu&numbcr=76
1 of 4
S:ttbject: Chen Xiao Ping/Manuscripts
- O .. te: TIm, 4 Mar 1999 15:37:00 -0800
From: "John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>
To: "Heimlich, Henry" <heimlich@iglou.com>
March 4, 1999
President
311 Straight Street
Dear Henry:
I was able to visit with Chen Xiao Ping on February 15th. During that
time, he provided me with an update on data obtained in the last four or
five months and we discussed at length the possible content of
manuscripts. I also had a chance to meet Dr. Bin Quan Xiao socially.
He is the director of the Municipal Health and Anti-Epidemic Station of
Guanzhou and is Chen Xiao Ping+s boss. I also met briefly with the
Director of the Department of Health for the city of Guanzhou and six
other city officials on New Year+s Day on their annual visit to the
Municipal Health and Anti-Epidemic Station. On February 15th (New
Year+s Eve), in the evening, I was invited to dinner with Dr. Chen, his
wife and daughter, and about 12 other members of his wife+s extended
family. It was a very pleasant and cheerful dinner . The city of
Guanzhou was quite dressed up with bright placards and many flowers as
this is a major aspect of Guanzhou+s celebration of the New Year.
In this letter, I want to cover several points regarding the
manuscripts. The identification of the other authors are on the
proposed papers was explained by Dr. Chen. Dr. Wen Jun Shi is a young
lady associate of Dr. Chen+s who does a great deal of the work for him;
Dr. Xiu Qiong He is the senior immunologist at the station; Hui Fang Xu
is the head of epidemiology there; Ikai Gao is the senior technician in
the group and Ji Li Rao is the parasitologist who provides the
standardized preparations of malaria for the studies . On another paper,
there are the names of Shu Guo Liu who is retired clinical professor and
Uyue Heng Lu who is a senior epidemiologist who is now retired . I
believed these latter two were associated with the Municipal Health
Station of Guanzhou.
I hope this helps with identification of people who Chen includes among
the authorship of papers.
I approached the matter of the manuscripts from the standpoint that it
might be useful to start over again and think of the papers from the
standpoint of what questions these studies were meant to answer. In
summary, it seems to me that there might be four separate manuscripts,
but that is something to be decided by you and Dr. Chen . The list of .
topics that I felt were distinguishable were:
A Is malaria harmful to persons with HIV infections?
B How can clinicians use malarial therapy?
C What impact does acute malaria have on the immune system of HIV .
persons?
D Is malarial therapy-beneficial to HIV/AIDS patients?
A. What are the clinical effects of malaria in HIV+ persons other
than effects on HIV infection?
For example, there are 11 or 12 persons in the present study (the 12th
person is a lady who had extremely advanced AIDS and died 6 months after
the end of malarial therapy. She is number 12 in his list of patients
in the present study). In addition, there are 8 patients who were part
of the initial study. Thus there are 19 or 20 HIV+ patients to report
on who have had malarial therapy. I thought that this paper could focus
3/5/99 8:04 AM
P;ngIM,"""';P"
mailbox:/C%7C/Program%20Filcs/Mail .. . 3@mcdhub.medctr.uc1a.edu&numbcr=76
2 of 4
the clinical observations . A careful and thorough exposition of the
observations that were made before malarial therapy, during and
afterwards could define the effects of acute malarial infection in HIV+
persons. The parameters should include weight, temperature, blood
pressure, lymph node and spleen measurements, kidney evaluations
urinalysis), liver tests including enzymes, musculoskeletal evaluatlons,
pulmonary chest x-ray, ocular or vision evaluations, heart, ekg, blood
pressure, pulse characteristics, neurologic examination in detail,
psychological assessments, GI and stool examinations, and Karnofsky ,
performance assessments . Also, hematology should be added with
evaluation of WBC, differentials with emphasis on lymphocytes, PMN,
eosynophils, RBC and hemoglobin. Status of infections such candidias,
cytomegalovirus infection or other infections should be reviewed. What
were the frequency of the tests, how much follow-up has there been on
the first group, and what has been their course during three years since
malarial therapy. The course for the second group should cover both
during malaria and the course in the follow-up year which will be up in
July 1999.
In the drafts of papers I+ve seen so far, for example, there+s no record
of the discomfort that occurs with the acute induced malaria, e.g. the
headaches, the sweating, the other discomfort and how they were dealt
with. So it would certainly be inappropriate to say that malarial
therapy has no impact on the people with HIV infection. It probably has
lots of impact during the acute phase and this should be detailed, in
other words, how many people did/did not have headaches, how many people
had skin reactions, weight loss or other problems associated with the
2-3 weeks of malarial induced fever.
A comparison can be made to the course of natural occurring malaria.
Some of that might have to be anecdotal, but there are probably articles
in the older literature about the clinical course and residual effects
of malarial infection. Also, you and Chen were involved in similar
malarial therapy for 7 cancer patients. The effects in cancer can be
compared to HIV infected persons. Certainly the HIV+ individuals are in
a different immunological state than either the normals or the cancer
patients. Is the clinical course different in the HIV+ and the cancer
patient? What impact does HIV have on the course of malaria? Actually,
Chen Xiao Ping has the impression that these people do quite well in
contrast to the cancer patients. However, quantitative clinical data is
needed as well as general opinions and observations. It seems to me
that this could be a contribution to the whole question of malaria and
HIV infection. Such a paper would also provide an opportunity to review
the published data on the relationship of natural malarial infection and
HIV infection. The published data indicates that malaria is probably
not harmful and may be beneficial. It seems to me that there is no
strong disadvantage in HIV infection to having superimposed malarial
infection. But this needs to be documented in a paper such as this one
which I am requesting here . Malaria stands in contrast, for example to
the effects of tuberculosis. This should be noted. This is a body of
experience that+s been accumulated (and is being accumulated) in the two
Guanzhou studies which is quite reasonable to consider as a contribution
to: the knowledge of clinical malaria and clinical AIDS . This is
entirely separate from the question of whether or not ther e is any
benefit from malaria on the course of HIV infection.
Anyway, I thought that this was a subject that could be dealt with, as a
distinct paper.
B. How to use malarial therapy?
If physicians are going to be asked to use malarial therapy, it has to
be recognized that the current generation of doctors is not familiar
with dealing with malaria. The idea and concept of giving malaria is
going to cause discomfort and present challenges that have not been
addressed in medical training for at least 3 or 4 decades. Thus, I
would suggest that if malarial therapy is to be advocated, there should
an article outlining how to select patients (for example, should people
with severe cardiac problems be given malarial therapy) (Should people
with severe neurologic diseases or mental problems be given malaria?)
36/99 R:04 AM
/ ,
./Xiao Ping/Manuscripts
mailbox:/C%7ClProgram%20FiIcs/Mail. .. 3@mcdhub.mcdctr.ucIa.cdu&numbcr=76
'\ ()f 4
Tna \: has to do with patient selection. Then those that do receive
malarial therapy, what should the doctor be prepared to see in signs and
symptoms. How can the physician help reduce the headaches, or reduce
the discomfort from the fever, or if there are shaking chills how to
deal with that. What are all of the clinical manifestations that might
be encountered and how should the physician and nursing staff be
prepared in advance to treat or ameliorate or prevent the complications
of the period of experiencing acute malaria? For example, aspirin.
Should that be given? What else might be given if people are not .
tolerant of aspirin, and so on. I think there is a whole clinical paper
here that should be prepared if malarial therapy is to be advocated in
developing countries or the western world.
C What impact does acute malarial therapy have on the immune
system in HIV patients?
This is a study that can be written fairly soon, e.g. when additional
measurements are made on plasma samples that are already available.
This will encompass the immunologic measurements made in a normal
population, as well as those made at baseline in the HIV positive
population as well as during and immediately following the malarial
therapies. The presentation should define the disordered immune system
at baseline and includes the cytokines and activation markers of
cytokine activity, e.g. neopterin and fi2M. A second category has to do
with the abnormalities on lymphocytes that are represented by CD28
measurements, by CD25 (IL2 receptor alpha chain) and by HLA-DR
(activation marker expression). It also has to do with the numbers of
CD4 and CD8 T cells during the febrile periods and immediately
afterwards. These measurements should not address the ultimate status
of the immune system, e.g. 3 months after following malarial therapy.
This data can be compared to what IL-2 administration does in HIV+
patients and what malaria does to cytokines in HIV negative persons or
in animal systems. Chen has assembled some of these publications and
can use it in this report. Also there can be a general assessment of
differences in the impact of acute malaria on the immune system in HIV
positive persons with advanced disease (very low CD4 levels),
intermediate disease and less severe disease (with relatively normal CD4
Tcell levels). There are other relevant things in the literature that
could be used to interpret the impact of this kind of stimulation on the
immune and can be compared with the effects of IL2 given in cancer
patients and in people . with HIV infection.
D. Is malarial therapy beneficial to patients with HIV-AIDS?
This is what Chen Xiao Ping has been trying to write and it is not
appropriate to write at the present time. What are the end points or
factors to be considered as beneficial? Antiretroviral therapies are
considered beneficial if they reduce viral load. Immune based therapies
can be considered beneficial if they improve CD4 count or immune
function. There has to be a definition of a significant increase in CD4
levels. In at least one study in the U.S.A., an increase of 200/mm3 of
CD4 cells is regarded as significant. How many of this current group of
12 people have had increases of 200 after therapy or in subsequent
months? The second question relates to how many people showed
increases. Is this increase temporary or sustained? What are the
characteristics of those who have increase in CD4 cells? Are the
characteristics of those who do not show a change or show a fall in CD4
cells? The stratification of patients in terms of disease severity as
manifest by the CD4 Tcell levels, e.g. over 500, 250-500, under 250 and
perhaps u n d e ~ 100. Is the virus load at baseline a factor in
determining whether malarial therapy is effective in increasing CD4
Tcells? Does malarial therapy provide a transitory or a sustained
increase in HIV plasma virus load in any or all of those subjects?
would this be considered a disadvantageous effect on the HIV-AIDS?
The information to write this paper is simply not available yet. It
will be available after the 12th month CD4 measures have been made
presumably in 1999. And after the virus load determinations are
completed and the clinical observations over a full year after cessation
of the malarial episode have been assembled. It is a concern to me that
Chen Xiao PingIManuscripts mailbox:/C%7ClProgram%20Files!Mail ... 3@mcdhub.medctr.ucla.cdu&numbcr=7()
~ f f ~ r t s are being made to write this kind of paper with inadequate data.
Indeed, somewhat misleading interpretations of the data to date were
included.
I was quite explicit about these points relating to papers he recently
proposed on the perported clinical benefit of malarial therapy. In
discussing these papers with him, I have used three papers by Kovacs,
Davey, and H. Clifford Lane that he is familiar with, as guidance for
reporting on immune-based therapies.
In summary, it seems to me that there could quite reasonably be four
papers reporting on various aspects of this study, especially if the
initial study is included in terms of clinical experience. I am
including a copy of the paper submitted to the Chinese Medical Society
Journal.
Sincerely,
John L. Fahey, M.D.
P.S. I will send copies of the new data that Chen gave me and some
interpretations within a week. Then we can talk on the phone .
..
f ~
""" , ~ '"'' C' . " 4 '" f
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
............... - - - - - - - - - - - - - - - - - - - - - - - - - - -
To: Valerie Harper
Of: Eleanor Naylor Dana Charitable Trust
Fax: (212) 754-2892
Date: March 5, 1999
This extensive report from Dr. John Fahey speaks for itself. It is certainly a very clear,
encouraging message, and it is evident that, in some way, this study must continue.
President
Heimlich Institute
Fax: +1 (513) 559-2403
1 of 4
- O .. te: TIm, 4 Mar 1999 15:37:00 -0800
March 4, 1999
President
311 Straight Street
Dear Henry:
persons?
3/5/99 8:04 AM
P;ngIM,"""';P"
2 of 4
July 1999.
distinct paper.
36/99 R:04 AM
/ ,
'\ ()f 4
included.
Journal.
Sincerely,
John L. Fahey, M.D.
..
f ~
""" , ~ '"'' C' . " 4 '" f
Paper manuscript of first studies of MT [or HIV
mailbox:/C%7C/Program%20Files/Mail. .. 9.9AOEC831@gzsums.edu.cn&number=78
1 of 1
Subject: Paper manuscript of first studies of MT for HIV
Date: Sat, 06 Mar 1999 19:31:53 +0800
Dear Dr. Heimlich:
Thank you very much for your email of February 12, 1999. Many things are
waiting for us to discuss. But I think we should first discuss the paper
manuscript of "Phase-I studies of malariotherapy for HIV infection".
What is your opinion on the paper title? You mean in your last email
that it is not appropriate to mention my hypothesis about cytokine
responses of malaria, but the aim of this paper is for submitting to a
Chinese medical journal here in China, so the manuscript will most
probably be sent to the board members who joined the review board
discussions about five years ago for review since they are the
authorities in the fields of AIDS and malaria here in China. It was that
this hypothesis persuaded them to allow us to treat a few HIV patients
with the therapy in our first studies of MT/HIV. I hope to receive your
response on this issue very soon. We will discuss many other things
later.
With best regards.
Chen Xiao Ping, MD
3/8/998:16 AM
To: Valerie Harper, The Eleanor Naylor Dana Charitable Trust
From: M.D., President, The Heimlich Institute
INSTIlUTE Re:
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
Date: March 12, 1999
It was evident to me Human Immunodeficiency Virus (HIV), the cause of AIDS, would
become resistant to drugs and would invade the brain where, due to the blood-brain
barrier, drugs cannot reach the virus. The Heimlich Institute, therefore, has concentrated
on strengthening the immune system to destroy HIV throughout the body.
For the past five years, The Heimlich Institute has been conducting research and treating
HIV/AIDS patients in China using malariotherapy. This method is proven to produce
interferons and interleukins, thereby boosting the immune system. The Institute has
treated twenty HIV positive patients in China and followed them from six months to three
years, with gratifying results.
Our work was presented at the 1995 International Congress of Immunology and, in 1996,
at the National Institutes of Health (NIH) and the XI International Conference on AIDS in
Vancouver. As a result, the University of California at Los Angeles (UCLA) Department
of Immunology requested to join us in this research, and has done so.
Please note from the enclosed Washington Times article that malariotherapy is relatively
cost-free and, consequently, suitable for African countries. The Heimlich Institute is
interested in treating patients in Africa and I am contacting you for assistance in
establishing a relationship with physicians and government authorities there. We also
wish to carry out this project in conjunction with your department. Additionally, based on
an article in The New York Times (November 15, 1998), AIDS is destroying the economy
in many African nations. Commercial interests, such as mining companies, etc., would
therefore, undoubtedly want to cooperate in this endeavor.
Enclosed is a published scientific paper which resulted from our presentation at the NIH.
AIDS and malaria are diseases of epidemic proportions in Africa. Some ask how this can
be if malariotherapy can overcome HIV infection. To find the answer, The Heimlich
Institute did an extensive review of published medical reports. The reason malaria and
AIDS coexist in Africa is based on how these diseases are spread, their distribution in
Africa (AIDS is primarily in the cities, malaria is extensive in the countryside), and the
need to use scientific standardization of malariotherapy for proper treatment of HIV.
311 STRAIGHT INTRODUCTION
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403 Henry J. Heimlich, M.D. , ScD. , President of The Heimlich Institute, Cincinnati, Ohio, is
heimlich@iglou.com
Benefiting
Humanity
Through
Health
and
Peace
credited with having saved more lives than anyone else in the world. His name appears
in most dictionaries. He is the only person whose name became a word during his
lifetime: n. He did the Heimlich ; v. I Heimliched him; adj. The Heimlich maneuver. Dr.
Heimlich is the best known physician of the twentieth century.
He invented the Heimlich Chest Drain Valve, which saves tens of thousands of lives
every year, the Heimlich Micro Trach for delivering oxygen, and the Heimlich Operation
for replacing the esophagus. He is currently researching cures for cancer and AIDS and
serving as head of "A Caring World," a program that promotes universal peace and
health.
Dr. Heimlich has attained international acclaim for the Heimlich maneuver, which saves
choking victims and resuscitates drowning victims. The Maneuver is now used to
prevent or overcome acute asthma attacks and may also be used to clear mucus from the
lungs of cystic fibrosis patients.
Phase I Studies paper
1 Mar 1999 18:08:36 -0500
: Henry J. Heimlich" <heimlich@iglou.com>
--=-= 7 I 1999
-;--A E- MAI L
C e n Xi ao ping
l
M.D.
Di r ect or, Center for AIDS Control & Research
No . 23, 3rd Zhongshan Road
Gua ngzhou 510080
Dear Dr. Chen,
We are currently reviewing your paper, "Phase-I Studies of
malariotherapy for HIV infection." The title of the paper is fine.
There are many mistakes in the English wording, such as misspelling
"syncytia" as "sincytia." If this paper is to be published in Chinese,
we won't worry about them. However, if the paper is to published in
English, these will need to be fixed. We are willing to help if you so
desire.
There were also several scientific difficulties with the paper. In the
Conclusion section of the Abstract, you say "The results indicate that
malariotherapy basically is safe ... but does not kill HIV in vivo." We
don't know whether or not malariotherapy kills HIV in vivo, so we can't
make this statement. This is why it is important to send us the results
of viral loads in our present series. without them, the scientific
community will not accept any claims regarding malariotherapy.
Reference 20 (our Mechanisms of Ageing and Development paper) in the
Introduction section is cited for the number of people treated with
malariotherapy. It is not an authoritative source for this number.
Reference 20 should be cited for the statement, "The idea of trying
malariotherapy for HIV/AIDS came to us (20) ... ", as well as for the
statement, " ... when Dr. Henry J. Heimlich (20) first proposed the idea
of malariotherapy for HIV/AIDS ... " in the Discussion section.
In the Introduction, "5. Safety of malariotherapy . . . over ten thousand
neurosyphilitics treated with the therapy" does not accurately represent
the situation. Published studies report the effects of malariotherapy
on 35,000-40,000 patients, and the NIH laboratory in South Carolina
reports providing 20,000 doses of malarial blood to hospitals for
malariotherapy of neurosyphilis. In addition to the 20,000 patients
treated, blood was taken from them to treat many other patients.
In the fourth paragraph of the discussion, you discuss weight loss of
the lymph nodes, but say that this has not been observed in our
patients. However, your followup reports to us did not report
enlargement of the lymph nodes, in contrast to the initial examination
reports that do mention lymph node enlargement.
In the Conclusions section, you use the phrase "immunological
affectation." This should be "immunological effect. " If the paper is
being published in Chinese, this may not be a problem with the paper,
but a mistranslation. If the paper is being published in English, this
is a significant problem, but we are willing to help ensure the phrasing
is correct.
In the acknowledgements, you should include the statement, "Funding for
this study was provided by the Eleanor Naylor Dana Charitable Trust,
David Mahoney, Chairman."
3/17/99 6:09 PM
~ ~ ~ = - ~ ~ ese dif ficulties, the paper looks good. Should you want
=e =e_p , please let us know. If we find any further problems, we
: e ~ you know as soon as possible.
3<::"- wi. shes,
~ e ry J. Heimlich, MD, ScD
?=esident
Researcher
3/17/996:09 PM
uscript
mailbox:/C%7C/Program%20Files/Mail. .. O.7FE8F8B8@gzsums.cdu.cn&number=82
- bject: Correction of paper manuscript
Date: Sun, 21 Mar 1999 10:50:41 +0800
Pres ident
The Hemlich Institute
Dear Dr. Heimlich:
Thank you for your email of March 17. All your suggestions on the paper
manuscript are right. Please you correct it directly on the manuscript
including its English language and scientific contents, then please mail
back to me as soon as you can. By the way, I also receive some
suggestions from Dr. Yunzhen Cao who works at the National Center for
AIDS Control and Prevention of China; she just returned to China last
year from the Aaron Diamond AIDS Research Center in New York City at
which Dr. David D. Ho works. I want to submit this manuscript to the
Chinese Medical Science Journal (English Edition) copyrighted by the
National Medical Scientific Academy of China after correction based on
your suggestions and Dr. Cao ' s. Publication of this paper in this
journal is very important to us if we want to try the malariotherapy for
100 HIV/AIDS patients more in China in the coming years since the
academy is the most powerful institution for medical research in China
(equals to NIH of USA) and the journal is published internationally. I
hope to receive your corrected copy of the manuscript not too late.
Thank you again .
with best regards.
Xiao Ping Chen, MD
Director
Center for AIDS Control and Research
at Municipal Health and Anti-Epidemic Station of Guangzhou
3/22/99 3:35 PM
' - - = _ ~ " " , - .. ' ... ' L"rgent mailbox :/C% 7C/Program %20Files/Mail. .. F.2C 11 B9C4@gzsums.edu.cn&number=85
b' ect: Corrected manuscript Urgent
lDate:. Sun, 28 Mar 199909:33:35 +0800
CC: "John L. Fahey" <jlfahey@microimmun.medsch.ucla.edu>,
Dear Dr. Heimlich:
Have you received my email of March 21? I just got a message from the
Department of Health of Guangdong Province that we need to get approval
from national review board organized either by the Ministry of Health
or by National Committee of Science and Technology of China if we want
to do phase-2 study of malariotherapy for HIV/AIDS here in China, which
contains control group and about 100 HIV/AIDS patients, So it is urgent
to published our second paper of phase-1 study in a top journal in
China. This is very important for us to get the approval for our third
study from the top review board of the country . I am now preparing the
protocol of the phase-2 study. Would you please send the corrected
manuscript of phase-1 study to me as soon as you can. Thank you. By the
way, we are working with Dr. Najib Aziz on the cytokine and receptor
testing. All things are going well here. The samples for viral load
testing will be send to UCLA very soon (we got CDC permission document
for shipment of HIV samples three days ago through Dr. Aziz). I hope all
things are going well with you.
Sincerely,
Chen Xiao ping, MD
3/29/998:17 AM
1 of 4
- O .. te: TIm, 4 Mar 1999 15:37:00 -0800
March 4, 1999
President
311 Straight Street
Dear Henry:
persons?
3/5/99 8:04 AM
P;ngIM,"""';P"
2 of 4
July 1999.
distinct paper.
36/99 R:04 AM
/ ,
'\ ()f 4
included.
Journal.
Sincerely,
John L. Fahey, M.D.
..
f ~
""" , ~ '"'' C' . " 4 '" f
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefitting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
.............. - - - - - - - - - - - - - - - - - - - - - - - - - - -
To:
Of:
Fax:
Pages:
Date:
Valerie Harper
(212) 754-2892
June 1, 1999
From the desk of.. .
President
Heimlich Institute
Fax: + 1 (513) 559-2403
OS/28 / 99 FRI 13:32 FAX 51342103 1 5 EI'l5COI':\L DlOCESE SU OH
g'k, ('}leUr
4 J/J't
Ok>- 46202
May 25, 1999
Henr y 1. Heimlich, MD., ScD
The Heiml ich Institute
3 I I Strait Street
Cincinnati . OH 45219
Fax: 559-2403
Dear Dr Heimlich .
Bishop Thompson has sent the attached letter to the eleven
Archbishops of the Anglican Communion in Africa. I hope it will serve as sufficient
introduction from which you might follow up with further details. I have also attached
the names and addresses of the Archbishops.
It was a great privilege to meet you and have the opportunity to discuss your
pioneering efforts with AIDS/ HIV and malariotherapy. The Bishop and I wish you well
in this important and potentially world-changing work. Please let me know ifI can help
in any additional ways. My number at the Diocese is 513-42] -0311.
This comes with greetings from Bishop Thompson and my every good wish
Sincerely yours.
E-::rence
Canon to the Ordinary
.

05 / 28 / 99 FHI 13 : 33 FAX 51342103J5 El' [SCOI'AL 0 lOeESE S O Oil
May 20, 1999
['/ tk .(}/Mh-
gk.

SIS-4.2I-OSI1
Dear Archbishop ____ -'
Greetings in the Name of our Risen Lord_ At this time of
preparation for Pentecost, may the outpouring of the Holy Spirit bring new life and
inspiration to all of the clergy and lay people of your great Province.
I am writing to share with you some exciting news I have learned about what may
be a revo lutionary breal.-through concerning the worst epidemic to affect our world in the
recent times, AIDS. This effort has been by Dr. Henry Heimlich, who has
been called "the best-known physician of the 20 Century." Dr. Heimlich is probably
best known for the development of what is called "The Heimlich Maneuver" for saving
victims who are choking. His work also includes the development of significant surgical
techniques for the replacement of the esophagus and the Heimlich MicroTrach to help
rehabilitate emphysema patients. He currently heads the Heimlich Institute Foundation
here in Cincinnati.
Recently, I met with Dr. Heimlich to learn about his proposed treatment of the
AIDS virus. It derives from a well-established treatment for neurosyphilis called
"malariotherapy." The original development of malariotherapy was of such significance
that its developer, Julius Wagner von Jauregg, was awarded the Nobel Prize in Medicine
in 1927. By intentionally affecting a patient with an easily curable form of malaria, Dr.
von Jauregg discovered, the auto-inunune system is enhanced, thereby fighting off other
infections. Dr. Heimlich' s studies indicate that malariotherapy is as effective against
AIDS as it has been against neurosyphilis_
Dr. Heimlich is especially interested in bringing his work to the attention of
leaders in the nations of Africa, which have felt the scourge of AIDS the most. A man uf
great compassion and commitment, Dr. Heimlich sees malariot herapy as an inexpensive
and effective way to deal with this deadly disease that has had such a catastrophic effect
on African peoples.
I have suggested that Dr. Heimlich contact you directly to share his thoughts and
plans and as a way of helping to communicate his understanding of this form of therapy.
I am writing to you in advance ofthat contact in order that you might be aware of his
work and give some thought about your own ideas and questions.
@U03
06 / 28 / 99 FRI 13:33 ~ A X 6134210316 EPISCOPAL DIOCESE SO 011
I am including with this letter a brief paper Dr. Heimlich has written on the
premise and scope of his work with malariotherapy. I hope it will help explain this
procedure more fully. I also hope that it may open up some new discussions about
possible forms of affordable treatment, including this one.
We know the human and global tragedy that HIV / AIDS has caused, particularly
for the people of Africa. I pray that God is leading us toward finding a cure for this
horrible disease, so that all may be restored to wholeness and receive the healing which
Christ intends for all of his world.
With every good wish, I am
Yours in Christ,
The Rt. Rev. Herbert Thompson, Jr.
Bishop of South em Ohio
~ 0 0 4
05 / 28 1 99 FHI 13:34 PAX 5134210315 EPISCOPAL fJ.IOCESE SO Ull
f4J (J05
The Most Rev. David Gitari
Archbishop ofProv. Of Kenya
Box 4050
Nairobi KENYA
The Most Rev. Winston H.
Njongonkulu Ndungane
Archbishop of Cape Town
l6-20 Bishopscourt Claremont
Cape Town Province 7708 SO.
The Most Rev. Robert Okine
Archbishop of West Africa
Box 980
Koforidua GHANA
The Most Rev. Njojo Byankya Eaz
Boga-Zaire
P. O. 21285
Nairobi, KENYA
The Most Rev. Joseph Adetiloye
Archbishop
Box 13
Lagos, NIGERIA
The Most Rev. Donald Mtetemela
Archbishop of Tanzania
Box 1028 Iringa
TANZANIA
The Rev. Nelson Koboji Nyumbe
Provincial Secretary Box 110
JubaSUDAN
The Most Rev. W. Khotso Makhulu
Archbishop of Central Africa
And Primate
Box 769
Gaborone, BOTSWANA
The Most Rev. Emmanuel Mbona-
Kolini
Primate
Eglise Episcopal de Rwanda
BP 225 Kigali RWANDA
Tpe Most Rev. Livingstone
Mpalanyi-Nkoyoyo
Box 14125
Kampala, UGANDA
The Most Rev. Samuel Ndayiisenga
Eglise Episcopate du Burundi
BP 98 Ngozi
BURUNDI
VI/
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAA 513-559-2403
heimlich@iglou.com
Benefitting
Humanity
Through
Health
and
Peace
June 1, 1999
Letters to the Editor
The New York Times Magazine
229 West 43rd Street
New York, NY 10036
E-mail: magazine@nytimes.com
Re: A Brutal Cure by Lisa Belkin, May 30,1999
Describing revived old treatments, Lisa Belkin writes (May 30): "In the 30's and 40's
mental institutions treated end-stage neurosyphilis with malaria therapy - they infected
syphilis patients with treatable malaria in the hope that the high fevers caused by one
would slow the mental degeneration caused by the other." This isn't quite the case.
Drugs and antibiotics had been tried, but failed to cure neurosyphilis because they cannot
cross the blood-brain barrier. From 1918 until 1975, when neurosyphilis was wiped out,
malaria therapy cured tens of thousands of neurosyphilitics. Its discoverer won a Nobel.
Similarly, AIDS cannot be cured by drugs because residual virus remains in the brain and
other tissues. Consequently, as Belkin mentions, malaria therapy has been revived as a
treatment for AIDS. Over the last ten years, studies throughout the world have shown
that malaria boosts the immune system. Other studies show malaria infection extends the
life of AIDS patients, and does not endanger them. Five years ago, we, at The Heimlich
Institute, initiated a clinical trial, treating HIV(AIDS) patients with malaria therapy. As
in treating neurosyphilis, a curable form of malaria is injected and the patient has malaria
for three weeks, at which time the malaria is cured with anti-malarial medication; no
further treatment of any kind is given. The results of treatment, an increase in the
immune cells to high normals which persists, are encouraging. The program is being
expanded to several countries.
President
e-mailed 6/1/99
Affiliated with The Deaconess Associations, Inc. I ~
I,
I
/!
I
1[
The landscape of Ihe chesl cavil,
is scrambled beyond recognition .... This is less a surgery, therefore, than an
excavation, as the surgeons chip their way through the anatomical debris.
provements in lobectomies in the decades since Pomerantz first learned to
perform them is the " muscle flap, " in which a piece of the latissimus dorsi,
or back muscle, is wrapped around the bronchia to seal the site and keep air
from getting in or out. Because tuberculosis needs air, this would poten-
tially increase Choummanivong's chance for a cure. But it would also re-
duce his muscle strength significantly, and his doctors all knew how im-
portant sportS were to him.
Pomerantz and Iseman, two avid athletes, debated over whether the flap
was necessary. Iseman argued that it was not, believing that the infection
was controlled well enough to justify the risk and that the lower lobe
would inflate sufficiently to fill the empty space. Pomerantz eventually
agreed. "Everything is a best guess of the moment, a trade-off between the
most extreme procedure and the life the patient will have after you save his
life," he says.
It was a best guess they would come to second-guess over time.
Instead of a clean bill of health, Choummanivong received word that he
would need to surgically surrender four ribs in an attempt to close the space
- called a thoracoplasty, this was another resurrected technique of the
50's. For months after, feeling vulnerable without calcified armor over what
remained of his lung, Choummanivong held his right arm tightly to his
chest, resisting the physical therapy that would restore full motion.
While he recovered from surgery, his drug doses were increased to
fight the growing infection, a change that sent him into a hallucinatory
hell. In a moment of psychosis, he painted a vampirish mermaid on the
wall of the lounge. The creature had claws instead of fingernails, with
blood dripping toward the floor. Its right arm was draped across its chest
and over its shoulder.
"Why did you paint it that way?" Gwen Huitt asked.
"To protect what I have," Choummanivong said.
ONE FfTITNG HISTORICAL FOOTNOTE IS THAT KAFKA HAD TB. THE LIFE the brains of Parkinson's patients, attempting to ease the trem-
E
ARLY IN THE CENTURY, NEUROSURGEONS MADE LESIONS ON
of a drug-resistant TB patient is a Kafka-esque existence - overmedicat- ors and rigidity that are the marks of the disease. In the 60's, the
ed, hallucinatory and surreal. As soon as Choummanivong arrived at Na- drug L-Dopa was introduced, and the surgery all but stopped.
tional Jewish in the summer of 1996, his first-line drugs were discontinued Over time L-Dopa was found to lose its effectiveness in some long-term
and he entered the realm of more desperate, more toxic, pharmaceuticals. patients, and the thalamotomy (creating a lesion on the thalamus) is be-
Like chemotherapy, AIDS treatments and other mixed blessings of mod- ing used once again.
ern science, these medications poison the body in order to cure it. No one
u
In the 30's and 40' s mental institutions treated end-stage neuroSYPhiliS]
who takes them is free of side effects, and Choummanivong quickly dis- with malaria therapy - they infected syphilis patients with treatable ma-
covered tfiat his reactions were particularly severe. . laria in the hope that the high fevers caused by one would slow the mental
Worst of all for him was the cycloserine. Called "psychoserine" by degeneration caused by the other. The discovery of penicillin ended the , ~
those who use and prescribe it, the side effects include unrelenting mi- treatment in the 40's. In the 80's and 90's the malaria treatment came back,
graines, incapacitating muscle spasms and violent psychosis. His sketch- this time in clinical trials on AIDS patients.
books from the summer of '96 show the imprint of the drugs; the land- Also in the 30's and 40's, scientists tried to treat tuberculosis and oth-
scapes and portraits are replaced by crazily colored abstracts along with er lung infections with a serum of antibodies taken from patients acutely
collages of mismatched body parts and one particularly unsettling crea- ill with the disease and given to other ill patients, as a boost to their own
ture with a green face and blue hair. One morning Choummanivong's at- immune systems. The theory was like that of a vaccine, except that the
tending physician, Gwen Huitt, found him sitting on his bed, staring recipient s were actively sick and the serum was used not to prevent, but
straight ahead. His lunch tray was nearby, and he was holding an un- to treat. Mortality was high, and the era of antibiotics made the serum
opened can of soda. As she sat beside him, his grip on the can grew so experiments too dangerous to justify. Today, in an era of multidrug-re-
tight that it exploded. "I just feel like hurting something," he said, raising sistant TB, AIDS and Ebola, some scientists are suggesting it is time to
his fork in his other hand. Huitt jumped quickly enough that the fork look into serums once again.
pierced the mattress instead of her thigh. Each return to the past is a radical decision, and before Choummani-
Choummanivong's hatred for cycloserine was equaled only by his ha- vong's doctors brought him to the operating room for a third surgery-
tred for capreomycin, an IV medication that made him so off-balance that this one to remove the lower half of his right lung - they changed his
he became nocturnal. sleeping all day and rousing himself in the late after- drug regimen one more time. The standard of care for tuberculosis (a
noon and early evening when the day's side eHects had ebbed. standard out of economic reach to much of the world) is " directly ob-
Choummanivong was discharged from National Jewish in the fall of 1996, served therapy," which, simply put, entails watching patients swallow ev-
three months after his first operation. His medications went home to Mich- ery tablet. It grew from the understanding that most people will balk at a
igan with him. He enrolled in the Kendall College of Art and Design, hoping daily regimen of large, vile-tasting pills with nasty side effects. Since
to become an art teacher. He drove to school exhausted, sat through lectures most drug resi stance is born of the start-:md-stOp approach to med-
and then drove home and collapsed. He didn't dare try to create anything ication, directly observed therapy programs have been shown to h:t\t epi-
during the week. In wood shop, for instance, the tools were such things as demics in their tracks - most recently the outbreak in New York City in
band saws, a terrifying thought for someone so dizzy he could barely stand. the early 1990's.
Somehow he finished the semester, and inJune 1997 returned to Nation- Choumnunivong's doctors had no reason to believe he was not being
:t\ Jewish for a checkup, expecting to be told that the lobectomy and a year rigorously compliant, but they asked him to move to Denver, where one
of medication had cured him, giving him a chance at a normal life. But his of their health workers could keep a closer eye on him. In the summer of
tests showed that his lower lobe had not expanded to fill the empty portion 1998, he rented a small one-bedroom apartment, which he shared with
in his chest cavity, as Iseman and Pomerantz had gambled that it would. As his brother Chip. The $475 rent was paid by Chip, who worked 10 hours
a result, an air pocket had fOnlled, and it was filling with TB-infested fluids. a day parking cars at a nearby casino. Toon' s job was taking his medicine.
38
~ \
n,ailbox:/C% 7C/Program%2 ... ctr.ucla.edu&number= 130 mailbox:/C% 7C/Program%20Files/Mail. .. @medhub.medctr.uc!a.edu&number= 130
1 of 2
Subject:
Date: Fri, 4 Jun 1999 14:07:44 -0700
To: "'chenxp@gzsums.edu.cn 111 <chenxp@gzsums.edu.cn>
CC: '"
naz
iz@ucla.edu'" <naziz@ucla.edu>, "'heimlich@iglou.com'" <heimlich@iglou.com>,
"bhered@ucla.edu'" <bherd@ucla.edu>
in Imlnunology and Disease (CIRID)
June 4, 1999
VIA EMAIL
Chen Xiao ping, M.D.
Dear Dr. Chen:
Many thanks for your letter of May 11 and the data on serial testing for
white blood cell and differential count and flow cytometry. Congratulations
on carrying out this study of 4 subjects for their comparability on 3
different measurement dates. In looking at the data, you might concentrate
on the percent CD4 and the percent CD8 and circle the data for each subject.
You will see that the agreement is fairly good for the CD4%. The major
difference between values is about 14% for subject 1 (35.6-31.3/31.3 = 0.14
or 14%). The difference for subject 2 is about 8% but more substantial in
subject 3, (about 15%) and 10% in subject 4. That is probably pretty good.
When you look at CD8% you will see that the differences are somewhat larger.
The differences inciude within persons and within procedure variability.
However, I would suggest that you repeat the process every 4-6 months with
samples from 2 individuals again on 3 different dates and see how well the
lab does in the testing. These data provides you with a way to calculate
the variability of serial observations and gives you some idea of the
reliability of single flow cytometry measurements in individuals. This does
not include the variabilities introduce by the white blood cell counts and
differentials. You should also calculate the variabilities for CD4 numbers
and CD8 numbers.
I would suggest that you review the data with the operator and leadership in
the flow cytometry lab.
Another reason for looking at this data in normals is to help decide how
much of a confirmed change has to occur in CD4% or numbers to be regarded as
significant and attributable to therapy. (Confirmed change means more than
one measurement at the new levels.) Remember that these serial measurements
in the controls were within a 4 day period. In contrast, your clinical
studies over 12 months have intervals of 3 or more months between most of
the testing dates. A greater variability would be expected with the longer
time intervals.
You can see the reasons why I suggested getting at least 2 baselines and
several measurements at the time that there is an expected change in CD4 or
CD8 levels. The same kind of thinking applies to other lymphocyte
components and immunologic tests and other measurements made to characterize
the stage of disease or status of patients.
I have spoken to Najib and Barbara Hered about getting the reagents to you
that you requested. Najib has been very busy recently with new people in
the labcratory but he said that he will secure these samples and that they
should be off to you soon.
We look forward to seeing the data that you have obtained on the latest
round of flow cytometry measurements as well as other laboratory testing.
~ )
6/7/99 8:07 AM
P.lailbox:/C% 7C/Program %2 ... ctr. ucla.edu&n umber= 130 mailbox:/C% 7C/Program %20Files/Mail...@medhub.medctr.ucla.edu&number=130
2 of 2
Sincerely,
John L. Fahey, M.D.
Cc: Dr. Najib Aziz
Dr. Henry Heimlich
Barbara Hered
6/7/998:07 AM
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 51 3-559-2403
heimlich@i glou com
Benefitting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
-----------------------------------------
To:
Of:
Fax:
Pages:
Date:
Valerie Harper
(212) 754-2892
June 7, 1999
President
Heimlich Institute
Fax: +1 (513) 559-2403
n,ailbox:/C% 7C/Program%2 ... ctr.ucla.edu&number= 130 mailbox:/C% 7C/Program%20Files/Mail. .. @medhub.medctr.uc!a.edu&number= 130
1 of 2
Subject:
Date: Fri, 4 Jun 1999 14:07:44 -0700
To: "'chenxp@gzsums.edu.cn 111 <chenxp@gzsums.edu.cn>
CC: '"
naz
iz@ucla.edu'" <naziz@ucla.edu>, "'heimlich@iglou.com'" <heimlich@iglou.com>,
"bhered@ucla.edu'" <bherd@ucla.edu>
in Imlnunology and Disease (CIRID)
June 4, 1999
VIA EMAIL
Dear Dr. Chen:
Many thanks for your letter of May 11 and the data on serial testing for
white blood cell and differential count and flow cytometry. Congratulations
on carrying out this study of 4 subjects for their comparability on 3
different measurement dates. In looking at the data, you might concentrate
on the percent CD4 and the percent CD8 and circle the data for each subject.
You will see that the agreement is fairly good for the CD4%. The major
difference between values is about 14% for subject 1 (35.6-31.3/31.3 = 0.14
or 14%). The difference for subject 2 is about 8% but more substantial in
subject 3, (about 15%) and 10% in subject 4. That is probably pretty good.
When you look at CD8% you will see that the differences are somewhat larger.
The differences inciude within persons and within procedure variability.
However, I would suggest that you repeat the process every 4-6 months with
samples from 2 individuals again on 3 different dates and see how well the
lab does in the testing. These data provides you with a way to calculate
the variability of serial observations and gives you some idea of the
reliability of single flow cytometry measurements in individuals. This does
not include the variabilities introduce by the white blood cell counts and
differentials. You should also calculate the variabilities for CD4 numbers
and CD8 numbers.
I would suggest that you review the data with the operator and leadership in
the flow cytometry lab.
Another reason for looking at this data in normals is to help decide how
much of a confirmed change has to occur in CD4% or numbers to be regarded as
significant and attributable to therapy. (Confirmed change means more than
one measurement at the new levels.) Remember that these serial measurements
in the controls were within a 4 day period. In contrast, your clinical
studies over 12 months have intervals of 3 or more months between most of
the testing dates. A greater variability would be expected with the longer
time intervals.
You can see the reasons why I suggested getting at least 2 baselines and
several measurements at the time that there is an expected change in CD4 or
CD8 levels. The same kind of thinking applies to other lymphocyte
components and immunologic tests and other measurements made to characterize
the stage of disease or status of patients.
I have spoken to Najib and Barbara Hered about getting the reagents to you
that you requested. Najib has been very busy recently with new people in
the labcratory but he said that he will secure these samples and that they
should be off to you soon.
We look forward to seeing the data that you have obtained on the latest
round of flow cytometry measurements as well as other laboratory testing.
~ )
6/7/99 8:07 AM
P.lailbox:/C% 7C/Program %2 ... ctr. ucla.edu&n umber= 130 mailbox:/C% 7C/Program %20Files/Mail...@medhub.medctr.ucla.edu&number=130
2 of 2
Sincerely,
John L. Fahey, M.D.
Cc: Dr. Najib Aziz
Dr. Henry Heimlich
Barbara Hered
6/7/998:07 AM
--
31 ) St ra ight Street Cincinnati, Ohio 4!)219
Mr. William H. Gates III
President & CEO
Microsoft Corporation
One Microsoft Way
Redmond, W A 98052-6399
Dear Mr. Gates:
June 7, 1999
(!) 13) !)!) 9 -2,12.1
Fax (!)13) 47!)-!)OS7
I am working with Henry J. Heimlich,M,D.,Sc.D., president of The Heimlich Institute, who
is on the verge of a major breakthrough for the treatment of AIDS. As you are undoubtedly
aware, no drug has ever cured a viral infection. A vaccine can control the epidemic
but it cannot cure the 33 million people worldwide already infected. We think malariotherapy
can cure the disease in a cost effective manner.
Dr. Heimlich and his colleagues at the University of California at Los Angeles (UCLA) ,
have been piloting the use of malariotherapy as a potential cure for HIV infection in China.
Malariotherapy, a well established treatment introduced in the early 1900's as a cure for
neurosyphilis, consists of giving a patient a 100% curable fonn of malaria (Plasmodium
vivax) . The malaria is cured after three weeks. Malariotherapy restores immunological function
by stimulating the immune system. This treatment enables the immune system to effectively
combat HIV infection.
To date, 18 Chinese patients are in various stages of treatment. Follow-up data collected on the
first eight HIV -infected patients who received a three week course of malariotherapy, and no
other treatment, revealed that six (75%) had a markea increase in immune cells (CD4 Tcells)
which persisted more than two years post treatment and the patients remain asymptomatic. The
ten additional patients show similar favorable trends in early follow-up.
We are moving very quickly and have an opportunity to expand our research to South Africa.
Dr. Koos Oostuizen, Primary Health Advisor to Randfontein Estates Ltd, has contacted us
to indicate his interest and the availability of 200-300 diagnosed HIV+ patients in Johannesburg
(see enclosed e-mail). Bishop Thompson of the Southern Ohio Episcopal Diocese has sent the
enclosed letter to the eleven Archbishops of the Anglican Communion in Africa.
--_._--- _._--_._ ----- --_._--_ .. -- ---- . . __ ._-_ .. __ .-
Servin,'.:. The f)etl c()ne,..;,..; Ass()c io/ i()ns , Inc.
Dr. Heimlich proposes to treat the African patients with a single three week course of
malariotherapy. A detailed case history, physical examination, and blood testing will be
completed prior to inoculation. Each patient will be fully aware of the experimental nature of the
study through the informed consent process. Follow-up blood tests and viral load counts will be
conducted at one, three, six, 12, 18, 24, 30, and 36 months following treatment.
Through the development of the Heimlich maneuver, a procedure that has saved the lives of
tens of thousands of individuals around the world, the name of Henry J. Heimlich,M.D., Sc.D.,
has become a household word that now appe9Is in most dictionaries. It is entirely possible that,
through your foresight and generosity, his name will also be remembered for discovering the
cure for AIDS. Virtually all of this work has been completed under the auspices of The
Heimlich Institute, founded 1960 in New York, in collaboration with an international collection
of scholars, scientists and researchers at leading universities and research facilities. In 1969,
Dr. Heimlich relocated The Heimlich Institute to Cincinnati, Ohio; in the Spring of 1998, The
Heimlich Institute became a member of Deaconess Association,Inc.
We sincerely hope you will provide support to this promising treatment which may cure
HIV -positive patients in Africa and worldwide. A funding level of 1.2 million dollars is need to
complete the research. Dr. Heimlich and/or I would be pleased to visit with you or discuss the
project with you by telephone at any time. Thank you for the opportunity to appeal to you for
financial support to continue this international lifesaving project.
Sincerely,
~ ~ ~
Charles P. McDowell
President
Enclosures
Research in Malariotherapy
mailbox:/C% 7C/Program%20Filcs/MaiI...3B25A06D I B40@NJCIJPCORO&number= 135
lof2
SUbject: Research in Malariotherapy
Date: Mon, 14 Jun 199909:01:43 +0200
From: "Koos Oostuizen Dr (James Park)" <MOosthui@jci.co.za>
To: heimlich@iglou.com
Dr Heimlich,
Sorry it seems we miss each other on the phone continuously. I
want to confirm that we can do the test you require because we use it in
our determination or AIDS cases. Currently we use both CD4/CD8 and viral
load. We have excellent facilities available and the laboratory we use
is a private company with excellent quality control. We are still
looking at the information we received from you but from the Western
Areas Ltd/Placer Dome joint venture they have expressed their interest.
I am looking forward to meet you.
Thanks,
Koos Oosthuizen
-----Original Message-----
From: Koos Oostuizen Dr (James Park)
Sent: Friday, June 04, 1999 07:54 AM
To: 'heimlich@iglou.com'
Subject: FW: Donation Malariotherapy
Dr Heimlich,
Unfortunately I haven't received more detail on this
topic from you and would like to consider the proposal. Maybe you could
fax me the details as we discussed per phone.
Fax +2711 411 2237
Thank you,
Koos Oosthuizen
Sent: Friday, May 28, 1999 07:03 AM
Subject: Donation Malariotherapy
Dr Heimlich,
I am Dr Koos Oosthuizen the Primary and Occupational
Health Advisor to Randfontein Estates Gold Mine (Randfontein Estates
Ltd) and Placer Dome Western Areas Ltd joint venture. I received your
letters requesting donations from the above said companies. I would like
more information on exactly what you intend to do as the preliminary
findings of the trial are not of any statistical significance. We have
excellent facilities available and can assist in a clinical trial of
this nature. Dr N F Alberts has participated in various clinical trials
and have the necessary qualification to assist you in this type of
trial. We would be able to ensure that your trial can be done with at
least 200-300 patients. The current HIV prevalence on the mine varies
between 35-40 percent. Our workers from the rural areas of Mozambique
and Kwa Zulu in fact usually return in the summer months back from leave
infected with Malaria(falciparum)
I tried to contact you telephonically to discuss this
concept with you, but the phone number 091- 513-221 0002 is out of
order. Could you please send me
more information or contact me to ensure that our executives can make a
decision on the donations.
Thank you,
Koos Oosthuizen
Phone : +27 11 411 2210
Mobile: +27 82 654 0590
6/14/998:21 AM
facsimile
TRANSMITTAL
.............. ---------------------------
311 STRAIGHT To:
STREET
CINCINNATI or ..
OHIO
45219
513-559-2391 Fax:
FAX 513-559-2403
heimlich@iglou,com
Benefitting
Humanity
Through
Health
and
Peace
Pages:
Date:
Valerie Harper
(212) 754-2892
July 1, 1999
From the desk of. ,.
Henry J, Heimlich, MD
President
Heimlich Institute
Fax: +1 (513) 559-2403
Research in Malariotherapy
mailbox:/C% 7C/Program%20Filcs/MaiI...3B25A06D I B40@NJCIJPCORO&number= 135
lof2
SUbject: Research in Malariotherapy
Date: Mon, 14 Jun 199909:01:43 +0200
Dr Heimlich,
Sorry it seems we miss each other on the phone continuously. I
want to confirm that we can do the test you require because we use it in
our determination or AIDS cases. Currently we use both CD4/CD8 and viral
load. We have excellent facilities available and the laboratory we use
is a private company with excellent quality control. We are still
looking at the information we received from you but from the Western
Areas Ltd/Placer Dome joint venture they have expressed their interest.
I am looking forward to meet you.
Thanks,
Koos Oosthuizen
Sent: Friday, June 04, 1999 07:54 AM
Subject: FW: Donation Malariotherapy
Dr Heimlich,
Unfortunately I haven't received more detail on this
topic from you and would like to consider the proposal. Maybe you could
fax me the details as we discussed per phone.
Fax +2711 411 2237
Thank you,
Koos Oosthuizen
Sent: Friday, May 28, 1999 07:03 AM
Subject: Donation Malariotherapy
Dr Heimlich,
I am Dr Koos Oosthuizen the Primary and Occupational
Health Advisor to Randfontein Estates Gold Mine (Randfontein Estates
Ltd) and Placer Dome Western Areas Ltd joint venture. I received your
letters requesting donations from the above said companies. I would like
more information on exactly what you intend to do as the preliminary
findings of the trial are not of any statistical significance. We have
excellent facilities available and can assist in a clinical trial of
this nature. Dr N F Alberts has participated in various clinical trials
and have the necessary qualification to assist you in this type of
trial. We would be able to ensure that your trial can be done with at
least 200-300 patients. The current HIV prevalence on the mine varies
between 35-40 percent. Our workers from the rural areas of Mozambique
and Kwa Zulu in fact usually return in the summer months back from leave
infected with Malaria(falciparum)
I tried to contact you telephonically to discuss this
concept with you, but the phone number 091- 513-221 0002 is out of
order. Could you please send me
more information or contact me to ensure that our executives can make a
decision on the donations.
Thank you,
Koos Oosthuizen
Phone : +27 11 411 2210
Mobile: +27 82 654 0590
6/14/998:21 AM
From:
To:
Date:
Subject:
Dr. Oostuizen
Charles McDowell
SMTP GATEWAY ("MOosthui@jcLco.za")
6/14/9910:33am
Malariotherapy Research
Just a short note to let you know we received your e-mail this
morning. Your news is wonderful and we are looking forward
to working together on the malariotherapy research.
Could you please confirm the best way to decide where we go from
here. Perhaps a prearranged time and date for a telephone
conference call would be best. You can e-mail me at my office
(the address should be posted) or at my home which is
mcdowell@eos.net
Thank you for contacting us and I look forward to hearing from you
soon. My U.S. telephone number with voicemail is: (513) 559-2664.
Sincerely.
Charles McDowell
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefitting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
............... - - - - - - - - - - - - - - - - - - - - - - - - - - - -
To:
Of:
Fax:
Pages:
Date:
Valerie Harper
(212) 754-2892
.,1;, including this cover sheet.
~ j 1999
President
Heimlich Institute
Fax: +1 (513) 559-2403
RE: Malar!;>therapy mailbox:/C% 7C/Program %20Files/Mail...3B25A078FB 1 E@NJCIJPCORO&number= 161
1 of 1
Subject: RE: Malariotherapy
Date: Tue, 3 Aug 1999 08:00:12 +0200
Dr Heimlich,
Somewhere our communications must have broken down or
otherwise you haven't received all my E-mails.
We are in fact extremely excited about the expected trials and Dr
Alberts has done some preparatory work. He had a look at the CD4 counts
of patients who were known HIV positive and had contracted plasmodium
falciparum and those that didn't. It actually confirms your preparatory
trials. There CD4 count were raised. I think we should start with the
trials as soon as possible and would like your advice on the road
ahead??
Thanks,
Koos Oosthuizen
From: Henry J. Heimlich, MD, ScD
[mailto:heimlich@ig:ou.com]
Sent: Monday, August 02, 1999 17:55 PM
To: Koos Oostuizen Dr (James Park)
Subject: (no subject)
Dear Dr. oostuizen:
We were just wondering how your program is progressing.
Hope all is
well.
Sincerely,
8/3/998:13 AM
mailbox:/C% 7C/Program %2 ... ctr. ucla.edu&n umber= 166 mailbox:/C% 7C/Program %20Files/Mail. .. @medhub.medctr.ucla.edu&o -
1 of 1
Subject:
Date: Tue, 17 Aug 199906:43:51 -0700
To: Chen Xiao Ping <chenxp@gzsums.edu.cn>
CC: "'heimlich@iglou.com'" <heimlich@iglou.com>, "'naziz@ucla.edu'" <naziz@ucla.edu>
August 17, 1999
Dear Dr. Chen:
I want to acknowledge that I have your letter of June 8 and the information
on the 9 month CD4 levels data for following malarial therapy for HIV/AIDS.
Thank you for the table.
In evaluating CD4 change following malarial therapy, there are several
questions: How many show a CD4 increase? Decrease? No change? Are CD4
changes transitory or sustained. What is the definition of significant
change in number of CD4 T cells (100, 150 or 200 cells/mm3) or % (3, 4, 5
or ?). One way is to make it.
Because there is a substantial variability in serial measurements it is not
appropriate to say that patients responded with sustained higher or lower
levels of CD4 unless that change is verified. Thus, a confirmed directional
change requires two sequential measurements documenting the increase or
decrease in relation to baseline. Example of maintained lower levels of CD4
T cell levels might be patient 2 at band 9 months and patient 3 at 1, 3, 6
and 9 months. Examples of unchanged levels could be patients 3 and 10. The
whole CD4% increase is seen in patient 5.
We can discuss the basis for selecting CD4 200/mm3 or 5% or some other level
as markers of change when we get together in Hong Kong. The key lie in two
portions of your own data. We can look at the two measurements before
therapy in each of your 11 subjects. Also, we can look at your data on
serial analyses in the same week of 5 normal subjects. We can review
differences between measurements in these comparisons.
In usage the definition of an increase or decrease of 5% or of 200 cells/mm3
is partially presented by Kovacs, Lane, et al. in their New England Journal
of Medicine papers, I think you have a copy of that paper. Also, in the
ongoing ACTG 328 protocol evaluating therapeutic effects of IL-2, a change
of that dimension is on of the criteria in the protocol design. This is a
protocol we shared with you when you were here. However, you can establish
other limits on the basis of the data that you have now accumulated. I hope
this is helpful.
Sincerely,
John L. Fahey, M.D.
Cc: Dr. Henry Heimlich
Dr. Najib Aziz
8117/99 2:22 PM
mailbox:/C% 7C/Program%20FileslNets .... 3397D9BC@gzsums.edu.cn&number= 17 1
. Re: Malariotherapy project
Date: Mon, 23 Aug 1999 16:56:23 +0800
To: "Henry J. Heimlich" <heimlich@iglou.com>
Dear Dr . Heimlich:
How are you? I received your last email (except August 19') on the
discussion of the phase-I study manuscript on March 17, 1999 before Dr. Aziz
v isited me. So it was really a period of time that we did not communicate
with each other. We have had the data of 9th and 12th month follow-up. But
in our research protocol, we had no the arrangement of 9th month follow-up;
it was Dr. Fahey's suggestion when he visited me on the Chinese Spring
Festival (in February 1999). Dr. Xiao (the President of the station) said
that we would send the data to you after we receive the funding for third
and 6th month follow-up according to our new agreement made in Cincinnati
1997. By the way, we still owe Yishou Hospital. It costs a lot including the
payment of patients hospitalization and the testing. The reagents that Dr.
Fahey sent to us only account for a part of the cost, we need to buy a lot
of other things such as Ficoll for PBMC isolation, RNAse and PI for CD4 PCD
testing, medium for cell freezing and many other things for single use.
The sample shipment is a big problem since China has a new regulation that
blood samples can not be sent to outside China. We spent about 4 months on
dealing with the shipment procedure but we failed . The only thing we can do
now is to purchase a machine (bONA or RT-PCR) for HIV load testing in
Guangzhou, China. We have got a funding from Guangzhou Government to buy the
machine but we need Dr . Fahey's support for reagent supply. I will meet him
in Hong Kong on August 27 to discuss this issue. I expect he can help us. I
hope all things are going well with you.
Best regards and wishes
Chen xiao Ping, M.D.
Henry J. Heimlich wrote:
> August 19,1999
>
> Chen xiao Ping, MD
> Department of Microbiology
> The Municipal Health and Anti-Epidemic Station of Guangzhou
> No. 23 3rd Zhongshan Rd.
> Guangzhou 510080, P.R. China
>
> Dear Dr. Chen,
>
> It has been some time since we have had contact with you. We had sent
> several e-mails to you regarding the malariotherapy project, but did not
> receive a response. Can you tell us when you last received e-mail from
> us?
>
> In the event that you did not receive our e-mails, we will try to
> briefly cover the points that were in them here.
>
> Dr. Aziz informed us that he had given you a permission letter from the
> CDC concerning the importation of blood samples into the U.S. He told
> us that you were in the process of translating this letter into Chinese
> so that the appropriate authorities could give their approval to
> shipping blood samples. How is this coming? Will it be possible to ship
> the blood samples soon? Or could Dr. Fahey bring them back?
>
> Our records indicate that we should have 9- and 12-month follow-up
> reports on the latest series of patients. Do we have these? Will we be
> able to get them soon? How are the patients doing?
>
> Because of our previous communication difficulties, please let us know
8/23/997:59 AM
mailbox:/C% 7C/Program %20FileslNets .... 3397D9BC@gzsums.edu.cn&number=171
> ~ ~ yo received this letter bye-mail as soon as possible.
>
> 3e51: wi shes,
>
> ~ e ry J. Heimlich, MD, ScD
>
> Eri c G. Spletzer, PhD
8/23/99 7:59 AM
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 513-559-2403
heimlich@iglou.com
Benefitting
Humanity
Through
Health
and
Peace
Fax
To: Valerie Harper
Of:
From: Joan Steinberg
Fax:
(212) 754-2892
Pages: 2
Date:
August 23, 1999
Valerie, Dr. Heimlich asked me to fax the following e-mail which we received this
morning.
Hope all is well with you.
Regards,
Henry J , Heimlich, M.D.
President
t: Malariotherapy project
rnailbox:/C% 7C/Prograrn%20Files!Nets .... 3397D9BC@gzsurns.edu.cn&nurnber= 17 j
SUbject: Re: Malariotherapy project
Date: Mon, 23 Aug 1999 16:56:23 +0800
Dear Dr. Heimlich:
How are you? I received your last email (except August 19') on the
discussion of the phase-I study manuscript on March 17, 1999 before Dr. Aziz
visited me. So it was really a period of time that we did not communicate
with each other. We have had the data of 9th and 12th month follow-up. But
in our research protocol, we had no the arrangement of 9th month follow-up;
it was Dr. Fahey's suggestion when he visited me on the Chinese Spring
Festival (in February 1999). Dr. Xiao (the President of the station) said
that we would send the data to you after we receive the funding for third
and 6th month follow-up according to our new agreement made in Cincinnati
1997. By the way, we still owe Yishou Hospital. It costs a lot including the
payment of patients hospitalization and the testing. The reagents that Dr.
Fahey sent to us only account for a part of the cost, we need to buy a lot
of other things such as Ficoll for PBMC isolation, RNAse and PI for CD4 PCD
testing, medium for cell freezing and many other things for single use.
The sample shipment is a big problem since China has a new regulation that
blood samples can not be sent to outside China. We spent about 4 months on
dealing with the shipment procedure but we failed. The only thing we can do
now is to purchase a machine (bONA or RT-PCR) for HIV load testing in
Guangzhou, China. We have got a funding from Guangzhou Government to buy the
machine but we need Dr. Fahey's support for reagent supply. I will meet him
in Hong Kong on August 27 to discuss this issue. I expect he can help us. I
hope all things are going well with you.
Best regards and wishes
> August 19,1999
>
> Chen xiao Ping, MD
> No. 23 3rd Zhongshan Rd.
>
> Dear Dr. Chen,
>
> It has been some time since we have had contact with you. We had sent
> several e-mails to you regarding the malariotherapy project, but did not
> receive a response. Can you tell us when you last received e-mail from
> us?
>
> In the event that you did not receive our e-mails, we will try to
> briefly cover the points that were in them here.
>
> Dr. Aziz informed us that he had given you a permission letter from the
> CDC concerning the importation of blood samples into the U.S. He told
> us that you were in the process of translating this letter into Chinese
> so that the appropriate authorities could give their approval to
> shipping blood samples . How is this coming? Will it be possible to ship
> the blood samples soon? Or could Dr. Fahey bring them back?
>
> Our records indicate that we should have 9- and 12-month follow-up
> reports on the latest series of patients. Do we have these? Will we be
> abl e to get them soon? How are the patients doing?
>
> Because of our previous communication difficulties, please let us know
8/23/997:59 AM
Paper manuscrip
mailbox:/C% 7C/Program%20Files!N ets .... 80A039 B2@gzsums.edu.cn&number= 1 --

SUbject: Paper manuscrips
Date: Tue, 24 Aug 1999 10:26:12 +0800
To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com>, "Henry J. Heimlich" <heimlich@juno.com>
Dear Dr. Heimlich:
At t ached are our two paper manuscripts to expose the side-effect or
c omplications of malariotherapy for H1V/A1DS and the clinical experience
of our work (I wrote them based on Dr. Fahey's suggestion). I hope you
review them and then give me your comment and suggestion as well as
correct them either in scientific component or in English language.
Maybe the description of "no significant change of H1V load" should be
changed to "the H1V load testing is being conducted" or something like
this. Anyway, these are only grafts, please give me your all ideas on
the manuscripts. I think, they can be submitted to international
journals as soon as we both reach an agreement. By the way, I will meet
Dr. Fahey in Hong Kong on August 27 and we will discuss this issue and
other things such as viral load testing. I look forward to receiving
your response. (Please note, yesterday I sent you an email response)
Sincerely yours,
Chen xiao ping, M.D.
Part 1.3
Name: IS ACUTE VIV AX MALARIA HARMFUL TO HIV.doc
Part 1.2 Type: application/msword
. Encoding: base64
Name: HOW TO USE MALARIOTHERAPY IN TREATING HIV
PATIENTS.doc
Type: application/msword
Encoding: base64
Name: Data of Clinical Assessment of MT for HIV.doc
Encoding: base64
Name: P.vivax density correlates to CD4 baselines.doc
Encoding: base64
1 of 1 8 _6/99 : 1 - AM
IS ACUTE VIVAX MALARIA HARMFUL
TO HIV/AIDS PATIENTS?
Xiao Ping Chen, M.D., Henry J. Heimlich, M.D., Bin Quan Xiao, Ph.D., Hui Fang Xu, M.D.,
Wen Jun Shi, Ph.D., Kai Gao, B.S., Ji Li Rao, M.D., Xiu Qiong He, Ph.D.,
and Eric' G. Sp/etzer, Ph.D.
From the Center for AIDS Control and Research, Municipal Health and Anti-
Epidemic Station (Centers for Public Health and Disease Control) of Guangzhou
(X.P.C., B.Q.X., H.F.X., W.J.S., K.G., J.L.R., X.Q.H.), Guangzhou, China; and the
Heimlich Institute (H.J.H., E.G.S.), Cincinnati, USA. Address reprint requests to Dr.
Chen at the Center for AIDS Control and Research, Municipal Health and Anti-
Epidemic Station (Centers for Public Health and Disease Control) of Guangzhou, No.
23, 3
rd
Zhongshan Road, Guangzhou 510080, The People's Republic of China.
Supported by Guangdong Provincial Committee of Science and Technology 1997
priority grant (China), Eleanor Dana Charitable Trust, David Mahoney, Chairman
(USA) and National Institutes of Health (NIH, USA) grant FW 00003.
, ,
. ' .
Telephone number: 020-83802426
Fax number: 020-83815255
E-mail address:chenxp@gzsums.edu.cn
June, 1999
Abstract Background. Not hannful but beneficial interaction between human immunodeficiency
viruses (HIV) or HIV-like viruses and malarial parasites in human bodies or in animal models was
observed in the past years. This remmded us of the history that therapeutic vivax malaria
(malariotherapy) had been successfully used to treat neurosyphilis. A proposal of malariotherapy
for treating patients with HIV infection and acquired immunodeficiency syndrome (AIDS) was
approved from three review boards in China.
Methods. Total 20 HIV/AIDS patients were selected for the phase-I studies of malariotherapy
and were intravenously infected with Plasmodia vivax to induce artificial malaria. Malaria was
terminated with chloroquine after 10-20 malarial febrile episodes. Clinical assessments were
given before (baseline), during (malarial phase) and after (post) termination of therapeutic vivax
malaria .. The density of Plasmodia in peripheral blood from the HIV I AIDS patients were
compared to that from HIV -negative parasitized blood donors.
Results. There were no significant difference of Plasmodium density between the HIV/AIDS
patients and the HIV -negative blood donors. But it was found that the more severe of
immunodeficiency caused by HIV the milder of malarial symptoms and parasitemia in HIV I AIDS
patients with CD4 cell count baselines below 500 or 6001)l1. All patients got every day or every
other day fever episode with tolerant headache and shaking chill. Rates of spleen and liver
enlargement were respectively 15/20 and 4120 and rate of liver damage represented by increase of
serum glutamic-pyruvic transaminase was 2/20 during malarial phase. Most patients experienced
mild to medium anemia and 6 of the 20 patients got thrombocytopenia during malarial phase. But
all these side-effects or complications disappeared after termination of malaria or within one
month thereafter. No any severe complications occurred in all patients.
Conclusions. There are indeed some side-effects or complications occurred in HIV I AIDS
patients while infected therapeutic acute vivax malaria but they are relatively mild, transient and
tolerated by the patients and accepted by their physicians based on comparing them to the clinical
and immunological improvement ofHIV/AIDS from the therapy.
A lot of recent reports have suggested that there is no harmful interaction between malarial
parasites and human immunodeficiency viruses (HIV). That means, malaria does not promote
progression of HIV infection to acquired 'immunodeficiency syndrome (AIDS), neither HIV
infection worsens malarial symptoms and interferes with treatment of malaria in human bodies.
l
-6
On the contrary, a beneficial interaction between HIV -like viruses and malarial parasites has been
observed in animal model studies. That is, infection of HIV-like viruses significantly diminishes
the gravity of neurological manifestations therefore decreased the mortality of malaria in mice and
vice versa, Plasmodium coinfection delays progression of murine AIDS.
7
,8 A similar beneficial
effect of malaria on HIV infection of human bodies was also observed in a study, in which 71
AIDS patients died at the rate of 35%, but nobody died among 41 AIDS patients coinfected with
malaria during the same observed period and there were no deaths in malaria patient with
symptomatic HIV infection compared to 14% in HIV-negative subjects.
9
These phenomena
reminded us of the history that therapeutic malaria (malariotherapy) had been successfully used to
treat neurosyphilislO and the idea of malariotherapy for HIV/AIDS came to us when we
comprehensively analyzed these data. 11 Numerous review board discussions on this proposal were
organized respectively by the Municipal Department of Health of Guangzhou, by Provincial
Department of Health of Guangdong and by the Provincial Committee of Science and Technology
of Guangdong, China. A fmal approval of phase-I studies of malariotherapy for HIV/AIDS was
obtained from the three levels of review boards.
Total 20 HIV I AIDS patients have been treated with malariotherapy in Guangzhou, China since
then and they got some clinical as well as 'immunological improvements of HIV/AIDS from the
therapy during 1-3 years follow-up after the treatment. That means, the total trends of CD4 cell
counts and interleukin-2 (IL-2) levels increased, neopterin (NPT) decreased and an opportunistic
infection, pneumocystis carinii pneumonia (PCP) disappeared in a full-blown AIDS patient with
no significant change of HIV viral load levels after malariotherapy. In the other hand, there were
no any severe complications occurred during malarial phase and thereafter. These results have
been or will be published elsewhere.
II
-
14
But there were really some or mild
complications occurred during malarial phase. This report exposes the clinical and parasitological
responses and detailed sides-effects or complications of therapeutic acute vivax malaria in
HIV I AIDS patients.
METHODS
Total 20 HIV/AIDS patients (all were HIV-1 positive and confrrmed by Western Blot) who were
naive of any kinds of anti-retroviral therapy at entry were selected for the phase-I studies of
malariotherapy. Informed consent was obtained from all patients before the treatment. The clinical
data baselines of the patients are listed in Table 1. Ages of the patients were 21-42 year-old at
entry. Case17 and 20 are women, the others are men. Case 1, 2, 13, 19 and 20 got HIV from
sexual transmission, the others from injection drug use (sharing needles). Case 3-8 came from
2
malarial endemic area and the others lived in non-endemic regions. CD4 cell baselines (measured
by solid-phase enzyme assay in case 1-8 and by flow cytometry in case 9-20) before the therapy
in case 1 and 3-13 were 5001Jll, in case 2 and 14-18 were 499-2001).11, in case 19 was 144/JlI
and in case 20 was 151).11. That means, case 20 was a patient with very late stage of AIDS
accompanied ulcer of external genital and PCP (clinical diagnosis) with dyspnea, needed oxygen
inhalation and Karnofsky performance only 10-20 before malariotherapy. There were no any
symptoms and enlargement of lymph nodes in case 1 and no any other HIV -related symptoms but
enlargement of lymph nodes (see Table 1) in case 2-19 (case 19 belonged to AIDS patient
according to the 1993 AIDS defmition of Centers for Disease Control of USA).
Malarial blood was taken from patients with acute vivax malaria. All parasitized blood donors
were tested for excluding HIV infection, syphilis, hepatitis A, B, C, D, E, F, G and other kinds of
(especially falciparum) malaria. An aliquot (about ten milliliter) of whole blood contained about
10 Plasmodia vivax was intravenously injected into each HIV/AIDS patient to induce artificial
malaria.
Clinical assessments included patients' constitutions, symptoms and signs of malaria and related
laboratory tests before (baseline), during (malarial phase, assessments were given at least 2 times
per week at this phase) and after (post) malaria. Plasmodium density of peripheral blood from
HIV/AIDS patients was compared with that from parasitized blood donors (the mean value of
parasite density at 4th to 7
th
fever episodes of the HIV/AIDS patients was compared with that of
the blood donors because all malarial blood was taken at 4th to 7
th
malarial fever episodes from the
donors).
RESUSTS
Clinical incubation periods (from injectlori "of Plasmodium to beginning of malarial fever) were
5-17 days. Patients got every day or every other day febrile paroxysm. The fever severity
represented by Tsq (see the note section of Fig 1) positively correlated to the level of CD4 cell
counts among the HIV/AIDS patients with CD4 baselines below 500 (only those whose CD4
levels were measured by flow cytometry are ,involved in the correlation analysis, see Fig 1). There
was no significant difference (P > 0.2) of J.>lasmodium density between the HIV/AIDS patients
(mean SD: 1800 19001Jll, only 11 patients namely case 9-16 and case 18-20 had Plasmodium
calculation) and the parasitized blood donors (mean SD: 2000 26001).11, total 12 HIV-negative
blood donors with acute vivax malaria). SUnilarly, the density of malarial parasites positively
correlated to the level of CD4 counts among the HIV/AIDS patients with CD4 baselines below
600 (see Fig 2). Chloroquine was used to terminate malaria after 10-20 fever episodes (10-20
episodes in case 1-7 and exact 10 episodes in case 9-11 and case 13-20). Malarial fever and
parasitemia naturally disappeared in case 12 (5 episodes) and case 20 (2 episodes) without using
any kinds of anti-malarial drug. fever in case 8 (5 episodes) also naturally disappeared
but parasitemia still existed, needed chloroquine for termination of parasitemia. All patients were
cured of malaria without recrudescence or relapse (there is defmitely no relapse of hematogenous
vivax malaria) after one standard course (10 tablets) of chloroquine treatment.
The results of clinical assessments at baseline, during malarial phase and at 10
th
day after
termination of malaria were described in Table 1, Table 2 and Table 3. As seen in the Tables, acute
vivax malaria did not affect the vital signs of HIV/AIDS patients. Karnofsky performance
worsened only at malarial fever time in most patients but quickly recovered at intervals of fever
episodes and after termination of malaria. Case 20 (full-blown AIDS patient) got apparently
clinical improvement including disappearance of ulcer of external genital, dyspnea and PCP
(confirmed by chest X-ray) with recovery of Karnofsky performance (to around normal level) and
normal life after two medium malarial fever episodes. If increase or decrease of body weight by 2
kilograms was judged as gaining or losing weight, 3 (case 4, 6 and 7) loss and 2 (case 3 and 13)
gained weight among the 20 patients during malarial phase compared with the baselines; but 8
(case 3, 5, 6, 7, 10, 13, 17 and 20) gained and 3 (case 4, 14 and 19) loss weight among the patients
at post malaria compared with the baselines.' Most patients (except case 20) got high fever (over
40C) and all patients had tolerant headache, shaking chill and sweating during malarial phase.
Lymph nodes seemed to decrease in size in all patients who had enlargement at baseline but only
one (case 17) reached the cutoff level judged by the standard described in the note section of Table
1. Rates of spleen and liver were respectively 15/20 and 4120 during malarial phase,
3/20 and 0/20 at post malaria judged by palpation (all recovered to baselines within one month
3
after malariotherapy). Neither musculoskeletal, neurological, psychological and vision evaluations
nor chronic abnonnalities of chest X-ray (case 9) and electrocardiogram (EKG, case 5) were
affected during malarial phase or at post malaria. No changes of stool routine examination,
urinalysis and kidney function represented by blood urea nitrogen (BUN) were observed in the
whole course of malariotherapy. Most patients (except case 20) experienced mild or medium
anemia during malarial phase and quickly came back to around baselines at post malaria and
completely recovered to baselines within one month after the therapy (data not shown) without
blood transfusion. Total trend of white blood cell counts (WBC) decreased during malarial phase
compared to that at baseline (paired t-test, P < 0.001), but most patients were still at nonnallevels
and recovered at post malaria (compared to baselines, P > 0.1). No change of percentages of
lymphocytes was observed in the whole course of malariotherapy. Platelet level decreased in 6
(case1, 3, 9, 10, 16 and 19) of the 20 patients during malarial phase, but no bleeding manifestation
was observed during the phase and therefore there was no need of platelet or blood transfusion as
well as quickly recovered at post malaria. Liver damage represented by increase of serum
glutamic-pyruvic transaminase (SGPT or ALT) in 2 (case 15 and 19) of the 20 patients during
malarial phase but also quickly recovered at post malaria (no need to terminate malaria before the
end of expected course of the therapy). No jaundice occurred in all patients.
DISCUSSIONS
It was plausible that the more severe of immunodeficiency caused by HIV, the more severe of
malarial symptoms and parasitemia were in HIV/AIDS fatients while coinfected with Plasmodia,
because HIV infection induces depletion of CD4 cells 5,16 and CD4 cells play a major role in
immunity against in and
mtnc OXIde or through TH2 subset m helpmg productIon of ann-malanal antIbodies.' , But the
fmding of our present study was opposite, which is identical to the results of animal model studies
of HIV-like virus and Plasmodium coinfection. Although there is no convincing immunological
explanation of how immunity to malaria could develop effectively without CD4 cell involvement
that was obviously observed in our patient group of CD4 baselines lower than 500 especially in
case 20 who was a full-blown AIDS patient. A hypothesis was proposed by Imberti et al. that HIV
infection may induce a selective depletion ofT-lymphocyte subpopulations that are not evolved in
the anti-malarial immune response.
19
This seemed to be confinned by the results of Migot et al.
that immune response obtained after stimulation of peripheral blood mononuclear cells (PBMC)
by Plasmodium schizont extract was not affected in AIDS patients compared with healthy subjects
but the response to non-specific mitogens such as phytohemagglutinin (PHA) and purified protein
derivative (PPD) of tuberculin was apparently damaged in the AIDS patient group.20 Other
researchers also observed in animal models that while development of murine AIDS affected T-
lymphocyte memory of infection of malarial parasites, it did not alter Plasmodium killing by
macrophages.
8
This may be explained by the hypothesis proposed by Stevenson, et al. that parasite
is able to induce IL-12 secretion directly by macrophage 21 and then IL-12 induces production of
IFN-y from T and NK cells,22,23 which would in turn maintain macrophage activation. Another
more close explanation is the fmdings by Ekwalanga, et al. in animal models that infection of
HIV-like viruses prevent death from cerebral malaria and the protection induced by murine AIDS
increases with the severity of immunodeficiency as well as IL-10 secreted by splenic T -cells plays
a critical role in the protection.
7
But to better explain why the more severe of immunodeficiency
induced by HIV the more effective of immunity against malarial parasites was produced found in
our present studies is to postulate that there may be a mutually inhibitive interaction between these
two kinds of pathogens, either through immune response in human body orland through the
components of the pathogens proper.
It seemed that the symptoms of malaria in our HIV/AIDS patients were not more serious and not
more difficult for curing than those HIV -negative subjects according to our previous experience in
treating over one hundred vivax malaria patients. In our previous studies of malariotherapy,
among 7 advance cancer patients who received the therapy, one patient with lung cancer got
bronchial asthma during malarial phase, needed to terminate malaria before the end of the
expected course. Another patient with nasophalyngocarcinoma got mild to medium fever with
pain of knee joints at every day after malariotherapy (strictly excluded recrudescence or relapse of
malaria). Anemia in advance cancer patients seemed more serious during malarial phase and
thereafter, most patients needed blood transfusion (unpublished data). These phenomena suggest
4
that there may be different clinical response of malaria or remaining side-effects in different
patients who had different basic diseases or had different stages of disease before infected with
Plasmodium vivax.
Severe complications such as renal failure, disseminated intravascular coagulation (DIC),
pulmonary damage, adult respiratory distress syndrome (ARDS), coma and epileptic seizures only
occur in patients with falciparum malaria and vivax or benign tertian malaria is usually free from
serious complications. But if patient had a basic disease or had some physiological changes such
as severe glucose 6-phosphate dehydrogenase deficiency, leukemia or pregnancy and other
apparent alterations of physiology and pathology before infection or coinfected with other
pathogens, vivax malaria may induce these grave complications.
24
-
3o
Nevertheless, HIV infection
or AIDS seems not the case or few data show the case. This concept is supported by our present
observation in the 20 HIV/AIDS patients coinfected with therapeutic vivax malaria. And also,
there were no any remaining side-effects of malariotherapy during the one to three years follow-
up. Of cause, we should consider the situation that our HIV/AIDS patients hospitalized, were
given strict medical monitor, intensive care and fluid transfusion during malarial phase would help
to reduce or alleviate complications of malaria.
In conclusion, there are indeed some side-effects or complications such as high fever episodes
with headache and shaking chill, liver (even function damage) and spleen enlargement, anemia
and thrombocytopenia in the course of malariotherapy for HIV/AIDS, but they are mild, limited
and transient. Most importantly, they are tolerated by HIV/AIDS patients and accepted by the
patients and their physicians based on comparing them to the clinical and immunological
improvement ofHIV/AIDS from the
ACKNOWLEDGEMENTS
We thank Drs. Fu Yuan Kuang, Nai Du Li and Ms. Bi Qiao Chen (head nurse) for providing
excellent medical care for the HIV/Aill$,patients while hospitalized. Appreciation is given to Drs.
Shu Guo Liu and Yue Heng Lu for joining a part of work in treating the first 8 HIV patients.
Special thanks must be given to Dr. John L. Fahey for many good suggestions, comments on the
project of malariotherapy for HIV/AIDS and for review of the manuscript.
5
REFERENCES
1. Greenberg AE, Nsa W, Ryer RW, et al. Plasmodium falciparum malaria and perinatally
acquired human immunodeficiency virus Type 1 infection in Kinshasa, Zaire: A prospective,
longitudinal cohort study of587 children. N Eng J Med. 1991; 325:105-109.
2. Muller 0 and Moser R. The clinical and parasitological presentation of Plasmodium
falciparum malaria in Uganda is unaffected by HIV -1 infection. Trans Roy Soc Trop Med
Hyg. 1990; 84:336-338.
3. Morrow RH, Colebunders RL and Chin J. Interactions ofHIV infection with endemic tropical
diseases. AIDS. 1989; 3(suppl 1): S79-S87.
4. Fleming AF. Opportunistic infections in AIDS in developed and developing countries. Trans
Roy Soc Trop Med Hyg. 1990; 84 (suppl. 1): 1-6.
5. N'Gom PT, Jaffar S, Ricard D, et al. Immune stimulation by syphilis and malaria in HIV-2-
infected and uninfected villagers in West Africa. Br J Biomed Sci. 1997; 54: 251-255.
6. Chandramohan D and Greenwood BM. Is there an interaction between human
immunodeficiency virus and Plasmodium falciparum? International Journal of Epidemiology.
1998; 27: 296-301.
7. Eckwalanga M, Marussig M, Dias Tavarcs M, et al. Murine AIDS protects mice against
experimental cerebral malaria: down regulation by IL-1O of a THI CD4+ cell-mediated
pathology. Proc Natl Acad Sci USA. 1 9 ~ 4 ; 91: 8097-8101.
8. Marussig M, Renia L and Mazier D. Interactions between AIDS viruses and malaria
parasites: a role for macrophages? Res Virol. 1996; 147: 139-145.
9. Davachi F, Kabongo L and Nagule K.Decreased mortality from malaria in children with
symptomatic HIV infection (abstract W. A. 1291). Proceedings of the VI International
Conference on AIDS. Florence, 1990. .
10. Chernin E. The malariatherapy of neurosyPhilis. J Parasitol. 1984; 70: 611-617.
11. Heimlich HJ, Chen XP, Xiao BQ, et al. Malariotherapy for HIV patients. Mechanisms of
Ageing and Development. 1997; 93: 79-85.
12. Chen XP, Heimlich HJ, Xiao BQ, et al. Phase-l studies of malariotherapy for HIV infection.
Chin Med Sci J. In press.
13. Chen XP, Heimlich HJ, Xiao BQ, et al. Malaria protects rather than harms to HIV/AIDS
patients. Submitted.
14. Chen XP, Heimlich HJ, Xiao BQ, et al. Impacts of acute vivax malaria on immune system of
HIV I AIDS patients. Submitted.
15. Elisadr W, Marmor M, Zolla-Pazner S, et al. Four-year prospective study of homosexual men:
correlation of immunologic abnormalities, clinical status and serology to human
immunodeficiency virus. J Infect Dis. 1987; 155: 789-793.
16. Miedema F, Tersmette M and VanLier RA. AIDS pathogenesis: a dynamic interaction
between HIV and the immune system. Irllmunol Today. 1990; 11: 293-297.
17. Brown J. Greenwood BM and Terry RJ. Cellular mechanisms involved in recovery from acute
malaria in Gambian Children. Parasite Immunol. 1986; 8: 551-564.
18. Taylor-Robinson AW, Phillips RS, Severn A, et al. The role ofTHI and TH2 cells in a rodent
malaria infection. Science. 260: 1931-1934.
19. Imberti L, Sottini A, Bettinardi A, et al. Selective depletion in HIV infection of T cells that
bear T cell receptor Vp sequences. Science. 254: 860-862.
20. Migot F, Ouedraogo JB, Diallo J, et al. Selected P. falciparum specific immune responses are
maintained in AIDS adults in Burkina Faso. Parasite Immunology. 1996; 18: 333-339.
21. Stevenson M, Tam MF, Wolf S, et al. IL-12-induced inhibition against blood-stage
Plasmodium chabaudi AS require IPN-yand TNF-u and occurs via a nitric oxide-dependent
mechanism. J Immunol. 1995; 155: 2445-2556.
22. D'Andrea RM, Villiante NM, Chehini " et al. Production of natural killer cell stimulatory
factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med. 1992; 176: 1387-
1396.
23. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell
stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J
Exp Med. 1989; 176: 1387-1392.
24. Khoo KL, Tan WL, Eng P, et al. Malaria requiring intensive care. Arm Acad Med Singapore.
1998; 27: 553-557.
6
25. Pukrittayakamee S, Chantra A, Vanijanonta S, et al. Pulmonary oedema in vivax malaria.
Trans R Soc Trop Med Hyg. 1998; 92: 421-422.
26. Munteis E, Mellibovsky L, Marquez MA, et al. Pulmonary involvement in a case of
Plasmodium vivax malaria. Chest. 1997; 111: 834-835.
27. Perren A, Beretta F and Schubarth P. [ARDS in plasmodium vivax malaria] (Article in
German, abstract in Medline database). Schweiz Med Wochenschr. 1998; 128: 1020-1023.
28. Lakhkar BB, Babu S and Shenoy V. DIC in vivax malaria. Indian Pediatr. 1996; 33: 971-972.
29. Tilluckdharry CD, Chadee DD, Doon R, et al. A case of vivax malaria presenting with
psychosis. West Indian Med J. 1996; 45: 39-40.
30. Patial RK, Kapoor D and Mokta JK. Cerebral dysfunction in vivax malaria: a case report.
Indian J Med Sci. 1998; 52: 159-160.
7
50
Tsq
40
30
20
10

0
0

r=O.819, P<O.05
100 200 300

CDt
400
Fig 1. Correlation between Tsq and CD4levels of baseline in lllV/AIDS patients with
CD4 < 500/ml. Tsq: "Temperature squares", means the mean area represented by the
numbers of small squares or checks (of all fever episodes) circled by temperature
curve and the line at 37C in temperature chart, considering the height and duration of
fever which is the major symptom in malaria patients.
Fig 2. Correlation between density of Plasmodium vivax (DPv, x 10
6
/ml)
700 CD4
600
500
400

300
r=O.908, ~ 0 . 0 2
200
100
0
~ - - - - ~ - - - - - - ~ - - - - ~ - - - - ~ U V
0 2 4 6 8
and CD4levels of baseline in HIV/AIDS patients with CD4 < 600/ml
CLINICAL EXPERIENCE OF USING MALARIOTHERAPY
TO TREAT HIV/ AIDS PATIENTS
Xiao Ping Chen, J M.Do, Henry J. Heimlich, 2 M.D., Bin Quan Xiao, J Ph.D., Ji Li Rao, J M.D.
1. Center for AIDS Control and Research, The Municipal Health and Anti-Epidemic Station of
Guangzhou, Guangzhou 510080, P. R. China
2. The Heimlich Institute, Cincinnati, Ohio, USA
In medical history, the successful examples of using a disease to prevent or treat another were
the applications of cowpox for prevention of smallpox and malariotherapy (therapeutic malaria)
for treatment of neurosyphilis. This concept has been expanded in our recent studies of
malariotherapy for treatment of human immunodeficiency virus (HIV) infection and acquired
immunodeficiency syndrome (AIDS). Total 20 HIV/AIDS patients have been treated with
malariotherapy since 1993 in Guangzhou, China. Most patients got some immunological
improvement and some patients got clinical improvement from the therapy. That means, CD4 cell
count and interleukin-2 (IL-2) levels increased and neopterin (NPT) decreased in most patients
and some opportunistic infections, such as pneumocystis carinii pneumonia (PCP) and ulcer of
genital disappeared but there were no significant changes of HIV virus load and no any severe
complications occurred during the.:course of therapeutic malarial fever episodes (malarial phase)
and thereafter. In comparison with highly active antiretroviral therapy (HAART) or so called
"cocktail" therapy, the aim of malariotherapy is to reverse the abnormality of immune system
caused by HIV and then restore immune function therefore delay the progression of HIV infection
to AIDS and improve symptoms ofHIV/AIDS but HAART is to kill HIV in vivo (of course, then
restore a part of immune function in sOi1}e patients). Another advantage of malariotherapy is that
only a very short term treatment (10 fever episodes, that is a duration of 10-20 days)
needs to be given and then its efficacy seems to last 3 months to two years. So its side-effects will
be transient and may be mild if controlled well. Moreover, malariotherapy is much cheaper than
HAART or IL-2 therapy, so it is especially suitable for the treatment of HIV I AIDS patients living
in developing countries who account for about 90% in the world, otherwise they are unable to
afford the drugs. And also, malariotherapy can still be used in developed countries especially to
treat those patients who are not able to tolerate HAART and IL-2 therapy.
Nevertheless, malariotherapy which was very popular in treating neurosyphilis in European
countries and the United States has been discontinued for about 30 years. Furthermore, malaria is
not epidemic in developed countries nowadays, so a very big challenge is that malaria or
malariotherapy has not been addressed in medical training for at least three or four decades in the
developed countries (from Dr. John L. Fahey, personal correspondence). In western physicians'
eyes, giving malaria is going to cause discomfort or complications. Because of these reasons, this
paper presents our clinical experience on malariotherapy for treating HIV/AIDS patients (20
cases), advance cancer patients (7 cases) and on routine treatment of about three thousand patients
with vivax malaria. .
Patient selection According to the results of our phase-1 studies of malariotherapy for
HIV/AIDS which involved 20 cases, patients with CD4 count baseline between are
quite suitable for malariotherapy regardless with or without HIV -related symptoms. This is
different from HAART (as we know, the earlier the better if treated with HAART). Patients with
CD4 baselines over or at stage of acute infection seems not good for the treatment (the
exact mechanism is still unknown). Patients with CD4 below seems to be transient (only
about three month) in restoration of immune function including increase of CD4 count, but it
seems to be helpful in elimination of opportunistic infections such as PCP, thrust and ulcer of
genital.
Patients with one of following conditions should not be treated with malariotherapy: cardiac,
renal or lever dysfunction; bronchial asthma, aortic aneurysm, splenomegaly, cachexia, coma and
seizures. But mild to medium glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is not
strict contraindication since there is no need to use primaquine for prevention of malaria relapse
(described in following section). And also, patients with mild or medium neurological impaiiment
or psychological symptoms caused by HIV even AIDS dementia or a complication of AIDS,
neurosyphilis may be tried with malariotherapy based on the success of the therapy for
neurosyphilis in history and on the recent finding that malaria induces IL-6 production and IL-6
helps proliferation of neurons (this may be a part of mechanism of malariotherapy for
neurosyphilis, which was unknown in history). Inactive tuberculosis is also not strict contra-
indication if patient's general condition is good. Although malaria infection promotes
development of tuberculosis in HIV -negative subjects due to the harmful interaction between
these two kinds of pathogens, but there seems no evidence of harmful interaction among the three
pathogens. In our recent observation, fibrotic tuberculosis in a HIV patient was not worsened
during and after malariotherapy.
Selection of malarial parasites It is very important to select Plasmodia for malariotherapy.
According to our experience, strictly select hematogenous Plasmodium vivax which is sensitive to
chloroquine is very critical. Parasitized blood donors must be tested for excluding HIV infection,
syphilis, hepatitis A, B, C, D, E, F and G, other kinds of malaria (by repeated thick and thin blood
smear examination) and any other infections suggested by history and physical examination.
Falciparum malaria must be absolutely excluded based on the history of malariotherapy for
neurosyphilis since fatality and severe complications caused by the treatment would sometime
occurred while using Plasmodia fa1ciparum. Any kinds of animal malarial parasites should not be
used in malariotherapy; since besides of the known virus inducing yellow fever, many unknown
pathogens may exist in animal blood. One thing should be noted, monkey's blood containing
Plasmodium cynomolgi (biologically simihir to Plasmodium vivax) was injected into human
bodies during the decades of malariotherapy for neurosyphilis. Therefore, whether HIV originated
from SIV (simian immunodeficiency viruses) during that time or not might be questioned.
Mosquito transmitted vivax malaria should also not advocated due to need of primaquine use for
prevention of relapse, which may induce intravascular hemolysis (especially in patients with G-6-
PD deficiency) and then perhaps renal dysfunction.
In general, safety or doing no harm is ' the most important thing in the clinical trial of
malariotherapy (even in any kinds of clinica:! trials) either to the treated patients or to the whole
human being in the future. This ethical consideration was repeatedly addressed in numeral review
board discussions before the approval of phase-I studies on malariotherapy for HIV/AIDS was
obtained from the boards in China.
Medical care and treatment of malaria or complications No any severe or fatal
complications have been yet observed in our studies of malariotherapy for HIV/AIDS but a patient
with advance lung cancer during our previous study of malariotherapy for tumor complicated
bronchial asthma during malarial phase but was quickly cured after treatment with aminophylline,
dexamethasone and termination of malaria. This reminds us again of the importance of selecting
Plasmodium vivax which is sensitive to chloroquine; that means, when malaria is urgently needed
to be terminated in a patient, physicians are easily able to reach the goal. In Guangzhou suburban
counties (by the way, Guangzhou urban area is not malaria endemic region), we have totally
directly and indirectly (through our guidance) treated about three thousand natural vivax malaria
patients with one standard course (10 tablets) of chloroquine during these three decades. All were
sensitive to chloroquine and there were no cardiac complication related to chloroquine occurred in
all patients. But these patients needed to be treated with primaquine for prevention of relapse or
for biological cure of malaria. Among the some 3000 cases, about 20 complicated intravascular
hemolysis induced by primaquine but no renal dysfunction and no deaths occurred due to in time
and correct medical administration. In Guangdong Province (Guangzhou is the capital city of the
province), there were totally about 20,000 patients with vivax malaria and no bodies died in the
recent two decades due in part to the standard treatment, only a few imported patients with
fa1ciparum malaria died during the same period (unpublished data). Therefore, malariotherapy
using hematogenous Plasmodia vivax which are sensitive to chloroqume would be extremely safe
if controlled well as described as follow. .
During malarial phase, most patients would get high fever (39-42C) episodes with shaking
chill, headache and then sweating. At the fever time, the most important treatment is fluid
transfusion, keeping water and electrolyte balance which can be judged by daily volume of urine
and related manifestations or blood chemistry analysis. This may be the best way to alleviate the
symptoms and to prevent complications. Aspirin, acetaminophen or codeine is not necessary or in
fact, there is only quite limited effect of these drugs in treating malarial fever and headache (but
you can still try one of them). Ice-compress . on the head is suggested if headache is untolerated
2
due to high fever such as above 41 DC. There seems no way to deal with shaking chill but
fortunately it just lasts some 10-30 minutes at the beginning of fever. Another most important
thing is to strictly monitor the vital signs and prodrome of severe complications during malarial
phase. If following conditions occur, immediate termination of therapeutic malaria should be
considered: 1) Impending vascular collapse such as tachycardia of 130 per minute or more when
afebrile or systolic blood pressure below 90 nunHg despite intravenous fluid and electrolyte
support (combined with digitalis and! or vasopressors as indicated). 2) Blood urea nitrogen (BUN)
over 8 nmollL. 3) Jaundice. 4) Repeated hypothermia. 5) Intractable vomiting. 6) Uncontrolled
delirium. Although these conditions are extremely rare in vivax malaria, clinicians should know
them in case one comes out of million. Mild and medium anemia is common during malarial
phase, but only those with hemoglobin $; 60 gramIL need blood transfusion. Thrombocytopenia
may occur in some patients during the course of malariotherapy, but it seems no need of
transfusion of platelet or whole blood if no prodrome or manifestation of bleeding (there was a
patient whose platelet level was 24 x 10
9
/L without bleeding therefore there was no need of
platelet transfusion in our studies of malariotherapy). We do not know whether platelet transfusion
increases possibility of neurological complications such as cerebral malaria which due in part to
adhering of platelets and red blood cells to the wall of brain vessels or not. However, if bleeding
occurs due to thrombocytopenia, it is no doubt to treat with platelets or fresh whole blood
transfusion.
Different considerations between therapeutic and natural malaria Researchers and
physicians should know that malariotherapy or therapeutic (artificial) malaria is not natural
malaria. When a natural malaria patient . comes in, physicians would immediately prescribe
chloroquine after diagnosis comes out. At this situation, physicians are unable to observed the
whole course of malaria (it is unethical if you want to see the whole course without using
chloroquine immediately). And also, physicians who had no experience on malariotherapy never
face the situation that some patients would ask for terminating malaria before the end of expected
course and others would request to longer the course even though you told them 10 fever episodes
were standard course before infonned consent was obtained (in fact we have not yet known how
long or how many fever episodes are the standard course of malariotherapy for HN/AIDS patients
but 10-12 was suggested in the history of the therapy for neurosyphilis; there seems no difference
in immune response between 5 and 20 in our studies). The fonners perhaps exaggerate
and the latters would contract the malarial symptoms. Researchers and physicians should
communicate with patients more frequently, linking up in mind and thought and establishing very
good relationship with each other. These will help you finish the expected course of
malariotherapy and correct your judgement about the degree of malarial symptoms, prodrome of
severe complications and your purpose of studies, for instance, otherwise it is very difficult to
complete a long term follow up without any further treatment for the patients (this is different
from any kinds of drug therapies).
In conclusion, our phase-I studies have basically confirmed the safety of malariotherapy for
HIV/AIDS and suggest a potential benefit to HIV/AIDS patients based on the responses of CD4
cells, cytokines, receptors and activation markers. A well controlled phase-II studies should
immediately be conducted in a place where there are at least two hundred selectable HN/AIDS
patients and laboratory facilities such as flow cytometer and HN viral load testing system and
well trained staff. We do not advocate a routine treatment of malariotherapy for HN / AIDS
without strictly scientific research design by the best minds and! or without good facilities and
well trained staff at the present timt'!. Furthermore, patients should not be advocated to go to
malaria endemic area to get natural'imilaria; because this is dangerous without selection of form of
malarial parasites and without strict medical monitor. The era of malariotherapy for neurosyphilis
is over, during which there were no well controlled trials, no uniform of observed parameters, no
rigorous selection of Plasmodia and some physicians advocated patients to go to malarial regions
to get natural malaria.
Acknowledgement We tharlk Drs. ' Du Li, Fu Yuang Kuang, Vue Heng Lu and Ms. B-
Qiao Chen (head nurse) for excellent medical care while patients hospitalized. Appreciation is
given to Drs. Wen Jun Shi, Hui Fang Xu, Kao Gao, Xiu Qiong He and Qing Yu Kong for
laboratory testing and follow-up. Special Thanks are given to Dr. John L. Fahey for help in
research design, providing reagents and review of the manuscript. The last thank is given to Dr.
Najib Aziz for guidance in cytokine testing.
3
Table 1. Clinical data of HI VI AIDS patients before malariotherapy (baseline)
Case Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Kamofskya 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 20
Weight (kg) 56 58 59 48 59 52 50 61 54 50 53 45 54 52 54 54 41 62 57 46
Blood pressure b 18/10 17/12 15/10 13/10 16/9 14/9 13110 15/7 14/10 14/9 15/9 14/8 15/10 15/9 15/10 15/8 14.8 14/9 14/10 14/8
Pulse (per minute) 84 76 82 90 82 80 83 80 80 80 74 78 80 80 80 74 78 78 80 96
Temperature (0C) 37.0 36.8 36.7 37.3 36.7 36.5 37.4 36.8 36.5 36.5 36.3 36.3 36.4 36.3 36.5 36.4 36.5 36.2 35.5 37.8
Headache C
Shaking chill d
Sweating e
Lymph node f
+ + + + + + + + + + + + + + + + + +
. +
Spleen g
Liver h
Musculoskeletal i N N N N N N N N N N N N N N N N N N N N
Neurological j N N N N N N N N N N N N N N N N N N N N
Psychological k N N N N N N N N N N N N N N N N N N N N
Vision evaluation 1 N N N N N N N N N N N N N N N N N N N N
Chest-X-ray N N N N N N N N Ab
m
N N N N N N N N N N Ab
EKG N N N N
AbO
N N N N N N N N N N N N N N N
Stool N N N N N N N N N N N N N N N N N N N N
Urinalysis 0 N N N N N N N N N N N N N N N N N N N N
BUNP N N N N N N N N N N N N N N N N N N N N
Hemoglobulin q 140 130 120 125 105 100 120 110 139 134 135 16.3 122 122 132 133 106 133 147 102
Red blood cell r 480 440 410 410 356 340 410 375 445 448 434 534 437 432 433 457 364 453 482 445
%Eosinophil 1 2 0 0 0 1 0 6 0 0 0 0 0 0 0 0 0 0 0 0
Platelet S 140 80 170 180 130 100 160 150 200 247 209 211 92 185 300 259 142 85 9.2 110
White blood cell t 5.0 3.7 12.2 7.4 12.3 6.2 8.9 5.8 7.4 10.5 4.2 8.8 6.0 5.9 5.8 5.2 6.2 2.1 4.1 3.3
%Lymphocyte 33 36 30 26 26 29 23 27 56 30 67 37 54 42 37 41 23 64 54 36
SGPT (ALT) U N N N N N N N N N N N N N N N N N N N N
Total bilirubin v N N N N N N N N N N N N N N N N N N N N
a: Kamofsky performance assessments. b: Kapa as the unit. c: No headache is defined as "-", tolerant headache as "+", intolerant (need to terminate malaria) as "++". d: Measured as
headache's. e: No sweating as "-", sweating as "+". f: No enlargement as "-", size likes bean to broad bean as "+", apparently larger than broad bean as "++". g: Unpalpable as "-", palpable
within 3 cm under rib costa as "+", over 3 cm under rib costa as "++". h: measured as spleen's. i: evaluations including myodynamia, muscular tension and joint movement. j:
Including physiological and pathological reflex examination and visual memory test. k: Examined by conversation. I: Vision evaluated only by visual acuity test chart. m: There were flaking
and striping shadows in the fields of up lungs, diagnosed lung tuberculosis (fibrosis). n: Incomplete right bundle-branch block. 0 : Including WBC, RBC and occult blood examination. p:
Normal value < 7.0 nmollL. q: gIL. r: x\OlO/L. s & t: xI0
9
/L. u: Normal value < 30 unit. v: Normal value < 20 JlmollL. N: Normal. Ab: Abnormal. All these descriptions are also suitable for
Table 2 and Table 3.
Table 2. Clinical data of HIV/AIDS patients coinfected with therapeutic acute vivax malaria (malarial phase*)
Case Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Kamofsky a 70 70 60 60 70 70 70 70 60 60 60 70 60 70 70 70 60 70 80 90
Weight (kg) 56 57 63 44 60 50 48 61 55 51 53 45 56 53 55 54 41 63 57 57
Blood pressure 15/10 16110 14/9 16/10 15/10 14/9 14/9 15/10 15/8 13/8 14/9 14/8 13/7 12/9 15/8 14/9 13.8 15/9 13/8 13/8
Pulse (per minute) 130 130 104 120 108 120 116 100 152 125 128 116 128 128 134 130 112 126 124 88
Temperature (0C) 42.0 41.2 41.4 41.5 41.4 41.7 41.9 41.0 40.9 41.2 41.1 40.1 41.8 41.0 41.5 41.2 41.1 41.3 40.9 38.4
Headache
+ + + + + + + + + + + + + + + + + + + +
Shaking chill
+ + + + + + + + + + + + + + + + + + + +
Sweating
+ + + + + + + + + + + + + + + + + + + +
Lymph node
+ + + + + + + + + + + + + + + + + +
Spleen
+ + + + + + + + + + + + + + +
Liver
+ + + +
Musculoskeletal N N N N N N N N N N N N N N N N N N N N
Neurological N N N N N N N N N N N N N N N N N N N N
Psychological N N N N N N N N N N N N N N N N N N N N
Vision evaluation N N N N N N N N N N N N N N N N N N N N
m
N N N N N N N N N N N
EKG N N N N Ab
n
Urinalysis N N N N N N N N N N N N N N N N N N N N
BUN N N N N N N N N N N N N N N N N N N N N
Hemoglobulin 120 95 80 100 6.5 90 95 80 78 113 111 146 103 112 119 72 98 109 102 110
Red blood cell 410 323 274 340 221 306 323 275 248 371 359 487 361 394 396 272 344 359 312 419
%Eosinophil 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Platelet 95 100 24 120 150 200 210 170 64 74 120 113 87 200 204 54 108 30 37 113
White blood cell 3.7 4.2 4.9 4.3 6.4 5.4 6.6 4.5 4.2 6.3 4.2 4.7 6.1 5.1 6.9 4.3 3.5 2.0 2.3 3.7
%Lymphocyte 37 30 32 56 35 38 36 48 37 47 41 38 34 35 38 57 39 41 45 31
SGPT(ALT) N N N N N N N N N N N N N N 130 N N N 75 N
Total bilirubin N N N N N N N N N N N N N N N N N N N N
'" All parameters refer to the worst ones during the phase. a: Only refers to at the time of malarial fever episodes, the Kamofsky performance in the intervals of fever episodes recovered to the
base lines except case 20. m & n: No change compared with the baseline.
Table 3. Clinical data of HIV / AIDS patients at 10
th
day after termination of therapeutic malaria (post malaria)
Case Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Karnofsky perform. 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 90
Weight (kg) 56 57 62 45 62 55 53 61 55 53 54 46 60 50 54 53 43 61 55 48
Bp (kapa) 15/10 15/8 15/10 14/9 15/10 15/10 15/9 15/10 14/9 14/9 13/8 15/9 14/8 13/10 13/8 14/8 13/8 14/8 14/8 13/8
Pulse (time/minute) 76 80 82 83 82 88 86 83 80 80 78 79 76 84 80 78 78 76 78 80
Temperature (0C) 36.5 36.8 36.6 36.3 36.4 36.2 36.3 36.7 36.5 36.5 36.9 36.3 36.4 36.9 36.4 36.2 36.6 36.4 36.5 36.4
Headache
Shaking chill
Sweating
Lymph node
+ + + + + + + + + + + + + + + + + +
Spleen
+ + + +
Liver
Musculoskeletal N N N N N N N N N N N N N N N N N N N N
Neurological N N N N N N N N N N N N N N N N N N N N
Psychological N N N N N N N N N N N N N N N N N N N N
Vision evaluation N N N N N N N N N N N . N N N N N N N N N
m
N N N N N N N N N N N
EKG N N N N Ab
n
Urinalysis N N N N N N N N N N N N N N N N N N N N
BUN N N N N N N N N N N N N N N N N N N N N
Hemog10bu1in 120 110 90 110 90 90 100 9.5 80 116 113 139 105 123 10.7 114 98 124 130 103
Red blood cell 410 375 306 375 306 306 340 323 246 383 367 450 349 443 359 367 337 414 388 394
%Eosinophi1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0
Platelet 130 120 220 170 170 220 200 190 270 377 283 147 194 345 251 258 96 177 137 110
White blood cell 5.2 4.6 9.3 8.7 11.3 6.7 6.3 5.9 7.4 7.9 7.8 5.5 5.7 5.0 5.7 4.8 5.0 2.9 3.0 3.7
%Lymphocyte 36 34 27 34 24 35 32 35 56 46 50 34 35 40 31 45 40 49 49 27
SGPT (ALT) N N N N N N N N N N N N N N N N N N N N
Total bilirubin N N N N N N N N N N N N N N N N N N N N
m & n: No change compared with the baseline and malarial phase.
, '-
The Municipal Health and Anti-Epidemic Station of Guangzbou
r-fti 510080, 'f'w'=:Ba 23 % No. 23, 3rd Zhongshan Road, Guangzhou 510080
EI:! 0 (Telephone): 020-83802426 - f t ~ (Fax): 020-83815255
October 5, 1999
VtaExpress
Henry 1. Heimlich, M.D.
311 Straight Street
U.S.A
Dear Dr. Heimlich:
I met Dr. Fahey in August in Hong Kong. We discussed the two manuscripts Is
therapeutic acute vivax malaria harmful to HIV I AIDS patients" and ''Bow to use
malariotherapy for treatment of HIV/AIDS patients?" Dr. Fahey suggested to
combine these two papers to one. I thought this was a good idea So a new paper
manuscript has been completed recently. Attached is the new manuscript titled
Procedure and clinical assessment of malariotherapy: Experience in treating
HIV positive patients." Please you review and correct it and then send back to me.
Any comments and suggestions are welcome. I want to cancel all the manuscripts
titled "Clinical responses and changes of T -lymphocyte subsets and CD4+ cell
apoptosis in HIV/AIDS patients infected with hematogenous vivax malaria",
Malaria protects rather than harms to HIV/AIDS patients" and the other two
mentioned above. I will try to prepare other three manuscripts titled ''Early impact of
acute vivax malaria on the immune system of HIV positive patients", Long term
impact of acute vivax malaria on the immune system of HIV positive patients"
and Is malariotherapy beneficial to HIV positive patients?" All these manuscripts
involve only one year' s data. I will mention again "Dr. Henry J. Heimlich first
proposed the idea of malariotherapy for HIV' in the last manuscript which includes
the viral load data and discuss the efficacy of the therapy. Finally, I suggested you
write the conclusive paper when two year' s follow up is completed, maybe the title
should be "A further study of malariotherapy for HIV infection" (or other title).
Thus, the statement of "Dr. Heimlich first proposed the idea" has been and will be
documented in many places such as in abstracts of three International AIDS
Conferences (San Francisco, Vancouver and Geneva), in our first two and last two
published papers during the period of our first two studies of malariotherapy for HIV
infection.
There is a new regulation in China from the Ministry of Health that any kinds of
human samples can not be sent abroad. So we decide to spend a lot of money (41
thousand USD for Chiron bDNA machine and another payment of 15 thousand USD
for the assemble facilities as a whole system of viral load assay system) on buying a
set of machine system for HIV load testing. We will complete the viral load testing in
the corning months of this year. We hope you wire us the funding according to our
new agreement to pay Yishou Hospital (we still owe them) and pay for all single-use
materials in laboratory for our project.
Best regards and wishes to all my friends in Cincinnati.
Sincerely,
ChenXiao Ping, MD.
Director
at The Municipal Health and Anti-Epidemic Station
(Centers for Public Health and Disease Control) of Guangzhou
Guangzhou 510080
Tel: 8620-83802426
Fax: 8620-83815255
2
Update message mailbox:/C%7C/Program%20Files/Nets ...
Subject: Update message
Date: Sat, 20 Nov 1999 10:56:39 -0800
To: egspletzer@hotmail.com, heimlich@iglou.com
Update message: The bDNA machine has come to my lab. and the assay
training will be conducted next week. That means, we will have HIV load
data very soon.
Please review our paper manuscript "Procedure and clinical assessment of
malariotherapy: Experience in treating HIV positive patients" which is
being planed to submit to New England Journal of Medicine and then send
it back to me with your suggestions, comments and correction
considerations. I look forward to hearing from you.
Sincerely,
11/22/99 8:04 AM
lof!
Subject:
Date: Thu, 23 Dec 1999 09:50:30 -0800
From: "Fahey, John" <JLFahey@mednet.ucla.edu>
To: "'chenxp@gzsums.edu.cn '" <chenxp@gzsums.edu.cn>
CC: "'heimlich@iglou.com '" <heimlich@iglou.com>
I am currently trying to fax the attachment to you.
-Keri
Asst. to Dr. Fahey
December 23, 1999
Fax: 86 (20)83815255
chenxp@gzsums.edu.cn
Dear Dr. Chen,
I was pleased to have your paper on "Procedures and Clinical Assessment of
Malariotherapy." Unfortunately it arrived at a time when we were extremely
busy in preparing two large multi-center grant applications which have
consumed most all of my time these past two months. However, I have read
the paper and suggested some modifications. In particular, I have revised
the abstract because that is the key information for all future readers. We
are returning the manuscript in the hope that you will further strengthen
the presentation.
Selecting an appropriate journal does present a dilemma. I believe you
should consult with Dr. Heimlich so that he can introduce the paper to an
American or British journal. The British journals such as the British
Medical Journal, I believe, may be more widely read in parts of the world
where malarialtherapy may be tried further. However, in the USA, the JAMA
is a possibility, and The American Journal of Medicine, the Annals or the
Archives of Internal Medicine are probably not good venues. There is a new
journal called AIDS Medicine which could be a possibility, if the others
fail.
I look forward to seeing the final version of this paper. You have made
good progress in preparing this report. The 3 enormous tables do present
problems. Perhaps summary tables showing the changes in the mean values or
frequencies at the various stages could be prepared with retention of
something like table 2 with the situation during malarial therapy in all 20
persons. I would suggest that you include a fever chart on 1 person. Those
are impressive and a representative graph would clearly indicate the
temporary effect of malarial therapy.
I look forward to seeing drafts of your other papers. I promise not to hold
them more than 3 weeks. These past 3 months have been unusual.
Sincerely,
John L. Fahey, M.D.
Cc: Dr. Henry Heimlich
12/24/99 10:00 AM
311 STRAIGHT
STREET
CINCINNATI
OHIO
45219
513-559-2391
FAX 51 3-559-2403
heimlich@iglou.com
www.heimlichinstitute.org
Benefitting
Humanity
Through
Health
and
Peace
facsimile
TRANSMITTAL
I I I I I I I I I I I I I I I ~ - - - - - - - - - - - - - - - - - - ~ - - - - - - - - -
To: Valerie Harper
Fax: 212/754-2892
This is an amazing day. We have approval to begin treatments in South Africa.
The letter from Michael Burke resulted from contact made from the Bishop of Southern
Ohi() to the Archbishop of Tanzania. They are ready for collaboration on treatments in 13
hospitals.
David Mahoney enabled us to get to this point through the original grants provided from
the Eleanor Naylor Dana Charitable Trust. I am asking you to forward this information to
David. We are on the road to curing AIDS and I am asking him, from my heart, to help
us obtain funds from whatever sources to complete this project as quickly as possible.
This will be David's greatest legacy for humanity.
From the desk of...
Affiliated with The Deasconess Associations, Inc.
,
.: Malariotherapy
1 0f2
Subject: RE: Malariotherapy
Date: 11m, 27 Jan 200015:29:21 +0200
From: "Frannie Albertse Dr (Shared Serv)" <FAlberts@jci.co.za>
To: "'Henry J. Heimlich'" <heimlich@iglou.com>
CC: "Koos Oostuizen Dr (Shared Serv)" <MOosthui@jci.co.za>
Dear Dr Heimlich
Thank you for your letter of January 14, 2000 and the relevant information.
Again my apology not for answering promptly, but I could only see the CEO
yesterday.
The company has given us the permission to start the process and to do the
Trial .
I suggest the following :
a) I will revisel rewrite protocol to meet
all international and local standards
b) Thereafter - get MRc/MCC approval as
well as Ethical Committee approval
c)Then we are in the position to invite you
out here I vice versa.
Please give me your thoughts on this.
Kind regards
Alberts, Nicolaas F MBChB MFGP(SA) MPharm Med
> ----------
> From:
> Sent:
> To: Frannie
> Subject:
>
Henry J. Heimlich[SMTP:heimlich@iglou.com]
Friday, January 14, 2000 12:12 AM
Albertse Dr (Shared Serv)
Malariotherapy
> January 13, 2000
>
> Dear Drs. Oosthuizen and Alberts,
>
> I hope you both had an enjoyable holiday. I am writing because of a
> January 9, 2000 article from the Associated Press which focused on the
> AIDS crisis in South Africa.
>
> The article noted that 10% of South Africa's population is infected with
> HIV and that this epidemic poses a huge challenge to the health system.
> The AP reported that some hospitals in the Johannesburg area are
> limiting lab tests and releasing HIV patients earlier in order to
> stretch their budgets. They are also training HIV patients' families to
> care for them at home. A researcher from the University of Natal in
> Durban stated it honestly - "We can't afford to spend money on people
> who are going to die."
>
> The article also reported South Africa's Health Minister, Manto
> Tshabalala-Msimang, said, "The government will never be able to cope
> with it (AIDS) alone."
>
> As we all know, even with new expensive drugs, HIV infection remains a
> death sentence. It is hard to convey my great sorrow regarding the
> situation in South Africa; I can only imagine how very hard and
> frustrating it must be for you.
>
> Although genetically engineered IL-2 has been proposed for the treatment
> of HIV, it is expensive, has significant side effects, and will take a
> minimum of 20 years (if ever) to be developed into a viable cure.
> Malariotherapy is proven to stimulate the production of a variety of
> immune substances, including interleukins (IL-6, IL-2R), interferons
1/28/00 11 :29 All
l<.E:' Malariotherapy
20f2
> (IFN- , IFN- ) and sCDB. These are the substances that can produce a
> cure. Malariotherapy has been shown to be safe in treating tens of
> thousands of neurosyphilis patients. We can send a copy of a report
> from the Harvard School of Public Health which documents that fact.
>
> Our results of treating HIV patients with malariotherapy continue to be
> positive; CD4 counts remain elevated and the patients remain clinically
> well. Your study that was mentioned in the e-mail of August 3, 1999
> confirms that CD4 counts are increased in those HIV patients who had
> contracted malaria. There is no doubt that malariotherapy is
> scientifically sound, will do no harm, and is inexpensive.
> Malariotherapy, at this time, is the only possible means for controlling
> and possibly curing HIV infection.
>
> As you know, the Heimlich Institute is responsible for significant
> advances in medical treatment: the Heimlich chest drainage valve, the
> Heimlich MicroTrach for transtracheal oxygen delivery, and the Heimlich
> maneuver for choking, drowning and asthma. If we press ahead with this
> research, malariotherapy for the treatment of HIV infection can be the
> next significant advancement. This would be a good time to press
> forward with this project. How can we expedite starting this project,
> so that we can provide the only available hope for South Africa's HIV
> patients?
>
> We look forward to your thoughts.
>
> Sincerely,
>
> Henry J. Heimlich, MD , ScD
> President
> Heimlich Institute
>
>
> PS: We can send the following articles which may be o f some i nt erest:
> "Heimlich tri es using malaria as low-cost HIV treatment. vlashington
> Times, July 15, 1996.
> Cherni n E. J Parasitol 1984;70:611-617.
> If y ou can send us your surface mail addresses, we will then send copies
> of these.
>
1/28/00 11 :29 AM
Re: Malariotherapy for HIV
lof2
Subject: Re: Malariotherapy for HIV
Date: Thu, 27 Jan 2000 19:35:19 -0800
From: Mjburke@maf.org (MJBURKE)
Dear Dr. Eric G. Spletzer, PhD
Thankyou so much for your reply.
My work is basically a public health task. I am an Australian. I have
been working here since 1992. I will attach a copy of my DEC 99
report. This has addresses etc. This will give you a brief picture of
what we are attempting from this office.
We are interested in collaboration.
There is a National Institute of Medical Research - I attend their
annual conference next month. There is a National Aids Control
Program.
Research protocols need to be approved by the Ministry. I know the
Minister. Do you have any other contacts in the Tanzanian Ministry of
Health or in WHO?
Yours sincerely,
Michael Burke
Subject:
Reply Separator
Author:
Date:
"Henry J. Heimlich" <heimlich@iglou.com> at INTERNET
1/26/00 3:47 PM
January 25, 2000
Dear Mr. Burke,
Thank you for your letter of January 6, 2000.
In regards to more recent information, our treatment of HIV-positive
patients with a three-week course of malariotherapy, following which the
malaria is cured, continues in China. An additional 20 patients have
been treated. Like our previously treated patients, these 20 patients
also experienced an sustained increase in their CD4 counts and remain
clinically well without further treatment of any kind. At this time,
malariotherapy is the only possible means for controlling and possibly
curing HIV infection.
We are currently obtaining viral load measurements. Our Chinese
collaborators are the Public Health Department, headed by the Director
of AIDS Research for Guangzhou province. They have recently obtained
the scientific laboratory apparatus to perform viral counts and DNA
factors.
You will find two papers attached: the first is our electronic version
of a paper from the Harvard School of Public Health showing safety and
efficacy of malariotherapy for neurosyphilis, and the second is a draft
of a paper showing the two-year results of our first 8 patients, which
has been submitted for publication. Both are in Corel WordPerfect 6.0
format. We have additional information which we would like to send you.
will you please send us your surface mailing address so that we can
send this to you. Dr. Heimlich will travel to Tanzania when
arrangements for collaboration and treatment of patients is established.
Sincerely,
Researcher
Heimlich Institute
1/28/0011:43 AM
ACT Health December 1999 Report.
ACT HEALTH
Anglican Church of Tanzania
P.O. Box 899
Dodoma, Tanzania
Ph: (255) 061-21437/21860
Fax: (255) 061-324565
Email: cpt@maf.org
Dear Bishop / Diocesan Development Officer / Diocesan Health Officer/ Medical Officer in Charge
A Health Office within the Provincial ACT Health Office is being established. Our agreed basis is
VISION STATEMENT
A sustainable health care system delivered with the compassion of Christ, characterised by Quality,
Affordability and Respect for Creation resulting in happy, healthy and peaceful communities.
MISSION STATEMENT
To further the healing Ministry of Christ through promotion, collaboration and provision of quality,
wholistic curative, preventative and rehabilitative health care for all, especially to those most in need.
GOAL
To facilitate the provision of quality and sustainable health care to the people in Tanzania by 2002
PURPOSE
Improved health services provided by the Anglican Dioceses in Tanzania.
The last few months have been busy in the ACT Health office. Please note the following :-
1. The "ACT HEALTH Quality Health Care Programme 2000 - 2002" has been submitted to a range of
donors. Answers are awaited.
2. The ACT Provincial Synod was a great time of fellowship and talking about health opportunities with
senior people from many dioceses. Thank you for your encouragement. We look forward to continue to
work together.
3. Community Based Health Funds (CBHF). CBHF are pre-payment health funds that a famil y or
community joins and then is able to gain a range of health services at a much reduced cost later in the year.
It would allow people to invest in their health after a harvest when money is most available. This initiative
is being implemented in other churches in Tanzania. The Ministry of Health is also pilotting a similar
program in various districts.
* A French donor is looking for a partner diocese to pilot an Anglican CBHF.This would initially be a
research phase of three to six months. If you are interested please contact ACT Health Office.
4. Health Sector Reform(HSR). The Government of Tanzania is implementing a process of Civil Service
Reform. The Health sector is at the forefront. HSR has several parts. This includes decentralisation,
privatisation, democratisation and the Ministry of Health concentrating more on policy and quality issues
and less on implementation. There will probably be continuing changes in the mix of the public / private
non profit / private for profit services.
One key element for the churches is the formation of District Health Management Teams (DHMTs). The
church health institutions are entitled to have one member on each DHMT. Different church health services
will have to work together to choose a member to represent them on the DHMT. In order to influence
district health policies and allocation of district health funds, please ensure you are represented. There is
much to be gained by being represented. There is much to lose by not being represented on the DHMT.
The Government wil l commence implementation in 35 thirty five local government authorities from
01012000. The list is included of these 35 authorities. ACT Health Office has already discussed this with
Mpwapwa, Masasi and Tabora Dioceses.
* ACT Health Office in partnership with Christian Social Services Commission (CSSC) are willing to offer
support during this important change in the health sector.
*Please make sure you participate in your District Health Management Team from the earliest opportunity.
The benefits of doing so are potentially very high.
5. ACT Health office has commenced to negotiate with a bednet (vyandalua) provider. Research shows that
an Insecticide Treated Nets (ITNs) are able to reduce malaria attacks by 30 - 40%. This is a very big public
health gain. Pliot programs have been in place. The Ministry of Health (MOH) now wants to implement
this acrosss Tanzania. ACT Health office in partnership with the MOH, partner organisations and other
NGOs wants to support diocesan health services implement this program so our communities are healthier.
onference in San Francisco mailbox:/C%7C/Program%20Files/Nets .... 914D1D76@gzsums.edu.cn&number=329
Subject: Conference in San Francisco
Date: Mon, 14 Feb 200016:27:19 +0800
From: Chen Xiao Ping <chenxp@letter.gzsums.edu.cn>
Dear Dr. Heimlich:
I attended the 7th Conference on Retroviruses and Opportunistic
Infection on January 30-February 2, 2000 in San Francisco. I called your
office but the number had changed and then called your home but you were
not in, so only leaving you a message. The time schedule was very tight,
so I was unable to visit you in Cincinnati this time since I needed to
return to China immediately after the conference because as you know,
the dates were in the Chinese New Year holidays-Spring Festival, the
most important holiday in China. And -also, I was not sure whether I
could go or not in that I got my visa from US Consulate just three hours
before my departure time from Guangzhou to San Francisco. So please
excuse me that I did not tell you this in advance. I did not present any
paper in the conference, I was just one of six Chinese representatives
invited by the conference committee two weeks before the conference
dates. It was an excellent national AIDS meeting of USA. I learnt a lot
and got to know many new friends during the conference.
Today is the first working day after the Spring Festival, I will email
you again on other issues. Happy Spring Festival and give my best
regards to my mom, Jane and Dr. Spletzer.
Sincerely yours,
2/14/008:13 AM
Thank you for your greetings cards
Subject: Thank you for your greetings cards
Date: Fri, 25 Feb 2000 15:39:20 +0800
From: Chen Xiao Ping <chenxp@letter.gzsums.edu.cn>
Dear Dr. Heimlich:
Thank you very much for your beautiful electronic greetings cards. If it
had not been the Holiday of Chinese New Year this time I would have
flown to Cincinnati to visit you again after the US AIDS meeting in San
Francisco. But I would find an opportunity to visit you again in a not
far future and you are warmly welcome to visit Guangzhou again at any
t ime.
Good luck and best wishes to you, your family and all my f rie nds in
Cincinnati.
2/25/00 8:22 AM - - - - - - -
r-ffl510080, if'1lJ==J&23 % No. 23, 3
n1
ZhongshanRoad, Guangzhou510080
(Telephone): 020-83802426 (Fax): 020-83815255
March 3, 2000
Hemy J. Heimlich, M.D.
311 Straight Street
U.S.A
Dear Dr. Heimlich:
Enclosed is our paper "Phase-l Studies of Malariotherapy for mv Infection"
published in Chinese Medical Sciences Journal (Attached are also the first page and
the catalog page of the journal). The abstract win be cited in Medline Database.
Please note: There are some things wrong with the editing such as some numbers of
the References and the word "assay" wrong as "essay." But I think the main results
and ideas are clear enough to audiences.
By the way, I need the first page and the catalog pages of the journal of Mechanisms
of Ageing and Development in which our paper Malariotherapy for mv Patients is
published. Please send me a copy of these pages.
Best regards and wishes to you and all my friends in Cincinnati.
Sincerely, oj;;!
Chen Xiao Ping, MD. /
Director C/ .:>
at The Municipal Health and Anti-Epidemic Station
(Centers for Public Health and Disease Control) of Guangzhou
No. 23, 3td Zhongshan Road
Guangzhou 5] 0080
Tel: 8620-83802426
Fax: 8620-83815255
I
lof!
mailbox:lC%7C/Program%20FileslNetscapelNa .. .38DB IF93.EC745303@gzsums.edu.cn&numl.:'-' r=94
ubject: Express
Dat,e: Fri, 24 Mar 2000 15:56:03 +0800
Dear Dr. Heimlich:
Please email me whether you have received my Federal Express enclosed
our paper Phase-1 Studies of Malariotherapy for HIV Infection published
in Chin Med Sci J or not. Please send me a copy of the cover page and
the catalog page(s) of the journal in which our paper Malariotherapy for
HIV Patients was published. I remember that Dr. Spetzer attended the XII
International Conference on AIDS in Geneva in 1998. I want to know if he
had a presentation on malariotherapy for HIV/AIDS in the conference and
if the presentation was signed the names of the Guangzhou part of the
cooperation researchers as the authors or co-authors. If so, please send
us a copy of the abstract with the cover page of the proceedings. Please
send them via express to us. We need these documents.
Unfortunately, Dr. Fahey has ended the reagent support to us including
those for cytokines testing and HIV viral load measurement. So we have a
big gap in funding in our second study of malariotherapy for HIV/AIDS.
So we hope you make an effort to support us according to our agreement
when I was in Cincinnati so that we can complete the project within two
or three months. Thank you.
Sincerely yours,
3
'<4/{)o
!J I .
F cI dies
lofl
Subj ect: Further studies
Date: Wed, 05 Apr 2000 16:35:50 +0800
To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com>,
We should not give up malariotherapy! We have spent nine years long on
and got a lot of findings from the studies. But as you know, Guangzhou
is not a good site for phase-II studies of Malariotherapy for HIV/AIDS,
because there are no so many HIV-infected persons found in Guangzhou at
present time. We need at least 200 selected HIV-positive patients for
phase-II studies, among them, 100 for treatment group and additional 100
for control group. I think we should find a way for further research in
the USA if we wan to do phase-II clinical trials. If this needs, I will
to go there. But at the moment, we are facing a problem in measurement
of HIV viral load even though we have made a great effort to set up bDNA
system, the reagents are too expensive to us. So we really need your
financial support based on our previous cooperation agreement. We the
Guangzhou part have taken all responsibilities in the research project
and we hope that you the Heimlich Institute part take too.
I found a few paper abstracts very interesting and useful via Internet,
but I could not find their original articles at libraries in Guangzhou.
Could you please help me to find out these articles at libaries in
Cincinnati and send me a copy of them? These articles are:
1. Chougnet C, et al. Kinetics of lymphocyte subsets from peripheral
blood during a Plasmodium falciparum malaria attack. Clin Exp Immunol
1992; 90: 405-408.
2. Worku S, et al. Lymphocyte activation and subset redistribution in
the peripheral blood in acute malaria illness: distinct T cell patterns
in Plasmodium falciparum and P. vivax infection. Clin Exp Immunol 1997;
108: 34-41.
3. Wahlgren M, et al. Adhesion of Plasmodium falciparum-infected
erythrocytes to human cells and secretion of cytokines. Scand J Immunol
1995; 42: 626-663.
4. Kalyesubula I, et al. Effects of malaria infection in human
immunodeficiency virus type I-infected Ugandan children. Pediatr Infect
Dis J 1997; 16: 876-881.
5. Allen S, et al. Human immunodeficiency virus and malaria in a
representative sample of childbearing women in Kigali, Rwanda. J Infect
Dis 1991; 164: 67-71.
6. Tswana SA, et al. The relationship between malaria and HIV. Cent Afr
J Med 1999; 45: 43-45.
Thank you very much.
4/5/00 8:09 AM
of
Subject:
Date: Tue, 11 Apr 200017:13:30 -0700
From: "Fahey, John" <JLFahey@medneLuc1a.edu>
To: "'chenxp@gzsums.edu.cn '" <chenxp@gzsums.edu.cn>
CC: "'heimlich@iglou.com III <heimlich@iglou.com>
April 11, 2000
Dear Dr. Chen,
I have reviewed the manuscript on Procedures and clinical assessments etc.
I have made some changes in the text. The new Table 2 is very clear.
Please regard them as suggestions.
I changed the title. The phrase (Experience in treating patients with HIV
infection) indicates the treatment effects will be reported. But that is a
separate paper. Thus, I suggest - "Recent Experience in 20 HIV+ patients"
which indicates that it is a great deal more than a case report.
I took out the references to HAART therapy. That is not relevant to the
thrust of this paper which is about the effect of malarial therapy and the
clinical conduct of malarial therapy. It is distracting and incomplete.
The comparison can corne after the paper on malarial therapy effects on HIV
infection is published.
I took out the references to tuberculosis because that also did not seem to
be important from the standpoint of the contributions in the present paper.
In addition, there was no reference to the interaction of tuberculosis and
malaria.
Parts of the abstract were reworked to provide more emphasis on the
contribution of this paper.
The changes in the Results were only to regroup the presentation into
formats that seem somewhat easier to follow.
On page 5, there was a sentence referring to treatment of acute HIV
infection and to not using malarial therapy at that time. I did not realize
that any of the people studied in this study were in the acute phase of HIV
infection. If there is no experience with acute HIV infection, then a
recommendation should be based on some rationale which you would have to
provide. Meanwhile, I deleted that part.
Also, in the credits for support, I thank you for thinking to include
reference to support from the National Institutes of Health. However, I
would ask you to delete that since we did not apply for NIH HSPC approval.
It can be included, however, in the paper on immunologic changes associated
I do look forward to seeing the manuscript on immunologic changes in
malarial therapy. I suspect that you have done all the analyses. Viral
load information is not critical to that report.
The additional freezing cups are being sent soon and you will have word from
Barbara Hered when they are shipped.
In relation to the problems of detecting intracellular cytokines, I have
4/12/009:33 AM
asked Dr. Najib Aziz to respond. I can tell you that problems are very
common in carrying out these tests. They require some skill and practice.
Your colleagues at the Guangzhou Provincial People's Hospital should contact
Dr. John Bradley, Flinders Medical Center, Adelaide, Australia at email:
imjb@flinders.edu.au to receive the samples of the flow cytometry
proficiency testing program. I am alerting Dr. Bradley to save a sample for
them. The shipments are going out now so they should contact him promptly.
Finally, how is the HIV viral load testing proceeding? I would suppose
there was a period needed to become familiar with the procedures, and to be
sure about the analytic results.
Keep the manuscripts coming.
Sincerely,
John L. Fahey, M.D.
p.s. Reference numbers 7 and above need to be changed in References and in
the text. Also, reference is needed for problems with palsmodium faciparum.
Attachment - manuscript Chen Xiao Ping.doc
Cc: Dr. Henry Heimlich (heimlich@iglou . com)
_ Name: Chen Xiao Ping.doc
t ~ ~ C h e n Xiao Ping.doc Type: Program File (application/msword)
- Encoding: base64
4/12/009:33 AM
Final version of manuscript
Subject: Final version of manuscript
Date: Fri, 21 Apr 2000 17:59:56 +0800
From: Chen Xiao Ping <chenxp@gzsums.edu.co>
To: "Dr. Henry J. Heimlich" <Heimlich@iglou.com>,
Attached is the final version (if you agree) of our paper manuscript
Procedures and Clinical Assessments of Malariotherapy: Recent Experience
in 20 HIV+ Patients reviewed by Dr. John L. Fahey. If you agree, I would
like to first try to submit to AIDS journal in the form of FASTTRACK of
the journal which publishes papers within four months if accepted.
Please sign the form of Submission to AIDS Journal--Authors'
Confirmation and then send back to me by fax or email if you agree the
final version and agree to submit to the journal. I will to take your
suggestions into account. You are also welcome to introduce to a British
or American journal other than AIDS.
By the way, have you received my last E-mail of April 5?
I am looking forward to hearing from you and receiving your signatures
of the attached form.
Best wishes and regards.
Chen xiao Ping, MD
c:
Name: Recent experience in 20 HIV+ patients.doc
experience in 20 HIV+ patients.doc Type: Word Document
(apphcatlOn/msword)
Encoding: base64
Name: Form of Authors.doc .
of Authors,doc Type: Microsoft Word Document (application/msword)
- Encoding: base64
of 1
4/21/00 11:03 AM
of 1
SUbj ect:
Date: Thil, 27 Apr 200015:52:57 -0700
From: "Fahey, John" <JLFahey@medneLucia.edu>
To: n'chenxp@gzsums.edu.cn"' <chenxp@gzsums.edu.cn>
CC: n 'heimlich@iglou.com"' <heimlich@iglou.com>
Ce nter for Interdisciplinary Research
in I mmunology and Disease (CIRID)
April 27, 2000
No . 23, 3rd Zhongshan Rd.
Dear Dr. Chen,
I am pleased that you are prepared to send the manuscript for publication.
If you and Dr. Heimlich could identify a general medical journal I would
suggest that would be better than AIDS. The editors and readership of AIDS
want to know the relationship of the study to the effect on AIDS. That is
not in this paper. Your paper is really about malarial therapy. Again, if
you could identify some type of journal where this could reasonably go, such
as the British Medical Journal. I am quite sure that it will not be
accepted by the New England Journal of Medicine. I would suggest you put it
in appropriate format. The nature of the paper is not the sort of thing
that usually warrants a fast track publication. However, the main thing is
to get it accepted by a reput able journal.
We have sent off today by express delivery copies of 5 of the 6 articles
that you requested last month. I regret the delay but I hope it will help
you in presentation of immunol ogic effects of malarial therapy. I promise
to respond more rapidly with comments about future manuscripts .
Sincerely,
John L. Fahey, M.D.
Cc : Dr. Henry Heimlich (email: heimlich@iglou.com)
4/28/008:14 AM
Ze:your email
, of 1
Subject: Re: your email
Date: Fri , 28 Apr 200010:10:41 +0800
To: "Fahey, John" <JLFahey@medneLucla.edu>
CC: "Dr. Henry J. Heimlich" <Heimlich@iglou.com>
Dear Dr. Fahey:
Thank you for your suggestion. I have found the British Medical Journal (BMJ) to
which the manuscript can be submitted via E-mail . I will first try the BMJ
based on your suggestion if Dr. Heimlich agree (I will contact him soon).
Sincerely,
Chen xiao p i ng, M.D.
Fahey, John wrote:
> Center for Interdisciplinary Research
> in Immunology and Disease (CIRID)
>
> April 27, 2000
>
> Chen Xiao ping, M.D.
> No. 23, 3rd Zhongshan Rd.
> chenxp@gzsums.edu.cn
>
> Dear Dr. Chen,
>
> I am pleased that you are prepared to send the manuscript for publication.
> If you and Dr . Heimlich could identify a general medical journal I would
> suggest that would be better than AIDS . The editors and readership of AIDS
> want to know the relationship of the st udy to the effect on AIDS. That is
> not in thi s paper. Your paper is really about malarial therapy. Again, if
> you could identify some type of journal where this could reasonably go, such
> as the British Medical Journal . I am quite sure that it will not be
> accepted by the New England Journal of Medicine. I would suggest you put it
> in appropriate format. The nature of the paper is not the sort of thing
> that usually warrants a fast track publication . However , the main thing is
> to get it accepted by a reputable journal.
>
> We have sent off today by express delivery copies of 5 of the 6 articles
> that you requested last month. I regret the delay but I hope it will help
> you in presentation of immunologic effects of malarial therapy. I prom.ise
> to respond more rapidly with comments about future manuscripts.
>
> Sincerely,
>
> John L. Fahey, M.D.
> Director, CIRID at UCLA
>
> Cc: Dr. Henry Heimlich (email: heimlich@iglou . com)
4/28/00 8:14 AM
,e: Latest paper
of!
Subject: Re: Latest paper
Date: Fri, 28 Apr 2000 10:37:38 +0800
Dear Dr. Heimlich:
I have changed my mind that we should first try our latest manuscript to
the British Medical Journal (BMJ) based on Dr. Fahey's suggestion. What is
your opinion? If you agree, I will change the format matching the AIDS
journal to the one matching the BMJ to which the manuscript can be
submitted via E-mail (both formats are very similar). I am looking for your
response.
> Dear Dr. Chen,
>
> We received your e-mail and y our fax. Dr. Heimlich will be in tomorrow
> (April 26, 2000). I will get him to look at the paper then and we will
> respond as soon as possible.
>
> Best wishes,
>
> Eric G. Spletzer, PhD
> Heimlich Institute
4/28/008:14 AM
. .
Program 'on
bject: Program discussion
Date: Thu, 08 Jun 200011:12:02 +0800
From: Cben Xiao Ping <chenxp@gzsums,edu,cn>
"John L. Fahey" <jlfahey@microimmun.medsch.ucla.edu>
oar Dr . Heimlich:
Xl' bead, Dr . Xiao Bin Quan entrust me to talk with you very openly on
e of the idea of malariotherapy for HIV/AIDS. I admit that you
are be first person who proposed the idea of malariotherapy for HIV
early in 1992. But you are not the unique one who had this
' e a i n early 1990s. I also admit, I have never told you before t hat I
t a' the idea too separately in early 1993 (but I told this to Dr. Xiao
Q an). After our first discussion on the topic of malariotherapy for
::: _ - infection in mid 1993 in Guangzhou, we got to know, you advocated
ari otherapy for cancer, HIV infection and Lyme disease, but I favored
therapy for cancer, HIV infection and systemic lupus erythematosus
I told my colleagues that I never considered the therapy should
be given to patients with Lyme disease even though the disease was
ea erni c in northern China during that period. To tell the true, I really
you, I did not want to argue with you. We can trace to early
0 when our good friend, Dr. Cionci visited Guangzhou and told me that
70 advocated the therapy for cancer and I told him that this idea was
7 e=y r easonable. But we knew very quick this was not really your
because some other authors had proposed this idea or practiced
before you. Nevertheless, anyone should admit the fact that Dr.
first proposed the ideas of malariotherapy for HIV infection
c= ' disease and Dr. Chen separately proposed the ideas of the
for HIV infection and SLE e ven though Chen had the idea of
for HIV infection later than Heimlich about a half year .
e = had got some data that t here was no harmful interaction between
and Pl asmodium based on my knowledge and exper ience of working in
of infectious disease for 13 years (13 years on malaria and 5
on AIDS ) and on obtaining new information by reading reported
es till early 1993. And also, I had been quite familiar with the
of malariotherapy for neurosyphilis by t heoretical study and the
of clinical research of malariotherapy for cancer through the
.:. with you by early 1993. My brain often naturally came up
e question that why we did not try malariotherapy to treat
s with HIV infection during the months in early 1993. I was very
you told me through a letter you would come to Guangzhou to
__ s with us the feasibility on cooperation of malariotherapy for HIV
and I immediately told my head, Dr. Xiao that Dr. Heimlich had
- -e s=,Q i dea! But when we discussed the feasibility in Guangzhou in mid
_:==, = that you had the idea earlier than I had about a half
rtbermore, I realized that you got stronger evidence than I did
=-t t hi s idea when you gave me a copy of the paper abstract
= =--S<i:.n t he VI International Conference on AIDS in 1990. This is a
; So I would admit forever that Dr . Heimlich is the first
e u nique ) person who proposed this idea. This is similar to
- =- that Dr. Montagnier in France and Dr. Gallo in USA
=0 nd HIV (LAV/HTLVIII) in 1983 and 1984 respectively.
important thing is that, after our discussion in mid
__ i pal Department of Health of Guangzhou organized a couple
( t he member s included clinicians, epidemi ologists,
__ _arasitologists, virologists, social and ethical
__ __ - - a s well as government officers) discussions. In t he
- i scuss ion, about 70% board member s opposed this
=-_ -sed on that malar i a induces variety of cytokines and
are to HIV/AI DS patient s. But in
ard s , it was that I proposed the
rel a ted f actors would do increase d r ' 9
- -'" == '-o.:: d s arp::'y decreased to baseli
.:.:=e:- - e a =t e r t ermina tion o f a l a ria g t
6 00 ,_ Al\ t
Program discussion
2 of 2
a feedback mechanism of immune system. It was this hypothesis that
reversed the percentage of the board members who originally opposed us
from about 70% to about 30%, which leaded to the final approval of
phase-I studies of malariotherapy for HIV infection conducted in
Guangzhou. Of course, Dr. Xiao Bin Quan played a very important role in
the discussions. I remember that you did not attended any board
discussions.
So it is uneven if you persist in mentioning Dr. Heimlich proposed the
idea of malariotherapy for HIV infection in any manuscripts of ours. We
strongly consider that it is enough when Dr. Chen wrote the first paper
abstract presented in the 9th International Congress on Immunology in
San Francisco in 1995, putting the name of Dr . Heimlich first; Dr.
Heimlich presented a paper abstract as the first author in the XI
International Conference on AIDS in Vancouver in 1996; Dr. Heimlich
wrote the first paper as the first author published in Mech Ageing Dev
1997; Dr. Chen wrote the second paper published in Chin Med Sci J 1999
i 'n which Dr. Heimlich first proposed the idea was mentioned. It is
absolutely enough as a history document.
Dr. Xiao also entrust me to talk with you very openly on the issue of
our Cooperation Agreement. According to our New Cooperation Agreement
made in Cincinnati in 1997, the Heimlich Institute part (HI) needs to
pay 84,000 US dollar ($7000 per case, 7000 times 12 = 84000) for the
Second project of Malariotherapy for HIV/AIDS if Dr. Fahey does not
provide reagents for HIV viral load testing (note: if Dr. Fahey provides
reagents for viral load testing, the payment will be $5000 per case).
Nevertheless, HI only paid $14,000 for the whole project. My colleagues
(all are new to you except Dr. Xiao) said that HI did nothing in the
second project except the 14,000 dollar payment. Therefore they argued
with me that we might take HI out from authors in our new paper
manuscripts, we just need t o say thanks to HI in the sect ions of
acknowledgement. But I e xplained that Dr. Heimlich first proposed the
idea of malariotherapy for HIV infection early in 1992 even though I had
the same idea separately in early 1993. I excuse them because they do
not know the history (I would like to let you know that they are all
young fellows). And as you know, most colleagues of mine who joined the
Projects of Malariotherapy for cancer patients and for the first eight
HIV patients including Drs. Rao JL, Liu SG, Lu YH, Li NO and Kuang FY
retired one to three years ago . But anyway, I would pers i st in putting
Dr. Heimlich in the position of second author in our new manuscripts on
the 12 HIV patients who received malariotherapy. But Dr . Xiao and I also
persist in that this will be based on the responsibility taken by HI in
the project according our Cooperat i on Agreement
However, in the deep hearts of Dr. Xiao and I, Dr. Heimlich is our good
friend and we hope to keep the friendship forever which has been
established since 1990 when we started to discuss cooperation on the
program of malariot herapy for cancer after introduction of Dr. Cionci.
By the way, the HIV viral load has been measured through a great deal
effort in borrowing the bONA reagents from Dr. Yunzheng Cao working at
the National AIDS Research Center of China in Beijing (she returned to
China in 1998 from the Aaron Diamond AIDS Research Center in New York).
Wi th my best wishes and regards to all colleagues at Heimlich Institute.
Chen Xiao Ping , M.D.
6/8/008:28 AM
Re: Your letters of June 8, 2000 and July 6, 2000
1 of 1
Subject: Re: Your letters of June 8, 2000 and July 6, 2000
Date: Fri, 07 Jul 2000 12:53:23 -0400
From: "Henry J. Heimlich" <heimlich@iglou.com>
CC: JLFahey@medneLucla.edu
Dear Dr. Chen,
Concerning your note of June 8, Dr. Heimlich appreciates your statement
that Dr. Heimlich is "the first person who proposed the idea of
malariotherapy for HIV infection early in 1992." A small correction
should be noted in this regard - Dr. Heimlich first proposed this
concept and made it known in the late 1980's when his nephew died of
AIDS after receiving an injection of infected plasma for hemophilia. It
is interesting to now learn you conceived of the idea of malariotherapy
for AIDS seven years ago.
Traditionally, in scientific articles, the first person to conceive of a
treatment is always mentioned in this regard in the historical
background. It is not unusual for others to have the same idea at a
later date. You are the originator of suggesting the use of
malariotherapy for systemic lupus erythematosus (SLE) and credit should
certainly be given to you in any papers on malariotherapy for SLE.
We agree with Dr. Fahey's statement to you in his letter of June 8,
"Regarding authorship, it is incontrovertible that you and your
colleagues have done the work carried out in these projects." The
acknowledgments in our first full paper state this. Certainly, if it
were not for our joint efforts, we would not have achieved what we h ~ v e .
Your e-mail of July 6 caught us somewhat by surprise since we did not
know the paper had been submitted for publication, and had not received
any message from the British Medical Journal. Upon looking at your
e-mail closely, we found that Dr. Martyn had spelled our e-mail address
incorrectly (igloo instead of iglou). We cannot open some portions of
your attached manuscripts since you have switched to Microsoft Word from
Corel WordPerfect. Please fax a copy of the manuscript that was sent,
so we can respond appropriately. Our FAX number is 513-559-2403.
We will respond to the rest of your June 8 e-mail shortly. We look
forward to continuing our mutual friendship and research.
Eric G. Spletzer
Researcher
Heimlich Institute
cc: John L. Fahey, MD
7/7/00 12:53 PM
10fl
Subject:
Date: Fri, 22 Dec 2000 09:25:30 -0800
From: "Fahey, John" <1LFahey@medneLuc1a.edu>
To: "'chenxping@netease.com It, <chenxping@netease.com>
CC: "'heimlich@iglou.com It, <heimlich@iglou.com>
December 22, 2000
chenxping@netease.com
Dear Dr. Chen,
I read the paper and am sending it back with some suggestions. However, I
did want to raise again the question of which journal is most suitable. We
looked at the information available at website
http://www.thelancet.com/info/info.isa?nl-authorinfo&n2=Writing+for+The+Lanc
et. In reviewing that and then looking at a recent issue of Lancet, it
seemed that there were two possible difficulties with the paper. First of
all, Lancet seems interested in the clinical reports rather than laboratory
science and this paper is really reporting on the immunologic consequences
of malarial therapy in HIV+ persons rather than the clinical procedures and
clinical outcomes.
A second point relates to the style of the narrative. It seemed to me that
the narrative is fairl y discursive. For example, the Summary really
contains almost all the information in the paper. Journals usually require
a very concise summary with the main points, not all of the issues or data
in the paper.
It occurred to me that Nature Medicine -might be more suitable. The
information on Nature Medicine can be obtained at
http://www.nature.com/nm/info/guide authors/#authors. I hope this is
helpful. But, certainly you must trim the abstract . I will try and do that
so that you can get a n idea of what I am thinking of. I am not sure if you
have access to the journal Nature Medicine . I can understand that could be
a problem for you. Howe ver , the point about trimming the summary or
abstract applies to any western journal that you might submit your papers
to. Nature Medicine limits abstracts to 100-150 words and the main text to
3000 words maximum.
Sincerely,
John L. Fahey, M.D.
Enclosure - manuscript Impact of acute vivax .doc
CC: Henry Heimlich, M.D. (heimlich@iglou.com)
_ Name: Impact of acute vivax .doc
~ ~ ~ I m p a c t of acute vivax .doc Type: Winword File (application/msword)
- Encoding: base64
12/26/008: 11 At'-
Subject: Re: Re: Discussion conclusions
Date: Fri, 23 Feb 200117:54:27 +0800
From:
To:
CC:
chenxiaoping <chenxping@netease.com>
Henry J.Heimlich <heimlich@iglou.com>
"John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>
Dear Dr. Heimlich:
Thank you for your email response of Feb. 22, 2001. We agree that we did all things in
our previous research projects according to our agreements and we were happy during the
cooperation. This leaded to that in our first study of malariotherapy for HIV infection, we
totally presented two abstracts in two important international meetings and published two
papers in science journals. But there is no use to talk the previous issues including
funding, because all participants in Guangzhou part have known the past through a couple
of discussions. We should take a time to resolve the current problems in our second
HIV -malariotherapy project. You should remember that in our very difficult time, we
asked for the funding from the Heimlich Institute, but we failed to get it due to the
agreement obligation. We had to spent a lot of time on dealing with the funding and make
a great effort to persuade the governments to fund the research. Finally, we got it from
several departments. The project, therefore has been completed, but this also leaded to a
change of the major funding originally from Heimlich Institute later to the local
governments and other institutions.
I suggest that, you do not need the authorship of the paper titled "Impact of acute vivax
malaria on the immune system of HIV + patients" which focuses on the early immune
response (only 3 months data), not really on the efficacy of malariotherapy, but we would
still like to thank you in the acknowledgements section like: "We acknowledge Dr. Henry
1. Heimlich for his successful cooperation with us in the pilot study of malariotherapy for
HIV infection during 1993-1996. He independently proposed the idea of malariotherapy
for HIV infection in 1992 (note: in the contributors section: Dr. Chen independently
proposed the idea of malariotherapy for HIV/AIDS in early 1993 will be mentioned). He
also helped us to get a part of funding from Eleanor Dana Charitable Trust in our present
study. Dr. Heimlich works at the Heimlich Institute in Cincinnati, USA." I hope you
accepted this acknowledgement. Doing so is very important for me to comfort my
colleagues and the officials. Because the conflict of funding and authorship issues made
me a deep embarrassment, this directly leaded to the intervention of officials. I am afraid
that I will lose my colleagues and then lose the opportunity for our future cooperation.
Please note, the situation here in China is very different from that in the USA, even
though China is in progress. My another suggestion is that you should make a supplement
to fund the research so that your authorship remains in the next paper which focuses on
the data of CD4 level and HIV viral load for two years follow up. It will be the most
important paper up to now in the research of malariotherapy for HIV infection. I will
explain in my greatest effort to my colleagues that Dr. Heimlich should be the second
author in this paper and I will insist in making a notification like: Dr. Heimlich and Dr.
Chen independently proposed the idea of malariotherapy for HlV infection respectively
in 1992 and in early 1993 or like: Dr. Chen and Dr. Heimlich equally contribute to this
paper. But your funding is very important for comforting either my colleagues or the
officials.
Our future study will be a very big project, needing a huge funding: a multiple-center
phase-II study of malariotherapy for HlV infection which includes 100 patients for the
treatment group and 100 patients for control group. This needs to screen over 400 patients
for their CD4 count level for patient selection. We also need to sign a new agreement in a
research funding style (that means funding go ahead of data obtaining) if we come
together again in the future. By the way, a private company in China and an institution in
Italy are willing to fund the phase-II study, but I have not yet accepted, because this will
let the research goes a business way and I am waiting for the cooperation with you.
We do not hope to contact with any embassies or consulates or directly with the officials,
because our cooperation is completely scientific but absolutely not political.
Regarding to the letter from Dr. Cionci to Dr. Heimlich, it is not true for saying that Dr.
Heimlich spoke to my group on the use of malariotherapy for HlV. The fact is that in
1990, Dr. Cionci as a representative of Philadelphia Red Cross Society visited to
Guangzhou. I met him in the White Swan Hotel where he stayed. We talked very
friendly, when I told him about my hypothesis on that HlV might originated from the
molecular hybridization of SlV and human sperm gene (I published this idea in early
1990), then he told me the idea of malariotherapy for cancer proposed by Dr. Heimlich,
when my response was "this idea is very reasonable" since I had been a physician for
infectious disease for many years and had treated over one hundred malaria patients.
Then Dr. Cionci returned to USA and told Dr. Heimlich about my interest in
malariotherapy for cancer even though I had been worked at AIDS laboratory since 1988.
Dr. Heimlich came to Guangzhou in 1991 to talk with us on the cooperation of
malariotherapy for cancer. Dr. Heimlich did give lectures in Zengcheng County People's
Hospital and Dongshan District Hospital, and I did be there as an interpreter for Dr.
Heimlich, but Dr. Heimlich never mentioned malariotherapy for HlV in his lectures and
thereafter until the middle 1993. It was that I first time spoke to Dr. Xiao, the Director of
my station about the idea of malariotherapy for HlV in early 1993 on the first working
day after a long vacation of Chinese New Year holidays. Three months later I received a
letter from Dr. Heimlich by which I first time knew Dr. Heimlich had the same idea and I
told Dr. Xiao about this. Then we came together again after completion of malariotherapy
for cancer. Then Dr. Hua Hong Shun came a couple of times on behalf of Dr. Heimlich
(he also visited us a couple of times for our cancer research project). The unique
document telling us that Dr. Heimlich proposed the idea in 1992 is a written letter from
Dr. Heimlich to me in 1994. Any statements saying Dr. Heimlich proposed the idea prior
to 1992 are unacceptable. Simultaneously, any statements denying Dr. Chen
independently proposed the same idea in early 1993 are also unacceptable. These
statements will lead to no way to go for our cooperation, because these statements are not
true. We also had different ideas on malariotherapy for different diseases: Heimlich's
L _"II1 di ease idea and Chen's SLE idea which I mentioned before.
It is unrea onable for saying that the immune system manuscript is in Dr. Heimlich's
house computer not in the office one, because these computers link to the internet: not
only Dr. Heimlich but also I can email to your office if I have your email address. In
addition, a floppy disc can be used from the house to the office.
I look forward to hearing from you, especially the answers on the acknowledgement in
the immune system paper and the funding and authorship in the efficacy paper as well as
the future cooperation. I suggest that we should talk and resolve any problems between us
before the intervention of officials which complicates any existed problems. So timely
communication is very important because we have computers which link to the internet.
Please give me your new office and Eric's email addresses.
Please excuse me to CC this message to Dr. Fahey, because I think we should talk very
openly, and Dr. Fahey helped us a lot in HIV-malariotherapy projects.
Best wishes and regards to you, your family and colleagues.
Reply to your e-mail of Feb 23, 2001
1 of 1
SUbject: Reply to your e-mail of Feb 23, 2001
Date: Fri, 23 Mar 200117:16:49 -0500
From: "Henry 1. Heimlich" <heimlich@iglou.com>
To: chenxping@netease.com
CC: lLFahey@mednet.ucla. edu
Dear Dr. Chen,
We received your e-mail of February 23, 2001. It is so complete and
thorough, it is best if we cover one item at a time. Let us first
resolve the matter of whether you conceived of malariotherapy for HIV in
early 1993 before hearing about it from Dr. Heimlich.
Dr. Heimlich had presented his concept at meetings in the United States
for several years starting in the late 1980s. As Dr. Cionci wrote, he
clearly remembers Dr. Heimlich spoke about malariotherapy for HIV and
cancer at a large meeting at the Municipal Health and Anti-Epidemic
Station of Guangzhou where you were present. Dr . Cionci was then
escorted to another room in the building where he and seven other
doctors saw a short video of a man described as the first AIDS patient
to die in China. Dr. Cionci then told Dr. Heimlich about the film. Dr.
Heimlich, once again in the presence of other physicians, mentioned that
pe intended to treat HIV patients with malariotherapy . You informed Dr.
Cionci and Dr. Heimlich at that time that HIV was not a problem in
China. That is why you started treating cancer patients.
It is not unusual for a person to hear of something, forget about it,
then, at a later date think it is his original thought . Here is a
suggestion. You sent Dr. Fahey copies of your last letter, therefore,
we will send a copy of this letter to him. We both have a great deal of
respect for Dr . John Fahey; furthermore, he is independent of both of
us. Dr. Heimlich arranged for you to spend several weeks at Dr. Fahey's
laboratories in 1997, before this misunderstanding arose. Through the
copy of this letter, we us ask Dr. Fahey to tell us whether you told him
malariotherapy for HIV was your independent concept during that visit.
If he says you did so, and you told him the date, Dr. Heimlich would
consider that fact in resolving this matter.
A f ~ e r this is cleared up, we can proceed to discussing other matters.
Best wishes to you and your coworkers .
Sincerely,
Heimlich Institute
3/23/015:17 PM
-
Subject:
Re: your e-mail of March 23, 2001
Date:
Thu, 29 Mar 2001 16:26:34 +0800
From:
chenxiaoping <chenxping@netease.com>
To:
Henry J .Heimlich <heimlich@iglou.com>
CC:
"John L. Fahey, M.D." <jlfahey@microimmun.medsch.ucla.edu>
Dear Dr. Heimlich:
We can not accept the statement "As Dr. Cionci wrote, he clearly remembers Dr.
Heimlich spoke about malariotherapy for HIV and cancer at a large meeting at the
Municipal Health and Anti-Epidemic Station of Guangzhou where you were present."
Because this is not true. Nobodies knew in Guangzhou part "Dr. Heimlich spoke about
malariotherapy for HIV" during his visit in 1991. But Dr. Heimlich did speak about
malariotherapy for cancer to the audiences at that time. This has been documented in a
letter from Dr. Heimlich to Dr. Chen in 1994: Dr. Heimlich proposed the idea of
malariotherapy for HIV infection early in 1992. This is also documented in our second
published paper entitled "Phase-1 studies of malariotherapy for HIV infection", in which
Dr. Heimlich requested to write down the same thing before submitting to the journal.
Therefore, there is no witness to say Dr. Heimlich spoke about malariotherapy for HIV to
the audiences in Guangzhou in 1991. Professor Xiao says that Professor Heimlich wants
to made more stories about malariotherapy in his email to Dr. Chen in March 23, 2001,
but these stories are absolutely not true, nobodies accept them.
Dr. Chen not only independently proposed the same idea in early 1993, which I
mentioned many time before, but also proposed the possible mechanisms of
malariotherapy for HIV infection (this is documented in our second published paper) in
the same year in the review board discussions, otherwise the research could not be
approved by the board (please remember, Dr. Heimlich did not attend any review board
discussions during the whole course). It is absolutely unreasonable to ask our friend, Dr.
John L. Fahey to clarify our dispute, because I got to know Dr. Fahey and then became
his friend in 1997, four years later after the concept was conceived in early 1993. Please
remember, when we talk the possibility of cooperation on malariotherapy-HIV project in
middle 1993, Dr. Cionci was not in.
Professor Xiao says that it is no need to talk further if Heimlich Institute deny the fact
that Dr. Chen independently proposed the idea of malariotherapy for HIV infection.
Because Professor Xiao heard the idea first time from Dr. Chen. In fact, we can not
confirm Dr. Heimlich proposed the same idea in 1992, but we do not deny it, and wrote it
down in our second published paper while Dr. Heimlich requested to do so before he
permitted to publish the paper.
The Guangzhou part decide not to talk any more if Heimlich Institute persists in denying
Dr. Chen independently proposed the same idea of malariotherapy for HIV infection in
early 1993. The cooperation therefore discontinues due to this issue and funding event.
Because these indicate that we do not trust again each other.
Sincerely,
Chen, Xiao Ping, M.D. , Ph.D.
Director,
Municipal Health and Anti-Epidemic Station of Guangzhou
311 STRAIGHT
STRE E T
CINCINNATI
OHIO
45219
513-559-2391
F AX 513-559-2403
heimlich@glou.com
WoMN.heimlichinstitute.org
B en ef i t i n g
Hu m an i t y
Th r o u g h
Heal t h
an d
Peac e
November 18, 2002
Ms. Barbara R. Sporck-Stagmaier
2401 Ingleside Avenue #IID
Dear Barbara,
You have always been so kind to remember and support our work each year. I feel the
enclosed report I received aweek ago will be as gratifying to you as it is to me.
The archbishop of theAnglican church of Nigeria met with me originally when hevisited
Christ Church in Cincinnati. Dr. Wakama, and another physician from Nigeria, came to
The Heimlich Institute inOctober under the auspices of theAnglican church of Nigeria.
They spent aweek learning how to carry out our treatment of malariotherapy for
HIV/AIDS. The doctors expect to commence treatment of HIV/AIDS patients in Nigeria
this month.
Inaddition, two physicians from South Africa spent the past week with us. They also
intend to initiate treatment in that country. During the first week of December,
physicians will be arriving from Ghana for the same purpose.
The ineffectiveness of drugs for HIV/AIDS was established this year. Our
malariotherapy is the only hope at this time and is receiving wide recognition.
I amgoing out of town for Thanksgiving, but will call you upon my return in the hope of
getting together before the end of the year.
Encl.
Affiliated with Deaconess Associations Inc.
j y
f J ~ ' 1
--- - .----~/
(
/ ~ ~ / - - ~ ' - c
J t J
December 18,2001
\
Ms. Barbara R. Sporck-Stagmaie~
2401 Ingleside Avenue #IID
..
Dear Ms. Sporck-Stagmaier:
Thank you for your generous contribution to The Heimlich Institute. We are grateful for your
commitment and support of The Institute's efforts.
Dr. Heimlich and the Institute continue to actively pursue research into issues which are important
to the medical and scientific communities, including cancer, AIDS and Asthma. In addition, we
continue to invest in a nationwide educational effort to increase the public's awareness of the
Heimlich Maneuver's effectiveness and success in saving choking and drowning victims. Support
such as yours will help ensure that these important efforts continue.
Ms. Sporck-Stagmaier, I know Dr. Heimlich personally appreciates your significant support and
recognition of his achievements andtalents. Thank you again for helping Deaconess foster his work
... and best wishes for a delight ful holiday season!
Sinc erely,
E. ANTHONY WOODS
President & CEO
c c : Dr. H. Heimlic h
Dear Dr. Heimlich:
Due to many things to do in the new year, I just have time to finish the abstracts and
translations related to Chen Xiao Ping's affair. All the related materials are summarized
in the enclosed package.
I believe the material are suffice to prove Chen's attitude. I really feel ashamed of it.
Anyway, if there is any need, I can be your witness.
Please send my best regard to your family.
Fraternally,
~
- /
~
Hongshun
0110412002
APPENDIX
1 Dr. Heimlich's letter to me, December 31,1990, with a letter written by Chen
Xi ao Ping to Dr. Cionci.
Chen' s letter said, ''Thanks for your information and letter. I am also interested in the
malaria therapy on treating people with cancer and AIDS."
Chen knew about malaria therapy of cancer and AIDS after Dr. Cionci's visit to
Guangzhou in May 1990.
2 Chen Xiao Ping's letter to me, March 5, 1991, with a translated abstract of that
letter in English by me.
Chen asked us to provide him materials concerning malaria therapy carried out in Mexico
and also about malaria therapy on neurosyphilis.
When Dr. Heimlich, Dr. Cionci and I went to Nanjing to observe Dr. Ma Yongquan's
initial several cases of malaria therapy of cancer, Chen came to Nanjing to learn how Dr.
Ma started. After malaria therapy got approved by the Ministry of Health of J iangsu
Province, then Chen Xiao Ping was able to got approval from Guang Dong Province,
Which supervised Guangzhou.
3 Agreement on the Cooperative Project of Malaria Therapy of Cancer by
Guangzhou Institute of Preventive Medicine, Yisou Hospital and the Heimlich
Institute, signed by both Chinese and US parties at June 15,1992
Chen Xiao Ping was among the Guangzhou Party. They promised to provide manual
labor and equipment. Dr. Heimlich represented the US party, promising to provide all
the necessary related medical and technical material.
4 Chen Xiao Ping's letter to me, October 11, 2001
Chen mentioned in his letter,"Dr. Cionci visited Guangzhou in 1990. That was for the
first time mentioned to me about malaria therapy of cancer. I agreed that is a very
reasonable assumption. Not until the Spring Festival of 1993, I proposed to the Director
of the Municipal Health & Anti-Epidemic Station of Guangzhou, Dr. Shao Bin Quan that
malaria therapy of HIV might be a more valuable treatment method and later I got Dr.
Shao's full support. Two months later, I received Dr. Heimlich's letter suggesting that
malaria therapy might be used in treatment of AIDS. This was a co-incidence. Chen
Xiao Ping independently proposed malaria therapy in treatment ofHlV infection."
5 Combating AIDS by Using Malaria Therapy (abstract)
Dr.Ho Da Yi discovered Cocktail Therapy ,but the therapy can not eliminate virus in the
storage site. Dr. Chen Xiao Ping of the Municipal Health & Anti-epidemic Station of
Guangzhou using his malaria therapy can help patient increase CD4 cells and discovered
some of its mechanism. Chen proposed a new treatment regime by combining malaria
therapy plus cocktail therapy.
<Followed by a brief review of malaria therapy of neurosyphilis and reports of AIDS
patients with malaria>
In the 90's of 20
th
century, Chen Xiao Ping proposed the malaria therapy of AIDS. In
1993, The health system of Guangzxhou discussed and assessed the feasibility of malaria
therapy on AIDS. Finally, Chen got approval from various related organizations of
Guangzhou government. Chen started the world's first attempt. From 1993, Chen with
his research group started to treat a group of20 patients and in 1955 Chen published his
essay and read before an international meeting.
<Followed by Chen's explanation of how CD4 cells count increased>
In conclusion, the paper said that if the integration of malaria therapy and cocktail
therapy got success, then AIDS patients will be tremendously benefited.
Note: There is no author of this article. A very interesting thing is that th name of Chen
Xiao Ping appeared 21 times throughout the article. No single word about Dr. Heimlich,
Dr. Cionci or the Heimlich Institute.

D D. Heimlich:
Thank ou for your email response of Feb. 22, 2001. We agree that we did all things in
our previous research projects according to our agreements and we were happy during the
cooperation. This leaded to that in our first study of malariotherapy for HIV infection, we
totally presented two abstracts in two important international meetings and published two
papers in science journals. But there is no use to talk the previous issues including
funding, because all participants in Guangzhou part have known the past through a couple
of discussions. We should take a time to resolve the current problems in our second
HIV-malariotherapy project. You should remember that in our very difficult time, we
asked for the funding from the Heimlich Institute, but we failed to get it due to the
agreement obligation. We had to spent a lot of time on dealing with the funding and make
a great effort to persuade the governments to fund the research. Finally, we got it from
several departments. The project, therefore has been completed, but this also leaded to a
change of the major funding originally from Heimlich Institute later to the local
governments and other institutions.
I suggest that, you do not need the authorship of the paper titled "Impact of acute vivax
malaria on the immune system of HIV+ patients" which focuses on the early immune
response (only 3 months data), not really on the efficacy of malariotherapy, but we would
still like to thank you in the acknowledgements section like: "We acknowledge Dr. Henry
J. Heimlich for his successful cooperation with us in the pilot study of malariotherapy for
HIV infection during 1993-1996. He independently proposed the idea of malariotherapy
for HIV infection in 1992 (note: in the contributors section: Dr. Chen independently
proposed the idea of malariotherapy for HIV/AIDS in early 1993 will be mentioned). He
also helped us to get a part of funding from Eleanor Dana Charitable Trust in our present
study. Dr. Heimlich works at the Heimlich Institute in Cincinnati, USA. " I hope you
accepted this acknowledgement. Doing so is very important for me to comfort my
colleagues and the officials. Because the conflict of funding and authorship issues made
me a deep embarrassment, this directly leaded to the intervention of officials. I am afraid
that I will lose my colleagues and then lose the opportunity for our future cooperation.
Please note, the situation here in China is very different from that in the USA, even
though China is in progress. My another suggestion is that you should make a supplement
to fund the research so that your authorship remains in the next paper which focuses on
the data of CD4 level and HIV viral load for two years follow up. It will be the most
important paper up to now in the research of malariotherapy for HIV infection. I will
explain in my greatest effort to my colleagues that Dr. Heimlich should be the second
author in this paper and I will insist in making a notification like: Dr. Heimlich and Dr.
Chen independently proposed the idea of malariotherapy for HIV infection respectively
in 1992 and in early 1993 or like: Dr. Chen and Dr. Heimlich equally contribute to this
paper. But your funding is very important for comforting either my colleagues or the
officials.
Our future study will be a very big project, needing a huge funding: a multiple-center
phase-II study of malariotherapy for HIV infection which includes 100 patients for the
treatment group and 100 patients for control group. This needs to screen over 400 patients
for their CD count level for patient selection. We also need to sign a new agreement in a
research funding tyle (that means funding go ahead of data obtaining) if we come
together again in the future. B the way, a private company in China and an institution in
Italy are willing to fund the phase-II study, but I have not yet accepted, because this will
let the research goes a business way and I am waiting for the cooperation with you.
We do not hope to contact with any embassies or consulates or directly with the officials,
because our cooperation is completely scientific but absolutely not political.
Regarding to the letter from Dr. Cionci to Dr. Heimlich, it is not true for saying that Dr.
Heimlich spoke to my group on the use of malariotherapy for HIV. The fact is that in
1990, Dr. Cioncj as a representative of Philadelphia Red Cross Society visited to
Guangzhou. I met him in the White Swan Hotel where he stayed. We talked very
friendly, when I told him about my hypothesis on that HIV might originated from the
molecular hybridization of SIV and human sperm gene (I published this idea in early
1990), then he told me the idea of malariotherapy for cancer proposed by Dr. Heimlich,
when my response was "this idea is very reasonable" since I had been a physician for
infectious disease for many years and had treated over one hundred malaria patients.
Then Dr. Cionci returned to USA and told Dr. Heimlich about my interest in
malariotherapy for cancer even though I had been worked at AIDS laboratory since 1988.
Dr. Heimlich came to Guangzhou in 1991 to talk with us on the cooperation of
malariotherapy for cancer. Dr. Heimlich did give lectures in Zengcheng County People's
Hospital and Dongshan District Hospital, and I did be there as an interpreter for Dr.
Heimlich, but Dr. Heimlich never mentioned malariotherapy for HIV in his lectures and
thereafter until the middle 1993. It was that I first time spoke to Dr. Xiao, the Director of
my station about the idea of malariotherapy for HIV in early 1993 on the first working
day after a long vacation of Chinese New Year holidays. Three months later I received a
letter from Dr. Heimlich by which I first time knew Dr. Heimlich had the same idea and I
told Dr. Xiao about this. Then we came together again after completion of malariotherapy
for cancer. Then Dr. Hua Hong Shun came a couple of times on behalf of Dr. Heimlich
(he also visited us a couple of times for our cancer research project). The unique
document telling us that Dr. Heimlich proposed the idea in 1992 is a written letter from
Dr. Heimlich to me in 1994. Any statements saying Dr. Heimlich proposed the idea prior
to 1992 are unacceptable. Simultaneously, any statements denying Dr. Chen
independently proposed the same idea in early 1993 are also unacceptable. These
statements will lead to no way to go for our cooperation, because these statements are not
true. We also had different ideas on malariotherapy for different diseases: Heimlich's
Lyme disease idea and Chen's SLE idea which I mentioned before.
It is unreasonable for saying that the immune system manuscript is in Dr. Heimlich's
house computer not in the office one, because these computers link to the internet: not
only Dr. Heimlich but also I can email to your office if I have your email address. In
addition, a floppy disc can be used from the house to the office.
I look fOf\vard to bearing from you, especially the answers on the acknowledgement in
the immune :stem paper and the fundi ng and authorship in tbe efficacy paper as well as
the future coopera ion. I suggest that we sbould talk and resolve any problems between us
before the interven ion of officials whicb complicates any existed problems. So timely
communication is very important because we bave computers which link to the internet.
Please gi e me your new office and Eric's email addresses.
Please excuse me to CC tbis message to Dr. Fahey, because I tbink we should talk very
openly, and Dr. Fabey belped us a lot in HIV-malariotberapy projects.
Best wisbes and regards to you, your family and colleagues.
Dear Dr. Hua: March 5, 1991
I have received your two l etters and several articles about
'Malaria- the r apy of c a ncer project". Because of Chinese new
year holidays , I h av e to wait until this month' then to
contact t h e var i ous related government office, oncology
hospital a nd mal aria clinics .
Now I got the reply from Guangzhou municipal government that they
full y s uppor t this joint project. The director and experts of
cancer hospital showed much interest in this experimental
research, and doctors of malaria clinics would supply
malaria patients' blood for' blood transfer'.
For the time being, we still need more supporting materials before
we can make a definite decision and a working schedule.
We would lilke to know the detailed progress of malaria therapy
carried out in Mexico, e.g. the number of cases, what kind
of cancer patient are been treated, their preliminary results
etc. Also, we would like to get materials about malaria-
therapy on neurosyphilis. A meeting will be held under the
direction of the Municipal Ministry of Health ,participated
by government officials, cancer exper t s and doctors of infectious
diseases to discuss this project. With all these convincing
materials, that would help them to make the decision.
We are looking forward to the next visit of Dr. Heimlich and
Dr. Cionci. Please let me know the date and schedule of their
visit.
Sincerely,
Chen, Xiao-ping

... -.. .. ..... .......... '-.. ... . I I ; 4:.
-.
The $0 ynite
.... !!!I!! ' ..
t 1l'.A.
,"(.;,rs l' I \ \;'1:.JV\:LtD
APRPid Ip.\nn
0",1,..
ACUJ..(O

'eUe ... 0{
C.,A. n .. wd M"!IIb.:,
Vot.:rs
ufP;'IX',.yI utNa
net. 'on,

7. 20f)U
Dr. J, H.;:icnli<;:h
Thl' Heimlkh InslilUh'
311 Strl\igh1
Cilldnnuti, OH
Dt:ar Dr.
Dr. Juk ('O"ei. ltaul'ldc:f.
'.(lInf' -
fte)'tUtdn
",hClP p,In n" C",Ollr . 6tll
As yO'J I huvc wy re;,'oJlel't ion of (llll c()1lccmini malariotht-L,py, as you
Tn Novernb..:r. 1991, you and I neW 0\11 of San F rancisc(\ to Mainland China to conduct
maluri(Hhel During {:rossing. we once ugain discussed your hope
tb.lt n/41ari')lht-IIIFY cculd .10d pm .. y 1 c\;'(Tain of
111i::i was my third trip to Chin,'\, My fi.rst was in \9S0, wheu 1 WilS inviTed alt.'ng with 3t other
phySicians, c:duc!tors and varil:\.1 fo!' a. VII' medical and ,uJtural It was then that
1 intmdu .. --:d the llei.ll1lit:h M41t'1t:'uvt'r t<:. Dr, HClng Shu1'I Hua in th..: N a.o.l ina 'Pt'opk, Hospital
In MIlY, 1990, 1 in ... . ty \0 present iOl'mallt:ctures on AILlS (0 hund1'cd!.' of
m..;dlcal in six or China's main I was lold I was the Western doctor It') do so.
10 help pa!)s the. tin1t: dUling ()U! flig.ht. aod I explored the pn"ls and cons of
maluriolht::rap)". Quit" you advised me Ihnt for yeats you hi1d bee!, researching Ule USt:
of malariotherupy for AIDS ;:md you what r thoughl abvul the po$.\ibility of peor1e with
HIVIl\IDS.
A few day" b\tt".r in Chi!'!:!, W' . Otnd h(,Md un TV annou.nce to rha that he telOted
(or AIDS vin.l!,;, Ooa agiJi!l, we agw;:d ho\v \\'(lodtdul it would bt if could
;:-.
SEP- $')-'!-t: .. H("
LI k.. .' H 1.- L 1 II r" ' t. t
FeY !8.
\ dls: il1;; ly [c . embc, I.ni g on ' of Y lUI lectures W in Guangzh<)u, th<lt 1 asked
.,. , of de,,- .ors 10 b\\' e l.;crure hAll him. lit' ,ouk to &notlw wing ot medical
bw.J ' ();t \<)00' wil h t\ TV. With seven o\h.:r dCX,'.h.1TS popped ir. a video ilnd
to d /l .t' it lhe firs: pe:son vihv die.d in 1'r;)))1 A 10S con1i-,J)<,'utionS, it W(lS iii color and very
it dll -: um,n
l
..:-<l \a:;l six of tht' He "vas a. ymmg man from Thail and
wh<.' .a user and a mllk prostitute. II "nd p;1thelic.
FC'II:,
w
i.lg YQUl k.:tun:: . T fC wrat I had on lh;; vldet'. In Iht' prcsen<.:e \)( the otl1er
NI,,' .;Igllin YO'l mentionel,1 to(I" Y(lU hoped ,(.1 <,\,medilY lise mala.riotherapy on people infected
w:th HI\ . Wt: at thilt AIDS not n plOblelli in CbIH\ .
Fr:ncrually.

I
In Jack Ctouci ,.'
200 1if.12 A 12 B CWJ1Joff'fhN)
$J CDC I roJ
cp . . !I@>500), CDC II f5J&f.
'
(CD4Wj!l<200).
$J $J m ,CD4 Wj!l@ tE 15 7t :
?!'\ffff' 1993 .RffI5) , 41
, if, , {f ;
' ElIY:J r J ffl r 'Jt r J *iff&9E:
R tzo4' L $J
1i15l'5t!i6IY:J IlJil/Fp , 83m- J1nlW-ra9 B j!(li : r:p * 51 r m i@ :
, !:)!tCr $J ).
J ,
19i&'
&:tfHiJB'C'
, ffff i'Ufj 7 19 fflm-i'iJ
$J + cpM(CDC IIW,f,;g-
g:
CD4roJ ,
ft ftlJ 20t!t*.e.
90
if{-t tE
1993
if1fflMi, J!j.f/j'ZP:$ =.t:.
m ' J!j.f/j, zP: ttl:17 J;) if 1 1 Fl 1;..
1t
, jfmg
$J tEws cp 7 m ilj' it!!. 3tCPtljJ!j.f m (
Ij'ZP:IW8'!J 8i rxlliJ
, :tJIt.i53ljJ!!lE : ws $ tt:it {'F :
Mra9ff
35
%9EL' fffff5J&f,f. *.!l!ttl:1 ' ff1lE,'/;!\ .RiUHV,f,;g- lliJ IT IJ i! J!{.
'Ji f. CD4Wj!l8'!JttrlJo ' rc9 '
-
r J
r xlliJ
i!m> .
J!j.f/j''Pm r J
{flli-ft r 'lfE1l! iE
, en - t1 OJ ttt .1Jo ,f. :g- .
an ,
'
r J
m i! m 89
(...t) f4
\ 89&f
'" . -@: Ji: 1t. 1 j!.iij
(41C-42C' W rS ffj
J!. mrm 1IW'l ttJ

. ft
.
rf! $.:j: t\\.H1J, A 89 CD4 klII
J . Jffi!. 1IlHiUU
CD4
mtm*zp:
. ffift5* .
tHilJl.ff
J! : WJltI5JIlif .
M;
. . ;l'l;1&89&f
- tB 1:. HD l: r Ji: . ft!!.89ti?J!rr ll T . @ '& *!.Jl r fJ! 11
$J 1&.
- K::
f{JaWlJffi!1f-*2.
Ff< . 2fS.
Ul:.1'M89
. . aklll
. . itit
. y
.
tEI&89t5*-
.
0 Ji: IJ\ m ft r 1i WlJffi!lf{:tf{J it it itt . 1
. ttJ rf! ffj $J r)]
*J:ff-' r J;)$l;t$J
.ll* :t g,*!I9ffj$'
.jf-A15 cp .
.
ffii7CktBJf-ft!!.1l"i BWlJffi!iftijL:$l:ff-' m:ll.y!i1JD .
: fiRfS @1*!.Jl
. 1& .
. I\!lf!
m1i1.i$

I-
a:
o
D..
w
a:
..J
c(
o
W
.... :
...a..-;. -
..

. . .
m (f:]fJJ ft . R -N M
200-500Zra'(f:]CDC II . tlf1ilE ,- .
0 .
. .1ilEJ;) r J , .

. 0
. .
. 7tJJU&J;) r J fO r J mffi 0 r fi! j
1l!'f$ J . 0 j

r J + r J
-fl - 0

. r.mm J k4EJIeI .

. . 0

fi 0 _ .

;. (f:]CD4JJ;J; E r
0

0 r J

. .
r J 0
r J 0 i fii
J r J (f:]CD.tWlJffl! . r J

r J oTfigfi r J m$&ii'fI!i!(f:]{'Fffl rzgJlt . . r
. DOL i itHi@1l!'f$ J .
. . .

r J . 0
...
$ 11/f'!:1- J, .. j
ttl1 J &ft 1 i 1J!l i'i 1'2 / -It Ti
J \i] i- ;:: 'fo%r i:;t ,

Y1.v:,"kil t11's 12 J , {+ 2-: :1;>
{ iJ,ff is II' i 1{Ji * J
, 2 'i
v(}I'Z-J!2'4 <Sj207jLJ,-
j i.- I 1- IX- v-:; 'f!.- I::J , I A l'

UCLA i <ij Ac,,<:# J. :It 00 t IV 3 1. t 3
1
[ /
, -1\1 11; tK,JJ 1' 1'* h rll J >J / lM111,,, tf ;U{, (.Jg.
/\1:x"z11l {1'; t 4 7 ) 3,(
a- S Hb/1\/.:dl f 4dt
3 ci / 4' l' 2: "1' ;;;iJiL -iJ-;tU, yj) f.)L {ric J"
/ if:J 1{7 3-);: J7 iiTY '
1 if; J! til I qq 04 1'1; 7-flt,
if 1* Ii {i;; i i /11t-tll
J fi 4 tfj $ ,' I \<l c:e" j I q!if IIp
-1 % r-frt ,0 krz Wi {v q rl';," l1c. h If f&
t{:i;, u- Ifd; ,f1;-
ifit. j311 '1#1; f /;;i/, y-lli;f) ro
1 'i 'Y')( . A . ) 11 '7
;?r; r -! 11' 7&1-b!fr fp l1; {tJ1 L ,,7 :> 7--/\'
SIC fi:r!; :if t 1 G. Of I q q
3

/ t 2-1(vtl I iffoJ 14 4, ; r?
7ut 9t g :r ItJJ ;t
rq' , j{]:}l t I it: (,9 1;, 'i ? i Tv ) j; H ;" ti'ff
:;Vq 1tQ>z, jt?vHn
1
?8)
'f ff 2 11; -;pfJt- I:f/i g:}'iZP!l,
1d iJiyJ-fl fi;Hf vI,;ft I
I i{ 111 I-j 14":
/1 }4 dJ t I { 7-1 Ii II'
':l. )It )
'Sf r). / k 1-/71 1-ttt C 2JK 00 11 U
)"'--0) I '$ (jj,{qq> ..
J
c.tI ' 1; >.<i hJ? .-f'.1 . -,.h '"'{ I- , '" -f:
l' l!, at' YZ-r- Zld\0 10: v>' 1 oL 1 1:: -:iff.:]I
f 1 lZ/1 is (tAl If I 1}" Hy.;t;(q:t
12 , f1Ji
1
1
,1\ HIU pi I rI-tl",(,:c!\ t ! JAtt,
(f, '"
11,,--;(1). l;;i /' ':l I q q if 1> H 1 'iar vd /
") fI-- g c...- 1
11
,\ c;-!) U/"I \ .
It ar:;{1 j if'
wt-t I yZ .\1 Iqq iJv'<tli-VI i:t
'!::f/ t [.b#JJ 1'-.1
{w-jJ ft j lit- {1j 't -If%) t ff i) at
rqq 3 n tg,VjH i -t-i -r;1\ J ')
:t1 fA9 t ti 4 f!f 1, H i / f f
H
\ I ' I /> v? .--, I J ' L \ I ) --i 7"
. VIP 1; jf 1 I' 'r <l>t . 1"t n-tM>1 lC h 1"2 .;f,
1 'I 1t J I qqq-+ f1j
( I skid, ef trr H Iv 4-
e
"Y
Yt i 1rn ;ffi m
iVY H\ll /)}II/<, I
I -il?-p-J . ;q'11'dl J ,
'f / w- I qq 11- $ c:en
11 t'D \:f;) i
fil
i! 1%jc Pr1(i ;j1;1/ih i#f
} " /
/ q q f i .fi,fM: i t-)f fll,z J I q q
1
cf; ')
t'i 4, ;ft i1; f, i jJ HI U $,-J;}. r -f'1 f j I q 1 0 ff;f fiI
;ji1kd'J If; i i JrI i 3 / ;qq Jf ?;J r}:i: iff iii
y1?! .. iJKi01)V;ziAf;l;fi4i
S L E .,.j:1<t. t tiS IT" i < 1
')};-t:t / )p 11 I 'ill '
{ 14 j] 11lJI\ H IV , t!1t-
M 1.:f lJ,f Hj)
. tMt.fi If/ jJ HI V I ;,. JJ-1fN I),D?J:.
J1 :i)'ff :riveS 1-Jtt l}, @ J- l' J,
8 #}
i--10- yti";:L (.J 5J- ' ;J 1 U+ r1 #11 #1f
)

/.7 Itt.:t- \

pi, I t, II.
.-.

: 1i1i A if :{,i z :$ 0

JJ * .& PIHz: % J'G FJT I'f.J .lL :R; FJT * 1ft flL ?J'- i 1!;l. ({ ) ffl"
iJ< i.$!. - 1J, ({ :P:ij lz: % 1i1f FJT II 1J< i;z * = jj 0 th- 1;Z'' tJ. T Ai- jj
00:
jlU:a
")7H" 1JW:" '-' ;.; .. ,.,. ::; .
......... : " ..
.. 5.
..
c :
j
1
-{ i
i !
: I
..
"-. ,
, ..
. .
-. .
T

+;:;t;:.l , ",

-

!;l. 0

-\-
-:.,-
.: ; J'
- -

;.

. if qm A f 4 Et: 5 liT I J!1J3 JI3 0 1lA

:lJW:

* f0 ,. if;t: (f.Jl1Us} 0
aw 1 0 0 0 Wsfiffi 6

f Ii (f.J t#} :
Jj B ( 1 9 9 3 3 Jj.3 0 B) C 1 0 )

xJ.:lJFcJ f0 lji:IJ ::ftt;f!J m
lit :IJ ::f *fJ ffl 0

(I

-2-
.. i -
-.
: 1- :
. ,
. . , . .
. . -.-:::
.. .
. .. ...
. . .. ; '
. .' ::. :: ... - ~ :
", "
', '
.. ::- -
-
,
.' .
-3-
Dear Dr. Heimlich,
I have contacted the related officers of the municipal and provincial governments. They
have promised, the issue of cooperation continuation will be discussed later on and they
pleased you do not contact with the Embassy of The People's Republic of China in
Washington, D.C. and do not directly contact with the heads of the governments, because
this is a department (science and technology committee) issue of the local governments.
They said that our cooperation agreement was not a scientific research agreement but a
trade contract after they reviewed it, because there is no a scientific research funding
comes after research data obtaining. I understand that, they said so because they have
paid a lot of money for the project. .
An urgent issue is that you should give us a written declaration to declare that you agree
to publish our paper titled "Impact of acute vivax malaria on the immune system of HIV +
subjects" in a format I sent you in my email of Feb. 7. And also, I have not yet received
your response on this manuscript which I sent you by email over two months ago. So we
have not yet known your any ideas about this manuscript so far. This has delayed our
paper publication and is unusual internationally. Based on this and the research payment
issue, Dr. Xiao and my other colleagues as well as the officials of the governments
recommended many times to cancel your authorship in this paper but instead in the
section of acknowledgements. But I persist in putting your name in the position of the
second author based on our both understanding.
Best regards to you, your family and your colleagues.
= a 7 e co ~ a c - e ~ ~ e related officers of the municipal and provincial governments. T
~ ~ ~ g e t i ssue is that you s houl d give us a written declaration to declare that you
3es regards to you, your family and your colleagues.
C' e xi ao ping, M.D.
At 01- 1-26 12:02:00 you wrote:
>Dear Dr. Chen:
>
>Thank you for your e-mail of December 8, 2000. We are glad to hear your
>viral load lab is fully operational.
>
>Apparently your municipal and provincial governments have the incorrect
>impression that "the Heimlich Institute broke the cooperation
>agreement." Perhaps their translators did not make the terms of the
>agreement clear. It is important that we correct this misunderstanding
>so that we can continue to carry out our research together.
>
>You will recall, as we discussed and agreed upon during your 1997 visit
>here, and in our correspondence, it was required that viral loads be
>performed at the time of pre-treatment, post-treatment and follow-up
>examinations. This was vital because: 1) it was necessary to ensure
>patients were definitely HIV-infected, 2) determination of
>malariotherapy's ability to control the infection needed to be made, and
>3) medical reviewers require such data for our results to be accepted.
>Our agreement (as discussed and agreed upon) also called for payment by
>The Heimlich Institute upon receipt of complete patient reports. Since
>viral loads and other data are part of these complete reports, and none
>have been received, payment is not due.
>
>The provincial and municipal governments should be advised the delay in
>getting the viral loads was through no fault of yours or Dr. Xiao. It
>resulted, as you wrote, because the Chinese government had forbidden
>blood to be sent out of China; therefore, you could not send blood
>samples to Dr. Fahey's laboratory. Additionally, the university in
>Guangzhou did not want to handle HIV-infected blood.
>
>The Heimlich Institute is known internationally for meeting its
>obligations, and, as you know, Dr. Heimlich has maintained a good
>relationship with the Chinese government for many years. Please feel
>free to inform the officials that their impression was inaccurate. If
>you prefer, we can send this information to the heads of the provincial
>and municipal governments, through a contact at the Embassy of The
>People's Republic of China in Washington, D.C. We would include the
>agreement, the above information, and our bank records indicating the
>dates and amounts transferred to the numbered accounts in China. This
>should satisfy them and allow us to continue our work together.
>
>Dr. Heimlich and I look forward to the continuation of our studies with
>you. Please extend our greetings and best wishes to your family and all
>of our colleagues for the upcoming New Year.
>
>Sincerely,
>
>Eric Spletzer, PhD
2/12/01 8:12 AM
D ar Dr. Chen:
Thank you for your Holiday greetings.
My Chinese friends have sent me a copy of a newspaper for which you have provided
information. They have translated this into English for me. It concerns the
malariotherapy for AIDS. They are concerned that your name appeared six times in the
article with no single mention of Dr. Heimlich, The Heimlich Institute or Dr. Cionci.
You also state you proposed malariotherapy of AIDS in 1993.
In an e-mail of March 29, 2001 you claim, "Dr. Heimlich proposed the idea of
malariotherapy for HIV infection early in 1992." You also claim that you independently
proposed the same idea a year later in 1993.
I have in my hand a letter dated December 3, 1990, handwritten in English by you, to Dr.
Cionci. Your letter responds to his having told you about my discovery of using
malariotherapy to treat people with cancer and AIDS. You state, "Dear Dr. Cionci: Many
thanks for your letter and information. I am also interested in the Malariotherapy on
treating people with cancer and AIDS. I am glad you said Dr. Heimlich had asked you to
accompany him to the opening of the clinic in Nanjing. But I have one question about it.
Why don't you plan to open the clinic in Guangzhou instead of Nanjing?" You have
proved in this letter that in 1990 you were told about my discovery and research for using
malariotherapy to treat cancer and AIDS.
I have been informed there will be two more parts to the story in the Chinese newspaper.
If you have corrected your omissions and given proper credit to my origination of
malariotherapy for cancer and AIDS, we will be most pleased. As I stated once before, it
is not unusual for one to learn of a new concept and, several years later, think it was
conceived independently. If this is the case, you need only write to me and others to
withdraw your claim.
If I do not hear from you to that effect within the next two weeks, it would be appropriate
we put this information before our colleagues and the public. I propose to do it in the
following fashion:
1) I suggested once before that I will provide your letter, and all other
information, to the People' s Republic of China embassy. In addition, similar information
will be provided to be distributed to officials and medical colleagues in China to obtain
an official opinion of the evidence.
2) My colleagues in China, and Chinese colleagues in the U.S. , will write to the
newspaper and the authorities mentioned above with their opinion.
cc: Dr. Hua
Dr. Fahey
Dr. Cionci
=
Jear Dr. Heimlich:
After I majled the package of the material on Malaria Therapy of my last week, I tried to
find more evidence. Because I used to keep my correspondences, finally I found several
printed articles enclosed here as Appendix 6.
These were articles on the Philadelphia Inquirer sent to me after Dr. Cionci's May, 1990
visit to China. Please look at the places circled with red pen. Apparently, by that time,
you already told Dr. Cionci the idea of malaria therapy of mY, and Dr. Cioinci has
introduced the this idea to Chen and others during his visit in Guangzhou. Chen's letter to
Dr. Cionci, dated September 3, 1990 mentioned that he thanked for the information and
he was interested in malaria therapy of cancer and AIDS.
Also, there is another section in Chen's letter in his letter to me in Appendix 4,in which
Chen wrote: "In 1994, Heimlich mentioned in his letter to me that he had already had the
ides (of malaria therapy of AIDS patients) in 1992. By that time, I thought :' Had he
thought of malaria therapy of AIDS in 1992, he would have been the world's first
personbf that ides.' But he had not disclosed that ides, and I have never heard of such an
idea. In fact, two persons proposed the idea independently, one is Heimlich and the
another one is Chen Xiao Ping." Chen betrayed himself
I have mailed a copy of all these material to Dr. Cionci. He certajnly will be able to
provide you more evidence to support you.
Fraternally,
Hongshun
Area M.D., task force member
takes AIDS mess e to China
By Tony SWllnlck
Imagine it is 1981. There are only
300 or so reported cases of AIDS in a
r('llIliv('ly small and restricted area .
The federal governmenl nnd the
medical communily mobilize to
learn as much as they can about the
dreaded disease and lake steps to
prevent irs spread.
Now imagine II person with a great
deal of knowledge aboulthe subject
coming in to educate the doctors and
government leaders on just what
course il should lake. If Ihls scenario
sounds like II fanlasy il isn't. That is
exactly the positil)n the People's
ncpublic of China finds itself in to-
day.
Enle. Jack Cioncl, M.D.
Cionci, a member of the board of
directors of the Montgomery County
AIDS Task Force, recently returned
from China afler a five-city tour
where he spoke to doctors and
Because of Dr. Cloud's
trip, Dr. Henry J.
Heimlich, will be able to
estahlish a clinic to u!'Ie
"Malaria therapy" in the
treatment of cancer,
Lyme disease and perhaps
even AIDS ... Story page 7.
government leaders about the posi-
tive things which have occurred in
the United Slates since AIDS was
recognized in 1981, and about the
mistakes made here.
"Hopefully, we can gel a jump on
the spread of the disease in China in-
stead of letting It get a jump on us
the way It happened here," said
Cioncl as he relaxed al his Dresher
home. "The AIDS epidemic Is In its .
infancy in China. In February they
reported 300 cases which puts them
where we were in 1981. Already
there are a great many misunder
tandings about the disease in
hina, as there were here when lhe
utbreak first occurred. Fortu-
nately, they can learn from and
our experience."
It was Cioncl who was chosen to
bring the most basic Information
about the disease, what he calls
"AIDS-IOI," to the Chinese doctors.
Clonci's trip was sponsored by
such groups as the AIDS Task Force
of Philadelphia, the American Red
Cross of Southeastern Pennsylvania
and REBASHT EdllC',..Ung
R1ll!:!t;!: ."bout SP.xu;rlllealth Issu'!S).
He was lhe first. wp-stern physida n to
tr'lvel to China to pr0vide AIDS
education and training.
Clond visiled the cities of NanJ-
lng, Shang Hai, Beijing, Canton and
Xlan and spoke to hundreds of doc-
tors abOut the illness, how to Ireat it,
Please turn to Page 7
With Dr. Cionci, second from left, in China, are Bin Quan Xiao, M.D., far left , Jin Zing Liv,
M.D., and Xiao Ping Chen, M.D.
AIDS cropping
i. .;. : ... . ,
Continued (rom Png(' r. 1
The trip was arranged t.hrough
an exchange program between
the American and Chinese Red
Cross, and sponsored by the
AIDS Task Force of Philadel -
phia, The American Red Cross of
Southeast Pennsylvania and BE-
BASHL
Clonci paid his own way. lIe
traveled to Xian, Bel Jlng, Gunng
Zho, Nan Jing, and Shanghai,
training doctors and educating
government officials about AIDS.
It was his second trip to Chinn.
In 1980 he went as part of a
group of doctors on a cultural
and medical exchange tour. He
. saw many changes in the 10 yeatS.
"On that first trip we did not
go anywhere on our own," he
said. "We couldn't communicate
with the people for one thing, be-
cause almost no one spoke Eng-
lish. The hotels were very primi-
tive, no European style services
or food, and you couldn't get any-
thing but chopsticks to eat with.
"That was all changed this
time. I was welcomed with open
arms . People would come to
greet me and hold up the Red
Cross flag. They seemed much
more opel1."
In 1980 everyone wore the drab
blue trouser and jacket uniform
of the People's Republic, and he
saw no television sets in ordinary
homes. This spring, the streets
were full of color, western style
garb was everywhere, televisions
were common and the children
had many more toys. But Clonci
said there was still a closed quali-
ty on some Issues.
"I am well aware of what hap-
pened in Tiananmen Square but
I was able to talk about that with
only one person. The purpose of
my visit was to teach the doctors,
not to discuss phiiosophkal or
political differences."
Cionci said the differences
made by China's open-door poli-
cy showed In other, nf.'gat!ve wnys.
During his 1980 trip he wu::.
told that v.enereal disease had
been virlually wiped out between
1950 and 1957 because of a strict
program of enforced medical
treatment for anyone with R. ve
norenl C\lSCRSll, al1d InW8 .. bcnrihltagej AIDS' 18 one ot the
prostllnllon n crlmo punishable top klfters,' Cloncl floinUld bUt.
by deportallon to a Islnnd colony "These women, aged-15 to 44, are
as well as harsh re-educatlon pro- the most vulnerable segment of
grams. . the population and the majority
In April Cloncl was told that of new cnses of HIV infection are
Chinn has at least 300 cases of women.
AIDS and there has been a re-
surgence of other sexually trans-
mllted diseases. Clonci trained
doctors at clinics and hospitals,
Including "the barefoot doctors"
who work in poverty and primi-
tive conditions in remote com-
. "We do not have a cure, yet,
and education is the best weapon
we have." . ..
munes. And he met Important
goverment officials, among them '
a minister of h'alth and a doctor
who runs a 100-bed cancer re-
search center .
Those two meetings may mean
a quick return to China for Cion-
ci. He got a letter from the minis- .
ter of health authorizing an ex- I
change program which will allow
Dr. Henry Heimlich of Cincin-
nati to work In China on an ex-
perimental cancer therapy pro
gram at the
Heimlich has asked Cionci to
go with him, perhaps as early as
next spring, to get the program
going.
For now, Cionci has a full
schedule of lectures and training
sessions around the count.ry, in-
cluding the preparation Of a cur-
riculum for Southeastern Univer-
sity of Health Sciences in Miami
for training physicians In dealing
wlt.h and treating AIDS patients,
a task he was recruited for and Is
excited about.
"We have pathetically low
training of physicians in treating
AIDS," he said. About 10 doctors
. in Philadelphia take care of an
estimated 2,859 AIDS patients.
"And people are not listening
to the message ahout practicir:g
safe sex. STDs are spreading like
wildfire" he added. "Since 1984
, the number of cases of syphilis
have tripled across the U.S., and
. quadrupled In Philadelphia.
" STDs weaken the Immune
. system and the more often a per-
son. contacts an STD the more
vulnerable they become.
"Right now for women or child
Il.D. 's trip pave
way for use of .
'Malariatherapy'
8y Tony Swanlek
Jack Cloncl may have traveled the People's Republic of China In
April to teach doctors .there aboutAlDS, but he also made important
s ides.in er thera .
. Because of Cionci's trip, Henry J . Heimlich, M.D. will be able to
tablish a clinic in China to practice "Malaria therapy" which may
ave implications for the treatment of cancer, Lyme ,disease and.
rhaps even AIDS. .
onc Irst visited China In 1980 with 31 others as part of a medical
and cultural group. The group was composed of doctors, novelists,
proCessors and others of diverse Cloncl! for hit! part,
'l!)rked to I-Ici:nlh::h ivlaneuver.
I On his most reccut trip, Cionci's time was spent teaching AIDS
education to doctors. However Cionci, a member of the board of direc-
tors of the Montgomery County AIDS Task Force, also went as a rep-
resentative oC his friend, Dr. Heimlich, president of Cincinnati 's
Heimlich Institute Foundation Inc. Heimlich ,,'ants to treat cancer pa-
tients there by giving them Malaria.
According to Heimlich, It's not a far fetched as It may sound. Malar-
iatherapy, he said In a recent phone interview, was used since 1917 as a
treatment for syphilis of the brain until the disease was all but wiped
ont. Heimlich's plan is to Introduce Malaria to those with With cancer.
He said hyperthermia - Increasing the body temperature can kill
cancer cells .
According to Heimlich, recent reports indicate that when a person
has Malaria, the body produces tumor necrosis factors, TNF, which
nre " known to destroy cancers, It In addition to TNF, Malaria patients
also produce other regulators of cellular immunity ' Buchas In-
terleukins.
In 1917, Dr. Wagner Jauregg reported treating neurosyphilis by in-
troducing benign Malaria. The Malaria was halted after three weeks.
Through the use of this procedure, tens of thousands of people were
cured from 1917 to 1975, Heimlich said, and Wagner Jauregg won the
Nobel prize in 1927 for his efforts. .
It was generally believed at the time that fever was responsible for
curing the neurosyphilis, but Heimlich said that was a simplistic con-
clusion. Heimlich said it was an immune reaction which was the cu-
rative factor due to the production of TNF.
In an April article In The New England Journal of Medicine,
Heimlich cited the possibility for using Malariatherapy for cu1'lng
Lyme disease - an ' affliction which Is endemic to Montgomery and
Bucks counties. According to Heimlich, ailhough penicillin,
tetracycline and ceCtriaxone are used to successfully treat early Lyme
dlsca nt neurolo Ie diseRlle oc urs In some cases.
elmlich said he also Is studying the effects of a ar a lerapy on
treating people with AIDS. _
, n wan 0 say we lave a cure-all for everything and I don't
want to hold out any false hope," Heimlich said, "but we've been
discovering the effect of Malariatherapy on treating AIDS. I personal-
ly believe it has great potential."
Cionci may be retUrning to China sooner than he originally thought.
He said Heimlich has asked him to accompany him to the opening of
the clinic In Nanjing.
"If this procedures works for cancer It wlll be II landmark," Cioncl
said. "It will make a form of cancer therapy available to third world
nations that they do not currently have. Most people in third world na-
tions can't afford chemotherapy or radiation therapy which is often
worse than the illness. This procedure is relalively inexpensive. If it
works, they wll\ be erecting statues of Dr. Heimlich all over Ule third
world. It would be nice to know I had some small part in making that
happen."
---------.
Thursday, Nov. 22, 1990.
/
HEALT
/ .
. ,
AIDS authority .says
disease has
.. more . con
. - ' .-
but l' nsulin -and other medicatior.
By Shaun Stanert
10 Th< '"quor" have made it manageable," he said
It's unlikely that a cure for acquired The methods currently availab!
immune deficiency syndrome will be are drugs that retard the virus' repl
discovered in this century, but there's cation, treat opportunistic infectior
good news: Its symptoms and methods and bolster the immune syster
of transmission have been identified, Cionci said. .
money is being spent to try to find a Researchers are trying to impe(
cure, and ' there are ways to short- ' the replication process further . .
circuit the virus' replication, increas- "Then, maybe, victims can live 1
ing the length and quality of AIDS IS, 20 years," Cionci said.
victims' lives: . . .' '. The severity of the insidious vin
That was the message Dr. Jack has prompted the government to fu '
Cionci, an Internationally 30 times more money IX
AIDS authority and chairman ofthe 'eapita to AIDS research" than io'
Montgomery County AIDS Task Force, .studyof other major diseases, Cion
brought to abOut SO people at the '" . .
weekly adult forum of the Yardley As of last month, more than lSO,O<'
United Methodist Church on Sunday. AIDS cases had been reported in U
He is to speak again at the church United States in 1981. More than 90,0<'
next Sunday. . of the AIDS patients have died; aecor
The AIDS virus, human hnmunode- ing to the Centersfor Disease Contr
ficiency virus (HIV), weakens the in Atlanta .
body's immune system,: leaving ;the . The illness is 'underreported, Cion
victim vulnerable to many opportu- contends, because families sometim
nlstic infections and rare cancers. The request doctors making out death a
disease causes death within three tificates to name only the opportun
years, on the average, from the time tic infections that killed loved on
symptoms appear. with AIDS. And some people comn-
Moreover, the virus, which spreads suicide before their mv infection t
mainly through exchange of bodily comes symptomatic.
fluids, bas mutated into hundreds of
strains. It can take up to a year after exr
"It changes geographically," Cionci sure to the virus to test positive, wi
said. "We don't know why." an average of 14 weeks, he said..
This evolution makes it <lifncult to According to Cionci, recent ngur
find the ammunition needed to ldll inc11cate that the rise in the number
the. virus' variouS strains. . confirmed cases hAs slowed.. When t
The latest advances focus on mak- virus was first isolated, confirm
1ng the disease more controllable, cases "were doobllDg every 12 to
Cionci said. . months because no one knew what
"People used to die from diabetes, do about it or where it was from
~ O : 0 . Chen Xiao Ping
- 0.>: Dr. Henry J. Heimlich
D. IE: January 18,2002
I wish to advise you of the following facts:
1) I have in my hand a newspaper article from one of the leading newspapers in the
United States, the Philadelphia Inquirer, dated Thursday, November 22, 1990. Dr. Jack
Cianci and Dr. Hua Hong Shun also have this newspaper article. The story tells of Dr.
Cionci's trip to China in 1990, and that he traveled through China speaking on his
specialty, AIDS, to many Chinese doctors. It describes how Dr. Cionci told the Chinese
doctors about Dr. Heimlich's method of malariatherapy for the treatment of cancer, Lyme
disease and AIDS. On the first page of the article is a picture, measuring 61/2 x 4 inches,
showing the doctors who were present when Dr. Cionci was arranging to establish a
clinic in Guangzhou for the treatment of cancer and AIDS. Under the picture, it states,
"With Dr. Cionci, second from left, in China, are Bin Quan Xiao, M.D., far left, Jin Zing
Liv, M.D., and Xiao Ping Chen, M.D." Your picture is very clear. Next to you is a large
sign saying, "Welcome to Dr. Cionci Our Guide". You were present in 1990 when Dr.
Cionci described Dr. Heimlich's method of using malariotherapy to treat AIDS.
2) Drs. Cianci, Hua and Heimlich each possess a letter you sent to Dr. Cionci on the
stationary of The Municipal Health & Anti-epidemic Station of Guangzhou. The letter is
from you to Dr. Cianci, dated September 3, 1990. You say,
"Dear Dr. Cionci:
Many thanks for your letter and information. I am also interested in the
Malariotherapy on treating people with cancer and AIDS. I am glad you said Dr.
Heimlich had asked you to accompany him to the opening of the clinic in
Nanjing. But I have one question about it. Why don't you plan to open the clinic
in Guangzhou instead of Nanjing?"
::.:- _ -ou describe the reasons why we should treat cancer and AIDS patients in
. er than in Nanjing_ Your letter is not typed; it is hand-written and signed
-_ G-;:u Xiao PinK Thanks to Dr. Cionci ' s lecture, you were fully aware of my
"'ry of using malariotherapy for cancer and AIDS when you wrote to him on
ember 3, 1990_
3) In your e-mail of February 23, 2001, you state you would like to put the following
quote in a scientific paper,
"We acknowledge Dr. Henry J _ Heimlich for his successful cooperation with us in
the pilot study of malariotherapy for HIV infection during 1993-1996. He
independently proposed the idea of malariotherapy for HIV infection in 1992
(note: in the contributors section: Dr. Chen independently proposed the idea of
malariotherapy for HIV/AIDS in early 1993 will be mentioned)."
You add,
"Dr. Heimlich and Dr. Chen independently proposed the idea of malariotherapy
for HIV infection respectively in 1992 and in early 1993".
It is evident from points 1 and 2 above, that you did not independently propose the idea
of malariotherapy for HIV infection. You learned it in 1990 from Dr. Cionci's report to
you and your colleagues, wherein, he described my work.
I am advised of the following from Dr. Hua: On December 12 and 26, 2001, an article
appeared in the paper The Chinese Medical Research, published in New York in the
Chinese language, and distributed in New York, Taiwan and China. The material was
obviously provided by you. The name Chen Xiao Ping appears 21 times throughout this
article. It states that Chen Xiao Ping proposed malariotherapy for the treatment of AIDS
in 1993. There is not one mention about Dr. Cionci, Dr. Hua, Dr. Heimlich or The
Heimlich Institute. Furthermore, there was no mention of the tens of thousands of dollars
The Heimlich Institute granted to the account of Dr. Chen Xiao Ping for carrying out the
research. As you know, we possess the receipts for the funds sent to and received by your
.. - ~ in China.
also informed me of your letter to him dated October 11, 2001, in which you
d in Chinese),
"Dr. Cionci visited Guangzhou in 1990. That was for the first time mentioned to
me about malaria therapy of cancer. I agree that is a very reasonable assumption.
Not until Spring Festival of 1993, I proposed to the Director of the Municipal
Health & Anti-Epidemic Station of Guangzhou, Dr. Shao Bin Quan that malaria
therapy of HIV might be a more valuable treatment method and later I got Dr.
Shao's full support. Two months later, I received Dr. Heimlich's letter suggesting
that malaria therapy might be used in treatment of AIDS. This was a co-
incidence. Chen Xiao Ping independently proposed malaria therapy in treatment
of HIV infection In fact, two persons proposed the idea independently, one is Dr.
Heimlich and the other one is Chen Xiao Ping."
Dr. Chen, I strongly recommend that you inform the Medical Research newspaper that:
Dr. Henry Heimlich, President of The Heimlich Institute in Cincinnati, Ohio,
USA, was the first to discover malariotherapy for treating cancer and AIDS. Dr.
Heimlich carried out his research in the 1980's. This fact was reported to Dr.
Chen Xiou Ping and his colleagues in Guangzhou in May, 1990, by Dr. Jack
Cionci, a prominent AIDS specialist from Philadelphia, P A, in the United States.
These facts were described in the newspaper, The Philadelphia Inquirer, on
November 22, 1990. Your newspaper statement that Dr. Chen Xiao Ping
independently proposed malariatherapy for treating AIDS in 1993 is not correct.
Dr. Chen learned of Dr. Heimlich's discovery from Dr. Cionci, in 1990 in
Guangzhou. Dr. Hua Hong Shun participated with Dr. Cionci and Dr. Heimlich
in providing all of the medical references cited by Dr. Chen Xiao Ping in his
papers and in your newspaper. The Heimlich Institute granted many thousands of
dollars for the treatment of AIDS patients and studies done in Guangzhou.
I: is - - ry important that you provide this same information to your colleagues and
-= : rom fit agencies who have been told that, in 1993, Chen Xiao Ping independently
'- vered malariotherapy for the treatment of AIDS. By carrying out this action, you
",ill relieve me of the necessity to inform our colleagues and my friends in the Chinese
government of this matter, by sending them a copy of the Philadelphia Inquirer, your
letter of September 3,1990, and my receipts for the money sent to you.
I expect you to inform me within the next two weeks that you have taken this action.
Sincerely,
CC: Drs. Cionci, Hua, Fahey
p!!!!!" .
HEALTH I
. .
AIDS authority says
disease has "become
more controllable:::
" ,
By Shaun Stanert
Sp.iol 10 '"quircr
but Insulin ' and other medications
have made it manageable," he said.
It's unlikely that a cure for acquired The methods currently available
immune deficiency syndrome will be are drugs that retard the virus' repli
discovered in this century, but there's cation, treat opportunistic infections
good news: Its symptoms and methods and bolster the immune system.
of transmission have been identified, Cionci said. "
money is being spent to try to find a Researchers are trying to impede
cure, and ' there are ways to short- 'the replication process further. "
circuit the virus' replication, increas- ''Then, maybe, victims can live 10,
ing the length and quality of AIDS IS, 20 years," Cionci said.
victims' lives: " ' The severity of the insidious virus
That was the message Dr. Jack ' has prompted the government to fun.
Cionci, an Internationally recognized nel 30 times more money per
AIDS authority and chairman of the :eapita to AIDS research" than into
Montgomery County AIDS Task Force, study of other major diseases, Cionci
brought to abOut SO people at the ", said. ' ' ,
weekly adult forum of the Yardley As of last month, more than 150,000
United Methodist Church on Sunday. AIDS cases had been reported in the
He Is to speak again at the church United States in 1981. More than 90,000
next Sunday. '
The AIDS virus, human immunode- of the AIDS patients have died; aCGOrd
fic1ency virus (lllV, ), weakens the ' tng to the Centersfor Disease Control
tnAtlanta. '
body's immune system,: leaving ,the : The illness Is'underreported, Cionci
victim vulnerable to many opportu
nistlc infections and rare cancers. The contends, because families sometimes
disease causes death within three request doctors making out death cer
years, on the average, from the time tificates to name only the opportunis-
symptoms appear. tic infections that killed loved ones
Moreover, the virus, which spreads with AIDS. And some people commit
mainly through exchange of bodily suicide before their mv infection be-
fluids, has mutated into hundreds of comes symptomatic.
strains. It can take up to a year after expo-
"It changes geographically," Cionci sure to the virus to test positive, with
said. "We don't know why." an averege of 14 weeks, be said.
This evolution makes It dlfftcult to ACGOrding to Cionci. recent n&ures
find the ammunition needed to ldll inc11cate that the rise in the number of
the, virus' variouS strains. confirmed cases has slowed. When the
The latest advances focus on mak "virus was first isolated. confirmed
tog the diseage more controllable, cases "were doubling every 12 to 15
Cioncl said. months because no one knew what to
"People used to die from diabetes, do about it or where it was fro!ll."
Pee p e
.. -; _:: - '; .. ' >.1 .. .. .. :
.ot-. ,;.':_ ...___ ... ':...... __ .......... .. .. .. ..,;..;):......._ ....... _ ... lllll .. _l"""L:-....... ... ... ... ... - .
-. -_ _ _ 8 ,
- - - - 1 -
. Phil adelphia DO educates Chinese about AIDS
.I at- - Ci nei. DO. a semirelired gen-
e ... 1 pranilioner from Philadelphia,
$pen( three weeks lasl spt-ing edu-
cHin' Chinese physicia ns aboul ac-
qttired imlllune defIc iency syn-
drollte.
T his was hi s second trip lo
China. III 1 Dr Cionci hecallle
(l lle of the firsl physicians from lhe
West to enler China since it was
riosed to foreign visitors in 1949.
I Ie W; IS the only no among phy-
'ia liS Oil a cull ural anti Ilted ical ex-
change.
During that t rip, Dr Cionci was
smprised to find that the Chinese
h;\d 110 knowledge of the Heimlich
In;\nClI\'cr. so he began demonstrat -
ing it. He becallle acquainted with
;\ surgeon in Hong-Shun
Hila . who was eager to learn
tIIore aboul the technique. The two
pll\'siriam became friends and cor-
roplln<icd lIIonthl\'. E\'enttl;tlly. Dr
1111;1 1I\()\'t'd the Uniled States and
is 11011' working , for Henry J.
Heimlich. MD, in EI Monle, Calif.
Dr Cionci a promise that
he \\'()t1ld relUrn to China in 10
yea rs.
III t he mid-I !lHOs, 1 h Cillnci he-
C\II\e fallliliar with AIDS while work-
illg at a health cenler for sexually
lr;lI\smitled diseases (STDs) in Phila-
delphia. He was immedialely fasci -
natcd with the deadly virus and be-
gan studying the disease. Dr Cionci
lIas ' certifIed by Philadelphia's
Hahnelllalln University School of
1'.ledicine in .!anuary to lrain other
physicians on AIDS.
'I'll F. DO Novemher 1990
Dr H ua was able to contact as-
sociates back in China, who ar-
ranged for DrCionci to visit thecoun-
try officially as an AIDS spokesman
through the Chinese Red Cross. He
is believed to be the lirst Western
physician to travel through China
providing AIDS education and train-
mg.
Throtlgh an interpreter, Dr
Cillnci icC! lII'ed in hospitals alld c1ill-
ics ill five cities: Nanjillg, Shallg-
hai, Xi'an, Beijing and Guangzhou.
He represented several US organi-
zations, incltlding the American Red
Cross, the AIDS Task Force of Phila-
ddphia and BEBASHI (Blacks Edu-
CHing Blacks Abollt Sexual Health
hsues). The World Health Organi-
sellt Dr Cionci videotapes and
brodlllres, and the US Centers for
Disease Control provided six sets
of slides.
In each city, Dr Cionci says he
received a warm reception and
found a willingness to learn. One
physician in Guangzholl who had
spent tilll: in the United States in-
Dr Cionci (ce nter) in
a panel discussion on AIDS while
in China.
qllired aboul settiIlg up a COIIIITlU-
nity-based organization and a lask
force for AIDS education.
"It was slich a moving experi -
ence," he says. "Ther love words
like friendship and cultuml exc/uwgl' .
They're a very proud people. They
were fascinated in learning about
AIDS. They thirsted for knowledge.
And they would ralher Icaru hy ver-
bal exchallge lhan hy reading."
Chilla has approximalel y :\O(J
reported cases of AIDS, most pur-
portedly due to intravenous drug
use. Although Chinese laws rigidly
restricl the use and sale of illegal
and prohibit prWltilUtioli. Dr
Cionci . says drugs come into tile
country from its neighbors Nepal
and Bhutan. Although Dr Ciollci
saw 110 AIDS patients, he did hear
ahout a handful of people who had
contractecl the human imlTluno-
deficiency virus. The of
AIDS cases, he says, have stayed in
the provinces near China's south-
ern border.
Dr Ciollci observed little overt
People 43
e 'ery most you see is
and lhe Chinese have
asexuality,"
- - , ho 'ever, China has
;an increase in STDs,
e '0 an in ux of foreign-
en. especiall uden, Dr Cianci
ina has a least 300,000 re-
ned cases of, el ereal disease, the
majorit} of ,hidl are cases of gon-
orrhea or ;yphilis.
AIDS strike China as it
has 111.1 II Y other countries, Dr Cionci
sa. s the disease would have a pro-
found e(fect. "They're trying to pre-
vent AI[)S from exploding expo-
nenlially Ii ke it has in the United
States," he says. "If ever it starts to
spread like it has spread here, it will
devastat e them."
China is an exceptionally poor
count ry with a population exceed-
ing I billion. Already, a vast major-
ity of its citizens cannot afford ade-
quate healthcare, and many villages
are situated far from hospitals. In
the cities he visited, Dr Cionci ob-
served Illany unclean facilities, de-
teriorating equipment and over-
worked physicians.
'They' re going to have a prob-
lem in testing people [for AIDS] be-
cause it's going to be an extra ex-
pense. And when aHyone get
sick, they're going to spread other
diseases [such as opportunistic in-
fections] because Chinese hospitals . i
don't have complete sterilization,"
he explains. "They've already had
this in Russia. and Russia is not
nearly as poor as China.
"Worse, the Chinese are not go-
ing to spend the kind of money
[needed to get zidovudine]: they
just don't have it. They don't even
have enough money for chemo-
therapy for cancer patients."
Dr Cionci says he probably will
return to China next year with Dr
Heimlich, who is trying to set up
an iilstitute for malaria therapy for
THE DO November 1990 .
treating cancerous tumors. Dr
Cionci has received several lellers
from variotls physicians in Chilla
asking that he return.
Most recently, Dr Cionci re-
ceived a federal grant to develop
a module for training Florida phy-
sicians about AIDS. The module will
be taught at the state's four medical
schools, induding the Southeastern
University of the Health Sciences
,College of Osteopathic Medicine
in North Miami Beach. The mod-
ule, called ''Train the Trainer," will
he completed in January 1991.
-Ruth A. Mack
- 5 Feb 2002 10:33:1 9 , page 1
p. g" <chenxping@netease. com>
r " <heimlich@juno.com>
2002 11 :56: 15 +0800
lich:
ow what media you refer to. I checked the media which I know,
e statements as follow:
1995 in Reference News: Dr. Chen and Dr. Heimlich tried malariotherapy
or HIV/AIDSi-i-The reporters got the message from the International
Immunology Conference in San Francisco where we attended the meeting.
1996 in Yangcheng Evening: Heimlich Institute of USA and Municipal
Health and Anti-Epidemic Station of Guangzhou got a progress from the
cooperation in the project of malariotherapy for HIV/AIDSi-i-.
2000 in Health News: Dr. Chen and Dr. Heimlich further cooperate in
malariotherapy for HIV after completion of malariotherapy for cancefj-i-
2001 in the Health News: Dr. Chen and his team got a progress in
findings of mechanisms of malariotherapy for HIV infection and based on
these findings, Dr. Chen further proposed a new idea of highly active
antiretroviral therapy (HAART) plus malariotherapy in attempting to
eradicate HIV in vivOi-i-(by the way, according my memory, you opposed
the idea of malariotherapy plus HAART in an email to me).
I could not find any words like iOinventedi, iOinventioni in any
original media reports.
In fact, any contributions of you to malariotherapy for HIV/AIDS have
well documented in a couple of meeting abstracts and two published
papers. If malariotherapy alone for HIV/AIDS will win the Nobel Prize in
the future, you must be one of the winners even though you have
discontinued the study since 1997.
It really was a pity that your wrong memory leaded the discontinuation
of our cooperation. We have a document with your Signature to confirm
that the earliest time you independently proposed the idea of
malariotherapy for HIV/AIDS is 1992. We will preserve this document for
final use.
The fact is in the follow, which I mentioned before:
Regarding to the letter from Dr. Cionci to Dr. Heimlich, it is not true
for saying that Dr. Heimlich spoke to my group on the use of
malariotherapy for HIV. The fact is that in 1990, Dr. Cionci as a
representative of Philadelphia Red Cross Society visited to Guangzhou. I
met him in the White Swan Hotel where he stayed. We talked very friendly,
when I told him about my hypothesis on that HIV might originated from the
molecular hybridization of SIV and human sperm gene (I published this
idea in early 1990), then he told me the idea of malariotherapy for
cancer proposed by Dr. Heimlich, when my response was "this idea is very
reasonable" since I had been a physician for infectious disease for many
years and had treated over one hundred malaria patients. Then Dr. Cionci
returned to USA and told Dr. Heimlich about my interest in malariotherapy
for cancer even though I had been worked at AIDS laboratory since 1988.
Dr. Heimlich came to Guangzhou in 1991 to talk with us on the
cooperation of malariotherapy for cancer. Dr. Heimlich did give lectures
in Zengcheng County People's Hospital and Dongshan District Hospital, and
I did be there as an interpreter for Dr. Heimlich, but Dr. Heimlich never
mentioned malariotherapy for HIV in his lectures and thereafter until the
Fe 2 02 10:33:1 9 , page 2
. e spoke to Dr. Xiao, the Director of
-e ' ea 0 alariotherapy for HIV in early 1993 on the
- ; - -. -=---0 a I g vacation of Chinese New Year holidays.
I received a letter from Dr. Heimlich by which I first
had e same idea and I told Dr. Xiao about this.
e er again after completion of malariotherapy for
a Ho g Shun came a couple of times on behalf of Dr.
.. eel us a couple of times for our cancer research /
e document telling us that Dr. Heimlich proposed the
a . en letter from Dr. Heimlich to me in 1994. Any
- - - sa ' g Dr. Helm lich proposed the idea prior to 1992 are
e. S' ultaneously, any statements denying Dr. Chen
e proposed the same idea in early 1993 are also unacceptable.
ese s!ate ents will lead to no way to go for our cooperation, because
ese s!ate ents are not true. We also had different ideas on
ala ' erapy for different diseases: Heimlich's Lyme disease idea and
C IS S E idea which I mentioned before.
lease excuse me to CC this message to Dr. Fahey, because I think we
o Id talk very openly, and Dr. Fahey helped us a lot in
IV-malariotherapy projects.
Sincerely,
Xiao Ping Chen, M.D., Ph.D.
- Original Message -----
From: Henry J Heimlich <heimlich@juno.com>
To: <chenxping@netease.com>
Sent: Saturday, January 26, 2002 2:41 AM
Subj ect: malariotherapy for hiv/AIDS
> TO: Dr. Chen Xiao Ping
>
> FROM: Dr. Henry J. Heimlich
> Date: January 25, 2002
>
>
> I wish to advise you of the following:
>
> 1. It has come to my attention that there is a report in current media
> on malaria therapy of hiv/AIDS. It states that Dr. Chen Xiao Ping
> independently invented that treatment in 1993.
>
> 2. There is firm documentation that proves:
> a) Chen Xiao Ping was informed of malaria therapy for the treatment of
> hiv/AIDS prior to 1992.
> b) Chen Xiao Ping received comprehensive literature on malaria therapy
> from the
> Heimlich Institute .
> c) It is through the Heimlich Institute that Chen Xiao Ping learned of
> malaria therapy to treat both AIDS and cancer.
> d) Chen Xiao Ping's research on malaria therapy was funded by the
> Heimlich Institute.
>
>
> Dr. Chen, I strongly recommend that you inform the media that Dr. Henry
> J. Heimlich, President of The Heimlich Institute in Cincinnati, Ohio,
> USA, was the first to discover malaria therapy for treating cancer and
Fri, 15 Feb 2002 10:33:19, page 3
carried out his research in the 1980's. This fact
Dr. Chen Xiou Ping and his colleagues in Guangzhou in
:J . Jack Cianci, a prominent AIDS specialist from
USA Your newspaper statement that Dr. Chen Xiou
> ' - = - proposed malariatherapy for treating AIDS in 1993 is not
. C en learned of Dr. Heim lich's discovery from Dr. Cianci,
G a gzhou. Dr. Hua Hong Shun participated with Dr. Cionci
lich in providing all of the medical references cited by Dr.
> Xia P' g. Funds for the treatment of AIDS patients and studies done
> G a gzhou were granted by the Heimlich Institute ..
>
> . also very important that you provide this same information to
your
> coll eagues and government agencies who have been told that, in 1993,
Chen
> Xiao Ping independently discovered malariotherapy for the treatment of
> AIDS. By carrying out this action, you will relieve me of the
necessity
> to inform and present documentation to our colleagues and my friends in
> the government of this matter.
>
> I expect you to inform me within the next two weeks that you have taken
> this action.
Benefiting
Humanity
Through
Health
and
Peace
Affiliated with Deaconess Associations Inc.
'r'- -r r MWw
1- J4 J). A-I])$ -t, tlA..{.. H i>:I 4

ar J w- 1; r-k
:J,;r
1 .;.. ;[7) 1$ .A-U- ")r Aio - I ..w "--
R.ML S't. /.}L:jt rJ>.<.. .
9.A.L +Mu
I. ,(JL-hJt 1-
.. -b; 11- tJ..t? f).,4.,

).,. MU-
i..-p f;, jfL hllifwifQAo. (;j

-a .'
:; Cl - .
- . Cj f-; i; r1-
1;, i;..t..r
1- VJ;.v {)-Jf,. be u-..}JJL

;pro "-' -ffi. ..

. .
fp U1-L 1; tv+;-- tMt r O.
;P1A.v
0Rw- It q,r .. it if y..t. .
.;. J.J; t;, /}.fJ..
1- Hvv J 7
8'1t>\ MJ
. r 1<k !r'-. .
,
Bd tf, Dr. a.J., Jw L -te. .

"
..1.e _d:unicipal Institute For Preventive Medicine of Guangzhou

""-a: ... F; , 5 = 8
No. 23. The 3rd Zhongsban Road, Ouangzhou
IE, 1714103 ( .am )
eury J, Heimlich, M.D., Sc.D. '
HeWich Institute Foundation. Inc.
Ohio'45206
Dear Dr. Heimlich:
Tel. 777'103 (ext)
April 8, 1993
We have considered, thoroughly the use of ' llalariatherapy for treating HlV
infected patients. Halariatherapy has proven to be a and effective method
for treating cancer. is every reason to be, convinced that it can be
effective and safe for AIDS. We are ready to provide malariatherapy to
HIV positive patients at this tiae.,
My background experience with AIDS includes:- I have worked in the field of
infectious diseases for thirteen years and special in the field of ,AIDS ' for five
years. I have extensive, and deep knowledse on AIDS in the l'espests of eteology,
epidemiology and clinics., Four years ago, ,I first proposed the hypothesis of HlV
origenatiIl9. froll human spirlll genes in an international coilference. In lIlY
, laboratory. I can do.any things on AIDS including HIV culture.
The_ scientific evidence we possess of the ' possibility of increasing production
of iuune substances is,very,souna. 'The ' study showill9the survival of . children
who' have AIDSand-lRalarla,whHe 35';' of those with AIDS alone died is very
") -. ..-'
convincill9.
It . is obviously not pQs'sible- to .. predict what our findings will be frolll our
research stu4ies. -To not .a.ti,eIl1Pt aalariatherapy. however. AIDS patients
with'" no pOS$ibility of effective treataent. 'r
..., ,
Sincerelc::k \ . . . .
Dr. Chen Xiaoping
The Municipal Health and Anti-epidelllic St.-ation of Guangzhou,
No.23, 3rd ZhoIl9shan Road, Guangzhou 510080, P.R. China
(no
lof2
b . ect : (no subject)
Date: ed, ~ O Feb 2002 10:27:56 -0500
From: "Henry 1. Heimlich, MD, ScD" <heimlich@iglou.com>
Jl1!:anization: Heimlich Institute
To: chenxping@netease.com
Joctors Fahey, Hua, and Cionci
e - ail to me of 6 Feb 2002, contains several errors. You say, once
I t ha t Dr. Cionci, during his visit to Guangzhou in 1990, spoke to
abo t Dr. Heimlich's plan to use malariotherapy to treat cancer.
~ g n o r e the fact that Dr. Cionci told you about Dr. Heimlich's idea
o se malariotherapy to treat AIDS. You also say, "Any statements
saying Dr. Heimlich proposed the idea (using malariotherapy for HIV)
pri o r to 1992 are unacceptable. Simultaneously, any statement denying
Jr . Chen independently proposed the same idea in early 1993 are also
acceptable."
In your e-mail of 23 Feb 2001, you state you would like to put the
following quote in a scientific paper: "Dr. Heimlich and Dr. Chen
independently proposed the idea of malariotherapy for HIV infection
respectively in 1992 and in early 1993." The documents cited below
prove that Chen xiao ping learned about Dr. Heimlich ' s idea for using
malariotherapy to treat AIDS from Dr. Cionci in 1990. The documents
also confirm that Chen did not independently propose malariotherapy for
AIDS. They further prove that Dr. Xiao Bin Quan, Head of the Municipal
Health & Anti-Epidemic Station of Guangzhou, was misinformed, in 1993,
when Chen advised him that the proposal to use malariotherapy for AIDS
was Chen's independent idea.
1) I have in my possession a newspaper article from a well respected
newspaper, the Philadelphia Inquirer, dated Thursday, November 22,
1990. The article was sent to me by Dr. John Cionci and Dr. Hua Hong
Shun. The story tells of Dr. Cionci's travels through China in May
1990, and that he spoke there on his specialty, AIDS, to many Chinese
doctors. The headline states "Area M.D., task force member takes AIDS
message to China." It describes how Dr. Cionci told the Chinese doctors
about Dr. Heimlich's method of malariatherapy for the treatment of
cancer, Lyme disease and AIDS. The article also tells of Dr. Cionci's
plan to establish a clinic in China to treat patients with cancer and
AIDS, using malariatherapy. On the first page of the article is a
photo, measuring 6 1/2 x 4 inches, showing doctors who were present when
Dr. Cionci presented that information on AIDS. The caption under the
photo states, "with Dr. Cionci, second from left, in China, are Bin Quan
Xiao, M.D., far left, Jin Zing Liv, M.D., and Xiao Ping Chen, M.D."
Your picture is unmistakable. Next to you is a large sign saying,
"WELCOME DR. CIONCI TO OUR STATION AS OUR GUIDE". The picture is taken
at the Municipal Health & Anti-Epidemic Station of Guangzhou. However,
your e-mail to me of February 6, 2002, says you only "met him (Dr.
Cionci) in the White Swan Hotel". You fail to mention that you were
present when Dr. Cionci spoke at your Station. In that e-mail you only
say Dr. Cionci was a representative of the Red Cross. You fail to
mention, as stated in the newspaper, Dr. Cionci's lecture was on AIDS
and was "sponsored by the AIDS Task Force of Philadelphia".
The facts are clear: You did not independently propose malariotherapy to
treat AIDS in 1993 because you were present in 1990, when Dr. Cionci
described Dr. Heimlich ' s method of using malariotherapy to treat AIDS.
2)You wrote a letter to Dr. Cionci on the stationary of The Municipal
Health & Anti- epidemic Station of Guangzhou, dated September 3, 1990.
Dr. Cionci sent Drs. Hua and Heimlich copies of this letter of September
3, 1990, which are in our possession. In this letter, you say,
"Dear Dr. Cionci:
Many thanks for your letter and information. I am also interested in
the Malariatherapy on treating people with cancer and AIDS. I am glad
you said Dr. Heimlich had asked you to accompany him to the opening of
2/20/02 10:57 AM
(no
___ i a njing . But I have one question about it. Why don't you
- ope the clinic in Guangzhou instead of Nanjing?"
is hand-written and signed Chen xiao Ping.
=ac-s are clear: You were fully aware of Dr. Heimlich's proposal to
for cancer and AIDS when you wrote to Dr. Cionci on
3, 1990. You did not independently propose malariatherapy for
"!.-;S 993 .
3 J : your e-mail of 6 Feb 2002, once again, you claim that you
i2 e?e dently proposed the idea of malariotherapy for AIDS in 1993. You
the same claim in a letter to Dr. Hua Hong Shun, dated October 11,
200: .
:t is e vident from documents cited in points 1 and 2 above, that you did
not independently propose the idea of malariotherapy for HIV infection
in 1993. You learned about the concept in 1990 from Dr. Cionci's report
to you and your colleagues, when he described Dr. Heimlich's idea to
treat AIDS with malariotherapy.
In keeping with your desire that we "should talk very openly", I am
sending copies of this e-mail, the Philadelphia Inquirer, and your
letter of September 3, 1990, to Dr. Fahey, whose knowledge and
integrity are well known to us.
Perhaps we are each interpreting the meaning of "independently proposed"
differently. To us, a person who "independently proposed" an idea means
he conceived of it and had never heard of it being thought of before by
anyone else. That could not be the case with your 1993 proposal for
malariotherapy to treat HIV since you heard about my concept and
background research in 1990. On the other hand, perhaps you feel
"independently proposed" means that you independently proposed to Dr .
Xiao that my method be used to treat HIV and you should be credited with
recommending it be used in his Station. If so, that is acceptable.
We should also talk very openl y with Dr. Xiao Bin Quan. I suggest you
tell Dr. Xiao your memory was incorrect when you informed him in 1993
that you independently proposed using malariotherapy for AIDS. It is
always better to correct an error when you learn of it, rather than have
people hear it from other sources. I will be pleased to send Dr. Xiao
copies of the 1990 Philadelphia Inquirer and your letter of September 3,
1990, if he wishes me to do so.
I look forward to your response within the next two weeks. We can then
address the matter of the media.
_ of 2 2/20/02 10:57 AM
ElINDS RECEIVED
May 8, 1996 $ 50,000
August 16, 1996 $100,000
Total $150,000
DISBlJRSEMENTS
Use of
Month
Eacil.i4'
fhoru: fus1age Supplies Salaries IraYci Equip.. Thtal
May 433.34 150.00 240.50 41.70 4418.24 1315.75 -0- 6599.53
June 450.00 120.99 206.34 189.60 8240.43 668.60 -0- 9875.96
July 450.00 157.72 908.50 91.55 6373.66 1528.95 -0- 8431.43
August 450.00 130.32 139.00 98.72 4496.07 500.14 -0- 5914.25
September 450.00 144.64 149.00 30.70 7129.76 337.50 -0- 8241.60
October 450.00 150.00 110.50 132.02 1614.94 1261.63 7942.50 11211.59
November 450.00 203.84 178.50 84.28 5018.84 1202.06 -0- 7137.53
December 450.00 75.0 50.00 30.52 5949.06 1104.35 323.64 7982.34
Totals 3583.34 1132.51 1982.34 699.09 43241 7918.98 8266.14 65394.23
Interval Payment to China - 11/19/96 400000
Total Disbursements
69394.23
J anuary 1997thru May 1998
FUNDS RECEIVED
May 8, 1996 sSO,OOO
August 16, 1996 $100,000
February 19, 1997 $100,000
Total $250,000
DISBURSEMENTS
Use of Month
.l221 rmlilx ~
Postage Supplies Salaries II:iMl E m!iJ l. I2lal
J anuary 450.00 227.02 100.00 200.00 3328.69 - 0 - - 0 - 4305.71
February 450.00 122.93 100.00 - 0 - 2952.46 - 0 - - 0 - 3625.39
March 450.00 110.86 100.00 65.05 2952.46 - 0 - 75.00 3753.37
April 450.00 110.17 - 0 - - 0 - 3291.44 - 0 - - 0 - 3851.61
May 450.00 103.73 53.34 - 0 - 3291.44 - 0 - - 0 - 3898.51
J une 450.00 97.41 34.00 - 0 - 3291.44 854.90 73.50 4801.25
J uly 450.00 98.28 131.46 82.42 3667.67 155.00 161.32 4746.15
August 450.00 66.79 29.50 15.24 3291.44 5170.00 103.34 9126.31
September 450.00 77.83 88.50 75.33 3291.44 - 0 - - 0 - 3983.10
October 450.00 80.12 7.25 129.81 2783.75 1500.00 - 0 - 4951.18
November 450.00 75.67 14.75 66.08 3333.20 - 0 - - 0 - 3939.70
December 450.00 78.32 288.06 67.63 3333.20 - 0 - - 0 - 4217.21
Totals 5400.00 1249.13 946.86 701.56 38808.63 7679.90 413.16 55199.49
Interval Payment to China - 10/24/97 6000.00
Total Disbursements Year 1997 61199.49
Page 2
DISBURSEMENTS
Use of Month
~ Wli1Y ~ Postae.e
Sypplies Salaries I.I:inl<l E m lil2 .. Imal
J anuary 450.00 77.17 97.18 17.31 3356.92 ~- 146.34 4144.92
February 450.00
~-
48.00
~-
3356.92 ~- - 0 - 3854.92
March 450.00 132.37 ~- 27.55 3371.28 ~- - 0 - 3981.20
April 450.00 93.73 ~- 13.64 3371.28 1309.93 ~- 5238.58
May 450.00 21.17 32.58 49.94 4945.88 ~- ~-
5499.57
Totals 2250.00 324.44 177.76 108.44 18402.28 1309.93 146.34 22719.19
Total Disbursements:
1996 s 69,394.23 (Detailed report submitted 112197)
1997 61,199.49
1998 22.719.19
TOTAL DISBURSEMENTS s
s
153,312.91
Balance
96,687.09
6/98 Installment for 10patients in China 14,000.00
*
Expenditures restricted for treatment and two-year follow-up for 10patients in China
9/24/98
January 1, 1999 thru May 31, 1999
FUNDS RECEIVED
May 8,1996 $ 50,000
August 16, 1996 $100,000
February 19, 1997 $100,000
Total $250,000
DISBURSEMENTS
Use of
Month
1999
~
Phone Postage Supplies Salaries Travel
~
Total
January 450.00 13.65 45.50 34.50 3400.00 838 -0- 4781.65
February 450,00 13.65 41.00 16.36 3400.00 1842 146 5909.01
March 450,00 13.65 95.00 18.00 3400.00 90 -0- 4066.65
April 450.00 13.65 115.00 46.00 3400.00 1428 -0- 5452.65
May 450.00 13.65 85.00 21.00 3400.00 2791 -0- 6760.65
Totals 2,250.00 68.25 381.50 135.86 17,000.00 6989 146 26,970.61
1996 $ 69,394.23
1997 61, 199.49
1998 57,612.19
7/98 Installment to China 14,000.00
1199 thru 5/31199 26,970.61
TOTAL DISBURSEMENTS $ 229,176.52
Balance $ 20,823.48
Funds from other sources have been reserved to enable completion of the follow-up of the ten patients over
a two-year period.
January 1998 thru December 1998 Page 2
DISBURSEMENTS
Use of Month
1998 Facility Phone Postage Suoolies Salaries Travel Equip. Total
January 450.00 77. 17 97. 18 17.31 3356.92 -0- 146.34 4144.92
February 450.00 -0- 48.00 -0- 3356.92 -0- -0- 3854.92
March 450.00 132.37 -0- 27.55 3371.28 -0- -0- 3981.20
April 450.00 93.73 -0- 13.64 3371.28 1309.93 -0- 5238.58
May 450.00 21.17 32.58 49.94 4945.88 -0- -0- 5499.57
June 450.00 7.00 13.00 285.00 3400.00 1351.00 -0- 5506.00
July 450.00 7.00 16.00 -0- 3400.00 -0- -0- 3873.00
August 450.00 9.00 17.00 285.00 3400.00 1078.00 -0- 5239.00
September 450.00 7.00 6.00 12.00 3400.00 158.00 -0- 4033.00
October 450.00 7.00 41.00 453.00 3400.00 1989.00 -0- 6340.00
November 450.00 7.00 32.00 154.00 3400.00 436.00 -0- 4479.00
December 450.00 7.00 28.00 19.00 3400.00 1519.00 -0- 5423.00
Totals 5400.00 375.44 330.76 1316.44 43518.72 7840.93 146.34 57612. 19
1996 $ 69,394.23
1997 61, 199.49
1998 57,612. 19
DISBURSEMENTS $ 188,205.91
7/98 Installment to China 14,000.00
TOTAL DISBURSEMENTS $ 202,205.91
Balance $ 47,794.09
6/29/99
!
I
!
!
1296 SOUTH OCEAN BLVD.
PALM BEACH, FL 33480
lOllt"". Uemry HdmHdht
:);ll1 tlF"<eet
CU.JrlldJrlllfll<dld, Ohu.o 45'21l9
lD)(e,dllF" lH[;auotlk.,
Tlhl;amlk. Y0llJ[ ffOlt"" YOU[]t"" off M;aunch :);oth, whu.clhl l[
necdved today. l[ ;aIm OJrlry th;allt YollJ[r phoJrlle caU to lme welne
a lmy JrllllJ[mbelt"" exoeplt ffOlt"" tlhte ;aut""ea cod(e lhl;alve
Jrllot chaJrllged un ,dllbnfllolt llO y(e,dllt""Y l[Jrll;am eveJrllt, JfOlt"" ffu[1tu[]t""e
1t""effe1t""eJrllCe the 1fllllJ[mbelt"" u. aJrlld the ff.:atx u. 561l=:);'2=
6
559'
How lfllu.oe th,allt Y0llJ[ wuU be pealldJrllg at the lBleiilldhl
ROllJ[Jrlld Tablle mexlt )l;aLJOl1ll[;allry. The lmomlelfllt Y0llJ[ klfllOW Ith(e (eX,dlct
d,al1te, pll(eiill(e 1m(e klfllOW o we CiillJrll lmiilllkte ;al dat(e JfOlt"" Olt""
di.JrllJrllelt"" ;al wdU
][ Wiill h;alpPY to 1neiilld that tlhlte thelt""apy to tlneiillt
Al[lOl h,dl beeJrll ]pllF"Olmu.H.lfllg, that YollJ['v(e h,dld llJ[Icoe H.lfll Clhlu.lfll<dl,
aJrlld that the ollJ[th Affdciilllfll tlt""eatmeJrllt wiU lpllF"Ovu.de the
lfll(eCea1ry evu.deJrllce to lmalkte u.t accepted throllJ[ghollJ[t the
woJdld. lBllt"";alvo,. H;amk! lOlavilldl u.mdl(e(ed be to e(e
whiillt Y0llJ[ h,alV(e dOJrlle, i.Jf he halfll'lt allJt""(e;aldy!!!!
Love to Y0llJ[ iillJrlld )laJrlle aJrlld l[ ffoll"Wan:ll to eeRng Y0llJ[
mext )laJrllllJ[;allry, iff Jrllot beffore,
A (ev(elt"",.
1 of 1
mailbox: C '" l XDO'V Application%20Data/MozillaIProfiles/def...
"", r""'"_,,,. -:::-w: Re: onta t "ith Beijing
J Heimlich <heimli hgjuno.com>
_ 1ar _00 10:_9:-l8
hgiglou.com
--------- message ----------
.:-:::-: - Heimlich <heimlich@juno . com>
:::
==.-:.=: .:::::::, .. ar 2002 10 : 25 : 33 - 0500
conLaCL with Beijing
.. <20020304 . 102735 . - 239985 . 0 . he imlich@juno . com>
::c::gshun,
accompli shed out goal! The information you have obtained is
I s uppose we should wait for a response to our last message
-:. c then act accordingly. Do you agree to this?
3est: wi s he s,
::enry Heimlich
GST I NTERNET ACCESS FROM JUNO !
J no offers FREE or PREMIUM Internet access for less!
Joi n Juno today ! For your FREE software , visit :

3/4/02 12:30 P 1
-------------- --~
FACSIMILE
Date: Oct. 17, 2002
To: J ohn L. Fahey, MD
From: Henry J . Heimlich, MD
Number of pages to follow: 3
Attached is asecond letter from the anonymous "Dr. Bob Smith." Oddly, both letters show "Bob
Smith" receives his e-mail from aserver in Czechoslovakia. Similar letters have been sent out
over thelast ten years.
cc: Steven Peckman
c<opy _,PJ:esse note 00: list for addressee
Ootoba e. ZOO2
Dr. 'Leonard Madu, Director
panAfrica AIDS Conferenoe 2002
1016 18:thAve. Sooth
NutN'., T N . 37212
Dear Dr. MadlJ :
y,ou may recalJ I'd copied you on my letter of October 2 to Mr. steven Peckman,
Aasooia1e !Oirector of UCLA'. Offtoe for the Protection of Reaearcn SUbjects,
Since :tending that letter, fve received some unexpected information which 1felt
should be brought tothe attention of the PanAfrica 2002 Conference.
In my letter to Mr. Peokman, as youtll recan, I raised concerns about UCLA's
pa~ in ab-u&lve AIDS experiments which have been conducted in China
by Or. Henry J . Heimlich. Chinese patients with HJ V and fuU-bIown AIDS have
been given mUM by being injected with malarial blood and subjected to weeks
of feVM exceeding 105 degrees. I provided substantial documentation showing
that th. woric has been widely denounced 8$a medical research atrocity and
eritlcized for H$ questionable scientific merit.
t also provided substantial documentation from Dr. Heimlich's fundraising
newsle1tel'$ and interviews in which he dalmed that the Univer$ity of California at
Loa An.;eles and two UCLA profesaora were in partnel1lhip W 'ith him in this
research. My ~tter, along with full documentation and a contact list may be
found at:the following web add ..... :
http://researchwatch.web1000.comlUCLA.html
T he day after t sent my letter to UCLA. I ~ an e-mail from Or. J ohn Fahey.
one of the UCLA profe880r8 in question, which took me by surprise. Dr. Fahey
advised me. along with long I i8t of othef& he copied. that he wee not involved
with the Heimlich AIDS malaria experiments. that no UCLA funds W8I1I used, that
Dr. Heimlich's claims of his participation were misrepresentations, and that he
was contacting Dr. HeimHch to cease using his name and that of UCLA.
A ffNI days later, I received an ... mail from Mr. Peckman, who advised that he
had taken my concems seriously and that his office was conducting an
Inveetigation into these matters.
\
\
\
Due to the ove:rwhetrmng international efitjc~ of theHeimlich mataria
experimen1$, ' w a s uncerta in w hy Dr. HeimliCh' w e. I nvtted tobeIIfeatured
speaker at PeMfrica 2002 and to promote "malariotherapy" at the conference.
Tha t i& w tTy ~brought my letter to Mr. Peckman toyour attention.
Now, a dded to 'these scientlfic and ethical concerns, Dr. Heimlich's claims of his
atmtat}on 'fIi!ith UCLA and Dr. Fahey have been refuted by Or. Fahey a nd are
~ invectigated by UCLA. J have not received a responae from Or. Heinlic:h.
\
Before my' letter to Mr. Peckman, you may n~ have been aware of the
con1roYef' s jes regarding Dr. Heimlich's "m.. ariotherapyz projects in China and
MexiCo. Considering the information in my preVIous letter and this new
Infonnation about UCLA, Ifelt you should bemade aware of the situation.
Iwould ~ your reply regarding the position of PanAfrica 2002 on these
ma tters , in particular, w hy Dr. Heimlich was invited as a spaker, Iwould also
invite' you to conta ct Mr, Packman and Or. Heimlich to clarify the. issues,
linorder to protect my privacy and that my colleagues. Iamsubmitting this
letter t..n:ier a ps eudonym.
Thank you for your time and consideration. I look forward to your reply.
Sincerely,
"Dr. Bob Smith"
E..ma il: bob-amith@VoIny.cz
voicemail & FAX: (978)4 77 -8349
00: Cha ne, Peterson, Director General
PanAtriea 2002
Henry J ..Heim. lich, MD, President tI I /L__
The Heimlich Institute .........
Steven Packman, Aisoctate Olrvctor
UCLA, Office for the Protection of Research Subjects
Or. J ames Hefner, PreSident
Tennessee State University
2
\
\
\
\
\
\
Ra,mcnd v. aUmann. Chairman, P.... ident. ceo
Men:k. Co.
Petet 'Dolan, CnaalTTlanl CEO
BristoJ ..Myers Squibb Co.
MEvin Foot., President
eon.tituency for Africa
J ames L. Pahla, Chainnan.
Deaconess Associations Inc.
&Board Member, The Heimlich Institute
Or. Charles Bemstei", Chainnan
o.acon ... HOsPital Ethics Committee
3
I, I kmy ,I,J lcj mlich. \ 11) _:llld I. I\ll.!:id.:_\\ :lld(thl' 1\,]1Il""l~I_l_tali_\ L'(11the Ik:lL'PI]cs,,:,
.'\""(1Ci~lll(l1l li)lIl_~Lttillll), (hcrcinallcr rclcrrcd tll ~l"the "Donors"). :-'llk :llld absolute
\)\\ 1lL'1~lll' thc-. m.ucri.rl. dll hcrcb , trun-Icr. !!I\ L',!:'.r'1I1t.~llld~"':-.igll tll till' l -Ili\ L'rsit: Ill'
Cincinnuti (hcrcin.utc:: till' "l IlihT"'lt:") .Illd Ih "'UCL'l:-'''',l!'.., .md a..,..,i!:!lhthc m.ucriul-.
dc-cribc.] ~h Il)llll\\ ":
,\\\<lld:-, iilc-; h,111l--"',1
1
Ih
l
!ll!:!laph.., CI1ITL'''PIl!hklll'L', rcport-. ~lIld,1thlT w rittcu d,ll'lIl11l'll['"
III paper and L'kctl,llliL' torm.u- currcmlv hllU"'L'dIII till' I l cimlich ln-titutc ~llldl'!..,l'whl'll'
ill thePlT'-.(lJ l~tI((ll lccti,111Ill' l)r I kiln ,I. I lcuuli.h.
( 'op~Tight
Donors tr.m-J cr ,tlll'(1!)\TI~~hh th.u i)1111IlI"h(lld ill the ru.ucrial-, hl the l Ili\LT'-.Il\.
1)11IH1I:--' intend tI111h:--'-.I(;tlh L',lJ l\l'\ thL' m.ucriul-, [II till' l :llI\LT"'lt\ h\ mcun-, ruutu.ill ,
s:ltisLIL't(ll'\lllthl'I)llll\lr'-.~llldthl'llli\l'hlt\ IlIlllrhL'I(lrL'\Llll'h ],_ '11]],
Dunor-. Il'L'(l~!lli/L' that .m-, m.ucri.il-, that the l 111\ l'hlt\ dL'krJ llillL's III he ill~lppr(1pri;ttl' 1(11
retention III thecol lcct ion \\ iii hl' dl'-.P(l'-.L'l1(11111,ll'l'(lrd:tlll',_' \\ iil: "t:tII,LlIli \\ ink lcr ('L'IllL'1
I(1)'thc l l i-torv 11I'thl' I ic.rlth I'r(lIL':-...,I(llh proccdurc-.
Research ,\n:ess
l ionor-, Il'Cllglli/L' til,lt the l lIi\l'hlt\ \\ 11111LIl--L' tlll''''l' m.ucri.il-, (lPL'11t(l qualified
)"l'"l'~lrchl')"''']111l"'U~lIlt [11the ~ICl'l'''''']1,dICll''-.olthc \\ ink lcr ('l'llk)" 1(1)" thl'lli..,tl'l'\ Ilj'tlll'
I Ic.ilth l'r. lI(:s'-.il.n-;
lut 1I rc 'I'run sfers
I hetLTI1I:"tll thi-, lnxtrumcnt ,11(iill \\ ill CI1\lT .rl l future tr.mslcr olmatcri.rl h\ the
Donor-. 1I11k:-.s~lxpcci l ic .uldcndum ~ln'(llllp~1I1IL''''~lparticul.u' t)"~llhkr Ill' m.ucrial-;
/ I
I,
Donor Slgll;ltllrL': _l ;"'-/ ,{
Prillkd '\:II11l': Ill'III) J : lle_ J il_ 1J {(.:I L '~1i)
/
}I l
Donor \i!..!lIdtU)"l' :
.- --7----- _ --~~---
Prilltni '\ ~1l11l':I'_:lt)"i~:k~\'A[d lRl'prl''''l'llt,lti, L'Ilj' till' Dl'~Il'\ lIIL"S :\"''''1 lci~ltillll I-I.und.ui. III
I I " I /

File Three: Selected Chronology of Heimlich Institute's "Malariotherapy" Experiments Via University of Cincinnati's Winkler Library

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

File Three: Selected Chronology of Heimlich Institute's "Malariotherapy" Experiments Via University of Cincinnati's Winkler Library

Uploaded by

Copyright:

Available Formats

~Yw!~~--------:--He-nry-J' H-eiml-ich, M-.D.

AGREEMENT FOR J OI NT PROJ ECT

You might also like